

# *Era of Hope*

**Department of Defense  
Breast Cancer Research  
Program Meeting**



**June 8–11, 2005  
Pennsylvania Convention Center  
Philadelphia, Pennsylvania**

**PROGRAM**

This page intentionally left blank.

---

## **About the Meeting**

---

### **Meeting Intent**

The Era of Hope Meeting is designed to report research studies funded by the Department of Defense (DOD) Breast Cancer Research Program (BCRP). This year's Era of Hope will highlight the multidisciplinary and innovative approaches that the DOD BCRP has funded and will provide a forum for scientists, clinicians, and breast cancer survivors to share their ideas and to reflect on promising, innovative avenues of research for the upcoming years.

Investigators funded by the DOD BCRP from FY2001 through FY2003 are obliged to attend the meeting and report on their research findings. In honor of their long-standing research in breast cancer, those investigators funded in previous years (FY1992 through FY2000) have also been invited to present abstracts at the meeting. Because breast cancer consumer participation is integral to every aspect of the BCRP and the Era of Hope, consumer advocacy organizations have also been chosen to present abstracts.

### **Unifying Themes and Format**

#### **Program Highlights**

- The fourth Era of Hope has been organized around three themes to address the question, "Where are we in the conquest of breast cancer?" The three themes are Understanding Risk – A Different Perspective; Understanding Who Needs Intervention; and Understanding Treatments – Effectively Treating Primary and Metastatic Disease.
- A Special Keynote Address will be presented by Dr. Rosabeth Moss Kanter, Ernest L. Arbuckle Professor of Business Administration, Harvard Business School, a world-renowned speaker on thinking out-of-the-box and implementing change.
- Daily Morning and Plenary Sessions addressing each theme are planned. Focused Symposia Sessions and Poster Sessions highlighting the work of the DOD grantees as well as consumers are at the heart of the meeting.
- Innovator Sessions will highlight the DOD Innovator Award recipients, FY2001-FY2003, who will present their visions of the future of breast cancer research.

---

## **Table of Contents**

---

About the Meeting .....	1
Letter from the Acting Commander, United States Army Medical Research and Materiel Command.....	2
Letter from the Director, Congressionally Directed Medical Research Programs .....	3
Technical Planning Committee .....	4
Technical Planning Subcommittees .....	5
BCRP Leadership.....	5
BCRP Integration Panel Members .....	6
Invited Speakers .....	6
Co-Chairs and Moderators .....	8
Pennsylvania Convention Center Floorplans .....	11
Questions.....	12
General Information.....	13
Continuing Education Accreditation.....	15
Program at-a-Glance .....	16
Agenda .....	20
Poster Sessions at-a-Glance .....	38
Poster Sessions.....	39
Poster/Author Index .....	128
Faculty Disclosure Statement .....	155
Notes .....	163

This book belongs to:



DEPARTMENT OF THE ARMY  
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND  
504 SCOTT STREET  
FORT DETRICK, MD 21702-5012

REPLY TO  
ATTENTION OF

APR 29 2005

Office of the Acting Commander

Dear Colleagues:

Welcome to the Department of Defense (DOD) Breast Cancer Research Program (BCRP) 2005 Era of Hope meeting. This gathering represents the collaborative endeavor of many people to affect breast cancer's impact on the lives of all who are touched by it. The 2005 meeting highlights the multidisciplinary and innovative research that the DOD BCRP has funded in our efforts to eradicate breast cancer.

This collaboration among the research community, breast cancer consumers, and the US Government is the result of the hard work initiated and sustained by survivors and advocates, the decision of Congress to continue funding, and the dedication of scientists and clinicians to the program. The 2005 Era of Hope Meeting, a hallmark of the DOD BCRP, demonstrates the commitment of the US Army Medical Research and Materiel Command to manage the DOD BCRP in a manner responsive to the vision and equal to the dedication of all our partners.

The 2005 Era of Hope meeting builds on this collaboration by addressing the broad question, "Where are we in the conquest of breast cancer?" To facilitate communication and encourage greater interaction among the many diverse disciplines in attendance, the meeting is organized around three unifying themes: Understanding Risk – A Different Perspective; Understanding Who Needs Intervention; and Understanding Treatments – Effectively Treating Primary and Metastatic Disease. All BCRP award recipients from fiscal years 2001-2003 were invited to present their research findings and exchange ideas at this meeting. Also, many award recipients from previous fiscal years (1992-2000) were invited to provide updates on advancements in their research. Breast cancer consumers, who have been integral to the success of the DOD BCRP since its inception, are serving side-by-side with the scientists as co-chairs and participants in all sessions.

My staff and I thank you for your continuing partnership in our efforts to eliminate this disease, sustain health, and improve the quality of life for those living with breast cancer.

Sincerely,

  
James A. Romano, Jr.  
Colonel, Medical Service Corps  
Acting Commander



REPLY TO  
ATTENTION OF

**DEPARTMENT OF THE ARMY**  
**US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND**  
**1077 PATCHEL STREET**  
**FORT DETRICK MD 21702-5024**

June 8, 2005

Congressionally Directed Medical Research Programs

Dear Colleagues:

*Era of Hope 2005* is the fourth meeting of the US Department of Defense (DOD) Breast Cancer Research Program (BCRP). The DOD BCRP is a leader in funding innovative, multidisciplinary, breast cancer research that explores new avenues, addresses neglected issues, and brings new investigators into the field. The scientific excellence and innovation of the research presented at this *Era of Hope* meeting testifies to the many talented, creative scientists and clinical researchers supported by the DOD BCRP.

The DOD BCRP was created in response to the concerns of those directly affected by breast cancer. Breast cancer survivors and advocates have had a tremendous impact on this program by their participation in program vision setting and proposal review. Collaboration among breast cancer survivors, research advocates, scientists, clinicians, and the federal government is one of the DOD BCRP's most important achievements. The success of this partnership is due to the shared dedication and commitment to eradicate breast cancer. I extend my deepest gratitude to the following DOD BCRP participants:

- Breast cancer survivors and advocates, whose courage and commitment created this program, and whose passion, inspiration, and vision of eradicating breast cancer continue to infuse it.
- The scientists and clinicians funded by the program who, through their research, provide hope for finding a cure.
- Members of the Integration Panel, present and past, who craft a responsive, dynamic, and comprehensive program every year through fiscally responsible investment strategies, creating award mechanisms to support these strategies, and identifying the research that will most effectively move us closer to a cure.
- Members of the DOD BCRP peer review panels who have met the challenge of reviewing over 25,000 proposals during the past 13 years. Their expertise and perseverance has assisted us in finding and funding the best science.
- Members of the DOD, the US Army Medical Research and Materiel Command, the BCRP Program Management Team, and support staff, whose energy, enthusiasm, and diligence sustain the DOD BCRP.

The strength, skill, vision, and devotion of all these dedicated individuals have created a research program that forges new pathways toward eradicating breast cancer. This fourth *Era of Hope* meeting is the culmination of 13 years of progress of the DOD BCRP in the fight against breast cancer. I thank you for your participation.

Sincerely,

*Janet R. Harris*

Janet R. Harris, RN, PhD  
Colonel, US Army Nurse Corps  
Director

## Technical Planning Committee

### Dennis J. Slamon, M.D., Ph.D.

(TPC Co-Chair)

Professor of Medicine, Director, Division of Clinical/Translational Research, Jonsson Comprehensive Cancer Center, Chief, Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA

### Frances M. Visco, Esq.

(TPC Co-Chair)

President, National Breast Cancer Coalition (NBCC)

### Anna D. Barker, Ph.D.

(TPC Co-Chair)

Deputy Director, Strategic Scientific Initiatives, National Cancer Institute

### Patricia Modrow, Ph.D.

(Conference Chair)

Department of the Army, U.S. Army Medical Research and Materiel Command, (USAMRMC) Congressionally Directed Medical Research Programs

### Carol A. Evans

(Program Representative)

Integration Panel Liaison, Science Applications International Corporation (SAIC)

### Beth Mathews-Bradshaw

(Program Representative)

Senior Program and Policy Analyst, SAIC

### Leslie Bernstein, Ph.D. (Thursday Day Co-Chair)

Professor, Preventive Medicine, AFLAC, Inc., Chair in Cancer Research, USC/Norris Comprehensive Cancer Center and USC Keck School of Medicine

### Mina J. Bissell, Ph.D.

Distinguished Scientist, Lawrence Berkeley National Laboratory

### Frank J. Calzone, Ph.D. (Friday Day Co-Chair)

Associate Director, Cancer Biology, Amgen Inc.

### Robert D. Cardiff, M.D., Ph.D.

Professor of Pathology, University of California at Davis (UCD) Center for Comparative Medicine

### Graham Casey, Ph.D.

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation

### Kay Dickersin, Ph.D.

Professor of Medical Science, Brown University

### Kunio Doi, Ph.D.

Ralph W. Gerard Professor in the Biological Sciences, Director of Kurt Rossmann Laboratories for Radiologic Image Research, Department of Radiology, University of Chicago

### Stanley R. Hamilton, M.D.

Professor and Division Head, Pathology and Laboratory Medicine, M. D. Anderson Cancer Center

### Gregory J. Hannon, Ph.D.

Professor, Cold Spring Harbor Laboratory

### James R. Heath, Ph.D.

Elizabeth W. Gilloon Professor of Chemistry, California Institute of Technology

### M. Carolina Hinestrosa, M.A., M.P.H. (Saturday Day Co-Chair)

Executive Vice President, Programs and Planning, NBCC

### H. Kim Lyerly, M.D.

Director, Duke Comprehensive Cancer Center

### Ngina Lythcott, Dr.P.H. (Friday Day Co-Chair)

Breast Cancer Liaison, Black Women's Health Imperative and Vice Dean and Dean of Students, Mailman School of Public Health, Columbia University

### John R. Mackey, M.D.

Associate Professor, Department of Oncology, Cross Cancer Institute, University of Alberta

### Robert Mass, M.D.

Director, Clinical Oncology Group, Genentech, Inc.

### William H. Redd, Ph.D.

Professor, Oncological Sciences, Mount Sinai School of Medicine

### Rosemary Rosso, J.D. (Thursday Day Co-Chair)

Greater Baltimore-Washington Breast Cancer Group

### George W. Sledge Jr., M.D. (Abstract Subcommittee Chair)

Professor of Medicine and Pathology, Ballvé-Lantero Professor of Oncology, Indiana Cancer Pavilion

### Patricia S. Steeg, Ph.D. (Saturday Day Co-Chair)

Chief, Women's Cancers Section, Laboratory of Pathology, Director, Molecular Therapeutics Program, National Cancer Institute

### Saraswati Sukumar, Ph.D.

Barbara B. Rubenstein Professor of Oncology, Professor of Pathology, Director of Basic Research, Breast Cancer Program, Johns Hopkins Oncology Center

### Alice Yaker, J.D.

Executive Director, Self Help for Women with Breast and Ovarian Cancer (SHARE)

---

## **Technical Planning Subcommittees**

---

**Abstract Subcommittee:**

George W. Sledge Jr., M.D. (*Chair*)

Vimla Band, Ph.D.

James P. Basilion, Ph.D.

Pedro J. Beltran, Ph.D.

Jonine Bernstein, Ph.D.

Leslie Bernstein, Ph.D.

Mina J. Bissell, Ph.D.

Deborah J. Bowen, Ph.D.

Harold J. Burstein, M.D., Ph.D.

Myles C. Cabot, Ph.D.

Frank J. Calzone, Ph.D.

Robert D. Cardiff, M.D., Ph.D.

Graham Casey, Ph.D.

Ercole L. Cavalieri, D.Sc.

Steve Coats, Ph.D.

Stanley N. Cohen, M.D.

Massimo Cristofanilli, M.D.

Kay Dickersin, Ph.D.

Kunio Doi, Ph.D.

Gregory J. Hannon, Ph.D.

James R. Heath, Ph.D.

M. Carolina Hinestrosa, M.A., M.P.H.

Mien-Chie Hung, Ph.D.

Elizabeth Jaffee, M.D.

Mary Justice, R.N., B.C., M.S.N.

H. Kim Lyerly, M.D.

Ngina Lythcott, Dr.P.H.

John R. Mackey, M.D.

Robert Mass, M.D.

Daniel Medina, Ph.D.

Sandra A. Norman, Ph.D.

Christine K. Norton

Karin D. Noss, M.A., M.P.A.

Vasilis Ntziachristos, Ph.D.

Robert G. Oshima, Ph.D.

Donald B. Plewes, Ph.D.

Michael F. Press, M.D., Ph.D.

William H. Redd, Ph.D.

Rosemary Rosso, J.D.

Lupe Salazar, M.D.

Dennis C. Sgroi, M.D.

Jerry W. Shay, Ph.D.

David I. Smith, Ph.D.

Mark E. Stearns, Ph.D.

Patricia S. Steeg, Ph.D.

Janet L. Stein, Ph.D.

Sarawati Sukumar, Ph.D.

Debu Tripathy, M.D.

Frances M. Visco, Esq.

Cindy A. Wilson, Ph.D.

Alice Yaker, J.D.

Dihua Yu, M.D., Ph.D.

**Consumer Subcommittee:**

Karin D. Noss, M.A., M.P.A. (*Chair*)

M. Carolina Hinestrosa, M.A., M.P.H.

Mary Justice, R.N., B.C., M.S.N.

Ngina Lythcott, Dr.P.H.

Christine K. Norton

William H. Redd, Ph.D. (Scientist Representative)

Rosemary Rosso, J.D.

Frances M. Visco, Esq.

---

## **BCRP Leadership**

---

Responding to the National Breast Cancer Coalition's efforts to increase research aimed at overcoming breast cancer, Congress appropriated funds to the DOD beginning in FY1992 to be directed toward breast cancer research. The USAMRMC was given responsibility for managing the BCRP. A management team of scientists, headed by Colonel Janet R. Harris, is dedicated to the fight against breast cancer. An Integration Panel provides scientific and consumer expertise to fulfill the goals of the Program.

**James A. Romano Jr., Ph.D.**

Colonel, U.S. Army Medical Services Corps.  
Acting Commander, USAMRMC

**Janet R. Harris, Ph.D.**

Colonel, U.S. Army Nurse Corps.  
Director, CDMRP, USAMRMC

**Elaine Melissa Kaime, M.D., F.A.C.P**

Captain, U.S. Navy Medical Corps.  
Deputy Director, CDMRP, USAMRMC

**Patricia C. Modrow, Ph.D.**

Conference Chair, CDMRP, USAMRMC

**Breast Cancer Research Program Management Team:****Richard H. Kenyon, Ph.D.**

Program Manager, BCRP, CDMRP, USAMRMC

**Katherine H. Moore, Ph.D.**

Grants Manager, BCRP, CDMRP, USAMRMC

**Carole Christian, Ph.D.**

Grants Manager, BCRP, CDMRP, USAMRMC

**Donna Kimbark, Ph.D.**

Grants Manager, BCRP, CDMRP, USAMRMC

**Theresa Miller, Ph.D.**

Grants Manager, BCRP, CDMRP, USAMRMC

**Carol A. Evans**

Integration Panel Liaison, SAIC

**Isabelle Bisceglie, Ph.D.**

Assistant Vice President for Program Management, SAIC

**Stephanie Birkey Reffey, Ph.D.**

BCRP Coordinator, SAIC

**Anna Dipietrantonio, Ph.D.**

Biomedical Scientist, SAIC

**June Traicoff, Ph.D.**

Biomedical Scientist, SAIC

**Karen Tountas, Ph.D.**

Biomedical Scientist, SAIC

**Susan Stern, Ph.D.**

Peer Review Coordinator, Constella Health Sciences

---

## **BCRP Integration Panel Members**

---

### **Integration Panel Members**

The U.S. Army gratefully acknowledges the intellectual strength and vision that past and present Integration Panel members have provided in crafting a BCRP that has received accolades from Congress and both the scientific and the consumer communities. Current Integration Panel members include:

#### **Executive Committee**

Frances M. Visco, Esq. (Chair)  
H. Kim Lyerly, M.D. (Chair-Elect)  
M. Carolina Hinestrosa, M.A., M.P.H. (Chair Emeritus)  
Anna D. Barker, Ph.D. (Member-At-Large)  
Graham Casey, Ph.D. (Member-At-Large)

#### **Members**

Mauro Ferrari, Ph.D.  
Alan S. Lichter, M.D.  
Ngina Lythcott, Dr.P.H.  
Donald B. Plewes, Ph.D.  
William H. Redd, Ph.D.  
Rosemary Rosso, J.D.  
Steven Shak, M.D.  
Danny R. Welch, Ph.D.

---

## **Invited Speakers**

---

### **Christine B. Ambrosone, Ph.D.**

Chair, Department of Epidemiology, Roswell Park Cancer Institute

### **James P. Basilion, Ph.D.**

Assistant Professor of Radiology, Massachusetts General Hospital

### **Leslie Bernstein, Ph.D.**

Professor, Preventive Medicine, AFLAC, Inc., Chair in Cancer Research, USC/Norris Comprehensive Cancer Center and USC Keck School of Medicine

### **Donald A. Berry, Ph.D.**

Chairman, Department of Biostatistics and Applied Mathematics, University of Texas M.D. Anderson Cancer Center

### **Mina J. Bissell, Ph.D.**

Distinguished Scientist, Lawrence Berkeley National Laboratory

### **Joan S. Brugge, Ph.D.**

Professor and Chair, Department of Cell Biology, Harvard Medical School

### **Nigel Bundred, M.D.**

Professor of Surgical Oncology, South Manchester University Hospital Education and Research Center

### **Robert D. Cardiff, M.D., Ph.D.**

Professor of Pathology, UCD Center for Comparative Medicine

### **Jenny Chang, M.D.**

Associate Professor, Breast Center at Baylor College of Medicine

### **Wendy Demark-Wahnefried, Ph.D., R.D., L.D.N.**

Associate Professor, Department of Surgery, Director, Program of Cancer Prevention, Detection & Control Research, Duke Comprehensive Cancer Center

### **Kay Dickersin, Ph.D.**

Professor of Medical Science, Brown University

### **Gerald J. Diebold, Ph.D.**

Professor of Chemistry, Brown University

### **James H. Doroshow, M.D.**

Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute

### **Stephen J. Elledge, Ph.D.**

Gregor Mendel Professor of Genetics and of Medicine, Harvard Medical School

### **Mauro Ferrari, Ph.D.**

Associate Vice President for Technology, Ohio State University Davis Heart & Lung Research Institute

### **M. Judah Folkman, M.D.**

Julia Dyckman Andrus Professor of Pediatric Surgery, Children's Hospital, Karp Family Research Laboratories

### **Matthew Freedman, M.D.**

Instructor in Medicine, Harvard Medical School, Massachusetts General Hospital, Broad Institute of MIT and Harvard

### **Juri G. Gelovani, M.D., Ph.D.**

Professor and Chair, Experimental Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center

---

## *Invited Speakers*

---

**Joe W. Gray, Ph.D.**

Associate Laboratory Director, Bioscience, Lawrence Berkeley National Laboratory, Director, Life Sciences Division, Lawrence Berkeley National Laboratory, Professor, Laboratory Medicine and Radiation Oncology, University of California at San Francisco

**Naomi J. Halas, Ph.D.**

Stanley C. Moore Professor of Chemistry, William Marsh Rice University

**Gregory J. Hannon, Ph.D.**

Professor, Cold Spring Harbor Laboratory

**Lyndsay N. Harris, M.D.**

Assistant Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute

**M. Carolina Hinestrosa, M.A., M.P.H.**

Executive Vice President, Programs and Planning, NBCC

**Rosabeth Moss Kanter, Ph.D.**

Ernest L. Arbuckle Professor of Business Administration, Harvard Business School

**Pamela M. Klein, M.D.**

Group Director, Clinical Oncology, Genentech, Inc.

**Gottfried E. Konecny, M.D.**

Adjunct Assistant Professor, Medical Oncology and Hematology, David Geffen School of Medicine at UCLA

**Joshua LaBaer, M.D., Ph.D.**

Director, Harvard Institute of Proteomics

**Susan M. Love, M.D., M.B.A.**

President and Medical Director, Susan Love MD Breast Cancer Foundation

**H. Kim Lyerly, M.D.**

Director, Duke Comprehensive Cancer Center

**Lynn M. Matrisian, Ph.D.**

Ingram Distinguished Chair of Cancer Research, Vanderbilt University Medical Center, Professor and Chair, Department of Cancer Biology

**Carol Matyka**

CARE Advocates

**Daniel Medina, Ph.D.**

Professor, Department of Molecular and Cell Biology, Baylor College of Medicine

**Paul S. Meltzer, M.D., Ph.D.**

Head, Section of Molecular Genetics, National Human Genome Research Institute

**Karin D. Noss, M.A., M.P.A.**

Virginia Breast Cancer Foundation, NBCC

**Olufunmilayo I. Olopade, M.D., F.A.C.P.**

Professor of Medicine, University of Chicago Hospitals

**Robert G. Oshima, Ph.D.**

Program Director and Professor, Oncodevelopmental Biology, The Burnham Institute

**Soonmyung Paik, M.D.**

Director, Division of Pathology, National Surgical Adjuvant Breast and Bowel Project (NSABP), NSABP Foundation

**Richard Pazdur, M.D., F.A.C.P.**

Division Director, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Mark D. Pеграм, M.D.**

Associate Professor, Medical Oncology and Hematology, David Geffen School of Medicine at UCLA

**Michele Rakoff**

Long Beach Memorial Medical Center, Breast Friends Program

**David F. Ransohoff, M.D.**

Professor of Medicine, University of North Carolina at Chapel Hill

**Timothy R. Rebbeck, Ph.D.**

Associate Professor of Epidemiology, Department of Biostatistics and Epidemiology, Senior Scholar, Center for Clinical Epidemiology and Biostatistics (CCEB), University of Pennsylvania School of Medicine

**Rosemary Rosso, J.D.**

Greater Baltimore-Washington Breast Cancer Group

**Erkki Ruoslahti, M.D., Ph.D.**

Distinguished Professor, The Burnham Institute

**Helen Schiff**

SHARE

**William R. Sellers, M.D.**

Assistant Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute

**Steven Shak, M.D.**

Chief Medical Officer, Genomic Health, Inc.

**Joy Simha**

Founder, Young Survival Coalition

**Dennis J. Slamon, M.D., Ph.D.**

Professor of Medicine, Director, Division of Clinical/Translational Research, Jonsson Comprehensive Cancer Center, Chief, Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA

**George W. Sledge Jr., M.D.**

Professor of Medicine and Pathology, Ballve-Lantero Professor of Oncology, Indiana Cancer Pavilion

**Michael B. Sporn, M.D.**

Professor of Pharmacology and Medicine, Dartmouth Medical School

---

## **Invited Speakers**

---

**Patricia S. Steeg, Ph.D.**

Chief, Women's Cancers Section, Laboratory of Pathology, Director, Molecular Therapeutics Program, National Cancer Institute

**Beverly Teicher, Ph.D.**

Vice President, Oncology Research, Genzyme Corporation

**Laura J. van't Veer, Ph.D.**

Head, Family Center Clinics, Department of Pathology, The Netherlands Cancer Institute

**Valerie M. Weaver, Ph.D.**

Assistant Professor, Department of Pathology and Laboratory Medicine, Member, Institute for Medicine and Engineering, University of Pennsylvania

**Max S. Wicha, M.D.**

Professor of Internal Medicine and Director, University of Michigan Comprehensive Cancer Center

**Michael H. Wigler, Ph.D.**

Professor, Cold Spring Harbor Laboratory

**Cindy A. Wilson, Ph.D.**

Assistant Professor, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA

**Alice Yaker, J.D.**

Executive Director, SHARE

**Junying Yuan, Ph.D.**

Professor, Harvard University School of Medicine

---

## **Co-Chairs and Moderators**

---

**Mary Barker**

Breast Cancer Coalition of North Carolina, NBCC

**James P. Basilion, Ph.D.**

Assistant Professor of Radiology, Massachusetts General Hospital

**Barbara Beckwith, M.A.**

Breast Cancer Prevention Educator, Columbus Community Clinical Oncology Program

**Leslie Bernstein, Ph.D.**

Professor, Preventive Medicine, AFLAC, Inc., Chair in Cancer Research, USC/Norris Comprehensive Cancer Center and USC Keck School of Medicine

**Geri Blair**

Minority Women with Breast Cancer Uniting

**Vernal H. Branch**

Virginia Breast Cancer Foundation, NBCC

**Robert D. Cardiff, M.D., Ph.D.**

Professor of Pathology, UCD Center for Comparative Medicine

**Christine Carpenter, M.A.**

President, Iowa Breast Cancer Edu-action

**Graham Casey, Ph.D.**

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation

**Ercole L. Cavalieri, D.Sc.**

Professor, University of Nebraska Medical Center, Eppley Institute for Research in Cancer and Allied Diseases

**Robert Clarke, Ph.D., D.Sc.**

Professor, Department of Oncology, Department of Physiology and Biophysics, Georgetown University School of Medicine

**Maryellen Delapine**

Living Beyond Breast Cancer

**Peggy Devine**

Executive Director, Cancer Information & Support Network (CISN)

**Kay Dickersin, Ph.D.**

Professor of Medical Science, Brown University

**Gerald J. Diebold, Ph.D.**

Professor of Chemistry, Brown University

**Ruth Eldredge**

Georgia Breast Cancer Coalition, NBCC

**Mary Elliott**

Susan G. Komen Breast Cancer Foundation

**Bingliang Fang, M.D., Ph.D.**

Department of Thoracic & Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center

**M. Judah Folkman, M.D.**

Julia Dyckman Andrus Professor of Pediatric Surgery, Childrens Hospital, Karp Family Research Laboratories

**Ann Fonfa**

President, The Annie Appleseed Project

**Gail Frankel**

Adelphi NY Statewide Breast Cancer Hotline and Support Program

**Marilie D. Gammon, Ph.D.**

Associate Professor, Cancer Epidemiology, University of North Carolina at Chapel Hill

**Andrew K. Godwin, Ph.D.**

Department of Medical Oncology, Fox Chase Cancer Center

**Anne Grant**

SHARE

---

## ***Co-Chairs and Moderators***

---

**Bettye Green, R.N.**

African American Women in Touch

**Kathleen Harris**

Founding Member, Past President, Wisconsin Breast Cancer Coalition

**Patricia Haugen**

NBCC

**M. Carolina Hinestrosa, M.A., M.P.H.**

Executive Vice President, Programs and Planning, NBCC

**Mien-Chie Hung, Ph.D.**

Professor and Chair of the Department of Molecular and Cellular Oncology, University of Texas M.D. Anderson Cancer Center

**Mary Justice, R.N., B.C., M.S.N.**

Breast Cancer Alliance of Greater Cincinnati

**Joshua LaBaer, M.D., Ph.D.**

Director, Harvard Institute of Proteomics

**Debbie Laxague**

Breast Cancer Services of Siskiyou County

**Mildred Leigh-Gold**

Milwaukee Breast and Cervical Cancer Awareness Program

**Liz Lostumbo**

Greater Baltimore-Washington Breast Cancer Group

**Zhenkun Lou, Ph.D.**

Division of Oncology Research, Mayo Clinic

**H. Kim Lyerly, M.D.**

Director, Duke Comprehensive Cancer Center

**Ngina Lytheott, Dr.P.H.**

Breast Cancer Liaison, Black Women's Health Imperative and Vice Dean and Dean of Students, Mailman School of Public Health, Columbia University

**John R. Mackey, M.D.**

Associate Professor, Medical Oncology, Cross Cancer Institute, University of Alberta

**Wish Martin**

Sisters Network Dayton

**Lynn M. Matrisian, Ph.D.**

Ingram Distinguished Chair of Cancer Research, Vanderbilt University Medical Center, Professor and Chair, Department of Cancer Biology

**Carol Matyka**

CARE Advocates

**Marlene McCarthy**

Chair, Rhode Island Breast Cancer Coalition

**Arthur M. Mercurio, Ph.D.**

Professor and Vice Chairman, Department of Cancer Biology, University of Massachusetts Medical School

**Kathy D. Miller, Ph.D.**

Assistant Professor of Medicine, Division of Hematology/Oncology, Indiana Cancer Pavilion

**Suzanne Miller, Ph.D.**

Senior Member, Division of Population Science, Director, Psychosocial and Behavioral Medicine Program, Director, Behavioral Research Core Facility, Director, Behavioral Center of Excellence in Breast Cancer, Fox Chase Cancer Center

**Susan Moreno**

Florida Breast Cancer Coalition

**Paola Muti, M.D.**

Professor and Chair, Department of Cancer Epidemiology, Italian National Cancer Institute

**Sandra A. Norman, Ph.D.**

Research Associate Professor, Department of Biostatistics and Epidemiology, University of Pennsylvania

**Christine K. Norton**

Minnesota Breast Cancer Coalition

**Karin D. Noss, M.A., M.P.A.**

Virginia Breast Cancer Foundation, NBCC

**Robert G. Oshima, Ph.D.**

Program Director and Professor, Oncodevelopmental Biology, The Burnham Institute

**Jane Perlmutter, Ph.D.**

Y-ME National Breast Cancer Organization

**Richard J. Pietras, M.D., Ph.D.**

Associate Professor of Medicine, University of California, Los Angeles, School of Medicine

**Michele Rakoff**

Long Beach Memorial Medical Center, Breast Friends Program

**Sylvia Rickard**

Utah Breast Cancer Network

**Rosemary Rosso, J.D.**

Greater Baltimore-Washington Breast Cancer Group

**Irma H. Russo, M.D., F.C.A.P., F.A.S.C.P.**

Member, Medical Science Division, Chief, Molecular Endocrinology Section, Fox Chase Cancer Center

**Nancy Ryan**

New Hampshire Breast Cancer Coalition

**Lupe G. Salazar, M.D.**

Tumor Vaccine Group, University of Washington

**Ivis Sampayo**

Latino SHARE

**Dennis C. Sgroi, M.D.**

Associate Professor of Pathology, Harvard Medical School, Massachusetts General Hospital

---

## *Co-Chairs and Moderators*

---

**Mark Sliwkowski, Ph.D.**

Staff Scientist and Director, Translational Oncology,  
Genentech, Inc.

**David I. Smith, Ph.D.**

Professor, Mayo Foundation, School of Medicine

**Patricia S. Steeg, Ph.D.**

Chief, Women's Cancers Section, Laboratory of Pathology,  
Director, Molecular Therapeutics Program, National Cancer  
Institute

**Saraswati Sukumar, Ph.D.**

Barbara B. Rubenstein Professor of Oncology, Professor of  
Pathology, Director of Basic Research, Breast Cancer Pro-  
gram, Johns Hopkins Oncology Center

**Eva Surmacz, Ph.D.**

Associate Professor, Sbarro Institute for Cancer Research and  
Molecular Medicine, Temple University, College of Science  
and Technology

**Carolyn Tapp**

Women of Color Breast Cancer Survivors Support Project

**Vicki Tosher**

Vice President, Sense of Security, Inc.

**Daniel van der Weide, Ph.D.**

Professor, Electrical & Computer Engineering, University of  
Wisconsin

**Mary Jo Vazquez**

Nueva Vida

**Linda Vincent, M.P.H.**

UCSF Breast SPORE Advocacy Core

**Frances M. Visco, Esq.**

President, NBCC

**Sandra Walsh**

California Breast Cancer Organizations, Y-ME National  
Breast Cancer Organization-California

**Louis M. Weiner, M.D.**

Vice President, Translational Research, Chairman, Depart-  
ment of Medical Oncology, Fox Chase Cancer Center

**Danny R. Welch, Ph.D.**

Leonard H. Robinson Professor of Pathology, University of  
Alabama at Birmingham

**Max S. Wicha, M.D.**

Professor of Internal Medicine and Director, University of  
Michigan Comprehensive Cancer Center

**Kay Wissmann**



Government Relations Manager, Y-ME National Breast  
Cancer Organization

**Anna H. Wu, Ph.D.**


Professor, Preventive Medicine, Division of Epidemiology,  
University of Southern California Keck School of Medicine

## Pennsylvania Convention Center Floorplans

### 200 Level Floorplan




### Ballroom Level Floorplan




Opening, Plenary,  
Keynote, and  
Innovator Sessions

Registration  
and Welcome  
Reception



## Pennsylvania Convention Center Floorplans

### 300 Level Floorplan



## Questions



### Questions

#### Overall Direction/Media:

Erika Petersen, SAIC

Manager, Conferences and Media Relations

Phone: (301) 698-5991      Fax: (301) 698-6188

e-mail: eraofhope@saic.com



#### Consumers/Speakers Reimbursements:

Missy Hall, SAIC

Phone: (301) 698-5991      Fax: (301) 698-6188

e-mail: eraofhope@saic.com

#### Abstracts/Poster Presentations/Audiovisuals:

Margie McDonald, SAIC

Abstract and Conference Coordinator

Phone: (301) 698-5991      Fax: (301) 698-6188

e-mail: eraofhope@saic.com

## **General Information**

**All events will start and end on time. Your promptness and consideration for the speakers who have devoted significant time to the preparation of outstanding presentations are deeply appreciated.**

### **Meeting Location**

Pennsylvania Convention Center  
One Convention Center Place  
1101 Arch Street, Philadelphia, PA 19107

### **This is a Non-Smoking Meeting**

### **Registration & Information Center**

#### **Pennsylvania Convention Center Grand Hall**

All participants must register for the meeting. The registration fee provides (1) admittance to all scientific and poster sessions, (2) meals and refreshments concurrent with the Technical Program sessions, and (3) one copy of the Conference Proceedings and Program Book, plus conference materials. The sole intent of the registration fee is to promote, enhance, and facilitate technical discussions and long-term professional relationships/collaborations.

### **Name Badges**

Name badges must be worn at all times for admission to the meetings, poster sessions, and all receptions.

### **On-Site Registration Hours**

Wednesday, June 8, 2005, 12:00 noon – 8:00 p.m.

Thursday, June 9, 2005, 7:00 a.m. – 7:00 p.m.

Friday, June 10, 2005, 7:00 a.m. – 7:00 p.m.

Saturday, June 11, 2005, 7:00 a.m. – 7:00 p.m.

### **Special Assistance**

The DOD is committed to making this meeting accessible to all participants. Registrants with special requirements for transportation or hotel accommodations should inform the conference staff in advance of the meeting by calling Margie McDonald at (301) 698-5991 or by sending an e-mail to eraofhope@saic.com.

### **Consumer/Advocate Hospitality Lounge**

A Consumer/Advocate Hospitality Lounge is available for use during conference hours in Room 301/302.

### **Internet Access**

Four terminals with free Internet access will be available in the Grand Hall near the registration area. Wireless service (Wi-Fi) is available in all common areas of the Convention Center for individuals traveling with laptop computers.

### **Speaker Ready Room**

The Speaker Ready Room will be located in Room 202A and will be staffed to assist presenters. Speakers are required to use the equipment in this area to check the order and position of their slides before the sessions in which they are scheduled

to appear. This room opens at 4:00 p.m. on Wednesday, June 8 and will be open from 7:00 a.m. to 7:00 p.m. on Thursday, June 9 through Saturday, June 11. Speakers should turn in their presentation disks, drives, or slides to a staff member in the Speaker Ready Room upon arrival at the meeting and not less than 1 hour prior to their session.

### **Audiovisual**

#### ***Guidance for all Presentations***

If you plan to use the LCD projection system, your presentation must be on an IBM PC-compatible disk, CD-ROM, zip disk, or USB flash drive (thumb drive) and must be in Microsoft PowerPoint (Office 2000, 2003, or XP). If you prepare your presentation in Microsoft Office 97, please check the formatting changes by opening it in Office 2000. We will NOT be able to connect your individual computer to the projector. Please do not bring laptop computers.

Font recommendations: Arial or Times New Roman for text, Symbol and Monotype Sorts will also be supported. Other fonts will not necessarily be guaranteed and could cause formatting issues.

All 35mm slides should be copies, not originals, in case of loss. Slides should be thumb-spotted by placing a mark in the upper right-hand corner of the slide when it is loaded properly in the slide tray, and numbered in the proper sequence. Use standard horizontal format. Vertical and super slides should be avoided; extra slide carousels are available.

#### ***Audiovisual Guidelines for the Opening, Keynote, Plenary, and Innovator Sessions***

Sessions will be presented in double projection. Both slide projectors and a computer with an LCD projection system will be provided. Speakers must bring either two sets of 35mm slides or a single disk or drive for this purpose. OVERHEAD PROJECTORS WILL NOT BE AVAILABLE. Slides/images will be projected on two separate screens, one on each side of the presenter's platform.

#### ***Audiovisual Guidelines for the Symposia and Early Morning Sessions***

A single slide projector and a computer with an LCD projection system will be provided in the Symposia and Early Morning Session rooms. Presenters in these sessions must bring one set of slides or a disk or drive. OVERHEAD PROJECTORS WILL NOT BE AVAILABLE.

### **Message Center**

Messages will be posted on the message board (near the Registration Center). Era of Hope conference staff members will be available to answer questions and assist you throughout the meeting.

## **General Information**

---

### **Concurrent Sessions**

#### ***Early Morning***

Five to six sessions are scheduled to run concurrently during each early morning block; participants may move among Early Morning Sessions. Presenters are asked to adhere to the strict time schedule of 1 hour.

#### ***Symposia***

Five to seven sessions are scheduled to run concurrently during each Symposia block, and participants may move among Symposia. Presenters are asked to adhere to the strict time schedules. All Symposia presentations will be 10 minutes in length, followed by 5 minutes for questions.

### **Poster Sessions**

Posters will be exhibited in Exhibit Hall A. Poster board assignments and sessions can be found beginning on page 38. An informational kiosk detailing the exact location of each poster will be located in the front of Exhibit Hall A.

All individuals with invited abstracts are obliged to have their posters assembled and ready for display in Exhibit Hall A by 3:00 p.m. on Thursday, June 9. Poster boards will be available for setup beginning at 1:00 p.m., Wednesday, June 8 and from 7:00 a.m. to 3:00 p.m. on Thursday, June 9. Investigators must be at their posters during the times designated for their Poster Sessions. Within each Poster Session, odd-numbered poster presenters must man their posters during the first hour; even-numbered, during the second hour.

All posters must remain on display until 9:00 p.m. on Saturday, June 11. Materials must be removed by 12:00 noon on Sunday, June 12.

### **Receptions**

All registrants are invited and encouraged to attend the following activities that have been planned as additional opportunities to interact with colleagues and make new acquaintances with similar interests:

- Welcome Reception—Wednesday, 8:45 p.m.
- Era of Hope Reception/Party—Friday, 8:45 p.m.

### **Lunch**

Lunch will be provided during the Poster Session on Friday, June 10, 2005. The Reading Terminal Market located on the Street Level of the Convention Center will be available for lunch on Thursday, June 9 and Saturday, June 11.

### **Conference Services—Registration and Travel**

SAIC Conference Services will be handling registration for the Era of Hope Meeting. If you charge your registration fees to a credit card, please expect to see SeeUThere on your credit card bill/statement, not Era of Hope. If you have questions, please see a registration staff member.

A staff member will be on site to assist attendees traveling on Invitational Travel Orders (ITOs) and through SAIC Travel.

### **Transportation**

The Pennsylvania Convention Center, Philadelphia Marriott, Loews Hotel, Courtyard Hotel, and Hilton Garden Inn are located just 25 minutes from Philadelphia International Airport.

#### ***Transportation to/from Airport***

The R1 Airport rail line provides service from the airport to Center City every half-hour daily from 6:00 a.m. to midnight. The line stops at Amtrak's 30th Street Station, Suburban Station (16th Street and John F. Kennedy Boulevard), and Market East Station (attached to the Pennsylvania Convention Center). Travel time is 23 minutes; the maximum weekday fare is \$7. For more information, call (215) 580-7800 or visit [www.septa.org](http://www.septa.org).

#### ***Cabs***

A fleet of 1,400 cabs serves the area. Fare is metered at first 1/6 mile \$2.30, each additional 1/6 mile is \$.30. Fare from the airport to Center City is a flat rate of \$20.

#### ***Limousine Services***

A number of limousine companies operate on a 24-hour basis with vans departing as needed. Service counters are located in each terminal at the airport. Average cost between the airport and Center City is \$8-\$10 one way.

Additional information, including driving directions, can be found on the following website: <http://www.paconvention.com/visit/driving.asp>

### **Abstracts on the Internet**

All preregistered participants will receive one copy of the Conference Proceedings and Program Book. Additionally, Scientific Abstracts that were provided to conference organizers will be available on the Era of Hope Internet home page: <http://cdmrp.army.mil/bcrp/era/default.htm>.

### **Audiotapes**

Many of the meeting sessions will be technically reproduced. They will be available for purchase in the registration area.

### **Press Relations**

The Press Office is located in the Room 202B. All members of the press should report to the Press Room to register. Erika Petersen is the Era of Hope Press Manager. All press activities will be managed by Lisa Weiss and Lynn Rudinsky of Cooney Waters.

## **Continuing Education Accreditation**

### **Continuing Medical Education (CME) for Physicians and Continuing Education Units (CEUs) for Nurses**

This activity is jointly sponsored by USAMRMC and the Medical Education Collaborative (MEC). MEC is a nonprofit organization that has been certifying quality educational activities since 1988.



### **Purpose Statement**

The planning committee for this activity has determined that an important need exists to provide physicians and nurses involved in breast cancer prevention, diagnosis, treatment, or quality of life care with important updates to stay informed of new research and the most current technologies and treatments for breast cancer. This activity is being given because breast cancer is a major health concern affecting one in eight women. The ability to cure breast cancer decreases with disease progression and therefore new detection, diagnostic, therapeutic, and quality of life research is needed to find prevention strategies and new cures or improve patient survival and life after breast cancer. This activity will provide a forum in which the research coming from the DOD BCRP will be presented together with symposia and plenary presentations by leading experts in oncology and breast cancer consumer advocates, providing the medical community with important updates in the progress toward the above goals.

### **Target Audience**

This educational activity is designed for civilian and military physicians, nurses, and researchers, especially oncologists, radiologists, pathologists, general/family practitioners, and osteopaths who might be involved in patient diagnosis, treatment, prevention, or post-cancer care.

### **Learning Objectives**

At the conclusion of this activity, participants should be able to:

- Describe and discuss recent research results; the innovative approaches that are now being used to study the basic biology, prevention, detection, diagnosis, and treatment of breast cancer; and ways to improve patient quality of life.

- Understand the latest advances in the genetics and biology of breast cancer.
- Understand the latest advances in the field of breast cancer prevention.
- Understand the latest advances in the identification and characterization of molecular targets that can serve as the basis for individualized breast cancer therapy.
- Interact and collaborate with breast cancer researchers who work in different scientific and clinical disciplines and network with consumer advocacy organizations.

### **Accreditation Statements**

#### **Physicians**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of MEC and USAMRMC. MEC is accredited by ACCME to provide continuing medical education for physicians.

MEC designates this educational activity for a maximum of 31.25 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

#### **Nurses**

MEC designates that this education activity is approved for 37.5 contact hour(s) of continuing education for RNs, LPNs, LVNs, and NPs. This program is cosponsored by MEC and USAMRMC. MEC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. The provider is approved by the California Board of Registered Nursing, Provider Number CEP 12990, for 37.5 contact hour(s).

### **Instructions for Credit**

To receive continuing education credit for this course, participants must attend at least one full presentation, fill out a credit application and evaluation form, and hand in the form to conference staff at the Continuing Education Booth. Certificates will be mailed within 6-8 weeks after the program.

*Please note the faculty disclosure statement is at the end of this Program Book.*

**All participants who wish to receive CME/CEU credits must sign in at the Continuing Education Booth on each day of the meeting for which they plan to apply for credit.**

## *Program at-a-Glance*

Wednesday, June 8, 2005

NOON																	
1:00–6:00 p.m.																	
6:00–6:30 p.m.																	
6:30–8:45 p.m.																	
8:45 p.m.																	

## Program at-a-Glance

### Thursday, June 9, 2005

		EARLY MORNING SESSIONS						
		Room 201A	Room 201B	Room 201C	Room 204A	Room 204B	Room 204C	
7:00–8:00 a.m.	How Do We Investigate the Effect of a Risk Factor on Breast Cancer?	The Normal Breast: A Collection of Ducts	Genetic Modifiers of Experimental Breast Cancer	Stem Cells in Normal Human Breast Development and Cancer: Therapeutic Implications	Health Disparities and Breast Cancer	Large Scale Genomic Association Studies in Cancer		Registration Grand Hall 7:00 a.m.– 7:00 p.m.
8:00–8:10 a.m.								Poster Board/ Exhibitor Setup <i>Exhibit Hall A</i> 7:00 a.m.– 3:00 p.m.
8:10–9:50 a.m.								
9:50–11:00 a.m.								
11:00–11:15 a.m.								
11:15 a.m.– 12:45 p.m.								
12:45–2:00 p.m.								
WELCOME AND MOMENT OF SILENCE – Ballroom A								
2:00–4:00 p.m.	Symp. 1 – Mammary Gland Development and Its Dysregulation in Tumorigenesis	Symp. 2 – Hereditary Breast Cancer: Genetics, Counseling, and Disease Control	Symp. 3 – Biological Markers of Risk: Finding Needles in a Haystack	Symp. 4 – Optical Imaging Approaches for Breast Cancer Detection	Symp. 5 – Premalignancy	Symp. 6 – The Estrogen Receptor Pathway: New Wine in Old Bottles		
4:00–4:15 p.m.								
4:15–6:15 p.m.	Symp. 7 – Identifying and Evaluating Interventions to Prevent Breast Cancer	Symp. 8 – Biological Pathway Discovery and Targeted Interference	Symp. 9 – Stem Cells: The Roots of Breast Cancer	Symp. 10 – Stromal Cell Modulation of Tumorigenesis and Progression	Symp. 11 – Benign Breast Disease and Breast Cancer Risk Center of Excellence Discussion	Symp. 12 – Regulation of the Estrogen Receptor Complex	Symp. 13 – Factors Contributing to Risk and Progression	
6:15–6:30 p.m.								
CONCURRENT SYMPOSIA SESSIONS I								
		Room 201A	Room 201B	Room 201C	Room 204A	Room 204B	Room 204C	
CONCURRENT SYMPOSIA SESSIONS II								
		Room 201A	Room 201B	Room 201C	Room 204A	Room 204B	Room 204C	Room 203A/B
POSTER SESSION/RECEPTION – <i>Exhibit Hall A</i>								
P1	Oncogenes	P10	Invasion and Metastasis I	P19	Antiangiogenesis	P19		
P2	Signal Transduction I	P11	Tumor Progression	P20	Symptom Management	P20		
P3	Mammary Gland Development	P12	Tumor Immunology	P21	Evolving Therapeutic Targets	P21		
P4	DNA Damage and Repair	P13	Biomarkers I	P22	Complementary Health and Alternative Medicine	P22		
P5	Transcription, Translation, and Modification	P14	Computer-Aided Diagnostics	P23	Behavioral Sciences and Decision Making	P23		
P6	Genomics and Proteomics	P15	Nuclear Medicine Imaging	P24	Environmental Epidemiology	P24		
P7	Hormone Receptors I	P16	Drug Design and Development I					
P8	Endocrine Carcinogenesis	P17	Radiotherapy					
P9	Angiogenesis	P18	Hormonal Therapy					

---

## *Program at-a-Glance*

Friday, June 10, 2005

EARLY MORNING SESSIONS						Registration <i>Grand Hall</i> 7:00 a.m.– 7:00 p.m.	
7:00–8:00 a.m.	Room 201A	Room 201B	Room 201C	Room 204A	Room 204B		
Molecular Imaging	Tumor Microenvironment	Functional Proteomics for Biomarker and Target Discovery	Cell Lines: Refined Characterization Using Genomic Technology	Breast Cancer Nanotechnologies			
8:00–8:10 a.m.		<b>WELCOME AND MOMENT OF SILENCE – Ballroom A</b>					
8:10–10:10 a.m.		<b>PLENARY SESSION – Ballroom A</b> Genetic Profiling and Studies of Gene Expression					
10:10–10:25 a.m.		<b>INNOVATOR SESSION – Ballroom A</b>					
10:25 a.m.– 11:55 noon		Break					
11:55 a.m.– 12:05 p.m.		<b>POSTER SESSION/LUNCH – Exhibit Hall A</b>					
12:05–2:05 p.m.		P25 BRCA2 Tumor Suppressor P26 EGF Superfamily I P27 p53 P28 TGF-β P29 Cell Cycle P30 Tumor Suppressor Genes I P31 Signal Transduction II P32 Functional Study of Biological Molecules I P33 Tyrosine Kinase Signaling		P34 Hormone Metabolism P35 Hormone Receptors II P36 Mechanism of Hormone Action P37 Chemical/Physical Carcinogenesis P38 Invasion and Metastasis II P39 Regulation of the Immune Response P40 Biomarkers II P41 Digital Imaging P42 X-Ray Imaging	P43 Drug Design and Development II P44 Targeted Therapies I P45 Vaccines and Immunotherapies P46 Gene Therapy P47 Photodynamic Therapy P48 Clinical and Surgical Management of Breast Cancer P49 Genetic Epidemiology P50 Breast Cancer Centers of Excellence		
2:05–2:15 p.m.		<b>PLenary Session – Ballroom A</b>					
2:15–4:45 p.m.		<b>Emerging Issues Regarding the Diagnostic Utility of Gene Expression Profiles in Breast Cancer</b>					
4:45–5:00 p.m.		Break					
5:00–6:30 p.m.	Room 201A	Room 201B	Room 201C	Room 204A	Room 204B		
	Symp. 14 – Estrogen as an Initiator of Breast Cancer	Symp. 15 – Relationship between Biomarkers and Breast Cancer Pathology I	Symp. 16 – DNA Damage and Repair I	Symp. 17 – Endocrine-Derived Therapies	Symp. 18 – Epithelial to Mesenchymal Transition: When Good Cells Go Bad		
6:30–6:45 p.m.		Break					
6:45–8:45 p.m.	Room 201A	Room 201B	Room 201C	Room 204A	Room 204B	Room 204C	Room 203A/B
	Symp. 19 – Estrogen-Mediated Carcinogenesis Center of Excellence Discussion	Global Molecular Approaches to Identify Specific Biomarkers of Breast Cancer Detection and Prognosis	Non-Hereditary Factors Contributing to Breast Cancer Risk and Outcomes	Inflammation, Immunomodulation, and Cellular Therapy	Symp. 23 – Site-Specific Metastasis: Tumors in Search of a Home	Symp. 24 – Causes and Impact of Adverse Outcomes	Symp. 25 – Diagnostic Molecular Imaging: MR and Nuclear Applications for Improving Breast Cancer Detection
8:45 p.m.	<b>RECEPTION/PARTY AT PHILADELPHIA MARRIOTT – Marriott Hotel Salons A-F</b>						

## Saturday, June 11, 2005

EARLY MORNING SESSIONS						Registration Grand Hall 7:00 a.m.– 7:00 p.m.
	Room 201A	Room 201B	Room 201C	Room 204A	Room 204B	
7:00–8:00 a.m. Gene Expression Profile as Prognostic and Predictive Marker	Clinical Trial Design in the Era of Targeted Therapy	Tissue Architecture and Pathology	New Vascular and Tumor Drug Targets: Discovery, Validation, and Path Forward	What Is Happening with Vaccines?		
8:00–8:10 a.m.	<b>WELCOME AND MOMENT OF SILENCE – Ballroom A</b>					
8:10–10:30 a.m. <b>Bridges to the Future: Understanding the Treatment of Primary and Metastatic Disease</b>						
10:30–10:45 a.m.	Break					
10:45 a.m.– 12:15 p.m.	<b>INNOVATOR SESSION – Ballroom A</b>					
12:15–1:15 p.m.	Lunch					
1:15–2:45 p.m.	<b>PLENARY SESSION – Ballroom A</b> Emerging Issues in Clinical Approaches					
2:45–3:00 p.m.	Break					
<b>CONCURRENT SYMPOSIA SESSIONS V</b>						
	Room 201A	Room 201B	Room 201C	Room 204A	Room 204B	Room 203A/B
3:00–5:00 p.m. Symp. 26 – The Business of Life and Death: Apoptosis Induction and Telomerase	Symp. 27 – Therapeutic Vaccines: Bench to Bedside	Symp. 28 – Arresting Cancer Proliferation through Early Detection and Anti-Angiogenic Therapies	Symp. 29 – How and Why of Metastasis	Symp. 30 – Resistance to HER2 Targeted Therapies	Symp. 31 – People and Populations	Symp. 32 – Readily Acceptable Approaches to Improving Clinical Detection of Breast Cancer
5:00–5:15 p.m.	Break					
<b>CONCURRENT SYMPOSIA SESSIONS VI</b>						
	Room 201A	Room 201B	Room 201C	Room 204A	Room 204B	Room 204C
5:15–6:45 p.m. Symp. 33 – Relationship between Biomarkers and Breast Cancer Pathology II	Symp. 34 – Antibodies: Innate versus Engineered	Symp. 35 – Biological Function of High Risk Genes	Symp. 36 – DNA Damage and Repair II	Symp. 37 – Identifying and Targeting Biological Mechanisms of Angiogenesis	Symp. 38 – Behavioral Centers of Excellence: Treating More Than the Tumor	
6:45–7:00 p.m.	Break					
<b>POSTER SESSION/RECEPTION – Exhibit Hall A</b>						
	P51 BRCA1 Tumor Suppressor	P58 Apoptosis	P65 Agent Development			
	P52 EGF Superfamily II	P59 Stroma-Epithelial Interactions	P66 Drug Resistance			
	P53 Growth Factors/Cytokines	P60 Invasion and Metastasis III	P67 Targeted Therapies II			
7:00–9:00 p.m.	P54 Tumor Suppressor Genes II	P61 Nutrition and Nutraceuticals	P68 Health Care Delivery			
	P55 Functional Study of Biological Molecules II	P62 Risk and Prevention	P69 Quality of Life			
	P56 Genomic Instability	P63 Magnetic Resonance Imaging	P70 Surveillance and Descriptive Epidemiology			
	P57 Familial and Hereditary Carcinogenesis	P64 Novel Imaging	P71 Summer Undergraduate Training Programs			

**Wednesday, June 8, 2005**

12:00 noon–8:00 p.m.	<b>Registration</b>	Grand Hall
1:00–6:00 p.m.	<b>Poster Board Setup</b>	Exhibit Hall A
6:00–6:30 p.m.	<b>WELCOME AND MOMENT OF SILENCE</b> Frances M. Visco    COL Janet R. Harris    USAMRMC Representative	Ballroom A
6:30–8:45 p.m.	<b>OPENING SESSION - What Is Breast Cancer and Where Are We in the Conquest of It?</b> Moderator: Frances M. Visco M. Carolina Hinestrosa    Leslie Bernstein Joan S. Brugge    Dennis J. Slamon	Ballroom A
8:45 p.m.	<b>Welcome Reception</b>	Grand Hall

**Thursday, June 9, 2005**

7:00 a.m.	<b>Registration Opens</b>	Grand Hall
7:00 a.m.–3:00 p.m.	<b>Poster Board Setup</b>	Exhibit Hall A
7:00–8:00 a.m.	<b>EARLY MORNING SESSIONS</b> <i>How Do We Investigate the Effect of a Risk Factor on Breast Cancer?</i> Kay Dickersin (Introduction by Ann Fonfa)	Room 201A
	<i>The Normal Breast: A Collection of Ducts</i> Susan M. Love (Introduction by Peggy Devine)	Room 201B
	<i>Genetic Modifiers of Experimental Breast Cancer</i> Robert G. Oshima (Introduction by Barbara Beckwith)	Room 201C
	<i>Stem Cells in Normal Human Breast Development and Cancer: Therapeutic Implications</i> Max S. Wicha (Introduction by Mary Justice)	Room 204A
	<i>Health Disparities and Breast Cancer</i> Moderator: Ngina Lythcott	Room 204B
	<i>Predictive Markers</i> : Jenny Chang	
	<i>Risk</i> : Olufunmilayo I. Olopade	
	<i>Large Scale Genomic Association Studies in Cancer</i> Matthew Freedman (Introduction by Mary Jo Vazquez)	Room 204C
8:00–8:10 a.m.	<b>WELCOME AND MOMENT OF SILENCE</b> Rosemary Rosso	Ballroom A
8:10–9:50 a.m.	<b>PLENARY SESSION: Understanding Risk as a Basis for Preventing Breast Cancer</b> Moderator: Rosemary Rosso	Ballroom A
	<i>Consumer Perspective on Risk</i> Alice Yaker	
	<i>Prediction and Modification of Genetic Risk: The Paradigm of BRCA1/2 Mutations</i> Timothy R. Rebbeck	
	<i>The Interaction of Genes and External Environmental Exposures in the Development of Breast Cancer</i> Christine B. Ambrosone	
	<i>New Opportunities for Chemoprevention of Breast Cancer</i> Michael B. Sporn	
9:50–11:00 a.m.	<b>KEYNOTE SESSION</b> Rosabeth Moss Kanter (Introduction by Frances M. Visco)	Ballroom A
11:00–11:15 a.m.	<b>Break</b>	

11:15 a.m.–12:45 p.m.

**PLENARY SESSION: Emerging Opportunities in Preventing Metastasis in Breast Cancer**

Ballroom A

Moderator: Vernal H. Branch

**A Systems Biology Standpoint**

Joe W. Gray

**Molecular Approaches to the Prevention of Metastasis**

Patricia S. Steeg

**Who's on First?**

Karin D. Noss

**Therapeutic Perspective on Metastasis in Breast Cancer**

George W. Sledge Jr.

12:45–2:00 p.m.

**Lunch**

2:00–4:00 p.m.

**CONCURRENT SYMPOSIA SESSIONS I****Symposium 1 - Mammary Gland Development and Its Dysregulation in Tumorigenesis** Room 201A*Co-Chairs: Irma H. Russo and Ann Fonfa***Axon Guidance Cues in Mammary Gland Development**

Lindsay Hinck

**Protein Convertases in Breast Development and Tumorigenesis**

Robert Shiu

**Singleminded-2 in Breast Cancer and Mammary Gland Development**

Weston Porter

**Developmental Stage-Specific Effects of c-MYC in the Mammary Epithelium**

Collin M. Blakely

**Telomerase Reactivation and Genomic Instability during Immortal Transformation of Cultured Human Mammary Epithelial Cells**

Martha Stampfer

**Cytoskeletal Control of Mammary Epithelial Morphogenesis and Tumorigenesis**

Celeste M. Nelson

**RELB/p52 NF-KAPPAB Complexes Promote Carcinogenesis of the Mammary Gland and Late Mouse Mammary Gland Development**

Elizabeth Demicco

**Symposium 2 - Hereditary Breast Cancer: Genetics, Counseling, and Disease Control** Room 201B*Co-Chairs: Graham Casey and Anne Grant***Educating Women about Risk Counseling/Genetic Testing Makes a Difference in Intended Use of Services, Especially among Those at High Risk: Results of a Randomized Trial of Callers to the Cancer Information Service**

Linda Fleisher

**Four Year Follow-Up of Outcomes Following Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers**

Noah D. Kauff

**Cancer-Specific Distress in African American Women at Increased Risk for Hereditary Breast Cancer**

Chanita Hughes

**Impact of Risk Factors and Genetic Polymorphisms in Metabolic Enzymes on Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers and Non-Mutation Carriers: A Population-Based Study**

Laufsey Tryggvadottir

**Inherited Susceptibility to Breast Cancer in Healthy Women: Mutations in Breast Cancer Genes, Immune Surveillance, and Psychological Distress**

Dana Bovbjerg

**Effect of Self-Hypnotic Relaxation on Pain and Anxiety Associated with Large Core Breast Biopsy**

Elvira V. Lang

2:00–4:00 p.m.

**CONCURRENT SYMPOSIA SESSIONS I (Continued)****Symposium 3 - Biological Markers of Risk: Finding Needles in a Haystack**

Room 201C

Co-Chairs: Anna H. Wu and Barbara Beckwith

**Changes in Insulin-Related Biomarkers during Pubertal Development among Girls in the Dietary Intervention Study in Children (DISC)**

Ellen Velie

**Human Leukocyte Antigen Genotype and Racial/Ethnic Differences in Breast Cancer: Preliminary Results for Class I**

Sally L. Glaser

**Estrogens, Genetic Polymorphisms and Breast Cancer Risk**

Michael Nkwor Okobia

**Detection and Identification of Biomarkers in Nipple Fluid by Mass Spectrometry**

Helena Chang

**Glucose Metabolism, Sex Steroids, Melatonin, and Risk of Breast Cancer**

Paola Muti

**Genetic Mapping of Low-Penetrance Modifier LOCI and Identification of Candidate Genes That Influence Susceptibility to Breast Cancer**

D. Joseph Jerry

**Nutritional and Genetic Determinants of Early Puberty**

Loic Le Marchand

**Symposium 4 - Optical Imaging Approaches for Breast Cancer Detection**

Room 204A

Co-Chairs: Daniel van der Weide and Peggy Devine

**Toward Optical Imaging of Small Tumors in Breasts Using Cumulant Forward Model and Independent Component Analysis**

Min Xu

**Near Infrared Fiber Optic Probe for Improving the Accuracy of Breast Core Needle Biopsy**

Carmalyn Lubawy

**In-Vivo Fluorescence Molecular Tomography of Mammary Adenocarcinomas in Transgenic Mice Bearing an Activated C-NEU Oncogene**

Stephen Windsor

**Quenchable Fluorescent Microbubbles for High Resolution Optical-Ultrasound Imaging Modality**

Omayra L. Padilla De Jesus

**Optical Biopsy for Real-Time Diagnosis, Staging and Prognostication in Breast Cancer**

Mohammed Keshtgar

**A New Approach to Early Detection for Women's Medicine**

Britton Chance

**Application of Near Infrared Spectroscopy to Detect Early Effects of Cancer Therapy**

Jae G. Kim

**Symposium 5 - Premalignancy**

Room 204B

Co-Chairs: Robert D. Cardiff and Mary Barker

**Insights from Mouse Models of DCIS**

Daniel Medina

**The Role of CXCL12 and CXCL14 Chemokines in Epithelial Stromal Cell Interactions during Breast Tumor Progression**

Kornelia Polyak

**Epigenetic and Genetic Changes Control Tumorigenic Phenotypes and Occur in Vivo in Human Mammary Epithelial**

Thea D. Tsly

**Investigation of Lobular Neoplasia, Using Molecular Genetic Techniques, for the Involvement of Novel Genes**

Teresa Mastracci

**Characterization of Mammary Epithelial Cell Populations by FACS and Real-Time Imaging**

Bryan Welm

**Cooperative Interactions during Human Mammary Epithelial Cell Immortalization**

Paul Yaswen

**Symposium 6 - The Estrogen Receptor Pathway: New Wine in Old Bottles**

Room 204C

Co-Chairs: Eva Surmacz and Bettye Green

**SRA, a New Kind of Molecule Functional Both at the RNA and the Protein Levels, Interferes with the Estrogen Receptor Signaling Pathway in Breast Cancer**

Etienne Leygue

**Dietary Genistein Negates the Inhibitory Effect of Letrozole on the Growth of Aromatase-Overexpressing Estrogen-Dependent Human Breast Cancer (MCF-7CA) Cells Implanted in Ovariectomized Athymic Mice**

Bill Helferich

**Screening of Compounds That Bind to the Estrogen Receptor Using a Quartz Crystal Microbalance Biosensor**

Linda A. Luck

**Resistance to Endocrine Therapy in Breast Cancer**

Robert Clarke

**Development of Designer Coactivators to Identify Novel Estrogen Related Receptor-Alpha Target Genes**

Stephanie Gaillard

**Contrasting Effect of Fulvestrant on Tamoxifen-Resistant Cells Depends on Estrogen Levels**

Maricarmen D. Planas-Silva

**The Role of Estrogen Receptor-BETA in Breast Cancer**

Leigh C. Murphy

4:00–4:15 p.m.

**Break**

4:15–6:15 p.m.

**CONCURRENT SYMPOSIA SESSIONS II****Symposium 7 - Identifying and Evaluating Interventions to Prevent Breast Cancer**

Room 201A

Co-Chairs: Kay Dickersin and Ivis Sampayo

**The Chemopreventive Effects of Celecoxib, Tamoxifen and Bexarotene in the Ovarian Hormone Dependent and Independent NEU-Induced Rat Breast Cancer Models**

Stephen Woditschka

**Breast Cancer Chemoprevention by Grape Seed Extract in Rats and Its Dependence on Diet Composition**

Helen Kim

**Prevention of Mammary Tumor Development by Intermittent Caloric Restriction. Importance of the Manner in Which Calories Are Consumed**

Margot P. Cleary

**Celecoxib Decreases PGE2 in Women with Breast Cancer But Not in At Risk Women**

Edward R. Sauter

**Aberrant Mammary Phenotype in GPX1 Null Mice**

Anna deFazio

**Modulation of Biomarkers of Growth and Differentiation in Breast Cancer by Soy Isoflavones**

Omer Kucuk

**A Model of COX-2 Mediated Bone Metastasis in Human Breast Cancer**

Anthony Lucci, Jr.

4:15–6:15 p.m.

**CONCURRENT SYMPOSIA SESSIONS II (Continued)****Symposium 8 - Biological Pathway Discovery and Targeted Interference**

Room 201B

*Co-Chairs: Mien-Chie Hung and Geri Blair***The Synthetic Lethal Trap: A General Approach for Screening Small-Molecule Protein Inhibitors Using Genetic Triangulation in the Yeast *Saccharomyces cerevisiae****David S. Bellows***Germline Transmission of RNA Interference in Mice***Michelle Carmell***Genome-Wide RNA Interference Screen for Novel E2F Regulators and Cancer Genes***Jianrong Lu***Proteomic Identification of Heat Shock Protein 90 (HSP90) as a Candidate Target for p53 Mutation Reactivation by PRIMA-1 in Breast Cancer Cells***Sayed Daoud***Functional Genomic Analysis of the Wingless/WNT Signaling Pathway***Ramanuj Dasgupta***Selection of Aptamers to BAX***David Andrews***A Novel Targeting Strategy for Mammary Adenocarcinoma - Nuclear Localization Peptide Discovery via Differential Phage Display***Todd Giorgio***Symposium 9 - Stem Cells: The Roots of Breast Cancer**

Room 201C

*Co-Chairs: Max S. Wicha and M. Carolina Hinestrosa***Detection of Putative Breast Cancer Tumor Stem and Progenitor Cells in Primary and Metastatic Lesions***Albert D. Donnenberg***Prospective Isolation of Cancer and Normal Murine Breast Stem Cells***Neethan Lobo***Normal Adult Breast Stem Cells as "Targets" for Breast Carcinogenesis: Implications for Chemoprevention and Chemotherapy***Chia-Cheng Chang***WNT/Beta-Catenin-Mediated Radiation Resistance of Mouse Mammary Stem-Like/Progenitor Cells***Mercy Chen***Towards the Identification of Stem Cells in a Novel Human Mammary Epithelial Culture (HMEC) System That Reproducibly Demonstrates Ductal Organotypic Architecture in 3 Weeks***Jean J. Latimer***Symposium 10 - Stromal Cell Modulation of Tumorigenesis and Progression**

Room 204A

*Co-Chairs: Robert G. Oshima and Sylvia Rickard***The Tumorigenic Potential of Reconstituted Tissues with Predefined Cellular Histology: A Model for Tumor Invasion***Izak Haviv***Gene Expression Profiling of Breast Cancer Stroma***Dennis C. Sgroi***Identification of Molecules Involved in the Regulatory Effect of Breast Fibroblasts on Epithelial Cell Growth***Andrea Sadlonova***Chronic Overexpression of Epimorphin/Syntaxin-2 in the Mouse Mammary Gland Leads to Mammary Adenocarcinoma and Lobular Hyperplasia***Jamie L. Bascom***Breast Myoepithelial Cells Are Natural Autocrine and Paracrine Suppressors of Breast Cancer Progression***Sanford H. Barsky*

**Analysis of Breast Cell-Lineage Response Differences to Taxol Using a Novel Co-Culture System**

Lauren Gollahon

**Recruitment of Circulating Bone Marrow-Derived Cells in Breast Cancer Pathogenesis**

Piyush B. Gupta

**Symposium 11 - Benign Breast Disease and Breast Cancer Risk Center of Excellence Discussion**

Room 204B

Co-Chairs: Robert D. Cardiff and Nancy Ryan

**Benign Breast Disease: Evidence for Precursor Lesions**

Lynn C. Hartmann

**Statistical Methods to Assess the Timing and Side of Breast Cancer Relative to Benign Breast Biopsies: Implications for Potential Precursor Lesions**

V. Shane Pankratz

**Multifocal Atypia Confers Increased Risk of Breast Cancer**

Amy C. Degnim

**Temporal Changes in Benign Breast Disease 1967 to 1991**

Karthik Ghosh

**Symposium 12 - Regulation of the Estrogen Receptor Complex**

Room 204C

Co-Chairs: Richard J. Pietras and Christine K. Norton

**FKHR as a Corepressor of the Estrogen Receptor Signaling in Breast Cancer**

Lanfang Qin

**Scaffold Attachment Factor B1 (SAFB1) Suppresses ER Alpha-Mediated Transcription in Part via Interaction with N-COR**

Shiming Jiang

**Regulation of the Estrogen Receptor Alpha by a Scaffold Attachment B-1/ Ret Finger Protein Complex**

Steven M. Townsend

**Modulation of Human Estrogen Receptor Alpha Function by BRCA1**

Thomas G. Boyer

**Constitutive Versus Inducible Estrogen Receptor Activity: Distinct Mechanisms of Activation and Altered Target Gene Expression**

Amy M. Fowler

**Regulation of Estrogen-Related Receptor Alpha's Transcriptional Activities via the Epidermal Growth Factor Receptor (EGFR) and ERBB2 Signaling Pathways**

Janet E. Mertz

**Symposium 13 - Factors Contributing to Risk and Progression**

Room 203A/B

Co-Chairs: Robert Clarke and Kathleen Harris

**A Novel Functional Screen for Mutator Genes in Breast Cancer**

Piri L. Welcsh

**Breast Cancer Predictive Molecular Markers**

Indira Poola

**Transgenic Overexpression of IGF-IR Is Sufficient to Induce Mammary Epithelial Hyperplasia and Tumor Formation**

Roger Moorehead

**Studies of Farnesylthiosalicylic Acid (FTS), an Antagonist of Growth Factor Signaling Pathways, in Breast Cancer**

Richard J. Santen

**Development of Animal Models to Study How Timing of Surgery during the Menstrual Cycle May Affect Breast Cancer Metastasis and Survival**

Ann F. Chambers

4:15–6:15 p.m.

**CONCURRENT SYMPOSIA SESSIONS II Symposium 13 (Continued)**

**Transformation in Breast Ductal Carcinomas Requires Protein Synthesis and Is Mediated by Elevated Levels of the Initiation Factor EIF4G**

Robert J. Schneider

**Tumor-Secreted Phosphoglucose Isomerase/Autocrine Motility Factor: Causal Role in a Mouse Model of Cachexia**

John M. Chirgwin

**A Declining Plasma Fibrinogen Alpha Fragment Identifies HER2 Positive Breast Cancer Patients and Reverts to Normal Levels Post-Surgery**

Qian Shi

6:15–6:30 p.m.

**Break**

6:30–8:30 p.m.

**POSTER SESSION/RECEPTION**

P1 Oncogenes	P10 Invasion and Metastasis I
P2 Signal Transduction I	P11 Tumor Progression
P3 Mammary Gland Development	P12 Tumor Immunology
P4 DNA Damage and Repair	P13 Biomarkers I
P5 Transcription, Translation, and Modification	P14 Computer-Aided Diagnostics
P6 Genomics and Proteomics	P15 Nuclear Medicine Imaging
P7 Hormone Receptors I	P16 Drug Design and Development I
P8 Endocrine Carcinogenesis	P17 Radiotherapy
P9 Angiogenesis	P18 Hormonal Therapy

**Exhibit Hall A**

P19 Antiangiogenics
P20 Symptom Management
P21 Evolving Therapeutic Targets
P22 Complementary Health and Alternative Medicine
P23 Behavioral Sciences and Decision Making
P24 Environmental Epidemiology

**Friday, June 10, 2005**7:00 a.m. **Registration Opens**

Grand Hall

7:00–8:00 a.m.

**EARLY MORNING SESSIONS****Molecular Imaging**

James P. Basilion (Introduction by Anne Grant)

Room 201A

**Tumor Microenvironment**

Lynn M. Matrisian (Introduction by Wish Martin)

Room 201B

**Functional Proteomics for Biomarker and Target Discovery**

Joshua LaBaer (Introduction by Liz Lostumbo)

Room 201C

**Cell Lines: Refined Characterization Using Genomic Technology**

Paul S. Meltzer (Introduction by Christine K. Norton)

Room 204A

**Breast Cancer Nanotechnologies**

Mauro Ferrari (Introduction by Linda Vincent)

Room 204B

8:00–8:10 a.m.

**WELCOME AND MOMENT OF SILENCE**

Ballroom A

Ngina Lythcott

8:10–10:10 a.m.

**PLENARY SESSION: Genetic Profiling and Studies of Gene Expression**

Ballroom A

Moderator: Michele Rakoff

**Consumer Perspective**

Joy Simha

**Molecular Imaging Using Animal Models as Examples**

Juri G. Gelovani

**Global Genetics Screening and Gene Expression for Diagnosis Purposes**

Michael H. Wigler

**How a Predictive Marker Might Drive Decision about Who Gets Treatment, i.e., EGFR Story**

William R. Sellers

**Influence of Gene Expression in DCIS Models and New Trial Development**

Nigel Bundred

## *Agenda*

June 10, 2005

<p><b>10:10–10:25 a.m.</b></p> <p><b>10:25–11:55 p.m.</b></p> <p><b>11:55 a.m.–12:05 p.m.</b></p> <p><b>12:05–2:05 p.m.</b></p> <p><b>2:05–2:15 p.m.</b></p> <p><b>2:15–4:45 p.m.</b></p> <p><b>4:45–5:00 p.m.</b></p> <p><b>5:00–6:30 p.m.</b></p>	<p><b>Break</b></p> <p><b>INNOVATOR SESSION</b></p> <p>Moderators: Lynn M. Matrisian and Frances M. Visco Gregory J. Hannon Junying Yuan Gerald J. Diebold Stephen J. Elledge</p> <p><b>Break</b></p> <p><b>POSTER SESSION/LUNCH</b></p> <p>P25 <i>BRCA2 Tumor Suppressor</i> P26 <i>EGF Superfamily I</i> P27 <i>p53</i> P28 <i>TGF-β</i> P29 <i>Cell Cycle</i> P30 <i>Tumor Suppressor Genes I</i> P31 <i>Signal Transduction II</i> P32 <i>Functional Study of Biological Molecules I</i> P33 <i>Tyrosine Kinase Signaling</i> P34 <i>Hormone Metabolism</i> P35 <i>Hormone Receptors II</i></p> <p>P36 <i>Mechanism of Hormone Action</i> P37 <i>Chemical/Physical Carcinogenesis</i> P38 <i>Invasion and Metastasis II</i> P39 <i>Regulation of the Immune Response</i> P40 <i>Biomarkers II</i> P41 <i>Digital Imaging</i> P42 <i>X-Ray Imaging</i> P43 <i>Drug Design and Development II</i></p> <p><b>PLenary Session: Emerging Issues Regarding the Diagnostic Utility of Gene Expression Profiles in Breast Cancer</b></p> <p>Moderator: Ngina Lythcott</p> <p><b>Consumer Perspective</b></p> <p>Helen Schiff</p> <p><b>Molecular Profiling Guides Treatment of Breast Cancer</b></p> <p>Laura van't Veer</p> <p><b>A 21 Gene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer</b></p> <p>Steven Shak</p> <p><b>Stratification of Human Breast Cancer by mRNA Expression Profiling</b></p> <p>Cindy A. Wilson</p> <p><b>Gene Expression Markers Are “Continuous or Quantitative Variables”</b></p> <p>Gottfried E. Konecnny</p> <p><b>An Epidemiologist Perspective: Rules of Evidence for Cancer Molecular-Marker Discovery</b></p> <p>David F. Ransohoff</p> <p><b>Break</b></p> <p><b>CONCURRENT SYMPOSIA SESSIONS III</b></p> <p><b>Symposium 14 - Estrogen as an Initiator of Breast Cancer</b></p> <p>Co-Chairs: Ercole L. Cavalieri and Nancy Ryan</p> <p><b>A Family-Based Genetic Association Study of Breast Cancer Risk in Relation to Variants in Estrogen Biosynthesis and Metabolism Genes</b></p> <p>Yu Chen</p> <p><b>A Model of Estrogen Induced Human Breast Carcinogenesis</b></p> <p>Sandra V. Fernandez</p> <p><b>Evidence That EMCA1 Is a Genetic Determinant of E2-Induced Mammary Tumor Incidence and Tumor Multiplicity in the ACI Rat</b></p> <p>Beverly S. Schaffer</p> <p><b>Central Leptin Gene Therapy to Reduce Breast Cancer Risk Factors</b></p> <p>Urszula T. Iwaniec</p>	<p><b>Ballroom A</b></p> <p><b>Exhibit Hall A</b></p> <p>P44 <i>Targeted Therapies I</i> P45 <i>Vaccines and Immunotherapies</i> P46 <i>Gene Therapy</i> P47 <i>Photodynamic Therapy</i> P48 <i>Clinical and Surgical Management of Breast Cancer</i> P49 <i>Genetic Epidemiology</i> P50 <i>Breast Cancer Centers of Excellence</i></p> <p><b>Ballroom A</b></p> <p><b>Room 201A</b></p>
---	---	---

5:00–6:30 p.m.

**CONCURRENT SYMPOSIA SESSIONS III Symposium 14 (Continued)****Defining the Molecular Actions of Lenoleic Acid in Breast Cancer: Modulation of Peroxisome Proliferator-Activated Receptor Gamma**

Clinton D. Allred

**Symposium 15 - Relationship between Biomarkers and Breast Cancer Pathology I**

Room 201B

Co-Chairs: Saraswati Sukumar and Carolyn Tapp

**Small Integrin Binding Ligand N-Linked Glycoprotein (Sibling) Gene Family Expression in Breast Cancer**

Alka Jain

**Inflammatory Breast Cancer Biobank and Clinical Database**

Ginny Mason

**The Role of Calgranulins in Breast Cancer Progression**

John Pink

**Linking Transcriptional Elongation and mRNA Export to Metastatic Breast Cancers**

Andrew K. Godwin

**Eukaryotic Initiation Factor 4E Elevation Increases Risk for Cancer Recurrence and Death in Node-Negative Breast Cancer Patients**

Benjamin Li

**Symposium 16 - DNA Damage and Repair I**

Room 201C

Co-Chairs: David I. Smith and Marlene McCarthy

**The Function of ATM in Mammary Tumorigenesis**

Y. Alan Wang

**BRCA2 Is a Component of the Centrosome**

Fergus J. Couch

**BRCA1-Dependent Ubiquitination of Gamma-Tubulin Regulates Centrosome Number and Function**

Lea Starita

**Molecular Genetic Study of Aurora-A Kinase: From Centrosome to Mitotic Spindle**

Jian Du

**Symposium 17 - Endocrine-Derived Therapies**

Room 204A

Co-Chairs: John R. Mackey and Michele Rakoff

**SXR – A Novel Target for Breast Cancer Prevention and Treatment**

Michelle M. Tabb

**Restoration of Tamoxifen Sensitivity in Breast Cancer Cells. Reactivated Tamoxifen-Complexed Estrogen Receptor Recruits Distinct Chromatin-Modifying Complexes**

Dipali Sharma

**Limiting Effects of RIP140 in Estrogen Signaling: Potential Mediation of Anti-Estrogenic Effects of Retinoic Acid**

Kelly C. Heim

**Anticarcinogenic Activities of Retinoic Acid through Its Nuclear Receptor and Binding Protein**

Leslie Willmert

**Vitamin D Signaling in Breast Cancer: Genomic and Non-Genomic Mechanisms**

Meggan E. Valrance

**Symposium 18 - Epithelial to Mesenchymal Transition: When Good Cells Go Bad**

Room 204B

Co-Chairs: Arthur M. Mercurio and Mary Elliott

**Cellular Plasticity of Epithelial Cells—Cause of Metastasis?**

Liangfeng Han

**Are Mammary-Stromal Vascular Cells True Endothelial Progenitors?**

Margot M. Ip

**Mechanism of Recurrence of Neu-Induced Mammary Tumors**

Denise Perez

**The Developmental Gene Goosecoid Promotes Breast Cancer Metastasis**

Kimberly Hartwell

**Visualization of Epithelial-Mesenchymal Transition in Mammary Carcinogenesis**

Alain de Bruin

6:30–6:45 p.m. **Break****CONCURRENT SYMPOSIA SESSIONS IV****Symposium 19 - Estrogen-Mediated Carcinogenesis Center of Excellence Discussion**

Room 201A

Co-Chairs: Paola Muti and Mary Justice

**The Etiology of Breast Cancer. Prevention Is Now the Solution**

Ercole L. Cavalieri

**Development of Breast Cancer in the ERKO/Wnt-1 Model**

Richard J. Santen

**Estrogen and Its Metabolites 4 Hydroxy Estradiol and 2 Hydroxy Estradiol Induce Mutations in Human Breast Epithelial Cells**

Jose Russo

**Effects of Estradiol, 4-Hydroxyestradiol and Estradiol 2,3 and 3,4 Quinones on Mutagenesis in Vivo and in Vitro**

Joseph Guttenplan

**Symposium 20 - Global Molecular Approaches to Identify Specific Biomarkers of**

Room 201B

**Breast Cancer Detection and Prognosis**

Co-Chairs: Joshua LaBaer and Jane Perlmutter

**Whole Genome Amplification Technologies for Screening Cancer Biomarkers in Fresh or Paraffin Tissue Samples and in Bodily Fluids in Breast Cancer**

G. Mike Makrigiorgos

**Discovery of a Novel Two-Gene Expression Ratio That Predicts Clinical Outcome in Breast Cancer Patients Treated with Tamoxifen**

Dennis C. Sgroi

**Methylated Genes as Early Detection Markers for Breast Cancer**

Saraswati Sukumar

**Circulating Tumor Marker Discovery Using Proteolytic Peptide Profiling**

Francisco J. Esteva

**Identification of Breast Cancer Biomarkers in Nipple Aspirate Fluid Using Proteomic Analysis**

Edward R. Sauter

**Molecular Differentiation of Breast Carcinoma in Situ**

Maria J. Worsham

**An Innovative Microarray Strategy for Identification of Breast Cancer-Associated Genes**

Michael Mitas

**Symposium 21 - Non-Hereditary Factors Contributing to Breast Cancer Risk**

Room 201C

**and Outcomes**

Co-Chairs: Marilie D. Gammon and Vicki Tsohier

**Excessive Weight Gain during Mimicked Pregnancy Increases Mammary Tumorigenesis in Zucker Rats**

Sonia de Assis

**Clustering of Cases by Early Life Residence: Evidence for Early Life Environmental Exposures in the Etiology of Breast Cancer?**

Daikwon Han

**Placental Weight, Birth Weight and Risk of Breast Cancer after Giving Birth: A Population-Based Swedish Cohort Study**

Sven Cnattingius

**Acrylamide Intake and Breast Cancer Risk in a Large, Prospective Study among Swedish Women**

Lorelei Mucci

**Modifiable Risk Factors for Breast Cancer in a Multiethnic Population**

Esther M. John

6:45–8:45 p.m.

**CONCURRENT SYMPOSIA SESSIONS IV Symposium 21 (Continued)*****Perinatal Factors and Mortality from Breast Cancer***

Maureen Sanderson

***Early Life Factors and Breast Cancer Risk***

Mary Beth Terry

**Symposium 22 - *Inflammation, Immunomodulation, and Cellular Therapy***

Room 204A

Co-Chairs: H. Kim Lyerly and Wish Martin

***Homeostatic T-Cell Expansion to Induce Anti-Tumor Autoimmunity in Breast Cancer***

Roberto Baccala

***Inhibition of Breast Tumor Growth in the Neu-Transgenic Mouse Following Depletion of Regulatory T Cells with an Interleukin-2 Immunotoxin***

Keith Knutson

***The Endogenous Danger Signaling Molecule, Uric Acid, Converts Immunity from Non-Protective to Protective When Used as a Vaccine Adjuvant***

Keith Knutson

***Toll-Like Receptor 9 Agonists Induce Invasion of Breast Cancer Cells in Vitro***

Katri Selander

***Increased Anti-Tumor Responses Using the Proteasome Inhibitor, Bortezomib, with Human NK Cells in Breast Carcinoma***

William J. Murphy

***Vaccine for Epithelial Neoplasms***

Albert Deisseroth

***Adoptive Immunotherapy of Breast Tumor Using Effector Lymphocytes Redirected with Anti-HER2/Neu Specificity***

Zelig Eshhar

**Symposium 23 - *Site-Specific Metastasis: Tumors in Search of a Home***

Room 204B

Co-Chairs: Patricia S. Steeg and Liz Lostumbo

***Cancer Metastasis Homing Genes***

Anton Wellstein

***Cytokines and Growth Factors Involved in Host-Tumor Interactions in Breast Cancer******Bone Metastasis***

Janet E. Price

***FC-OPG Inhibits Osteoclast Activity, While Tumor-Derived OPG Enhances Tumor Growth***

Matthew T. Gillespie

***Trafficking of Breast Cancer Metastatic Cells in Bone***

Robyn Mercer

***Genes That Mark and Mediate Breast Cancer Metastasis to Lung***

Gaorav Gupta

***RT-PCR Detects Clinically Significant Nodal Metastases in Patients Enrolled in Multicenter Sentinel Node Trial***

Kathryn M. Verbanac

***A Novel Rat Model of Sporadic, Blood-Borne, Visualizable Micro-Metastases of Mammary Carcinoma in the Brain***

Lois A. Lampson

***Antiproteolytic Therapy Targeting Urokinase-Plasminogen Activator for the Treatment of Breast Cancer – A Phase I Study***

Olaf G. Wilhelm

**Symposium 24 - Causes and Impact of Adverse Outcomes**

Co-Chairs: Sandra A. Norman and Kay Wissmann

Room 204C

**Oxidative Stress, DNA Repair, and Acute Side Effects of Radiotherapy in Breast Cancer Proteins**

Christine B. Ambrosone

**ATM Mutations and the Development of Severe Radiation-Induced Morbidity Following Radiotherapy for Breast Cancer**

Barry Rosenstein

**Treatment Related Cardiac Toxicity in Patients Treated for Breast Cancer**

Robert Prosnitz

**The Use of Exercise to Increase Lymphocyte Activation Following Chemotherapy for Breast Cancer**

Andrea M. Mastro

**Incidence, Time Course, and Determinants of Menstrual Bleeding after Breast Cancer Treatment. A Prospective Study**

Michelle Naughton

**Risk Factors for Lymphedema in Breast Cancer Survivors**

Mary Anne Rossing

**The Effects of Low to Moderate Intensity Exercise on Fatigue in Breast Cancer Patients Following Clinical Treatment**

Katherine Kemble

**Symposium 25 - Diagnostic Molecular Imaging: MR and Nuclear Applications for Improving Breast Cancer Detection**

Room 203A/B

Co-Chairs: James P. Basilion and Sandra Walsh

**XE-129 MRI Biosensors for Multiplexed Imaging of Breast Cancer Markers**

P. Aru Hill

**Breast Cancer Gene Therapy: Development of Novel Non-Invasive Magnetic Resonance Assay to Optimize Efficacy**

Ralph P. Mason

**Application of Dynamic Contrast Enhanced Magnetic Resonance (MR) Imaging in Combination with Lactate-Specific MR Spectroscopy in the Assessment of Breast Tumor Angiogenesis**

Manickam Muruganandham

**Molecularly Targeted Agents for Improved Breast Cancer Detection**

Darryl Bornhop

**TC-99M Labeled and VIP-Receptor Targeted Liposomes for Effective Imaging of Breast Cancer**

Hayat Onyuksel

**Detection of Breast Cancer Cells by Fluorescence Imaging of Tumor Marker Gene Expression Using Molecular Beacons**

Lily Yang

**Preclinical Pharmacology and Toxicology of Indium-111 Labeled Fab Fragments of Trastuzumab (Herceptin)**

Raymond M. Reilly

8:45 p.m. RECEPTION/PARTY AT THE PHILADELPHIA MARRIOTT HOTEL

Marriott Hotel Salons A-F

**Saturday, June 11, 2005**

7:00 a.m.	<b>Registration Opens</b>	Grand Hall
7:00–8:00 a.m.	<b>EARLY MORNING SESSIONS</b>	
	<b><i>Gene Expression Profiles as Prognostic and Predictive Marker</i></b>	Room 201A
	Soonmyung Paik (Introduction by Christine K. Norton)	
	<b><i>Clinical Trial Design in the Era of Targeted Therapy</i></b>	Room 201B
	Lindsay N. Harris (Introduction by Marlene McCarthy)	
	<b><i>Tissue Architecture and Pathology</i></b>	Room 201C
	Valerie M. Weaver (Introduction by Susan Moreno)	
	<b><i>New Vascular and Tumor Drug Targets: Discovery, Validation, and Path Forward</i></b>	Room 204A
	Beverly Teicher (Introduction by Vernal H. Branch)	
	<b><i>What Is Happening with Vaccines?</i></b>	Room 204B
	H. Kim Lyerly (Introduction by Sandra Walsh)	
8:00–8:10 a.m.	<b>WELCOME AND MOMENT OF SILENCE</b>	Ballroom A
	M. Carolina Hinestrosa	
8:10–10:30 a.m.	<b>PLENARY SESSION: Bridges to the Future: Understanding the Treatment of Primary and Metastatic Disease</b>	Ballroom A
	Moderator: Carol Matyka	
	<b><i>Integration of Biologic Agents Into the Treatment of Breast Cancer: Recent Results and Future Challenges</i></b>	
	Mark D. Pegram	
	<b><i>Genetic Approaches to Target Discovery and Validation</i></b>	
	Gregory Hannon	
	<b><i>Mouse Models for Preclinical Trials</i></b>	
	Robert D. Cardiff	
	<b><i>Clinical Validation of Diagnostics and Functional Imaging</i></b>	
	Pamela M. Klein	
	<b><i>Non-Drug Interventions: Diet and Exercise</i></b>	
	Wendy Demark-Wahnefried	
	<b><i>Consumer Perspective</i></b>	
	Carol Matyka	
10:30–10:45 a.m.	<b>Break</b>	
10:45 a.m.–12:15 p.m.	<b>INNOVATOR SESSION</b>	Ballroom A
	Moderators: Lynn M. Matisian and Frances M. Visco	
	Mina J. Bissell	M. Judah Folkman
	Erkki Ruoslahti	Naomi J. Halas
12:15–1:15 p.m.	<b>Lunch</b>	
1:15–2:45 p.m.	<b>PLENARY SESSION: Emerging Issues in Clinical Approaches</b>	Ballroom A
	Moderator: M. Carolina Hinestrosa	
	James H. Doroshow	Richard Pazdur
	Donald A. Berry	Rosemary Rosso
2:45–3:00 p.m.	<b>Break</b>	

3:00–5:00 p.m.

**CONCURRENT SYMPOSIA SESSIONS V****Symposium 26 - *The Business of Life and Death: Apoptosis Induction and Telomerase***

Room 201A

*Co-Chairs: Bingliang Fang and Christine Carpenter***A Small Molecule SMAC Mimic Sensitizes TRAIL- and Etoposide-Induced Apoptosis in Breast Cancer Cells***Katrina Bockbrader***Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) Induces Caspase-Dependent Apoptosis through the Newly Identified IGFBP-3 Receptor in Human Breast Cancer Cells***Youngman Oh***Identification of the Types, Properties, and Functional Characteristics of Telomerase Expressing Cells in Breast Cancer***William C. Hines***Role of GRIM19 and STAT3 in Vitamin D3 Mediated Apoptosis in MCF-7 Breast Cancer Cells***Belinda Byrne***Telomerase Vaccination of Metastatic Breast Cancer Patients Induces Antigen-Specific Tumor Infiltrating Lymphocytes and Tumor Necrosis***Susan M. Domchek***Combined Treatment with Epidermal Growth Factor Receptor and Cyclooxygenase-2 Inhibitors Synergistically Inhibit Cell Growth and Induce Apoptosis in HER-2/NEU Overexpressing Breast Cancer Cells***Susan Lanza-Jacoby***Cellular Senescence, Aging and Breast Cancer***Jean-Philippe Coppe***Symposium 27 - *Therapeutic Vaccines: Bench to Bedside***

Room 201B

*Co-Chairs: Lupe G. Salazar and Debbie Laxague***Development of a Breast Cancer Vaccine***Sandra J. Gendler***A MUC1-Based Plant Engineered Vaccine for Breast Cancer***Julia Pinkhasov***A Minigene Vaccine against VEGF Receptor-2 Suppresses Growth of Metastatic Breast Cancer***Rong Xiang***Control of Tumor Growth in Normal and Transgenic Mice by Listeria Monocytogenes Based Vaccines for Her-2/neu and the Identification of Regions of Her-2/neu with Potential CD8+ T Cell Epitopes***Reshma Singh***Immunity to Breast Cancer in Mice Immunized with Fibroblasts Transfected with a cDNA Expression Library from Breast Cancer Cells. A New Vaccination Strategy***Edward P. Cohen***Fusions of Dendritic Cells (DC) and Breast Carcinoma Demonstrate an Activated Phenotype and Potently Stimulate Anti-Tumor Responses***Donald W. Kufe***Novel MHC Class II Breast Cancer Vaccine Using RNA Interference (RNAI) to Down Regulate Invariant Chain***James Andrew Thompson***Symposium 28 - *Arresting Cancer Proliferation through Early Detection and Anti-Angiogenic Therapies***

Room 201C

*Co-Chairs: M. Judah Folkman and Mildred Leigh-Gold***LOIS – Novel Imaging Modality for Early Diagnosis of Breast Cancer in Situ***Alexander Oraevsky***Molecular and Functional MRI of Breast Cancer***Hadassa Degani*

6:45–8:45 p.m.

**CONCURRENT SYMPOSIA SESSIONS V Symposium 28 (Continued)*****Imaging Tumor Angiogenesis Using Optical Tomography with Ultrasound Guidance****Quing Zhu****Phase I Combined Biological Therapy of Breast Cancer Using Two Humanized Monoclonal Antibodies Directed against Her2 Proto-Oncogene and Vascular Endothelial Growth Factor (VEGF)****Mark D. Pegram****Anti-Angiogenic and Vascular Targeting Therapy of Breast Cancer by Targeting Endoglin (CD105) of Tumor Vasculature****Ben K. Seon****Molecular-Targeted Antitumor Agents. Two New Classes of Small Molecules That Potently Inhibit Hypoxia-Inducible Factor-1 Activation in Breast Tumor Cells****Dale G. Nagle***Symposium 29 - *The How and Why of Metastasis***

Room 204A

*Co-Chairs: Danny R. Welch and Ruth Eldredge****Curcumin Suppresses Metastasis in a Human Breast Cancer Xenograft Model: Association with Suppression of Nuclear Factor-KAPPAB, Cyclooxygenase-2 and Matrix Metalloproteinase****Bharat B. Aggarwal****Identification and Characterization of Novel Genes That Induce Migration and Invasion of Mammary Epithelial Cells****Ruwanthi Gunawardane****Linear Polymeric Contrast Agents for Distinguishing Metastatic from Non-Metastatic Tumors****Egidijus Uzgiris****Enhancement of DC-Based Immunotherapy Using a Small Molecule TGF-Beta Inhibitor****Emmanuel Akporiaye****Carbohydrate-Dependent Breast Cancer Metastasis****Michiko N. Fukuda****Genetic Alterations in Tumor Epithelium and Host Endothelium Associated with Metastatic Progression in a Murine Model of Breast Cancer Metastasis****Belinda S. Parker****A Radiologic-Pathologic Method to Quantify Response to Neoadjuvant Chemotherapy******Predicts Time to Distant Recurrence****W. Fraser Symmans***Symposium 30 - *Resistance to HER2 Targeted Therapies***

Room 204B

*Co-Chairs: Mark Sliwkowski and Gail Frankel****PTEN Activation Contributes to Tumor Inhibition by Trastuzumab and Loss of PTEN Predicts Trastuzumab Resistance in Patients****Dihua Yu****Synergistic Inhibitory Effect of Rapamycin and Herceptin on Growth and Tumorigenicity of ERBB2 Over-Expressing Breast Cancer Cells****Lu-Hai Wang****Transcriptional Regulation of the ERBB2 Proto-Oncogene in Breast Cancer****Rachelle Dillon****The Scaffolding Adapter GAB2 Is Critical for HER2/NEU Induced Carcinogenesis and Is Required for PYMT Antigen Induced Metastasis****Mohamed Bentires-Alj****PC-Cell Derived Growth Factor (PCDG/GP88) Stimulates Growth and Confers Herceptin Resistance in ERBB2-Overexpressing Breast Cancer Cells****Wes E. Kim****Association of Topoisomerase II-Alpha (TOP2A) Gene Amplification with Responsiveness to Anthracycline-Containing Chemotherapy among Women with Metastatic Breast Cancer Entered in the Herceptin H0648G Pivotal Clinical Trial****Michael F. Press*

**Constructing Predictive Profiles for Herceptin-Containing Therapy in HER2 Positive Early Stage Breast Cancer Using RNA Microarray**

*Lyndsay Harris*

---

**Symposium 31 - People and Populations**

*Co-Chairs: Suzanne Miller and Maryellen Delapine*

**Room 204C**

**The Wait for Diagnosis Is Associated with Increased Stress in Women after Large Core Breast Biopsy**

*Elvira V. Lang*

**Obese and Upper Body Fat Phenotype Postmenopausal African-American Women Have a Sex Hormonal Profile Associated with Increased Risk of Breast Cancer**

*Junaiddah B. Barnett*

**Can Medicare Claims Be Used to Assess Mammography Usage?**

*Christopher Quale*

**Screening Mammography in the American Elderly**

*Christopher Quale*

**Delays and Refusals in Treatment of Breast Cancer among New Mexico Women**

*Elba L. Saavedra*

**Challenges of Living with Breast Cancer in the Family: Special Issues Confronting Adult Daughter Caregivers**

*Victoria H. Raveis*

**Impact of Culture on Breast Cancer Screening in Chinese American Women**

*Judy Wang*

---

**Symposium 32 - Readily Acceptable Approaches to Improving Clinical Detection of Breast Cancer**

**Room 203A/B**

*Co-Chairs: Gerald J. Diebold and Marlene McCarthy*

**Clinically Practical Magnetic Resonance Imaging/Spectroscopy Protocol for Improved Specificity in Breast Cancer Diagnosis**

*Luminita Alina Tudorica*

**Using Bold and GD-DTPA Contrast Enhanced MRI for Early Evaluation of Breast Cancer Chemotherapy**

*Lan Jiang*

**Stereomammography for Improvement of Breast Cancer Detection**

*Heang-Ping Chan*

**Interval Change Analysis of Corresponding Clustered Microcalcifications on Serial Mammograms Based on Automated Regional Registration**

*Lubomir Hadjiiski*

**Physician Predictors of Mammographic Accuracy**

*Philip Chu*

**Proton MR Spectroscopy Using Choline Signal as Malignancy Marker Improves Positive Predictive Value Compared to Conventional MRI in Diagnosis of Breast Cancer: A Preliminary Study**

*Lia Bartella*

**Time-Series Analysis of Human Interpretation Data in Mammography**

*Craig A. Beam*

5:00–5:15 p.m. **Break**

5:15–6:45 p.m.

**CONCURRENT SYMPOSIA SESSIONS VI****Symposium 33 - Relationship between Biomarkers and Breast Cancer Pathology II***Co-Chairs: Dennis C. Sgroi and Patricia Haugen***Room 201A****Human Tissue Kallikreins as Biomarkers for Breast, Ovarian, and Other Malignancies**  
Eleftherios Diamondis**Novel Image Analysis to Link Sub-Nuclear Distribution of Proteins with Cell Phenotype in Breast Neoplasia**

David W. Knowles

**Cancer Specific Proliferating Cell Nuclear Antigen as a Novel Diagnostic Marker for the Detection of Breast Cancer**

Derek Hoelz

**Sandwich Test ELISA with SCFV Antibodies: An Alternative to an All-Time Favorite**

Nathalie Scholler

**Symposium 34 - Antibodies: Innate versus Engineered****Room 201B***Co-Chairs: Louis M. Weiner and Linda Vincent***Circulating Autoantibodies for Early Detection of Breast Cancer**

Jean Latimer

**Treatment of Breast Cancer with Antibodies against Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Death Receptors in Combination with Chemotherapy**

Donald Buchsbaum

**Inhibition of Breast Cancer Metastasis with Ligand Mimetic Antibodies from Cancer Patients**

Brunhilde Felding-Habermann

**Antibody-NKG2D Ligand (RAE-1BETA) Fusion Protein for Breast Cancer Therapy**

Seung-Uon Shin

**Cloning, Expression, and in Vitro Activity of a Pair of Truncated Bi-Specific Antibodies Targeting C1q to HER2**

Xiaofeng Yang

**Symposium 35 - Biological Function of High Risk Genes****Room 201C***Co-Chairs: Andrew K. Godwin and Mary Jo Vazquez***Effects of Estrogen, Pregnancy, and Therapeutic Drugs on Mammary Tumor Formation in BRCA1-Conditional Mutant Mice**

Chuxia Deng

**Genome Wide Analysis of Allelic Imbalance in Tumor Epithelium and Stroma in BRCA1- and BRCA2-Related Breast Cancers**

Frank Weber

**BRCA1-Deficient Mammary Tumors Have Distinct Tumorigenesis Processes and Chemotherapy Response**

Christopher R. Smith

**BRCA1 Interacts with Highly Conserved Components of the Transcription Elongator Complex**  
Craig B. Bennett**BRCA1 Directly Modulates Gene Expression Required for Estrogen Biosynthesis: A Possible Mechanism of Tissue-Specific Tumor Suppression**

Yanfen Hu

**Symposium 36 - DNA Damage and Repair II****Room 204A***Co-Chairs: Zhenkun Lou and Karin D. Noss***Investigating the Genetic Interaction of the Homologous Recombination Proteins: RAD51, BRCA2, and BLM**

Teresa Marple

**Involvement of Human MOF In ATM Function**

Girdhar G. Sharma

**Involvement of the FHIT Gene in the Ionizing Radiation-Activated ATR/CHK1 Pathway**  
Ya Wang

**Distinct in Vivo Kinetics of DNA Double-Strand Break Repair Factor Responses to Laser-Induced DNA Damage**  
Kyoko Yokomori

---

**Symposium 37 - Identifying and Targeting Biological Mechanisms of Angiogenesis**

**Room 204B**

*Co-Chairs: Kathy D. Miller and Susan Moreno*

**T-Cadherin Supports Mouse Mammary Tumor Growth through an Angiogenic Mechanism**  
Barbara Ranscht

**Pericyte Support of Breast Cancer Cells**  
Peter V. Hauschka

**Screening and Characterization of Peptides Specifically Targeting Breast Cancer**  
Lianglin Zhang

**A Critical Role of EphA2 Receptor Tyrosine Kinase in Breast Tumor Angiogenesis and Metastasis**  
Jin Chen

**Targeting The Mammary Tumor Vasculature Using the TVA-RCAS System**  
Virginie Vervoort

---

**Symposium 38 - Behavioral Centers of Excellence: Treating More Than the Tumor**

**Room 204C**

*Co-Chairs: Leslie Bernstein and Christine K. Norton*

**Predictors of Depression in Younger Women with Breast Cancer during the First Two Years Post-Diagnosis**  
Stephanie R. Walsh

**Tailored Communication to Enhance Adaptation across the Breast Cancer Spectrum**  
Suzanne M. Miller

**Arm and Hand Swelling among Young Breast Cancer Survivors One to Three Years Post-Surgery**  
Electra D. Paskett

**Predictors of Sexual Arousal and Satisfaction among Young Breast Cancer Survivors One Year Post-Surgery**  
Maria J. MacRae

6:45–7:00 p.m.

**Break**

7:00–9:00 p.m.

**POSTER SESSION/RECEPTION**

P51 BRCA1 Tumor Suppressor  
P52 EGF Superfamily II  
P53 Growth Factors/Cytokines  
P54 Tumor Suppressor Genes II  
P55 Functional Study of Biological Molecules II  
P56 Genomic Instability  
P57 Familial and Hereditary Carcinogenesis

P58 Apoptosis  
P59 Stromal-Epithelial Interactions  
P60 Invasion and Metastasis III  
P61 Nutrition and Neutraceuticals  
P62 Risk and Prevention  
P63 Magnetic Resonance Imaging  
P64 Novel Imaging  
P65 Agent Development

P66 Drug Resistance  
P67 Targeted Therapies II  
P68 Health Care Delivery  
P69 Quality of Life  
P70 Surveillance and Descriptive Epidemiology  
P71 Summer Undergraduate Training Programs

**Exhibit Hall A**

## Poster Sessions at-a-Glance

<b>Poster Session Title</b>	<b>Number</b>	<b>Page</b>	<b>Poster Session Title</b>	<b>Number</b>	<b>Page</b>
<b>Thursday, June 9, 2005</b>			Mechanism of Hormone Action	P36	84
<b>6:30-8:30 p.m.</b>			Chemical/Physical Carcinogenesis	P37	85
Oncogenes	P1	39	Invasion and Metastasis II	P38	85
Signal Transduction I	P2	40	Regulation of the Immune Response	P39	87
Mammary Gland Development	P3	42	Biomarkers II	P40	88
DNA Damage and Repair	P4	44	Digital Imaging	P41	90
Transcription, Translation, and Modification	P5	46	X-Ray Imaging	P42	90
Genomics and Proteomics	P6	47	Drug Design and Development II	P43	91
Hormone Receptors I	P7	49	Targeted Therapies I	P44	92
Endocrine Carcinogenesis	P8	51	Vaccines and Immunotherapies	P45	94
Angiogenesis	P9	51	Gene Therapy	P46	95
Invasion and Metastasis I	P10	53	Photodynamic Therapy	P47	96
Tumor Progression	P11	54	Clinical and Surgical Management of Breast Cancer	P48	97
Tumor Immunology	P12	56	Genetic Epidemiology	P49	97
Biomarkers I	P13	58	Breast Cancer Centers of Excellence	P50	99
Computer-Aided Diagnostics	P14	59			
Nuclear Medicine Imaging	P15	61	<b>Saturday, June 11, 2005</b>		
Drug Design and Development I	P16	61			
Radiotherapy	P17	63	BRCA1 Tumor Suppressor	P51	101
Hormonal Therapy	P18	64	EGF Superfamily II	P52	103
Antiangiogenics	P19	65	Growth Factors/Cytokines	P53	104
Symptom Management	P20	65	Tumor Suppressor Genes II	P54	105
Evolving Therapeutic Targets	P21	66	Functional Study of Biological Molecules II	P55	107
Complementary Health and Alternative Medicine	P22	67	Genomic Instability	P56	108
Behavioral Sciences and Decision Making	P23	68	Familial and Hereditary Carcinogenesis	P57	110
Environmental Epidemiology	P24	69	Apoptosis	P58	110
<b>Friday, June 10, 2005</b>			Stromal-Epithelial Interactions	P59	112
<b>12:05-2:05 p.m.</b>			Invasion and Metastasis III	P60	113
BRCA2 Tumor Suppressor	P25	70	Nutrition and Neutraceuticals	P61	115
EGF Superfamily I	P26	71	Risk and Prevention	P62	116
p53	P27	72	Magnetic Resonance Imaging	P63	118
TGF-β	P28	74	Novel Imaging	P64	118
Cell Cycle	P29	74	Agent Development	P65	121
Tumor Suppressor Genes I	P30	76	Drug Resistance	P66	121
Signal Transduction II	P31	78	Targeted Therapies II	P67	123
Functional Study of Biological Molecules I	P32	79	Health Care Delivery	P68	125
Tyrosine Kinase Signaling	P33	81	Quality of Life	P69	125
Hormone Metabolism	P34	82	Surveillance and Descriptive Epidemiology	P70	126
Hormone Receptors II	P35	82	Summer Undergraduate Training Programs	P71	127

**P1 Oncogenes**

6:30–8:30 p.m.

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

**P1-1 AN AUTOCRINE MECHANISM FOR CONSTITUTIVE WNT PATHWAY ACTIVATION IN HUMAN CANCER CELLS**

A. Bafico, G. Liu, L. Goldin,  
V. Harris, S. A. Aaronson  
*Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY*

**P1-2 THE ROLE OF RAP-GTPASE IN MAMMARY EPITHELIAL CELL GROWTH AND TRANSFORMATION**

X. Zhao, N. Pokhriyal, V. Band  
*ENH Research Institute, Northwestern University, Evanston, IL*

**P1-3 MECHANISM OF DELAYED MAMMARY TUMORIGENESIS OF THE NF-KAPPAB C-REL SUBUNIT**

K. Belguise,<sup>1</sup> S. Guo,<sup>1</sup>  
D. C. Seldin,<sup>2</sup> R. D. Cardiff,<sup>3</sup>  
G. E. Sonenshein<sup>1</sup>  
*Departments of <sup>1</sup>Biochemistry and <sup>2</sup>Medicine, Boston University Medical School, Boston, MA; Center for Comparative Medicine, <sup>3</sup>University of California at Davis, Davis, CA*

**P1-4 DEVELOPMENTAL STAGE-SPECIFIC EFFECTS OF C-MYC IN THE MAMMARY EPITHELIUM**

C. M. Blakely, L. Sintasath,  
C. M. D'Cruz, K. T. Hahn,  
K. D. Dugan, G. K. Belka,  
L. A. Chodosh  
*Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA*

**P1-5 MECHANISMS OF REGRESSION AND RECURRENCE OF WNT1-INITIATED TUMORS FOLLOWING ABROGATION OF ONCOGENE EXPRESSION**

M. T. Debies  
*Pennsylvania State University College of Medicine, Hershey, PA*

**P1-6 A NOVEL MOUSE MODEL FOR GENETIC VALIDATION OF THERAPEUTIC TARGETS IN BREAST CANCER**

G. I. Evan, L. Soucek, D. Murphy,  
L. B. Swigart  
*Cancer Research Institute, Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA*

**P1-7 IDENTIFICATION AND CHARACTERIZATION OF PEA3 SUBFAMILY ETS SUBFAMILY TARGET GENES IN HUMAN BREAST TUMOR CELL LINES**

D. Vaz, D. Gludish, T. Shepherd,  
S. Perron, J. A. Hassell  
*Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada*

**P1-8 RCL, A NOVEL BREAST CANCER ONCOGENE?**

R. Janknecht, S. Shin  
*Mayo Clinic College of Medicine, Rochester, MN*

**P1-9 GENE EXPRESSION PROFILING OF MAMMARY TISSUES FROM MMTV-ERBB2/NEU TRANSGENIC MICE REVEALS BIMODAL REGULATION OF THE TRANSFORMING GROWTH FACTOR-BETA SIGNALING PATHWAY IN ERBB2/NEU-INDUCED MAMMARY TUMORS**

M. D. Landis, D. D. Seachrist,  
M. E. Montañez-Wiscovich,  
R. A. Keri  
*Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH*

**P1-10 EVALUATING THE ROLES OF ID1 AND ID2 IN MAMMARY GLAND DEVELOPMENT AND CARCINOGENESIS**

R. A. Keri, J. D. Mosley,  
E. L. Milliken, M. D. Landis  
*Departments of Pharmacology and Oncology, Case Western Reserve University School of Medicine, Cleveland, OH*

**P1-11 HUMAN MUC1 ONCOPROTEIN REGULATES GENE TRANSCRIPTION BY TARGETING THE NUCLEUS OF BREAST CANCER CELLS**

D. Kufe, Z. Wei, L. Huang  
*Dana-Farber Cancer Institute, Boston, MA*

**P1-12 THE ROLE OF THE ETS TRANSCRIPTION FACTOR ERM IN MAMMARY GLAND DEVELOPMENT AND ONCOGENESIS**

N. A. Kurpios  
*McMaster University, Hamilton, ON, Canada*

**P1-13 PROTEIN ELONGATION FACTOR EEF1A2 IS A PUTATIVE BREAST CANCER ONCOGENE THAT INCREASES CELL GROWTH AND ADHESION**

S. Jeganathan,<sup>1</sup> A. Amiri,<sup>1</sup>  
T. D. Wu,<sup>2</sup> J. M. Lee<sup>1</sup>  
<sup>1</sup>*Department of Biochemistry, University of Ottawa, Ottawa, ON, Canada;* <sup>2</sup>*Department of Bioinformatics, Genentech Inc, South San Francisco, CA*

**P1-14 ESTROGEN RECEPTOR POSITIVITY IN MAMMARY TUMORS OF WNT-1 TRANSGENIC MICE IS INFLUENCED BY COLLABORATING ONCOGENIC MUTATIONS**

X. Zhang,<sup>1</sup> K. Podsypanina,<sup>2</sup>  
S. Huang,<sup>1</sup> S. K. Moshin,<sup>1</sup>  
G. C. Chamness,<sup>1</sup> S. Hatsell,<sup>3</sup>  
P. Cowin,<sup>3</sup> R. Schiff,<sup>1</sup> Y. Li<sup>1,4,5</sup>  
<sup>1</sup>*Breast Center and <sup>4</sup>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX;* <sup>2</sup>*Varmus Laboratory, Program in Cell Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY;* <sup>3</sup>*Departments of Cell Biology and Dermatology, New York University School of Medicine, New York, NY*

**P1-15 AKT ACTIVATION IS SUFFICIENT FOR MAINTENANCE OF RAS-INITIATED TUMOR GROWTH IN VIVO**

K-H. Lim  
*Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC*

P1-16	<b>DETECTING AND TARGETING ONCOGENIC MYC IN BREAST CANCER</b> S. Katz, R. Ponzielli, P. Boutros, C. Ho, F. Khosravi, L. Z. Penn <i>Ontario Cancer Institute/Princess Margaret Hospital, Toronto, ON, Canada</i>	P1-22	<b>NON-EPITHELIAL RESTRICTION OF MAMMARY TUMORS BY ETS2 INACTIVATION</b> F. Wen, J. A. Tynan, R. G. Oshima <i>Molecular Pathology Program, University of California at San Diego, San Diego, CA; The Burnham Institute, La Jolla, CA</i>	P2-2	<b>THE ROLE OF THE GAB2 DOCKING PROTEIN IN HUMAN BREAST CANCER</b> T. Brummer, D. Schramek, R. J. Daly <i>Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia</i>
P1-17	<b>THE ETS TRANSCRIPTION FACTOR ESE-1 TRANSFORMS HUMAN MAMMARY EPITHELIAL CELLS VIA A NOVEL NONTRANSCRIPTIONAL CYTOPLASMIC MECHANISM</b> J. Prescott, K. Koto, A. Gutierrez-Hartmann <i>University of Colorado Health Sciences Center, Denver, CO</i>	P1-23	<b>CHARACTERIZATION OF THE 8P11-12 AMPLICON IN BREAST CANCER</b> Z-Q. Yang, S. P. Ethier <i>Karmanos Cancer Institute, Wayne State University, Detroit, MI</i>	P2-3	<b>REGULATION AND IMPORTANCE OF THE AUTONOMOUS ACTIVITY OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IV</b> F. A. Chow, K. A. Anderson, P. K. Noeldner, A. R. Means <i>Duke University, Durham, NC</i>
P1-18	<b>RNA-BINDING PROTEINS AS NOVEL ONCOPROTEINS AND TUMOR SUPPRESSORS IN BREAST CANCER</b> E. M. Ruidiaz, M. Gorospe, <sup>1</sup> G. Brewer <i>Robert Wood Johnson Medical School-University of Medicine and Dentistry of New Jersey, Piscataway, NJ; <sup>1</sup>National Institute on Aging, National Institutes of Health, Baltimore, MD</i>	P1-24	<b>CONTROL OF C-MYC FUNCTION BY THE TUMOR SUPPRESSOR P19ARF</b> Y. Qi, M. Gregory, S. Hann <i>Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN</i>	P2-4	<b>A NOVEL MECHANISM BY WHICH STAT5A REGULATES CYCLIN D1 PROTEIN LEVELS IN THE MAMMARY GLAND</b> I. Cotarla, P. A. Furth <i>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC</i>
P1-19	<b>THE ROLE OF TISSUE FACTOR IN BREAST CANCER</b> H. H. Versteeg, B. M. Mueller, <sup>1</sup> W. Ruf <i>Department of Immunology, The Scripps Research Institute, <sup>1</sup>La Jolla Institute of Molecular Medicine, La Jolla, CA</i>	P1-25	<b>NUCLEOCYTOPLASMIC SHUTTLING CONTRIBUTES TO THE ONCOGENIC ROLE OF NUCLEOPHOSMIN</b> Y. Yu, J. D. Weber <i>Washington University School of Medicine, St. Louis, MO</i>	P2-5	<b>KINASE INACTIVE GSK3BETA PROMOTES WNT SIGNALING AND MAMMARY TUMORIGENESIS</b> M. Farago, I. Dominguez, E. Landesman, X. Xu, D. C. Seldin <i>Section of Hematology-Oncology and Program in Molecular Medicine, Department of Medicine, Boston University School of Medicine, Boston, MA</i>
P1-20	<b>MECHANISMS OF C-MYC-INDUCED BREAST CANCER RECURRENCE</b> M. Wang, C. Bailey, G. Belka, B. Keister, L. Chodosh <i>University of Pennsylvania School of Medicine, Philadelphia, PA</i>	P1-26	<b>INDUCTION OF OSTEOPOONTIN EXPRESSION IN BREAST CANCER CELLS</b> D. R. Zweitzig, <sup>1</sup> G. R. Beck Jr., <sup>2</sup> E. Moran Jr. <sup>1</sup> <sup>1</sup> Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA; <sup>2</sup> Laboratory of Cancer Prevention, National Cancer Institute, Frederick, MD	P2-6	<b>MOLECULAR TARGETS OF AKT-DEPENDENT CHEMORESISTANCE</b> G. A. Shostak, D. C. Berwick, M. Le-Khac, M. Mansukhani, T. F. Franke <i>Departments of Pharmacology and Clinical Pathology, College of Physicians and Surgeons, Columbia University, New York, NY</i>
P1-21	<b>CHARACTERIZATION OF MAMMARY EPITHELIAL CELL POPULATIONS BY FACS AND REAL-TIME IMAGING</b> B. Welm, Z. Werb <i>Department of Anatomy, University of California at San Francisco, San Francisco, CA</i>	P2-1	<b>MECHANISMS OF UBIQUITINATION OF THE SERINE-THREONINE KINASE SGK-1</b> A. M. Bogusz, D. R. Brickley, S. D. Conzen <i>Departments of Pathology and Medicine, University of Chicago, Chicago, IL</i>	P2-7	<b>STABILITY-BASED MECHANISMS OF APOPTOSIS SUPPRESSION DOWNSTREAM OF AKT: IMPLICATIONS FOR BREAST CANCER TREATMENT</b> D. C. Berwick, Z. Xu, G. A. Shostak, M. Mansukhani, L. A. Greene, T. F. Franke <i>Departments of Pharmacology and Pathology, College of Physicians and Surgeons,</i>

## **P2 Signal Transduction I**

**6:30-8:30 p.m.**

*Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.*

P2-1	<b>MECHANISMS OF UBIQUITINATION OF THE SERINE-THREONINE KINASE SGK-1</b> A. M. Bogusz, D. R. Brickley, S. D. Conzen <i>Departments of Pathology and Medicine, University of Chicago, Chicago, IL</i>
------	--

	Columbia University, New York, NY	P2-12	BIOCHEMICAL CHARACTERIZATION OF WITH NO LYSINE (K) KINASE 1 (WNK1) AND ITS IMPACT ON WNK4 L. Y. Lenertz, B-H. Lee, X. Min, B. Xu, E. J. Goldsmith, M. H. Cobb <i>University of Texas Southwestern Medical Center at Dallas, Dallas, TX</i>	P2-18	ACTIVATION OF MITOCHONDRIAL APOPTOTIC CASCADE INVOLVING MCL-1 AND BIM IN GRANZYME B-TREATED BREAST CARCINOMA CELLS J. Han, L. A. Goldstein, H. Rabinowich <i>University of Pittsburgh School of Medicine, Department of Pathology and University of Pittsburgh Cancer Institute, Pittsburgh, PA</i>
P2-8	<b>INHIBITION OF ANCHORAGE-INDEPENDENT GROWTH AND TUMOR FORMATION OF A HUMAN BREAST CANCER CELL LINE THROUGH TARGETED INACTIVATION OF THE SRC SIGNALING PATHWAY</b> J. D. Bjorge, <sup>1</sup> M. Funnell, <sup>1,2</sup> K-Y. Chen, <sup>1</sup> A. M. Magliocco, <sup>2</sup> D. J. Fujita <sup>1</sup> <i>Departments of <sup>1</sup>Biochemistry and Molecular Biology, <sup>2</sup>Oncology and Pathology, University of Calgary Health Sciences Centre, Calgary, AB, Canada</i>	P2-13	INTEGRATION OF THE PRO- AND ANTI-APOPTOTIC SIGNALS BY PROTEIN PHOSPHATASE 2A IN ADENOVIRAL E1A-MEDIATED CHEMOSENSITIZATION Y. Liao, M-C. Hung <i>University of Texas M.D. Anderson Cancer Center, Houston, TX</i>	P2-19	THE ROLE OF IQGAP1 IN MODULATING MITOGEN-ACTIVATED PROTEIN (MAP) KINASE SIGNALLING M. Roy, Z. Li, D. B. Sacks <i>Brigham and Women's Hospital, Harvard Medical School, Boston, MA</i>
P2-9	<b>PHYLOGENETIC ANALYSIS OF PLECKSTIN HOMOLOGY (PH) DOMAINS USING SEQUENCE ALIGNMENT ALGORITHMS</b> D. Keleti, M. A. Lemmon <i>University of Pennsylvania, Philadelphia, PA</i>	P2-14	PROTEOMIC ANALYSIS: AKT SUBSTRATES IN THE MAMMARY GLAND T. R. Lyons, S. M. Andersen <i>Program in Molecular Biology, Department of Pathology, University of Colorado Health Sciences Center, Aurora, CO</i>	P2-20	SPHINGOSINE KINASE 2 SIGNALING IN MCF7 HUMAN BREAST CANCER CELLS H. Sankala, N. Hait, L. Elmore, S. Milstien, S. Spiegel <i>Virginia Commonwealth University, Richmond, VA</i>
P2-10	<b>GENOME WIDE ANALYSIS OF AKT SIGNALING BY RNAI IN DROSOPHILA</b> L. Kockel, <sup>1</sup> K. Kerr, <sup>1</sup> M. Melnick, <sup>2</sup> N. Perrimon <sup>1</sup> <sup>1</sup> <i>Department of Genetics, Harvard Medical School, Boston, MA;</i> <sup>2</sup> <i>Cell Signaling Technologies, Beverly, MA</i>	P2-15	CDC42 AND ACK-1 MEDIATE INTEGRIN SIGNALING LEADING TO CELL MIGRATION THROUGH A COMPLEX WITH P130CAS, FAK AND SRC K. Modzelewska, L. Newman, R. Desai, P. Keely <i>Department of Pharmacology, University of Wisconsin-Madison, Madison, WI</i>	P2-21	MELANOMA DIFFERENTIATION ASSOCIATED GENE-7/INTERLEUKIN-24 PROMOTES TUMOR CELL-SPECIFIC APOPTOSIS THROUGH BOTH SECRETORY AND NONSECRETORY PATHWAYS M. Sauane, R. V. Gopalkrishnana, P. B. Fisher <i>Columbia University, Medical Center, College of Physicians and Surgeons, New York, NY</i>
P2-11	<b>SL0101, THE FIRST p90 RIBOSOMAL S6 KINASE-SPECIFIC INHIBITOR, A POTENTIAL CHEMOTHERAPEUTIC AGENT FOR BREAST CANCER</b> D. A. Lannigan, <sup>1,2</sup> J. A. Smith, <sup>2,3</sup> C. E. Poteet-Smith, <sup>2</sup> Y. Xu, <sup>4</sup> T. M. Errington, <sup>2</sup> S. M. Hecht <sup>4</sup> <sup>1</sup> <i>Department of Microbiology, Center for Cell Signaling, Department of Pathology, Department of Chemistry, University of Virginia, Charlottesville, VA</i>	P2-16	TYROSINE PHOSPHATASES AND THEIR BINDING PROTEINS IN NORMAL AND NEOPLASTIC BREAST B. G. Neel, M. Bentires-Alj, H. Keilhack, R. Chan, S. Gil, H. Gu <i>Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, MA</i>	P2-22	AN IMPORTANT ROLE FOR AIB1 PHOSPHORYLATION IN THE ESTROGEN AGONIST ACTIVITY OF TAMOXIFEN J. Shou, <sup>1</sup> P. Choudhury, <sup>1</sup> R. Cook, <sup>2</sup> G. Chamness, <sup>1</sup> K. Osborne, <sup>1</sup> R. Schiff <sup>1</sup> <sup>1</sup> <i>Breast Center and Departments of Medicine and Molecular and Cellular Biology, <sup>2</sup>Department of Immunology, Baylor College of Medicine, Houston, TX</i>
		P2-17	SYNTHESIS OF SMALL MOLECULES THAT HETERODIMERIZE HSP90 AND ESTROGEN RECEPTOR PROTEINS B. R. Peterson, L. Mottram <i>Department of Chemistry, Pennsylvania State University, University Park, PA</i>		

P2-23	<b>NOVEL ROLE OF ANX7 IN IP3-DEPENDENT APOPTOTIC CALCIUM SIGNALING PATHWAY IN BREAST CANCER</b> M. Srivastava, K. Mezhevaya, S. Naga, O. Eidelman <i>Department of Anatomy, Physiology and Genetics, and Institute for Molecular Medicine, Uniformed Services University of the Health Sciences, School of Medicine, Bethesda, MD</i>	P3-2	<b>THE ORIGIN AND SIGNIFICANCE OF MAMMARY INTRADUCTAL FOAM CELLS</b> S. H. Barsky, M. L. Alpaugh, N. J. Karlin, Y. Ye, R. M. Hoffman <i>University of California at Los Angeles, School of Medicine, Los Angeles, CA; Olive View Medical Center, Sylmar, CA; Anticancer, Inc., San Diego, CA</i>	P3-7	<b>ROLE OF THE STEM CELL NICHE IN HORMONE-INDUCED TUMORIGENESIS IN FETAL MOUSE MAMMARY EPITHELIUM</b> G. Chepko, L. Hilakivi-Clarke <i>Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC</i>
P2-24	<b>DEVELOPMENT OF CHEMICAL ANTAGONISTS OF PIP3/PH DOMAIN</b> A. Degterev, <sup>1</sup> M. Reibarkh, <sup>2</sup> W. Sun, <sup>3</sup> D. Ma, <sup>3</sup> G. Wagner, <sup>2</sup> J. Yuan <sup>1</sup> <sup>1</sup> <i>Department of Cell Biology and</i> <sup>2</sup> <i>Department of Biochemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;</i> <sup>3</sup> <i>Shanghai Institute of Organic Chemistry, Shanghai, China</i>	P3-3	<b>BREAST MYOEPITHELIAL CELLS ARE NATURAL AUTOCRINE AND PARACRINE SUPPRESSORS OF BREAST CANCER PROGRESSION</b> S. H. Barsky, M. L. Alpaugh, N. J. Karlin, Y. Ye, S. M. Love <i>University of California at Los Angeles, School of Medicine, Los Angeles, CA; University of California at Los Angeles, Olive View Medical Center, Sylmar, CA; Dr. Susan Love Research Foundation, Santa Barbara, CA</i>	P3-8	<b>RELB/P52 NF-KAPPAB COMPLEXES PROMOTE CARCINOGENESIS OF THE MAMMARY GLAND AND LATE MOUSE MAMMARY GLAND DEVELOPMENT</b> E. G. Demicco, <sup>1</sup> K. T. Kavanagh, <sup>1</sup> R. Romieu-Mourez, <sup>1</sup> S. R. Shin, <sup>1</sup> E. Landesman-Bollag, <sup>2,3</sup> D. C. Seldin, <sup>2,3</sup> G. E. Sonenshein <sup>1,3</sup> <i>Departments of <sup>1</sup>Biochemistry and <sup>2</sup>Medicine and <sup>3</sup>Division of Research on Women's Health, Boston University School of Medicine, Boston, MA</i>
P2-25	<b>ANTI-SRC ACTIVITY OF CSK HOMOLOGOUS KINASE (CHK) IN BREAST CANCER IS INCREASED BY HIGHER AFFINITY BINDING OF CHK TO HER2 RECEPTOR</b> R. Zagodzon, S. Kim, R. Kaminski, A. Meisler, J. D. Baleja, Y. Fu, S. Avraham, H. Avraham <i>Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Biochemistry, Tufts University School of Medicine, Boston, MA</i>	P3-4	<b>DIFFUSION RELATED PROLIFERATION OF MOUSE MAMMARY EPITHELIAL CELLS IN SPATIALLY CONSTRAINED MICROENVIRONMENTS</b> H. Yu, <sup>1</sup> C. Alexander, <sup>2</sup> D. J. Beebe <sup>1</sup> <sup>1</sup> <i>Department of Biomedical Engineering, <sup>2</sup>McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI</i>	P3-9	<b>GENETIC ANALYSIS OF FRINGE GENES IN MAMMARY DEVELOPMENT AND BREAST CANCER</b> K. Xu, S. Juneja, T. Gridley, <sup>1</sup> S. Egan <i>Program in Developmental Biology, Hospital for Sick Children, Toronto, ON Canada;</i> <sup>1</sup> <i>Jackson Laboratory, Bar Harbor, ME</i>
P3-1	<b>ABC2 PLAYS A COMPLEX ROLE IN MAMMARY GLAND DEVELOPMENT</b> C. Bailey, M. Wang, G. Belka, L. Chodosh <i>Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA</i>	P3-5	<b>THE ROLE OF PROSTAGLANDIN E<sub>2</sub> IN NORMAL MAMMARY GLAND DEVELOPMENT AND MAMMARY EPITHELIAL TRANSFORMATION</b> S. Chandrasekharan, <sup>1</sup> N. A. Foley, <sup>1</sup> L. Jania, <sup>1</sup> L. P. Audoly, <sup>2</sup> B. H. Koller <sup>1</sup> <sup>1</sup> <i>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC;</i> <sup>2</sup> <i>Merck-Frosst, Kirkland, QC, Canada</i>	P3-10	<b>CHARACTERIZATION OF MAMMOSPHERES</b> J. Schneider, M. Yan, R. Gear, S. C. Heffelfinger <i>Department of Pathology, University of Cincinnati, Cincinnati, OH</i>
P3-6	<b>WNT/BETA-CATENIN-MEDIATED RADIATION RESISTANCE OF MOUSE MAMMARY STEM-LIKE/PROGENITOR CELLS</b> M. S. Chen, W. A. Woodward, F. Behbod, M. P. Alfaro, T. A. Buchholtz, J. M. Rosen <i>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX</i>	P3-11	<b>AXON GUIDANCE CUES IN MAMMARY GLAND DEVELOPMENT</b> L. Hinck, G. Shin, P. Strickland <i>University of California at Santa Cruz, Santa Cruz, CA</i>		

### **P3 Mammary Gland Development**

**6:30–8:30 p.m.**

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

#### **P3-1 ABCG2 PLAYS A COMPLEX ROLE IN MAMMARY GLAND DEVELOPMENT**

C. Bailey, M. Wang, G. Belka, L. Chodosh  
*Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA*

#### **P3-6 WNT/BETA-CATENIN-MEDIATED RADIATION RESISTANCE OF MOUSE MAMMARY STEM-LIKE/PROGENITOR CELLS**

M. S. Chen, W. A. Woodward, F. Behbod, M. P. Alfaro, T. A. Buchholtz, J. M. Rosen  
*Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX*

- P3-12 AN ALTERNATIVE, AUTHENTIC MODEL OF NORMAL BREAST DEVELOPMENT AND BREAST CANCER**  
 J. F. Trott, A. S. Barndollar,  
 J. M. Scudder, K. C. Horigan,  
 R. C. Hovey  
*Lactation and Mammary Gland Biology Group, Department of Animal Science, University of Vermont, Burlington, VT*
- P3-13 INVOLVEMENT OF EXTRACELLULAR MATRIX (ECM) COMPONENTS IN MAMMARY GLAND DEVELOPMENT AND/OR CARCINOGENESIS**  
 R. Zahedi, S. Krause,  
 C. Sonnenschein, M. J. Bissell,  
 B. P. Toole, A. M. Soto  
*Tufts University School of Medicine, Boston, MA*
- P3-14 GENETIC ANALYSIS OF DNA NUCLEOTIDE EXCISION REPAIR DEFICIENCY IN NOVEL NON-TUMOR ADJACENT AND TUMOR CELL LINES SUGGESTS A NEW PARADIGM OF BREAST CANCER ETIOLOGY**  
 J. J. Latimer,<sup>1,5,8</sup> J. M. Johnson,<sup>5,8</sup>  
 C. M. Kelly,<sup>1,8</sup> K. Beaudry-Rodgers,<sup>6,8</sup> V. G. Vogel,<sup>2,8</sup>  
 J. Kelly,<sup>3,8</sup> R. Johnson,<sup>3,8</sup>  
 A. Amortegui,<sup>4</sup> L. Mock,<sup>4,8</sup>  
 S. G. Grant<sup>1,7,8</sup>  
*Departments of <sup>1</sup>Obstetrics, Gynecology and Reproductive Science, <sup>2</sup>Medicine, <sup>3</sup>Surgery and <sup>4</sup>Pathology and <sup>5</sup>Biochemistry and Molecular Genetics Program, University of Pittsburgh School of Medicine, Pittsburgh, PA; Departments of <sup>6</sup>Human Genetics and <sup>7</sup>Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; <sup>8</sup>Magee-Womens Research Institute, Pittsburgh, PA*
- P3-15 TOWARDS THE IDENTIFICATION OF STEM CELLS IN A NOVEL HUMAN MAMMARY EPITHELIAL CULTURE (HMEC) SYSTEM THAT REPRODUCIBLY DEMONSTRATES DUCTAL ORGANOTYPIC ARCHITECTURE IN 3 WEEKS**  
 J. J. Latimer,<sup>1,6,8</sup> D. B. Stoltz,<sup>2</sup>  
 K. Giuliano,<sup>3</sup> C. M. Kelly,<sup>7,8</sup>

- J. M. Johnson,<sup>6,8</sup> D. Focht,<sup>9</sup>  
 A. Amortegui,<sup>4</sup> V. G. Vogel<sup>5,8</sup>  
*Departments of <sup>1</sup>Obstetrics, Gynecology and Reproductive Science, <sup>2</sup>Cell Biology and Physiology, <sup>3</sup>Pharmacology, <sup>4</sup>Pathology, <sup>5</sup>Medicine, and <sup>6</sup>Biochemistry and Molecular Genetics Program, University of Pittsburgh School of Medicine, Pittsburgh, PA; Department of <sup>7</sup>Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; <sup>8</sup>Magee-Womens Research Institute, Pittsburgh, PA; <sup>9</sup>Bioparts, Inc., Butler, PA*
- P3-16 ROLE OF PYGO2, A PUTATIVE NUCLEAR MEDIATOR OF WNT SIGNALING, IN NORMAL AND MALIGNANT MAMMARY GLAND DEVELOPMENT**  
 B. Li, M. Hu, V. Bilanchone,  
 X. Dai  
*Department of Biological Chemistry, School of Medicine, University of California at Irvine, Irvine, CA*
- P3-17 PROSPECTIVE ISOLATION OF CANCER AND NORMAL MURINE BREAST STEM CELLS**  
 N. Lobo,<sup>1</sup> R. Cho,<sup>2</sup> M. Clarke<sup>3</sup>  
*<sup>1</sup>Cellular and Molecular Biology Program, <sup>2</sup>Department of Pediatric Hematology/Oncology, <sup>3</sup>Department of Internal Medicine and Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI*
- P3-18 CANINE MAMMARY INTRAEPITHELIAL LESIONS: A SPONTANEOUS ANIMAL MODEL OF PRENEOPLASTIC BREAST LESIONS**  
 E. Antuofermo, M. A. Miller,  
 S. Badve, P. Snyder,  
 S. Mohammed  
*Department of Veterinary Pathobiology, Purdue University, West Lafayette, IN; Department of Pathology, Indiana University School of Medicine, Bloomington, IN*
- P3-19 CONSTITUTIVE ACTIVATION OF SMOOTHENED LEADS TO ENHANCED PROLIFERATION AND DUCTAL HYPERPLASIA IN THE MOUSE MAMMARY GLAND**  
 R. C. Moraes, N. N. Harrington,  
 M. T. Lewis  
*Breast Center, Baylor College of Medicine, Houston, TX*
- P3-20 PROGESTERONE INDUCTION OF CALCITONIN EXPRESSION IN THE MURINE MAMMARY GLAND**  
 A. Mukherjee, P. M. Ismail,  
 F. J. Demayo, P. Amato,<sup>1</sup>  
 J. P. Lydon  
*Department of Molecular and Cellular Biology and <sup>1</sup>Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX*
- P3-21 CYTOSKELETAL CONTROL OF MAMMARY EPITHELIAL MORPHOGENESIS AND TUMORIGENESIS**  
 C. M. Nelson, M. J. Bissell  
*Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA*
- P3-22 INAPPROPRIATE P-CADHERIN EXPRESSION IN THE MOUSE MAMMARY EPITHELIUM IS COMPATIBLE WITH NORMAL MAMMARY GLAND FUNCTION**  
 G. L. Radice,<sup>1</sup> C. L. Sauer,<sup>2</sup>  
 I. Kostetskii,<sup>1</sup> A. P. Soler,<sup>2</sup>  
 K. A. Knudsen<sup>2</sup>  
*<sup>1</sup>Center for Research on Reproduction and Women's Health, University of Pennsylvania School of Medicine, Philadelphia, PA; <sup>2</sup>Lankenau Institute for Medical Research, Wynnewood, PA*
- P3-23 CHARACTERIZING CELL DIVISION PLANE IN THE MOUSE MAMMARY EPITHELIUM**  
 R. D. Rajaram, L. Ciarloni,  
 J. Storre, C. Briskin  
*Swiss Institute for Experimental Cancer Research, NCCR Molecular Oncology, Epalinges, Switzerland*

P3-24	<b>STEM CELLS IN NORMAL HUMAN BREAST DEVELOPMENT AND CANCER: THERAPEUTIC IMPLICATIONS</b> M. S. Wicha, G. Dontu, S. Liu, I. Mantle <i>University of Michigan Comprehensive Cancer Center, Ann Arbor, MI</i>	P4-2	<b>NUCLEAR DYNAMICS OF HUMAN XRCC3 AND RAD51C PROTEINS DURING DNA DOUBLE STRAND REPAIR</b> B. T. Bennett <i>University of Massachusetts Medical School, Worcester, MA</i>	Stanford University School of Medicine, Stanford, CA
P3-25	<b>AN ORPHAN RECEPTOR TYROSINE KINASE AND THE CONTROL OF MULTI-POTENT MAMMARY PROGENITOR CELLS</b> C. A. Wilson, G. Bernardo, H. M. Rong, J. Dering <i>David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA</i>	P4-3	<b>ROLE OF THE BLM HELICASE IN HOMOLOGOUS RECOMBINATION</b> W. L. Bussen, L. Krejci, <sup>1</sup> I. D. Hickson, <sup>2</sup> P. Sung <sup>1</sup> <i>Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX; <sup>1</sup>Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT; <sup>2</sup>Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK</i>	P4-9 <b>LOSS OF RE-REPLICATION CONTROL IN SACCHAROMYCES CEREVISIAE RESULTS IN EXTENSIVE DNA DAMAGE</b> B. Green, J. Li <i>Department of Biochemistry and Biophysics and Department of Microbiology and Immunology, University of California at San Francisco, San Francisco, CA</i>
P3-26	<b>ROLE OF THE ROR1 RECEPTOR TYROSINE KINASE IN ER-NEGATIVE BASAL BREAST CANCER</b> C. Wilson, J. Dering <i>David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA</i>	P4-4	<b>ABSTRACT WITHDRAWN</b>	P4-10 <b>BRH2-DSS1 INTERPLAY ENABLES PROPERLY CONTROLLED RECOMBINATION IN USTILAGO MAYDIS</b> M. Kojic, <sup>1</sup> Q. Zhou, <sup>1</sup> M. Lisby, <sup>2</sup> W. K. Holloman <sup>1</sup> <i><sup>1</sup>Department of Microbiology and Immunology, Hearst Microbiology Research Center, Cornell University Weill Medical College, New York, NY; <sup>2</sup>Department of Genetics and Development, Columbia University College of Physicians and Surgeons, New York, NY</i>
P3-27	<b>THE ROLE OF NF-KAPPAB SIGNALING IN MACROPHAGES ON MAMMARY DEVELOPMENT AND NEOPLASIA</b> T. Sherrill, C. Robinson-Benion, M. Arutiunov, D-S. Cheng, T. Blackwell, F. Yull <i>Department of Cancer Biology and Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, TN</i>	P4-5	<b>GERMLINE TRANSMISSION OF RNA INTERFERENCE IN MICE</b> M. A. Carmell, <sup>1</sup> L. Zhang, <sup>2</sup> D. S. Conklin, <sup>1</sup> G. J. Hannon, <sup>1</sup> T. A. Rosenquist <sup>2</sup> <i>Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY; <sup>2</sup>Department of Pharmacology, Stony Brook University, Stony Brook, NY</i>	P4-11 <b>IDENTIFICATION OF NOVEL INHIBITORS Ku70/80 DNA REPAIR COMPLEX AS POTENTIAL LEADS IN CANCER TREATMENT</b> S. Kamalakaran, <sup>1,4</sup> W. Taofu, <sup>3</sup> M. Johnson, <sup>3</sup> W. T. Beck <sup>1,2</sup> <i><sup>1</sup>Departments of Molecular Biology and Genetics, <sup>2</sup>Biopharmaceutical Sciences, <sup>3</sup>Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, Chicago, IL; <sup>4</sup>Cold Spring Harbor Laboratory, Cold Spring Harbor, NY</i>
P4-1	<b>ROLE OF CA+ IN HOMOLOGOUS RECOMBINATION AND RESPONSE TO DNA DAMAGE IN BREAST CANCER</b> B. Torabi, J. Kim, B. Olofsson, C. Kelly, A. Mazin, J. Azizkhani-Clifford <i>Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA</i>	P4-6	<b>CHARACTERIZATION OF PUTATIVE BREAST CANCER STEM CELLS</b> D. L. Crowe <i>University of Southern California, Los Angeles, CA</i>	P4-12 <b>CHARACTERIZING THE ROLE OF REVERSIBLE UBIQUITINATION MEDIATED BY THE DEUBIQUITINASE UBPM</b> M. A. Keaton, T-P. Yao <i>Duke University, Durham, NC</i>
P4-7	<b>ESTROGEN AND RETINOID REGULATION OF DNA REPAIR IN BREAST CANCER</b> D. L. Crowe <i>University of Southern California, Los Angeles, CA</i>	P4-8	<b>LOSS OF NUCLEOTIDE EXCISION REPAIR AS A SOURCE OF GENOMIC INSTABILITY IN BREAST CANCER</b> J. M. Ford, A. W. Kurian, V. B. Sharma, N. Chun, K. Kingham, M. Mills <i>Program for Clinical Cancer Genetics, Division of Oncology,</i>	

## **P4 DNA Damage and Repair**

**6:30–8:30 p.m.**

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

### **P4-1 ROLE OF CA+ IN HOMOLOGOUS RECOMBINATION AND RESPONSE TO DNA DAMAGE IN BREAST CANCER**

B. Torabi, J. Kim, B. Olofsson, C. Kelly, A. Mazin, J. Azizkhani-Clifford  
*Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA*

### **P4-8 LOSS OF NUCLEOTIDE EXCISION REPAIR AS A SOURCE OF GENOMIC INSTABILITY IN BREAST CANCER**

J. M. Ford, A. W. Kurian, V. B. Sharma, N. Chun, K. Kingham, M. Mills  
*Program for Clinical Cancer Genetics, Division of Oncology,*

- P4-13 DNA DAMAGE RESPONSES TO THE TOPOISOMERASE II POISONS. HOW SIMILAR CHEMOTHERAPEUTIC AGENTS INDUCE DIFFERENT CELLULAR RESPONSES**  
 E. U. Kurz, M. I. Siponen, P. Douglas, S. P. Lees-Miller  
*Southern Alberta Cancer Research Institute and Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada*
- P4-14 IN VITRO ACTIVATION OF YEAST CHECKPOINT PROTEIN RAD53**  
 J-L. Ma, S-J. Lee, J. K. Duong, D. F. Stern  
*Department of Pathology, Yale University School of Medicine, New Haven, CT*
- P4-15 ANALYSIS AND IDENTIFICATION OF NOVEL RADIATION RESPONSE GENES IN MCF10A CELLS**  
 J. L. Malone,<sup>1</sup> R. L. Ullrich<sup>2</sup>  
<sup>1</sup>*University of Colorado Health Sciences Center, Aurora, CO;*  
<sup>2</sup>*Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO*
- P4-16 EDD IS A NOVEL MEDIATOR OF CHK2 ACTIVATION IN DNA DAMAGE SIGNALLING**  
 M. Munoz,<sup>1</sup> M. J. Henderson,<sup>1</sup> D. N. Saunders,<sup>1</sup> J. L. Clancy,<sup>1</sup> A. J. Russell,<sup>1</sup> B. Williams,<sup>2</sup> K. K. Khanna,<sup>3</sup> D. Pappin,<sup>4</sup> S. P. Jackson,<sup>2</sup> C. K. W. Watts<sup>1</sup>  
<sup>1</sup>*Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, NSW, Australia;*  
<sup>2</sup>*The Wellcome Trust and Cancer Research UK Gurdon Institute of Cancer and Developmental Biology, and Department of Zoology, University of Cambridge, Cambridge, UK;*  
<sup>3</sup>*The Queensland Institute of Medical Research, Herston, QLD, Australia;*  
<sup>4</sup>*Advanced Research and Technology Group, Applied Biosystems, Framingham, MA*
- P4-17 COMPARING TELOMERIC RECOMBINATION RATES IN TELOMERASE POSITIVE AND ALT POSITIVE CANCER CELLS**  
 O. E. Bechter, S. Natarajan, J. W. Shay, W. E. Wright  
*University of Texas Southwestern Medical Center at Dallas, Dallas, TX*
- P4-18 BIOCHEMICAL ACTIVITIES OF FANCD2 AND UBIQUITINATED FANCD2**  
 W-H. Park, S. Margossian, A. Horwitz, A. M. Simons, A. D. D'Andrea, J. D. Parvin  
*Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA*
- P4-19 GENOME-WIDE SCREENS TO IDENTIFY EUKARYOTIC GENES INVOLVED IN THE DNA DAMAGE RESPONSE**  
 F. Romesberg  
*The Scripps Research Institute, La Jolla, CA*
- P4-20 DNA REPAIR GENE POLYMORPHISMS IN HEREDITARY BREAST CANCER**  
 L. Santi-Ruiz, C. Corio, C. Isaacs, P. G. Shields  
*Georgetown University, Lombardi Cancer Center, Washington, DC*
- P4-21 PHOSPHORYLATION OF H2AX (GAMMAH2AX) IN BREAST CANCER CELLS TREATED WITH CYTOTOXIC CHEMOTHERAPY: A POTENTIAL MARKER AND THERAPEUTIC TARGET**  
 N. Taneja,<sup>1</sup> S. J. Kron,<sup>2</sup> R. R. Weichselbaum<sup>1</sup>  
*Departments of <sup>1</sup>Radiation and Cellular Oncology and <sup>2</sup>Molecular Genetics and Cell Biology, Center for Molecular Oncology, University of Chicago, Chicago, IL*
- P4-22 INVOLVEMENT OF 53BP1 IN DNA DAMAGE SIGNALING AND TUMOR SUPPRESSION**  
 B. Wang,<sup>1</sup> S. Matsuoka,<sup>1</sup> J. C. Morales,<sup>4</sup> P. B. Carpenter,<sup>4</sup> S. J. Elledge<sup>1,2,3</sup>  
*<sup>1</sup>Department of Medicine, Brigham and Women's Hospital, Boston, MA; <sup>2</sup>Department of Genetics, Harvard Medical School, Boston, MA; <sup>3</sup>Howard Hughes Medical Institute, Boston, MA; <sup>4</sup>Department of Biochemistry and Molecular Biology, University of Texas Health Sciences Center, Houston, TX*
- P4-23 DISTINCT IN VIVO KINETICS OF DNA DOUBLE-STRAND BREAK REPAIR FACTOR RESPONSES TO LASER-INDUCED DNA DAMAGE**  
 J-S. Kim,<sup>1</sup> T. Krasieva,<sup>2</sup> H. Kurumizaka,<sup>3</sup> D. J. Chen,<sup>4</sup> M. R. Taylor,<sup>5</sup> K. Yokomori<sup>1</sup>  
<sup>1</sup>*Department of Biological Chemistry, College of Medicine, <sup>2</sup>Beckman Laser Institute, Department of Surgery, Laser Microbeam and Medical Program, University of California, Irvine, CA;*  
<sup>3</sup>*Department of Electrical Engineering and Bioscience, School of Science and Engineering, Waseda University, Tokyo, Japan;*  
<sup>4</sup>*Molecular Radiation Biology Division, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX;*  
<sup>5</sup>*CR-UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, UK*
- P4-24 REGULATION AND THERAPEUTIC POTENTIAL OF CHK1 KINASE IN BREAST CANCER**  
 Y-W. Zhang, R. T. Abraham  
*Cancer Research Center, The Burnham Institute, La Jolla, CA*
- P4-25 FUNCTIONAL ANALYSIS OF TUMOR SUPPRESSOR BRCA1 IN DNA DAMAGE RESPONSE**  
 X. Yu, J. Chen  
*Department of Oncology, Mayo Clinic and Foundation, Rochester, MN*

**P5 Transcription,  
Translation, and  
Modification**

**6:30–8:30 p.m.**

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

**P5-1 DISCOVERY OF SEQUENCE-SPECIFIC MODULATORS OF TRANSLATIONAL EFFICIENCY CONTRIBUTING TO THE PATHOGENESIS OF HUMAN BREAST CANCER**

S. W. Blume, Z. Meng, Y. Liu, A. Hill, S. Meleth, C. R. Stockard, W. E. Grizzle  
*University of Alabama at Birmingham Departments of Medicine, Biochemistry & Molecular Genetics, Pathology, Biostatistics, and Comprehensive Cancer Center*

**P5-2 THE 12.5 KDA PRODUCT OF THE HUMAN C-MYC UPSTREAM OPEN READING FRAME AS A POSSIBLE TUMOR SUPPRESSOR**

S. W. Blume, V. Guarcello, K. Shrestha, N. L. Jackson, C. Jenkins, D. R. Shaw  
*Departments of Medicine, Biochemistry and Molecular Genetics, and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL*

**P5-3 PROMOTER AND COFACTOR REQUIREMENTS FOR SERM-ER ACTIVITY**

J. S. Carroll, M. Brown  
*Dana-Farber Cancer Institute, Boston, MA*

**P5-4 IDENTIFICATION OF GENES REGULATED BY TRANSCRIPTION FACTOR IIS IN SACCHAROMYCES CEREVISIAE TREATED WITH PEROXIDE**

A. Guan, S. Archer-Evans, C. Kane  
*University of California at Berkeley, Berkeley, CA*

**P5-5 POST-TRANSCRIPTIONAL REGULATORY NETWORKS IN BREAST CANCER**

B. S. Henderson, T. A. Levins, D. M. Spencer, R. B. Cheatham  
*Ribonomics, Inc., Durham, NC*

**P5-6 NUCLEAR RECEPTOR COREPRESSOR REGULATION OF ESTROGEN RECEPTOR ANTAGONIST FUNCTION**

B.-G. Ju, V. Perissi, S. H. Back, K. Jepsen, M. G. Rosenfeld  
*Howard Hughes Medical Institute, School of Medicine, University of California at San Diego, La Jolla, CA*

**P5-7 THE DEACETYLASE HDAC6 REGULATES HSP90 ACETYLATION AND CHAPERONE-DEPENDENT ACTIVATION OF SIGNALING PROTEINS**

J. J. Kovacs,<sup>1</sup> P. J. M. Murphy,<sup>2</sup> X. Zhao,<sup>1</sup> J.-T. Wu,<sup>1</sup> C. V. Nicchitta,<sup>3</sup> M. Yoshida,<sup>4</sup> D. O. Toft,<sup>5</sup> W. B. Pratt,<sup>2</sup> T.-P. Yao<sup>1</sup>  
*Departments of <sup>1</sup>Pharmacology and Cancer Biology, <sup>2</sup>Cell Biology, Duke University, Durham, NC; <sup>2</sup>Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI; <sup>3</sup>Chemical Genetics Laboratory, RIKEN, Wako, Saitama, CREST Research Project, Japan Science and Technology Corporation, Saitama, Japan; <sup>5</sup>Department of Biochemistry and Molecular Biology, Mayo Graduate School, Rochester, MN*

**P5-8 UNDERSTANDING AND UTILIZATION OF BIOLOGICAL SPECIFICITIES IN TRANSCRIPTION CONTROL AND OTHER PROCESSES**

J. Ma, Y. Wen, D. Fu, W. Wang, E. Tillitz, R. Doerning, D. Mou, L. McDonald  
*Cincinnati Children's Hospital Research Foundation, Division of Developmental Biology, Cincinnati, OH*

**P5-9 REGULATION OF T-TYPE CYCLINS IN BREAST CANCER**

R. M. Marshall, J. Garriga, X. Graña  
*Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA*

**P5-10 HETEROCHROMATIN PROTEIN 1 AS A CANDIDATE BREAST CANCER METASTASIS SUPPRESSOR**

T. J. Moss, L. E. Norwood, N. Margaryan, S. L. Cook, L. Wright, M. J. C. Hendrix, D. A. Kirschmann, L. L. Wallrath  
*Department of Biochemistry, University of Iowa, Iowa City, IA; Medical Scientist Training Program, University of Iowa, Iowa City, IA; Children's Memorial Hospital, Northwestern University, Chicago, IL*

**P5-11 IDENTIFICATION OF BCNP, A NOVEL GENE ENCODING A PROTEIN WITH HOMOLOGY OF NOPP140, AS A SITE OF COMMON PROVIRAL INSERTION IN MMTV-INDUCED MAMMARY TUMORS**

G. Chatterjee, C. Millerick, C. Galvao, A. S. Perkins  
*Department of Pathology, Yale University School of Medicine, New Haven, CT*

**P5-12 CBP REGULATES APOPTOSIS IN HUMAN MAMMARY EPITHELIAL CELLS: A MODEL OF EARLY MAMMARY CARCINOGENESIS**

E. C. Dietze, M. L. Bowie, K. Mrozek, E. Caldwell, G. R. Bean, V. L. Seewaldt  
*Duke University School of Medicine, Durham, NC; Ohio State University, Columbus, OH; Fred Hutchinson Cancer Research Center, Seattle, WA*

**P5-13 PATTERNS OF MICRO RNA EXPRESSION IN BREAST CANCER CELLS LINES**

L. Sempere, C. Heath, C. Cole  
*Departments of Biochemistry and Genetics, Dartmouth Medical School, Hanover, NH*

**P5-14 SYNTHETIC SHRNAs AS POTENT RNAI TRIGGERS**

D. Siolas, C. Lerner, J. Burchard, W. Ge, P. Linsley, G. J. Hannon, M. A. Cleary  
*Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; Rosetta Inpharmatics, Kirkland, WA*

- P5-15 THE INFLUENCE OF THE EXTRACELLULAR MATRIX ON TRANSCRIPTION FACTOR AND NUCLEAR MATRIX ORGANIZATION**  
V. A. Spencer, R. Xu, M. Bissell,  
*Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA*
- P5-16 TRANSCRIPTIONAL REGULATION OF THE HETEROCHROMATIN PROTEIN 1 ALPHA GENE IN BREAST CARCINOMA CELLS**  
N. Tanese, M. Kaminsky,  
J. Lieberthal, C. Parkhurst,  
D. Lam  
*Department of Microbiology, New York University School of Medicine, New York, NY*
- P5-17 ABOLITION OF SPECIFIC HISTONE DEACETYLASES BY ACTIVATED NUCLEAR FACTOR-KAPPAB IN BREAST CANCER CELLS**  
M. W. Van Dyke, V. Gopal,  
T. S. Arora  
*University of Texas M.D. Anderson Cancer Center, Houston, TX*
- P5-18 MANGANESE SUPEROXIDE DISMUTASE SUPPRESSES HYPOXIC INDUCTION OF HYPOXIA INDUCIBLE FACTOR-1 IN BREAST CANCER CELLS**  
M. Wang, J. S. Kirk,  
L. W. Oberley, G. R. Buettner  
*Free Radical and Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA*
- P5-19 ROLE OF THE GADD34/PROTEIN PHOSPHATASE 1 COMPLEX IN REGULATING PROTEIN SYNTHESIS, PROLIFERATION AND APOPTOSIS IN BREAST CANCER CELLS**  
D. C. Weiser, S. Shenolikar  
*Duke University Medical Center, Durham, NC*

- P5-20 DEFINING THE MECHANISMS THAT REGULATE MAMMARY-SPECIFIC BETA-CASEIN GENE TRANSCRIPTION**  
W. Xian, E. Kabotyanski,  
J. Rosen  
*Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX*
- P5-21 FROM EXTRACELLULAR SIGNALING TO CHROMATIN STRUCTURE: HOW DO EXTRACELLULAR MATRIX AND PROLACTIN REGULATE MOUSE BETA-CASEIN TRANSCRIPTION**  
R. Xu, V. Spensor, M. J. Bissell  
*Lawrence Berkeley National Laboratory, Berkeley, CA*
- P5-22 DOMINANT REPRESSION OF AP-2 REGULATED GENES BY KRAB-AP2 RECOMBINANT PROTEINS INDUCES APOPTOSIS IN BREAST CANCER CELLS**  
V. G. Yennu Nanda,  
M. W. Van Dyke  
*University of Texas M.D. Anderson Cancer Center, Houston, TX*

- Biostatistics, <sup>3</sup>Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA; <sup>4</sup>Affymetrix, Inc. Santa Clara, CA*
- P6-3 A NOVEL DNA MICROARRAY APPROACH TO STUDY INDUCIBLE GENE EXPRESSION IN BREAST CANCER CELLS**  
C-W. Chang,<sup>1</sup> M. T. Paulsen,<sup>1</sup> Y-C. Tsan,<sup>1</sup> D. Beer,<sup>2</sup> M. Ljungman<sup>1,3</sup>  
<sup>1</sup>Department of Radiation Oncology, <sup>2</sup>Department of Surgery, <sup>3</sup>Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI
- P6-4 QUANTITATIVE ANALYSIS OF SOMATOSTATIN RECEPTOR-2 ON A BREAST CANCER TISSUE MICROARRAY**  
G. G. Chung, S. Ghosh,  
M. P. Zerkowski, R. L. Camp,  
D. L. Rimm, J. Murren  
*Department of Medical Oncology and Pathology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT*
- P6-5 A GENOMIC APPROACH TO DETERMINE THE CONTRIBUTION OF TYROSINE KINASES TO THE BREAST CANCER PHENOTYPE**  
C. Eiffert, K. Farley,  
D. S. Conklin  
*Gen\*NY\*Sis Center for Excellence in Cancer Genomics, University at Albany, State University of New York, Rensselaer, NY*
- P6-6 RESULTS FROM A GENOME-WIDE LINKAGE SCAN USING A COLON/BREAST CANCER PHENOTYPE**  
D. Daley,<sup>1</sup> R. C. Elston,<sup>1,5</sup> S. Lewis,<sup>2</sup> M. McMillen,<sup>2</sup> S. D. Markowitz,<sup>3,5</sup> G. L. Wiesner<sup>2,4,5</sup>  
*Departments of Epidemiology and Biostatistics, <sup>2</sup>Genetics, <sup>3</sup>Medicine, <sup>4</sup>Center for Human Genetics, and <sup>5</sup>Ireland Comprehensive Cancer Center, Case Western Reserve University and University Hospitals, Vancouver, BC, Canada*

P6-7	<b>MOLECULAR ANALYSIS OF DIFFERENCES IN BREAST CANCER CELLS FROM AFRICAN AMERICAN AND CAUCASIAN WOMEN</b> R. Das, R. Hammamieh, J. Mason, N. Chakraborty, A. Day, M. Jett <i>Division of Pathology, Walter Reed Army Institute of Research, Silver Spring, MD; Howard University Cancer Center, Washington, DC</i>	P6-13	<b>IDENTIFYING THE CHROMOSOMAL TARGETS OF ONCOGENIC TRANSCRIPTION FACTORS BY SEQUENCE TAG ANALYSIS OF GENOMIC ENRICHMENT</b> J. Kim, A. A. Bhinge, V. R. Iyer <i>Center for Systems and Synthetic Biology, Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX</i>	McGill University, Montreal, QC, Canada; <sup>1</sup> Institut de Recherches Cliniques de Montréal, Université de Montréal, Montréal, QC, Canada	
P6-8	<b>TOWARDS THE IDENTIFICATION OF TRANSLATIONALLY CONTROLLED GENES IN MOUSE MAMMARY TUMOR MODELS</b> M. J. del Prete, J. A. Garcia-Sanz <i>Centro de Investigaciones Biológicas CSIC, Madrid, Spain</i>	P6-14	<b>CLONING AND CHARACTERIZATION OF EXPANDED CAG REPEAT CONTAINING GENOMIC LOCI IN BREAST CANCER SAMPLES</b> H. Jarjanazi, <sup>1,2</sup> N. Pabalan, <sup>1,2</sup> H. Li, <sup>1,2</sup> H. Ozcelik <sup>1,2,3</sup> <i><sup>1</sup>Fred A. Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute; <sup>2</sup>Department of Laboratory Medicine and Pathology, Mount Sinai Hospital; <sup>3</sup>Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada</i>	P6-18	<b>PROTEOMIC ANALYSIS OF GENISTEIN MAMMARY CANCER CHEMOPREVENTION</b> C. Rowell, C. A. Lamartiniere <i>Department of Pharmacology and Toxicology, University of Alabama at Birmingham Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL</i>
P6-9	<b>DEVELOPMENT OF RNAI LIBRARIES FOR TARGET VALIDATION AND THERAPEUTICS</b> T. Giordano, A. Strat, L. Gao <i>Louisiana State University Health Sciences Center, Shreveport, LA</i>	P6-15	<b>FUNCTIONAL GENOMIC ANALYSIS OF BREAST CANCER CELL TUMORIGENICITY</b> A. Kourtidis, M. Curley, D. S. Conklin <i>Gen*NY*Sis Center for Excellence in Cancer Genomics, University at Albany, State University of New York, Rensselaer, NY</i>	P6-19	<b>MEMBRANE-ASSOCIATED AND SECRETED GENES IN BREAST CANCER</b> B. G. Mar, N. O. Stitsiel, J. Liang, C. A. Westbrook <i>Departments of Biochemistry and Molecular Genetics and Bioengineering, University of Illinois at Chicago, Chicago, IL; Department of Medicine, Boston University, Boston, MA</i>
P6-10	<b>ARGONAUGHTY: THE SECRET LIFE OF SLICER</b> G. J. Hannon <i>Cold Spring Harbor Laboratory, Cold Spring Harbor, NY</i>	P6-16	<b>IDENTIFICATION AND FUNCTIONAL STUDIES OF ONCOGENES CO-AMPLIFIED IN BREAST CANCER</b> S. S. Kwek, A. M. Snijders, Ylstra, D. G. Albertson <i>University of California at San Francisco, San Francisco, CA</i>	P6-20	<b>PROFILING GLOBAL TYROSINE PHOSPHORYLATION PATTERNS IN BREAST CANCER. A NOVEL MOLECULAR DIAGNOSTIC APPROACH</b> K. Machida, C. Thompson, B. J. Mayer <i>Raymond and Beverly Sackler Laboratory of Genetics and Molecular Medicine, Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT</i>
P6-11	<b>PROTEOMIC ANALYSIS OF SINGLE MCF7 BREAST CANCER CELLS BY ONE- AND TWO-DIMENSIONAL CAPILLARY ELECTROPHORESIS</b> M. M. Harwood, N. J. Dovichi <i>Department of Chemistry, University of Washington, Seattle, WA</i>	P6-17	<b>FUNCTIONAL GENOMICS OF ESTROGEN RECEPTOR ALPHA AND ESTROGEN-RELATED RECEPTOR ALPHA IN BREAST CANCER CELLS</b> J. Laganière, <sup>1,2</sup> G. Deblois, <sup>1</sup> C. Lefebvre, <sup>1</sup> A-R. Bataille, <sup>3</sup> F. Robert, <sup>3</sup> V. Giguère <sup>1,2</sup> <i><sup>1</sup>Molecular Oncology Group, McGill University Health Centre, Montreal, QC, Canada; <sup>2</sup>Department of Biochemistry,</i>	P6-21	<b>THE USE OF DNA MICROARRAY TO DETERMINE PATHWAYS OF METASTASIS IN BREAST CANCER</b> S. L. Moulder, N. Diaz, C. Beam, T. Yeatman <i>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL</i>
P6-12	<b>CAN GENE EXPRESSION PATTERN ANALYSIS PREDICT RECURRENCE IN NODE-NEGATIVE BREAST CANCER?</b> A. Immaneni, <sup>1,3</sup> Z. Li, <sup>3</sup> A. Tsimelzon, <sup>3</sup> S. G. Hilsenbeck, <sup>3</sup> G. M. Clark, <sup>3</sup> D. C. Allred, <sup>3</sup> C. K. Osborne, <sup>3</sup> P. O'Connell <sup>2,3</sup> <i><sup>1</sup>Department of Molecular and Cellular Biology and <sup>3</sup>Breast Center, Baylor College of Medicine, Houston, TX; <sup>2</sup>Medical College of Virginia, Virginia Commonwealth University, Richmond, VA</i>	P6-22	<b>IDENTIFICATION OF HIGH-DIMENSIONAL PROGNOSTIC GENE SIGNATURES FOR BREAST CANCER SURVIVAL</b> D. R. Peterson <i>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY</i>		

**P6-23 COMPARISON OF GENOME-WIDE ALLELIC LOSS PATTERNS IN LOBULAR AND DUCTAL BREAST CANCER**

P. L. Porter, L. W. M. Loo,  
D. I. Grove, L. Hsu, C. Ton,  
J. R. Daling, K. M. Malone,  
C. I. Li  
*Fred Hutchinson Cancer Center, Seattle, WA*

**P6-24 THE WISTAR-KYOTO MAMMARY CARCINOMA SUSCEPTIBILITY LOCUS, MCS5, CONTAINS THREE INDEPENDENT SUSCEPTIBILITY LOCI: TWO RESISTANCE LOCI AND A LOCUS CONFERRING INCREASED SUSCEPTIBILITY**

D. J. Samuelson, J. D. Haag,  
B. A. Aperavich, L. L. Gardner,  
M. N. Gould  
*McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI*

**P6-25 MODULATION OF CYTOKERATIN 19 IN HUMAN BREAST CANCER CELLS BY THE TOMATO CAROTENOID LYCOPENE**

P. P. Tadi-Uppala, T. Andacht,  
H. Kim, T. Dissmore  
*Departments of Environmental and Occupational Health and Nutrition, School of Public Health, Loma Linda University, Loma Linda, CA; Proteomics Resource Facility, University of Georgia, Athens, GA; University of Alabama at Birmingham, Birmingham, AL*

**P6-26 PROTEOMIC APPROACHES TO EARLY DETECTION OF BREAST CANCER**

M. A. Tainsky, J. Wojciechowski,  
S. Mohapatra, K. C. Amirika,  
N. Levin, S. Draghici  
*Barbara Ann Karmanos Cancer Institute and Department of Computer Science, Wayne State University, Detroit, MI*

**P6-27 PHARMACOLOGICAL REDIFFERENTIATION OF BREAST CANCER CELLS**

S. Diehl, S. Senaratne,  
M. A. Zeiger, C. B. Umbricht  
*Johns Hopkins University School of Medicine, Baltimore, MD*

**P6-28 GENE EXPRESSION SIGNATURE OF PLEURAL METASTATIC BREAST CANCER: A PRELIMINARY STUDY**

C. A. Westbrook, N. O. Stitziel,  
R. Mehta, J. Liang  
*Boston University Medical Center, Boston, MA; University of Illinois at Chicago, Chicago, IL*

**P7 Hormone Receptors I**

**6:30–8:30 p.m.**

*Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.*

**P7-1 COMPUTATIONAL CHARACTERIZATION AND PREDICTION OF ESTROGEN RECEPTOR ALPHA COACTIVATOR BINDING INHIBITORS**

B. J. Bennion, K. S. Kulp,  
M. Cosman, F. C. Lightstone  
*Biology and Biotechnology Research Program, Lawrence Livermore National Laboratory, Livermore, CA*

**P7-2 LOCATION OF THE ESTROGEN RESPONSE ELEMENT WITHIN A NUCLEOSOME AFFECTS BINDING OF THE ESTROGEN RECEPTOR**

J. C. Chrivia, L. Cox, M. F. Ruh  
*Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, Saint Louis, MO*

**P7-3 AKT PHOSPHORYLATING ER ALPHA S305 AND RELEASE MTA1-L1 INHIBITION OF ER ALPHA ACTIVITY**

Y. Cui, S. A. W. Fuqua  
*Breast Center and Department of Medicine, Baylor College of Medicine, Houston, TX*

**P7-4 ESTROGEN RECEPTOR STIMULATED BREAST CANCER CELL GROWTH INDEPENDENT OF DNA BINDING ACTIVITY**

D. G. DeNardo, H. Kim, K. Wu,  
A. V. Lee, P. H. Brown  
*Breast Center, Baylor College of Medicine, Houston, TX*

**P7-5 MECHANISMS UNDERLYING MAPK-MEDIATED DOWNREGULATION OF ESTROGEN RECEPTOR EXPRESSION**

S. Murthy, A. Hilger, J. Bayliss,  
J. Holloway, D. El-Ashry  
*Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan and University of Michigan Comprehensive Cancer Center, Ann Arbor, MI*

**P7-6 CONSTITUTIVE VERSUS INDUCIBLE ESTROGEN RECEPTOR ACTIVITY: DISTINCT MECHANISMS OF ACTIVATION AND ALTERED TARGET GENE EXPRESSION**

A. M. Fowler, E. T. Alarid  
*Department of Physiology, University of Wisconsin-Madison, Madison, WI*

**P7-7 EXPRESSION OF EZRIN-RADIXIN-MOESIN (ERM) BINDING PROTEIN 50 (EBP50) IS ASSOCIATED WITH RESISTANCE TO TAMOXIFEN**

Y. Cui, S. A. W. Fuqua  
*Breast Center, Baylor College of Medicine, Houston, TX*

**P7-8 DEVELOPMENT OF DESIGNER COACTIVATORS TO IDENTIFY NOVEL ESTROGEN RELATED RECEPTOR-ALPHA TARGET GENES**

S. Gaillard, C. L. Haeffele,  
D. P. McDonnell  
*Department of Pharmacology, Duke University Medical Center, Durham, NC*

**P7-9 LIMITING EFFECTS OF RIP140 IN ESTROGEN SIGNALING: POTENTIAL MEDIATION OF ANTI-ESTROGENIC EFFECTS OF RETINOIC ACID**

K. A. White, K. C. Heim,  
M. M. Yore, D. Deng,  
M. J. Spinella  
*Department of Pharmacology and Toxicology, Dartmouth Medical School, and Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Hanover, NH*

P7-10	<b>THE K303R ESTROGEN RECEPTOR ALPHA MUTATION IS PRESENT IN INVASIVE BREAST CANCER</b> M. H. Herynk, I. Parra, Y. Cui, S. K. Mohsin, A. Beyer, S. G. Hilsenbeck, S. A. W. Fugua <i>Departments of Medicine, Molecular and Cellular Biology, Breast Center, Pathology, Baylor College of Medicine, Houston, TX; Methodist Hospital, Houston, TX</i>	<sup>2</sup> Département De Biochimie, Université De Montréal, Montréal, QC, Canada; <sup>3</sup> Institut De Génétique et De Biologie Moléculaire et Cellulaire, Illkirch, Cédex, France	P7-20	<b>RESTORATION OF TAMOXIFEN SENSITIVITY IN BREAST CANCER CELLS. REACTIVATED TAMOXIFEN-COMPLEXED ESTROGEN RECEPTOR RECRUITS DISTINCT CHROMATIN-MODIFYING COMPLEXES</b> D. Sharma, <sup>1</sup> N. K. Saxena <sup>2</sup> <sup>1</sup> Winship Cancer Institute, <sup>2</sup> Department of Medicine, Emory University School of Medicine, Atlanta, GA	
P7-11	<b>IDENTIFICATION OF A NEGATIVE REGULATORY SURFACE WITHIN ESTROGEN RECEPTOR ALPHA PROVIDES EVIDENCE IN SUPPORT OF A ROLE FOR COREPRESSORS IN REGULATING CELLULAR RESPONSES TO AGONISTS AND ANTAGONISTS</b> H.-J. Huang, J. D. Norris, D. P. McDonnell <i>Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC</i>	P7-15	<b>TARGETING EXPRESSION OF ESTROGEN RECEPTOR(A) FOR THERAPY</b> M. B. Martin, S. Angeloni, A. Fahkro, M. Saceda, C. Ting, G. Storchan <i>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC</i>	P7-21	<b>ESTROGEN RECEPTOR ALPHA G525L KNOCK-IN MICE</b> K. W. Sinkevicius, <sup>1</sup> K. A. Temple, <sup>2</sup> S. L. Sugg, <sup>3</sup> F. E. Wondisford, <sup>2</sup> K. S. Korach, <sup>4</sup> G. L. Greene <sup>1</sup> <sup>1</sup> Ben May Institute for Cancer Research, University of Chicago, Chicago, IL; <sup>2</sup> Department of Medicine and Committee on Molecular Metabolism and Nutrition, Biological Sciences Division, University of Chicago, Chicago, IL; <sup>3</sup> Department of Surgery, Medical College of Wisconsin, Milwaukee, WI; <sup>4</sup> Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC
P7-12	<b>SCAFFOLD ATTACHMENT FACTOR B1 (SAFB1) SUPPRESSES ER ALPHA-MEDIATED TRANSCRIPTION IN PART VIA INTERACTION WITH N-COR</b> S. Jiang, R. Meyer, K. Kang, J. Wong, S. Oesterreich <i>Breast Center, Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX</i>	P7-16	<b>THE ROLE OF ESTROGEN RECEPTOR-BETA IN BREAST CANCER</b> L. Murphy, G. Skliris, B. Peng, E. Emberley, A. Lewis, K. Ung, A. Kemp, Y. Niu, L. Curtis-Snell, J. Davie, R. Shiu, E. Leygue, P. Watson <i>Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg, MB, Canada</i>	P7-22	<b>STRUCTURAL BASIS FOR A NOVEL MODE OF SERM-MEDIATED ER ANTAGONIST</b> Y.-L. Wu, <sup>1</sup> X. Yang, <sup>2</sup> Z. Ren, <sup>2</sup> D. P. McDonnell, <sup>3</sup> J. D. Norris, <sup>3</sup> T. M. Wilson, <sup>4</sup> G. L. Greene <sup>1</sup> <sup>1</sup> Ben May Institute for Cancer Research and Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL; <sup>2</sup> Renz Research, Inc., Westmont, IL; <sup>3</sup> Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC; <sup>4</sup> GlaxoSmithKline, Research Triangle Park, NC
P7-13	<b>TRANSLATIONAL CONTROL OF ESTROGEN RECEPTOR ALPHA BY AN UPSTREAM OPEN READING FRAME IN THE PROXIMAL PROMOTER TRANSCRIPT</b> M. Luo, B. Pentecost <i>Wadsworth Center, Albany, NY</i>	P7-17	<b>INHIBITING PROTEASOMAL PROTEOLYSIS SUSTAINS ESTROGEN RECEPTOR ACTIVATION</b> K. P. Nepheuw, M. Fan <i>Medical Sciences, Indiana University School of Medicine, Bloomington, IN</i>		
P7-14	<b>ROLE OF HELIX 12 POSITIONING IN TRANSCRIPTIONAL REPRESSION OF ESTROGEN RECEPTOR ALPHA BY FULL ANTIESTROGENS</b> M. Lupien, <sup>1</sup> A. Auger, <sup>2</sup> G. Dayan, <sup>2</sup> S. Anghel, <sup>2</sup> G.-A. Pinard, <sup>2</sup> C. Loch, <sup>3</sup> J.-M. Wurtz, <sup>3</sup> D. Moras, <sup>3</sup> S. Mader <sup>1,2</sup> <sup>1</sup> Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, QC, Canada;	P7-18	<b>GENE REGULATION IN AN MCF-7 CELL LINE THAT NATURALLY EXPRESSES AN ESTROGEN RECEPTOR UNABLE TO DIRECTLY BIND DNA</b> B. T. Pentecost, L. Bradley, J. F. Gierthy, Y. Ding, M. Fasco <i>Wadsworth Center New York State Department of Health, Albany, NY</i>		
P7-19	<b>THE ROLE OF NOVEL PHOSPHORYLATION SITES IN ESTROGEN RECEPTOR ALPHA IN THE ANTAGONIST AND AGONIST ACTION OF TAMOXIFEN</b> A. Basu, Y. Shah, M. Al-Dhaheri, A. El-Ghabawny, B. G. Rowan <i>Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA</i>				

- P7-23** **FUNCTIONAL ESTROGEN DEPRIVATION BY ACTIVATING THE ORPHAN NUCLEAR RECEPTOR PXR AND CAR**  
 S. S. P. Saini, H. Gong, D. Toma, S. Ren, W. Xie  
*Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA*
- P7-24** **ABNORMAL MAMMARY GLAND DEVELOPMENT AND GROWTH RETARDATION IN FEMALE MICE AND MCF7 BREAST CANCER CELLS LACKING ANDROGEN RECEPTOR**  
 S. Yeh, Y. C. Hu, P. H. Wang, C. Xie, Q. Xu, M. Y. Tsai, Z. Dong, R. S. Wang, T. H. Lee, C. Chang  
*Departments of Urology and Pathology, University of Rochester, Rochester, NY*

## **P8 Endocrine Carcinogenesis**

**6:30–8:30 p.m.**

*Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
 Even-numbered – 7:30–8:30 p.m.*

- P8-1** **DEVELOPMENT OF A MOUSE MODEL TO INVESTIGATE THE ROLE OF CATECHOL-O-METHYLTRANSFERASE (COMT) AND ESTROGEN CATECHOL METABOLITES IN BREAST CANCER**  
 C. Borgeest, J. D. Yager  
*Johns Hopkins Bloomberg School of Public Health, Baltimore, MD*
- P8-2** **ABERRANT MAMMARY PHENOTYPE IN GPX1 NULL MICE**  
 A. deFazio,<sup>1,2</sup> L. L. Scurr,<sup>1,2</sup> C. J. Kennedy,<sup>1,2</sup> C. L. Clarke,<sup>2</sup> J. B. De Haan<sup>3</sup>  
<sup>1</sup>Department Gyn Oncology and <sup>2</sup>WICR, University of Sydney at WMI, Westmead Hospital, Sydney, NSW, Australia; <sup>3</sup>Oxidative Stress and Diabetic Complications Group, Baker Heart Research Institute, Prahran, VIC, Australia

- P8-3** **ROLE OF DEFCAP GENE IN THE TRANSFORMATION OF HUMAN BREAST EPITHELIAL CELLS**  
 S. V. Fernandez, M. H. Lareef, I. H. Russo, B. R. Balsara, J. Russo  
*Breast Cancer Research Laboratory and Human Genetics Program, Fox Chase Cancer Center, Philadelphia, PA*

- P8-4** **A MODEL OF ESTROGEN INDUCED HUMAN BREAST CARCINOGENESIS**  
 P. A. Russo, M. H. Lareef, J. Garber, I. H. Russo, S. Fernandez, R. Fernbaugh, B. Balsara, F. Sheriff, G. Balogh, D. Mailo, R. Heulings, J. Russo  
*Breast Cancer Research Laboratory and Human Genetics Program, Fox Chase Cancer Center, Philadelphia, PA*

- P8-5** **AN IN VITRO/IN VIVO MODEL OF ESTROGEN INDUCED HUMAN BREAST CARCINOGENESIS**  
 P. A. Russo, M. H. Lareef, J. Garber, I. H. Russo, S. Fernandez, R. Fernbaugh, B. R. Balsara, F. Sheriff, G. Balogh, D. Mailo, R. Heulings, J. Russo  
*Breast Cancer Research Laboratory and Human Genetics Program, Fox Chase Cancer Center, Philadelphia, PA*

- P8-6** **MECHANISM OF PREGNANCY PROTECTION AGAINST BREAST CANCER**

- P. K. Siiteri,<sup>1</sup> B. A. Cohn<sup>2</sup>  
<sup>1</sup>Departments of Obstetrics and Gynecology and Reproductive Medicine, School of Medicine, University of California at San Francisco, San Francisco, CA;  
<sup>2</sup>Center for Research on Women's and Children's Health and Child Health and Development Studies, Public Health Institute, Berkeley, CA

- P8-7** **ESTROGEN AND ITS METABOLITES ALTER THE MIGRATORY BEHAVIOR OF HUMAN BREAST EPITHELIAL CELLS**  
 J. Vanegas, P. A. Russo, I. H. Russo, J. Russo  
*Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA*

- P8-8** **INTERACTIONS OF ESTROGEN AND PROGESTIN ACTIVE ENVIRONMENTAL CHEMICALS ON BREAST CANCER CELL PROLIFERATION, SURVIVAL, AND GENE EXPRESSION**  
 T. E. Wiese,<sup>1</sup> H. Li,<sup>1</sup> H. M. Nguyen,<sup>1</sup> S. R. Hill<sup>2</sup>  
<sup>1</sup>Xavier University of Louisiana College of Pharmacy, New Orleans, LA; <sup>2</sup>Tulane University School of Medicine, New Orleans, LA

- P8-9** **NATURALLY-OCCURRING ESTRADIOL-17BETA-FATTY ACID ESTER, BUT NOT ESTRADIOL-17BETA, PREFERENTIALLY INDUCES THE DEVELOPMENT OF MAMMARY TUMOR IN FEMALE ACI RATS**  
 L. H. Mills, A. J. Lee, B. T. Zhu  
*Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC*

## **P9 Angiogenesis**

**6:30–8:30 p.m.**

*Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
 Even-numbered – 7:30–8:30 p.m.*

- P9-1** **ABOLISHING SYNCHRONOUS INTERACTION BETWEEN D-CYCLIN AND THE CDK IS A CONTROLLING FACTOR FOR TUNICAMYCIN-INDUCED UNFOLDED PROTEIN RESPONSE-MEDIATED CELL CYCLE ARREST IN CAPILLARY ENDOTHELIAL CELLS**  
 D. K. Banerjee,<sup>1</sup> A. Sanchez,<sup>2</sup> S. Saha,<sup>1</sup> K. Baksi<sup>2</sup>  
<sup>1</sup>Department of Biochemistry, School of Medicine, Medical Sciences Campus, University of Puerto Rico, San Juan, PR;

<sup>2</sup>Department of Anatomy and Cell Biology, School of Medicine,

<p>Universidad Central del Caribe, Bayamon, PR</p>	<p>and Cancer Institute of New Jersey, New Brunswick, NJ</p>	<p><sup>2</sup>Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY; <sup>3</sup>Samuel Lunenfeld Research Institute, University of Toronto, ON, Canada</p>
<p><b>P9-2 A CRITICAL ROLE OF EphA2 RECEPTOR TYROSINE KINASE IN BREAST TUMOR ANGIOGENESIS AND METASTASIS</b></p> <p>D. Brantley-Sieders, W. B. Fang, D. Hicks, J. Chen <i>Vanderbilt-Ingram Cancer Center, Department of Medicine and Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN</i></p>	<p><b>P9-7 CHARACTERIZATION OF THE ROLE OF HEYL IN ANGIOGENESIS AND BREAST CANCER DEVELOPMENT</b></p> <p>L. Han, S. Sukumar <i>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD</i></p>	<p><b>P9-13 LASER CAPTURE MICRODISSECTION OF ENDOTHELIAL CELLS FROM HUMAN BREAST TUMORS</b></p> <p>N. Klauber-Demore, R. Bhati, D. Ketelson, C. M. Perou, C. Patterson <i>Lineberger Comprehensive Cancer Center and the Carolina Cardiovascular Biology Center, University of North Carolina at Chapel Hill, Chapel Hill, NC</i></p>
<p><b>P9-3 PROMOTING LYMPHANGIOGENESIS IN VIVO UTILIZING ALGINATE GELS WITH VEGF-C AND ANG-2</b></p> <p>M. A. Contreras, S. A. Slavin <i>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA</i></p>	<p><b>P9-8 CELLULAR PLASTICITY OF EPITHELIAL CELLS—CAUSE OF METASTASIS?</b></p> <p>L. Han, S. Sukumar <i>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD</i></p>	<p><b>P9-14 THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR-C AND HEPATOCYTE GROWTH FACTOR IN LYMPHANGIOGENESIS AND METASTASIS</b></p> <p>B. T. Kloos <i>Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY</i></p>
<p><b>P9-4 THE ROLE OF EPHA2 RECEPTOR TYROSINE KINASE IN HOST-TUMOR INTERACTIONS</b></p> <p>D. M. Brantley-Sieders,<sup>1</sup> W. B. Fang,<sup>2</sup> Y. Shyr,<sup>3</sup> J. Chen<sup>1,2</sup> <i>Departments of <sup>1</sup>Medicine, <sup>2</sup>Cancer Biology, and <sup>3</sup>Biostatistics, Vanderbilt University School of Medicine, Nashville, TN</i></p>	<p><b>P9-9 MOLECULAR DISRUPTION OF BREAST TUMOR ANGIOGENESIS BY TARGETED DOWN-REGULATION OF PAI-1 GENE EXPRESSION</b></p> <p>P. J. Higgins <i>Albany Medical College, Center for Cell Biology and Cancer Research, Albany, NY</i></p>	<p><b>P9-15 MODULATION OF VEGF BIOAVAILABILITY IN BREAST TUMORS BY DIRECT MMP CLEAVAGE</b></p> <p>S. Lee, M. L. Iruela-Arispe <i>University of California at Los Angeles, Los Angeles, CA</i></p>
<p><b>P9-5 SMALL INTEGRIN BINDING LIGAND N-LINKED GLYCOPROTEINS MODULATE MATRIX METALLOPROTEINASES AND ANGIOGENESIS</b></p> <p>N. Fedarko,<sup>1</sup> L. W. Fisher,<sup>2</sup> A. Jain<sup>1</sup> <i><sup>1</sup>Department of Medicine, Johns Hopkins University, Baltimore, MD; <sup>2</sup>National Institutes of Health, Department of Health and Human Services, Bethesda, MD</i></p>	<p><b>P9-10 INTERFERENCE WITH UPSTREAM STIMULATORY FACTOR OCCUPANCY OF AN E BOX MOTIF IN THE HUMAN PAI-1 GENE INHIBITS PAI-1 SYNTHESIS AND BASEMENT MEMBRANE INVASION</b></p> <p>P. J. Higgins <i>Albany Medical College, Center for Cell Biology &amp; Cancer Research, Albany, NY</i></p>	<p><b>P9-16 ALTERNATIVE WNT SIGNALING PATHWAYS IN HUMAN BREAST CANCER AND PRIMARY ENDOTHELIAL CELLS</b></p> <p>T. N. H. Masckauchan, J. Kitajewski <i>Columbia University, New York, NY</i></p>
<p><b>P9-6 INHIBITION OF BREAST CANCER-INDUCED ANGIOGENESIS BY A DIVERGED HOMEBOX GENE THAT INHIBITS NUCLEAR FACTOR-KAPPAB-DEPENDENT GENE EXPRESSION IN VASCULAR ENDOTHELIAL CELLS</b></p> <p>S. Patel, A. D. Leal, H. Sohail, D. H. Gorski <i>University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School</i></p>	<p><b>P9-11 ARE MAMMARY-STROMAL VASCULAR CELLS TRUE ENDOTHELIAL PROGENITORS?</b></p> <p>M. M. Ip, D. Liu, P. Wallace, B. Lisafeld, P. A. Masso-Welch <i>Roswell Park Cancer Institute, Buffalo, NY</i></p> <p><b>P9-12 ROLE OF NOTCH/VEGFR-3 IN BREAST TUMOR ANGIOGENESIS AND LYMPHANGIOGENESIS</b></p> <p>C. Shawber,<sup>1</sup> Y. Funahashi,<sup>1</sup> E. Francisco,<sup>1</sup> S. Podgrabsinska,<sup>2</sup> M. Voronchikhina,<sup>1</sup> K. Shiraishi,<sup>1</sup> K. Chawengsaksophak,<sup>3</sup> J. Rossant,<sup>3</sup> M. Skobe,<sup>2</sup> J. Kitajewski<sup>1</sup> <i><sup>1</sup>Department of Pathology and OB/GYN, Columbia University Medical Center, New York, NY;</i></p>	<p><b>P9-17 T-CADHERIN SUPPORTS MOUSE MAMMARY TUMOR GROWTH THROUGH AN ANGIOGENIC MECHANISM</b></p> <p>L. W. Hebbard,<sup>1</sup> M. Garlatti,<sup>1</sup> L. J. T. Young,<sup>2</sup> R. D. Cardiff,<sup>2</sup> R. G. Oshima,<sup>1</sup> B. Ranscht<sup>1</sup> <i><sup>1</sup>The Burnham Institute, La Jolla, CA; <sup>2</sup>Department of Pathology, University of California at Davis, Davis, CA</i></p>

**P9-18 ANALYSIS OF RASGRP3 IN MOUSE BLOOD VESSEL DEVELOPMENT AND TUMOR ANGIOGENESIS**

D. M. Roberts, A. L. Anderson, M. Hidaka, R. L. Sweteburg, C. Patterson, W. L. Stanford, V. L. Bautch

*University of North Carolina at Chapel Hill, Chapel Hill, NC*

**P9-19 BREAST CANCER VASCULATURE AND METASTASIS**

J. Pilch, L. Zhang, S. Steiniger, T. Duza, E. Ruoslahti  
*The Burnham Institute, La Jolla, CA*

**P9-20 NOTCH AND VEGFR-3 INTERACTIONS IN ENDOTHELIAL CELLS AND BREAST CANCER VASCULATURE**

C. J. Shawber,<sup>2</sup> E. Francisco,<sup>2</sup> N. Feirt,<sup>1</sup> T. Roe,<sup>1,2</sup> S. Podgrabsinska,<sup>4</sup> Y. Kitamura,<sup>3</sup> K. Shiraishi,<sup>2</sup> K. Chawengsaksophak,<sup>5</sup> J. Rossant,<sup>5</sup> D. Accili,<sup>3</sup> M. Skobe,<sup>4</sup> J. Kitajewski<sup>1,2</sup>  
*Departments of <sup>1</sup>Pathology, <sup>2</sup>OB/GYN, and <sup>3</sup>Medicine, Columbia University Medical Center, New York, NY; <sup>4</sup>Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY; <sup>5</sup>Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada*

**P9-21 ANTIANGIOGENIC ACTION OF CHEMICALLY MODIFIED TETRACYCLINES IN BREAST CANCER**

S. R. Simon, M. Kothari  
*Departments of Biochemistry and Pathology, State University of New York at Stony Brook, Stony Brook, NY*

**P9-22 TARGETING THE MAMMARY TUMOR VASCULATURE USING THE TVA-RCAS SYSTEM**

V. S. Vervoort, M. Lu, F. Valencia, G. Breier, E. B. Pasquale  
*The Burnham Institute, La Jolla, CA*

**P9-23 SCREENING AND CHARACTERIZATION OF PEPTIDES SPECIFICALLY TARGETING BREAST CANCER**

L. Zhang, M. Essler, E. Ruoslahti  
*Cancer Research Center, The Burnham Institute, La Jolla, CA*

**P10 Invasion and Metastasis I**

6:30–8:30 p.m.

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

**P10-1 HMGA2 AND PROGRESSION IN BREAST CANCER**

D. Sankarasharma, M. Zaidi, K. Chada  
*Department of Biochemistry, University of Medicine and Dentistry, New Jersey-Robert Wood Johnson Medical School, Piscataway, NJ*

**P10-2 CARBOHYDRATE-DEPENDENT BREAST CANCER METASTASIS**

M. N. Fukuda, H. Kawashima, M. Fukuda  
*Glycobiology Program, The Burnham Institute, La Jolla, CA*

**P10-3 ROLES OF PROSTAGLANDIN E2 (EP) RECEPTORS IN COX-2 MEDIATED HUMAN BREAST CANCER PROGRESSION**

A. V. Timoshenko, C. Chakraborty, P. K. Lala  
*Department of Anatomy and Cell Biology, University of Western Ontario, London, ON, Canada*

**P10-4 STROMAL AND VASCULAR INVASION OF NORMAL AND HYPERPLASTIC APPEARING HUMAN BREAST DUCTAL CELLS**

Y. Man  
*Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC*

**P10-5 DIFFERENTIAL EXPRESSION OF TUMOR INVASION RELATED PROTEINS IN CELLS OVERLYING FOCALLY DISRUPTED MYOEPITHELIAL CELL LAYERS AND ADJACENT CELLS WITHIN THE SAME DUCT**

Y. Man,<sup>1</sup> P. E. Berg,<sup>2</sup> Q-X. A. Sang<sup>3</sup>

<sup>1</sup>Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC; <sup>2</sup>Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC; <sup>3</sup>Department of Chemistry and Biochemistry, Florida State University, Tallahassee, FL

**P10-6 EXPRESSION OF BP1, A HOMOBOX GENE, CORRELATES WITH PROGRESSION AND INVASION OF MALE AND UNCOMMON FORMS OF BREAST TUMORS**

Y. Man, P. E. Berg  
*Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC; Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC*

**P10-7 FOCAL DEGENERATIONS IN SURROUNDING STRUCTURES AND INFILTRATION OF IMMUNOREACTIVE CELLS ARE A POTENTIAL TRIGGER FOR INVASION OF BREAST AND OTHER EPITHELIUM-DERIVED TUMORS**

Y. Man  
*Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC*

**P10-8 GENETICALLY DIFFERENT PRIMARY BILATERAL BREAST TUMORS SHOW SIMILAR SIGNS OF POTENTIAL PROGRESSION AND INVASION**

Y. Man

*Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC*

**P10-9 CD8 AND MAST CELL TRYPTASE POSITIVE CELLS ARE DIFFERENTIALLY DISTRIBUTED IN BENIGN AND MALIGNANT BREAST TISSUES WITH AND WITHOUT MYOEPITHELIAL CELL LAYERS**

Y. Man

*Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC*

**P10-10 GENETIC ALTERATIONS IN TUMOR EPITHELIUM AND HOST ENDOTHELIUM ASSOCIATED WITH METASTATIC PROGRESSION IN A MURINE MODEL OF BREAST CANCER METASTASIS**

B. Parker, N. Pouliot, A. Natoli, R. Anderson

*Peter MacCallum Cancer Centre, Victoria, Australia*

**P10-11 CHEMOTAXIS OF METASTATIC BREAST CANCER CELLS IN PARALLEL GRADIENT MICROFLUIDIC CHAMBERS**

W. Saadi, S-J. Wang, F. Lin, N. L. Jeon

*Department of Biomedical Engineering, University of California at Irvine, Irvine, CA*

**P10-12 TOLL-LIKE RECEPTOR 9 AGONISTS INDUCE INVASION OF BREAST CANCER CELLS IN VITRO**

M. A. Merrell, K. W. Harris, E. Rosenthal, T. Millender, B. Gehrs, K. S. Selander  
*Department of Medicine, Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL*

**P10-13 BISPHOSPHONATES EXHIBIT OPPOSING EFFECTS ON BREAST CANCER GROWTH BY ACTIVATING P38 AND INHIBITING THE MEVALONATE PATHWAY IN VITRO**

M. A. Merrell, S. Wakchoure, K. W. Harris, K. S. Selander  
*Department of Medicine, Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL*

**P10-14 CALCIUM BINDING PROTEIN ANNEXIN II REGULATES BREAST CANCER CELL INVASION AND MIGRATION**

M. Sharma,<sup>1</sup> M. Lazorik,<sup>1</sup> G. P. Tuszyński,<sup>2</sup> M. Shrama<sup>3</sup>  
<sup>1</sup>Drexel University College of Medicine, Philadelphia, PA, <sup>3</sup>University of Pennsylvania, Philadelphia, PA; <sup>2</sup>Temple University, Philadelphia, PA

**P10-15 IDENTIFICATION OF GENES INVOLVED IN BREAST TUMOR INVASION UTILIZING AN UBIQUITIN-MEDIATED PROTEOLYSIS IN VITRO SCREEN**

Y. M. Tan, C. Spruck  
*Sidney Kimmel Cancer Center, San Diego, CA*

**P10-16 ROLE OF CLUSTERIN IN HOMOTYPIC AND HETEROGENIC CELL-CELL INTERACTIONS IN METASTATIC PROGRESSION IN BREAST CANCER**

M. Tenniswood, L. Whyte, L. Flanagan  
*Department of Biological Sciences, University of Notre Dame, Notre Dame, IN*

**P10-17 MICROTUBULE ACETYLATION INHIBITS DYNAMIC INSTABILITY**

A. Tran, C. Bulinski  
*Department of Biological Sciences, Columbia University, New York, NY*

**P10-18 DIETARY GENISTEIN REDUCES METASTASIS IN A POST-SURGICAL ORTHOTOPIC BREAST CANCER MODEL**

S. A. Vantyghem,<sup>1,3</sup> S. M. Wilson,<sup>3</sup> C. O. Postenka,<sup>3</sup>

W. A. Al-Katib,<sup>3</sup> A. B. Tuck,<sup>1,2,3,4</sup> A. F. Chambers<sup>1,2,3,5</sup>

<sup>1</sup>Departments of Pathology and <sup>2</sup>Oncology, University of Western Ontario, London, ON, Canada; <sup>3</sup>London Regional Cancer Program, <sup>4</sup>London Health Sciences Centre, London, ON, Canada

**P10-19 CANCER METASTASIS HOMING GENES**

A. Wellstein, M. Schmidt, R. T. Henke, K. McDonnell, A. T. Riegel  
*Lombardi Cancer Center, Georgetown University, Washington, DC*

**P10-20 BREAST CANCER CELLS GENERATE INDEPENDENT MOTILE MICROPLASTS IN CULTURE**

G. Yount, K. Rachlin, T. Luu, S. Champion, S. Dairkee  
*California Pacific Medical Center Research Institute, San Francisco, CA*

**P11 Tumor Progression**

**6:30-8:30 p.m.**

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

**P11-1 MUC1 INTERACTS WITH C-SRC AND INFLUENCES POLYOMAVIRUS MIDDLE T ANTIGEN TRANSFORMATION**

A. N. Al Masri,<sup>1</sup> S. J. Gendler<sup>1,2</sup>  
<sup>1</sup>Department of Biochemistry and Molecular Biology and <sup>2</sup>Tumor Biology Program, Mayo Clinic College of Medicine, Mayo Clinic Scottsdale, Scottsdale, AZ

**P11-2 THE ROLE OF P120CTN IN CADHERIN SWITCHING IN BREAST CANCER**

D. I. Bellovin, A. M. Mercurio  
*Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA*

**P11-3 “CLUSTER BOMBING” OF NEIGHBOR ANTIOXIDANT AND BREAST TUMOR SUPPRESSOR LOCI**

F. H. Burton, J. L. Whittaker  
*Department of Pharmacology, University of Minnesota, Minneapolis, MN*

**P11-4 NUCLEAR OVEREXPRESSION OF HuR, WHICH BINDS TO THE 3'UNTRANSLATED REGION OF COLONY-STIMULATING FACTOR-1 RECEPTOR PROTO-ONCOGENE RNA, IMPARTS A POOR PROGNOSIS TO BREAST CANCER PATIENTS**

Y. Zhou,<sup>1</sup> W. Zheng,<sup>2</sup> M. Gilmore-Hebert,<sup>2</sup> E. C. Ulukus,<sup>2</sup> H. M. Kluger,<sup>3</sup> S. K. Chambers<sup>1</sup>  
<sup>1</sup>*Arizona Cancer Center, University of Arizona, Tucson, AZ;* <sup>2</sup>*Department of Pathology, Yale University School of Medicine, New Haven, CT;*  
<sup>3</sup>*Department of Internal Medicine/Oncology, Yale University School of Medicine, New Haven, CT*

**P11-5 ROLE OF SNAIL IN BREAST CANCER PROGRESSION**

D. Perez, J. W. Jang, S. E. Moody, T-C. Pan, C. P. Portocarrero, K. L. Notorfrancesco, L. A. Chodosh  
*Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA*

**P11-6 MECHANISM OF RECURRENCE OF NEU-INDUCED MAMMARY TUMORS**

S. E. Moody, D. Perez, T. Pan, C. J. Sarkisian, C. P. Portocarrero, C. J. Sterner, K. L. Notorfrancesco, R. B. Boxer, R. D. Cardiff, L. A. Chodosh  
*Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA*

**P11-7 MAMMARY STEM CELLS IN RESIDUAL NEOPLASTIC DISEASE**

D. Perez, G. K. Belka, S. E. Moody, S. Bakewell, K. L. Notorfrancesco, L. A. Chodosh  
*Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA*

**P11-8 THE ROLE OF HGCP3-PSORIASIN INTERACTION IN HUMAN BREAST CANCER**

C. M. Cooper, E. D. Emberley, P. H. Watson  
*Department of Pathology, University of Winnipeg, MB, Canada*

**P11-9 POLYCOMB PROTEINS AND BREAST EPITHELIAL CELL TRANSFORMATION**

S. Datta, V. Band, G. P. Dimri  
*Department of Medicine, Division of Cancer Biology, ENH Research Institute, Evanston, IL*

**P11-10 EFFECT OF LIPOSOME-ENCAPSULATED CLODRONATE ON TUMOR-ASSOCIATED MACROPHAGES AND BREAST CANCER GROWTH**

B. Gao, L. Feng, N. Van Rooijen, M-F. Tsan  
*Institute for Clinical Research, VA Medical Center, Washington, DC; Vrije Universiteit, Amsterdam, Netherlands*

**P11-11 BREAST CANCER LYMPH NODE METASTASIS IS ASSOCIATED WITH SITE SPECIFIC TRANSCRIPTIONAL PROGRAMS AND ALTERED EXPRESSION OF A SUBSET OF METASTASIS AND PROGNOSIS ASSOCIATED GENES**

M. Donaton,<sup>1</sup> D. Giri,<sup>2</sup> A. Olshen,<sup>1</sup> K. Panageas,<sup>1</sup> S. Levcovici,<sup>1</sup> P. La,<sup>1</sup> E. Brogi,<sup>1</sup> C. Hudis,<sup>1</sup> K. Vanzee,<sup>1</sup> L. Tan,<sup>1</sup> W. Gerald<sup>1</sup>  
<sup>1</sup>*Memorial Sloan-Kettering Cancer Center, New York, NY;* <sup>2</sup>*Rhode Island Hospital, Providence, RI*

**P11-12 FC-OPG INHIBITS OSTEOCLAST ACTIVITY, WHILE TUMOR-DERIVED OPG ENHANCES TUMOR GROWTH**

J. L. Fisher, R. J. Thomas, J. Elliott, D. K. Hards, N. A. Sims, J. Slavin, T. J. Martin, M. T. Gillespie  
*St. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia*

**P11-13 INHIBITION OF TISSUE FACTOR ON RAT MAMMARY TUMOR GROWTH IN AN IN-VIVO FIBRIN-Z CHAMBER MODEL**

T-S. Lai, Z. A. Haroon, C. S. Greenberg  
*Department of Medicine, Duke University Medical Center, Durham, NC*

**P11-14 IDENTIFICATION OF THE TYPES, PROPERTIES, AND FUNCTIONAL CHARACTERISTICS OF TELOMERASE EXPRESSING CELLS IN BREAST CANCER**

W. C. Hines, J. K. Griffith  
*Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, NM*

**P11-15 THE ROLE OF RAS IN MYC AND WNT-INDUCED MAMMARY TUMORIGENESIS**

J. W. Jang, R. B. Boxer, E. J. Gunther, G. K. Belka, L. A. Chodosh  
*Department of Cancer Biology, University of Pennsylvania School of Medicine, Philadelphia, PA*

**P11-16 A RAT MODEL FOR HUMAN BREAST CARCINOMA IN SITU**

R. Lakshmanaswamy,<sup>1,2</sup> R. C. Guzman,<sup>1</sup> S. Nandi<sup>1</sup>  
<sup>1</sup>*Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA;* <sup>2</sup>*Department of Pathology, Texas Tech University Health Science Center, El Paso, TX*

**P11-17 THE ROLE OF THE HYPOXIC MICROENVIRONMENT ON TUMOR FORMATION IN THE MAMMARY GLAND**

D. Liao, T. Seagroves, R. Johnson  
*University of California at San Diego, La Jolla, CA*

**P11-18 THE ROLE OF CRELD1 ISOFORM 9B IN THE PATHOGENESIS OF BREAST CANCER**

C. L. Maslen  
*Oregon Health and Science University, Portland, OR*

**P11-19 INVESTIGATION OF LOBULAR NEOPLASIA, USING MOLECULAR GENETIC TECHNIQUES, FOR THE INVOLVEMENT OF NOVEL GENES**

T. L. Mastracci,<sup>1,2</sup> S. Tjan,<sup>3</sup>

A. Shadéo,<sup>4</sup> S. Colby,<sup>5</sup>

A. L. Banke,<sup>1,2,3</sup> S. Bull,<sup>5</sup>

W. Lam,<sup>4</sup> F. P. O'Malley,<sup>2,3</sup>

I. L. Andrusis.<sup>1,2</sup>

*<sup>1</sup>Samuel Lunenfeld Research Institute, Fred A. Litwin Centre for Cancer Genetics, Mount Sinai Hospital, Toronto, ON, Canada;*

*<sup>2</sup>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; <sup>3</sup>Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; <sup>4</sup>B.C.*

*Cancer Research Centre, Department of Cancer Genetics and Developmental Biology, Vancouver, BC, Canada; <sup>5</sup>Samuel Lunenfeld Research Institute, Prosserman Centre for Health Research, Mount Sinai Hospital, Toronto, ON, Canada*

**P11-20 RAPID MOUSE MODELS TO INVESTIGATE GENETIC INTERACTIONS DURING MAMMARY TUMORIGENESIS**

B. Xiang, A. Rosenberg,

S. Muthuswamy

*Cold Spring Harbor Laboratory, Cold Spring Harbor, NY*

**P11-21 INVESTIGATING THE ROLE OF FIP200 IN MAMMARY CARCINOGENESIS USING A TRANSGENIC MOUSE MODEL**

T. Nagy, T-L. Shen, X. Peng, J-L. Guan

*College of Veterinary Medicine, Cornell University, Ithaca, NY*

**P11-22 ROLE OF GALECTINS-3 IN BREAST TUMOR PROGRESSION AND ITS INHIBITION BY MCP**

P. Nangia-Makker, M. Shekhar, L. Tait, A. Raz  
*Karmanos Cancer Institute, Wayne State University, Detroit, MI*

**P11-23 PROLACTIN ACTS DIRECTLY ON THE MAMMARY GLAND EPITHELIUM TO MODULATE HYPERPLASTIC CELL PROLIFERATION AND TUMOUR GROWTH IN THE C3(1)/SV40 T ANTIGEN MODEL OF MOUSE MAMMARY CARCINOGENESIS**

S. R. Oakes,<sup>1</sup> F. G. Robertson,<sup>1</sup>

J. E. Green,<sup>2</sup> C. J. Ormandy<sup>1</sup>

*<sup>1</sup>Cancer Program, Garvan*

*Institute of Medical Research, Darlinghurst, NSW, Australia;*

*<sup>2</sup>Transgenic Oncogenesis Group, Laboratory of Cell Regulation and Carcinogenesis, Bethesda, MD*

**P11-24 DIRECT VISUALIZATION OF PROSTATE CANCER PROGRESSION UTILIZING A LIVER BIOREACTOR**

D. B. Stoltz, C. Yater, L. Griffith,<sup>1</sup>

A. Wells

*University of Pittsburgh, Pittsburgh, PA; <sup>1</sup>Massachusetts Institute of Technology, Cambridge, MA*

**P11-25 S100A7 – JABBER AWAY AT THE HEART OF BREAST CANCER**

P. H. Watson, E. D. Emberley,

E. Leygue, L. C. Murphy

*Department of Pathology and Biochemistry and Molecular Biology, University of Manitoba and Manitoba Institute of Cell Biology, Winnipeg, MB, Canada*

**P11-26 A CRITICAL EVOLUTIONARY ROLE FOR HEAT SHOCK PROTEIN FUNCTION IN BREAST CANCER**

L. Whitesell, C. Dai,

R. A. Gatenby, S. L. Lindquist  
*Whitehead Institute for Biomedical Research, Cambridge, MA; University of Arizona, Tucson, AZ*

**P11-27 EXPRESSION OF MHC CLASS I AND II EXPRESSION SIGNIFICANTLY DISCRIMINATES AMONG BENIGN, CARCINOMA IN SITU, AND MALIGNANT LESIONS OF THE BREAST**

M. J. Worsham, J. J. Yang,

X. Sheng, R. Sheffer, J. Cheng,

U. Raju

*Henry Ford Health System, Detroit, MI*

**P11-28 DELINEATING A MOLECULAR CONTINUUM FOR BREAST CANCER PROGRESSION: MOLECULAR MODELING INDIVIDUAL GENE LOCI ALTERATIONS IN BREAST CANCER**

M. J. Worsham, J. Yang,

N. Tiwari, K. M. Chen, J. Cheng,

V. Shah, U. Raju

*Henry Ford Health System, Detroit, MI; University Hospital of Wales, Cardiff, Wales*

**P11-29 MOLECULAR DIFFERENTIATION OF BREAST CARCINOMA IN SITU**

U. Raju, S. Sethi, M. Lu,

H. Qureshi, J. Cheng, J. Yang,

N. Tiwari, K. M. Chen,

M. J. Worsham

*Henry Ford Health System, Detroit, MI*

**P11-30: DIFFERENT ROLES OF CARBONIC ANHYDRASE IX IN BREAST CANCER PROGRESSION**

Y. Cao, C-Y. Li, M. W. Dewhirst

*Department of Radiation Oncology, Department of Pathology, Duke University Medical Center, Durham, NC*

**P12 Tumor Immunology**

**6:30-8:30 p.m.**

**Posters Manned: Odd-numbered – 6:30–7:30 p.m.**

**Even-numbered – 7:30–8:30 p.m.**

**P12-1 HOMEOSTATIC T-CELL EXPANSION TO INDUCE ANTI-TUMOR AUTOIMMUNITY IN BREAST CANCER**

R. Baccala, R. Gonzalez-Quintial, A. N. Theofilopoulos

*Department of Immunology, The Scripps Research Institute, La Jolla, CA*

**P12-2 CAN WE MONITOR HLA CLASS I ANTIGEN-TUMOR ANTIGEN-PEPTIDE COMPLEX EXPRESSION ON BREAST CARCINOMA CELLS?**

M. Campoli, F. Ferro, X. Wang, S. Ferrone

*Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY*

**P12-3 TREATMENT OF METASTATIC BREAST CANCER BY PHOTODYNAMIC THERAPY INDUCED ANTI-TUMOR IMMUNITY IN A MURINE MODEL**  
 A. Castano, M. R. Hamblin  
*Massachusetts General Hospital, Boston, MA*

**P12-4 VACCINES TARGETING HER2 FOR PREVENTION OF BREAST CANCER RELAPSE**  
 D. Webster, L. Salazar,  
 C. delaRosa, V. Goodell,  
 J. Childs, P. Fintak, D. Higgens,  
 K. Knutson, M. L. Disis  
*University of Washington, Seattle, WA*

**P12-5 DENDRITIC CELLS ACQUIRE FUNCTIONAL PEPTIDE-MHC COMPLEXES FROM DEAD TUMOR CELLS**  
 B. P. Dolan, K. D. Gibbs Jr.,  
 S. Ostrand-Rosenberg  
*University of Maryland Baltimore County, Baltimore, MD*

**P12-6 SEARCH FOR BREAST CANCER TESTIS ANTIGENS VIA STUDYING DNA METHYLATION PATTERNS OF NORMAL TESTES AND PAIRED BREAST CANCER SAMPLES**  
 V. Jurukovski, K. Tian,  
 H. X. Duffy  
*Department of Biochemistry and Cell Biology, State University of New York at Stony Brook, Stony Brook, NY*

**P12-7 ADOPTIVE IMMUNOTHERAPY OF BREAST TUMOR USING EFFECTOR LYMPHOCYTES REDIRECTED WITH ANTI-HER2/NEU SPECIFICITY**  
 Z. Eshhar, T. Waks,  
 D. Friedmann-Morvinski  
*Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel*

**P12-8 ACTIVE IMMUNIZATION USING A PEPTIDE MIMIC OF A CARBOHYDRATE TUMOR ANTIGEN**  
 J. Heimburg, K. Rittenhouse-Olson  
*Department of Microbiology and Immunology, University at Buffalo, Buffalo, NY*

**P12-9 CYTOLYTIC T LYMPHOCYTES IN ORGANOTYPIC BREAST CARCINOMA CULTURE**  
 D. Herlyn, K. Berencsi, E. Miller,  
 P. Rani, Q. Wan, A. Wondimu  
*The Wistar Institute, Philadelphia, PA; Virtua Memorial Hospital, Mt. Holly, NJ*

**P12-10 INHIBITION OF BREAST TUMOR GROWTH IN THE NEU-TRANSGENIC MOUSE FOLLOWING DEPLETION OF REGULATORY T CELLS WITH AN INTERLEUKIN-2 IMMUNOTOXIN**  
 K. L. Knutson, Y. Dang, H. Lu,  
 K. Makary, M. L. Disis  
*Tumor Vaccine Group, University of Washington, Seattle, WA; Mayo Clinic College of Medicine, Rochester, MN*

**P12-11 THE ENDOGENOUS DANGER SIGNALING MOLECULE, URIC ACID, CONVERTS IMMUNITY FROM NON-PROTECTIVE TO PROTECTIVE WHEN USED AS A VACCINE ADJUVANT**  
 G. Vielhauer, E. Makary,  
 W. Wagner, M. L. Disis,  
 K. L. Knutson  
*Tumor Vaccine Group, University of Washington, Seattle, WA; Mayo Clinic College of Medicine, Rochester, MN*

**P12-12 IMMUNIZATION OF HER-2/NEU-OVEREXPRESSING BREAST CANCER PATIENTS WITH HER-2/NEU HLA CLASS II PEPTIDE-BASED VACCINES INDUCES EXTRA-MOLECULAR EPITOPE SPREADING AND PROLONGS SURVIVAL**  
 K. Howard, M. L. Disis,  
 L. Salazar, H. Lu, K. L. Knutson  
*Tumor Vaccine Group, University of Washington, Seattle, WA; Mayo Clinic College of Medicine, Rochester, MN*

**P12-13 CONTROL OF TUMOR GROWTH IN NORMAL AND TRANSGENIC MICE BY LISTERIA MONOCYTOGENES BASED VACCINES FOR HER-2/NEU AND THE IDENTIFICATION OF REGIONS OF HER-2/NEU WITH POTENTIAL CD8+ T CELL EPITOPES**

R. Singh,<sup>1</sup> M. E. Dominiecki,<sup>2</sup>  
 E. M. Jaffee,<sup>2</sup> Y. Paterson<sup>1</sup>

<sup>1</sup>Department of Microbiology, University of Pennsylvania, Philadelphia, PA; <sup>2</sup>Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD

**P12-14 NOVEL MHC CLASS II BREAST CANCER VACCINE USING RNA INTERFERENCE (RNAI) TO DOWN REGULATE INVARIANT CHAIN**  
 J. A. Thompson,  
 S. K. Dissanayake,  
 S. Ostrand-Rosenberg  
*Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD*

**P12-15 NOVEL IMMUNO-GENE THERAPIES TARGETING TRANSLATED RNA IN TUMOR CELLS**  
 N. Tsuda, C. Efferson,  
 M. Frederick, R. Schmandt,  
 J. Celestino, D. Gonzalez,  
 A. Garcia-Sastre, C. G. Ioannides  
*University of Texas M.D. Anderson Cancer Center, Houston, TX; Mt. Sinai School of Medicine, New York, NY*

**P12-16 A MINIGENE VACCINE AGAINST VEGF RECEPTOR-2 SUPPRESSES GROWTH OF METASTATIC BREAST CANCER**  
 Y. P. Luo, H. Zhou, M. Mizutani,  
 N. Mizutani, R. A. Reisfeld,  
 R. Xiang  
*Department of Immunology, The Scripps Research Institute, La Jolla, CA*

**P13 Biomarkers I**

6:30–8:30 p.m.

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.**P13-1 MOLECULAR MARKERS OF BREAST METASTASIS**

P. Mohan, R. Achary, H. Zhao,  
T. Ray,<sup>1</sup> C. Miyamoto  
*Department of Radiation Oncology and Division of Endocrinology, <sup>1</sup>Department of Medicine, Temple University School of Medicine, Philadelphia, PA*

**P13-2 RELATIONSHIP BETWEEN MAMMOGRAPHIC DENSITY AND IGF LEVELS AMONG HISPANIC AND NON-HISPANIC WHITE WOMEN**

L. Arendell, Z. Chen  
*University of Arizona, Tucson, AZ*

**P13-3 EUKARYOTIC INITIATION FACTOR 4E ELEVATION INCREASES RISK FOR CANCER RECURRENCE AND DEATH IN NODE-NEGATIVE BREAST CANCER PATIENTS**

K. Byrnes, K. Norton, Q. Chu,  
H. Yu,<sup>2</sup> L. Johnson,<sup>1</sup> K. Sehon,<sup>1</sup>  
J. Alley,<sup>1</sup> C. Meschonet,  
M. Abbas, B. D. L. Li  
*Louisiana State University Health Sciences Center, Shreveport, LA; <sup>1</sup>LSU Health Sciences Center, Monroe, LA; <sup>2</sup>Yale University School of Medicine, New Haven, CT*

**P13-4 HYPERMETHYLATION OF ACTIVATOR PROTEIN-2 ALPHA AS A PROGNOSTIC MARKER FOR DUCTAL CARCINOMA IN-SITU**  
H. Carraway, J. Herman,  
S. Baylin  
*Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD***P13-5 PROMOTER HYPERMETHYLATION AS A MOLECULAR MARKER FOR BREAST CANCER**  
H. Carraway, J. Lange, J. Wood,  
J. Herman  
*Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD***P13-6 CPG ISLAND METHYLATION AND ALTERED GENE EXPRESSION DURING BREAST CANCER PROGRESSION IN THE MCF10A MODEL**

J. K. Christman, M. Dawlaty,  
J. Yang,<sup>1</sup> L. Tang, M. J. Boland,  
D. L. Klinkebiel  
*University of Nebraska Medical Center, Omaha, NE; <sup>1</sup>Shanghai International Joint Cancer Institute, Shanghai, China*

**P13-7 TRUNCATED P95 HER-2 DEFINES A SUBSET OF HER-2 POSITIVE BREAST CANCER WITH WORSE OUTCOME**

E. E. Ramsey, R. Sáez,  
M. A. Molina, M.-J. García-Barchino, F. Rojo, J. Albañell,  
G. Sexton, E. J. Keenan, A. Lluch,  
J. García-Conde, J. Baselga,  
G. M. Clinton  
*Oregon Health and Science University, Portland, OR; University of Valencia, Valencia, Spain; Hospital Clínico Universitario, Valencia, Spain; Vall d'Hebron Hospital, Barcelona, Spain*

**P13-8 INCREASED EXPRESSION OF PERIPHERAL BENZODIAZEPINE RECEPTOR (PBR) IN BREAST CANCER**

S. Mukhopadhyay, B. R. Ballard,  
S. Mukherjee, S. K. Das  
*Department of Biochemistry, Meharry Medical College, Nashville, TN*

**P13-9 HUMAN TISSUE KALLIKREINS AS BIOMARKERS FOR BREAST, OVARIAN, AND OTHER MALIGNANCIES**

E. P. Diamandis  
*Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada*

**P13-10 PROTEOME ANALYSIS OF SERUM GLYCOPROTEINS IN HEALTHY WOMEN AND BREAST CANCER PATIENTS USING ISOTOPE-CODED AFFINITY TAGS**

F. J. Esteva, B. Zhang, D. Hawke,  
G. N. Hortobagyi, R. Kobayashi  
*University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P13-11 CIRCULATING TUMOR MARKER DISCOVERY USING PROTEOLYTIC PEPTIDE PROFILING**

F. J. Esteva, B. Zhang, H. Zhao,  
K. Baggerly, D. Hawke,  
J. Koomen, G. N. Hortobagyi,  
R. Kobayashi  
*University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P13-12 METHYLATED GENES AS EARLY DETECTION MARKERS FOR BREAST CANCER**

M. J. Fackler, J. Lange, T. Swift-Scanlan, E. Garrett, P. Argani,  
S. Sukumar  
*Departments of Oncology, Surgery, Pathology, and Clinical Trials and Biometry, Johns Hopkins University School of Medicine, Baltimore, MD*

**P13-13 CANCER SPECIFIC PROLIFERATING CELL NUCLEAR ANTIGEN AS A NOVEL DIAGNOSTIC MARKER FOR THE DETECTION OF BREAST CANCER**

D. J. Hoelz, B.-S. Herbert,  
R. Arnold, L. E. Dobrolecki,  
Y. Liu, J. Liu, L. Schnaper,  
S. Badve, R. J. Hickey,  
L. H. Malkas  
*Indiana University School of Medicine, Indianapolis, IN; Indiana University, Bloomington, IN; Greater Baltimore Medical Center, Baltimore, MD*

**P13-14 BC200 RNA IN BREAST CANCER: A MOLECULAR INDICATOR OF INVASIVENESS**

A. Iacoangeli,<sup>1</sup> H. Tideg<sup>1,2</sup>  
<sup>1</sup>Department of Physiology and Pharmacology, <sup>2</sup>Department of Neurology, State University of New York, Brooklyn, NY; Health Science Center at Brooklyn, Brooklyn, NY

**P13-15 SMALL INTEGRIN BINDING LIGAND N-LINKED GLYCOPROTEIN (SIBLING) GENE FAMILY EXPRESSION IN BREAST CANCER**

A. Jain,<sup>1</sup> L. W. Fisher,<sup>2</sup>

N. S. Fedarko<sup>1</sup>

<sup>1</sup>Department of Medicine, Johns Hopkins University, Baltimore, MD; <sup>2</sup>National Institutes of Health, Department of Health and Human Services, Bethesda, MD

**P13-16 SMALL INTEGRIN BINDING LIGAND N-LINKED GLYCOPROTEINS (SIBLINGS) BIND AND ACTIVATE MATRIX METALLOPROTEINASES**

A. Jain,<sup>1</sup> L. W. Fisher,<sup>2</sup>

N. S. Fedarko<sup>1</sup>

<sup>1</sup>Division of Geriatric Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD; <sup>2</sup>National Institutes of Health, Department of Health and Human Services, Bethesda, MD

**P13-17 METABOLIC REGULATOR AND THERAPEUTIC TARGET S14 IS UBIQUITOUS IN BREAST CANCER AT ALL STAGES AND INCREASES WITH TUMOR GRADE. IMMUNOHISTOCHEMICAL ANALYSIS OF 132 CASES AND COMPARISON WITH FATTY ACID SYNTHASE**

W. B. Kinlaw,<sup>1,3</sup> J. G. Chambers,<sup>3</sup>  
B. Cole,<sup>3</sup> G. N. Schwartz,<sup>1,3</sup>

W. A. Wells<sup>1,3</sup>

Departments of <sup>1,3</sup>Medicine and <sup>2</sup>Pathology, <sup>3</sup>Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH

**P13-18 CIRCULATING AUTOANTIBODIES FOR EARLY DETECTION OF BREAST CANCER**

A. Lokshin, A. Marrangoni,  
L. Velikokhatnaya, M. Winans,  
B. Nolan, E. Gorelik

University of Pittsburgh Cancer Institute, Pittsburgh, PA

**P13-19 THE ROLE OF CALGRANULINS IN BREAST CANCER PROGRESSION**

J. J. Pink,<sup>1</sup> T. Radivoyevitch,<sup>3</sup>  
N. Wang<sup>2</sup>

Departments of <sup>1</sup>Radiation Oncology, <sup>2</sup>Pathology, and <sup>3</sup>Biostatistics, Case Western

Reserve University, Cleveland, OH

**P13-20 IDENTIFICATION OF MOLECULAR BIOMARKERS OF CANCER RISK IN CYTOLOGICALLY NORMAL BREAST EPITHELIAL CELLS**

I. H. Russo, R. Wang,  
G. A. Balogh, F. Sheriff,  
A. Masny, M. Daly, M. Torosian,  
J. Russo

Breast Cancer Research Laboratory, Margaret Dyson Family Risk Assessment Program, and Department of Surgery, Fox Chase Cancer Center, Philadelphia, PA

**P13-21 A DECLINING PLASMA FIBRINOGEN ALPHA FRAGMENT IDENTIFIES HER2 POSITIVE BREAST CANCER PATIENTS AND REVERTS TO NORMAL LEVELS POST-SURGERY**

Q. Shi,<sup>1</sup> L. N. Harris,<sup>1</sup> X. Lu,<sup>2,3</sup>  
A. Petkovska,<sup>1</sup> X. Xu,<sup>2</sup> J. Hwang,<sup>1</sup>  
N. P. McElroy,<sup>1</sup> R. Gentlemen,<sup>2</sup>  
J. D. Iglehart,<sup>1,4</sup> A. Miron<sup>1,4</sup>

<sup>1</sup>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA; <sup>2</sup>Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA;

<sup>3</sup>Department of Statistics, Harvard University, Boston, MA;

<sup>4</sup>Department of Surgery, Brigham and Women's Hospital, Boston, MA

**P13-22 STROMAL HYPOXIA IN BREAST CANCER PROGRESSION**

L. Tomes, L. J. Curtis,

P. H. Watson

Department of Pathology, University of Manitoba, Winnipeg, MB, Canada

**P13-23 MAMMALIAN COG COMPLEX SERVES AS A "DOCKING STATION" FOR RETROGRADE GOLGI VESICLES**

S. Zolov, V. Lupashin

Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR

**P14 Computer-Aided Diagnostics**

6:30–8:30 p.m.

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

**P14-1 A LIKELIHOOD RATIO CLASSIFIER FOR COMPUTER-AIDED DIAGNOSIS IN MAMMOGRAPHY**

A. Bilska-Wolak, C. E. Floyd Jr.  
Department of Radiology, Duke University Medical Center, Durham, NC; Department of Biomedical Engineering, Duke University, Durham, NC

**P14-2 COMPUTERIZED ANALYSIS OF CONTRAST-ENHANCED MR IMAGES OF THE BREAST: AUTOMATED IDENTIFICATION OF SIGNAL-TIME CURVES**

W. Chen, M. Giger, G. Newstead, U. Bick, L. Lan  
Department of Radiology, Committee on Medical Physics, University of Chicago, Chicago, IL

**P14-3 INVESTIGATION OF THREE-GROUP CLASSIFIERS TO FULLY AUTOMATE DETECTION AND CLASSIFICATION OF BREAST LESIONS IN COMPUTER-AIDED DIAGNOSIS FOR MAMMOGRAPHY**

D. C. Edwards, C. E. Metz, R. M. Nishikawa, M. L. Giger  
Department of Radiology, University of Chicago, Chicago, IL

**P14-4 AUTOMATED ANALYSIS AND DISPLAY OF TEMPORAL SEQUENCES OF MAMMOGRAMS**

W. F. Good, X. H. Wang, G. Maitz

Department of Radiology, University of Pittsburgh, Pittsburgh, PA

- P14-5 INTERVAL CHANGE ANALYSIS OF CORRESPONDING CLUSTERED MICROCALCIFICATIONS ON SERIAL MAMMOGRAMS BASED ON AUTOMATED REGIONAL REGISTRATION**  
 L. M. Hadjiiski, H-P. Chan, B. Sahiner, M. A. Helvie, M. A. Roubidoux, C. Zhou  
*Department of Radiology, University of Michigan, Ann Arbor, MI*
- P14-6 MASS SEGMENTATION OF DENSE BREASTS ON DIGITIZED MAMMOGRAMS**  
 L. Kinnard,<sup>1,2</sup> S-C. B. Lo,<sup>2</sup> E. Duckett,<sup>3</sup> E. Makariou,<sup>2</sup> M. T. Freedman,<sup>2</sup> M. Chouikha<sup>1</sup>  
<sup>1</sup>*Department of Electrical and Computer Engineering, Howard University, Washington, DC;*  
<sup>2</sup>*Imaging Science and Information Systems Center, Georgetown University Medical Center, Washington, DC;* <sup>3</sup>*Advanced Radiology, Glen Burnie, MD*
- P14-7 COMPUTATIONAL FEATURE ANALYSIS OF MISSED CANCER IN SCREENING MAMMOGRAM**  
 L. Li, Z. Wu, Z. Chen, A. Salem, M. Kallergi, C. Berman  
*Departments of Medicine, Biochemistry and Molecular Genetics, Pathology, Biostatistics, and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL*
- P14-8 AN IMPROVED MAMMOGRAPHIC MASS COMPUTER AIDED DETECTION SYSTEM**  
 A. Baydush,<sup>1</sup> J. Lo,<sup>2</sup> D. Catarious,<sup>2</sup> S. Singh,<sup>2</sup> C. Floyd<sup>2</sup>  
<sup>1</sup>*Wake Forest University School of Medicine, Radiation Oncology, Winston-Salem, NC;* <sup>2</sup>*Department of Radiology, Duke University Medical Center, Durham, NC*
- P14-9 NEAR INFRARED FIBER OPTIC PROBE FOR IMPROVING THE ACCURACY OF BREAST CORE NEEDLE BIOPSY**  
 C. Lubawy, N. Ramanujam  
*Department of Biomedical Engineering, University of Wisconsin, Madison, WI*
- P14-10 EARLY BREAST CANCER DETECTION THROUGH THERMAL INFRARED IMAGING**  
 H. Qi,<sup>1</sup> Z. Liu,<sup>2</sup> C. Wang<sup>2</sup>  
<sup>1</sup>*Department of Electrical and Computer Engineering, University of Tennessee, Knoxville, TN;* <sup>2</sup>*Biowear, Inc., Houston, TX*
- P14-11 SIMILARITY/ROTATION INVARIANT ENHANCEMENT USING FOURIER DESCRIPTORS IN DIGITAL MAMMOGRAPHY**  
 W. Qian, M. Lei, D. Song, X. Sun, P. A. Romilly  
*H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL*
- P14-12 COMPUTERIZED ANALYSIS OF CELLULAR FEATURES FOR BREAST CANCER DIAGNOSIS**  
 W. Qian, D. Song, X. Sun, J. Zhou, M. S. Tockman, A. Sharma  
*H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL*
- P14-13 COMPUTER-AIDED MULTI-MODALITY BREAST MASS CHARACTERIZATION**  
 B. Sahiner, H-P. Chan, L. M. Hadjiiski, M. A. Roubidoux, C. Paramagul, M. A. Helvie  
*Department of Radiology, University of Michigan, Ann Arbor, MI*
- P14-14 EVIDENCE BASED DETECTION OF SPICULATED LESIONS AND ARCHITECTURAL DISTORTIONS**  
 M. Sampat, M. Markey, A. Bovik  
*Department of Biomedical Engineering, University of Texas at Austin, Austin, TX*
- P14-15 INTRAOPERATIVELY, IN VIVO, OPTICAL DIAGNOSIS OF NEGATIVE MARGINS, FOLLOWING THERMAL ABLATION**  
 G. Shafirstein, Y. J. Kaufmann, S. L. Ferguson, S. V. Klimberg  
*University of Arkansas for Medical Sciences, Little Rock, AR*
- P14-16 COMPUTER AIDED DETECTION OF BREAST MASSES IN MAMMOGRAPHY**  
 S. Singh,<sup>1</sup> D. Catarious,<sup>1</sup> C. Floyd,<sup>1</sup> A. Baydush,<sup>2</sup> J. Lo<sup>1</sup>  
<sup>1</sup>*Department of Radiology and Biomedical Engineering, Duke University Medical Center, Durham, NC;* <sup>2</sup>*Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC*
- P14-17 IPSILATERAL-MAMMOGRAM COMPUTER-AIDED DETECTION OF BREAST CANCER**  
 X. Sun, W. Qian, D. Song  
*H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL*
- P14-18 A DUAL SYSTEM FOR IMPROVEMENT OF COMPUTER-AIDED MASS DETECTION ON MAMMOGRAMS**  
 J. Wei, B. Sahiner, L. Hadjiiski, H-P. Chan, M. A. Helvie, M. A. Roubidoux  
*Department of Radiology, University of Michigan, Ann Arbor, MI*
- P14-19 TOWARD OPTICAL IMAGING OF SMALL TUMORS IN BREASTS USING CUMULANT FORWARD MODEL AND INDEPENDENT COMPONENT ANALYSIS**  
 M. Xu, M. Alrubaiee, W. Cai, S. K. Gayen, R. R. Alfano  
*Institute for Ultrafast Lasers and Spectroscopy, Physics Department, City College of the City University of New York, New York, NY*
- P14-20 COMPARTMENTAL MODELING OF INDOCYANINE GREEN KINETICS FOR BREAST CANCER DETECTION**  
 B. Alacam,<sup>1</sup> B. Yazici,<sup>1</sup> B. Chance<sup>3</sup>  
<sup>1</sup>*Electrical, Computer and Systems Engineering Department, Rensselaer Polytechnic Institute, New York, NY;* <sup>2</sup>*ART Advanced Research Technologies Inc., Canada;* <sup>3</sup>*Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA*

**P14-21 THREE DIMENSIONAL RECONSTRUCTION ALGORITHM FOR IMAGING PATHO-PHYSIOLOGICAL SIGNALS WITHIN BREAST TISSUE USING NEAR INFRARED LIGHT**  
H. Dehghani, B. W. Poque,  
B. A. Brooksby, K. D. Paulsen  
*Thayer School of Engineering,  
Dartmouth College, Hanover, NH*

---

## **P15 Nuclear Medicine Imaging**

**6:30–8:30 p.m.**

*Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.*

**P15-1 CYCLOPENTADIENYL RHENIUM (TECHNETIUM) TRICARBONYL COMPLEXES INTEGRATED IN ESTROGEN RECEPTOR (ER) LIGANDS FOR ER+ TUMOR IMAGING**  
N. C. Ackroyd,  
J. A. Katzenellenbogen  
*University of Illinois at Urbana-Champaign, Urbana, IL*

**P15-2 NOVEL THREE DIMENSIONAL ACQUISITION ORBITS WITH A DEDICATED EMISSION MAMMOTOMOGRAPHY SYSTEM**  
C. N. Brzymialkiewicz,  
M. P. Tornai  
*Duke University, Durham, NC*

**P15-3 INTRAOPERATIVE IMAGING OF AXILLARY SENTINEL LYMPH NODES IN PATIENTS WITH BREAST CANCER**  
C. M. Greene,<sup>1</sup> N. E. Hertel,<sup>1</sup>  
J. N. Aarsvold,<sup>2,3</sup> R. A. Mintzer,<sup>3</sup>  
S. F. Grant,<sup>2</sup> T. M. Styblo,<sup>3</sup>  
N. P. Alazraki,<sup>2,3</sup> B. E. Patt,<sup>4</sup>  
G. M. Caravaglia,<sup>4</sup> J. Li,<sup>4</sup>  
J. S. Iwanczyk<sup>4</sup>

<sup>1</sup>*Georgia Institute of Technology, Atlanta, GA;* <sup>2</sup>*Atlanta Veterans Affairs Medical Center, Atlanta, GA;* <sup>3</sup>*Emory University, Atlanta, GA;* <sup>4</sup>*Photon Imaging, Inc., Northridge, CA*

**P15-4 ASSESSMENT OF ESTROGEN RECEPTORS WITH 99MTC-LABELED ESTRADIOL**  
E. E. Kim, D. J. Yang, C. Oh,  
S. Kohanim, A. Azhdarinia,  
D-F. Yu  
*Division of Diagnostic Imaging,  
University of Texas M.D.  
Anderson Cancer Center,  
Houston, TX*

**P15-5 CARBON-11 LABELED RADIOTRACERS FOR IMAGING THE SIGMA-2 RECEPTOR STATUS OF BREAST CANCER**  
Z. Tu, C. S. Dence, J. Xu,  
K. T. Wheeler,<sup>1</sup> M. J. Welch,  
R. H. Mach  
*Washington University School of Medicine, St. Louis, MO;* <sup>1</sup>*Wake Forest University School of Medicine, Winston-Salem, NC*

**P15-6 NANOPROBE DIRECTED TUMOR IMAGING USING pH ACTIVATED PEPTIDES AS CONTRAST AGENT CARRIERS**  
J. Mata, S. Gustafson, R. Proteau,  
M. Slauson, J. Summerton  
*Colleges of Pharmacy and Veterinary Medicine and Department of Engineering, Oregon State University, Corvallis, OR*

**P15-7 TC-99M LABELED AND VIP-RECEPTOR TARGETED LIPOSOMES FOR EFFECTIVE IMAGING OF BREAST CANCER**  
H. Onyuksel, S. Dagar,  
A. Krishnadas, I. Rubinstein,  
M. Sekosan, B-S. Lee, M. Blend  
*University of Illinois at Chicago, Chicago, IL*

**P15-8 NON-INVASIVE DETECTION OF MATRIX METALLOPROTEINASE 2 AND 9 USING MICROPET IMAGING IN A MOUSE MODEL OF BREAST CANCER**  
J. E. Sprague, W. Li, S. Achilefu,  
C. J. Anderson  
*Washington University School of Medicine, St. Louis, MO*

**P15-9 DEVELOPMENT OF AN ULTRAHIGH RESOLUTION WHOLEBODY PET CAMERA WITH A DEDICATED BREAST PET TRANSFIGURATION**  
W-H. Wong, H. Li, H. Baghaei,  
Y. Wang, J. Uribe, R. Ramirez,  
S. Xie, S. Kim, Y. Zhang, J. Liu,  
S. Siu  
*University of Texas M.D.  
Anderson Cancer Center,  
Houston, TX*

**P15-10 (64)CU-ATSM MICROPET IMAGING OF TUMOR HYPOXIA IN ANIMAL TUMOR MODELS: COMPARISON WITH HYPOXIA IMMUNOSTAINING**  
H. Yuan, T. Schroeder,  
J. E. Bowsher, L. W. Hedlund,  
C. T. Wheeler, D. B. Daniel,  
G. Akabani, M. W. Dewhirst  
*Departments of Radiation Oncology and Radiology, Duke University Medical Center, Durham, NC*

---

## **P16 Drug Design and Development I**

**6:30–8:30 p.m.**

*Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.*

**P16-1 MN(III) TETRAKIS(N-ETHYL PYRIDINIUM-2-YL)PORPHYRIN IS A POTENT ANTI-ANGIOGENIC COMPOUND**  
I. Batinic-Haberle,<sup>1</sup> B. J. Moeller,<sup>1</sup>  
I. Spasojevic,<sup>2</sup> A. Okamoto,<sup>3</sup> B. Selvakumar,<sup>4</sup>  
Y. Zhao,<sup>1</sup> Z. Vujaskovic,<sup>1</sup>  
I. Fridovich,<sup>3</sup> M. W. Dewhirst<sup>1</sup>  
*Departments of <sup>1</sup>Radiation Oncology, <sup>2</sup>Medicine, <sup>3</sup>Biochemistry, and <sup>4</sup>Cell Biology, Duke University Medical Center, Durham, NC*

**P16-2 NOVEL COMPOUNDS TARGETING CHROMATIN AS THERAPY IN BREAST CANCER: A CHEMICAL GENETIC APPROACH**  
T. Gatbonton, J. Possakony,  
A. Bedalov  
*Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA*

- P16-3 THE SYNTHETIC LETHAL TRAP: A GENERAL APPROACH FOR SCREENING SMALL-MOLECULE PROTEIN INHIBITORS USING GENETIC TRIANGULATION IN THE YEAST *SACCHAROMYCES CEREVISIAE***  
 D. S. Bellows, P. Jorgensen, M. Tyers  
*Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada*
- P16-4 INHIBITION OF HER2 TRANSCRIPTION BY SMALL ORGANIC MOLECULE**  
 Y. Choi, S. Asada, H. Shimogawa, M. Uesugi  
*Baylor College of Medicine, Houston, TX*
- P16-5 IDENTIFICATION OF INOSINE MONOPHOSPHATE DEHYDROGENASE AS AN ANGIOGENIC DRUG TARGET**  
 C. R. Chong, F. Pan, J. O. Liu  
*Department of Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD*
- P16-6 INHIBITING MDR BREAST TUMORS: SYNTHESIS OF GSTP1-1-ACTIVATED NITRIC OXIDE GENERATORS**  
 B. K. See, D. J. Creighton  
*University of Maryland, Baltimore County, Baltimore, MD*
- P16-7 INHIBITION OF BREAST CANCER GROWTH BY AFP-DERIVED PEPTIDE: STUDY OF MECHANISM**  
 L. A. DeFreest, T. T. Andersen,<sup>1</sup> J. A. Bennett  
*Center for Immunology and Microbial Disease and <sup>1</sup>Center for Cardiovascular Science, Albany Medical College, Albany, NY*
- P16-8 RELATIONSHIPS OF STRUCTURES OF N-METHYLTHIOLATED BETA-LACTAM ANTIBIOTICS TO THEIR APOPTOSIS-INDUCING ACTIVITY IN HUMAN BREAST CANCER CELLS**  
 D. Kuhn, Y. Wang, V. Minic, C. Coates, G. S. Kumar Reddy, G. D. Kenyon, J-Y. Shim,
- D. Chen, K. R. Landis-Piwowar, E. Turos, Q. P. Dou  
*The Prevention Program, Barbara Ann Karmanos Cancer Institute, and Department of Pathology, School of Medicine, Wayne State University, Detroit, MI; Department of Chemistry, College of Arts and Sciences, University of South Florida, Tampa, FL*
- P16-9 POLYMER BASED ADJUVANT THERAPY FOR BREAST CANCER**  
 A. De Fail, C. Lee, S. Mathews, K. Marra, H. Edington  
*Department of Surgery, Divisions of Surgical Oncology and Plastic Surgery and the McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA*
- P16-10 TARGETING BREAST CANCER METASTASIS WITH ONCOLYTIC POLIOVIRUSES**  
 S. Moore, C. Kaiser, R. Grisham, M. Gromeier  
*Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC*
- P16-11 ENGINEERING POLYMERS FOR LOCALIZED BREAST CANCER GENE THERAPY**  
 M. Haider,<sup>1</sup> J. Cappello,<sup>2</sup> H. Ghandehari<sup>1,3,4</sup>  
*<sup>1</sup>Department of Pharmaceutical Sciences, <sup>3</sup>Greenebaum Cancer Center, <sup>4</sup>Program in Bioengineering, University of Maryland, Baltimore, MD; <sup>2</sup>Protein Polymer Technologies, Inc., San Diego, CA*
- P16-12 DEVELOPMENT OF NOVEL TC-99M-LABELED STEROIDS AS IMAGING AGENTS FOR ESTROGEN-RESPONSIVE BREAST CANCER**  
 R. N. Hanson, P. Tongcharoensirikul, E. McCaskill, R. B. Hochberg  
*Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA; Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT*
- P16-13 SOLID PHASE COMBINATORIAL APPROACH TO ESTRADIOL TAMOXIFEN/RALOXIFENE HYBRIDS: NOVEL CHEMOTHERAPEUTIC/PROPHYLACTIC SELECTIVE ESTROGEN RECEPTOR MODULATORS**  
 R. N. Hanson, P. Tongcharoensirikul, E. McCaskill, R. Dilis, A. Hughes, E. R. Desombre  
*Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA; Ben May Institute for Cancer Research, University of Chicago, Chicago, IL*
- P16-14 SYNTHESIS AND SCREENING OF NOVEL SUBSTITUTED BIPHENYL PROTEOMIMETICS AS POTENTIAL ANTI-ESTROGENIC AGENTS FOR THE TREATMENT OF HORMONE-RESPONSIVE BREAST CANCER**  
 R. N. Hanson, E. McCaskill, R. Dilis, S-M. Ho  
*Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA; Departments of Surgery and Urology, University of Massachusetts Medical Center, Worcester, MA*
- P16-15 IDENTIFICATION OF HUMAN METHIONINE AMINOPEPTIDASE TYPE I (HMETAP1) AS A NEW ANTICANCER TARGET**  
 X. Hu  
*Johns Hopkins University, School of Medicine, Baltimore, MD*
- P16-16 NEW ANTIESTROGENS FROM LIBRARIES OF HOMOALLYLIC AMIDES, ALLYLIC AMIDES AND C-CLOPROPYLALKYLAMIDES**  
 J. M. Janjic,<sup>1,3</sup> P. Wipf,<sup>1,2,3</sup> B. W. Day<sup>1,2</sup>  
*Department of <sup>1</sup>Pharmaceutical Sciences, <sup>2</sup>Chemistry, and <sup>3</sup>Center for Chemical Methodologies and Library Development, University of Pittsburgh, Pittsburgh, PA*

**P16-17 ARRESTING BREAST CANCER BY INHIBITION OF METASTASIS AND FACILITATION OF APOPTOSIS WITH TRUNCATED GALECTIN-3**

C. M. John, A. Trivedi,  
H. Cheng,<sup>1</sup> G. A. Jarvis  
*MandalMed, Inc., San Francisco, CA;* <sup>1</sup>*Veterans Affairs Medical Center, San Francisco, CA*

**P16-18 TOXICOLOGY AND ANTI-TUMOR EFFICACY OF LIPOSOMAL-DIMETHYL-SPHINGOSINE IN HIGHLY TAXOL-RESISTANT HER-2/NEU OVER-EXPRESSING HUMAN BREAST ADENOCARCINOMA ORTHOTOPIC XENOGRAFT**

E. Auzenne, M. Khodadadian,  
B. Rivera, R. E. Price, Y. Zou,  
J. Klostergaard  
*Departments of Molecular and Cellular Oncology and Imaging Physics Research, University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Oncology, Albert Einstein College of Medicine, Bronx, NY*

**P16-19 DEVELOPMENT OF NOVEL LIGAND-DRUG HYBRID NANOCRYSTALS TO TARGET BREAST CANCER**

Y. Yang, T. Li  
*University of Kentucky, College of Pharmacy, Lexington, KY*

**P16-20 DEVELOPMENT OF A UNIVERSAL CHEMOSENSITIZER TO SUPPORT BREAST CANCER TREATMENT: BASED ON THE HEREGULIN SEQUENCE**

R. Lupu, J. A. Menendez  
*Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL; Northwestern University Feinberg School of Medicine, Chicago, IL*

**P16-21 DISCOVERY OF POTENT CELL MIGRATION INHIBITORS FOR CANCER THERAPY EXPLOITING MIGRASTATIN AND ISOMIGRASTATIN**

M. Mandal, D. C. Dorn,  
K. Zhang, M. A. S. Moore,  
S. J. Danishefsky  
*Memorial Sloan Kettering Cancer Center, New York, NY*

**P16-22 5-FLUORO-2'-DEOXYCYTIDINE INHIBITS DNA METHYLATION AND INDUCES RE-EXPRESSION OF HYPERMETHYLATION SILENCED GENES IN HUMAN BREAST CANCER CELL LINES**

E. M. Newman, C. Li,  
D. Villacorte  
*City of Hope Beckman Research Institute, Duarte, CA*

**P16-23 FATTY ACID SYNTHASE AS A DRUG TARGET IN BREAST CANCER**

J. W. Smith, L. Knowles,  
C. Bronwe, S. Gramatikova,  
R. Richardson  
*The Burnham Institute, La Jolla, CA*

**P16-24 MECHANISMS FOR BLOCKING BREAST CANCER METASTASIS. CXCR4, A NOVEL TARGET**

J. O. Trent,<sup>1</sup> K. B. Napier,<sup>1</sup>  
Z. Wang,<sup>2</sup> H. Tamamura,<sup>3</sup>  
N. Fujii,<sup>3</sup> S. C. Peiper<sup>2</sup>  
<sup>1</sup>*J. G. Brown Modeling Facility, Brown Cancer Center, University of Louisville, Louisville, KY;*  
<sup>2</sup>*Department of Pathology and Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA;* <sup>3</sup>*Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan*

**P16-25 CONVERGENT SYNTHESIS OF BIFUNCTIONAL GLYCOPEPTIDES BEARING DIFFERENTIAL GLYCANS: TOWARD THE TOTAL SYNTHESIS OF A FULLY FUNCTIONAL ERYTHROPOIETIN**

J. D. Warren, S. J. Danishefsky  
*Sloan-Kettering Institute for Cancer Research, New York, NY*

**P16-26 CHEMICAL PROBES OF INTEGRATED ESTROGEN SIGNALING**

R. V. Weatherman, J. Trebley,  
E. Rickert  
*Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN*

**P17 Radiotherapy**

6:30–8:30 p.m.

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

**P17-1 OXIDATIVE STRESS, DNA REPAIR, AND ACUTE SIDE EFFECTS OF RADIOTHERAPY IN BREAST CANCER PATIENTS**

J. Chang-Claude, O. Popanda,  
X-L. Tan, S. Kropp, P. Schmezer,  
C. Tian, J. Ahn, C. B. Ambrosone  
*German Cancer Research Center, Heidelberg, Germany;*  
*Department of Epidemiology, Roswell Park Cancer Institute, Buffalo, NY;* *Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY*

**P17-2 A PARTNERSHIP TRAINING PROGRAM IN BREAST CANCER DIAGNOSIS: CONCEPT DEVELOPMENT OF THE NEXT GENERATION DIAGNOSTIC BREAST IMAGING USING DIGITAL IMAGE LIBRARY AND NETWORKING TECHNIQUES**

M. F. Chouikha, S-C. Ben Lo,<sup>1</sup>  
A. Jendoubi, P. Wang,<sup>2</sup> J. Zeng  
*Department of Electrical and Computer Engineering, Howard University, Washington, DC;*  
<sup>1</sup>*Radiology Department, ISIS Center, Georgetown University Medical Center, Washington, DC;* <sup>2</sup>*Department of Radiology, Howard University, Washington, DC*

**P17-3 SMC1 PHOSPHORYLATION PEPTIDES CAN INTERFERE WITH ATM-MEDIATED DNA DAMAGE PATHWAYS AND INCREASE BREAST TUMOR RADIOSensitivity**

X. Cui, S. Callens, B. Xu  
*Department of Genetics and Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA*

P17-4	<b>MOLECULAR MODELING, SYNTHESIS, AND CHARACTERIZATION OF RADIOIODINATED QUINAZOLINONE DERIVATIVES FOR ENZYME-MEDIATED BREAST CANCER DIAGNOSIS AND THERAPY</b> A. I. Kassis, K. Chen, K. Wang, A. F. Al Aowad, S. J. Adelstein <i>Department of Radiology, Harvard Medical School, Boston, MA</i>	of Texas M.D. Anderson Cancer Center, Houston, TX	P18-2	<b>RESISTANCE TO ENDOCRINE THERAPY IN BREAST CANCER</b> K. Bouker, Y. Zhu, R. Riggins, A. Zwart, R. Nehra, B. Gomez, R. Clarke <i>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC</i>
P17-5	<b>GENETICALLY TARGETED RADIOTHERAPY USING SODIUM IODIDE SYMPORter IN BREAST CANCER CELLS</b> K. Krager, A. Gaut, M. Madsen, D. Trask, M. Graham, F. Domann <i>Departments of Radiology, Radiation Oncology, and Otolaryngology, University of Iowa Hospitals and Clinics, Iowa City, IA</i>	P17-10 <b>DEVELOPING BIOMARKERS OF RADIATION RESPONSE: THE CORRELATION BETWEEN PLASMA TGF-BETA AND FRACTION SIZE</b> A. Bevan, C. Minami, C. Park <i>University of California at San Francisco, San Francisco, CA</i>	P18-3	<b>HUMAN X BOX BINDING PROTEIN IN ANTIESTROGEN RESISTANCE</b> B. Gomez, R. Riggins, Y. Zhu, A. Zwart, R. Clark <i>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC</i>
P17-6	<b>SEGMENT-BASED BREAST IMRT USING A GENETIC DOSE OPTIMIZATION ALGORITHM</b> T. Li, C. Cotrutz, D. Gofinett, L. Xing <i>Department of Radiation Oncology, Stanford University, Stanford, CA</i>	P17-11 <b>RESISTANCE TO IRRADIATION CYTOTOXICITY AND INCREASED TRANSFORMATION IN BREAST DUCTAL CARCINOMAS REQUIRES PROTEIN SYNTHESIS AND IS MEDIATED BY Elevated LEVELS OF THE INITIATION FACTOR EIF4G</b> S. Braunstein, <sup>1</sup> S. Formenta, <sup>2</sup> K. Karpisheva, <sup>1</sup> R. J. Schneider <sup>1</sup> <i>Departments of <sup>1</sup>Microbiology and <sup>2</sup>Radiation Oncology, New York University School of Medicine, New York, NY</i>	P18-4	<b>VITAMIN D3 ANALOG, 1-ALPHA-HYDROXY-D5, EXERTS GROWTH INHIBITORY ACTION VIA UPREGULATION OF P21(WAF-1) AND P27(KIP-1) EXPRESSION IN BREAST CANCER CELLS</b> E. A. Hussain, R. G. Mehta <i>Department of Surgical Oncology, University of Illinois at Chicago, Chicago, IL</i>
P17-7	<b>CHARACTERIZATION OF HELICAL ELECTRON BEAMS FOR BREAST RADIATION THERAPY</b> L. Ma <i>University of Maryland School of Medicine, Baltimore, MD</i>	<b>P18 Hormonal Therapy</b> <i>6:30–8:30 p.m.</i> Posters Manned: Odd-numbered – 6:30–7:30 p.m. Even-numbered – 7:30–8:30 p.m.	P18-5	<b>EVALUATION OF EFFECTS OF PROGNOSTIC FACTORS BY USING MEDIAN RESIDUAL LIFETIMES IN BREAST CANCER</b> J-H. Jeong, S-H. Jung <i>University of Pittsburgh, Pittsburgh, PA; Duke University, Durham, NC</i>
P17-8	<b>TREATMENT RELATED CARDIAC TOXICITY IN PATIENTS TREATED FOR BREAST CANCER</b> L. B. Marks <i>Duke University Medical Center, Durham, NC</i>	P18-1 <b>CLASSIFICATION OF ENDOCRINE RESPONSIVENESS IN BREAST CANCER PATIENTS</b> M. Liu, Y. Zhu, W. R. Miller, J. M. Dixon, M. Wang, A. Zwart, J. Zhang, J. Xuan, J. Wang, R. Clarke <i>Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC; Department of Oncology, Breast Unit, University of Edinburgh, Edinburgh, Scotland; Department of Electrical Engineering and Computer Science, Catholic University of America, Washington, DC; Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University (Virginia Tech), Arlington, VA</i>	P18-6	<b>MOLECULAR CHANGES IN RESPONSE TO ENDOCRINE THERAPIES</b> J. K. Richer, N. Spoelstra, D. Harvell, K. B. Horwitz, M. Singh, A. Elias <i>University of Colorado Health Sciences Center, Aurora, CO</i>
P17-9	<b>ACTIVATION OF ESTROGEN RECEPTOR-ALPHA BY DNA METHYLTRANSFERASE AND HISTONE DEACETYLASE INHIBITORS RADIOSENSITIZES HUMAN ESTROGEN RECEPTOR-ALPHA NEGATIVE BREAST CANCER CELLS</b> A. Munshi, T. A. Bucchholz, R. E. Meyn <i>Department of Experimental Radiation Oncology, University</i>	P18-7 <b>CONTRASTING EFFECT OF FULVESTRANT ON TAMOXIFEN-RESISTANT CELLS DEPENDS ON ESTROGEN LEVELS</b> M. C. Stone, M. L. Coleman, M. D. Planas-Silva <i>Department of Pharmacology, Penn State College of Medicine, Hershey, PA</i>		

**P18-8 ANTI-CANCER EFFECTS OF ESTREN IN BREAST CANCER**

Y-J. Wen, A. T. Mancino,  
S. Shaaf, T. Kieber-Emmons  
*University of Arkansas for Medical Sciences, Little Rock, AR*

**P19 Antiangiogenics****6:30–8:30 p.m.**

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

**P19-1 REGULATION OF BREAST CANCER CELL GROWTH AND MIGRATION BY ANNEXIN II NANOPARTICLES**

J. Liu, J. Vasic, V. Labhsetwar,  
J. Vishwanatha  
*University of North Texas Health Science Center, Fort Worth, TX;  
University of Nebraska Medical Center, Omaha, NE*

**P19-2 ANGIOGENESIS INHIBITORS IN BREAST CANCER**

A. Luque, M. L. Iruela-Arispe  
*Department of Molecular, Cell and Developmental Biology,  
University of California at Los Angeles, Los Angeles, CA*

**P19-3 REGULATION OF TIE2 EXPRESSION AND FUNCTION BY VASCULAR ENDOTHELIAL GROWTH INHIBITOR (VEGI)**

L. J. Metheny-Barlow,<sup>1</sup> L-Y. Li<sup>2</sup>  
<sup>1</sup>*Department of Oncology,  
Georgetown University,  
Washington, DC;* <sup>2</sup>*University of Pittsburgh Cancer Institute,  
Pittsburgh, PA*

**P19-4 TARGETABLE POLYMER-ANTIANGIOGENIC DRUG CONJUGATES FOR SYSTEMIC BREAST CANCER THERAPY**

A. Nan,<sup>1</sup> H. Ghandehari<sup>1,2,3</sup>  
*Departments of <sup>1</sup>Pharmaceutical Sciences, <sup>2</sup>Greenebaum Cancer Center, and <sup>3</sup>Bioengineering Program, University of Maryland, Baltimore, MD*

**P19-5 ENGINEERED MURINE MAMMARY CANCER CELLS PRODUCING SOLUBLE HUMAN PLASMINOGEN KRINGLE 5 PEPTIDE ARREST TUMOR GROWTH**

S. R. Perri,<sup>1</sup> M. Francois,<sup>2</sup>  
J. Galipeau<sup>3</sup>  
<sup>1</sup>*Lady Davis Institute for Medical Research, McGill University, Montreal, QC, Canada;* <sup>2</sup>*Lady Davis Institute for Medical Research, Montreal, QC, Canada;* <sup>3</sup>*Division of Hematology/Oncology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada*

**P19-6 SQUALAMINE SUPPRESSES TUMOR-ASSOCIATED ANGIOGENESIS AND ENHANCES ANTITUMOR EFFECTS OF GROWTH FACTOR RECEPTOR INHIBITORS IN HUMAN BREAST CANCER**

R. J. Pietras, H-W. Chen,  
M. Gorrin-Rivas, D. C. Marquez  
*Division of Hematology/Oncology, University of California at Los Angeles, School of Medicine, Los Angeles, CA*

**P19-7 ANTI-ANGIOGENIC AND VASCULAR TARGETING THERAPY OF BREAST CANCER BY TARGETING ENDOGLOBIN (CD105) OF TUMOR VASCULATURE**

B. K. Seon, S. Uneda, M. Tsujie,  
N. Harada, K. Shiozaki, A. Haba,  
N. Takahashi, X. She, H. Tsai  
*Roswell Park Cancer Institute, Buffalo, NY*

**P19-8 EVALUATION OF THE ALPHAVBET3 INTEGRIN-TARGETING MAB CONSTRUCT FOR BREAST CANCER TREATMENT**

F. Guo,<sup>1</sup> S. Das,<sup>1</sup> C. Rader,<sup>2</sup>  
B. Mueller,<sup>3</sup> R. A. Lerner,<sup>1</sup>  
C. F. Barbas,<sup>1</sup> S. C. Sinha  
<sup>1</sup>*Department of Molecular Biology and the Skaggs Institute for Chemistry Biology, Scripps Research Institute, La Jolla, CA;* <sup>2</sup>*Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;* <sup>3</sup>*Cancer Biology Division,*

*La Institute for Molecular Medicine, San Diego, CA*

**P19-9 MODULATING TIE2 ACTIVITY TO INCREASE BREAST CANCER RESPONSIVENESS TO ANTIANGIOGENIC THERAPY**

J. H. Tsai, S. Makonnen,  
W. M. F. Lee  
*Department of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA*

**P20 Symptom Management****6:30–8:30 p.m.**

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

**P20-1 UNDERSTANDING THE EXPERIENCE OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY**

M. A. Bakitas  
*Norris Cotton Cancer Center, West Lebanon, NH*

**P20-2 THE DEVELOPMENT OF A COMPREHENSIVE INSTRUMENT TO MEASURE SYMPTOMS AND SYMPTOM DISTRESS IN WOMEN WITH BREAST CANCER AFTER TREATMENT COMPLETION**

M. M. Boehmke  
*University at Buffalo, Buffalo, NY*

**P20-3 A RANDOMIZED STUDY OF THE EFFECT OF TIBOLONE ON BONE DENSITY, MENOPAUSAL SYMPTOMS AND BREAST DENSITY IN HIGH-RISK WOMEN AFTER PROPHYLACTIC OOPHORECTOMY**

J. Garber, N. Tung, P. Ryan,  
H. Joffe, M. Leboff  
*Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital, Boston, MA*

**P20-4 CHEMOTHERAPY AGENTS AND THE INHIBITION OF NEURONAL BIRTHING IN THE BRAIN**

R. A. Gross,<sup>1,2</sup> M. Gallagher,<sup>1,2</sup>  
M. J. Berg,<sup>1</sup> J. Roscoe,<sup>3</sup>  
B. Thompson,<sup>4</sup> L. Opanashuk<sup>4</sup>  
<sup>1</sup>*Departments of <sup>1</sup>Neurology, <sup>2</sup>Pharmacology and Physiology, Wilmot Cancer Center*

<p><sup>3,4</sup>Toxicology, University of Rochester Medical Center, Rochester, NY</p>	<p>Mt. Nittany Medical Center, State College, PA</p>	<p>Wake Forest University School of Medicine, Winston-Salem, NC</p>
<p><b>P20-5 EXERCISE FOR BREAST CANCER SURVIVORS. ITS EFFECT ON WEIGHT AND BODY COMPOSITION</b> C. Ingram <i>School of Nursing, McMaster University, Hamilton, ON, Canada</i></p>	<p><b>P20-10 RISK FACTORS FOR LYMPHEDEMA IN BREAST CANCER SURVIVORS</b> M. A. Rossing, K. E. Malone, M-T. C. Tang <i>Fred Hutchinson Cancer Research Center, Seattle, WA</i></p>	<p><b>P20-15 PREDICTORS OF LYMPHEDEMA FOLLOWING BREAST CANCER SURGERY</b> K. Swenson,<sup>1</sup> M. J. Nissen,<sup>1</sup> J. Post-White,<sup>2</sup> J. Pukes<sup>3</sup> <sup>1</sup>Park Nicollet Institute, St. Louis Park, MN; <sup>2</sup>University of Minnesota, Minneapolis, MN; <sup>3</sup>North Memorial Medical Center, Robbinsdale, MN</p>
<p><b>P20-6 THE EFFECTS OF LOW TO MODERATE INTENSITY EXERCISE ON FATIGUE IN BREAST CANCER PATIENTS FOLLOWING CLINICAL TREATMENT</b> K. Kemble, T. R. Burnham, B. Gallucci <i>University of Washington, Biobehavioral Nursing and Health Systems, Seattle, WA</i></p>	<p><b>P20-11 FACILITATING LYMPHEDEMA SYMPTOM MINIMIZATION PRACTICES IN BREAST CANCER SURVIVORS</b> K. Sherman,<sup>1</sup> S. Miller,<sup>2</sup> M. Glenn,<sup>2</sup> M. Rodoletz,<sup>2</sup> L. Goldstein<sup>2</sup> <sup>1</sup>Macquarie University, Sydney, Australia; <sup>2</sup>Fox Chase Cancer Center, Philadelphia, PA</p>	<p><b>P21 Evolving Therapeutic Targets</b> 6:30–8:30 p.m.</p>
<p><b>P20-7 WHEN DOES LYMPHEDEMA OCCUR AFTER BREAST CANCER SURGERY?</b> M. Kosir,<sup>1</sup> C. Rymal,<sup>1</sup> R. Perczak,<sup>1</sup> S. O'Connor,<sup>1</sup> P. Koppolu,<sup>1</sup> W. Du,<sup>1</sup> D. Smith,<sup>1</sup> D. Pawlowski,<sup>1</sup> J. D. Dingell<sup>2</sup> <sup>1</sup>Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI; <sup>2</sup>VAMC, Detroit, MI</p>	<p><b>P20-12 PATTERNS AND PREDICTORS OF FUNCTIONAL STATUS AND SYMPTOM DISTRESS IN OLDER VERSUS YOUNGER WOMEN UNDERGOING ADJUVANT BREAST CANCER CHEMOTHERAPY</b> C. T. Stricker <i>Department of Medicine, University of Pennsylvania School of Nursing, Philadelphia, PA</i></p>	<p><b>P21-1 EG-1 AS A NOVEL TARGET IN SOLID TUMORS</b> M. N. Brooks <i>University of California at Los Angeles, Los Angeles, CA</i></p>
<p><b>P20-8 A PILOT STUDY TO EXPLORE CHANGES IN OVARIAN STROMAL FUNCTION AND ASSOCIATED SYMPTOMS IN PREMENOPAUSAL WOMEN UNDERGOING CHEMOTHERAPY FOR BREAST CANCER</b> C. L. Loprinzi, M. H. Frost, A. E. Kearns, D. R. Smith, K. M. Zahasky, L. A. Carpenter, J. A. Sloan, D. L. Barton <i>Mayo Clinic, Rochester, MN</i></p>	<p><b>P20-13 INCIDENCE, TIME COURSE, AND DETERMINANTS OF MENSTRUAL BLEEDING AFTER BREAST CANCER TREATMENT. A PROSPECTIVE STUDY</b> J. A. Petrek, M. Naughton, D. Case, E. Singletary, E. Naftalis, E. Paskett <i>Memorial Sloan-Kettering Cancer Center, New York, NY; Wake Forest University, Winston-Salem, NC; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Texas Southwestern Medical Center at Dallas, Dallas, TX; Ohio State University, Columbus, OH</i></p>	<p><b>P21-2 EFFECTS OF PERSIN, A MAMMARY-GLAND SPECIFIC PLANT TOXIN, ON THE GROWTH OF HUMAN BREAST CANCER CELLS IN VITRO</b> A. J. Butt, C. K. W. Watts, R. L. Sutherland <i>Cancer Program, Garvan Institute of Medical Research, Sydney NSW, Australia</i></p>
<p><b>P20-9 THE USE OF EXERCISE TO INCREASE LYMPHOCYTE ACTIVATION FOLLOWING CHEMOTHERAPY FOR BREAST CANCER</b> A. M. Mastro, N. A. Hutnick, N. I. Williams, W. J. Kraemer, R. H. Dixon, A. D. Bleznak <i>Pennsylvania State University, University Park, PA; University of Connecticut, Storrs, CT; Center Medical and Surgical Associates,</i></p>	<p><b>P20-14 INCIDENCE AND TIME COURSE OF BLEEDING AFTER LONG TERM AMENORRHEA FOLLOWING BREAST CANCER TREATMENT: A PROSPECTIVE STUDY</b> P. Sukumvanich, J. A. Petrek, M. Naughton, D. Case <i>Memorial Sloan-Kettering Cancer Center, New York, NY;</i></p>	<p><b>P21-3 INHIBITION OF BREAST CANCER GROWTH BY CYCLOPAMINE, A SPECIFIC (?) INHIBITOR OF HEDGEHOG NETWORK SIGNALING</b> N. Harrington, M. T. Lewis <i>Baylor College of Medicine, Houston, TX</i></p>
		<p><b>P21-4 EXPLORATION OF BETA-CATENIN/TCF SIGNALING AS A POTENTIAL THERAPEUTIC TARGET FOR HER2/NEU-INDUCED BREAST CANCER</b> L. R. Howe <i>Department of Cell and Developmental Biology, Weill Medical College of Cornell University and Strang Cancer Research Laboratory, New York, NY</i></p>

**P21-5 ALTERATIONS IN GENE EXPRESSION BY PROHIBITIN RNA INDUCED TUMOR REGRESSION IN RAT MAMMARY CANCER**

E. R. Jupe, S. Manjeshwar, M. R. Lerner, D. E. Branam, S. A. Lightfoot, D. J. Brackett  
*Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK; InterGenetics Incorporated, Oklahoma City, OK; Departments of Surgery and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK*

**P21-6 TARGETING CYP24 ONCOGENE FOR TREATMENT OF BREAST CANCER**

S. Sundaram  
*Department of Surgery, Dartmouth Medical School, Lebanon, NH*

**P21-7 WILMS' TUMOR 1 (WT1) AS A NOVEL MOLECULAR TARGET IN BREAST CANCER**

A. Tari, M. Tuna, P. Zapata-Benavides, A. Chavez-Reyes, G. Lopez-Berestein  
*Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P21-8 CHARACTERIZATION OF THERMAL THRESHOLDS AND ENHANCEMENT OF CRYOINJURY IN BREAST CANCER CELLS**

B. Han, R. Visaria, D. Swanlund, J. Bischof  
*Department of Mechanical Engineering, University of Minnesota, Minneapolis, MN*

**P21-9 TRANSCRIPTION FACTOR STAT 3, MEDIATES EXPRESSION OF SURVIVING PROTEIN, AS THERAPEUTIC TARGET FOR RADIATION SENSITIZATION IN BREAST CANCER**

Kwang Woon Kim,<sup>1</sup> Carolyn Cao,<sup>1</sup> Eric T. Shinohara,<sup>1</sup> Konjeti R. Sekhar,<sup>1</sup> Zefang Ren,<sup>2</sup> Qiuyin Cai,<sup>2</sup> Wei Zheng,<sup>2</sup> and Bo Lu<sup>1</sup>  
*Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, TN*

**P22 Complementary Health and Alternative Medicine**

**6:30–8:30 p.m.**

*Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
 Even-numbered – 7:30–8:30 p.m.*

**P22-1 CURCUMIN SUPPRESSES METASTASIS IN A HUMAN BREAST CANCER XENOGRAFT MODEL: ASSOCIATION WITH SUPPRESSION OF NUCLEAR FACTOR-KAPPAB, CYCLOXYGENASE-2 AND MATRIX METALLOPROTEINASE**

B. B. Aggarwal,<sup>1,2</sup> S. Shishodia,<sup>2</sup> S. Banerjee,<sup>2</sup> R. A. Newman,<sup>3</sup> C. E. Bueso-Ramos,<sup>4</sup> J. E. Price<sup>5</sup>  
<sup>1</sup>*Cytokine Research Laboratory, Departments of Bioimmunotherapy, Experimental Therapeutics, Pathology, and Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P22-2 ASSOCIATION OF GINSENG USE WITH SURVIVAL AND QUALITY OF LIFE AMONG BREAST CANCER PATIENTS**

Y. Cui,<sup>1</sup> W. Zheng,<sup>1</sup> Y-T. Gao,<sup>2</sup> M-H. Tao,<sup>1</sup> H. Cai,<sup>1</sup> Z-X. Ruan,<sup>2</sup> F. Jin,<sup>2</sup> X-O. Shu<sup>1</sup>  
<sup>1</sup>*Department of Medicine, Vanderbilt University Center for Health Services Research, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN;*  
<sup>2</sup>*Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China*

**P22-3 MOLECULAR MECHANISM OF BENEFICIAL EFFECT OF FISH OIL IN BREAST TUMOR GROWTH**

N. Ghosh-Choudhury, T. Ghosh-Choudhury, G. Fernandes, G. Ghosh-Choudhury  
*Departments of Pathology and Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX*

**P22-4 EFFECT OF SELF-HYPNOTIC RELAXATION ON PAIN AND ANXIETY ASSOCIATED WITH LARGE CORE BREAST BIOPSY**

E. V. Lang, K. Berbaum, O. Hatsiopoulou, N. Halsey, S. Faintuch, M. Berbaum, J. Baum  
*Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA*

**P22-5 THE WAIT FOR DIAGNOSIS IS ASSOCIATED WITH INCREASED STRESS IN WOMEN AFTER LARGE CORE BREAST BIOPSY**

E. V. Lang, K. Berbaum, O. Hatsiopoulou, N. Halsey, S. Faintuch, M. Berbaum, J. Baum  
*Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA*

**P22-6 PHASE I STUDY OF THE CHINESE HERB HUANGLIAN (HL) IN PATIENTS WITH ADVANCED SOLID TUMORS**

G. K. Schwartz, A. Vickers, T. Chuck, J. Winkelman, B. Cassileth  
*Memorial Sloan-Kettering Cancer Center, New York, NY*

**P22-7 TRITOLIDE INHIBITS BREAST CANCER CELLS AND ENDOTHELIAL CELLS**

S. Yang, Y. Su, Z. Xiao, P. Okunieff, L. Zhang  
*Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY*

**P22-8 FLAVONOID INHIBITION OF MAMMARY TUMOR GROWTH**

X. Yang, T. J. Murray, D. Liu, D. H. Sherr  
*Department of Environmental Health, Boston University School of Public Health, Boston, MA*

**P23 Behavioral Sciences and Decision Making**

**6:30–8:30 p.m.**

Posters Manned: Odd-numbered – 6:30–7:30 p.m.  
Even-numbered – 7:30–8:30 p.m.

**P23-1 EMERGING SOLUTIONS. ADVOCATE COLLABORATIVE MODEL**

P. Devine,<sup>1</sup> L. Esserman,<sup>2</sup>  
N. Hylton<sup>2</sup>

<sup>1</sup>Cancer Information and Support Network (CISN), Pleasanton, CA; <sup>2</sup>University of California, San Francisco (UCSF), San Francisco, CA

**P23-2 ELEVATED WORK-STRESS CORTISOL RESPONSES IN WOMEN AT FAMILIAL RISK FOR BREAST CANCER: PREDICTED BY INTRUSIONS ABOUT BREAST CANCER**

L. Dettenborn,<sup>1</sup>  
H. B. Valdimarsdottir,<sup>1</sup>  
G. D. James,<sup>2</sup> G. H. Montgomery,<sup>1</sup>  
D. H. Bovbjerg<sup>1</sup>

<sup>1</sup>Oncological Sciences, Mount Sinai School of Medicine, New York, NY; <sup>2</sup>Decker School of Nursing, Binghamton University, Binghamton, NY

**P23-3 PREVALENCE AND COMMUNICATION OF ADVANCE CARE PLANNING AMONG WOMEN WITH BREAST CANCER**

A. Z. Doorenbos, C. W. Given,  
B. Given  
*Michigan State University, East Lansing, MI*

**P23-4 EXERCISE IN TAIWANESE BREAST CANCER SURVIVORS**

H-T. Hsu, M. J. Dodd, S. M. Paul,  
K. A. Lee, G. V. Padilla,  
M-C. Liu, C-S. Hwang  
*University of California at San Francisco, San Francisco, CA*

**P23-5 BETTER-THAN-AVERAGE AND COMPARATIVE-OPTIMISM BIASES IN A COMMUNITY SAMPLE: EFFECTS ON BREAST CANCER SCREENING**

M. C. Katapodi, M. J. Dodd,  
N. C. Facione, K. A. Lee,  
B. Cooper  
*Department of Physiological Nursing, University of California, San Francisco, San Francisco, CA*

**P23-6 KNOWLEDGE OF SPORADIC AND GENETIC BREAST CANCER RISK FACTORS AMONG WOMEN IN THE COMMUNITY**

M. C. Katapodi, B. A. Aouizerat  
*Department of Physiological Nursing, University of California, San Francisco, San Francisco, CA*

**P23-7 PREDICTORS OF BREAST CANCER WORRY. SOCIODEMOGRAPHIC AND AFFECTIVE CHARACTERISTICS**

M. C. Katapodi  
*Department of Physiological Nursing, University of California, San Francisco, San Francisco, CA*

**P23-8 HOW DO EXPERIENCES WITH AFFECTED FAMILY MEMBERS, AFFECTED FRIENDS, AND BREAST SYMPTOMS INFLUENCE PERCEIVED BREAST CANCER RISK?**

M. C. Katapodi, M. J. Dodd,  
N. C. Facione, K. A. Lee,  
J. C. Humphreys, B. Cooper  
*Department of Physiological Nursing, University of California, San Francisco, San Francisco, CA*

**P23-9 HIGHER RISK WOMEN'S BASIC UNDERSTANDING AND INTEREST IN TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION**

I. Lipkus, P. Marcom, E. Peters  
*Duke University Medical Center, Durham, NC; Oregon Decisional Research Institute, Eugene OR*

**P23-10 TAILORED COMMUNICATION TO ENHANCE ADAPTATION ACROSS THE BREAST CANCER SPECTRUM**

S. M. Miller, J. S. Buzaglo,  
M. Daly, M. Diefenbach,  
L. Fleisher, A. Godwin,  
L. Goldstein, S. L. Manne,  
E. Ross, R. A. Schnoll  
*Fox Chase Cancer Center, Philadelphia, PA*

**P23-11 EDUCATING WOMEN ABOUT RISK COUNSELING/GENETIC TESTING MAKES A DIFFERENCE IN INTENDED USE OF SERVICES, ESPECIALLY AMONG THOSE AT HIGH RISK: RESULTS OF A RANDOMIZED TRIAL OF CALLERS TO THE CANCER INFORMATION SERVICE**

S. Miller, L. Fleisher, R. Schnoll  
*Fox Chase Cancer Center, Philadelphia, PA*

**P23-12 TELEPHONE LINKED CARE: ENHANCING SELF-CARE FOR WOMEN WITH BREAST CANCER**

K. Mooney, S. Beck, W. Dudley,  
R. Farzanfar, R. Friedman  
*University of Utah, Salt Lake City, UT*

**P23-13 PEER MENTORS PROMOTING BREAST CANCER CLINICAL RESEARCH**

M. Rakoff, J. Hilger, J. Link,  
A. Maxwell  
*Breast Friends, Long Beach Memorial Medical Center; Long Beach, CA; Breastlink Medical Group; University of California Los Angeles, Los Angeles, CA*

**P23-14 DECISION MAKING OF WOMEN WITH RECURRENT BREAST CANCER**

P. F. Pierce  
*University of Michigan School of Nursing, Ann Arbor, MI*

**P23-15 USE OF FOCUS GROUPS TO INFORM CLINICAL TRIAL DESIGN**

M. L. Smith, J. Perrott, E. Railey  
*Research Advocacy Network, Arlington Heights, IL*

**P23-16 BREAST CANCER RISK PERCEPTIONS AND PREVENTION CHOICES AT A COUNTY HOSPITAL HIGH RISK CLINIC**

T. Salant,<sup>1</sup> P. S. Ganschow,<sup>2</sup>  
O. I. Olopade,<sup>3</sup> D. S. Lauderdale<sup>4</sup>  
<sup>1</sup>Pritzker School of Medicine and the Committee on the History of Culture, University of Chicago, Chicago, IL; <sup>2</sup>Breast & Cervical Cancer Screening Program, Cook County Hospital, Chicago, IL; <sup>3</sup>Rush Medical College, Chicago, IL; <sup>4</sup>Center for Clinical Cancer Genetics, Hematology/Oncology Section, University of Chicago,

<p>Chicago, IL; <sup>4</sup>Department of Health Studies and Associate Director Robert Wood Johnson Foundation Clinical Scholars Program, University of Chicago, Chicago, IL</p>	<p><b>P23-22</b> EMOTIONAL, BIOLOGICAL, AND COGNITIVE IMPACT OF A BRIEF EXPRESSIVE WRITING INTERVENTION FOR AFRICAN AMERICAN WOMEN AT FAMILIAL BREAST CANCER RISK</p>	<p><b>P24-3</b> THE RELATIONSHIP BETWEEN POLLUTION BURDEN AND AGE-ADJUSTED BREAST CANCER INCIDENCE RATES AT THE TOWN LEVEL</p>
<p><b>P23-17</b> EFFECT OF REMINDER TELEPHONE CALLS ON MAMMOGRAPHY COMPLIANCE IN HIGH-RISK WOMEN C. L. Snyder <i>Department of Preventive Medicine, Creighton University, Omaha, NE</i></p>	<p>H. B. Valdimarsdottir, A. Forman, D. Moglia, E. Wahl, K. Brown, D. H. Bovbjerg <i>Departments of Oncological Sciences and Human Genetics, Mount Sinai School of Medicine, New York, NY</i></p>	<p>K. Burns <i>Sciencecorps.org, Lexington, MA</i></p>
<p><b>P23-18</b> COGNITIVE CORRELATES OF ADHERENCE TO MAMMOGRAPHY SCREENING AMONG AN AFRICAN AMERICAN SAMPLE OF WOMEN WITH FAMILY HISTORIES OF BREAST CANCER S. L. Steele, L. Adams-Campbell <i>Howard University Cancer Center, Washington, DC</i></p>	<p><b>P23-23</b> IMPACT OF CULTURE ON BREAST CANCER SCREENING IN CHINESE AMERICAN WOMEN J. H. Wang, W. Liang, M. Y. Chen, S. Feng, B. Yi, J. S. Mandelblatt <i>Georgetown University, Washington, DC</i></p>	<p><b>P24-4</b> PLACENTAL WEIGHT, BIRTH WEIGHT AND RISK OF BREAST CANCER AFTER GIVING BIRTH: A POPULATION-BASED SWEDISH COHORT STUDY S. Cnattingius, A. Torräng, A. Ekbom, F. Granath, G. Petersson, M. Lambe <i>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden</i></p>
<p><b>P23-19</b> COMORBIDITY IS AN IMPORTANT DETERMINANT OF AFRICAN AMERICAN DISPARITY IN BREAST CANCER SURVIVAL C. M. Tammemagi, C. Neslund-Dudas, C. S. Feldkamp <i>Josephine Ford Cancer Center, Henry Ford Health System, Detroit, MI</i></p>	<p><b>P23-24</b> DEVELOPMENT OF TAILORED INTERVENTION TO PROMOTE BREAST CANCER SCREENING AMONG ASIAN AMERICAN WOMEN T-Y. Wu <i>University of Michigan, Ypsilanti, MI</i></p>	<p><b>P24-5</b> OBESITY, HORMONE THERAPY, ESTROGEN METABOLISM, AND RISK OF POSTMENOPAUSAL BREAST CANCER F. Modugno,<sup>1</sup> K. E. Kip,<sup>1</sup> B. Cochrane,<sup>3</sup> L. Kuller,<sup>1</sup> T. L. Klug,<sup>4</sup> T. E. Rohan,<sup>5</sup> R. T. Chlebowski,<sup>6</sup> N. Lasser,<sup>7</sup> M. L. Stefanick<sup>8</sup></p>
<p><b>P23-20</b> ADVOCATES MAKE A DIFFERENCE! S. Walsh, M. Rakoff <i>California Breast Cancer Organizations, Davis, CA</i></p>	<p><b>P24 Environmental Epidemiology</b> 6:30–8:30 p.m. Posters Manned: Odd-numbered – 6:30–7:30 p.m. Even-numbered – 7:30–8:30 p.m.</p>	<p><sup>1</sup>University of Pittsburgh Graduate School of Health, Pittsburgh, PA; <sup>2</sup>University of Pittsburgh Cancer Institute, Pittsburgh, PA; <sup>3</sup>Fred Hutchinson Cancer Research Center, Seattle, WA; <sup>4</sup>Immunacare Corporation, Bethlehem, PA; <sup>5</sup>Albert Einstein College of Medicine, New York, NY; <sup>6</sup>Los Angeles Biomedical Research Institute, Torrance, CA; <sup>7</sup>University of Medicine and Dentistry of New Jersey, Newark, NJ; <sup>8</sup>Stanford University School of Medicine, Stanford CA</p>
<p><b>P23-21</b> DEVELOPMENT OF AN INTERVENTION TO INCREASE BREAST CANCER SURVEILLANCE AMONG AFRICAN AMERICAN BREAST CANCER SURVIVORS H. S. Thompson, M. Littles <i>Mount Sinai School of Medicine, Department of Oncological Sciences, New York, NY</i></p>	<p><b>P24-1</b> NUTRITIONAL STATUS, DNA DAMAGE, AND TUMOR PATHOLOGY S. J. Johnson,<sup>1</sup> S. A. Adams,<sup>2</sup> J. R. Hebert,<sup>2</sup> S. H. Berger<sup>1</sup></p>	<p><b>P24-6</b> CLUSTERING OF CASES BY EARLY LIFE RESIDENCE: EVIDENCE FOR EARLY LIFE ENVIRONMENTAL EXPOSURES IN THE ETIOLOGY OF BREAST CANCER? D. Han, J. L. Freudenheim, M. Bonner, J. Nie, D. Vito, P. Muti, M. Trevisan, C. Ambrosone, S. Edge, P. Shields</p>
<p><b>P24-2</b> IS BOVINE LEUKEMIA VIRUS IN HUMAN BREAST TISSUE A RISK FOR BREAST CANCER? G. C. Buehring,<sup>1</sup> H-M. Shen,<sup>1</sup> K. Y. Choi,<sup>1</sup> H. M. Jensen<sup>2</sup></p>	<p><sup>1</sup>School of Public Health, University of California at Berkeley, Berkeley, CA; <sup>2</sup>School of Medicine, University of California at Davis, Davis, CA</p>	<p><i>Department of Social and Preventive Medicine, University at Buffalo, Buffalo, NY</i></p>

**P24-7 MODIFIABLE RISK FACTORS FOR BREAST CANCER IN A MULTIETHNIC POPULATION**

E. M. John, A. I. Phipps, J. Koo  
*Northern California Cancer Center, Fremont, CA*

**P24-8 REPRODUCTIVE AND HORMONAL RISK FACTORS FOR BREAST CANCER IN BLIND WOMEN**

E. E. Evans,<sup>1</sup>  
E. S. Schernhammer,<sup>2</sup>  
E. S. Silver,<sup>3</sup> R. G. Stevens,<sup>4</sup>  
S. W. Lockley<sup>1,5</sup>

<sup>1</sup>*Division of Sleep Medicine, Brigham and Women's Hospital, Boston, MA;* <sup>2</sup>*Channing Laboratory, Department of Medicine and Brigham and Women's Hospital, Harvard Medical School, Boston, MA;* <sup>3</sup>*Cinta Latina Research, Red Bank, NJ;* <sup>4</sup>*Division of Epidemiology and Biostatistics, University of Connecticut Health Center, Farmington, CT;* <sup>5</sup>*Division of Sleep Medicine, Harvard Medical School, Boston, MA*

**P24-9 BIRTHWEIGHT AND THE INCIDENCE OF BREAST CANCER IN ADULTHOOD**

K. B. Michels, F. Xue,  
K. L. Terry, G. A. Colditz,  
W. C. Willett  
*Harvard University, Boston, MA*

**P24-10 DIETARY FAT, EICOSANOIDS AND BREAST-CANCER RISK**

S. Raatz, M. Kurzer, B. Redmon  
*Departments of Medicine and Nutrition, University of Minnesota, Minneapolis, MN*

**P24-11 GENE-ENVIRONMENT INTERACTION AND BREAST CANCER ON LONG ISLAND, NY**

S. L. Teitelbaum,<sup>1</sup> M. S. Wolff,<sup>1</sup>  
A. I. Neugut,<sup>2</sup> R. M. Santella,<sup>2</sup>  
M. D. Gammon<sup>3</sup>  
<sup>1</sup>*Mount Sinai School of Medicine, New York, NY;* <sup>2</sup>*Mailman School of Public Health, New York, NY;* and <sup>3</sup>*University of North Carolina, Chapel Hill, NC*

**P24-12 EARLY LIFE FACTORS AND BREAST CANCER RISK**

M. B. Terry, T. James,  
L. Konikov-Titievsky, D. Shah,  
E. Susser, P. Tehranifar  
*Mailman School of Public Health, Columbia University, New York, NY*

**P24-13 CHANGES IN INSULIN-RELATED BIOMARKERS DURING PUBERTAL DEVELOPMENT AMONG GIRLS IN THE DIETARY INTERVENTION STUDY IN CHILDREN (DISC)**

E. M. Velie,<sup>1</sup> J. C. Gardiner,<sup>1</sup>  
C. J. Rosen,<sup>2</sup> T. Yi,<sup>1</sup> J. Kerver,<sup>1</sup>  
J. F. Dorgan<sup>3</sup>  
<sup>1</sup>*Departments of Epidemiology/Statistics, Michigan State University, East Lansing, MI;* <sup>2</sup>*St. Joseph Hospital, Bangor, ME;* <sup>3</sup>*Fox Chase Cancer Center, Philadelphia, PA*

---

**P25 BRCA2 Tumor Suppressor**

12:05–2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.

**P25-1 CHARACTERIZATION OF A HUMAN BRCA2 BREAST CANCER CELL LINE**

R. Aloyz, P. Marcouiller,  
L. P. Chen, L. Quenneville,  
L. C. Panasci, W. Foulkes  
*Lady Davis Institute for Medical Research-Jewish General Hospital, Montreal, QC, Canada;* *Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, QC, Canada*

**P25-2 BRCA2-DEPENDENT DNA INTERSTRAND CROSSLINK REPAIR IN VITRO**

L. Cipak, M. Bessho, T. Bessho  
*Eppley Institute, University of Nebraska Medical Center, Omaha, NE*

**P25-3 BRCA2 IS A COMPONENT OF THE CENTROSOME**

F. J. Couch, S. Hinson, J. Wu,  
M. Rowley, J. Salisbury  
*Mayo Clinic College of Medicine, Rochester, MN*

**P25-4 FUNCTIONAL EVALUATION AND CANCER RISK ASSESSMENT OF BRCA2 UNCLASSIFIED VARIANTS**

F. J. Couch, K. Wu, S. R. Hinson,  
A. Ohashi, D. Farrugia,  
S. V. Tavtigian, A. Deffenbaugh,  
D. Goldgar  
*Mayo Clinic College of Medicine, Rochester, MN; International Agency for Research on Cancer, Lyon, France; Myriad Genetics Laboratories Inc., Salt Lake City, UT*

**P25-5 INVESTIGATING THE GENETIC INTERACTION OF THE HOMOLOGOUS RECOMBINATION PROTEINS: RAD51, BRCA2 AND BLM**

T. Marple, T. M. Kim, P. Hasty  
*Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX*

**P25-6 CHARACTERIZATION OF A POTENTIAL BRCA2 INTERACTION**

C. J. Huggins, I. L. Andrus  
*Samuel Lunefeld Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada*

**P25-7 REGULATION OF DNA HOMOLOGOUS RECOMBINATIONAL REPAIR BY BCCIP, A BRCA2 INTERACTING PROTEIN**

H. Lu, X. Meng, Z. Shen  
*Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM*

**P25-8 BIOCHEMICAL CHARACTERIZATION OF BRCA2 ROLE IN HOMOLOGOUS RECOMBINATION**

L. Krejci, J. S. Fillippo, J. Etchin, P. Sung  
*Yale University School of Medicine, Molecular Biophysics and Biochemistry, New Haven, CT*

- P25-9 THE FUNCTIONS OF BRCA2 IN HOMOLOGOUS RECOMBINATIONAL REPAIR**  
Y-C. Lio, K. Yano,  
M. A. Brenneman, D. J. Chen  
*University of Texas Southwestern Medical Center at Dallas, Dallas, TX*
- P25-10 ROLES OF BRCA2 INTERACTING PROTEIN FILAMIN-A IN DNA DAMAGE RESPONSE**  
Z. Shen, X. Meng, Y. Yuan  
*Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM*
- P25-11 IDENTIFICATION AND FUNCTIONAL STUDY OF A NOVEL MAJOR BRCA2 NUCLEAR PARTNER**  
B. Xia, D. Livingston  
*Dana-Farber Cancer Institute, Boston, MA*

**P26 EGF Superfamily I**

12:05-2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.

- P26-1 ASSOCIATION BETWEEN MICROTUBULE ASSOCIATED PROTEIN-2 AND THE EGFR SIGNALING IN BREAST CANCER**  
V. M. Adhami, H. Mukhtar  
*Department of Dermatology, University of Wisconsin-Madison, Madison, WI*
- P26-2 REGULATION OF EGFR ENDOCYTIC TRAFFICKING BY RAB7 ACTIVITY**  
B. Ceresa  
*Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK*
- P26-3 THE DUAL ERBB1/ERBB2 INHIBITOR, LAPATINIB (GW572016), COOPERATES WITH TAMOXIFEN TO INHIBIT BOTH CELL PROLIFERATION AND ESTROGEN DEPENDENT GENE EXPRESSION IN ANTIESTROGEN RESISTANT BREAST CANCER**  
I. Chu,<sup>1,3</sup> K. Blackwell,<sup>2</sup> S. Chen,<sup>1</sup>  
J. Slingerland<sup>1,4</sup>  
<sup>1</sup>*The Braman Family Breast Cancer Institute, University of*

- Miami Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL; <sup>2</sup>Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC; Comprehensive Cancer Center, Durham, NC; <sup>3</sup>Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; <sup>4</sup>Department of Biochemistry and Molecular Biology, University of Miami School of Medicine, Miami, FL*
- P26-4 REGULATION OF EGFR ACTIVATION BY RNA LOCALIZATION AND TRANSLATIONAL CONTROL DURING DROSOPHILA MELANOGASTER Oogenesis**  
J. S. Goodrich, T. Schupbach  
*Department of Molecular Biology, Howard Hughes Medical Institute, Princeton University, Princeton, NJ*
- P26-5 MODULATION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TRAFFICKING BY HUMAN SPROUTY2: POTENTIAL IMPLICATION OF EGFR SIGNALING IN BREAST CANCER**  
H. J. Kim,<sup>1</sup> L. Taylor,<sup>2</sup> D. Bar-Sagi<sup>2</sup>  
<sup>1</sup>*Department of Biochemistry and Cell Biology, <sup>2</sup>Department of Microbiology and Molecular Genetics, State University of New York at Stony Brook, Stony Brook, NY*
- P26-6 ERBB RECEPTOR SIGNALING IN CANCER CELL MEMBRANE MICRODOMAINS**  
J. G. Koland, E. C. Twait  
*Department of Pharmacology, University of Iowa, Iowa City, IA*
- P26-7 COMBINED TREATMENT WITH EPIDERMAL GROWTH FACTOR RECEPTOR AND CYCLOOXYGENASE-2 INHIBITORS SYNERGISTICALLY INHIBIT CELL GROWTH AND INDUCE APOPTOSIS IN HER-2/NEU OVEREXPRESSING BREAST CANCER CELLS**  
S. Lanza-Jacoby, R. Burd,  
A. R. Conant  
*Departments of Surgery and Radiation Oncology, Thomas Jefferson University, Philadelphia, PA*
- P26-8 STRUCTURAL STUDIES OF MEMBERS OF THE EGF (ERBB) RECEPTOR FAMILY**  
D. J. Leahy, H-S. Cho, S. Bouyain  
*Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD*
- P26-9 ERBB4 INDUCES APOPTOSIS IN HUMAN BREAST CANCER CELLS BY FUNCTIONING AS A PRO-APOPTOTIC BH3-ONLY PROTEIN**  
W. Long, F. E. Jones  
*Department of Structural and Cellular Biology, Tulane University, New Orleans, LA*
- P26-10 COOPERATIVE INTERACTION OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR WITH SRC TYROSINE KINASE AND TRANSFORMING GROWTH FACTOR ALPHA IN BREAST TUMORIGENESIS**  
N. V. Marozkina, S. J. Parsons  
*Department of Microbiology and Cancer Center, University of Virginia Health System, Charlottesville, VA*
- P26-11 REGULATION OF ESTROGEN-RELATED RECEPTOR ALPHA'S TRANSCRIPTIONAL ACTIVITIES VIA THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND ERBB2 SIGNALING PATHWAYS**  
J. E. Mertz, R. R. Kraus,  
V. C. Jordan, E. A. Ariazi  
*McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA*

- P26-12 STRUCTURE AND DYNAMICS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR CARBOXY-TERMINAL PHOSPHORYLATION DOMAIN**  
 N. Y. Lee, T. L. Hazlett,  
 J. G. Koland  
*Department of Pharmacology,  
 University of Iowa, Iowa City,  
 IA; Laboratory for Fluorescence  
 Dynamics, Department of  
 Physics, University of Illinois,  
 Urbana, IL*
- P26-13 ERBB4 IS A BREAST, PROSTATE, AND PANCREATIC TUMOR SUPPRESSOR**  
 S. E. Pitfield, R. M. Gallo,  
 K. L. Gettinger, I. Bryant,  
 D. J. Penington, D. J. Riese II  
*Purdue School of Pharmacy and  
 Purdue Cancer Research Center,  
 West Lafayette, IN*
- P26-14 DIFFERENTIAL SPLICING OF NEUREGULIN-2 MODULATES ITS INTERACTION WITH ERBB4**  
 S. Hobbs, K. Wilson, S. Coffing,  
 A. Le, E. Cameron, E. Williams,  
 M. Andrew, E. Blommel,  
 R. Hammer, H. Chang,  
 D. J. Riese II  
*Purdue School of Pharmacy and  
 Purdue Cancer Research Center,  
 West Lafayette, IN*
- P26-15 THE EGFR-S442F MUTANT DISPLAYS BROADER AGONIST SPECIFICITY AND AGONIST-INDEPENDENT COUPLING TO DOWNSTREAM SIGNALING EVENTS**  
 J. L. Gilmore, D. J. Riese  
*Purdue School of Pharmacy and  
 Purdue Cancer Research Center,  
 West Lafayette, IN*
- P26-16 ANTIESTROGEN RESISTANT, ER+ BREAST CANCER CELLS SHOW A MARKED REDUCTION IN ERBB-4 EXPRESSION**  
 P. Schoenlein, Y. Ding, S. Arun,  
 E. England, J. Delk, J. T. Barrett,  
 F. Yu  
*Medical College of Georgia,  
 Augusta, GA*
- P26-17 HERSTATIN, AN AUTOINHIBITOR OF THE ERBB RECEPTOR FAMILY, MODULATES IGF-1-INDUCED PROLIFERATION AND SURVIVAL SIGNALING IN MCF7 BREAST CANCER CELLS**  
 L. S. Shameih, J. M. Carroll,  
 C. T. Roberts Jr., G. M. Clinton  
*Departments of Biochemistry and  
 Molecular Biology and Pediatrics,  
 Oregon Health and Science  
 University, Portland, OR*
- P26-18 A NOVEL ROLE OF EGFR AND SHC IN ER ALPHA MEMBRANE TRANSLOCATION AND ACTIVATION OF MAPK IN BREAST CANCER CELLS**  
 R. X-D. Song, Z. Zhang,  
 M. B. Black, R. J. Santen  
<sup>1</sup>*Department of Internal Medicine,*  
<sup>2</sup>*Bioinformatic Unit, University  
 of Virginia School of Medicine,  
 Charlottesville, VA*
- P26-19 STUDIES OF THE NONRECEPTOR TYROSINE KINASE, ACK2, IN EGF RECEPTOR DEGRADATION**  
 C. J. Sterns, R. A. Cerione  
*Department of Chemistry and  
 Chemical Biology, Cornell  
 University, Ithaca, NY*
- P26-20 ECTODOMAIN CLEAVAGE OF ERBB-4, A RECEPTOR TYROSINE KINASE**  
 K. W. Thiel, L. B. Bennett,  
 G. Carpenter  
*Vanderbilt University, Nashville,  
 TN*
- P26-21 PRESENILIN-DEPENDENT G-SECRETASE PROCESSING REGULATES MULTIPLE ERBB4/HER4 ACTIVITIES**  
 G. Vidal,<sup>1</sup> L. Marrero,<sup>2</sup> F. Jones<sup>1</sup>  
<sup>1</sup>*Tulane University Health  
 Sciences Center, Tulane Cancer  
 Center, Department of Structural  
 and Cellular Biology, New  
 Orleans, LA; <sup>2</sup>Louisiana State  
 University Health Sciences  
 Center, Gene Therapy Program,  
 Morphology and Imaging Core  
 Laboratory, New Orleans, LA*
- P26-22 MODULATING EGFR SIGNALING BY TARGETING THE DEACETYLASE HDAC6-HSP90 COMPLEX/BREAST TUMORS**  
 T.-P. Yao, J. J. Kovacs  
*Duke University, Durham, NC*
- P26-23 THE ERBB3 SUPPRESSOR PROTEIN NRPD1 AS AN INHIBITOR OF BREAST TUMOR PROGRESSION**  
 L. Yen, X. Wu, C. A. Sweeney,  
 K. L. Carraway III  
*University of California at Davis  
 Cancer Center, Sacramento, CA*
- 
- P27 p53**  
**12:05–2:05 p.m.**  
*Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
 Even-numbered – 1:05–2:05 p.m.*
- P27-1 MAML1 INTERACTS WITH P53 AND INDUCES P53-MEDIATED SENESCENCE/APOPTOSIS**  
 I. Bhat, Y. Zhao, V. Band  
*ENH Research Institute,  
 Northwestern University,  
 Evanston, IL*
- P27-2 TRANSCRIPTIONAL GAIN-OF-FUNCTION OF p53 MUTANTS PREVALENT IN BREAST CANCER**  
 J. Zeng,<sup>1</sup> L. R. Dearth,<sup>1</sup> J. Yan,<sup>2</sup>  
 D. Mosbrook-Davis,<sup>2</sup>  
 S. M. Burgess,<sup>2</sup>  
 R. K. Brachmann<sup>1</sup>  
<sup>1</sup>*Department of Medicine,  
 Division of Hematology,  
 University of California at Irvine,  
 Irvine, CA; <sup>2</sup>Genome Technology  
 Branch, National Human Genome  
 Research Institute, National  
 Institutes of Health, Bethesda,  
 MD*
- P27-3 ALTERATIONS IN THE p53 REGULATORY PATHWAY DURING CELLULAR TRANSFORMATION IN CELLS HARBORING Deregulated CDK4 ACTIVITY**  
 C. Carbone, E. P. Reddy  
*Temple University School of  
 Medicine, Philadelphia, PA*

**P27-4 p53 MUTATION ANALYSIS TO PREDICT TUMOR RESPONSE IN PATIENTS UNDERGOING NEOADJUVANT TREATMENT FOR LOCALLY ADVANCED BREAST CANCER**

L. A. Carey,<sup>1</sup> L. Dressler,<sup>1</sup>  
L. Esserman,<sup>2</sup> M. Resnick,<sup>3</sup>  
C. Livasy,<sup>1</sup> C. Perou,<sup>1</sup> M. Schell,<sup>1</sup>  
S. Drouin,<sup>1</sup> B. Popko,<sup>1</sup>  
K. C. Dorsey<sup>1</sup>

<sup>1</sup>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; <sup>2</sup>University of California, San Francisco, San Francisco, CA; <sup>3</sup>National Institute of Environmental Health Sciences, Research Triangle Park, NC

**P27-5 A REQUIREMENT FOR THIOREDOXIN REDUCTASE IN ELECTROPHILE-MEDIATED p53 INACTIVATION AND APOPTOSIS**

P. Cassidy,<sup>1</sup> K. Edes,<sup>2</sup>  
F. Fitzpatrick,<sup>1,2</sup> P. Moos<sup>3</sup>  
*Departments of <sup>1</sup>Medicinal Chemistry, <sup>2</sup>Oncological Sciences, Huntsman Cancer Institute, <sup>3</sup>Pharmacology and Toxicology, University of Utah, Salt Lake City, UT*

**P27-6 PROTEOMIC IDENTIFICATION OF HEAT SHOCK PROTEIN 90 (HSP90) AS A CANDIDATE TARGET FOR p53 MUTATION REACTIVATION BY PRIMA-1 IN BREAST CANCER CELLS**

A. Rehman, M. S. Chahal,  
X. Tang, J. E. Bruce, Y. Pommier,  
S. S. Daoud  
*Department of Pharmaceutical Sciences, Pharmacology and Toxicology Graduate Program, Department of Chemistry, Washington State University, Pullman, WA; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD*

**P27-7 ESTROGEN RECEPTOR REPRESSES p53 TUMOR SUPPRESSOR FUNCTION BY DIRECT INTERACTION**

G. M. Das, W. Liu, S. D. Konduri,  
B. K. Nayak, S. Bansal,

P. Srivastava, A. K. Rajasekaran,  
S. A. Rajasekaran  
*Roswell Park Cancer Institute, Buffalo, NY; University of Texas Health Science Center at San Antonio, San Antonio, TX; Central Drug Research Institute, Lucknow, India; University of California at Los Angeles, Los Angeles, CA*

**P27-8 ROLE OF p53 IN MAMMARY EPITHELIAL CELL SENESCENCE**

A. Yadav, S. Datta, V. Band,  
G. P. Dimri  
*Department of Medicine, Division of Cancer Biology, ENH Research Institute, Evanston, IL*

**P27-9 NANOPARTICLE-MEDIATED RESCUE OF p53 THROUGH TARGETED DEGRADATION OF MDM2**

N. O. Fischer, R. Hong,  
D. J. Jerry, V. M. Rotello  
*Department of Chemistry, Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA*

**P27-10 THE C-TERMINUS REGULATES p53 FAMILY FUNCTION**

K. L. Harms, X. Chen  
*University of Alabama at Birmingham, Birmingham, AL*

**P27-11 IDENTIFICATION OF NOVEL p53 TARGET GENES IN MAMMARY EPITHELIAL CELLS**

J. Hearnes, D. Mays, L. Tang,  
K. Schavolt, K. Johnson, X. Jiang,  
J. Pietenpol  
*Vanderbilt University School of Medicine, Nashville, TN*

**P27-12 HIGH RESOLUTION CRYSTAL STRUCTURE OF THE MOUSE p53 CORE DOMAIN: AN ANALYSIS OF PROTEIN FLEXIBILITY AND A FRAMEWORK FOR STRUCTURE-BASED DRUG DESIGN**

W. C. Ho  
*The Wistar Institute, Philadelphia, PA*

**P27-13 FUNCTIONAL p53 MUTANTS ASSOCIATED WITH BREAST CANCERS THAT ALTER THE KINETICS AND SPECTRUM OF TRANSACTIVATION IN VIVO**

J. J. Jordan, A. Inga,  
M. A. Resnick  
*Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC*

**P27-14 MOLECULAR MECHANISMS OF BCL-3 FUNCTION: POTENTIAL INVOLVEMENT IN CONTROLLING p53**

D. Kashatus, A. S. Baldwin  
*Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC*

**P27-15 p53 POLYMORPHIC VARIANTS, TUMOR SUPPRESSION, AND PROGRAMMED CELL DEATH**

M. E. Murphy,<sup>1</sup> P. Dumont,<sup>1</sup>  
J. I-J. Leu,<sup>2</sup> D. L. George<sup>2</sup>  
<sup>1</sup>Fox Chase Cancer Center, Philadelphia, PA; <sup>2</sup>University of Pennsylvania School of Medicine, Philadelphia, PA

**P27-16 TEST FOR SENSITIVE DETECTION AND ACCURATE ASSIGNMENT OF Tp53 VARIANTS IN TUMOR DNA**

C. Telmer, D. Graziano, C. Shi,  
A. Alexander, J. Jarvik  
*Spectragenetics, Pittsburgh, PA*

**P27-17 TRANSCRIPTION AND FUNCTIONAL ACTIVITIES OF THE p53 GENE FAMILY**

A. Yang,<sup>1</sup> Z. Zhu,<sup>2</sup> D. Kampa,<sup>3</sup>  
P. Kapranov,<sup>3</sup> T. Gingeras,<sup>3</sup>  
F. McKeon,<sup>4</sup> K. Struhl<sup>1</sup>  
<sup>1</sup>Department of Biological Chemistry and Molecular Pharmacology, <sup>2</sup>Genetics, and <sup>4</sup>Cell Biology, Harvard Medical School, Boston, MA; <sup>3</sup>Affymetrix, Inc., Santa Clara, CA

**P28 TGF- $\beta$** 

12:05–2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.**P28-1 p38 MITOGEN-ACTIVATED PROTEIN KINASE CONTRIBUTES TO TUMOR INVASION AND METASTASIS ASSOCIATED WITH TRANSFORMING GROWTH FACTOR BETA**A. V. Bakin, Q. Zheng, A. Safina  
*Roswell Park Cancer Institute, Buffalo, NY***P28-2 RADIATION-INDUCED CENTROSOME ABNORMALITIES IN NON-MALIGNANT HUMAN MAMMARY EPITHELIAL CELLS ARE MODULATED BY TRANSFORMING GROWTH FACTOR BETA1**M. H. Barcellos-Hoff,  
A. E. Erickson, R. Gupta  
*Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA***P28-3 RAPID NUCLEAR TRANSLOCATION OF BETA-CATENIN IS REQUIRED FOR TGF-BETA-INDUCED PROLIFERATION OF HUMAN MESENCHYMAL STEM CELLS**H. Jian, X. Shen, I. Liu,  
X-F. Wang  
*Duke University Medical Center, Durham, NC***P28-4 SPECIFICITY OF TGF-BETA AND ACTIVIN A SIGNALING RESPONSES REVEALED BY EXPERIMENTAL AND BIOINFORMATICAL ANALYSES OF THEIR TRANSCRIPTIONAL PROGRAMS**T. H. Cheung,<sup>1</sup> P. J. Collins,<sup>2</sup>  
C. Riquelme,<sup>1</sup> Y. Gao,<sup>1</sup> P. Kwan,<sup>1</sup>  
T. B. Doan,<sup>2</sup> X. Liu<sup>1</sup><sup>1</sup>*Department of Chemistry and Biochemistry, University of Colorado-Boulder, Boulder, CO;*  
<sup>2</sup>*Agilent Technologies, Palo Alto, CA***P28-5 THE LIM-ONLY PROTEIN LMO4 MODULATES TGF $\beta$  SIGNALING BY INTERACTING WITH SMAD PROTEINS**Z. Lu, K. S. Lam, M. Cortes,  
B. Andersen  
*Departments of Medicine (Endocrinology) and Biological Chemistry, University of California at Irvine, Irvine, CA***P28-6 ISOFORM SPECIFIC REGULATION OF LATENT TRANSFORMING GROWTH FACTOR-BETA ACTIVATION BY REACTIVE OXYGEN SPECIES**M. F. Jobling, M. H. Barcellos-Hoff  
*Department of Cancer Biology, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA***P28-7 WNT10B MEDIATES P27KIP1 TURNOVER AND FUNCTIONS AS A GLOBAL ANTAGONIST OF TGF-BETA 1 MEDIATED CELL CYCLE ARREST IN MAMMARY GLAND NEOPLASIA**G. A. Miranda-Carboni,  
T. F. Lane  
*Jonsson Comprehensive Cancer Center, Department of Medicine, Department of Obstetrics and Gynecology and Biological Chemistry, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA***P28-8 SMAD3 INTERACTS WITH JUNB AND CBFA1/RUNX2 FOR TRANSFORMING GROWTH FACTOR-BETA1-STIMULATED COLLAGENASE-3 EXPRESSION IN HUMAN BREAST CANCER CELLS**N. Selvamurugan, S. Kwok,  
N. C. Partridge  
*Department of Physiology and Biophysics, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, NJ***P28-9 SMAD2 ACETYLATION IN THE TGF-BETA SIGNALING PATHWAY**A. W. Tu  
*University of California at Berkeley, Berkeley, CA***P29 Cell Cycle**

12:05–2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.**P29-1 FORMATION OF MACROH2A-CONTAINING SENESCENCE ASSOCIATED HETERO-CHROMATIN FOCI (SAHF) AND SENESCENCE DRIVEN BY ASF1A AND HIRA**P. D. Adams  
*Fox Chase Cancer Center, Philadelphia, PA***P29-2 ROLE OF GIF1 (CRIF1) IN BREAST CANCER**I. Bae  
*Georgetown University, Washington, DC***P29-3 ANTISENSE OLIGONUCLEOTIDE-MEDIATED DOWN-REGULATION OF GAMMA TUBULIN INHIBITS CELL PROLIFERATION AND INDUCES APOPTOSIS IN BREAST CANCER CELLS**A. Banerjee  
*Department of Biochemistry, University of Texas Health Science Center at San Antonio, San Antonio, TX***P29-4 OVEREXPRESSION OF THE ARYL HYDROCARBON RECEPTOR IN MAMMARY EPITHELIAL CELLS INCREASES PROLIFERATION BY INCREASING G1/S PHASE TRANSITION**J. Brooks, S. E. Eltom  
*Meharry Medical College, Nashville, TN***P29-5 MOLECULAR ANALYSIS OF THE INHERITANCE OF TRANSCRIPTIONAL SILENCING**L. E. Chu, J. J. Li  
*University of California at San Francisco, San Francisco, CA***P29-6 GENOTOXIC STRESS LEADS TO CENTROSOME AMPLIFICATION IN BREAST CANCER CELL LINES THAT HAVE AN INACTIVE G1/S CELL CYCLE CHECKPOINT**A. B. D'Assoro, T. Greenwood,  
G. J. Almodovar, R. Busy,  
I. E. Acu, M. Libra, P. Navolanic,

J. McCubrey, F. Stivala, J. L. Salisbury <i>Tumor Biology Program, Mayo Clinic College of Medicine, Rochester, MN</i>	<b>P29-13 CYCLIN E, A POWERFUL PREDICTOR OF SURVIVAL IN BREAST CANCER-A PROSPECTIVE STUDY</b> K. Keyomarsi, M. A. Hassett, A. Sahin, K. Hunt <i>University of Texas M.D. Anderson Cancer Center, Houston, TX</i>	<i>of Pharmacy, Rutgers, State University of New Jersey, Cancer Institute of New Jersey, Piscataway, NJ</i>
<b>P29-7 USING SHRNA LIBRARIES TO PROBE BREAST CANCER</b> T. Westbrook, M. Schlabach, G. Hu, M. Li, J. Hackett, S. Elledge <i>Harvard Medical School, Brigham and Women's Hospital, Boston, MA</i>	<b>P29-14 CDC25A AS A THERAPEUTIC TARGET: HEMIZYGOUS LOSS OF CDC25A INHIBITS EX VIVO TRANSFORMATION AND IN VIVO MAMMARY TUMORIGENESIS</b> D. Ray, Y. Terao, L-H. Chu, X. Zou, R. Franks, K. Chirstov, H. Kiyokawa <i>University of Illinois College of Medicine, Chicago, IL</i>	<b>P29-19 IDENTIFICATION OF HUMAN MPS1 RESIDUES IMPORTANT FOR KINASE ACTIVITY AND A HUMAN MPS1 INTERACTING PROTEIN</b> C. Mattison, M. Winey <i>University of Colorado-Boulder, Boulder, CO</i>
<b>P29-8 STUDIES OF THE TUMOR SUPPRESSOR CHK2</b> S. Matsuoka, B. Wang, D. Zhang, S. Elledge <i>Harvard Medical School, Brigham and Women's Hospital, Boston, MA</i>	<b>P29-15 REGULATION OF SPINDLE ASSEMBLY AND DISASSEMBLY BY THE IPL1/AURORA PROTEIN KINASE</b> C. Kotwaliwale, S. Biggins <i>Fred Hutchinson Cancer Research Center, Seattle, WA</i>	<b>P29-20 EXPRESSION OF P270(ARID1A), A COMPONENT OF HUMAN SWI/SNF COMPLEXES, IN HUMAN TUMORS</b> N. G. Nagl Jr., X. Wang, D. Wilsker, S. Flowers, D. Zweitzig, A. Patsialou, E. Moran <i>The Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA</i>
<b>P29-9 DETERMINING THE EFFECT OF CRYPTOCHROME LOSS AND CIRCADIAN CLOCK DISRUPTION ON TUMORIGENESIS IN MICE</b> M. A. Gauger, A. Sancar <i>Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC</i>	<b>P29-16 ROLES OF PROTEIN 4.1 IN CENTROSOME AND MITOTIC SPINDLE ABERRATIONS IN BREAST CANCER PATHOGENESIS</b> S. W. M. Go, J. R. Spence <i>Department of Genome Biology, Lawrence Berkeley National Lab, University of California at Berkeley, Berkeley, CA</i>	<b>P29-21 EVALUATION OF A ROLE OF THE NEUROPEPTIDE Y4 RECEPTOR IN MAMMARY GLAND DEVELOPMENT AND INHIBITION OF MITOGENESIS IN HUMAN BREAST CANCER CELLS</b> B. Sarcevic, A. Wilson, S. Oakes, C. J. Ormandy, H. Herzog <i>Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia</i>
<b>P29-10 CONTROL OF CYCLIN D1 DEGRADATION BY UBIQUITIN PROTEOSOME PATHWAY</b> J. Jin, J. W. Harper <i>Department of Pathology, Harvard Medical School, Boston, MA</i>	<b>P29-17 TOPBP1 RECRUITS BRG1/BRM TO REPRESS E2F1-INDUCED APOPTOSIS, A NOVEL PRB-INDEPENDENT AND E2F1-SPECIFIC CONTROL FOR CELL SURVIVAL</b> K. Liu, Y. Luo, F-T. Lin, W-C. Lin <i>University of Alabama at Birmingham, Birmingham, AL</i>	<b>P29-22 THE ROLE OF CDK-MEDIATED PHOSPHORYLATION OF RBP1 AND RBP1 ALPHA IN CELL CYCLE PROGRESSION AND BREAST CANCER</b> B. Sarcevic, A. Mawson, D. Bechtel, A. Wilson, M. Sadowski <i>Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney NSW, Australia</i>
<b>P29-11 REGULATION OF p21 (Cip1, Waf1) FUNCTIONS AND G1/S CELL CYCLE BY BCCIP, A p21 INTERACTING PROTEIN</b> X. Meng, J. Liu, Z. Shen <i>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM</i>	<b>P29-18 INHIBITION OF SMAD ANTIPIROLIFERATIVE FUNCTION BY CDK PHOSPHORYLATION</b> F. Liu, I. Matsuura, N. G. Denissova, G. Wang, J. Long, D. He, W. Xie, M. Reiss <i>Center for Advanced Biotechnology and Medicine, Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School</i>	<b>P29-23 REGULATION AND CHEMOTHERAPEUTIC TARGETING OF CDC25A</b> P. J. Scrivens, M. A. Alaoui-Jamali <i>Lady Davis Institute for Medical Research, SMBD Jewish General Hospital, Division of Experimental Medicine,</i>

<p>Department of Medicine, McGill University, Montreal, QC, Canada</p> <p><b>P29-24</b> <b>CHK2 AND PLK1 IN CELL CYCLE AND CENTROSOME REGULATION</b> L. Tsvetkov, A. Golan, R. Tsvekova, F. Stern <i>Department of Pathology, Yale University School of Medicine, New Haven, CT</i></p> <p><b>P29-25</b> <b>P21 AND P27 DO NOT HAVE AN INHIBITORY ROLE IN BREAST TUMORS EXPRESSING THE LOW MOLECULAR WEIGHT ISOFORMS OF CYCLIN E</b> H. Wingate, N. Zhang, K. Keyomarsi <i>Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX</i></p> <p><b>P29-26</b> <b>WHAT MAKES THE CHEMO DRUG WORK BETTER? DEVELOPMENT OF AN EXPRESSION CLONING METHOD FOR GENES THAT AFFECT SPINDLE POISON SENSITIVITY IN MAMMALIAN CELLS</b> H. Y. Yamada, G. J. Gorbsky <i>Oklahoma Medical Research Foundation, Oklahoma City, OK</i></p> <p><b>P29-27</b> <b>THE ROLE OF THE CYCLIN-DEPENDENT KINASE INHIBITOR PHOSPHORYLATION DURING MITOSIS</b> X. Zhu, P. R. Yew <i>Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX</i></p>	<p>School of Medicine, Philadelphia, PA</p> <p><b>P30-2</b> <b>NUCLEAR TRANSLOCATION OF THE PRO-APOPTOTIC BCL-2 FAMILY MEMBER BOK INDUCES APOPTOSIS</b> G. Bartholomeusz, Y. Wu, M. A. Seyed, W. Xia, K. Y. Kwong, G. Hortobagyi,<sup>1</sup> M-C. Hung<sup>1</sup> <i>Department of Molecular and Cellular Oncology, and <sup>1</sup>Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX</i></p> <p><b>P30-3</b> <b>EVALUATION OF P16CDKN2A IN A RAT MODEL OF ESTROGEN INDUCED MAMMARY CANCER</b> L. M. Bartsch, J. D. Shull <i>Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE</i></p> <p><b>P30-4</b> <b>A MOUSE MODEL TO INVESTIGATE THE ROLE OF DBC2 IN BREAST CANCER</b> V. L. Boka, P. Hasty <i>University of Texas Health Science Center at San Antonio, San Antonio, TX</i></p> <p><b>P30-5</b> <b>THE ROLE OF THE RETINOBLASTOMA TUMOR SUPPRESSOR IN THE THERAPEUTIC RESPONSE OF BREAST CANCER</b> E. E. Bosco, E. S. Knudsen <i>Department of Cell Biology, Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH</i></p> <p><b>P30-6</b> <b>SEMAPHORIN 3B (SEMA3B) INDUCES APOPTOSIS IN BREAST CANCER WHILE VEGF165 ANTAGONIZES THIS EFFECT</b> E. Castro-Rivera, S. Ran, J. Minna <i>Hamon Center for Therapeutic Oncology, University of Texas Southwestern Medical Center, Dallas, TX</i></p>	<p><b>P30-7</b> <b>INT6, A POTENTIAL BREAST TUMOR SUPPRESSOR, AND THE CONTROL OF CHROMOSOME SEGREGATION AND PROTEASOME FUNCTIONING</b> E. Chang,<sup>1</sup> L. Nelson,<sup>1</sup> J. Suo,<sup>1</sup> X. Cui,<sup>1</sup> A. Lee,<sup>1</sup> S. Jiang,<sup>1</sup> S. Oesterreich,<sup>1</sup> C. Wang,<sup>2</sup> S. Shin,<sup>2</sup> J. Sap<sup>2</sup> <sup>1</sup>Baylor College of Medicine, Breast Center, Houston, TX; <sup>2</sup>Department of Pharmacology, New York University School of Medicine, New York, NY</p> <p><b>P30-8</b> <b>TUMOR SUPPRESSOR ACTIVITY OF SPLEEN TYROSINE KINASE (SYK) IN BREAST CANCER</b> J. Dai, L. Wang, Y. Yuan, A. Sahin, R. Mendez, L. Duke <i>Department of Molecular Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX</i></p> <p><b>P30-9</b> <b>THE SCAFFOLD ATTACHMENT FACTOR SAFB1: A NEW PLAYER IN G2/M CHECKPOINT CONTROL?</b> K. M. Dobrzycka, S. Oesterreich <i>Baylor College of Medicine, Breast Center, Houston, TX</i></p> <p><b>P30-10</b> <b>LOSS OF SAFB1 LEADS TO A TUMORIGENIC PHENOTYPE OF MOUSE EMBRYO FIBROBLASTS (MEFS)</b> K. M. Dobrzycka, K. Kang, M. Ivanova, S. Jiang, S. Oesterreich <i>Baylor College of Medicine, Houston, TX</i></p> <p><b>P30-11</b> <b>CELLULAR PATHWAYS REGULATED BY DBC2 TUMOR SUPPRESSOR GENE</b> V. Siripurapu, J. L. Meth, N. Kobayashi, M. Hamaguchi <i>Cold Spring Harbor Laboratory, Cold Spring Harbor, NY</i></p> <p><b>P30-12</b> <b>RB2/P130 IS RECRUITED TO G1-S AND G2-M PROMOTERS DURING DOXORUBICIN INDUCED CELLULAR SENESCENCE IN MCF-7 BREAST CANCER CELLS</b> J. G. Jackson, O. Pereira-Smith <i>University of Texas Health Science Center, San Antonio, TX</i></p>
--	---	---

### P30 Tumor Suppressor Genes I

12:05-2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.

**P30-1** **CLONING AND ANALYSIS OF A NOVEL GENE SEN16 THAT RESTORES NORMAL CELL GROWTH AND SENESCENCE IN BREAST CANCER CELLS**

R. S. Athwal, G. P. Kaur

*Fels Institute for Cancer Research, Temple University*

**P30-13 MOLECULAR ACTION OF TUMOR SUPPRESSOR TID1 IN MAMMARY TUMORIGENESIS**

J.-D. Lee, S.-W. Kim

*Department of Immunology, The Scripps Research Institute, La Jolla, CA*

**P30-14 SMAD4 INHIBITS TUMOR GROWTH BY INDUCING APOPTOSIS IN ESTROGEN RECEPTOR ALPHA POSITIVE BREAST CANCER CELLS**

Q. Li, L. Wy, D. K. Oelschlager, C. R. Stockardt, W. E. Grizzle, N. Wang, M. Wan, H. Chen, X. Cao

*Department of Pathology, University of Alabama at Birmingham, Birmingham, AL*

**P30-15 MDC1 REGULATES DNA-PK AUTOPHOSPHORYLATION IN RESPONSE TO DNA DAMAGE**

Z. Lou, B. P-C. Chen, A. Asaithamby, K. Minter-Dykhouse, D. J. Chen, J. Chen  
*Department of Oncology, Mayo Clinic, Rochester, MN; Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX*

**P30-16 IDENTIFICATION OF GENES MODIFYING MAMMARY TUMOR DEVELOPMENT IN APCMIN/+ MICE**

A. R. Moser, H. Wang, A. Mayer, C. Kendziora  
*Department of Human Oncology and Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI*

**P30-17 DISTINCT SENESCENCE STATES DETERMINED BY FORMATION OF SENESCENCE-ASSOCIATED HETEROCHROMATIC FOCI**

S. Nunez, M. Narita, S. W. Lowe  
*Cold Spring Harbor Laboratory, Cold Spring Harbor, NY*

**P30-18 E-CADHERIN HOMOPHILIC INTERACTIONS ARE DIRECTLY INVOLVED IN THE INHIBITION OF CELL GROWTH**

M. Perez-Moreno,<sup>1</sup> M. Davis,<sup>2</sup> A. Reynolds,<sup>2</sup> B. Gumbiner,<sup>3</sup> E. Fuchs<sup>1</sup>

<sup>1</sup>*The Rockefeller University, New York, NY;* <sup>2</sup>*Vanderbilt University, Nashville, TN;* <sup>3</sup>*University of Virginia, Charlottesville, VA*

**P30-19 MAGNETIC RESONANCE SPECTROSCOPIC QUANTITATION AND PDT EFFECTS OF FLUORINE LABELED PHOTOSENSITIZERS**

S. Ramaprasad,<sup>1</sup> J. Pi,<sup>1</sup> S. Singh,<sup>1</sup> S. S. Joshi,<sup>2</sup> M. Dobhal,<sup>3</sup> J. Missert,<sup>3</sup> R. K. Pandey<sup>3</sup>

<sup>1</sup>*Department of Radiology, University of Nebraska Medical Center, Omaha, NE;* <sup>2</sup>*Department of Genetics and Cell Biology, University of Nebraska Medical Center, Omaha, NE;* <sup>3</sup>*Photodynamic Therapy Center, Roswell Park Cancer Institute, Buffalo, NY*

**P30-20 INT6 MAY INFLUENCE BREAST CANCER FORMATION BY REGULATING THE 26S PROTEASOME**

Z. Sha, E. Chang  
*Baylor College of Medicine, Houston, TX*

**P30-21 TRANSCRIPTION FACTOR STAT5, A NOVEL THERAPEUTIC PROTEIN, INHIBITS METASTATIC POTENTIAL AND INVASIVE CHARACTERISTICS OF HUMAN BREAST CANCER**

A. S. Sultan, H. Rui  
*Georgetown University Medical Center, Lombardi Cancer Center, Washington, DC*

**P30-22 THE SMAD8 CONNECTION TO BREAST CANCER**

S. Thiagalingam,<sup>1,3</sup> H. Pan,<sup>1</sup> J. F. Ponte,<sup>1</sup> K-H. Cheng<sup>1,3</sup>  
*Departments of <sup>1</sup>Medicine (Genetics Program and Cancer Research Center), <sup>2</sup>Genetics and Genomics, and <sup>3</sup>Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA*

**P30-23 INVOLVEMENT OF THE FHIT GENE IN THE IONIZING RADIATION-ACTIVATED ATR/CHK1 PATHWAY**

B. Hu, S.-Y. Han, X. Wang, M. Ottey, M. B. Potoczek, A. Dicker, K. Huebner, Y. Wang  
*Thomas Jefferson University, Philadelphia, PA*

**P30-24 SMALL RIBOSOMAL PROTEIN RPL41 FUNCTIONS AS A TUMOR SUPPRESSOR**

J. Huang, S. Xiao  
*Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA*

**P30-25 DUAL ROLE OF THE AIB3 (AMPLIFIED IN BREAST CANCER 3) GENE IN MAMMARY GLAND DEVELOPMENT AND BREAST CANCER**

J. Xu, H. Zhang, S-Q. Kuang, Q. Li, L. Liao  
*Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX*

**P30-26 EFFECT OF RB ACTIVATION ON BREAST CANCER PROGRESSION**

J. Zhe,<sup>1</sup> J. P. Thimio,<sup>1</sup> F. Dick,<sup>2</sup> E. Zackenhaus<sup>1</sup>  
*Division of Cell and Molecular Biology, Toronto General Research Institute – University Health Network, University of Toronto, Toronto, ON, Canada;* <sup>2</sup>*Biochemistry, Pediatrics, and Oncology, University of Western Ontario, London, ON, Canada*

**P30-27 APOPTOSIS FACTOR EI24/PIG8 IS A NOVEL ENDOPLASMIC RETICULUM-LOCALIZED BCL-2-BINDING PROTEIN WHICH IS ASSOCIATED WITH SUPPRESSION OF BREAST CANCER INVASIVENESS**

X. Zhao,<sup>1</sup> R. E. Ayer,<sup>1</sup> S. L. Davis,<sup>1</sup> S. J. Ames,<sup>1</sup> B. Florence,<sup>2</sup> C. Torchinsky,<sup>1</sup> J. S. Liou, L. Shen,<sup>1</sup> R. A. Spanjaard<sup>1</sup>  
*Departments of <sup>1</sup>Otolaryngology and Biochemistry and <sup>2</sup>Medicine, Cancer Research Center, Boston University School of Medicine, Boston, MA*

**P30-28 LAFORIN IS A PHOSPHATASE FOR GLYCOGEN SYNTHASE KINASE-3-BETA, AN IMPORTANT MODULATOR FOR WNT SIGNALING AND A TUMOR SUPPRESSOR**

P. Zheng, Y. Wang, Y. Liu, X. Zheng, C. Wu, T. Geiger, Z. Zheng, Y. Liu

*Division of Cancer Immunology, Department of Pathology, Ohio State University, Columbus, OH*

**P30-29 CONVERGENCE OF BRCA1 AND VITAMIN D PATHWAYS IN GROWTH INHIBITION OF BREAST CANCER CELLS**

R. Cohen,<sup>1,2</sup> M. Z. Papa,<sup>1</sup> U. Nir,<sup>2</sup> G. H. Posner,<sup>3</sup> R. I. Yarden<sup>1</sup>

<sup>1</sup>Laboratory of Genomic Applications, Department of Surgical Oncology, Sheba Medical Center, Tel-Hashomer, Israel; <sup>2</sup>Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel; <sup>3</sup>Department of Chemistry, Johns Hopkins University, Baltimore, MD

**P31 Signal Transduction II**

12:05–2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.

**P31-1 MOLECULAR BASIS OF A MINIMAL ONCOGENIC PLATFORM GENERATED BY RAL GTPASE ACTIVATION**

Y. Chien, M. A. White

*University of Texas Southwestern Medical Center at Dallas, Dallas, TX*

**P31-2 STRUCTURE AND FUNCTION OF HUMAN VPS20 AND SNF7 PROTEINS**

K. H. Ching

*Georgetown University Medical Center, Washington, DC*

**P31-3 THE DIFFERENTIAL ACTIVATION OF MNKS IN HER2 OVER-EXPRESSING BREAST CANCER CELLS**

C. A. Chrestensen, J. M. Kremer, T. W. Sturgill

*Department of Pharmacology, University of Virginia, Charlottesville, VA*

**P31-4 NUCLEOCYTOPLASMIC TRAFFICKING OF THE POZ-ZF TRANSCRIPTION FACTOR KAISO AND ITS BINDING PARTNER THE CATENIN P120<sup>CTN</sup>**

K. F. Kelly, A. A. Otchere, M. Graham, J. M. Daniel  
*Department of Biology, McMaster University, Hamilton, ON, Canada*

**P31-5 FUNCTIONAL GENOMIC ANALYSIS OF THE WINGLESS/WNT SIGNALING PATHWAY**

R. Dasgupta,<sup>1</sup> A. Kaykas,<sup>2</sup> R. T. Moon,<sup>2</sup> N. Perrimon<sup>1</sup>  
<sup>1</sup>Department of Genetics/HHMI, Harvard Medical School, Boston, MA; <sup>2</sup>HHMI/Department of Pharmacology/Center for Developmental Biology, University of Washington, School of Medicine, Seattle, WA

**P31-6 CK2 INDUCES IKK/IKEPSILON IN BREAST CANCER CELLS**

S. Eddy,<sup>1,3</sup> S. Guo,<sup>1,3</sup> E. Landesman-Bollag,<sup>2,3</sup> D. C. Seldin,<sup>2,3</sup> G. E. Sonenshein<sup>1,3</sup>  
*Departments of <sup>1</sup>Biochemistry and <sup>2</sup>Medicine, and <sup>3</sup>Division of Research on Women's Health, Boston University School of Medicine, Boston, MA*

**P31-7 IDENTIFICATION OF ETS TRANSCRIPTION FACTOR TARGET GENES ASSOCIATED WITH THE TRANSFORMED PHENOTYPE OF HUMAN BREAST CANCER CELLS**

C. A. Hauser, G. E. Foos  
*The Burnham Institute, La Jolla, CA*

**P31-8 BETA-CATENIN AND PROGESTERONE IN HORMONE RECEPTOR NEGATIVE BREAST CANCER**

M. M. Hiremath, J. P. Lydon, P. Cowin  
*Departments of Cell Biology and Dermatology, New York University Medical School, New York, NY; Department of Cell and Molecular Biology, Baylor College of Medicine, Houston, TX*

**P31-9 RAP1 REGULATES CELL PROLIFERATION AND TISSUE POLARITY IN HUMAN BREAST EPITHELIAL CELLS**

M. Itoh  
*Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA*

**P31-10 LIPID RAFT MEMBRANE SKELETONS AND NONGENOTROPIC ESTROGEN RECEPTOR SIGNALING**

J. Jacques, E. J. Luna,  
*Department of Cell Biology, University of Massachusetts Medical School, Worcester, MA*

**P31-11 MMTV ENV ENCODES AN ITAM RESPONSIBLE FOR TRANSFORMATION OF MAMMARY EPITHELIAL CELLS IN 3D CULTURE**

E. Katz,<sup>1</sup> M. H. Lareef,<sup>3</sup> J. C. Rassa,<sup>2</sup> S. M. Grande,<sup>1</sup> L. B. King,<sup>1</sup> J. Russo,<sup>3</sup> S. R. Ross,<sup>2</sup> J. G. Monroe<sup>1</sup>  
*Departments of <sup>1</sup>Pathology and Laboratory Medicine and <sup>2</sup>Microbiology, University of Pennsylvania, Philadelphia, PA; <sup>3</sup>Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA*

**P31-12 RHYTHMIC CLOCK GENE EXPRESSION IN MOUSE MAMMARY TISSUE**

D. J. Kennaway, A. Voultzios, L. M. Butler, W. D. Tilley  
*Department of Obstetrics, Gynaecology and Medicine, University of Adelaide, SA, Australia*

**P31-13 IKK MEDIATED INHIBITION OF BREAST CANCER**

A. Krishnamoorthy, R. Talwar, G. Ghosh  
*University of California at San Diego, La Jolla, CA*

**P31-14 CALMODULIN STABILIZES ESTROGEN RECEPTORS BY REDUCING PROTEASOME-DEPENDENT DEGRADATION**

L. Li, Z. Li, D. B. Sacks  
*Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA*

**P31-15 CONTROL OF TUMOR CELL FUNCTIONS BY INTRACELLULAR SIGNALING GENERATED BY MEMBRANE TYPE-1 MATRIX METALLOPROTEINASE BINDING OF TISSUE INHIBITOR OF METALLOPROTEINASE-2**

P. Mignatti,<sup>1,2,3</sup> S. D'alessio,<sup>1</sup> G. Ferrari,<sup>1</sup> K. Cinnante,<sup>1</sup> G. Pintucci<sup>1</sup>

<sup>1</sup>Department of Cardiothoracic Surgery, Seymour Cohn Cardiovascular Surgery Research Laboratory, <sup>2</sup>Department of Cell Biology, <sup>3</sup>New York University Cancer Institute, New York University School of Medicine, New York, NY

**P31-16 CAS SIGNALING IN BREAST CANCER**

A. B. Motoyama, R. Hooshmand-Rad, K. Vuori  
Cancer Center, The Burnham Institute, La Jolla, CA

**P31-17 THE ROLE OF NOTCH SIGNALING IN HUMAN BREAST CANCER PATHOGENESIS**

A. Rangarajan, R. A. Weinberg  
Whitehead Institute for Biomedical Research, Cambridge, MA

**P31-18 ROLE OF THE NUTRIENT-SENSITIVE MTOR SIGNALING PATHWAY IN BREAST CANCER DEVELOPMENT AND GROWTH**

J-H. Sheen, D. M. Sabatini  
Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA

**P31-19 STROMAL IMPACT ON HORMONAL RESPONSE OF BREAST CANCER CELLS**

M. P. V. Shekhar, K. Carolin-Amrikia, L. Tait  
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI

**P31-20 A CRITICAL ROLE FOR NHERF IN CELLULAR PROLIFERATION**

J. W. Voltz  
Duke University, Durham, NC

**P31-21 ARRESTIN DOMAINS THAT REGULATE N-FORMYL PEPTIDE RECEPTOR TRAFFICKING AND SIGNALING**

B. M. Wagener, E. R. Prossnitz  
University of New Mexico School of Medicine, Albuquerque, NM

**P31-22 HEDGEHOG SIGNALING WITHIN A GENE REGULATORY NETWORK FOR ENDOMESODERMAL DEVELOPMENT IN THE SEA URCHIN, LYTECHINUS VARIEGATUS**

K. D. Walton,<sup>1</sup> P. Hertzle,<sup>2</sup> D. R. McClay<sup>1</sup>

<sup>1</sup>Biology Department, DCMB Group, Duke University, Durham, NC; <sup>2</sup>Department of Biology, Central Michigan University, Mt. Pleasant, MI

**P31-23 TOWARDS IDENTIFICATION OF HUMAN P55PIK INTERACTING PROTEINS: PRODUCTION AND CHARACTERIZATION OF P55PIK RECOMBINANT PROTEINS AND ANTIBODIES**

Y. Wang, T. Deb, R. Dickson  
Georgetown University, Washington, DC

**P31-24 GROWTH FACTOR SIGNALING INDUCES METASTASIS GENES IN BREAST CANCER CELLS**

G. F. Weber,<sup>1</sup> G. Zhang,<sup>2</sup> B. He<sup>3</sup>  
<sup>1</sup>University of Cincinnati Medical Center, College of Pharmacy, Cincinnati, OH; <sup>2</sup>Department of Gastroenterology, First Affiliated Hospital, Nanjing, China; <sup>3</sup>New England Medical Center, Boston, MA

**P31-25 HEREGULIN BETA1-INDUCED RAC ACTIVATION PROMOTES HUMAN BREAST CANCER CELL PROLIFERATION**

C. Yang, Y. Liu, M. Kazanietz  
Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA

**P32 Functional Study of Biological Molecules I**

12:05-2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.

**P32-1 NUCLEAR ORGANIZATION AND EPIGENETIC STABILITY OF THE BREAST. THE NUCLEAR APPARATUS PROTEIN NUMA ACTS AS AN ORGANIZER OF HIGHER ORDER CHROMATIN STRUCTURE AND CONTRIBUTES TO THE MAINTENANCE OF NORMAL BREAST PHENOTYPE**

P. C. Abad,<sup>1</sup> J. E. Lewis,<sup>1</sup> I. S. Mian,<sup>2</sup> S. A. Lelièvre<sup>1</sup>

<sup>1</sup>Department of Basic Medical Sciences, Purdue University, West Lafayette, IN; <sup>2</sup>Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA

**P32-2 VASCULAR AND TUMOR PROGENITOR MARKERS IN BREAST CANCER**

L. E. Benjamin, A. Adini, Q. Niu, L. Sussman  
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

**P32-3 HUMAN RAD9 IS REQUIRED FOR THE ACTIVATION OF S-PHASE CHECKPOINT AND THE MAINTENANCE OF CHROMOSOMAL STABILITY**

T. Dang, S. Bao, X-F. Wang  
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC

**P32-4 EXPLORING THE ROLE OF HPOT1 AT THE TELOMERE**

K. T. Etheridge, C. M. Counter  
Duke University, Durham, NC

**P32-5 PROPERTIES OF WELL-VASCULARIZED REGIONS OF BONES THAT BECOME COLONIZED BY BREAST CANCER CELLS**

C. V. Gay, L. A. Makuch, D. L. Geffel, D. M. Sosnoski  
Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA

- P32-6 ROLE OF EPSTEIN-BARR VIRUS ENCODED SMALL RNAs IN BETA-CATENIN DEGRADATION**  
S. K. Ghosh, I. Akinsheye  
*Department of Medicine,  
Cancer Research Center, Boston  
University School of Medicine,  
Boston, MA*
- P32-7 DEFINING THE REGULATION OF TELOMERASE THROUGH IDENTIFICATION OF MAMMARY-SPECIFIC TELOMERASE INTERACTING PROTEINS**  
S. E. Holt  
*Departments of Pathology,  
Human Genetics, and  
Pharmacology and Toxicology,  
Massey Cancer Center, Virginia  
Commonwealth University,  
Richmond, VA*
- P32-8 THE EFFECTS OF FATTY ACIDS ON RETINOID SIGNALING IN HUMAN MAMMARY EPITHELIAL CELLS AND HUMAN BREAST CANCER CELLS**  
S. Langton, A. Tighe, L. J. Gudas  
*Weill Graduate School of Medical Sciences of Cornell University,  
New York, NY*
- P32-9 HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1 (Hai-1) REGULATES MATRIPTASE AT MULTIPLE LEVELS, INCLUDING PROTEIN BIOSYNTHESIS, INTRACELLULAR TRAFFICKING, PREVENTION OF UNCONTROLLED SPONTANEOUS ACTIVATION, AND REGULATED ACTIVATION**  
M. D. Oberst, L-Y. L. Chen, K-I. Kiyomiya, C. A. Williams, M-S. Lee, M. D. Johnson, R. B. Dickson, C-Y. Lin  
*Georgetown University,  
Washington, DC*
- P32-10 SIMULTANEOUS ACTIVATION AND HAI-1-MEDIATED INHIBITION OF MATRIPTASE INDUCED AT ACTIVATION FOCI IN HUMAN MAMMARY EPITHELIAL CELLS**  
M-S. Lee, K-I. Kiyomiya, C. Benaud, R. B. Dickson, C-Y. Lin  
*Department of Oncology,  
Lombardi Cancer Center,  
Georgetown University Medical Center, Washington, DC*
- P32-11 POLARITY AND PROLIFERATION ARE CONTROLLED BY DISTINCT SIGNALING PATHWAYS DOWNSTREAM OF PI3-KINASE IN BREAST EPITHELIAL TUMOR CELLS**  
H. Liu, D. C. Radisky, F. Wang, M. J. Bissell  
*Life Science Division, Lawrence Berkeley National Laboratory, Berkeley, CA*
- P32-12 HIGH RESOLUTION CRYSTAL STRUCTURE OF THE MOUSE p53 CORE DOMAIN: AN ANALYSIS OF PROTEIN FLEXIBILITY AND A FRAMEWORK FOR STRUCTURE-BASED DRUG DESIGN**  
W. C. Ho,<sup>1,2</sup> K. Zhao,<sup>1</sup> X. Chai,<sup>1</sup> R. Marmorstein<sup>1,2,3</sup>  
<sup>1</sup>*The Wistar Institute, Philadelphia, PA;* <sup>2</sup>*Department of Chemistry, University of Pennsylvania, Philadelphia, PA*
- P32-13 STRUCTURE-BASED DESIGN OF P18INK4c PROTEINS WITH INCREASED THERMODYNAMIC STABILITY AND CELL CYCLE INHIBITORY ACTIVITY**  
R. N. Venkataramani,<sup>1,3</sup> T. K. MacLachlan,<sup>2</sup> X. Chair,<sup>1</sup> W. S. El-Deiry,<sup>2</sup> R. Marmorstein<sup>1,3,4</sup>  
<sup>1</sup>*The Wistar Institute, University of Pennsylvania, Philadelphia, PA;* <sup>2</sup>*Howard Hughes Medical Institute, Chevy Chase, MD;* <sup>3</sup>*Department of Biochemistry and Molecular Biophysics,* <sup>4</sup>*Department of Chemistry, University of Pennsylvania, Philadelphia, PA*
- P32-14 TARGETED UBIQUITINATION OF CELLULAR PROTEINS BY THE DDB1-CUL4A-ROC1 LIGASE IN RESPONSE TO DNA DAMAGE**  
C. M. McCall, J. Hu, Y. Xiong  
*Department of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC*
- P32-15 DISRUPTION OF ABC PROTEIN KINASES FROM CENTROSOMES CAUSES ANEUPLOIDY THROUGH A FAILURE IN CYTOKINESIS**  
K. Mikule, A. Purohit, S. Doxsey  
*University of Massachusetts School of Medicine, Worcester, MA*
- P32-16 A ROLE FOR SUMOYLATION IN REGULATING ESTROGEN RECEPTOR-MEDIATED GENE EXPRESSION**  
Y-Y. Mo, H. Wu, S. Luster, W. T. Beck  
*Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL; Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL*
- P32-17 CHARACTERIZATION OF THE DNA-BINDING ACTIVITY OF P270, A HUMAN SWI/SNF COMPLEX SUBUNIT FREQUENTLY DOWNREGULATED IN BREAST CANCER**  
A. Patsialou, D. Wilsker, E. Moran  
*Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA*
- P32-18 THE E3 UBIQUITIN LIGASE EDD IS ESSENTIAL FOR YOLK SAC VASCULARISATION AND PLACENTAL DEVELOPMENT**  
D. N. Saunders,<sup>1</sup> S. L. Hird,<sup>1</sup> S. L. Withington,<sup>2</sup> S. L. Dunwoodie,<sup>2</sup> M. J. Henderson,<sup>1</sup> J. Clancy,<sup>1</sup> R. Morton,<sup>1</sup> R. L. Sutherland,<sup>1</sup> C. J. Ormandy,<sup>1</sup> C. K. W. Watts  
<sup>1</sup>*Cancer Research Program, Garvan Institute of Medical Research;* <sup>2</sup>*Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia*
- P32-19 TOWARD DEVELOPING A NOVEL INHIBITOR OF CYCLIN A-CDK2: UNDERSTANDING CYCLIN A-CDK2-SKP2 INTERACTIONS**  
B. A. Schulman, D. M. Duda, D. W. Miller, B. Waddell  
*Departments of Structural Biology and Genetics/Tumor*

*Cell Biology, St. Jude Children's Research Hospital, Memphis, TN*

**P32-20 ANAPLASTIC LYMPHOMA KINASE/PLEIOTROPHIN INTERACTION AND ITS IMPORTANCE IN MALIGNANT GROWTH**

G. E. Stoica, A. H. Kuo,  
E. T. Bowden, T. Luhusen,  
A. Wellstein  
*Department of Oncology,  
Georgetown University Medical Center, Lombardi Cancer Center, Washington, DC*

**P32-21 ASSESSING THE POSSIBLE ROLES OF LECITHIN: RETINOL ACYLTRANSFERASE (LRAT) IN MAMMARY EPITHELIAL CELL DIFFERENTIATION IN TRANSGENIC MICE**

D. Su, L. J. Gudas  
*Department of Pharmacology,  
Weill Graduate School of Cornell University, Weill Medical College of Cornell University, New York, NY*

**P32-22 PHOSPHORYLATION OF RHOC GTPASE BY AKT/PROTEIN KINASE B (PKB) IS REQUIRED FOR INFLAMMATORY BREAST CANCER CELL MIGRATION AND INVASION**

K. E. Groh, G. Radunsky,  
K. L. Van Golen  
*University of Michigan  
Comprehensive Cancer Center, Ann Arbor, MI*

**P32-23 P190B RHOGAP IS A CRITICAL REGULATOR OF MAMMARY GLAND DEVELOPMENT**

T. Vargo-Gogola, J. M. Rosen  
*Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX*

**P32-24 COOPERATIVE INTERACTIONS DURING HUMAN MAMMARY EPITHELIAL CELL IMMORTALIZATION**

P. Yaswen, J. Garbe, B. Gardie,  
T. Nijjar, G. Nonet, K. Chin,  
J. W. Gray, C. Collins,  
M. R. Stampfer  
*Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA; University of California, San Francisco*

*Comprehensive Cancer Center, San Francisco, CA*

**P32-25 FUNCTIONAL ANALYSIS OF BORIS, A NOVEL DNA-BINDING PROTEIN**

P. Yaswen, J. E. Mroczkowska,  
M. R. Stampfer, V. V. Lobanenkov  
*Life Science Division, Lawrence Berkeley National Laboratory, Berkeley, CA; Laboratory of Immunopathology, NIAID, NIH, Rockville, MD*

**P33-4 CHARACTERIZATION OF MOLECULAR FACTORS CRITICAL TO THE S100A4 (A METASTASIS-ASSOCIATED PROTEIN) – DEPENDENT INCREASE IN MOTILITY OF BREAST CANCER CELLS**

T. E. Haire  
*Cold Spring Harbor Laboratory, Cold Spring Harbor, NY*

**P33-5 ARGOS INHIBITS EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALLING BY LIGAND SEQUESTRATION**

D. E. Klein,<sup>1</sup> V. M. Nappi,<sup>1</sup>  
G. T. Reeves,<sup>2</sup> S. Y. Shvartsman,<sup>2</sup>  
M. A. Lemmon<sup>1</sup>

<sup>1</sup>*Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia, PA;* <sup>2</sup>*Department of Chemical Engineering and The Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ*

**P33-6 THE EPHB4 RECEPTOR TYROSINE KINASE INHIBITS BREAST CANCER CELL TUMORIGENICITY**

N. K. Noren, G. Foos,  
C. A. Hauser, E. B. Pasquale  
*The Burnham Institute, La Jolla, CA*

**P33-7 MET NUCLEAR LOCALIZATION AND SIGNALING IN BREAST CANCER**

S. Pozner-Moulis, D. Pappas,  
M. Cregger, R. L. Camp,  
D. L. Rimm  
*Department of Pathology, Yale University School of Medicine, New Haven, CT*

**P33-8 GROWTH INHIBITION OF BREAST CANCER CELL LINES MDA-MB-453 AND MCF-7 DUE TO INHIBITION OF PHOSPHORYLATION OF RECEPTOR TYROSINE KINASES BY COMPLEX FORMATION WITH ANGIOTENSIN II RECEPTOR AT2**

L. Pulakat,<sup>1</sup> C. Mandavya,<sup>1</sup>  
R. Kohle,<sup>1</sup> N. Gavini<sup>2</sup>  
<sup>1</sup>*Department of Biological Sciences, Bowling Green State University, Bowling Green, OH;* <sup>2</sup>*Department of Biological Sciences, Mississippi State University, Mississippi State, MS*

**P33-9 THE FPS/FES TYROSINE KINASE IS UPREGULATED IN THE MOUSE MAMMARY GLAND DURING LACTATION AND IS A COMPONENT OF THE E-CADHERIN BASED ADHERENS JUNCTION**

P. Truesdell, P. A. Greer  
*Department of Pathology and Molecular Medicine, Cancer Research Institute, Queen's University, Kingston, ON, Canada*

**P33-10 ROLE OF MEKK3 SIGNALING PATHWAY CANCER CELLS TO TNF-ALPHA-MEDIATED APOPTOSIS**

L. Yu, Q. Huang, J. Cheng, B. Su  
*University of Texas, M.D. Anderson Cancer Center, Houston, TX*

**P34 Hormone Metabolism**

12:05-2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.

**P34-1 THE IN VITRO METABOLISM OF ESTROGENS BY HUMAN FECAL BACTERIA; A COMPARISON OF EQUOL-PRODUCERS AND NON-PRODUCERS**

C. Atkinson,<sup>1</sup> S. Berman,<sup>2</sup>  
W. K. Thomas,<sup>1</sup> J. W. Lampe<sup>1</sup>  
<sup>1</sup>*Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA;* <sup>2</sup>*Bastyr University, Kenmore, WA*

**P34-2 INITIAL CHARACTERIZATION OF THE LECITHIN: RETINOL ACYL-TRANSFERASE (LRAT) KNOCKOUT MICE AS A MODEL FOR MAMMARY CARCINOGENESIS**

S. M. O'Byrne,<sup>1</sup> J. M. Libien,<sup>2</sup>  
K. Palczewski,<sup>3</sup> W. S. Blaner<sup>1,4</sup>  
*Departments of <sup>1</sup>Human Nutrition, <sup>2</sup>Pathology and <sup>3</sup>Medicine, Columbia University, New York, NY; <sup>4</sup>Department of Ophthalmology, University of Washington, Seattle, WA*

**P34-3 CENTRAL LEPTIN GENE THERAPY TO REDUCE BREAST CANCER RISK FACTORS**

U. T. Iwaniec,<sup>1</sup> M. G. Dube,<sup>2</sup>  
R. Torto,<sup>2</sup> R. T. Turner,<sup>3</sup>  
T. J. Wronski,<sup>1</sup> S. P. Kalra<sup>4</sup>  
<sup>1</sup>*Department of Physiological Sciences, <sup>2</sup>Department of Physiology and Functional Genomics, <sup>4</sup>Department of Neuroscience, University of Florida, Gainesville, FL;*  
<sup>3</sup>*Department of Orthopedics and Biochemistry and Molecular Biology, Mayo Foundation, Rochester, MN*

**P34-4 CHARACTERIZATION OF A NOVEL CLASS OF NONPOLAR 17BETA-ESTRADIOL METABOLITES FORMED BY HUMAN CYTOCHROME P450 ENZYMES**

J. Lee, B.T. Zhu  
*College of Pharmacy, University of South Carolina, Columbia, SC*

**P34-5 GLUCOSE METABOLISM, SEX STEROIDS, MELATONIN AND RISK OF BREAST CANCER**

P. Muti, V. Krogh, A. Micheli,  
G. Secreto, C. Adalberto,  
F. Berrino  
*Italian NCI "Regina Elena," Rome, Italy; Italian NCI, Milan, Italy*

**P35 Hormone Receptors II**

12:05-2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.

**P35-1 DEFINING THE MOLECULAR ACTIONS OF LENOLEIC ACID IN BREAST CANCER: MODULATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA**

C. D. Allred, M. W. Kilgore  
*University of Kentucky College of Medicine, Lexington, KY*

**P35-2 PROGESTERONE RECEPTOR ISOFORMS A AND B EXPRESSION AND RELATIONSHIP TO PROLIFERATION DURING MURINE MAMMARY GLAND DEVELOPMENT**

M. D. Aupperlee, K. T. Smith,  
A Kariagina, S. Z. Haslam  
*Cell and Molecular Biology Program and Department of*

*Physiology, Michigan State University, East Lansing, MI*

**P35-3 TARGETING THE MTA1S-LMO4 PATHWAY IN HORMONE RESISTANCE**

C. J. Barnes, R. Singh, R. Kumar  
*University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P35-4 THE ROLE OF ANDROGEN RECEPTOR SIGNALING IN BREAST CANCER**

L. M. Butler, S. N. Birrell,  
W. D. Tilley  
*Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Hanson Institute, Adelaide, SA, Australia*

**P35-5 TEMPORAL ACTIVATION OF ERK 1/2 MAPK BY LIGANDED PROGESTERONE RECEPTOR REGULATES BREAST CANCER CELL PROLIFERATION**

E. J. Faivre, C. A. Lange  
*Microbiology, Immunology and Cancer Biology Graduate Program, Department of Medicine, University of Minnesota, Minneapolis, MN*

**P35-6 E6-ASSOCIATED PROTEIN, E6-AP, IS INVOLVED IN THE TUMORIGENESIS OF MAMMARY GLAND**

X. Gao, Z. Nawaz  
*Creighton University, Omaha, NE*

**P35-7 CONJUGATED LINOLEIC ACID AND THE ESTROGEN RECEPTOR IN THE PREVENTION OF BREAST CANCER**

M. M. Ip, P. A. Masso-Welch,  
S. O. McGee, S. E. McCann  
*Roswell Park Cancer Institute, Buffalo, NY*

**P35-8 INCREASED EXPRESSION OF AIB1 STIMULATES AKT PHOSPHORYLATION AND CELL CYCLE PROGRESSION IN HUMAN BREAST CANCER CELLS**

J. Zhang, L-Y. Chang, X. Long,  
R. Goulet, G. Sledge, L. Cheng,  
L. Li, C. Kao, M-H. Jeng  
*Departments of Medicine, Urology, Pathology, Surgery, and the Walther Oncology Center, Indiana University School of*

- Medicine, and the Walther Center Institute, Indianapolis, IN*
- P35-9 SCREENING OF COMPOUNDS THAT BIND TO THE ESTROGEN RECEPTOR USING A QUARTZ CRYSTAL MICROBALANCE BIOSENSOR**  
L. A. Luck, R. E. Baltus, K. S. Carmon  
*Department of Chemistry and Chemical Engineering, Clarkson University, Potsdam, NY*
- P35-10 ENHANCED RETINOID-INDUCED APOPTOSIS OF MDA-MB-231 BREAST CANCER CELLS BY PKC INHIBITORS INVOLVES ACTIVATION OF ERK**  
F. Pettersson, M-C. Couture, N. Hanna, W. H. Miller  
*Lady Davis Institute for Medical Research, McGill University, Montreal, QC, Canada*
- P35-11 BREAST CANCER PREDICTIVE MOLECULAR MARKERS**  
I. Poola,<sup>1</sup> R. L. Dewitty,<sup>2</sup> J. J. Marshallack,<sup>3</sup> J. Abraham,<sup>1</sup> R. Bhatnagar,<sup>4</sup> L. D. Leffall<sup>2</sup>  
<sup>1</sup>*Department of Biochemistry and Molecular Biology, Howard University School of Medicine, Washington, DC; Departments of*  
<sup>2</sup>*Surgical Oncology and Pathology, Howard University Hospital, Washington, DC;*  
<sup>3</sup>*Department of Biology, University of Alberta, Edmonton, AB, Canada*
- P35-12 ERALPHA-NEGATIVE BREAST CANCERS EXPRESS SIGNIFICANT LEVELS OF ESTROGEN-INDEPENDENT TRANSCRIPTION FACTOR, ERBETA5: A POTENTIAL TARGET FOR CHEMOPREVENTION**  
I. Poola,<sup>1</sup> S. A. W. Fuqua,<sup>4</sup> R. L. Dewitty,<sup>2</sup> J. Abraham,<sup>1</sup> J. J. Marshallack,<sup>3</sup> A. Liu<sup>5</sup>  
<sup>1</sup>*Department of Biochemistry and Molecular Biology, Howard University School of Medicine, Washington, DC; Departments of*  
<sup>2</sup>*Surgical Oncology and Pathology, Howard University Hospital, Washington, DC;*  
<sup>3</sup>*Breast Center, Baylor College of Medicine, Houston, TX;* <sup>4</sup>*Biometry and Mathematical Statistics Branch, National Institute*
- of Child Health and Human Development, National Institutes of Health, Bethesda, MD*
- P35-13 FKHR AS A COREPRESSOR OF THE ESTROGEN RECEPTOR SIGNALING IN BREAST CANCER**  
R. Schiff, L. Qin, E. Schmitt, C. K. Osborne  
*Breast Center, Baylor College of Medicine, Houston, TX*
- P35-14 IDENTIFICATION OF NOVEL NUCLEAR RECEPTOR BINDING PARTNERS USING T7 PHAGE DISPLAY**  
A. B. Sherk, D. Fan, H. Cui, T. Hartney, C-Y. Chang, J. Norris, D. P. McDonnell  
*Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC*
- P35-15 BREAST CANCER PREVENTION BY INDUCED PREGNANCY-LIKE MAMMARY GLAND DIFFERENTIATION**  
Y. E. Shi  
*Institute for Medical Research, North Shore-Long Island Jewish Medical Center, Albert Einstein College of Medicine, New Hyde Park, NY*
- P35-16 GAMMA-SYNUCLEIN: A NEW BIOMARKER FOR BREAST CANCER PROGRESSION AND HORMONE RESPONSIVENESS**  
Y. E. Shi  
*Institute for Medical Research, North Shore-Long Island Jewish Medical Center, Albert Einstein College of Medicine, New Hyde Park, NY*
- P35-17 REGULATION OF THE ESTROGEN RECEPTOR ALPHA BY A SCAFFOLD ATTACHMENT B-1/RET FINGER PROTEIN COMPLEX**  
S. M. Townson,<sup>1</sup> K. Kang, S. Oesterreich<sup>2</sup>  
<sup>1</sup>*Department of Human Genetics/ Massey Cancer Center, Virginia Commonwealth University, Richmond, VA;* <sup>2</sup>*Breast Center, Baylor College of Medicine, Houston, TX*
- P35-18 AKT1 – A NEW MARKER FOR TAMOXIFEN RESISTANCE IN ER-DEPENDENT BREAST CANCER**  
A. Stoica, R. Clarke, A. Winder, K. Lehnes, M. Simoneaux, H. Summe, N. Kasid, J. Duncan, C. Muesli, Ch. H. Evans Jr., G. Stoica, M. Martin, R. Russell  
*Georgetown University, Washington, DC*
- P35-19 SXR – A NOVEL TARGET FOR BREAST CANCER PREVENTION AND TREATMENT**  
S. Verma, M. M. Tabb, B. Blumberg  
*Department of Developmental and Cell Biology, University of California at Irvine, Irvine, CA*
- P35-20 ANTICARCINOGENIC ACTIVITIES OF RETINOIC ACID THROUGH ITS NUCLEAR RECEPTOR AND BINDING PROTEIN**  
L. Willmert, N. Noy  
*Division of Nutritional Sciences, Cornell University, Ithaca, NY*
- P35-21 PEPTIDYL-PROLYL ISOMERASE 1 (PIN1) COACTIVATES STEROID RECEPTOR TRANSCRIPTION THROUGH REGULATING THE FUNCTION OF PHOSPHORYLATED STEROID RECEPTOR COACTIVATOR-3**  
P. Yi, J. Wong, S. Y. Tsai, M-J. Tsai, B. W. O'Malley  
*Baylor College of Medicine, Houston, TX*
- P35-22 HAPLOID INACTIVATION OF THE AMPLIFIED-IN-BREAST CANCER 3 COACTIVATOR REDUCES THE INHIBITORY EFFECT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AND RETINOID X RECEPTOR ON CELL PROLIFERATION AND ACCELERATES POLYOMA MIDDLE-T ANTIGEN-INDUCED MAMMARY TUMORIGENESIS IN MICE**  
H. Zhang, S-Q. Kuang, L. Liao, S. Zhou, J. Xu  
*Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX*

**P35-23 CHARACTERIZATION OF FKHR REPRESSION ACTION ON ESTROGEN RECEPTOR SIGNALING IN BREAST CANCER**  
 L. Qin, R. Schiff, R.E. Herrera, E. Schmitt, C.K. Osborne  
*Breast Center, Baylor College of Medicine, Houston, TX*

### **P36 Mechanism of Hormone Action**

**12:05-2:05 p.m.**

*Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
 Even-numbered – 1:05–2:05 p.m.*

**P36-1 SILENCING THE EXPRESSION OF CTIP CONFFERS TAMOXIFEN RESISTANCE AND ESTROGEN INDEPENDENCE IN HUMAN BREAST CANCER CELLS**

M. Wu,<sup>1</sup> R. Baer,<sup>2</sup> C. Hatzis,<sup>3</sup>

C. M. Aldaz<sup>1</sup>

<sup>1</sup>*Department of Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Smithville, TX;* <sup>2</sup>*Institute for Cancer Genetics, Columbia University, New York, NY;* <sup>3</sup>*Silico Insights, Inc., Woburn, MA*

**P36-2 P38 MITOGEN ACTIVATED PROTEIN KINASE AND THE RESISTANCE OF MCF-7 BREAST CANCER CELLS TO TAMOXIFEN**

W. Bai, W. Fu, J. Bao, X. Zhang, P. Li

*Department of Pathology, University of Southern Florida College of Medicine, Tampa, FL*

**P36-3 ROLE OF GRIM19 AND STAT3 IN VITAMIN D3 MEDIATED APOPTOSIS IN MCF-7 BREAST CANCER CELLS**

B. Byrne, J. Welsh

*Department of Biological Sciences, University of Notre Dame, Notre Dame, IN*

**P36-4 SEX HORMONE-BINDING GLOBULIN EXPRESSION IN BREAST CANCER**

S. M. Kahn, A. Nakhlra, D. J. Hryb, W. Rosner

*Columbia University and St. Luke's Roosevelt Hospital Center, New York, NY*

**P36-5 PROLIFERATION STIMULATED BY TAMOXIFEN-BOUND ESTROGEN RECEPTOR-ALPHA AND PROMOTER-SPECIFIC EFFECTS IN BREAST CANCER CELLS DEFICIENT IN THE COREPRESSORS N-COR AND SMRT**

E. K. Keeton, M. Brown

*Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA*

**P36-6 CROSSTALK BETWEEN ARYLHYDROCARBON RECEPTOR AND ESTROGEN RECEPTOR SIGNALLING PATHWAYS USING CAD GENE AS THE MODEL IN BREAST CANCER CELLS**

S. Khan, K. Kim, R. Barhoumi, R. C. Burghardt, S. Safe

*Department of Veterinary Physiology and Pharmacology, Texas A & M University, College Station, TX*

**P36-7 TARGETED CYTOPLASMIC LOCALIZATION OF ERALPHA IN C4-12 CELLS REVEALS NOVEL INSIGHT INTO LIGAND-STIMULATED PROTEASOME-MEDIATED DEGRADATION OF ERALPHA BUT DOESN'T SHOW NON-GENOMIC SIGNALING**

A. V. Lee, C. Thorne, P. Zhang,

Z. Lazard, S. Oesterreich

*Baylor College of Medicine, Houston, TX*

**P36-8 SRA, A NEW KIND OF MOLECULE FUNCTIONAL BOTH AT THE RNA AND THE PROTEIN LEVELS, INTERFERES WITH THE ESTROGEN RECEPTOR SIGNALING PATHWAY IN BREAST CANCER**

S. Choniedass-Kothari,

M. Hamedani, E. Leygue

*University of Manitoba, Winnipeg, MB, Canada*

**P36-9 STUDY OF STEROID EFFECTS ON TRANSCRIPTION ELONGATION IN BREAST CANCER CELLS**

C. Li, B. O'Malley

*Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX*

**P36-10 ANDROGEN-ANDROGEN RECEPTOR AXIS IN ESTROGEN RECEPTOR POSITIVE BREAST CANCER**

H. Linden, E. Schubert, T. Lawton, P. Petra, B. Anawalt, D. Mankoff  
*University of Washington, Seattle, WA*

**P36-11 TARGETING OF THE NUCLEAR RECEPTOR COACTIVATOR ISOFORM DELTA3AIB1 IN BREAST CANCER**

A. Mani, R. Reiter, A. T. Riegel  
*Lombardi Cancer Center, Georgetown University, Washington, DC*

**P36-12 EVIDENCE THAT EMCA1 IS A GENETIC DETERMINANT OF E2-INDUCED MAMMARY TUMOR INCIDENCE AND TUMOR MULTIPLICITY IN THE ACI RAT**

B. S. Schaffer,<sup>1,2</sup> M. Tochacek,<sup>2,3</sup> K. L. Pennington,<sup>1,2</sup> J. L. Meza,<sup>4</sup> J. D. Shull<sup>1,2,3,5</sup>

<sup>1</sup>*Department of Genetics, Cell Biology and Anatomy,* <sup>2</sup>*Eppley Institute for Cancer Research,*

<sup>3</sup>*Department of Biochemistry and Molecular Biology,*

<sup>4</sup>*Department of Preventive and Societal Medicine,* <sup>5</sup>*Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE*

**P36-13 IDENTIFICATION OF RXR ALPHA TARGET GENES THAT ARE INVOLVED IN THE SUPPRESSION OF THE GROWTH IN HUMAN MAMMARY EPITHELIAL CELLS (HMEC)**

H-S. Seo, K. R. Coombes, J-S. Koo

*Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P36-14 ANALYSIS OF PROGESTIN EFFECTS ON HEPATOCYTE GROWTH FACTOR SIGNALING PATHWAYS IN RELATION TO PROLIFERATION AND ALVEOLAR MORPHOGENESIS OF NORMAL MAMMARY EPITHELIAL CELLS IN VITRO**

K. T. Smith, S. Z. Haslam  
*Cell and Molecular Biology Program and Department of Physiology and Human Medicine, Michigan State University, East Lansing, MI*

**P36-15 COACTIVATORS CAN CONTRIBUTE TO DOWN REGULATION OF ESTROGEN RECEPTOR-ALPHA EXPRESSION. EVIDENCE FOR FACTORS IN ADDITION TO AMPLIFIED IN BREAST CANCER-1 (AIB1)**

C. L. Smith, B. M. Jaber, S. Chaiet, F. E. K. Gordon  
*Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX*

**P36-16 ALTERED LOCALIZATION OF ER-COREGULATOR PELP1 PROMOTES ESTROGEN HYPERSENSITIVITY AND TAMOXIFEN RESISTANCE**

R. K. Vadlamudi, B. Manavathi, S. Balasenthil, Z. Yang, A. A. Sahin, R. Kumar  
*Louisiana State University Health Sciences Center, New Orleans, LA; University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P36-17 VITAMIN D SIGNALING IN BREAST CANCER: GENOMIC AND NON-GENOMIC MECHANISMS**

M. Valrance, J-E. Welsh  
*Department of Biological Sciences, University of Notre Dame, Notre Dame, IN*

---

**P37 Chemical/Physical Carcinogenesis**

**12:05–2:05 p.m.**

*Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
 Even-numbered – 1:05–2:05 p.m.*

**P37-1 NORMAL ADULT BREAST STEM CELLS AS ‘TARGETS’ FOR BREAST CARCINOGENESIS: IMPLICATIONS FOR CHEMOPREVENTION AND CHEMOTHERAPY**

C-C. Chang  
*Michigan State University, East Lansing, MI*

**P37-2 THE ROLES OF LIVER AND TARGET-TISSUE CYTOCHROME P450-MEDIATED METABOLISM IN 7,12-DIMETHYLBENZ[A] ANTHRACENE-INDUCED DNA ADDUCT FORMATION IN MOUSE MAMMARY GLAND**

X. Ding, H. Cui, J. Gu, L. Zhang, Q-Y. Zhang  
*Wadsworth Center, New York State Department of Health, and School of Public Health, State University of New York at Albany, Albany, NY*

**P37-3 INCREASED SUSCEPTIBILITY OF THE IMMATURE MAMMARY GLAND TO CARCINOGENESIS**

M. N. Gould, J. Ariaizi, J. D. Haag  
*McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI*

**P37-4 THE DEVELOPMENT OF A RAT BRCA2 KNOCKOUT MODEL**

M. N. Gould, M. Cotroneo, J. D. Hagg  
*McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI*

**P37-5 THE ROLE OF IODINE IN BREAST CARCINOGENESIS**

K. S. Iwamoto  
*David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA*

**P37-6 INDUCTION OF PHASE I AND PHASE II ENZYMES BY POLYCYCLIC AROMATIC HYDROCARBONS: ROLE OF CHEMOPREVENTIVE AGENTS**

S. R. Kondraganti, W. Jiang, L. Wang, K. Muthiah, B. Moorthy  
*Department of Pediatrics, Baylor College of Medicine, Houston, TX*

**P37-7 INVESTIGATING A VIRAL, HORMONE AND DIET HYPOTHESIS OF HUMAN BREAST CANCER**

J. Lawson, N. Whitaker, W. Delprado, M. Mok, W. Glenn, L. Lutze-Mann, F. Kan, E. Carpenter, B. Iacopetta  
*University of New South Wales, Sydney, NSW, Australia; Mount Sinai School of Medicine, New York, NY; University of Western Australia, Crawley, WA, Australia*

**P37-8 DEREGULATION OF CYCLIN D1, MDM2, AKT, AND P27KIP1 IN CARCINOGEN-INDUCED MAMMARY TUMORS**

S. A. Murray, S. Yang, E. Demicco, H. Ying, D. H. Sherr, L. Hafer, A. Rogers, G. E. Sonenshein, Z. X. Xiao  
*Boston University School of Medicine, Boston, MA*

---

**P38 Invasion and Metastasis II**

**12:05–2:05 p.m.**

*Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
 Even-numbered – 1:05–2:05 p.m.*

**P38-1 ANGIOPOIETIN-2 PROMOTES MCF-7 BREAST CANCER METASTASES AND CO-EXPRESSION OF VEGF WITH ANG2 POTENTIATES ANG2-INDUCED BREAST CANCER METASTASIS**

Y. Imanishi, P. Guo, M. Jarzynka, B. Hu, S-Y. Cheng  
*University of Pittsburgh Cancer Institute and Department of Pathology, Hillman Cancer Center, Pittsburgh, PA*

P38-2	<b>TUMOR-SECRETED PHOSPHOGLUCOSE ISOMERASE/AUTOCRINE MOTILITY FACTOR: CAUSAL ROLE IN A MOUSE MODEL OF CACHEXIA</b> J. M. Chirgwin, <sup>1</sup> L. W. Wessner, <sup>1</sup> C. Davies <sup>2</sup> <sup>1</sup> Department of Medicine, University of Virginia, Charlottesville, VA; <sup>2</sup> Department of Biochemistry, Medical University of South Carolina, Charleston, SC	P38-7	<b>VEGF AND METASTATIC PROGRESSION OF BREAST CANCER</b> Q-L. Yang, D. Saxena, D. Tamimi, J. Sison, J. Magee, C. Siegel, P. Hauschka <i>Children's Hospital Boston, Harvard School of Dental Medicine, Boston, MA</i>	P38-12	<b>A SUBSET OF CELL CLUSTERS OVERLYING FOCAL MYOEPITHELIAL CELL LAYER DISRUPTIONS EXHIBITS FEATURES OF MUTATED STEM CELLS</b> Y. Man <i>Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC</i>
P38-3	<b>ROLE OF RAC1 AND RAC3 IN BREAST CANCER METASTASIS</b> P. J. Baugher, L. Krishnamoorthy, M. Hoffmeyer, A. Lacy, R. Richards-Kortum, J. Price, S. F. Dharmawardhane <i>University of Texas at Austin, Austin, TX</i>	P38-8	<b>THE METASTASIS SUPPRESSOR GENE BRMS1 REDUCES EARLY SURVIVAL OF BREAST CANCER CELLS DURING METASTASIS</b> B. D. Hedley, I. C. MacDonald, A. C. Groom, C. O. Postenka, S. M. Wilson, D. R. Welch, <sup>1</sup> A. F. Chambers <i>London Regional Cancer Program, London Health Sciences Centre, and Department of Medical Biophysics, University of Western Ontario, London, ON, Canada; <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL</i>	P38-13	<b>CD8 AND MAST CELL TRYPTASE POSITIVE CELLS ARE PREFERENTIALLY ASSOCIATED WITH FOCAL MYOEPITHELIAL CELL LAYER DISRUPTIONS: IMPLICATIONS FOR BREAST TUMOR INVASION</b> Y. Man <i>Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC</i>
P38-4	<b>INHIBITION OF BREAST CANCER METASTASIS WITH LIGAND MIMETIC ANTIBODIES FROM CANCER PATIENTS</b> B. Felding-Habermann, R. A. Lerner, A. Lillo, S. Zhuang, M. R. Weber, S. Arrues, C. Gao, S. Mao, A. Saven, K. D. Janda <i>The Scripps Research Institute and Scripps Clinic, La Jolla, CA</i>	P38-9	<b>ANALYSIS OF THE INVASIVE PHENOTYPE OF SUM 149, AN INFLAMMATORY BREAST CANCER CELL LINE</b> M. Hoffmeyer, K. Wall, S. F. Dharmawardhane <i>University of Texas at Austin, Austin, TX</i>	P38-14	<b>A SUBSET OF FEMALE BREAST TISSUES CONTAINS ISOLATED SOLID CELL MASSES WITH UNUSUAL MORPHOLOGIC AND IMMUNOHISTOCHEMICAL FEATURES: SEEDS FOR DRUG RESISTANCE AND RECURRENCE?</b> Y. Man <i>Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC</i>
P38-5	<b>THE ROLE OF THE G12 FAMILY OF HETEROTRIMERIC G PROTEINS IN BREAST CANCER METASTASIS</b> P. Kelly, <sup>1</sup> B. Moeller, <sup>2</sup> M. A. Booden, <sup>3</sup> C. J. Der, <sup>3</sup> M. W. Dewhirst, <sup>2</sup> P. J. Casey, <sup>1,4</sup> T. A. Fields <sup>2</sup> <i>Departments of <sup>1</sup>Pharmacology and Cancer Biology, <sup>2</sup>Pathology, and <sup>4</sup>Biochemistry, Duke University Medical Center, Durham, NC; <sup>3</sup>Department of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, NC</i>	P38-10	<b>ANTIBODY INDUCED PERTURBATION – A NEW METHOD TO IDENTIFY PATHWAYS IN BREAST CANCER PROGRESSION</b> M. D. Johnson <i>Georgetown University, Washington, DC</i>	P38-15	<b>IMPACTS OF FOCAL MYOEPITHELIAL CELL LAYER DISRUPTIONS ON BIOLOGIC PRESENTATIONS OF OVERLYING EPITHELIAL CELLS: IMPLICATIONS FOR BREAST TUMOR PROGRESSION AND INVASION</b> Y. Man <i>Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC</i>
P38-6	<b>PERICYTE SUPPORT OF BREAST CANCER CELLS</b> P. Sharma, H. Ino, D. Cheney, J. Wong, C. S. Siegel, P. V. Hauschka <i>Children's Hospital Boston, Harvard School of Dental Medicine, Boston, MA</i>	P38-11	<b>GENE AMPLIFICATION OF HER-2/NEU IN BREAST CANCER CELLS RESULTS IN ALTERED TETRASPANIN GENE EXPRESSION TO PROMOTE METASTATIC POTENTIAL</b> D. P. Lombardi, <sup>1</sup> R. Ashfaq, <sup>2</sup> D. Tripathy, <sup>2</sup> J. Geraerts, <sup>3</sup> M. S. Sinha, <sup>1</sup> K. T. Toal <sup>1</sup> <sup>1</sup> Washington University School of Medicine, St. Louis, MO; <sup>2</sup> University of Texas Southwestern Medical Center at Dallas, Dallas, TX; <sup>3</sup> Roswell Park Cancer Institute, Buffalo, NY		

**P38-16 BNIP-3 MEDIATES HYPOXIA-INDUCED CELL DEATH IN NON-METASTATIC, BUT NOT METASTATIC MURINE BREAST CANCER**

D. Manka, Z. Spicer, M. B. Rojas, D. E. Millhorn  
*University of Cincinnati Genome Research Institute, Cincinnati, OH*

**P38-17 SECRETION OF PDGF, IGF AND TGF $\beta$  BY METASTATIC BREAST CANCER CELLS ALTERS OSTEOBLAST FUNCTION**

R. R. Mercer, D. R. Welch, C. V. Gay, A. M. Mastro  
*Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL*

**P38-18 ENDOTHELIAL CELL AGING AND BREAST CANCER CELL-INDUCED ENDOTHELIAL CELL INJURY**

C. J. Merkle, D. W. Montgomery  
*College of Nursing, University of Arizona, and Southern Arizona VA Health Care System, Tucson, AZ*

**P38-19 PROGRESSIVE LOSS OF SYK AND ABNORMAL PROLIFERATION IN BREAST CANCER CELLS**

G. Klus, M. Moroni, B. Haddad, S. C. Mueller  
*Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC*

**P38-20 PHENOTYPIC CHARACTERISTICS OF NEOPLASTIC PROGRESSION IN BREAST CANCER ARE MODULATED BY ALPHA-L-FUCOSE**

K. Yuan, G. Rezonew, G. P. Siegal  
*Department of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, AL*

**P38-21 IDENTIFICATION AND CHARACTERIZATION OF NOVEL GENES THAT INDUCE MIGRATION AND INVASION OF MAMMARY EPITHELIAL CELLS**

R. N. Gunawardane, J. S. Brugge  
*Department of Cell Biology, Harvard Medical School, Boston, MA*

**P38-22 FUNCTIONAL ANALYSIS OF THE ROLES OF RHOA AND RHOC GTPASES IN INVASIVE BREAST CARCINOMA**

K. J. Simpson, E. A. Lipscomb, S. Lyle, J. S. Brugge, A. M. Mercurio  
*Department of Cell Biology, Harvard Medical School, Boston, MA; Division of Cancer Biology and Angiogenesis, Beth Israel Deaconess Medical School, Boston, MA*

**P38-23 ACTIVATION OF GPR54 BY KISS-1 PEPTIDE INHIBITS BREAST CANCER CELL MIGRATION VIA RHO FAMILY OF SMALL GTPASES**

L. J. Stafford, D. Mitchell, Y. Cai, M. Liu  
*Texas A&M University Systems Health Science Center Institute of Biosciences and Technologies, Houston, TX*

**P38-24 A NOVEL SMALL MOLECULE SR 13179 INHIBITS GROWTH AND INVASION OF BREAST CARCINOMA CELLS BY INDUCTION OF TISSUE INHIBITOR OF METALLOPROTEASE-2 PROTEIN**

N. Zaveri, N. Waleh, W. R. Chao, B. Murphy  
*Biosciences Division, SRI International, Menlo Park, CA*

**P38-25 THE SEARCH FOR PARAMETERS OF NEGATIVE SENTINEL LYMPH NODE INDICATORS OF AXILLARY LYMPH NODE STATUS IN BREAST CANCER PATIENTS**

N. Zurgil, E. Afrimzon, M. Deutsch  
*Department of Physics, Bar-Ilan University, Ramat Gan, Israel*

**P38-26 IDENTIFICATION OF BIOMARKERS IN LYMPH USING PROTEOMIC-BASED APPROACH FOR EARLY DETECTION OF BREAST CANCER METASTASIS**

Sulma Mohammed, Gary Lants, El Woody Walls  
*Departments of Veterinary Pathobiology, Veterinary Clinical Sciences, and Basic Medical Sciences, Purdue University, West Lafayette, IN*

**P39 Regulation of the Immune Response**

**12:05-2:05 p.m.**

*Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.*

**P39-1 REGULATING NF-KAPPAB ACTIVITY IN DENDRITIC CELLS**

A. A. Beg, M. Prendes, X. Wang  
*Department of Biological Sciences, Columbia University, New York, NY*

**P39-2 INHERITED SUSCEPTIBILITY TO BREAST CANCER IN HEALTHY WOMEN: MUTATIONS IN BREAST CANCER GENES, IMMUNE SURVEILLANCE AND PSYCHOLOGICAL DISTRESS**

D. H. Bovbjerg, H. B. Valdimarsdottir  
*Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY*

**P39-3 IMMUNE SURVEILLANCE, CYTOKINES, AND BREAST CANCER RISK: GENETIC AND PSYCHOLOGICAL INFLUENCES IN AFRICAN-AMERICAN WOMEN**

D. Bovbjerg, K. Amend, J. Godbold, C. Ambrosone  
*Departments of Oncological Sciences and Community Medicine, Mount Sinai School of Medicine, New York, NY*

**P39-4 POSTDOCTORAL TRAINING PROGRAM IN BIOBEHAVIORAL BREAST CANCER RESEARCH**

D. H. Bovbjerg, W. H. Redd  
*Department of Oncological Sciences, Biobehavioral Medicine Program, Cancer Prevention and Control, Mount Sinai School of Medicine, New York, NY*

- P39-5 THE MOUNT SINAI CENTER FOR INTERDISCIPLINARY BIOBEHAVIORAL RESEARCH ON GENETIC FACTORS IN BREAST CANCER**  
 D. H. Bovbjerg,  
 H. B. Valdimarsdottir,  
 C. Ambrosone  
*Biobehavioral Medicine, Cancer Epidemiology, and Cancer Prevention and Control Programs, Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY*
- P39-6 ESTROGEN REGULATION OF AN ESTROGEN RECEPTOR-NEGATIVE BREAST CANCER CELL LINE XENOGRAFTED INTO SCID MICE: A ROLE FOR THE HOST IMMUNE RESPONSE?**  
 E. M. Curran, B. M. Judy,  
 N. Duru, D. M. Estes  
*Department of Pediatrics, Sealy Center for Vaccine Development, University of Texas Medical Branch at Galveston, Galveston, TX*
- P39-7 CYCLOOXYGENASE INHIBITORS MODULATE IMMUNE PARAMETERS THAT CONTROL BREAST CANCER METASTASIS**  
 A. M. Fulton, N. Kundu, X. Ma,  
 T. Walser, D. Holt  
*Department of Pathology and Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD*
- P39-8 ACTIVITY OF HER-2 DNA VACCINE ADMINISTERED WITH DNA ENCODING GITR LIGAND**  
 J. B. Jacob, K. D. Shim,  
 P. J. Whittington, R. F. Jones,  
 Y-C. M. Kong, W-Z. Wei  
*Karmanos Cancer Institute and the Department of Immunology and Microbiology, Wayne State University, Detroit, MI; State University of New York, Syracuse, Syracuse, NY*
- P39-9 CHARACTERIZATION OF NKLAM AS AN E3 LIGASE**  
 J. Fortier, J. Kornbluth  
*Saint Louis University Medical School, St. Louis, MO*
- P39-10 INHIBITION OF AG PRESENTATION TO NKT CELLS BY A CD1+ BREAST CANCER CELLS**  
 Y. Lin, R. R. Brutkiewicz  
*Department of Microbiology and Immunology, Indiana University School of Medicine, Walther Oncology Center, Indianapolis, IN; Walther Cancer Institute, Indianapolis, IN*
- P39-11 THE IMPACT OF BREAST CANCER RISK, PSYCHOLOGICAL DISTRESS AND DISPOSITIONAL OPTIMISM ON IMMUNE RESPONSES IN HEALTHY WOMEN**  
 N-J. Park, D-H. Kang  
*University of Alabama at Birmingham, Birmingham, AL*
- P39-12 ANTIBODY-NKG2D LIGAND (RAE-1BETA) FUSION PROTEIN FOR BREAST CANCER THERAPY**  
 S-U. Shin, J. D. Rosenblatt,  
 H-M. Cho, K. Tolba  
*University of Miami/Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Fla*
- 
- P40 Biomarkers II**  
**12:05-2:05 p.m.**  
*Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
 Even-numbered – 1:05–2:05 p.m.*
- P40-1 OBESE AND UPPER BODY FAT PHENOTYPE POSTMENOPAUSAL AFRICAN-AMERICAN WOMEN HAVE A SEX HORMONAL PROFILE ASSOCIATED WITH INCREASED RISK OF BREAST CANCER**  
 J. B. Barnett,<sup>1</sup> S. L. Gorbach,<sup>2</sup>  
 M. N. Woods,<sup>2</sup> C. Neels,<sup>1</sup>  
 B. Rosner,<sup>3</sup> R. F. Houser<sup>1</sup>  
 R. Siegel,<sup>4</sup> B. D. Hughes,<sup>5</sup>  
 C. Longcope<sup>6</sup>  
<sup>1</sup>Friedman School of Nutrition Science and Policy at Tufts University, Boston, MA; <sup>2</sup>Tufts Medical School, Boston, MA; <sup>3</sup>Harvard University, Boston, MA; <sup>4</sup>Tufts-New England Medical Center, Boston, MA; <sup>5</sup>Human Nutrition Research Center on Aging, Boston, MA; <sup>6</sup>Deceased
- P40-2 DETECTION AND IDENTIFICATION OF BIOMARKERS IN NIPPLE FLUID BY MASS SPECTROMETRY**  
 H. R. Chang, J. Gornbein,  
 L. Rovai, H. Shaw, K. Faull,
- P40-3 THE DIFFERENTIAL EXPRESSION OF DOUBLE-STRANDED RNA-DEPENDENT PROTEIN KINASE (PKR) AND p53 APOPTOSIS EFFECTOR RELATED TO PMP-22 (PERP) IN ESTROGEN PROTECTED VS. UNPROTECTED LEWIS RATS**  
 G. Cruz  
*University of California at Berkeley, Berkeley, CA*
- P40-4 HIGH-THROUGHPUT AUTOMATED QUANTITATIVE PROTEIN ANALYSIS OF 43 cDNA MICROARRAY-IDENTIFIED BIOMARKERS ON BREAST CANCER TISSUE MICROARRAYS REVEALS NOVEL ASSOCIATIONS WITH PATIENT OUTCOMES AND SIGNIFICANT DIFFERENCES BETWEEN PROTEIN LEVELS IN DISTANT NORMAL BREAST TISSUE**  
 M. Dolled-Filhart,<sup>1,2</sup> D. Tuck,<sup>1</sup>  
 J. Emerson<sup>3</sup> J. Ferguson,<sup>3</sup>  
 M. Neopolitano,<sup>1</sup> J. Kang,<sup>1</sup>  
 R. L. Camp,<sup>1</sup> D. L. Rimm<sup>1</sup>  
*Departments of <sup>1</sup>Pathology, <sup>2</sup>Genetics, and <sup>3</sup>Statistics, Yale University, New Haven, CT*
- P40-5 NANOMECHANICAL SENSORS FOR BREAST CANCER BIOMARKERS**  
 Y. Chen,<sup>1</sup> A. Kalinowski,<sup>2</sup>  
 P. Mohanty,<sup>1</sup> M. K. Hong,<sup>1</sup>  
 C. L. Rosenberg,<sup>3</sup> S. Erramilli<sup>1,2</sup>  
<sup>1</sup>Department of Physics and <sup>2</sup>Department of Biomedical Engineering, Boston University, Boston, MA; <sup>3</sup>Department of Medicine, Boston Medical Center, Boston, MA
- P40-6 LINKING TRANSCRIPTIONAL ELONGATION AND mRNA EXPORT TO METASTATIC BREAST CANCERS**  
 S. Guo,<sup>1</sup> M-A. Hakimi,<sup>2</sup>  
 D. Baillat,<sup>2</sup> X. Chen,<sup>1</sup>  
 M. J. Farber,<sup>1</sup> A. J. P. Klein-

Szanto, N. S. Cooch, <sup>2</sup> R. Shiekhattar, <sup>2</sup> A. K. Godwin <sup>1</sup> <i>Department of Medical Oncology,  'Fox Chase Cancer Center,  Philadelphia, PA; <sup>2</sup>The Wistar  Institute, Philadelphia, PA</i>	<b>P40-11 INDUCTION OF EPHS/  EPhRINS-MEDIATED TUMOR  CELLS-ENDOTHELIAL CELLS  REPULSION AS AN ANTI-CANCER  THERAPEUTIC APPROACH</b> M. Kandouz, G. Batist <i>Montreal Centre for Experimental  Therapeutics in Cancer, Lady  Davis Institute, and Department  of Oncology, McGill University,  Montreal, QC, Canada</i>	<b>P40-16 AN INNOVATIVE MICROARRAY  STRATEGY FOR IDENTIFICATION  OF BREAST CANCER-  ASSOCIATED GENES</b> K. Mikhitarian, W. E. Gillanders, J. S. Almeida, R. H. Martin, J. C. Varela, J. S. Metcalf, D. J. Cole, M. Mitas <i>Medical University of South  Carolina, Charleston, SC</i>
<b>P40-7 CONSTRUCTING PREDICTIVE  PROFILES FOR HERCEPTIN-  CONTAINING THERAPY IN  HER2 POSITIVE EARLY STAGE  BREAST CANCER USING RNA  MICROARRAY</b> L. Harris, <sup>1</sup> F. You, <sup>1</sup> S. Carter, <sup>2</sup> A. Eklund, <sup>3</sup> D. Sgroi, <sup>4</sup> A. Richardson, <sup>3</sup> Z. Szallasi, <sup>2</sup> J. D. Iglehart <sup>1,3</sup> <i><sup>1</sup>Department of Cancer Biology/  Adult Oncology, Dana-Farber  Cancer Institute, Boston, MA;  <sup>2</sup>Children's Hospital Boston,  Boston MA; <sup>3</sup>Brigham and  Women's Hospital, Boston,  MA; <sup>4</sup>Massachusetts General  Hospital, Boston, MA</i>	<b>P40-12 IMAGE-BASED ARCHITECTURAL  PROTEOMICS TO IDENTIFY  MALIGNANT CELLS WITHIN  LESIONS HISTOLOGICALLY  CLASSIFIED AS PREMALIGNANT  OR PREINVASIVE</b> S. A. Lelievre, <sup>1</sup> C. Plachot, <sup>1</sup> F. Long, <sup>2</sup> D. W. Knowles <sup>2</sup> <i><sup>1</sup>Department of Basic Medical  Sciences, Purdue University,  West Lafayette, IN; <sup>2</sup>Biophysics  Department, Life Sciences  Division, Lawrence Berkeley  National Laboratory, Berkeley,  CA</i>	<b>P40-17 CLINICAL CORRELATION OF A  QUANTITATIVE MOLECULAR  METHOD TO MONITOR  CIRCULATING BREAST CANCER  CELLS</b> M. R. Palomares, G. Schuster, K. M. Koehler, A. K. Thomas, D. E. Sabath <i>City of Hope Comprehensive  Cancer Center, Duarte, CA;  Seattle Cancer Care Alliance,  Seattle, WA; University of  Washington, Seattle, WA</i>
<b>P40-8 OBESITY AS A PREDICTOR FOR  SECRETOR STATUS AND TYPE  OF FLUID OBTAINED BY NIPPLE  ASPIRATION IN HEALTHY NON-  LACTATING PREMENOPAUSAL  WOMEN</b> Y. Huang, M. Nagamani, K. E. Anderson, J. J. Grady, L-J. W. Lu <i>University of Texas Medical  Branch, Galveston, TX</i>	<b>P40-13 SIMULTANEOUS PROFILING OF  PROTEIN AND RNA EXPRESSION  BY MASS SPECTROMETRY  IN INTACT BREAST TISSUE  SAMPLES</b> S. Levy, S. Cornett, B. Boone, A. Whitington <i>Vanderbilt University Medical  Center, Nashville, TN</i>	<b>P40-18 IDENTIFICATION OF BREAST  CANCER BIOMARKERS IN  NIPPLE ASPIRATE FLUID USING  PROTEOMIC ANALYSIS</b> H. Alexander, <sup>1</sup> A. L. Stegner, <sup>1</sup> C. Wagner-Mann, <sup>1</sup> G. C. Du Bois, <sup>2</sup> S. Alexander, <sup>1</sup> E. R. Sauter <sup>1</sup> <i><sup>1</sup>University of Missouri,  Columbia, MO; <sup>2</sup>Thomas  Jefferson University,  Philadelphia, PA</i>
<b>P40-9 WHOLE GENOME AMPLIFICATION  TECHNOLOGIES FOR SCREENING  CANCER BIOMARKERS IN FRESH  OR PARAFFIN TISSUE SAMPLES  AND IN BODILY FLUIDS IN  BREAST CANCER</b> J. Li, G. Wang, L. Harris, W-H. Liu, M. Kaur, L. Wang, P. Zhu, G. M. Makrigiorgos <i>Dana Farber Cancer Institute,  Boston, MA</i>	<b>P40-14 OPTICAL TRANSILLUMINATION  SPECTROSCOPY, A BIOMARKER  OF BREAST TISSUE DENSITY AND  AN INTERMEDIATE INDICATOR OF  BREAST CANCER RISK</b> L. Lilge, K. Blackmore, M. Nielsen, S. Dick, R. Jong <i>Ontario Cancer Institute  and Department of Medical  Biophysics, University of Toronto,  Toronto, ON, Canada</i>	<b>P40-19 CELECOXIB DECREASES PGE2 IN  WOMEN WITH BREAST CANCER  BUT NOT IN AT RISK WOMEN</b> W. Qin, <sup>1</sup> L. Schlatter, <sup>1</sup> A. Sherman, <sup>1</sup> J. T. Flynn, <sup>2</sup> E. R. Sauter <sup>1</sup> <i><sup>1</sup>University of Missouri Hospital  and Clinics, Columbia, MO;  <sup>2</sup>Thomas Jefferson University,  Philadelphia, PA</i>
<b>P40-10 THE SMALL RNAs PROFILE  OF BREAST CANCER VERSUS  NORMAL CELLS</b> M. Kandouz, G. Batist <i>Montreal Centre for Experimental  Therapeutics in Cancer, Lady  Davis Institute, and Department  of Oncology, McGill University,  Montreal, QC, Canada</i>	<b>P40-15 AN EXPLORATORY STUDY  OF CAVITY RINGDOWN  SPECTROSCOPY AS A  NONINVASIVE BREATH  DIAGNOSTIC FOR BREAST  CANCER</b> G. P. Miller <i>Department of Physics and  Engineering Physics, University  of Tulsa, Tulsa, OK</i>	<b>P40-20 MITOCHONDRIAL DNA  MUTATIONS IN BREAST CANCER  TISSUE AND IN MATCHED NIPPLE  ASPIRATE FLUID</b> W. Zhu, W. Qin, P. Bradley, A. Wessel, C. L. Puckett, E. R. Sauter <i>Ellis Fischel Cancer Center and  Department of Surgery, University  of Missouri, Columbia, MO</i>

**P40-21 DISCOVERY OF A NOVEL TWO-GENE EXPRESSION RATIO THAT PREDICTS CLINICAL OUTCOME IN BREAST CANCER PATIENTS TREATED WITH TAMOXIFEN**

D. C. Sgroi, X. J. Ma, D. Haber, P. Ryan, Z. Wang, J. Younger, S. Isakoff, B. Smith, J. Brugge, F. Couch, M. Goetz, V. Suman, W. Lingle, J. Ingle, M. G. Erlander

*Massachusetts General Hospital, Charlestown, MA; Harvard Medical School, Cambridge, MA; Mayo Clinic, Rochester, MN; Arcturus Biosciences, Inc., Mountain View, CA*

**P40-22 GENE EXPRESSION PROFILING OF BREAST CANCER STROMA**

D. C. Sgroi, X. J. Ma, Z. Wang, B. Muir, E. Chatfield, S. Dahiya, M. G. Erlander

*Massachusetts General Hospital and Harvard Medical School, Charlestown, MA; Arcturus Biosciences, Inc., Mountain View, CA*

**P40-23 OPTICAL PROPERTIES DIFFERENTIATE NORMAL, MALIGNANT AND NON-MALIGNANT LESIONS IN THE MOUSE MAMMARY GLAND**

M. C. Skala, G. M. Palmer, B. J. Sprague, A. R. Moser, N. Ramanujam

*University of Wisconsin, Madison, Madison, WI*

**P40-24 RT-PCR DETECTS CLINICALLY SIGNIFICANT NODAL METASTASES IN PATIENTS ENROLLED IN MULTICENTER SENTINEL NODE TRIAL**

K. M. Verbanac, C. J. Min, A. E. Mannie, M. Moreland, L. Tafra, E.C.U./A.A.M.C. Sentinel Node Study Group  
*East Carolina University, Greenville, NC; Anne Arundel Medical Center, Annapolis, MD*

**P41 Digital Imaging**

**12:05-2:05 p.m.**

*Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.*

**P41-1 STEREOMAMMOGRAPHY FOR IMPROVEMENT OF BREAST CANCER DETECTION**

H-P. Chan, M. M. Goodsitt, M. A. Helvie, L. M. Hadjiiski, B. Sahiner

*Department of Radiology, University of Michigan, Ann Arbor, MI*

**P41-2 A TOOL FOR THE QUANTITATIVE STUDY OF SPATIAL CELLULAR PATTERNS IN THE MAMMARY GLAND**

R. Fernandez-Gonzalez, C. Ortiz de Solorzano, M. H. Barcellos-Hoff

*Lawrence Berkeley National Laboratory, UC Berkeley – UC San Francisco Joint Graduate Group in Bioengineering, University of Navarre, Spain*

**P41-3 AN EVALUATION OF STEREOSCOPIC DIGITAL MAMMOGRAPHY FOR EARLIER DETECTION OF BREAST CANCER AND REDUCED RATE OF RECALL**

D. Getty, C. D'orsi,<sup>1</sup> R. Pickett, A. Karellas<sup>1</sup>

*BBN Technologies, Cambridge, MA; <sup>1</sup>Breast Imaging Center, Winship Cancer Institute, Emory University, Atlanta, GA*

**P41-4 PARTICLES FOR NANOSCALE PROTEOMICS**

S. G. Penn, G. Chakarova,

W. E. Doering

*Nanoplex Technologies, Inc., Menlo Park, CA*

**P41-5 A DUAL-ENERGY DIGITAL MAMMOGRAPHY TECHNIQUE TO SUPPRESS THE OBSCURING EFFECTS OF OVERLAPPING TISSUE STRUCTURES IN THE VISUALIZATION OF CALCIFICATIONS**

C. C. Shaw, S. C. Kappadath, X. Liu, G. J. Whitman

*University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P42 X-Ray Imaging**

**12:05-2:05 p.m.**

*Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.*

**P42-1 TIME-SERIES ANALYSIS OF HUMAN INTERPRETATION DATA IN MAMMOGRAPHY**

C. A. Beam,<sup>1</sup> E. F. Conant,<sup>2</sup> H. L. Kundel,<sup>2</sup> P. A. Romilly,<sup>1</sup> E. A. Sickles<sup>3</sup>

*<sup>1</sup>University of South Florida, Moffitt Cancer Research Center & Institute, Tampa, FL; <sup>2</sup>University of Pennsylvania, Philadelphia, PA*

**P42-2 A METHOD FOR PRODUCING SIMULATED MAMMOGRAMS**

M. A. Chinander, R. M. Nishikawa

*Department of Radiology, University of Chicago, Chicago, IL*

**P42-3 PHYSICIAN PREDICTORS OF MAMMOGRAPHIC ACCURACY**

R. Smith-Bindman, P. Chu, D. Miglioretti, C. Quale, R. Rosenberg, G. Cutter, B. Geller, P. Bacchetti, E. Sickles, K. Kerlikowske

*Departments of Radiology, Epidemiology, Biostatistics, Veterans Affairs, University of California at San Francisco, San Francisco, CA; Department of Biostatistics, University of Washington, Seattle, WA; Department of Radiology, University of New Mexico, Albuquerque, NM; University of Nevada School of Medicine, Reno, NV; University of Vermont, College of Medicine, Burlington, VT*

**P42-4 MULTI-SITE TELE-MAMMOGRAPHY SYSTEM FOR REMOTE PATIENT MANAGEMENT IN SCREENING MAMMOGRAPHY**

J. K. Leader, R. J. Clearfield, M. A. Ganott, C. Hakim, L. Hardesty, J. H. Sumkin, L. Wallace, J. M. Drescher, G. S. Maitz, D. Gur

*Department of Radiology, University of Pittsburgh School of Medicine, and Magee-Womens Hospital, Pittsburgh, PA*

**P42-5 WIDE FIELD COHERENT SCATTER MAMMOGRAPHIC IMAGING**

W. Zhou, W. W. Peppler,  
C. A. MacDonald  
*University at Albany, State  
University of New York, Albany,  
NY*

**P42-6 HIGH CONTRAST HIGH RESOLUTION MONOCHROMATIC IMAGING WITH CONVENTIONAL X-RAY SOURCES**

D. Li, N. Mail, F. R. Sugiro,  
W. W. Peppler, C. A. MacDonald  
*University at Albany, State  
University of New York, Albany,  
NY*

**P42-7 X-RAY POLARIZATION IMAGING**

A. D. A. Maidment, M. Albert,  
Y-H. Kao  
*Department of Radiology,  
University of Pennsylvania,  
Philadelphia, PA*

**P42-8 ALGORITHMIC CORRELATION OF LESION LOCATION ON FILM SCREEN MAMMOGRAPHY AND BREAST ULTRASOUND – INITIAL RESULTS**

M. P. McNamara Jr., S. Izen  
*Case Western Reserve University,  
Cleveland, OH; Uniformed  
Services University of the Health  
Sciences, Bethesda, MD*

**P42-9 COMPARISON OF IMAGE QUALITY AMONG VARIATIONS IN SPECIMEN TISSUE COMPRESSION USING DIFFRACTION ENHANCED IMAGING**

C. A. Parham, E. D. Pisano  
*University of North Carolina at  
Chapel Hill, Chapel Hill, NC*

**P42-10 TASK-SPECIFIC OPTIMIZATION OF MAMMOGRAPHIC SYSTEMS**

R. S. Saunders, E. Samei  
*Departments of Physics and  
Radiology, Duke University,  
Durham, NC*

**P42-11 SAPPHIRE: A NEW FLAT-PANEL DIGITAL MAMMOGRAPHY DETECTOR WITH AVALANCHE PHOTOCONDUCTOR AND HIGH-RESOLUTION FIELD EMITTER READOUT**

W. Zhao,<sup>1</sup> D. Li,<sup>1</sup> K. Tanioka,<sup>2</sup>

G. Pang,<sup>3</sup> J. A. Rowlands<sup>1</sup>

<sup>1</sup>*State University of New  
York at Stony Brook, Stony  
Brook, NY;* <sup>2</sup>*NHK Science and  
Technical Research Laboratory;*

<sup>3</sup>*Sunnybrook and Women's  
College Health Sciences Center,  
Toronto, ON, Canada*

**P43-4 DEUTERATED SELF PROTEINS IN IMMUNOTHERAPY: A NEW BREAST CANCER TREATMENT**

L. Li, J. C. Hinshaw  
*Department of Medicinal  
Chemistry, University of Utah,  
Salt Lake City, UT*

**P43-5 RING-CLOSING METATHESIS STRATEGIES TO NOVEL N-HYDROXY SULFAMIDE TEMPLATES**

J. H. Jun, J. A. P. Evans,  
P. R. Hanson  
*Department of Chemistry,  
University of Kansas, Lawrence,  
KS*

**P43-6 NON-STEROIDAL ANTI-INFLAMMATORY DRUG ETODOLAC AS A THERAPEUTIC AGENT FOR BREAST CANCER**

S. K. Kolluri, S. Y. James,  
N. Bruey-Sedano, W. Liu,  
J. Town, F. Lin, X. Zhang  
*Cancer Center, The Burnham  
Institute, La Jolla, CA*

**P43-7 ENHANCING 5-FLUOROURACIL EFFICACY THROUGH THE SUBVERSION OF URACIL-DNA DAMAGE REPAIR**

D. J. Krosky, J. T. Stivers  
*Department of Pharmacology  
and Molecular Sciences, Johns  
Hopkins School of Medicine,  
Baltimore, MD*

**P43-8 DISCOVERY OF SMALL MOLECULE INHIBITORS OF XIAP AS POTENTIAL NOVEL THERAPY FOR BREAST CANCER**

Y. Lu, Z. Nikolovska-Coleska,  
L. Xu, Z. Hu, Y. Tomita, D. Yang,  
S. Wang  
*University of Michigan, Ann  
Arbor, MI*

**P43-9 MOLECULAR-TARGETED ANTITUMOR AGENTS. TWO NEW CLASSES OF SMALL MOLECULES THAT POTENTLY INHIBIT HYPOXIA-INDUCIBLE FACTOR-1 ACTIVATION IN BREAST TUMOR CELLS**

D. G. Nagle, Y-D. Zhou,  
K. A. Mohammed, C. F. Hossain,  
T. W. Hodges, Y-P. Kim,  
F. D. Mora, S. R. Baerson,

**P43-3 SYNTHESIS OF TARGETED DRUGS FOR TREATING BREAST CANCER**

J. Sha, H-K. Lee, J. C. Hinshaw  
*Department of Medicinal  
Chemistry, University of Utah,  
Salt Lake City, UT*

- A. K. Agarwal, L. Zhang,  
R. K. Bruick, D. K. Jones  
*Department of Pharmacognosy  
and National Center for Natural  
Products Research, RIPS,  
School of Pharmacy, University of  
Mississippi, University, MS;  
U.S.D.A., Agricultural Research  
Service, Natural Products  
Utilization Research Unit,  
University, MS; Department of  
Biochemistry, University of Texas  
Southwestern Medical Center,  
Dallas, TX*
- P43-10 SYNTHETIC STUDIES ON THE SCHWEINFURTHIN FAMILY OF ANTICANCER COMPOUNDS**  
J. D. Neighbors, D. F. Wiemer  
*Department of Chemistry,  
University of Iowa, Iowa City, IA*
- P43-11 NOVEL ATYPICAL RAMBAS WITH POTENT ANTITUMOR ACTIVITY AGAINST HUMAN BREAST TUMOR XENOGRAFTS**  
V. C. O. Njar, J. B. Patel,  
C. Huynh, L. Gediya  
*University of Maryland School of  
Medicine, Baltimore, MD*
- P43-12 NOVEL DRUG COMBINATION USING RETINOIC ACID AND DIFFERENTIATION-INDUCING QUINOLINES SENSITIZE HUMAN BREAST CANCER CELLS TO ENHANCED ANTITUMOR ACTIVITY**  
R. Rahim-Bata,<sup>1</sup> J. S. Strobl<sup>1,2</sup>  
<sup>1</sup>*West Virginia University School  
of Medicine, Morgantown, WV;*  
<sup>2</sup>*Virginia College of Osteopathic  
Medicine, Blacksburg, VA*
- P43-13 INVESTIGATING THE ROLE OF REACTIVE OXYGEN SPECIES IN BETA-LAPACHONE-MEDIATED CELL DEATH**  
K. E. Reinicke,<sup>1</sup> M. Varnes,<sup>2</sup>  
D. Spitz,<sup>3</sup> J. J. Pink,<sup>2</sup>  
D. A. Boothman<sup>2</sup>  
*Departments of <sup>1</sup>Biochemistry  
and <sup>2</sup>Radiation Oncology, Case  
Western Reserve University,  
Cleveland, OH; <sup>3</sup>Department of  
Radiation Oncology, University of  
Iowa, Iowa City, IA*
- P43-14 PARALLEL SYNTHESIS AND BIOCATALYTIC AMPLIFICATION OF MARINE-INSPIRED LIBRARIES: AN INTEGRATED APPROACH TOWARD DISCOVERING NEW CHEMOTHERAPEUTICS**  
J. D. Ryan, M. A. Tius,  
D. S. Clark  
*Department of Chemical  
Engineering, University of  
California at Berkeley, Berkeley,  
CA; <sup>1</sup>Department of Chemistry,  
University of Hawaii, Honolulu,  
HI*
- P43-15 STUDIES OF FARNESYLTHIOSALICYLIC ACID (FTS), AN ANTAGONIST OF GROWTH FACTOR SIGNALING PATHWAYS, IN BREAST CANCER**  
R. Santen, R. McPherson,  
A. Lynch, J. Lawrence, W. Yue  
*Departments of Internal Medicine  
and Pharmacology, University of  
Virginia, Charlottesville, VA*
- P43-16 ELEMENTAL SELENIUM FOR THE TREATMENT OF BREAST CANCER**  
R. W. Sampson, K. Miyagi,  
M. D. Ostrowski,  
W. H. H. Günther, M. Krieg,  
F. Sieber  
*Medical College of Wisconsin,  
Milwaukee, WI; WHHG  
Consulting, West Chester, PA;  
GTP Glendale, Attleboro Falls,  
MA*
- P43-17 MODULATION OF BISPHOSPHONATE TOXICITY TOWARDS HUMAN BREAST CANCER CELLS IN CULTURE**  
R. Sridhar, A. Kassa, E. Ashayeri  
*Cancer Center and Department  
of Radiation Oncology, Howard  
University, Washington, DC*
- P43-18 CREATING TUMOR-SPECIFIC BREAST CANCER THERAPEUTICS: AN ASSAY FOR TUBULIN ISOTYPE-SPECIFIC ANTIMICROTUBULE DRUGS**  
S. Malcolm, T. Stearns  
*Department of Biological  
Sciences, Stanford University,  
Stanford, CA*
- P43-19 SCREENING CHEMICAL LIBRARIES FOR CDK INHIBITORS**  
Y. Tomita, H. O. Abaan,  
J. Sridhar, N. Akula, A. Uren,  
N. Pattabiraman  
*Lombardi Comprehensive Cancer  
Center, Georgetown University  
Medical Center, Washington, DC*
- P43-20 CHEMICAL MODULATORS OF KEAP1/NRF-2 INTERACTION AS BREAST CANCER PREVENTION AGENTS**  
J.-H. Wu, W.-M. Miao, G. Liang,  
G. Batist  
*Lady Davis Institute, McGill  
University, Montreal, QC,  
Canada*
- P43-21 SYNTHESIS OF CRYPTOPHYCINS AFFINITY LABELS AND TUBULIN LABELING**  
K. Yang, R. Vidya, G. I. Georg,  
R. H. Himes  
*Department of Medicinal  
Chemistry and Department of  
Molecular Biosciences, University  
of Kansas, Lawrence, KS*
- P44 Targeted Therapies I**  
12:05–2:05 p.m.  
Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.
- P44-1 DEVELOPMENT OF TARGETED RECOMBINANT VESICULAR STOMATITIS VIRUS TO TREAT BREAST CANCER METASTASES**  
I. Bergman, P. Whitaker-Dowling  
*Children's Hospital of Pittsburgh  
and University of Pittsburgh,  
Pittsburgh, PA*
- P44-2 ALPHA-V INTEGRIN TARGETED DELIVERY OF PACLITAXEL**  
X. Chen  
*Stanford University, Stanford, CA*
- P44-3 IN VITRO ANALYSIS OF MAGNETIC FIELD INDUCED SUPERPARAMAGNETIC NANOPARTICLE DYNAMICS IN THE EXTRACELLULAR MATRIX**  
S. J. Kuhn,<sup>1</sup> C.-C. R. Chen,<sup>1</sup>  
D. E. Hallahan,<sup>1,2</sup> T. D. Giorgio<sup>1,3</sup>  
<sup>1</sup>*Biomedical Engineering,  
Vanderbilt University, Nashville,  
TN; <sup>2</sup>Radiation Oncology,  
Vanderbilt University, Nashville,  
TN; <sup>3</sup>Chemical Engineering,*

Vanderbilt University, Nashville, TN	<b>P44-10 EGFR-SPECIFIC SINGLE-CHAIN ANTIBODY-PACLITAXEL CONJUGATE FOR TARGETING BREAST CARCINOMAS</b> K. P. Raisch, A. Safavy <i>University of Alabama at Birmingham, Birmingham, AL</i>	<b>P44-15 SYNTHESIS AND EVALUATION OF PACLITAXEL-ANTIBODY CONJUGATES FOR BREAST CANCER CHEMOIMMUNOTHERAPY</b> A. Safavy, K. P. Raisch, K. Safavy, J. A. Bonner, M. B. Khazaeli, D. J. Buchsbaum <i>University of Alabama at Birmingham, Birmingham, AL</i>
<b>P44-4 A NOVEL TARGETING STRATEGY FOR MAMMARY ADENOCARCINOMA - NUCLEAR LOCALIZATION PEPTIDE DISCOVERY VIA DIFFERENTIAL PHAGE DISPLAY</b> A. A. Weiner, T. D. Giorgio <i>Department of Biomedical Engineering, Vanderbilt University, Nashville, TN</i>	<b>P44-11 FIBRINOGEN-COATED DROPLETS OF OLIVE OIL FOR THE TARGETED DELIVERY OF LIPOPHILIC ANTICANCER AGENTS TO FIBRIN(ogen)-RICH TUMORS</b> G. S. Retzinger <i>Department of Pathology, University of Cincinnati, Cincinnati, OH</i>	<b>P44-16 TARGETING DRUG AND GAMMA-IRRADIATION RESISTANT BREAST CANCER WITH TR3 PEPTIDES</b> A. C. Satterthwait, X. Zhu, S. Kolluri, X. Zhang <i>The Burham Institute, La Jolla, CA</i>
<b>P44-5 TARGETED SILENCING OF HER2 ONCOGENE FOR THE TREATMENT OF METASTATIC BREAST CANCER</b> J. Wu, W. Chen, S. S. Bowersox, J. Hu <i>GMR Epigenetics, Palo Alto, CA</i>	<b>P44-12 PEPTIDE TRANSDUCTION-BASED THERAPIES FOR BREAST CANCER</b> M. Hitchens, X. Lu, J. Mai, Z. Mi, P. D. Robbins <i>Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA</i>	<b>P44-17 APTAMERS: AN EMERGING CLASS OF TUMOR TARGETING REAGENTS</b> C. L. Smith, S. Milea, G. Surdi <i>Molecular Biotechnology Research Laboratory, Boston University, Boston, MA</i>
<b>P44-6 CANCER SPECIFIC NANOPARTICLES FOR OPTICAL CONTRAST ENHANCEMENT, AND LOCAL, INDUCTIVE HYPERTHERMIC TREATMENT</b> K. A. Kang, H. Jin <i>Chemical Engineering Department, University of Louisville, Louisville, KY</i>	<b>P44-13 THE VASCULAR TARGETING AGENT VEGF121/RGEL INHIBITS BONE REMODELING AND SKELETAL METASTASES THROUGH A UNIQUE MECHANISM</b> K. A. Mohamedali, A. T. Poblenz, C. Sikes, T. Luster, N. Navone, P. Thorpe, B. Darnay, M. G. Rosenblum <i>University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Texas Southwestern Medical Center at Dallas, Dallas, TX</i>	<b>P44-18 CLONING, EXPRESSION, AND TUMOR TARGETING PROPERTIES OF RECOMBINANT FAB FRAGMENTS OF MONOCLONAL ANTIBODY CC49 EXPRESSED IN PICHIA PASTORIS</b> Y. Tang, S. Yang, J. Gariepy, D. A. Scollard, R. M. Reilly <i>Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada; Division of Nuclear Medicine, University Health Network, Toronto, ON, Canada</i>
<b>P44-7 ADVANCED DRUG DELIVERY SYSTEM FOR BREAST CANCER CHEMOTHERAPY</b> A. G. Lacko, M. Nair, S. Paranjape, L. Mooberry, W. J. McConathy <i>University of North Texas Health Science Center, Fort Worth, TX</i>	<b>P44-14 TARGETING OF BREAST TUMORS AND TUMOR CELLS USING INDUCTIVE MAGNETIC HEATING OF NANOPARTICLES</b> V. M. Rotello, <sup>1</sup> N. O. Fischer, <sup>2</sup> J. J. Jerry <sup>3</sup> <sup>1</sup> <i>Department of Chemistry, Program in Molecular and Cellular Biology, <sup>3</sup>Department of Veterinary and Animal Science, University of Massachusetts Amherst, Amherst, MA</i>	<b>P44-19 BIONANOPARTICLE TECHNOLOGY AND ITS POTENTIAL APPLICATIONS FOR IN VIVO IMAGING</b> Q. Wang, H. N. Barnhill <i>Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC</i>
<b>P44-8 NOVEL MAGNETIC FLUIDS FOR BREAST CANCER THERAPY</b> K. Mazuruk, N. Ramachandran <i>University of Alabama in Huntsville, Huntsville, AL; BAE SYSTEMS Analytical Solutions Inc., Huntsville, AL</i>		
<b>P44-9 MONITORING OF LIPOSOMAL DRUG DISTRIBUTION IN-VIVO USING MRI</b> A. M. Ponce, B. L. Viglianti, P. S. Yarmolenko, S. A. Abraham, C. R. Michelich, J. R. Macfall, M. B. Bally, M. W. Dewhirst <i>Duke University Medical Center, Durham, NC</i>		

**P44-20 SEQUESTRATION OF PARTICULATE RADIOPHARMACEUTICALS AFTER INTRATUMORAL INJECTION INTO BREAST CANCER GRAFTS IN RATS**

F. C. Wong, Y. Wang,  
A. Fonnegra, E. E. Kim  
*University of Texas M.D.  
Anderson Cancer Center,  
Houston, TX*

**P44-21 INTEGRATION OF PHOTOTHERMAL NANOTHERAPY AND NANODIAGNOSTICS FOR OPTIMIZATION AND GUIDANCE OF SELECTIVE TREATMENT OF BREAST CANCER TARGETED WITH NANOPARTICLES**

V. P. Zharov,<sup>1</sup> R. R. Letfullin,<sup>2</sup>  
E. N. Galitovskaya<sup>1</sup>  
<sup>1</sup>*Philips Classic Laser  
Laboratories, University of  
Arkansas for Medical Sciences,  
Little Rock, AR;* <sup>2</sup>*Department of  
Physics and Optical Engineering,  
Rose-Hulman Institute of  
Technology, Terre Haute, IN*

**P45 Vaccines and Immunotherapies****12:05–2:05 p.m.**

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.

**P45-1 ENHANCEMENT OF DC-BASED IMMUNOTHERAPY USING A SMALL MOLECULE TGF-BETA INHIBITOR**

E. T. Akporiaye, M. Rausch  
*Department of Microbiology  
and Immunology, University of  
Arizona, Tucson, AZ*

**P45-2 VACCINATION AGAINST TEM1 AND TEM8 FOR THE PURPOSE OF INHIBITING BREAST CANCER PROGRESSION**

O. F. Bathe, C. Yuen, M. Sarna,  
J. M. Cowan  
*Department of Surgery and  
Oncology, University of Calgary,  
Calgary, AB, Canada*

**P45-3 TREATMENT OF BREAST CANCER WITH ANTIBODIES AGAINST TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND DEATH RECEPTORS IN COMBINATION WITH CHEMOTHERAPY**

D. J. Buchsbaum, T. Zhou,  
T. R. Chaudhuri, K. R. Zinn,  
A. F. LoBuglio, W. E. Grizzle,  
P. G. Oliver  
*University of Alabama at  
Birmingham, Birmingham, AL*

**P45-4 FEVER-RANGE THERMAL STRESS PROMOTES EXPRESSION OF INTERCELLULAR ADHESION MOLECULE-1 IN TUMOR VESSELS VIA AN INTERLEUKIN-6 TRANS-SIGNALING MECHANISM**

Q. Chen, J. Passanese,  
W-C. Wang, E. Repasky,  
H. Baumann, S. Evans  
*Roswell Park Cancer Institute,  
Buffalo, NY*

**P45-5 IMMUNITY TO BREAST CANCER IN MICE IMMUNIZED WITH FIBROBLASTS TRANSFECTED WITH A cDNA EXPRESSION LIBRARY FROM BREAST CANCER CELLS. A NEW VACCINATION STRATEGY**

T. S. Kim, E. P. Cohen  
*Department of Microbiology and  
Immunology, University of Illinois  
College of Medicine, Chicago, IL*

**P45-6 VACCINE FOR EPITHELIAL NEOPLASMS**

A. B. Deisseroth  
*Sidney Kimmel Cancer Center,  
San Diego, CA*

**P45-7 TELOMERASE VACCINATION OF METASTATIC BREAST CANCER PATIENTS INDUCES ANTIGEN-SPECIFIC TUMOR INFILTRATING LYMPHOCYTES AND TUMOR NECROSIS**

S. M. Domchek, K. R. Fox,  
A. Recio, L. M. Schuchter,  
R. Davidson, A. DeMichele,  
M. D. Feldman,  
R. H. Vonderheide  
*Abramson Cancer Center,  
University of Pennsylvania School  
of Medicine, Philadelphia, PA*

**P45-8 CHARACTERIZATION OF SURFACE BINDING OF HEAT SHOCK PROTEIN 70 (HSP70) SUPERFAMILY MEMBERS TO SCAVENGER RECEPTORS**

J. G. Facciponte,<sup>1,2</sup> J-E. Park,<sup>3</sup>  
X-Y. Wang,<sup>2</sup> J. R. Subjeck<sup>2,4</sup>  
*Department of <sup>1</sup>Immunology,  
<sup>2</sup>Cellular Stress Biology,  
<sup>4</sup>Molecular Biophysics, Roswell  
Park Cancer Institute, Buffalo,  
NY; <sup>3</sup>Department of Medicine and  
Swim Across America Laboratory,  
Memorial Sloan-Kettering Cancer  
Center, New York, NY*

**P45-9 DEVELOPMENT OF A BREAST CANCER VACCINE**

S. J. Gendler, P. Mukherjee,  
L. B. Pathaney, J. Bradley,  
T. L. Tinder, L. Chen,<sup>1</sup> G. D. Basu  
*Mayo Clinic College of Medicine,  
Mayo Clinic, Scottsdale, AZ and  
<sup>1</sup>Rochester, MN*

**P45-10 FUSIONS OF DENDRITIC CELLS (DC) AND BREAST CARCINOMA DEMONSTRATE AN ACTIVATED PHENOTYPE AND POTENTLY STIMULATE ANTI-TUMOR RESPONSES**

D. Kufe, B. Vasir, Z. Wu,  
J. Rosenblatt, G. Cole, D. Avigan  
*Dana-Farber Cancer Institute,  
Beth Israel Deaconess Medical  
Center, Boston, MA*

**P45-11 THERAPEUTIC VACCINATION OF MICE WITH HER2-Neu+ BREAST TUMORS OR LUNG METASTASES**

X. Wang, L. B. Lachman  
*University of Texas M.D.  
Anderson Cancer Center,  
Houston, TX*

**P45-12 DEVELOPMENT OF A LISTERIA MONOCYTOGENES-BASED VACCINE AGAINST NY-ESO-1-EXPRESSING BREAST TUMORS**

P. C. Maciag, Y. Paterson  
*Department of Microbiology,  
School of Medicine, University of  
Pennsylvania, Philadelphia, PA*

**P45-13 DEVELOPMENT OF A CELL LINE FOR PRODUCTION OF THE SOLUBLE FORM OF HUMAN 4-1BBL**

M. Meseck, T-G. Huang,  
S-H. Chen, S. L. C. Woo  
*Mount Sinai School of Medicine,  
New York, NY*

**P45-14 INCREASED ANTI-TUMOR RESPONSES USING THE PROTEASOME INHIBITOR, BORTEZOMIB, WITH HUMAN NK CELLS IN BREAST CARCINOMA**

W. H. D. Hallett, W. J. Murphy  
*Department of Microbiology  
and Immunology, University  
of Nevada School of Medicine,  
Reno, NV*

**P45-15 A MUC1-BASED PLANT ENGINEERED VACCINE FOR BREAST CANCER**

J. Pinkhasov,<sup>1</sup> C. J. Arntzen,<sup>1</sup>  
H. S. Mason,<sup>1</sup> S. J. Gendler,<sup>2</sup>  
P. Mukherjee,<sup>2</sup> A. M. Walmsley<sup>1</sup>  
<sup>1</sup>*Arizona State University, School  
of Life Sciences, Tempe, AZ;*  
<sup>2</sup>*Mayo Clinic College of Medicine,  
Scottsdale, AZ*

**P45-16 IDO IN IMMUNE SUPPRESSION, CANCER, AND CANCER THERAPY**

A. J. Muller,<sup>1</sup> J. B. DuHadaway,<sup>1</sup>  
P. S. Donover,<sup>1</sup> E. Sutanto-Ward,<sup>1</sup>  
G. C. Prendergast<sup>1,2</sup>  
<sup>1</sup>*Lankenau Institute for Medical  
Research, Wynnewood, PA;*  
<sup>2</sup>*Department of Pathology,  
Anatomy and Cell Biology,  
Jefferson Medical College,  
Thomas Jefferson University,  
Philadelphia, PA*

**P45-17 VITAMIN E SUCCINATE AS AN ADJUVANT FOR DENDRITIC CELL VACCINES**

L. Ramanathapuram,  
E. T. Akporiaye  
*Department of Microbiology  
and Immunology, University of  
Arizona, Tucson, AZ*

**P45-18 SUPPRESSION OF ANGIOGENESIS INDUCED BY A DNA VACCINE ENCODING ENDOGGIN ERADICATES BREAST TUMOR METASTASES**

R. A. Reisfeld, N. Mizutani,  
S-H. Lee  
*The Scripps Research Institute, La  
Jolla, CA*

**P45-19 CCL21 TREATMENT OF PRIMARY MAMMARY TUMORS INHIBITS THEIR GROWTH AND REDUCES SPONTANEOUS LUNG METASTASES**

H. R. Turnquist,<sup>1,2</sup> R. K. Singh,<sup>1</sup>  
J. E. Talmadge,<sup>1</sup> J. C. Solheim<sup>1,2,3</sup>  
<sup>1</sup>*Eppley Institute for Research  
in Cancer and Allied Diseases,*  
<sup>2</sup>*Department of Pathology and  
Microbiology, and* <sup>3</sup>*Department  
of Biochemistry and Molecular  
Biology, University of Nebraska  
Medical Center, Omaha, NE*

**P45-20 BETA-GLUCANS AUGMENT THE KILLING ACTIVITY OF ANTI-TUMOR MONOClonal ANTIBODIES BY PROVIDING A NOVEL MECHANISM THAT PRIMES NEUTROPHIL CR3 TO KILL ANTIBODY TARGETED TUMOR CELLS**

J. Yan, D. J. Allendorf, R. Hansen,  
B. Li, G. Ross  
*Tumor Immunobiology Program,  
J. G. Brown Cancer Center,  
University of Louisville,  
Louisville, KY*

**P45-21 CONSTRUCTION OF SINGLE-CHAIN BI-SPECIFIC DIABODIES TO ACTIVATE COMPLEMENT TO SPECIFICALLY ATTACK BREAST CANCER CELLS OVER-EXPRESSING HER2/NEU**

X. Yang, H. Y. Hwang,  
R. J. Boackle  
*Department of Stomatology and  
Department of Microbiology and  
Immunology, Medical University  
of South Carolina, Charleston, SC*

**P45-22 TOLERANCE SUPPRESSION THERAPY AS A MEANS OF ENHANCING TUMOR VACCINES IN THE HER2/NEU MODEL OF BREAST CANCER**

P. E. Zarek, T. D. Armstrong,  
E. M. Jaffee, J. D. Powell  
*Department of Oncology, The  
Johns Hopkins University School  
of Medicine, Baltimore, MD*

**P46 Gene Therapy**

**12:05–2:05 p.m.**

*Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.*

**P46-1 SENSITIVITY OF BREAST TUMORS TO ONCOLYTIC VIRUSES**

M. Ahmed, D. S. Lyles  
*Wake Forest University School of  
Medicine, Winston-Salem, NC*

**P46-2 SUICIDE GENE THERAPY MEDIATED BY THE STRESS-INDUCIBLE GRP78/BIP PROMoter RESULTING IN ERADICATION OF HUMAN TUMORS**

D. Dong, A. S. Lee  
*Department of Biochemistry and  
Molecular Biology, University of  
Southern California Keck School  
of Medicine, Los Angeles, CA*

**P46-3 A DUAL-ACTION ARMED REPLICATING ADENOVIRUS FOR THE TREATMENT OF BONE METASTASES OF BREAST CANCER**

J. J. Cody, G. R. Lyons, M. Kim,  
J. T. Douglas  
*Division of Human Gene Therapy,  
Departments of Medicine,  
Pathology and Surgery and the  
Gene Therapy Center, University  
of Alabama at Birmingham,  
Birmingham, AL*

**P46-4 GENETICALLY ENGINEERED BONE MARROW STROMAL CELLS SECRETING MURINE INTERLEUKIN-12 FOR TREATMENT OF BREAST CANCER IN MICE**

N. Eliopoulos, M. Francois,  
J. Galipeau  
*Lady Davis Institute, McGill  
University, and Division of  
Hematology/Oncology, Jewish  
General Hospital, McGill*

University, Montreal, QC, Canada	P46-11 TARGETED DELIVERY OF VIRAL VECTORS TO BREAST CANCER CELLS USING VIRUS-MICROBEAD CONJUGATES	<b>P47 Photodynamic Therapy</b>
P46-5 PHI29 MOTOR PRNA FOR SPECIFIC DELIVERY OF siRNA AND RIBOZYME TO BREAST CANCER CELL P. Guo <i>Purdue Cancer Center, Purdue University, West Lafayette, IN</i>	M. W. Pandori, S. J. Farlow, A. Jerusalmi, T. Sano <i>Center for Molecular Imaging Diagnosis and Therapy and Basic Science Laboratory, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA</i>	12:05–2:05 p.m. Posters Manned: Odd-numbered – 12:05–1:05 p.m. Even-numbered – 1:05–2:05 p.m.
P46-6 A GENETICALLY MODIFIED HUMAN ENDOTHELIAL CELL-TARGETED ADENOVIRAL VECTOR C. Mahanivong, S. Huang <i>Department of Immunology, The Scripps Research Institute, La Jolla, CA</i>	P46-12 NOVEL THERAPEUTIC APPROACH FOR BREAST CANCER D. Sarkar, Z. Su, P. B. Fisher <i>Department of Pathology, Columbia University Medical Center, New York, NY</i>	P47-1 THIO AND SELENO RHODAMINE DERIVATIVES AS REVERSAL AGENTS OF MULTIDRUG RESISTANCE IN BREAST CANCER M. R. Detty, S. L. Gibson, D. J. Donnelly <i>Department of Chemistry, University of Buffalo, Buffalo, NY</i>
P46-7 ANGIOGENESIS-TARGETED CONDITIONALLY REPLICATING ONCOLYTIC ADENOVIRUS FOR BREAST CANCER TREATMENT S. A. Kaliberov, L. N. Kaliberova, V. Krendelchchikova, A. S. Petersen, V. Krasnykh, D. J. Buchsbaum <i>Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL</i>	P46-13 AN ARMED ONCOLYTIC ADENOVIRUS FOR TARGETING BREAST CANCER P. Seth, <sup>1</sup> Z-G. Wang, <sup>1</sup> M. Ramachandra, <sup>2</sup> W. Zhao, <sup>3</sup> M. Hosokawa, <sup>3</sup> L. Wakefield <sup>4</sup> <sup>1</sup> ENH Research Institute, Northwestern University, Evanston, IL; <sup>2</sup> Canji Inc., San Diego, CA; <sup>3</sup> Hokkaido University, Sapporo, Japan; <sup>4</sup> NIH, Bethesda, MD	P47-2 HEAVY-ATOM RHODAMINE DERIVATIVES AS PHOTOSENSITIZERS FOR USE IN PHOTODYNAMIC THERAPY OF BREAST CANCER D. J. Donnelly, S. L. Gibson, M. R. Detty <i>Department of Chemistry, University at Buffalo, State University of New York, Buffalo, NY</i>
P46-8 ENHANCEMENT OF BIK ANTITUMOR EFFECT BY BIK MUTANTS Y. M. Li, Y. Wen, B. P. Zhou, H-P. Kuo, Q. Ding, M-C. Hung <i>Department of Molecular and Cellular Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX</i>	P46-14 DESIGNING A NOVEL STRATEGY FOR REPAIRING RNA TRANSCRIPTS THAT MEDIATE BREAST CANCER SUSCEPTIBILITY S. M. Testa, D. Baum, P. Dotson, J. Sinha <i>Department of Chemistry, University of Kentucky, Lexington, KY</i>	P47-3 METAL NANOPARTICLES IN BREAST CANCER DIAGNOSIS AND PHOTOTHERAPY A. O'Brien, B. I. Habibi, S. M. Reed <i>Department of Chemistry, Portland State University, Portland, OR</i>
P46-9 MITOTIC SPINDLE DIRECTED THERAPEUTICS FOR EARLY STAGE BREAST CARCINOMA S. Mistry, A. J. Castaneda <i>Mount Sinai School of Medicine, New York, NY</i>	P46-15 MODULATION OF SURFACE CHARGE OF DNA-NANOPARTICLES TO INFLUENCE GENE EXPRESSION J. K. Vasir, V. Labhsetwar <i>University of Nebraska Medical Center, Omaha, NE</i>	P47-4 STRUCTURE-ACTIVITY RELATIONSHIP OF 21,23-CORE-MODIFIED PORPHYRINS FOR PHOTODYNAMIC THERAPY OF CANCER Y. You, S. L. Gibson, R. Hilf, M. R. Detty <i>Department of Chemistry, State University of New York at Buffalo, Buffalo, NY; Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY</i>
P46-10 ADENO-ASSOCIATED VIRUS MEDIATED ANTI-ANGIogenic CANCER GENE THERAPY T. Isayeva, C. Ren, S. Ponnazhagan <i>University of Alabama at Birmingham, Birmingham, AL</i>	P47-5 NEAR-INFRARED FLUORESCENCE IMAGING GUIDED THERAPY: MOLECULAR BEACON BASED PHOTOSENSITIZERS TRIGGERED BY C-RAF-1 MESSENGER RNA G. Zheng, <sup>1</sup> J. Chen, <sup>1</sup> K. Stefflova, <sup>2</sup> M. Niedre, <sup>3</sup> B. Wilson <sup>3</sup> <i>Departments of <sup>1</sup>Radiology and <sup>2</sup>Chemistry, University of Pennsylvania, Philadelphia, PA; <sup>3</sup>Department of Medical</i>	

Biophysics, University of Toronto,  
Toronto, ON, Canada

## **P48 Clinical and Surgical Management of Breast Cancer**

12:05–2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.

### **P48-1 OPERATIVE THERAPY AND THE GROWTH OF BREAST CANCER MICROMETASTASES: CAUSE AND EFFECT?**

S. E. Clare, P. Kolanko,  
H. Nakshatri

Department of Surgery, Indiana University School of Medicine, Indianapolis, IN

### **P48-2 POLY(ETHYLENE GLYCOL) HYDROGEL SYSTEM SUPPORTS REPARATIVE ADIPOGENESIS STRATEGY**

C. W. Patrick Jr,<sup>1</sup> P. Patel,<sup>1,2</sup>  
C. Frye<sup>1</sup>

<sup>1</sup>Laboratory of Reparative Biology and Bioengineering, University of Texas M.D. Anderson Cancer Center, Houston, TX; <sup>2</sup>Department of Chemical Engineering, Rice University, Houston, TX

### **P48-3 BREAST TUMOR CELLS ARE SENSITIZED TO IONIZING RADIATION BY A FRAGMENT OF THE XRCC4 PROTEIN EXPRESSED FROM ADENOVIRUS**

K. R. Jones,<sup>1</sup> K. Valerie,<sup>1</sup>  
D. G. Schatz,<sup>2</sup> S. M. Yannone,<sup>3</sup>  
L. Povirk,<sup>1</sup> D. A. Gewirtz<sup>1</sup>

<sup>1</sup>Virginia Commonwealth University, Richmond, VA; <sup>2</sup>Yale University School of Medicine, New Haven, CT; <sup>3</sup>Lawrence Berkeley Laboratory, Berkeley, CA

### **P48-4 EVASION OF CHEMOTHERAPY-INDUCED SENESCENCE AS A NOVEL MECHANISM OF DRUG RESISTANCE IN BREAST CANCER**

L. W. Elmore, X. Di, C. Dumur,  
S. E. Holt, D. A. Gewirtz  
Virginia Commonwealth University, Richmond, VA

### **P48-5 INFLUENCE OF ERYTHROPOEITIN ON SENSITIVITY TO CHEMOTHERAPEUTIC DRUGS IN BREAST TUMOR CELLS: IMPLICATIONS FOR ERYTHROPOEITIN USE IN CANCER PATIENTS**

T. D. Walker, X. Di, S. Sawyer,  
D. A. Gewirtz  
Virginia Commonwealth University, Richmond, VA

### **P48-6 RELATIONSHIP OF NEUROCOGNITIVE FUNCTION TO BREAST CANCER TREATMENT AND INDUCED MENOPAUSE**

A. L. Kenefick  
University of Connecticut, Storrs, CT

### **P48-7 AN MRI-GUIDED, MINIMALLY-INVASIVE LESION REMOVAL DEVICE FOR BREAST CANCER**

B. T. Larson, A. G. Erdman  
Department of Mechanical Engineering, University of Minnesota, Minneapolis, MN

### **P48-8 A RADIOLOGIC-PATHOLOGIC METHOD TO QUANTIFY RESPONSE TO NEOADJUVANT CHEMOTHERAPY PREDICTS TIME TO DISTANT RECURRENCE**

W. F. Symmans, R. Rajan,  
G. Whitman, L. Assad,  
L. Adepoju, T. Stephens,  
M. Dryden, L. Pusztai, H. Kuerer  
Departments of Pathology, Radiology, Breast Medical Oncology, and Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX

### **P48-9 SENTINEL NODE BIOPSY: THE STANDARD OF CARE FOR THE MANAGEMENT OF BREAST CANCER**

Z. Cheng, M. Moreland,  
K. Sawyer, K. Verbanac, L. Tafral  
E.C.U/A.A.M.C. Sentinel Node Study Group Anne Arundel Medical Center, Annapolis, MD; East Carolina University, Greenville, NC

### **P48-10 STATISTICAL INFERENCE FOR QUALITY-ADJUSTED SURVIVAL TIME**

H. Zhao  
Department of Biostatistics and Computational Biology,

University of Rochester,  
Rochester, NY

## **P49 Genetic Epidemiology**

12:05–2:05 p.m.

Posters Manned: Odd-numbered – 12:05–1:05 p.m.  
Even-numbered – 1:05–2:05 p.m.

### **P49-1 OFFSPRING'S AND FATHER'S HCG GENOTYPE AND RISK OF BREAST CANCER IN MOTHER**

H. Ahsan  
Columbia University, New York, NY

### **P49-2 CHEK2\*1100DEL C VARIANT AND BRCA1/2-NEGATIVE FAMILIAL BREAST CANCER – A FAMILY-BASED GENETIC ASSOCIATION STUDY**

H. Ahsan  
Columbia University, New York, NY

### **P49-3 GENETIC POLYMORPHISMS IN THE MANGANESE SUPEROXIDE DISMUTASE AND GLUTATHIONE PEROXIDASE 1 GENES, ANTIOXIDANT INTAKE, AND BREAST CANCER RISK: A POPULATION-BASED CASE-CONTROL STUDY**

Q. Cai,<sup>1</sup> X-O. Shu,<sup>1</sup> Q. Dai,<sup>1</sup>  
W. Wen,<sup>1</sup> J. R. Smith,<sup>1</sup> Y-T. Gao,<sup>2</sup>  
W. Zheng<sup>1</sup>  
<sup>1</sup>Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN; <sup>2</sup>Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China

### **P49-4 POLYMORPHISMS OF GENES OF THE INSULIN-LIKE GROWTH FACTOR-I PATHWAY, CIRCULATING LEVELS OF IGF-I AND IGFBP-3 AND BREAST CANCER RISK: RESULTS FROM THE EPIC STUDY**

F. Canzian, J. D. McKay,  
R. J. Cleveland, S. Rinaldi,  
E. Riboli, R. Kaaks  
International Agency for Research on Cancer, Lyon, France

**P49-5 ONE-CARBON METABOLISM AND BREAST CANCER SURVIVAL IN A POPULATION-BASED STUDY**

J. Chen, M. D. Gammon,  
J. G. Wetmur, Y-J. Zhang,  
R. M Santella

*Mount Sinai School of Medicine,  
New York, NY; University of  
North Carolina, Chapel Hill, NC;  
Columbia University, New York,  
NY*

**P49-6 A FAMILY-BASED GENETIC ASSOCIATION STUDY OF BREAST CANCER RISK IN RELATION TO VARIANTS IN ESTROGEN BIOSYNTHESIS AND METABOLISM GENES**

Y. Chen, A. S. Whittemore,  
R. T. Senie, M. Kibriya, Q. Wang,  
I. Gurvich, S. P. Hamilton,  
R. M. Santella, H. Ahsan  
*Columbia University, New York,  
NY*

**P49-7 PRESENCE OF THE ESTROGEN RECEPTOR ALPHA A908G (K303R) MUTATION IN BENIGN AND INVASIVE BREAST TISSUES FROM A CASE-CONTROL STUDY OF BENIGN BREAST DISEASE AND SUBSEQUENT BREAST CANCER**

K. Conway,<sup>1</sup> E. Parrish,<sup>1</sup>  
S. Edmiston,<sup>1</sup> D. Tolbert,<sup>1</sup>  
D. Novotny,<sup>1</sup> L. J. Melton,<sup>2</sup>  
L. Wold,<sup>2</sup> T. Sellers,<sup>2</sup>  
L. Hartmann<sup>2</sup>

<sup>1</sup>*University of North Carolina at  
Chapel Hill, Chapel Hill, NC;*  
<sup>2</sup>*Mayo Clinic, Rochester, MN*

**P49-8 POLYMORPHIC ONE-CARBON METABOLISM GENES, DIET AND THE RISK OF BREAST CANCER**

S. S. Cummings,  
J. L. Freudenheim, S. McCann,  
P. Muti, M. Trevisan, D. Vito,  
P. G. Shields  
*Cancer Genetics and  
Epidemiology Program,  
Lombardi Comprehensive Cancer  
Center, Georgetown University  
Medical Center, Washington,  
DC; Department of Social and  
Preventive Medicine, University  
of Buffalo, State University of  
New York, Buffalo, NY*

**P49-9 INTERACTIONS OF LIFESTYLE FACTORS AND MNSOD AND BREAST CANCER**

M. M. Gaudet,<sup>1</sup> M. D. Gammon,<sup>1</sup>  
R. Santella,<sup>2</sup> J. A. Britton,<sup>3</sup>  
S. L. Teitelbaum,<sup>3</sup> S. M. Eng,<sup>4</sup>  
M. B. Terry,<sup>5</sup> J. T. Bensen,<sup>1</sup>  
J. Schroeder,<sup>1</sup> A. F. Olshan,<sup>1</sup>  
A. I. Neugut,<sup>2,6</sup> C. B. Ambrosone<sup>7</sup>  
<sup>1</sup>*Department of Epidemiology,  
School of Public Health,  
University of North Carolina,  
Chapel Hill, NC;* <sup>2</sup>*Department of  
Environmental Health Sciences,  
Mailman School of Public Health,  
Columbia University, New York,  
NY;* <sup>3</sup>*Department of Community  
and Preventive Medicine, Mount  
Sinai School of Medicine, New  
York, NY;* <sup>4</sup>*Global Epidemiology,  
Worldwide Safety and Risk  
Management, Pfizer, Inc.,  
New York, NY;* <sup>5</sup>*Department of  
Epidemiology, Mailman School of  
Public Health and* <sup>6</sup>*Department of  
Medicine, College of Physicians  
and Surgeons, Columbia  
University, New York, NY;*  
<sup>7</sup>*Department of Epidemiology,  
Roswell Park Cancer Institute,  
Buffalo, NY*

**P49-10 HUMAN LEUKOCYTE ANTIGEN GENOTYPE AND RACIAL/ETHNIC DIFFERENCES IN BREAST CANCER: PRELIMINARY RESULTS FOR CLASS I**

S. L. Glaser, E. M. John,  
C. A. Clarke, H. M. Erlich  
*Northern California Cancer  
Center, Fremont, CA; Roche  
Molecular Systems, Alameda, CA*

**P49-11 GENETIC ANALYSIS OF CANDIDATE MODIFIER GENES IN BRCA1 AND BRCA2 MUTATION CARRIERS**

D. Hughes,<sup>1</sup> I. Coupier,<sup>2</sup>  
L. Barjhoux,<sup>1</sup> V. Gaborieau,<sup>1</sup>  
G. Lenoir,<sup>3</sup> D. Goldgar,<sup>1</sup>  
D. Stoppa-Lyonnet,<sup>2</sup>  
O. Sinilnikova<sup>1,4</sup>  
<sup>1</sup>*Unit of Genetic Epidemiology,  
International Agency for Research  
on Cancer, Lyon, France;* <sup>2</sup>*Institut  
Curie, Section Médicale, Paris,  
France;* <sup>3</sup>*CNRS – UMR 8125,  
Institut Gustave Roussy, Villejuif,  
France;* <sup>4</sup>*Centre Léon Bérard,  
Lyon, France*

**P49-12 NUTRITIONAL AND GENETIC DETERMINANTS OF EARLY PUBERTY**

L. Le Marchand, R. Novotny,  
J. S. Grove, R. Kaaks,  
Y. G. Daida, V. Viyajadeva  
*University of Hawaii, Honolulu,  
HI; International Agency for  
Research on Cancer, Lyon, France*

**P49-13 ASSOCIATIONS OF MAMMOGRAPHIC DENSITY AND ESTROGEN LEVELS WITH POLYMORPHISMS IN GENES RELATED TO BREAST CANCER**

G. Maskarinec, G. Lurie,  
Y. Takata, L. Le Marchand  
*Cancer Research Center of  
Hawaii, Honolulu, HI*

**P49-14 SULT1A1 ACTIVITY IN PLATELETS IN RELATION TO TAMOXIFEN TREATMENT**

S. Nowell  
*Roswell Park Cancer Institute,  
Buffalo, NY*

**P49-15 ESTROGENS, GENETIC POLYMORPHISMS AND BREAST CANCER RISK**

M. N. Okobia, C. H. Bunker,  
L. H. Kuller, R. E. Ferrell,  
E. E. O. Uche, S. N. C. Anyanwu,  
E. R. Ezeome  
*University of Pittsburgh,  
Pittsburgh, PA; University of  
Port Harcourt Teaching Hospital,  
Nigeria; Nnamdi Azikiwe  
University Teaching Hospital,  
Nigeria; University of Nigeria  
Teaching Hospital, Nigeria*

**P49-16 BREAST CANCER RISK IN RELATION TO URINARY ESTROGEN METABOLITES AND THEIR GENETIC DETERMINANTS: A STUDY WITHIN THE DUTCH “DOM” COHORT**

S. Rinaldi,<sup>1</sup> H. M. Petrra,<sup>2</sup>  
O. van der Hel,<sup>1,2</sup> M. S. Kurzer,<sup>3</sup>  
R. J. Kaaks<sup>1</sup>  
<sup>1</sup>*International Agency for  
Research on Cancer, Lyon,  
France;* <sup>2</sup>*Julius Center, University  
Medical Center Utrecht, Utrecht,  
The Netherlands;* <sup>3</sup>*University of  
Minnesota, St. Paul, MN*

**P49-17 SOY FOOD INTAKE, ESTROGEN RECEPTOR POLYMORPHISMS, AND BREAST CANCER SURVIVAL**

S. M. Boyapati, X. O. Shu,  
Z. X. Ruan, Q. Cai, J. R. Smith,  
W. Wen, Y-T. Gao, W. Zheng  
*Vanderbilt University, Nashville,  
TN; Shanghai Cancer Institute,  
Shanghai, China*

**P49-18 FATTY ACID SYNTHESIS GENE VARIANTS AND BREAST CANCER RISK: A STUDY WITHIN THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION (EPIC)**

O. M. Sinilnikova, S. V. Tavtigian,  
J. McKay, D. Desilva, F. Canzian,  
G. M. Lenoir, E. Riboli,  
R. J. Kaaks

*International Agency for Research  
on Cancer, Lyon, France*

**P49-19 BIOMARKERS FOR SUSCEPTIBILITY TO LUNG CANCER IN WOMEN WITH BREAST CANCER**

M. Tennis, F. Granath, P. Hall,  
P. G. Shields

*Lombardi Cancer Center,  
Georgetown University,  
Washington, DC; Karolinska  
Institutet, Stockholm, Sweden*

**P49-20 IMPACT OF RISK FACTORS AND GENETIC POLYMORPHISMS IN METABOLIC ENZYMES ON BREAST CANCER RISK IN BRCA1 AND BRCA2 MUTATION CARRIERS AND NON-MUTATION CARRIERS: A POPULATION-BASED STUDY**

L. Tryggvadottir, S. Stefansdottir,  
H. Hilmarsdottir,  
H. Hafsteinsdottir,  
E. J. Olafsdottir, J. E. Eyfjord  
*Icelandic Cancer Society,  
Reykjavik, Iceland*

**P49-21 A 19BP DELETION POLYMORPHISM OF A FOLATE-METABOLIZING GENE, DIHYDROFOLATE REDUCTASE (DHFR), AND RISK OF BREAST CANCER**

X. Xu, M. D. Gammon, M. Rao,  
J. G. Wetmur, S. L. Teitelbaum,  
J. A. Britton, M. M. Gaudet,

M. B. Terry, A. I. Neugut,  
R. M. Santella, J. Chen  
*Mount Sinai School of Medicine,  
New York, NY; University of  
North Carolina, Chapel Hill, NC;  
Columbia University, New York,  
NY*

**P49-22 INHERITED CRYPTIC GENOMIC ALTERATIONS AT BRCA1 AND BRCA2 AND RESIDUAL FAMILIAL RISK OF BREAST CANCER**

D. Xu  
*Department of Medicine  
(Medical Genetics), University of  
Washington, Seattle, WA*

**P49-23 ADMIXTURE AND BREAST CANCER RISK AMONG LATINA WOMEN IN THE SAN FRANCISCO BAY AREA**

E. Ziv, E. John, W. Lorizio,  
J. Kho, H. Matallana, E. Burchard  
*Department of Medicine,  
University of California at San  
Francisco, San Francisco, CA;  
Northern California Cancer  
Center, Freemont, CA*

**P50-3 THE ETIOLOGY OF BREAST CANCER. PREVENTION IS NOW THE SOLUTION**

E. L. Cavalieri, E. G. Rogan  
*Eppley Institute for Research in  
Cancer, University of Nebraska  
Medical Center, Omaha, NE*

**P50-4 MULTIFOCAL ATYPIA CONFERNS INCREASED RISK OF BREAST CANCER**

A. C. Degnim,<sup>1</sup> D. Visscher,<sup>1</sup>  
M. H. Frost,<sup>1</sup> L. J. Melton,<sup>1</sup>  
R. A. Vierkant,<sup>1</sup> S. D. Maloney,<sup>1</sup>  
V. S. Pankratz,<sup>1</sup> T. A. Sellers,<sup>2</sup>  
W. L. Lingle,<sup>1</sup> T. Tlsty,<sup>3</sup>  
H. Berman,<sup>3</sup> L. C. Hartmann<sup>1</sup>  
<sup>1</sup>*Mayo Clinic Cancer Center,  
Rochester, MN;* <sup>2</sup>*Moffitt Cancer  
Center, Tampa, FL;* <sup>3</sup>*University of  
California at San Francisco, San  
Francisco, CA*

**P50-5 MAGNETIC RESONANCE IMAGING REFLECTS THE BIOLOGY OF DUCTAL CARCINOMA IN SITU (DCIS)**

L. Esserman,<sup>1</sup> A. Herrera,<sup>1</sup>  
A. Kumar,<sup>1</sup> J. Leung,<sup>2</sup> Y-Y. Chin,<sup>3</sup>  
N. Hylton<sup>2</sup>  
*Departments of <sup>1</sup>Surgery,  
<sup>2</sup>Radiology, and <sup>3</sup>Pathology,  
University of California at San  
Francisco, San Francisco, CA*

**P50-6 ESTROGEN AND ITS METABOLITES 4 HYDROXY ESTRADIOL AND 2 HYDROXY ESTRADIOL INDUCE MUTATIONS IN HUMAN BREAST EPITHELIAL CELLS**

S. V. Fernandez, I. H. Russo,  
J. Russo  
*Breast Cancer Research  
Laboratory, Fox Chase Cancer  
Center, Philadelphia, PA*

**P50-7 TEMPORAL CHANGES IN BENIGN BREAST DISEASE 1967 TO 1991**

K. Ghosh,<sup>1</sup> L. C. Hartmann,<sup>1</sup>  
T. A. Sellers,<sup>2</sup> A. C. Degnim,<sup>1</sup>  
V. S. Pankratz,<sup>1</sup> C. Blake,<sup>3</sup>  
T. Tlsty,<sup>4</sup> L. J. Melton III,<sup>1</sup>  
D. W. Visscher<sup>1</sup>  
<sup>1</sup>*Mayo Clinic, Rochester,  
MN;* <sup>2</sup>*H. Lee Moffitt Cancer  
Center, Tampa, FL;* <sup>3</sup>*Wayne  
State University, Detroit, MI;*  
<sup>4</sup>*University of California at San  
Francisco, San Francisco, CA*

- P50-8 EFFECTS OF ESTRADIOL, 4-HYDROXYESTRADIOL AND ESTRADIOL 2,3 AND 3,4 QUINONES ON MUTAGENESIS IN VIVO AND IN VITRO**  
J. B. Guttenplan  
*New York University Dental and Medical Schools, New York, NY*
- P50-9 BENIGN BREAST DISEASE AND BREAST CANCER RISK**  
L. C. Hartmann, M. H. Frost, K. Ghosh, A. Degnim, R. A. Vierkant, S. D. Maloney, V. S. Pankratz, T. Tlsty, C. Blake, T. A. Sellers, W. L. Lingle, L. J. Melton, D. Visscher  
*Mayo Clinic Cancer Center, Rochester, MN; University of California, San Francisco, CA; Wayne State University, Detroit, MI; Moffitt Cancer Center, Tampa, FL*
- P50-10 BENIGN BREAST DISEASE: EVIDENCE FOR PRECURSOR LESIONS**  
L. C. Hartmann, A. Degnim, M. H. Frost, R. A. Vierkant, S. D. Maloney, T. A. Sellers, V. S. Pankratz, T. Tlsty, C. Blake, W. L. Lingle, D. W. Visscher  
*Mayo Clinic and Mayo Foundation, Rochester, MN; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of California at San Francisco, San Francisco, CA; Wayne State University, Detroit, MI*
- P50-11 DEVELOPMENT OF TARGETED THERAPY STRATEGIES FOR BREAST CANCER**  
G. N. Hortobagyi, G. Mills, W. H. Lee, M. C. Hung, A. Sahin, R. Cardiff, J. Galvez, L. K. Peterson, E. Y. Lee  
*University of Texas M.D. Anderson Cancer Center, Houston, TX; University of California at Irvine, Irvine, CA; University of California at Davis, Davis, CA*
- P50-12 RESEARCH DRIVEN BREAST CANCER PATIENT INFORMATION/DECISION SUPPORT SYSTEM: DEVELOPING STRUCTURE AND SCHEMA**  
M. Kamerick  
*University of California at San Francisco, Center of Excellence for Breast Cancer Care, San Francisco, CA*
- P50-13 BRCA1-DEFICIENT MAMMARY TUMORS HAVE DISTINCT TUMORIGENESIS PROCESSES AND CHEMOTHERAPY RESPONSE**  
E. Y-H. P. Lee, C. R. Smith, S-C. J. Lin,<sup>1</sup> A. Li, T. Tod, C-X. Deng  
*University of California at Irvine, Irvine, CA*
- P50-14 SMALL MOLECULES DISRUPTING BRCA2-RAD51 INTERACTION**  
J. Zhu, X. Lin, L. Zhou, P-L. Chen, W-H. Lee  
*Department of Biological Chemistry, University of California at Irvine, Irvine, CA*
- P50-15 TARGETING CRITICAL SIGNALING PATHWAYS IN BREAST CANCER**  
G. B. Mills, Y. Lu, H. Hall, Q. Yu, S. Yu  
*M.D. Anderson Cancer Center, Houston, TX*
- P50-16 A GENETIC, MOLECULAR, AND STRUCTURAL ANALYSIS OF HORMONAL CARCINOGENESIS**  
M. F. Press, C. Haiman, B. Henderson, M. Stallcup, D. Chingos, V. Hetrick, I. Cohen, K. Wissmann, B. Parker, G. L. Greene  
*Norris Comprehensive Cancer Center; University of Southern California at Los Angeles, Los Angeles, CA; Ben May Institute, University of Chicago, Chicago, IL*
- P50-17 THE ROLE OF ESTROGEN METABOLISM IN THE INITIATION OF HUMAN BREAST CANCER**  
E. G. Rogan, E. L. Cavalieri  
*Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, NE*
- P50-18 ESTRADIOL CAN CAUSE BREAST CANCER THROUGH A NON-RECEPTOR MEDIATED MECHANISM IN ER ALPHA KNOCKOUT/WNT-1 TRANSGENIC MICE**  
W. Yue, J-P. Wang, P. Fan, E. Rogan, E. Cavalieri, R. Santen  
*University of Virginia, Charlottesville, VA; University of Nebraska, Omaha, NE*
- P50-19 SANDWICH TEST ELISA WITH SCFV ANTIBODIES: AN ALTERNATIVE TO AN ALL-TIME FAVORITE**  
N. Scholler, B. Garvik, N. Urban  
*Fred Hutchinson Cancer Research Center, Seattle, WA*
- P50-20 MOLECULAR EPIDEMIOLOGY AND MECHANISMS FOR BREAST CARCINOGENESIS: ALCOHOL DRINKING AS A PARADIGM. A BREAST CANCER CENTER OF EXCELLENCE**  
P. G. Sheilds  
*Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC*
- P50-21 VALIDATING PROTEASES AS THERAPEUTIC TARGETS IN BREAST CANCER**  
B. F. Sloane,<sup>1</sup> K. Moin,<sup>1</sup> D. Schwartz,<sup>1</sup> F. Miller,<sup>1</sup> R. D. Cardiff,<sup>2</sup> J. P. Gregg,<sup>2</sup> L. Coussens,<sup>3</sup> F. Waldman,<sup>3</sup> T. Bugge,<sup>4</sup> B. Fingleton,<sup>5</sup> L. Matrisian<sup>5</sup>  
<sup>1</sup>Wayne State University, Detroit, MI; <sup>2</sup>University of California at Davis, Davis CA; <sup>3</sup>University of California at San Francisco, San Francisco, CA; <sup>4</sup>National Institute of Dental and Craniofacial Research, Bethesda, MD; <sup>5</sup>Vanderbilt University, Nashville, TN
- P50-22 STATISTICAL METHODS TO ASSESS THE TIMING AND SIDE OF BREAST CANCER RELATIVE TO BENIGN BREAST BIOPSIOS: IMPLICATIONS FOR POTENTIAL PRECURSOR LESIONS**  
V. S. Pankratz, R. A. Vierkant, S. D. Maloney, A. C. Degnim, L. C. Hartmann  
*Mayo Clinic, Rochester, MN*

**P51 BRCA1 Tumor Suppressor**

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.**P51-1 STUDIES OF BRCA1 AND COFACTOR OF BRCA1 (COBRA1) REGULATED GENES IN BREAST EPITHELIAL CELLS**S. E. Aiyar, D. A. Hopkinson,  
C. A. Moskaluk, R. Li  
*University of Virginia,  
Charlottesville, VA***P51-2 BRCA1 INTERACTS WITH HIGHLY CONSERVED COMPONENTS OF THE TRANSCRIPTION ELONGATOR COMPLEX**T. J. Westmoreland, A. L. Selim,  
W. Y. Saito, G. Huper, J. A. Olson,  
J. R. Marks, C. B. Bennett  
*Department of Surgery, Duke  
University Medical Center,  
Durham, NC***P51-3 LEVELS OF SPECIFIC UBIQUITINATED NUCLEAR PROTEINS CHANGE FOLLOWING MODULATION OF BREAST CANCER SUSCEPTIBILITY GENE 1 (BRCA1) EXPRESSION**E. S. Berleth  
*Roswell Park Cancer Institute,  
Buffalo, NY***P51-4 COORDINATE TRANSCRIPTION CONTROL BY BRCA1 AND THE KRAB-ZINC FINGER PROTEIN ZBRK1**T. G. Boyer, W. Tan, S. Kim  
*Department of Molecular  
Medicine and Institute of  
Biotechnology, University of  
Texas Health Science Center at  
San Antonio, San Antonio, TX***P51-5 MODULATION OF HUMAN ESTROGEN RECEPTOR ALPHA FUNCTION BY BRCA1**T. G. Boyer, A. M. Trauernicht,  
*Department of Molecular  
Medicine and Institute of  
Biotechnology, University of  
Texas Health Science Center at  
San Antonio, San Antonio, TX***P51-6 FUNCTIONAL ANALYSIS OF ATM-DEPENDENT BRCA1 PHOSPHORYLATION**C. Chao, Y. Xu  
*University of California at San  
Diego, La Jolla, CA***P51-7 BRCC36, A NOVEL SUBUNIT OF A BRCA1 E3 UBIQUITIN LIGASE COMPLEX, IS OVEREXPRESSED IN BREAST TUMORS AND IS INVOLVED IN IONIZING RADIATION-INDUCED APOPTOSIS IN BREAST CANCER CELLS**X. Chen,<sup>1</sup> C. A. Arciero,<sup>1</sup>  
Y. Dong,<sup>2</sup> M-A Hakimi,<sup>2</sup>  
R. Shiekhattar,<sup>2</sup> A. K. Godwin<sup>1</sup>  
<sup>1</sup>*Fox Chase Cancer Center,  
Philadelphia, PA;* <sup>2</sup>*The Wistar  
Institute, Philadelphia, PA***P51-8 PROTEIN STRUCTURE AND BREAST CANCER**F. J. Stevens,<sup>1</sup> J. Fackenthal,<sup>2</sup>  
F. R. Collart,<sup>1</sup> S. Moy,<sup>1</sup>  
C. Kuemmel,<sup>1</sup> E. Myatt,<sup>1</sup>  
G. Babnigg,<sup>1</sup> R. Wilton,<sup>1</sup>  
M. Schiffer,<sup>1</sup> W. E. Boernke,<sup>3</sup>  
S. Borowicz,<sup>2</sup> Y. Chen,<sup>2</sup>  
O. Olopade<sup>2</sup>  
<sup>1</sup>*Argonne National Laboratory,  
Argonne, IL;* <sup>2</sup>*University of  
Chicago Medical Center,  
Chicago, IL;* <sup>3</sup>*Nebraska Wesleyan  
University, Lincoln, NE***P51-9 BRCA1 UBIQUITINATION OF PHOSPHORYLATED RNA POLYMERASE II AND FUNCTIONAL EVALUATION OF BRCA1 MISSENSE MUTATIONS**N. Chiba, C. De La Cruz,  
W. Leizhen, J. D. Parvin,  
C. Ishioka  
*Department of Clinical Oncology,  
Institute of Development,  
Aging, and Cancer and Tohoku  
University Hospital, Tohoku  
University, Sendai, Japan***P51-10 IDENTIFYING SUBSTRATES AND FUNCTIONAL ROLES OF THE BRCA1 UBIQUITIN LIGASE**D. E. Christensen, P. S. Brzovic,  
C. Adamo, P. Welsch, R. E. Klevit  
*University of Washington, Seattle,  
WA***P51-11 EFFECTS OF ESTROGEN, PREGNANCY, AND THERAPEUTIC DRUGS ON MAMMARY TUMOR FORMATION IN BRCA1-CONDITIONAL MUTANT MICE**W. Li, R. Bachelder, W-H. Qiao,  
R-H. Wang, X. Xu, C-X. Deng  
*Genetics of Development and  
Diseases Branch, National  
Institute of Diabetes and  
Digestive and Kidney Diseases,  
National Institutes of Health,  
Bethesda, MD***P51-12 STRUCTURAL STUDIES OF THE BRCA1-ASSOCIATED HUMAN SWI/SNF COMPLEX**M. Holbert  
*The Wistar Institute, University of  
Pennsylvania, Philadelphia, PA***P51-13 BRCA1 PROTEIN COMPLEXES. COMPOSITION AND FUNCTION**A. A. Horwitz, L. M. Starita,  
J. D. Parvin  
*Biological Sciences Program,  
Harvard Medical School, Boston,  
MA***P51-14 BRCA1 DIRECTLY MODULATES GENE EXPRESSION REQUIRED FOR ESTROGEN BIOSYNTHESIS: A POSSIBLE MECHANISM OF TISSUE-SPECIFIC TUMOR SUPPRESSION**Y. Hu, S. Aiyar, W. Yue,<sup>1</sup>  
S. Ghosh, Y. Lu, R. Li  
*Departments of Biochemistry and  
Molecular Genetics, <sup>1</sup>Medicine  
and Division of Endocrinology,  
School of Medicine, University of  
Virginia, Charlottesville, VA***P51-15 BRCA1/BARD1 MEDIATED TARGETING OF RCC1 TO CHROMATIN IS REQUIRED FOR THE FIDELITY OF MITOSIS AND MITOTIC EXIT**V. Joukov,<sup>1</sup> T. Prokhorova,<sup>2</sup>  
R. Gerson,<sup>1</sup> E. White,<sup>1</sup>  
J. C. Walter,<sup>2</sup> D. M. Livingston<sup>1</sup>  
<sup>1</sup>*Dana-Farber Cancer Institute  
and Harvard Medical School,  
Boston, MA;* <sup>2</sup>*Department  
of Biological Chemistry and  
Molecular Pharmacology,  
Harvard Medical School, Boston,  
MA*

**P51-16 CONSEQUENCES OF CYCLIN D1/BRCA1 INTERACTION IN BREAST CANCER CELLS**

K. Kehn,<sup>1</sup> C. de la Fuente,<sup>1</sup>  
A. Pumfrey,<sup>1</sup> M-E. Bottazzi,<sup>2</sup>  
F. Kashanchi<sup>1</sup>

*George Washington University Medical Center, Washington, DC*

**P51-17 ROLE OF BRCA1/BARD1 IN COORDINATING THE INHIBITION OF 3' PROCESSING AND TRANSCRIPTION DURING DNA REPAIR**

D. Fonseca,<sup>1</sup> F. W. Baer,<sup>2</sup> R. Baer,<sup>2</sup>  
J. L. Manley,<sup>3</sup> F. E. Kleiman<sup>1</sup>

<sup>1</sup>Hunter College, City University of New York, New York, NY;

<sup>2</sup>Institute of Cancer Genetics and <sup>3</sup>Department of Biological Sciences, Columbia University, New York, NY

**P51-18 STRUCTURAL ANALYSIS OF THE BRCA1 INTERACTION WITH BRANCHED DNA**

J. A. A. Ladias, A. Varma,  
R. Brown, G. Birrane

*Molecular Medicine Laboratory and Macromolecular Crystallography Unit, Harvard Institutes of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA*

**P51-19 STRUCTURAL BASIS FOR THE BRCA1 INTERACTION WITH THE PROTEIN CTIP**

J. A. A. Ladias, A. Varma,  
R. Brown, G. Birrane

*Molecular Medicine Laboratory and Macromolecular Crystallography Unit, Harvard Institutes of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA*

**P51-20 MOLECULAR INSIGHT INTO THE ROLE OF BRCA1 AND ITS COFACTORS IN TRANSCRIPTIONAL REGULATION AND TISSUE-SPECIFIC TUMOR SUPPRESSION**

R. Li, S. Aiyar, J. Sun, S. Ghosh,  
A. Blair, Y. Lv, A. Amleh, Y. Hu  
*Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA*

**P51-21 FUNCTION OF BRCA1 AT A DNA REPLICATION ORIGIN**

J. Dheekollu, J. Zhou, Z. Deng,  
P. M. Lieberman  
*The Wistar Institute, Philadelphia, PA*

**P51-22 THE ROLE OF BRCA1-DEPENDENT UBIQUITINATION IN BREAST CANCER**

C-S. Lu, P. R. Yew  
*Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX*

**P51-23 THE ROLE OF BRCA1 PROMOTER METHYLATION IN DETERMINING CHEMOSENSITIVITY IN HUMAN BREAST CANCER CELLS**

R. Nanda, C. Collins, B. Patel,  
J. Xu, M. E. Dolan, O. I. Olopade  
*Section of Hematology/Oncology, University of Chicago, Chicago, IL*

**P51-24 BRCA1 AND FOXA1 PROTEINS INTERACT AND REGULATE THE EXPRESSION OF THE CYCLE DEPENDENT KINASE INHIBITOR P27 KIP1**

J. O'Kelly, E. A. Williamson,  
I. Wolf, S. Bose, S. Tanosaki,  
H. P. Koeffler  
*Department of Medicine, Hematology/Oncology, and Department of Pathology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA*

**P51-25 UTILIZING BUDDING YEAST TO IDENTIFY POTENTIAL MODIFIERS OF BRCA1 FUNCTION**

S. E. Plon, E. Strome  
*Departments of Pediatrics and Molecular and Human Genetics, Graduate Program in Cellular and Molecular Biology, Baylor College of Medicine, Houston, TX*

**P51-26 NUCLEAR DYNAMICS OF BRCA1-DEPENDENT TRANSCRIPTION REGULATION**

Z. D. Sharp,<sup>1</sup> W. Tan,<sup>1</sup> T. Boyer,<sup>1</sup>  
M. A. Mancini<sup>2</sup>  
<sup>1</sup>*Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center*

at San Antonio, San Antonio,

TX; <sup>2</sup>*Department of Cellular and Molecular Biology, Baylor College of Medicine, Houston, TX*

**P51-27 BRCA1-DEFICIENT MAMMARY TUMORS HAVE DISTINCT TUMORIGENESIS PROCESSES AND CHEMOTHERAPY RESPONSE**

C. R. Smith,<sup>1</sup> S-C. J. Lin,<sup>1,\*</sup>  
A. Li,<sup>1</sup> T. Tod,<sup>1</sup> C-X. Deng,<sup>2</sup>  
E. Y-H. P. Lee<sup>1,3</sup>

<sup>1</sup>*Departments of Biological Chemistry and Developmental and Cell Biology, University of California at Irvine, Irvine, CA;* <sup>2</sup>*Genetics of Development and Disease Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD;* <sup>3</sup>*Corresponding author: Eva Y-H. P. Lee, Department of Biological Chemistry and Department of Developmental and Cell Biology, University of California at Irvine, Irvine, CA;*

*\*Current address: Division of Developmental Biology, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH*

**P51-28 BRCA1-DEPENDENT UBIQUITINATION OF GAMMA-TUBULIN REGULATES CENTROSOME NUMBER AND FUNCTION**

L. M. Starita, S. Sankaran,  
J. D. Parvin  
*Harvard Medical School and Brigham and Women's Hospital, Boston, MA*

**P51-29 IDENTIFICATION OF TRANSCRIPTIONAL REPRESSORS OF BRCA1**

T-C. Suen  
*New York University School of Medicine, Tuxedo, NY*

**P51-30 CHARACTERIZATION OF THE INTERACTION OF BRCA1 AND PROTEIN PHOSPHATASE 1**

S. L. Winter, I. L. Andrusis  
*Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Medical Genetics, University of Toronto, Toronto, ON, Canada*

**P51-31 BRCA1 AND CDK INHIBITOR P18/INK4C COLLABORATE TO SUPPRESS BREAST CANCER**

X. Yue

*Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC***P52 EGF Superfamily II**

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.**P52-1 MOLECULAR MECHANISMS OF ERBB2 DEGRADATION THROUGH HSP90 INHIBITION**S. Akakura, M. Dimri, P. Zhou,  
V. Band, H. Band  
*Evanston Northwestern Healthcare Research Institute, Northwestern University Feinberg School of Medicine, Evanston, IL***P52-2 THE SCAFFOLDING ADAPTER GAB2 IS CRITICAL FOR HER2/NEU INDUCED CARCINOGENESIS AND IS REQUIRED FOR PYMT ANTIGEN INDUCED METASTASIS**M. Bentires-Alj, S. G. Gil,  
R. Chan, H. Keilhack, B. G. Neel,  
H. Gu  
*Cancer Biology Program, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA***P52-3 TRANSCRIPTIONAL REGULATION OF THE ERBB2 PROTO-ONCOGENE IN BREAST CANCER**R. Dillon,<sup>1</sup> S. Brown,<sup>2</sup>  
E. Andrechek,<sup>3</sup> S. Sadekova,<sup>1</sup>  
W. Muller<sup>1</sup>  
<sup>1</sup>*McGill University, Montreal, QC, Canada;* <sup>2</sup>*McMaster University, Hamilton, ON, Canada;* <sup>3</sup>*Duke University, Durham, NC***P52-4 THE TRANSMEMBRANE DOMAINS OF ERBB RECEPTORS DO NOT DIMERIZE STRONGLY IN MICELLES**A. M. Stanley, K. G. Fleming  
*T. C. Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, MD***P52-5 ANIMAL MODEL – DOXORUBICIN AND ANTI-ERBB2 SYNERGISTIC CARDIAC TOXICITY**K. Gabrielson,<sup>1</sup> R. Becker,<sup>1</sup>  
S. Alvey,<sup>1</sup> D. Bedja,<sup>1</sup>  
N. Muratore,<sup>1</sup> L. Wachtman,<sup>1</sup>  
S. Pin,<sup>1</sup> M. Servinsky,<sup>1</sup> W. Shi,<sup>1</sup>  
S. Barber,<sup>1</sup> K. Irani,<sup>2</sup> D. Kass,<sup>2</sup>  
R. Rodriguez,<sup>3</sup> N. Peterson<sup>1</sup>  
*Departments of <sup>1</sup>Comparative Medicine, <sup>2</sup>Medicine, and <sup>3</sup>Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD***P52-6 STIMULATION OF PHOSPHATIDYLINOSITOL-3-KINASE BY EGF BLOCKS HC11 LACTOGENIC DIFFERENTIATION BY MULTIPLE MECHANISMS**T. Galbaugh, W. Wang, C. Jose,  
M. L. Cutler  
*Department of Pathology, United States Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda, MD***P52-7 MOLECULAR MECHANISMS OF ERBB2 TYROSINE KINASE REGULATION**L. Gu, G. Birrane, J. A. A. Ladis  
*Molecular Medicine Laboratory and Macromolecular Crystallography Unit, Harvard Institutes of Medicine, Harvard Medical School, Boston, MA***P52-8 DIFFERENTIAL EFFECTS OF EGF GRADIENT PROFILES ON MDA-MB-231 BREAST CANCER CELL CHEMOTAXIS**S-J. Wang, W. Saadi, F. Lin,  
C. M-C. Nguyen, N. L. Jeon  
*Department of Biomedical Engineering, University of California at Irvine, Irvine, CA***P52-9 PC-CELL DERIVED GROWTH FACTOR (PCDF/GP88) STIMULATES GROWTH AND CONFERs HERCEPTIN RESISTANCE IN ERBB2-OVEREXPRESSING BREAST CANCER CELLS**W. E. Kim,<sup>1</sup> G. Serrero<sup>2</sup>  
<sup>1</sup>*Department of Pharmaceutical Sciences, University of Maryland, Baltimore School of Pharmacy, Baltimore, MD;* <sup>2</sup>*University of Maryland, Baltimore Greenebaum**Cancer Center, Baltimore, MD; A&G Pharmaceuticals, Columbia, MD***P52-10 MUTATIONAL ANALYSIS OF ERBB2'S EFFECT ON EPITHELIAL CELL POLARITY**A. Luks, S. Muthuswamy  
*Cold Spring Harbor Laboratory, Cold Spring Harbor, NY***P52-11 THE PRO-PEPTIDE DOMAIN OF LYSYL OXIDASE INDUCES PHENOTYPIC REVERSION OF RAS- AND HER-2/NEU-TRANSFORMED BREAST CANCER CELLS**C. Min,<sup>1</sup> S. Jeay,<sup>1</sup>  
A. H. Palamakumbura,<sup>2</sup> Y. Guo,<sup>2</sup>  
N. Pischedlo,<sup>2</sup> P. Sommer,<sup>3</sup>  
K. H. Kirsch,<sup>1</sup> P. C. Trackman,<sup>2</sup>  
G. E. Sonenschein<sup>1</sup><sup>1</sup>*Department of Biochemistry, Boston University School of Medicine;* <sup>2</sup>*Division of Oral Biology, Boston University Goldman School of Dental Medicine, Boston, MA;* <sup>3</sup>*Institut de Biologie et Chimie des Protéines, Université Claude Bernard, Lyon Cedex, France***P52-12 ERBB-2 AND ERALPHA CROSS-TALK IN MAMMARY TUMORIGENESIS AND METASTASIS**N. Dourdin,<sup>3</sup> V. Giguere,<sup>1,2,3</sup>  
W. J. Muller<sup>1,2,3</sup>  
<sup>1,2</sup>*Departments of Medicine and Biochemistry, Molecular Oncology Group, McGill University, Montreal, QC, Canada***P52-13 THE BIOLOGICAL EFFECTS OF ACTIVATING ERBB2 RECEPTOR TYROSINE KINASE IN POLARIZED GROWTH ARRESTED MAMMARY EPITHELIUM**M. E. Nolan, S. K. Muthuswamy  
*Genetics Program, State University of New York at Stony Brook, Stony Brook, NY; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY*

**P52-14 IMPACT OF C-neu/erbB2 ON ESTROGEN AND ESTROGEN RECEPTOR ALPHA-DEPENDENT PROLIFERATION OF MAMMARY EPITHELIAL CELLS**

G. Shyamala, Y-C. Chou,  
E. Vargas

*Lawrence Berkeley Laboratory,  
University of California at  
Berkeley, Berkeley, CA*

**P52-15 CO-EXPRESSION OF AN EGFR MUTANT WITH ERBB-2 ENHANCED MOTILITY AND INVASION**

H. Yu, W. Han, X. Gong,  
C. K. Tang

*Department of Oncology,  
Lombardi Cancer Center,  
Georgetown University Medical  
Center, Washington, DC*

**P52-16 MUC4 AND ERBB2 INTERACTIONS IN THE RAT MAMMARY GLAND DURING PREGNANCY**

G. Theodore, S. A. Price-Schiavi,  
M. Rong, E. Andrechek,  
W. J. Muller, C. A. Carothers  
Caraway, K. L. Caraway  
*University of Miami School of  
Medicine, Miami, FL; McMaster  
University, Hamilton, ON,  
Canada*

**P52-17 SYNERGISTIC INHIBITORY EFFECT OF RAPAMYCIN AND HERCEPTIN ON GROWTH AND TUMORIGENICITY OF ERBB2 OVER-EXPRESSING BREAST CANCER CELLS**

L-H. Wang, W. Li, J. Chan  
*Department of Microbiology,  
Mount Sinai School of Medicine,  
New York, NY*

**P52-18 CYCLIN E/CDK2 MEDIATES ERBB2 INDUCED PROLIFERATION OF THREE-DIMENSIONAL BREAST EPITHELIAL ACINI**

B. Xiang, R. Lucito,  
S. Muthuswamy  
*Cold Spring Harbor Laboratory,  
Cold Spring Harbor, NY*

**P52-19 TRANSCRIPTIONAL CONTROL OF THE HER-2/NEU PROMOTER BY DNA SECONDARY STRUCTURE**

A. Ziembra, Y. Krotova, M. Boros,  
R. Memmott, L. Hurley,  
S. Ebbinghaus

*University of Arizona, Tucson, AZ*

**P53 Growth Factors/  
Cytokines**

**7:00–9:00 p.m.**

*Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.*

**P53-1 HYPOXIA-INDUCIBLE AUTOCRINE ERYTHROPOIETIN SIGNALING PROTECTS FROM APOPTOSIS IN HUMAN BREAST CANCER CELLS**

G. Acs, M. Chen, X. Xu,  
C. J. Koch

*Departments of Pathology  
and Laboratory Medicine and  
Radiation Oncology, University of  
Pennsylvania School of Medicine,  
Philadelphia, PA*

**P53-2 MACROPHAGES PROTECT BREAST CANCER CELLS FROM TAMOXIFEN KILLING**

T. A. Bremner, Z. Jin,  
G. S. Morris

*Department of Biology, and  
Cancer Center, Howard  
University, Washington, DC*

**P53-3 A NOVEL ROLE OF C-SRC AND STAT3 IN AUTOCRINE HGF EXPRESSION IN INVASIVE BREAST CANCER**

E. J. Wojcik, S. Sharifpoor,  
T. Wright, R. Watering,  
E. A. Tremblay, C. R. Mueller,  
B. E. Elliott

*Division of Cancer Biology  
and Genetics, Cancer Research  
Institute, Queen's University,  
Kingston, ON, Canada*

**P53-4 DIFFERENTIAL ROLES OF INSULIN RECEPTOR SUBSTRATE-1 AND -2 IN MEDIATING INSULIN-LIKE GROWTH FACTOR-I ACTION IN BREAST CANCER CELLS**

S. Byron, D. Yee  
*University of Minnesota Cancer  
Center, Minneapolis, MN*

**P53-5 IDENTIFICATION OF A MAMMALIAN HOMOLOG OF DROSOPHILA KEK1, AN INHIBITOR OF BREAST TUMOR CELL GROWTH**

K. L. Caraway  
*University of California, Davis  
Cancer Center, Sacramento, CA*

**P53-6 EXPRESSION OF A DOMINANT NEGATIVE WNT RECEPTOR INHIBITS DUCTAL OUTGROWTH AND ALVEOLAR HYPERPLASIA IN MOUSE MAMMARY GLANDS**

L. A. Castelo-Soccio,  
K. R. Brennan, A. M. C. Brown  
*Weill Medical College of Cornell  
University and Strang Cancer  
Prevention Center, New York, NY*

**P53-7 WNT5B IS AN IN VITRO SUBSTRATE FOR STROMELYSIN-1**

G. J. P. Dijkgraaf, H. Kouros-Mehr, Z. Werb  
*Department of Anatomy,  
University of California at San  
Francisco, San Francisco, CA*

**P53-8 MULLERIAN INHIBITING SUBSTANCE SUPPRESSES TUMOR GROWTH IN THE C3(1)T ANTIGEN TRANSGENIC MOUSE MAMMARY CARCINOMA MODEL**

V. Gupta, J. L. Carey,  
H. Kawakubo, A. Muzikansky,<sup>1</sup>  
J. E. Green,<sup>2</sup> P. K. Donahoe,<sup>3</sup>  
D. T. MacLaughlin,<sup>3</sup>  
S. Maheswaran  
*Surgical Oncology, Massachusetts  
General Hospital and Harvard  
Medical School, Boston, MA;  
<sup>1</sup>Massachusetts General Hospital  
Biostatistics; <sup>2</sup>Laboratory of Cell  
Regulation and Carcinogenesis,  
National Institutes of Health,  
Rockville, MD; <sup>3</sup>Pediatric  
Surgery, Massachusetts General  
Hospital, Boston, MA*

**P53-9 TRANSGENIC OVEREXPRESSION OF IGF-IR IS SUFFICIENT TO INDUCE MAMMARY EPITHELIAL HYPERPLASIA AND TUMOR FORMATION**

R. A. Jones,<sup>1</sup> C. I. Campbell,<sup>1</sup>  
E. J. Gunther,<sup>2</sup> L. A. Chodosh,<sup>3</sup>  
R. Khokha,<sup>4</sup> R. A. Moorehead<sup>1</sup>  
*<sup>1</sup>Department of Biomedical  
Sciences, Ontario Veterinary  
College, University of Guelph,*

Guelph, ON, Canada; <sup>2</sup>Penn State Cancer Institute, Hershey, PA;  
<sup>3</sup>Department of Cancer Biology and Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA; <sup>4</sup>University Health Network/Princess Margaret Hospital, Toronto, ON, Canada

**P53-10 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGFBP-3) INDUCES CASPASE-DEPENDENT APOPTOSIS THROUGH THE NEWLY IDENTIFIED IGFBP-3 RECEPTOR IN HUMAN BREAST CANCER CELLS**

L. Fan, T. E. Paisley, H-S. Kim, Y. Oh  
*Department of Pathology, MCV Campus, Virginia Commonwealth University, Richmond, VA*

**P53-11 EVIDENCE FOR INTERLEUKIN-1 MEDIATED OSTEOLYSIS AND TUMOR PROGRESSION IN HUMAN BREAST CARCINOMA BONE METASTASIS**

A. G. Pantschenko,<sup>1</sup> R. Naujoks,<sup>1</sup> R. H. Quinn,<sup>2</sup> M. Sanders,<sup>3</sup> G. Gronowicz<sup>1</sup>  
<sup>1</sup>Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington, CT; <sup>2</sup>Department of Orthopaedics, University of New Mexico Health Sciences Center, Albuquerque, NM; <sup>3</sup>Department of Pathology, University of Connecticut Health Center, Farmington, CT

**P53-12 INFLUENCE OF A NOVEL CLASS OF KGFR TK INHIBITORS ON THE MOTILITY OF HUMAN BREAST CANCER CELLS**

T. X. Nguyen, X-P. Zang, R. W. Brueggemeier, J. Hackett, Z. Xiao, M. R. Lerner, D. J. Brackett, P-K. Li, J. T. Pento  
*Department of Pharmaceutical Sciences, University of Oklahoma, Oklahoma City, OK; Division of Medicinal Chemistry and Pharmacognosy, Ohio State University, Columbus, OH*

**P53-13 HIP1 REGULATION OF GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER**

K. Oravecz-Wilson, L. Li, S. Chamaillard, S. V. Bradley, T. S. Hyun, D. S. Rao, T. S. Ross  
*University of Michigan, Ann Arbor, MI*

**P53-14 IDENTIFICATION AND CHARACTERIZATION OF FIBROBLAST GROWTH FACTOR-BINDING PROTEIN 3**

M. R. Swift, E. Tassi, A. Wellstein  
*Department of Oncology, Georgetown University, Washington, DC*

**P53-15 RON RECEPTOR SIGNALING AUGMENTS MAMMARY TUMORIGENESIS IN MURINE MODELS OF BREAST CANCER**

S. E. Waltz, S. Beauman, M. Collins, M. Leonis, K. Toney, B. E. Peace  
*University of Cincinnati College of Medicine, Cincinnati, OH*

**P53-16 INHIBITION BY COPPER(II) BINDING OF HGF INTERACTION WITH ITS RECEPTOR MET AND BLOCKADE OF HGF/MET FUNCTION: A NOVEL THERAPEUTIC APPROACH FOR BREAST CANCER TREATMENT**

T. G. Wright, S. Molyneux, M. Chan, Z. Jia, B. E. Elliott  
*Division of Cancer Biology and Genetics, Queen's University Cancer Research Institute, Kingston, ON, Canada*

**P53-17 IDENTIFICATION OF A RECEPTOR FOR TUMOR SUPPRESSOR HIN-1**

J. Yao, M. Taylor-Parker, D. Porter, I. Krop, K. Polyak  
*Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA*

**P54 Tumor Suppressor Genes II**

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
 Even-numbered – 8:00–9:00 p.m.

**P54-1 REGULATION OF HDM2 ACTIVITY BY NUCLEOLIN**

J. A. Borowiec, A. Saxena, C. J. Rorie, D. Dimitrova, Y. Daniely  
*Department of Biochemistry and New York University Cancer Institute, New York University School of Medicine, New York, NY*

**P54-2 REGULATION OF PTEN TUMOR SUPPRESSOR**

T. Hoang, L. Odriozola, A. M. Chan  
*Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY*

**P54-3 ESTROGEN-INDUCED ACTIVATION OF WOX1/WWOXV1 AND WOX2/WWOXV2 IN VITRO: A POTENTIAL ROLE IN BREAST CANCER PROGRESSION**

N-S. Chang,<sup>1</sup> L. Schultz,<sup>1</sup> L-J. Hsu,<sup>1</sup> J. Lewis,<sup>1</sup> M. Su,<sup>2</sup> C-I. Sze<sup>2</sup>

<sup>1</sup>Guthrie Research Institute, Laboratory of Molecular Immunology, Sayre, PA;

<sup>2</sup>Department of Pathology, University of Colorado Health Sciences Center, Denver, CO

**P54-4 PROSTASIN SERINE PROTEASE IS A TUMOR SUPPRESSOR: ACTIONS AND MECHANISMS**

L. Chen, K. X. Chai  
*University of Central Florida, Orlando, FL*

**P54-5 INSIGHTS FROM A NOVEL BREAST TUMOR SUPPRESSOR PATHWAY**

J. Colicelli, M. Milstein, H. Hu  
*David Geffen School of Medicine and Jonsson Cancer Center, University of California at Los Angeles, Los Angeles, CA*

P54-6	<b>CAS PROTEINS AS SWITCHES IN EPITHELIAL-MESENCHYMAL TRANSITION IN BREAST CANCER</b> D. Dadke, E. Nicolas, H. Wu, A. K. Godwin, E. A. Golemis <i>Fox Chase Cancer Center, Philadelphia, PA</i>	P54-11	<b>TOWARDS THE STRUCTURAL DETERMINATION OF THE OVARIAN TUMOR DOMAIN COMPLEXED WITH UBIQUITIN</b> T. Messick, R. Marmorstein <i>Wistar Institute, University of Pennsylvania, Philadelphia, PA</i>	P54-17	<b>TELOMERASE REACTIVATION AND GENOMIC INSTABILITY DURING IMMORTAL TRANSFORMATION OF CULTURED HUMAN MAMMARY EPITHELIAL CELLS</b> M. Stampfer, J. Garbe, K. Chin, T. Tlsty, P. Yaswen <i>Lawrence Berkeley National Laboratory, Berkeley, CA; University of California at San Francisco, San Francisco, CA</i>
P54-7	<b>A NOVEL APPROACH TO IDENTIFY GENES RELATED TO BREAST CANCER USING RANDOM FRAMESHIFT MUTAGENESIS, SELECTION AND FINDING MUTANT GENES IN SELECTED CLONES THROUGH THE INHIBITION OF NONSENSE MEDiated mRNA DECAY</b> Y. Ionov <i>Roswell Park Cancer Institute, Buffalo, NY</i>	P54-12	<b>A POSSIBLE ROLE FOR P66-SHC IN BREAST CANCER TUMORIGENICITY</b> L. R. Nelson, <sup>1</sup> P. A. Davo, <sup>1</sup> C. O'Connell, <sup>2</sup> K. Langenbach, <sup>2</sup> P. Barker, <sup>2</sup> A. R. Frackelton Jr. <sup>1</sup> <sup>1</sup> <i>Department of Medicine, Roger Williams Hospital, Providence, RI;</i> <sup>2</sup> <i>Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, MD</i>	P54-18	<b>ROLE OF HUMAN SELENIUM BINDING PROTEIN (HSP56) IN THE PATHOBIOLOGY OF BREAST CANCER</b> A. J. Szychowski, T. Petan <i>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA</i>
P54-8	<b>CHARACTERIZATION OF THE NOVEL BREAST TUMOR SUPPRESSOR GENE DEAR1</b> A. M. Killary, D. S. Chandler, M. Rodriguez, H. Xie, S. Sen, K. Chaung, K. Keyomarsi, A. El-Naggar, S. M. Hewitt, S. T. Lott <i>University of Texas M.D. Anderson Cancer Center, Houston, TX; National Institutes of Health, Bethesda, MD</i>	P54-13	<b>MAMMARY GLAND-SPECIFIC PARITY-INDUCED CRE-EXPRESSION IN TRANSGENIC MOUSE LINE FVB/N-TG(MMTV-CRE)105AYN</b> Z. Zhou, A. Flesken-Nikitin, L. Cheng, A. Y. Nikitin <i>Department of Biomedical Sciences, Cornell University, Ithaca, NY</i>	P54-19	<b>GADD45 FAMILY OF GENES IN BREAST CANCER</b> J. S. Tront, B. Hoffman, D. A. Liebermann <i>Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA</i>
P54-9	<b>INHIBITION OF WISP3 (CCN6) EXPRESSION ENHANCES THE EFFECTS OF IGF-I AND PROMOTES NEOPLASTIC TRANSFORMATION OF BREAST EPITHELIAL CELLS</b> Y. Zhang, S. Monroe, S. D. Merajver, C. G. Kleer <i>Departments of Pathology and Internal Medicine, and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI</i>	P54-14	<b>REGULATION OF GENE EXPRESSION BY P63 IN BREAST MYOEPITHELIAL CELLS</b> C. A. Perez, J. A. Pietenpol <i>Department of Biochemistry, Center in Molecular Toxicology, The Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN</i>	P54-20	<b>CHROMOSOME 21 AND BREAST CANCER SUPPRESSION</b> C-M. Li, M. Guo, J. Jakob, A. Shaye, J. Yu, E. Yuan, N. Schupf, W. Silverman, W. Zigman, R. Parsons, B. Tycko <i>Columbia University and New York State Institute for Basic Research, New York, NY</i>
P54-10	<b>GENOME-WIDE RNA INTERFERENCE SCREEN FOR NOVEL E2F REGULATORS AND CANCER GENES</b> J. Lu, L. Ruhf, N. Perrimon, P. Leder <i>Department of Genetics, Harvard Medical School, Boston, MA</i>	P54-15	<b>SINGLEMINDED-2 IN BREAST CANCER AND MAMMARY GLAND DEVELOPMENT</b> H-I. Kwak, R. Metz, K. Kucera, W. Porter <i>Faculty of Toxicology, Texas A&amp;M University, College Station, TX</i>	P54-21	<b>CBP IS A POTENT TUMOR SUPPRESSOR IN MOUSE MAMMARY GLAND TISSUE</b> C. Tong, J. van Deursen <i>Mayo College of Medicine, Rochester, MN</i>
P54-16	<b>IDENTIFICATION OF NOVEL TUMOR SUPPRESSOR GENES FOR BREAST CANCERS</b> Y. Zhu, C. Qi <i>Northwestern University Medical School, Chicago, IL</i>	P54-22	<b>TIP30, A NEWLY IDENTIFIED TUMOR SUPPRESSOR IN BREAST CARCINOGENESIS</b> H. Xiao, C. Jiang, K. Bruck, J. Pecha, W. Tang, L. Berki, P. Lee <i>Eppley Institute for Research in Cancer and Allied Diseases, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE</i>		

**P54-23 BREAST-CANCER ASSOCIATED VARIANTS OF THE HBP1 TRANSCRIPTIONAL REPRESSOR**  
A. S. Yee,<sup>1,2,4</sup> K. E. Paulson,<sup>1,2</sup>  
M. A. McDevitt,<sup>5</sup> K. Rieger-  
Christ,<sup>6</sup> I. Summerhayes,<sup>6</sup>  
S. Kaufman,<sup>2</sup> D. Wazer,<sup>2</sup>  
S. P. Berasi,<sup>1,4</sup> J. Kim,<sup>1,3</sup>  
C-Y. Huang,<sup>2</sup> H. Ma,<sup>1</sup> X. Zhang<sup>1</sup>  
<sup>1</sup>Department of Biochemistry,  
Tufts University School  
of Medicine, Boston, MA;  
<sup>2</sup>Department of Radiation  
Oncology, Tufts-New England  
Medical Center, Boston, MA;  
<sup>3</sup>Program in Cell and Molecular  
Nutrition, School of Nutrition  
Science and Policy, Tufts  
University, Boston, MA; <sup>4</sup>Program  
in Genetics, Tufts University  
School of Medicine, Boston,  
MA; <sup>5</sup>Department of Medicine,  
Division of Hematology, Johns  
Hopkins University School  
of Medicine, Baltimore, MD;  
<sup>6</sup>Cell and Molecular Biology  
Laboratory, R.E. Wise M.D.  
Research and Education Institute,  
Lahey Clinic, Burlington, MA

**P54-24 MASPIN ASSOCIATES WITH CYTOSKELETON AND REGULATES CELL ADHESION VIA BETA1 INTEGRIN-DEPENDENT MECHANISM**  
N. Cella, K. Latha, Y. Deng,  
M. Zhang  
Baylor College of Medicine,  
Houston, TX

## P55 Functional Study of Biological Molecules II

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.

**P55-1 TISSUE FACTOR'S ROLE IN COAGULATION ON THE SURFACE OF HUMAN BREAST CANCER CELLS**  
F. C. Antonaci, J. H. Morrissey  
University of Illinois at Urbana-Champaign, Urbana, IL

**P55-2 TARGETING RNA STABILIZATION TO REDUCE GROWTH FACTOR EXPRESSION IN BREAST CANCER CELLS**

H. Avraham  
*Division of Experimental  
Medicine, Beth Israel Deaconess  
Medical Center, Harvard Medical  
School, Boston, MA*

**P55-3 CD133 (AC133) AS A MARKER FOR BREAST CANCER STEM CELLS IN BREAST TUMORS**

H. Avraham  
*Division of Experimental  
Medicine, Beth Israel Deaconess  
Medical Center, Harvard Medical  
School, Boston, MA*

**P55-4 INHIBITORS OF LARGE CYTOSOLIC PROTEASES ACT SYNERGISTICALLY TO KILL BREAST CANCER CELLS**

M. Gaczynska, P. A. Osmulski  
*Department of Molecular  
Medicine, Institute of  
Biotechnology, University of  
Texas Health Science Center at  
San Antonio, San Antonio, TX*

**P55-5 PROTEASES-RELATED MOLECULAR SIGNATURE OF BREAST CANCER**

P. A. Osmulski, X. Qin,  
M. Gaczynska  
*Department of Molecular  
Medicine, Institute of  
Biotechnology, University of  
Texas Health Science Center at  
San Antonio, San Antonio, TX*

**P55-6 EFFECTS OF CELLULAR POLYPHOSPHATE ON BREAST CANCER CELL SURVIVAL**

C. Haakenson, E. Crooke  
*Georgetown University Medical  
Center and Lombardi Cancer  
Center, Washington, DC*

**P55-7 FUNCTIONAL CHARACTERIZATION OF A NOVEL ESTROGEN-DEPENDENT SIGNALING PATHWAY IN THE MAMMARY GLAND**

H. Hathaway, E. Prossnitz,  
R. Early, C. Revankar  
*Department of Cell Biology and  
Physiology, University of New  
Mexico School of Medicine,  
Albuquerque, NM*

**P55-8 REGULATION OF JUNCTIONAL COMPLEX FORMATION IN MAMMARY EPITHELIA BY CELL SURFACE BETA 1,4-GALACTOSYLTRANSFERASE**

I H. Hathaway, C. McGee,  
L. de la Cruz  
*Department of Cell Biology and  
Physiology, University of New  
Mexico School of Medicine,  
Albuquerque, NM*

**P55-9 CHARACTERIZATION OF THE INTERACTION OF MUC1 AND THE ADENOMATOUS POLYPOSIS COLI TUMOR SUPPRESSOR IN BREAST CANCER**

C. L. Hattrup, S. J. Gendler  
*Mayo Clinic College of Medicine,  
Mayo Clinic Scottsdale,  
Scottsdale, AZ*

**P55-10 POTENTIAL ROLE OF THE XENOBIOTIC MEMBRANE TRANSPORTER, MRP2, IN BREAST CANCER CARCINOGENESIS**

K. Karnaky Jr., D. Hazen-Martin,  
J. Cornejo, B. Bivens,  
M. Contreras, L. Jones  
*Departments of Cell Biology  
and Anatomy, Pathology  
and Laboratory Medicine,  
and Pediatrics, and Marine  
Biomedical and Environmental  
Sciences Center, Medical  
University of South Carolina,  
Charleston, SC; Department of  
Physics and Astronomy, College  
of Charleston, Charleston, SC;  
Mt. Desert Island Biological  
Laboratory, Salisbury Cove, ME*

**P55-11 MITOCHONDRIAL STRUCTURE AND REACTIVE OXYGEN SPECIES IN MAMMARY ONCOGENESIS**

Y-F. C. Lau, T. Kido, G. Cecchini  
*Northern California Institute  
for Research & Education and  
University of California at San  
Francisco, San Francisco, CA*

**P55-12 CHARACTERIZATION OF A NOVEL FAMILY OF EXTRACELLULAR SULFATASES AND THE EXAMINATION OF THEIR ROLE IN BREAST CANCER PROGRESSION.**

D. H. Lum, B. Welm, Z. Werb  
*University of California at San  
Francisco, San Francisco, CA*

P55-13	<b>LOSS OF SHP-1 EXPRESSION INHIBITS MCF-7 SOFT AGAR GROWTH</b> P. D. Lyons, U. M. Lorenz <i>Department of Microbiology, University of Virginia School of Medicine, Charlottesville, VA</i>	P55-19	<b>PROPROTEIN CONVERTASES IN BREAST DEVELOPMENT AND TUMORIGENESIS</b> R. Shiu, A. Blanchard, I. Iwasio, A. Yarmill, M. Venditti, J. Silha, Y. Myal, P. Watson, L. Murphy, M. Chretien, <sup>1</sup> N. Seidah <sup>2</sup> <sup>1</sup> <i>University of Manitoba, Ottawa Health Research Institute, Winnipeg, MB, Canada;</i> <sup>2</sup> <i>Clinical Research Institute of Montreal, Montreal, QC, Canada</i>	P56-2	<b>NCI1: A NOVEL GENE IMPLICATED IN TELOMERE PROCESSING</b> B. Baumgartner, E. Pennock, E. Mandell, V. Lundblad <i>Salk Institute for Biological Sciences; Baylor College of Medicine, Houston, TX</i>
P55-14	<b>BECLIN 1 IS REQUIRED FOR CELLULAR MACROAUTOPHAGY BUT NOT ENDOCYTIC TRAFFICKING</b> W. A. Maltese, X. Zeng, J. H. Overmeyer <i>Department of Biochemistry and Cancer Biology, Medical College of Ohio, Toledo, OH</i>	P55-20	<b>THE ROLE OF PROHIBITIN IN BREAST CANCER: EXPRESSION AND LOCALIZATION OF PROHIBITIN IN BREAST CANCER TISSUE AND IN MCS-7 MCF-7, MDA-MB-231 AND HMEC-HTERT CELLS</b> W. E. Thompson, <sup>1,2</sup> W. L. Lingle, <sup>3</sup> J. K. Stiles, <sup>4</sup> V. C. Negron, <sup>3</sup> R. Bass-Gregory, <sup>1,2</sup> I. Chowdhury <sup>1,2</sup> <sup>1</sup> <i>Department of Obstetrics and Gynecology, <sup>2</sup>Cooperative Reproductive Science Research Center, <sup>4</sup>Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA; <sup>3</sup>Division of Experimental Pathology, Tumor Biology Program, Mayo Clinic Cancer Center, Rochester, MN</i>	P56-3	<b>A YEAST ARTIFICIAL CHROMOSOME TO SYSTEMATICALLY SCREEN FOR THE GENETIC BASIS OF GENOMIC INSTABILITY</b> J. A. Brown, N. M. Burrows, J. M. Brown <i>Stanford University, Stanford, CA</i>
P55-15	<b>INTERACTION BETWEEN ANNEXIN 1 AND ABC TRANSPORTERS</b> R. Muimo <i>Academic Unit of Child Health, Sheffield Children's Hospital, Sheffield, South Yorkshire, UK</i>	P55-21	<b>THE ROLE OF MAMMARY STEM CELLS IN NEU/ERBB2 MEDiated CARCINOGENESIS</b> R. Kaminski, H. Avraham <i>Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA</i>	P56-4	<b>INHIBITION OF CHROMOKINESINS INCREASES THE ANEUPLOID FREQUENCY OF S2 CELLS</b> D. W. Buster, D. J. Sharp <i>Albert Einstein College of Medicine, Bronx, NY</i>
P55-16	<b>THE NUCLEAR RECEPTOR COACTIVATOR AIB1 MEDIATES IGF-1 INDUCED PHENOTYPIC CHANGES IN HUMAN BREAST CANCER CELLS</b> A. S. Oh, H-J. List, R. Reiter, A. Mani, Y. Zhang, <sup>1</sup> E. Gehan, <sup>1</sup> A. Wellstein, A. T. Riegel <sup>1</sup> <i>Department of Biostatistics, Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC</i>	P56-5	<b>LEVELS OF TELOMERE PROTEIN mRNAs ARE PREDICTIVE OF TELOMERE CONTENT IN HUMAN BREAST TUMORS</b> K. S. Butler, <sup>1</sup> W. C. Hines, <sup>1</sup> D. Roberts, <sup>2</sup> C. A. Fordyce, <sup>1,3</sup> J. K. Griffith <sup>1</sup> <sup>1</sup> <i>Departments of <sup>1</sup>Biochemistry and Molecular Biology and <sup>2</sup>Mathematics and Statistics, University of New Mexico, Albuquerque, NM;</i> <sup>3</sup> <i>Department of Biochemistry and Biophysics, University of California at San Francisco, San Francisco, CA</i>	P56-6	<b>DETECTION OF GENETIC ALTERATIONS IN BREAST SENTINEL LYMPH NODE BY CGH</b> L. R. Cavalli, S. L. Santos, C. A. Urban, R. S. Lima, I. J. Cavalli, B. R. Haddad <i>Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC; Genetics Department, Federal University of Parana, Brasil; Surgery Department HNSG, Brasil</i>
P55-17	<b>RIBOFLAVIN CARRIER PROTEIN AND RIBOFLAVIN IN BREAST TUMOR TARGETING</b> M. A. Phelps, <sup>1</sup> J. T. Dalton, <sup>1</sup> P. W. Swaan <sup>2</sup> <sup>1</sup> <i>Biophysics Program and Division of Pharmaceutics, Ohio State University, Columbus, OH;</i> <sup>2</sup> <i>Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD</i>	P56-1	<b>GENETIC INSTABILITY OF BREAST CANCER CELLS INDUCED BY ABERRANT EXPRESSION OF HMPS1</b> S. Avraham <i>Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA</i>		
P55-18	<b>ROLE OF SIGMA RECEPTOR IN BREAST CANCER</b> L. Pusztai, B. Wang, R. Rouzier, C. T. Albaraccin, G. N. Hortobagyi <i>University of Texas M.D. Anderson Cancer Center, Houston, TX</i>				

## **P56 Genomic Instability**

**7:00–9:00 p.m.**

*Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.*

P56-1	<b>GENETIC INSTABILITY OF BREAST CANCER CELLS INDUCED BY ABERRANT EXPRESSION OF HMPS1</b> S. Avraham <i>Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA</i>
-------	---

- P56-7 USE OF TELOMERE DESTABILIZATION IN COMBINATION WITH ANTI-CANCER DRUGS TO INDUCE DEATH OF TUMOR CELLS**  
M. A. Cerone,<sup>1</sup> A. J. Londoño-Vallejo,<sup>2</sup> C. Autexier<sup>1</sup>  
<sup>1</sup>Department of Anatomy and Cell Biology, McGill University and Lady Davis Institute, Montreal, QC, Canada; <sup>2</sup>Telomeres and Cancer Laboratory, Pavillion Trouillet-Rossignol, Institut Curie, Paris, France
- P56-8 A TELOMERE SPECIFIC RPA MEDIATES REPLICATION AND PROTECTION OF CHROMOSOME ENDS**  
R. B. Cervantes, S. Post, J. Otero, E. Mandell, V. Lunblad  
Salk Institute for Biological Sciences, La Jolla, CA
- P56-9 THE ROLE OF THE CENTROSOMAL COMPONENT PERICENTRIN-380 IN CENTROSOMAL ABNORMALITIES ASSOCIATED WITH BREAST CANCER**  
T. N. Davis, C. M. Bello, M. Shimogawa  
Department of Biochemistry and Program in Molecular and Cellular Biology, University of Washington, Seattle, WA
- P56-10 MOLECULAR GENETIC STUDY OF AURORA-A KINASE: FROM CENTROSOME TO MITOTIC SPINDLE**  
J. Du, G. J. Hannon  
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
- P56-11 TELOMERE CONTENT IN DCIS AND ADJACENT HISTOLOGICALLY NORMAL CELLS**  
C. Fordyce, H. Berman, K. Chew, T. Tlsty  
Department of Pathology, University of California at San Francisco, San Francisco, CA

- P56-12 TELOMERE DNA CONTENT AND ALLELIC IMBALANCE IN HISTOLOGICALLY NORMAL TISSUE ADJACENT TO BREAST TUMORS**  
C. Heaphy, M. Bisoffi, C. A. Fordyce, A. Mangalik, J. K. Griffith  
Departments of Biochemistry and Molecular Biology, and Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM; Department of Pathology, University of California at San Francisco, San Francisco, CA
- P56-13 MUTATOR DNA POLYMERASES IN STRESS-INDUCED MUTATION**  
M. N. Hersh, N. C. Fonville, R. S. Harris, S. M. Rosenberg  
Baylor College of Medicine, Houston, TX
- P56-14 A NOVEL FUNCTIONAL SCREEN FOR MUTATOR GENES IN BREAST CANCER**  
P. L. Welsch, K. M. Chisholm, K. P. Freese, M-C. King  
Departments of Medicine and Genome Sciences, University of Washington, Seattle, WA
- P56-15 BREAST CANCER IN THREE DIMENSIONS: GENOMIC INSTABILITY AND HEREDITARY BREAST CANCER**  
S. Panigrahi,<sup>1</sup> L. R. Bégin,<sup>2</sup> K. Kotar,<sup>3</sup> B. Vermolen,<sup>4</sup> Y. Garini,<sup>4</sup> S. Mai,<sup>1</sup> W. D. Foulkes<sup>3</sup>  
<sup>1</sup>Manitoba Institute of Cell Biology, Cancer Care Manitoba, University of Manitoba, Winnipeg, MB, Canada; <sup>2</sup>Department of Pathology, Sacré Coeur Hospital, Montreal, QC, Canada; <sup>3</sup>Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, QC, Canada; <sup>4</sup>Department of Imaging Science and Technology, Delft University of Technology, Faculty of Applied Sciences, The Netherlands
- P56-16 TOPOISOMERASE III ACTS IN AN ALTERNATE PATHWAY TO RUVC**  
C. R. Lopez, S. A. Ray, R. W. Deibler, J. M. Pennington,
- P. J. Hastings, S. M. Rosenberg, E. L. Zechiedrich  
Interdepartmental Program in Cell and Molecular Biology, Department of Molecular Virology and Microbiology, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX
- P56-17 INDUCTION OF MUTAGENESIS AND GROSS CHROMOSOMAL REARRANGEMENTS DURING TELOMERE DEGRADATION**  
D. Meyer, A. Bailis  
Division of Molecular Biology, Beckman Research Institute, City of Hope National Medical Center Duarte, CA
- P56-18 CENTROSOME GENES INVOLVED IN CYTOKINESIS, GENETIC FIDELITY AND POTENTIALLY TUMORIGENESIS**  
S. Mirabelle  
University of Massachusetts Medical School, Worcester, MA
- P56-19 INVOLVEMENT OF HUMAN MOF IN ATM FUNCTION**  
A. Gupta,<sup>1</sup> G. G. Sharma,<sup>1</sup> C. S. H. Young,<sup>2</sup> M. Agarwal,<sup>1</sup> E. R. Smith,<sup>3,\*</sup> J. C. Lucchesi,<sup>3</sup> K. Khanna,<sup>4</sup> T. Ludwig,<sup>2</sup> T. K. Pandita<sup>1</sup>  
<sup>1</sup>Washington University School of Medicine, St. Louis, MO; <sup>2</sup>Columbia University, New York, NY; <sup>3</sup>Emory University, Atlanta, GA; <sup>4</sup>Queensland Institute of Medical Research, Brisbane, QLD, Australia; \*Present address: Rockefeller University, New York, NY
- P56-20 EXTENSIVE GENOME AND TELOMERE INSTABILITY IN THE RAD51D-DEFICIENT MOUSE**  
D. L. Pittman, P. G. Smiraldo, J. C. Osborn, A. M. Gruver  
Department of Physiology, Medical College of Ohio, Toledo, OH
- P56-21 TARGETING TELOMERASE USING RNAi AS A MEANS OF INDUCING BREAST TUMOR CELL SENSITIVITY**  
S. E. Holt, K. R.. Poynter  
Virginia Commonwealth University, Richmond, VA

**P56-22 TELOMERE-END PROCESSING: THE TERMINAL NUCLEOTIDES OF HUMAN CHROMOSOMES**

A. J. Sfeir, W. Chai, J. W. Shay, W. E. Wright

*Department of Cell Biology,  
University of Texas Southwestern  
Medical Center at Dallas, Dallas,  
TX***P56-23 CHARACTERIZATION OF HUMAN ORIGIN RECOGNITION COMPLEX ASSEMBLY**

K. Siddiqui, B. Stillman

*Cold Spring Harbor Laboratory,  
Cold Spring Harbor, NY***P56-24 EPIGENETIC AND GENETIC CHANGES CONTROL TUMORIGENIC PHENOTYPES AND OCCUR IN VIVO IN HUMAN MAMMARY EPITHELIAL**T. Tlsty, Y. Crawford, J. Zhang, C. Pickering, M. Gauthier  
*University of California at San Francisco, San Francisco, CA***P56-25 THE FUNCTION OF ATM IN MAMMARY TUMORIGENESIS**Y. A. Wang, S. Lu, K. C. Shen, Y. Wang, S. C. Brooks  
*Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI***P56-26 FUNCTIONAL SIGNIFICANCE OF MITOCHONDRIAL DNA MUTATIONS IN BREAST CANCER**L-J. C. Wong, D. Tan, R-K. Bai  
*Department of Oncology,  
Georgetown University Medical Center, Washington, DC***P56-27 THE POLYMORPHIC POLYGLUTAMINE OF AIB1 (AMPLIFIED IN BREAST CANCER) GENE AND ITS RELATIONSHIP TO BREAST CANCER**L-J. C. Wong V. Nazarov  
*Department of Oncology,  
Georgetown University Medical Center, Washington, DC***P56-28 MITOCHONDRIAL DNA MUTATIONS IN BREAST CANCER**L-J. C. Wong, D. Tan, R-K. Bai  
*Department of Oncology,  
Georgetown University Medical Center, Washington, DC***P57 Familial and Hereditary Carcinogenesis****7:00–9:00 p.m.***Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.***P57-1 GENETICS OF BREAST CANCER IN AFRICAN AMERICANS**C. Broome, M. Ashenafi, D. Beyene, J. Hill, Y. Kanaan, K. Utley, G. Dunston, L. Brody  
*Howard University College of Medicine, Washington, DC;  
NHGRI, Bethesda, MD***P57-2 ASSESSING DEVELOPMENTAL STAGE-SPECIFIC BREAST CANCER RISK IN MICE**G. K. Belka, C. P. Portocarrero, C. J. Sterner, P. Esmay, L. A. Chodosh  
*Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA***P57-3 AURORA-A AS A MODIFIER OF BREAST CANCER**F. J. Couch, L. Wang, J. E. Olson, S. Hebbring, R. A. Vierkant, Z. S. Fredericksen, V. S. Pankratz, S. N. Thibodeau, T. Rebbeck, K. Nathanson, J. Weitzel, C. Szabo, B. Weber, O. Sinilnikova, T. A. Seller  
*Mayo Clinic College of Medicine, Rochester, MN***P57-4 THE BARKER HYPOTHESIS AND THE EPIGENETICS OF BREAST CANCER**A. P. Feinberg, E. Steingrinnsson, H. Bjornsson  
*Johns Hopkins University School of Medicine, Baltimore, MD;  
UVS, Reykjavik, Iceland***P57-5 GENETIC MAPPING OF LOW-PENETRANCE MODIFIER LOCI AND IDENTIFICATION OF CANDIDATE GENES THAT INFLUENCE SUSCEPTIBILITY TO BREAST CANCER**A. C. Blackburn,<sup>1</sup> L. Z. Hill,<sup>2</sup> A. L. Roberts,<sup>2</sup> E. S. Dickinson,<sup>2</sup> J. Wang,<sup>3</sup> D. Aud,<sup>3</sup> J. Jung,<sup>3</sup> T. Nikolcheva,<sup>3</sup> J. Allard,<sup>3</sup> G. Peltz,<sup>3</sup> C. N. Otis,<sup>4</sup> Q. J. Cao,<sup>4</sup>R. St. J. Ricketts,<sup>4</sup> S. Marconi,<sup>4</sup>S. P. Naber,<sup>5</sup> D. J. Jerry<sup>2</sup><sup>1</sup>Australian National University, Canberra, ACT, Australia;<sup>2</sup>University of Massachusetts, Amherst, MA; <sup>3</sup>Roche Palo Alto, Palo Alto, CA; <sup>4</sup>Baystate Medical Center, Springfield, MA; <sup>5</sup>Tufts-New England Medical Center, Boston, MA**P57-6 GENOME WIDE ANALYSIS OF ALLELIC IMBALANCE IN TUMOR EPITHELIUM AND STROMA IN BRCA1- AND BRCA2-RELATED BREAST CANCERS**F. Weber,<sup>1,3</sup> L. Shen,<sup>4</sup> K. Sweet,<sup>1,2</sup> K. Cooper, C. D. Morrison,<sup>5</sup> T. Caldes,<sup>6</sup> C. Eng<sup>1,2,3</sup>  
*'Human Cancer Genetics Program, Comprehensive Cancer Center, <sup>2</sup>Division of Human Genetics, Department of Internal Medicine, <sup>3</sup>Department of Molecular Virology, Immunology and Medical Genetics, <sup>4</sup>Division of Epidemiology and Biometrics, <sup>5</sup>Department of Pathology, Ohio State University, Columbus, Ohio; <sup>6</sup>Laboratory of Molecular Oncology, San Carlos University Hospital, Madrid, Spain***P58 Apoptosis****7:00–9:00 p.m.***Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.***P58-1 SELECTION OF APTAMERS TO BAX**

S. Primorac, L. Billen, D. W. Andrews

*Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada***P58-2 ENDONUCLEASE G DEFICIENCY AND DECREASED SENSITIVITY TO DRUG-INDUCED APOPTOSIS IN INVASIVE HUMAN BREAST CANCER CELLS**A. G. Basnakian, E. O. Apostolov, X. Yin, S. N. Kolomeichuk, S. O. Abiri, A. B. Singh, S. V. Shah  
*University of Arkansas for Medical Sciences, Philander Smith College and Central*

- P58-3 A SMALL MOLECULE SMAC MIMIC SENSITIZES TRAIL- AND ETOPOSIDE-INDUCED APOPTOSIS IN BREAST CANCER CELLS**  
 K. M. Bockbrader, M. Tan, Y. Sun  
*Department of Radiation Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI*
- P58-4 HSPB2: A NOVEL INHIBITOR OF TRAIL-INDUCED APOPTOSIS IN BREAST CANCER**  
 S. Oshita, F. Chen, V. L. Cryns  
*Cell Death Regulation Laboratory, Feinberg School of Medicine, Northwestern University, Chicago, IL*
- P58-5 CASPASE PROTEOLYSIS OF HER-2 SUBVERTS ITS ANTI-APOPTOTIC FUNCTION BY RELEASING A PRO-APOPTOTIC CLEAVAGE PRODUCT**  
 A. Strohecker, F. Chen, V. L. Cryns  
*Cell Death Regulation Laboratory, Feinberg School of Medicine, Northwestern University, Chicago, IL*
- P58-6 THE MATRIX METALLOPROTEINASE, MMP-3/STROMELYSIN-1, MEDIATES RAPID MEMBRANE BLEBBING IN HUMAN BREAST EPITHELIAL CELLS**  
 J. E. Fata,<sup>1</sup> Z. Werb,<sup>2</sup>  
 M. J. Bissell<sup>1</sup>  
<sup>1</sup>*Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA;* <sup>2</sup>*Department of Anatomy, University of California at San Francisco, San Francisco, CA*
- P58-7 BETA-4-INTEGRIN: A MOLECULAR MARKER FOR APOPTOSIS-INDUCING THERAPEUTICS**  
 T-G. Jin, E. A. Lipscomb,  
 A. M. Mercurio, R. Khosravi-Far  
*Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA*
- P58-8 BREAST TUMOR CELLS UNDERGO APOPTOSIS UPON CONTACT WITH HUMAN MAMMARY ACINI**  
 R. M. Boudreau,<sup>1</sup> B. D. Engel,<sup>1</sup>  
 W. Gu,<sup>2</sup> T. Pellegrino,<sup>2</sup>  
 W. J. Parak,<sup>2</sup> A. P. Alivisatos,<sup>2</sup>  
 M. A. Le Gros,<sup>1</sup> C. A. Larabell<sup>1,3</sup>  
<sup>1</sup>*Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA;*  
<sup>2</sup>*Department of Chemistry, University of California at Berkeley, Berkeley, CA;*  
<sup>3</sup>*Department of Anatomy, University of California at San Francisco, San Francisco, CA*
- P58-9 ASSESSMENT OF INTEGRIN-LINKED KINASE MODULATION AS A TARGET IN HUMAN BREAST CANCER CELLS**  
 J. Y. Leung,<sup>1</sup> T. Blick,<sup>2</sup>  
 S. Dedhar,<sup>4</sup> M. Waltham,<sup>2</sup>  
 E. W. Thompson<sup>1,2,3</sup>  
<sup>1</sup>*University of Melbourne Department of Surgery,*  
<sup>2</sup>*St. Vincent's Institute and*  
<sup>3</sup>*Bernard O'Brien Institute for Microsurgery, St. Vincent's Hospital, Melbourne, Australia;*  
<sup>4</sup>*British Columbia Cancer Agency and Department of Biochemistry, University of British Columbia, Vancouver, BC, Canada*
- P58-10 NMR STRUCTURAL STUDIES OF MEMBRANE-BOUND BCL-2 FAMILY PROTEINS**  
 J. Choi, C. M. Franzin,  
 X-M. Gong, D. Zhai, J. C. Reed,  
 F. M. Marassi  
*The Burnham Institute, La Jolla, CA*
- P58-11 REGULATION OF TMS1/ASC BY DEATH RECEPTOR SIGNALING IN BREAST EPITHELIAL CELLS**  
 M. Parsons, P. Vertino  
*Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA*
- P58-12 IDENTIFICATION OF A POTENT APOPTOTIC PEPTIDE PRODUCED BY FIBROBLASTS; STUDIES TOWARDS THE DESIGN OF A NOVEL AGENT FOR BREAST CANCER THERAPY**  
 L. M. Petti  
*Albany Medical College, Albany, NY*
- P58-13 THE NF-KAPPAB REGULATED ANTIAPOPTOTIC KINASE SNARK IS A CRITICAL COMPONENT FOR CD95 INDUCED INVASION AND MOTILITY OF BREAST CANCER CELLS**  
 R. Schickel, P. Legembre,  
 B. C. Barnhart, M. E. Peter  
*Ben May Institute for Cancer Research, Committees on Immunology and Cancer Biology, University of Chicago, Chicago, IL*
- P58-14 MECHANISMS OF FADD-DN INDUCED APOPTOSIS IN NORMAL BREAST EPITHELIAL CELLS**  
 L. R. Thomas, A. Thorburn  
*Department of Cancer Biology, Wake Forest University Medical Center, Winston-Salem, NC*
- P58-15 A NOVEL CELL DEATH PATHWAY THAT IS SELECTIVELY INACTIVATED AT THE EARLIEST STAGES OF BREAST CANCER DEVELOPMENT**  
 J. S. Thorburn, A. Thorburn  
*Department of Pharmacology, University of Colorado Health Sciences Center, Aurora, CO*
- P58-16 SELECTION OF APTAMERS FOR CED-9/BCL-2 FAMILY CELL DEATH REGULATORS AND THEIR APPLICATION IN STUDY OF APOPTOSIS REGULATION AND DRUG DESIGN FOR BREAST CANCER**  
 C. Yang, N. Yang, X. Wang,  
 J. Parrish, Y. Shi, D. Xue  
*Department of MCD Biology, University of Colorado, Boulder, CO*

**P58-17 BCL-2 CONFORMATIONAL CHANGE AS AN INDICATOR FOR CHEMOTHERAPY RESPONSE**

B. Lin, X. Cao, X.-K. Zhang  
*The Burnham Institute, La Jolla, CA*

**P58-18 A NOVEL APOPTOTIC PATHWAY IN BREAST CANCER CELLS**

B. Lin, X. Cao, S. K. Kolluri, F. Lin, W. Liu, Y. Han, M. I. Dawson, J. C. Reed, X. Zhang  
*The Burnham Institute, La Jolla, CA*

**P59 Stromal-Epithelial Interactions**

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.

**P59-1 CHRONIC OVEREXPRESSION OF EPIMORPHIN/SYNTAXIN-2 IN THE MOUSE MAMMARY GLAND LEADS TO MAMMARY ADENOCARCINOMA AND LOBULAR HYPERPLASIA**

J. L. Bascom, J. E. Fata, M. J. Bissell  
*Life Science Division, Lawrence Berkeley National Laboratory, Berkeley, CA*

**P59-2 CELLULAR SENESCENCE, AGING AND BREAST CANCER**

J. Campisi  
*Lawrence Berkeley National Laboratory and Buck Institute for Age Research, Berkeley, CA*

**P59-3 INDUCING A HUMAN-LIKE SENESCENT PHENOTYPE IN MOUSE FIBROBLAST PROMOTES MAMMARY EPITHELIAL CELL PROLIFERATION AND TUMORIGENESIS: A MOUSE MODEL FOR HUMAN AGING**

J.-P. Coppe, S. Parrinello, A. Krtolica, C. K. Patil, J. Campisi  
*Lawrence Berkeley National Laboratory, Berkeley, CA*

**P59-4 VISUALIZATION OF EPITHELIAL-MESENCHYMAL TRANSITION IN MAMMARY CARCINOGENESIS**

A. De Bruin, A. J. Trimboli, K. Fukino, C. Eng, M. C. Ostrowski, G. Leone  
*Departments of Molecular Genetics and Molecular Virology, Immunology and Medical Genetics, and the Comprehensive Cancer Center, Ohio State University, Columbus, OH*

**P59-5 ANALYSIS OF BREAST CELL-LINEAGE RESPONSE DIFFERENCES TO TAXOL USING A NOVEL CO-CULTURE SYSTEM**

L. Gollahon, N. Collie  
*Department of Biological Sciences, Texas Tech University, Lubbock, TX*

**P59-6 RECRUITMENT OF CIRCULATING BONE MARROW-DERIVED CELLS IN BREAST CANCER PATHOGENESIS**

P. B. Gupta, C. Kuperwasser, A. Orimo, A. Karnoub, S. McAllister, R. A. Weinberg  
*Whitehead Institute for Biomedical Research/MIT, Cambridge, MA; Tufts University School of Medicine, Boston, MA*

**P59-7 THE DEVELOPMENTAL GENE GOOSECOID PROMOTES BREAST CANCER METASTASIS**

K. A. Hartwell, R. A. Weinberg  
*Whitehead Institute for Biomedical Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA*

**P59-8 ANALYSIS OF THE CONTRIBUTION OF STEM CELLS TO BREAST CANCER USING MICROCHIMERISM-BASED Y-CHROMOSOME STAINS AND HISTOPATHOLOGY**

H. Corbett, C. Restall, K. Alsop, M. J. Robbie, D. D. L. Bowtell, R. Anderson, I. Haviv  
*Peter MacCallum Cancer Centre, Melbourne, VIC, Australia*

**P59-9 THE TUMORIGENIC POTENTIAL OF RECONSTITUTED TISSUES WITH PREDEFINED CELLULAR HISTOLOGY: A MODEL FOR TUMOR INVASION**

C. Restall, K. Alsop, M. J. Robbie, Y. Khavar, E. Thompson, M. Leflour, R. Anderson, D. Bowtell, I. Haviv  
*Peter MacCallum Cancer Centre, Melbourne, VIC, Australia*

**P59-10 DECONSTRUCTING DIRECTIONAL CELL MOTILITY BY SUBSTRATUM MICROPATTERNING AND DYNAMIC IMAGING APPROACHES**

K. Kandere-Grzybowska,<sup>1</sup> C. Campbell,<sup>2</sup> Y. Komarova,<sup>1</sup> B. Grzybowski,<sup>2</sup> G. G. Borisy<sup>1</sup>

<sup>1</sup>Department of Cell and Molecular Biology, Northwestern University Medical School, Chicago, IL; <sup>2</sup>Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL

**P59-11 LOCAL AND SYSTEMIC EFFECTS DURING INVOLUTION PROMOTE BREAST TUMORIGENESIS**

P. Gupta,<sup>2</sup> S. McAllister,<sup>2</sup> T. Chavarria,<sup>2</sup> J. Weremowicz,<sup>1</sup> C. Kuperwasser<sup>1</sup>

<sup>1</sup>Tufts University School of Medicine, New England Medical Center, Molecular Oncology Research Institute, Boston, MA; <sup>2</sup>Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA

**P59-12 CARCINOGEN TREATMENT OF THE STROMA INDUCES MAMMARY CARCINOMA FORMATION**

M. V. Maffini, J. M. Calabro, C. Schaeberly, T. Shiota,<sup>1</sup> A. M. Soto, C. Sonnenschein  
*Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, MA;*  
*<sup>1</sup>Massachusetts General Hospital Cancer Center, Boston, MA*

**P59-13 IMPLICATIONS OF INCREASED TRANSGLUTAMINASE (TG2) EXPRESSION IN DRUG-RESISTANT AND METASTATIC BREAST CANCER**

K. Mehta, J. Herman

*University of Texas M.D.  
Anderson Cancer Center;  
Houston, TX***P59-14 NF-KAPPAB PROMOTES EPITHELIAL-TO-MESENCHYMAL TRANSITION OF IMMORTALIZED MAMMARY EPITHELIAL CELLS THROUGH ZEB-1 AND ZEB-2**

H. L. Chua, S. Badve,

H. Nakshatri

*Indiana University School of  
Medicine, Indianapolis, IN***P59-15 THE ROLE OF CXCL12 AND CXCL14 CHEMOKINES IN EPITHELIAL STROMAL CELL INTERACTIONS DURING BREAST TUMOR PROGRESSION**T. Imamura, M. Allinen, M. Hu,  
A. Richardson, S. Schnitt,  
K. Polyak*Dana-Farber Cancer Institute and  
Harvard Medical School, Boston,  
MA***P59-16 ALTERED BREAST CELL PHENOTYPE, SIGNALING, AND GENE EXPRESSION BY PHYSICAL PROPERTIES OF THE EXTRACELLULAR MATRIX**P. P. Provenzano, P. J. Keely  
*Department of Pharmacology,  
University of Wisconsin, Madison,  
WI***P59-17 STROMAL-EPITHELIAL INTERACTIONS, MAMMARY TISSUE ARCHITECTURE AND TUMOR ANGIOGENESIS**G. I. Rozenberg, J. N. Lakins,  
V. M. Weaver  
*Institute for Medicine and  
Engineering and Department  
of Pathology, University of  
Pennsylvania, Philadelphia, PA***P59-18 IDENTIFICATION OF MOLECULES INVOLVED IN THE REGULATORY EFFECT OF BREAST FIBROBLASTS ON EPITHELIAL CELL GROWTH**A. Sadlonova<sup>1</sup> V. Duncan,<sup>1</sup>G. Page,<sup>2</sup> A. R. Frost<sup>1</sup>*Departments of <sup>1</sup>Pathology and  
<sup>2</sup>Statistics, University of Alabama  
at Birmingham, Birmingham AL***P59-19 REMODELING OF THE MAMMARY TUMOR MICROENVIRONMENT FOLLOWING WEANING PROMOTES TUMOR CELL METASTASIS**P. Schedin, S. McDaniel,  
K. Rumer, S. Biroc, W. Porter,  
R. Metz*University of Colorado Health  
Sciences Center, Aurora,  
CO; AMC Cancer Research  
Center, Denver, CO; Berlex  
Pharmaceuticals, Richmond, CA;  
Texas A&M, College Station, TX***P59-20 DO PERTURBED EPITHELIAL-MESENCHYMAL INTERACTIONS DRIVE EARLY STAGES OF CARCINOGENESIS?**C. Sonnenschein, M. V. Maffini,  
J. M. Calabro, C. Wieloch,  
A. M. Soto*Tufts University School of**Medicine, Boston, MA***P59-21 ADHESION-LINKED PROTEIN TYROSINE PHOSPHATASES, MORPHOGENESIS, AND BREAST CANCER PROGRESSION**V. M. Weaver,<sup>1</sup> K. Johnson,<sup>2</sup>  
J. N. Lakins<sup>1</sup>*Departments of <sup>1</sup>Pathology and  
<sup>2</sup>Bioengineering, Institute for  
Medicine and Engineering,  
University of Pennsylvania,  
Philadelphia, PA***P59-22 SURVIVAL SIGNALING IN DORMANT BREAST CANCER CELLS**R. Wieder, M. Lindy, M. Boots,  
R. Korah  
*University of Medicine and  
Dentistry of New Jersey-New  
Jersey Medical School, Newark,  
NJ***P59-23 LAMININ REDUCES GROWTH REGULATION BY ESTROGEN IN ESTROGEN RECEPTOR POSITIVE, MCF-7 BREAST CANCER CELLS THROUGH ALTERED RAC SIGNALING**

J-W. Xie, S. Z. Haslam

*Department of Physiology,  
Michigan State University, East  
Lansing, MI***P59-24 THE NOVEL THREE DIMENSIONAL CELL CULTURE SYSTEM FOR HUMAN BREAST CANCER: CANCER INVASION AND CELL-CELL INTERACTION**Y. Zhao, A. Xiao, Q-X. A. Sang  
*Department of Chemistry and  
Biochemistry, Florida State  
University, Tallahassee, FL***P60 Invasion and Metastasis III****7:00–9:00 p.m.***Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.***P60-1 ESTROGEN-HOST INTERACTIONS: THE ROLE OF SEX STEROIDS IN METASTASIS**C. L. Banka, B. P. Eliceiri  
*La Jolla Institute for Molecular  
Medicine, San Diego, CA***P60-2 TIMP-1 INDUCES EPITHELIAL-MESENCHYMAL TRANSITION IN MCF-10A BREAST EPITHELIAL CELLS**R. Bigelow, J. Cardelli  
*Feist-Weiller Cancer Center,  
Louisiana State University Health  
Sciences Center, Shreveport, LA***P60-3 BREAST CANCER CELL MIGRATION IS STIMULATED BY BONE-DERIVED SECRETIONS INDEPENDENT OF OSTEONECTIN**D. A. Campo, C. V. Gay  
*Intercollege Graduate Degree  
in Physiology and Department  
of Biochemistry and Molecular  
Biology, Pennsylvania State  
University, University Park, PA*

**P60-4 DEVELOPMENT OF ANIMAL MODELS TO STUDY HOW TIMING OF SURGERY DURING THE MENSTRUAL CYCLE MAY AFFECT BREAST CANCER METASTASIS AND SURVIVAL**

A. F. Chambers, C. O. Postenka, S. M. Wilson, J. J. A. Marriott, S. A. Vantyghem  
*Department of Pathology, University of Western Ontario and London Regional Cancer Program, London, ON, Canada*

**P60-5 OSTEOBLASTIC PHENOTYPE AND METASTATIC POTENTIAL OF BREAST CANCER CELLS WITH ALTERED CONNEXIN EXPRESSION**

H. J. Donahue, Z. Zhou, Z. Li  
*Division of Musculoskeletal Sciences, Pennsylvania State University, Hershey, PA*

**P60-6 GENES THAT MARK AND MEDIATE BREAST CANCER METASTASIS TO LUNG**

G. P. Gupta, A. J. Minn, W. L. Gerald, J. Massagué  
*Cancer Biology and Genetics Program, and Department of Pathology, Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, NY*

**P60-7 SMALL GTP-BINDING PROTEIN RHO, NA-H EXCHANGER, AND FIBRONECTIN COOPERATE TO PROMOTE PULMONARY METASTASIS**

H-C. Cheng, B. U. Pauli  
*Department of Molecular Medicine, Cancer Biology Laboratories, Cornell University College of Veterinary Medicine, Ithaca, NY*

**P60-8 INVESTIGATION OF THE ROLE OF THE ARHGAP8 GENE IN REGULATION OF BREAST TUMOR CELL MIGRATION, INVASION, AND EPITHELIAL-TO-MESENCHYMAL TRANSITION**

C. N. Johnstone,<sup>1,2</sup>  
 M. J. Bowser,<sup>1,2</sup> L. M. Chang,<sup>1,2</sup>  
 A. K. Rustgi<sup>1,2,3</sup>  
<sup>1</sup>Gastroenterology Division, Department of Medicine,  
<sup>2</sup>Abramson Cancer Center and Family Cancer Research Institute,

*and <sup>3</sup>Department of Genetics, University of Pennsylvania, Philadelphia, PA*

**P60-9 A NOVEL RAT MODEL OF SPORADIC, BLOOD-BORNE, VISUALIZABLE MICRO-METASTASES OF MAMMARY CARCINOMA IN THE BRAIN**

L. A. Lampson, C. A. Tripp, D. S. Meredith  
*Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA*

**P60-10 PATHOGENESIS AND BLOOD-BRAIN BARRIER HETEROGENEITY OF BREAST CANCER BRAIN METASTASIS**

W. Lu, A. J. Schroit  
*Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P60-11 A MODEL OF COX-2 MEDIATED BONE METASTASIS IN HUMAN BREAST CANCER**

A. Lucci, B. Singh, J. A. Berry, A. Shoher  
*University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P60-12 CELL CLUSTERS OVERLYING FOCALLY DISRUPTED MYOEPITHELIAL CELL LAYERS CHANGE STATUS OF ESTROGEN RECEPTOR EXPRESSION DURING TUMOR INVASION**

Y. Man  
*Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC*

**P60-13 TRAFFICKING OF BREAST CANCER METASTATIC CELLS IN BONE**

R. J. Mercer,<sup>1</sup> P. A. Phadke,<sup>2</sup>  
 J. L. Jewell,<sup>1</sup> C. V. Gay,<sup>1,5</sup>  
 V. Gilman,<sup>1</sup> D. R. Welch,<sup>2,3,4,5</sup>  
 A. M. Mastro<sup>1,5</sup>  
<sup>1</sup>Department of Biochemistry and Molecular Biology, Penn State University, University Park, PA; <sup>2</sup>Department of Pathology, <sup>3</sup>Comprehensive Cancer Center, <sup>4</sup>Center for Metabolic Bone

Disease, <sup>5</sup>NFCR-Center for Metastasis Research, University of Alabama at Birmingham, Birmingham, AL

**P60-14 THE ROLE OF LYSYL OXIDASE LIKE PROTEIN-2 (LOXL2 OR LOR-1) IN THE PROGRESSION OF BREAST CANCER**

G. Akiri, Z. Vadas, V. Breckman, G. Neufeld  
*Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel*

**P60-15 USE OF A TISSUE ENGINEERING APPROACH TO STUDY THE PROGRESSION OF BREAST CANCER METASTASIS IN BONE**

D. Nie  
*Cancer Institute and Department of Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL*

**P60-16 ARE BREAST TUMOR STEM CELLS RESPONSIBLE FOR METASTASIS AND ANGIOGENESIS?**

Q. Pan, L. W. Bao, R. Cho, M. Clarke, S. D. Merajver  
*University of Michigan Comprehensive Cancer Center, Ann Arbor, MI*

**P60-17 COPPER DEFICIENCY INDUCED BY TETRAUTHIOMOLYBDATE SUPPRESSES TUMOR GROWTH AND ANGIOGENESIS**

Q. Pan, C. G. Kleer, K. L. van Golen, L. W. Bao, G. J. Brewer, S. D. Merajver  
*University of Michigan Comprehensive Cancer Center, Ann Arbor, MI*

**P60-18 THE ROLE OF LYSYL OXIDASE IN THE BREAST CANCER INVASIVE PHENOTYPE**

S. L. Payne, E. A. Seftor, N. V. Margaryan, A. R. Hess, R. R. Driskell, J. F. Engelhardt, M. J. C. Hendrix, D. A. Kirschmann  
*Children's Memorial Research Center, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine at Northwestern University,*

Chicago, IL; Department of Anatomy and Cell Biology at the University of Iowa, Iowa City, IA

**P60-19 FUNCTIONAL INTERACTIONS BETWEEN LAMININ-10, AVB3 INTEGRIN AND MATRIX METALLOPROTEINASE-9 IN BREAST CANCER METASTASIS TO BONE**

N. Pouliot,<sup>1</sup> A. Natoli,<sup>1</sup> B. Parker,<sup>1</sup> E. Sloan,<sup>1</sup> L. Zamurs,<sup>2</sup> E. Nice,<sup>2</sup> R. Anderson<sup>1</sup>

<sup>1</sup>Peter MacCallum Cancer Centre, VIC, Australia; <sup>2</sup>Ludwig Institute for Cancer Research, VIC, Australia

**P60-20 CYTOKINES AND GROWTH FACTORS INVOLVED IN HOST-TUMOR INTERACTIONS IN BREAST CANCER BONE METASTASIS**

J. E. Price, C. Miller, D. C. Lev, S. J. Kim, S. Yazici, I. J. Fidler  
University of Texas M.D. Anderson Cancer Center, Houston, TX

**P60-21 THE ROLE OF SDF-1ALPHA AND CXCR4 IN METASTATIC BREAST CANCER**

KM. W. Rahman, S. Banerjee, J. Liao, F. H. Sarkar  
Karmanos Cancer Institute, Wayne State University, Detroit, MI

**P60-22 NEW INSIGHTS FROM THE PMC42 MODEL OF EPITHELIAL-TO MESENCHYMAL TRANSITION (EMT) IN HUMAN BREAST CARCINOMA**

M. Waltham,<sup>1,3</sup> A. Arvanitis,<sup>1,3</sup> R. Wafai,<sup>1</sup> M. M. Bills,<sup>1</sup> T. Blick,<sup>3</sup> E. C. Walker,<sup>3</sup> J. T. Price,<sup>2,3</sup> S. Lebret,<sup>4</sup> L. Ackland,<sup>4</sup> D. F. Newgreen,<sup>5</sup> E. W. Thompson<sup>1,3</sup>  
*Departments of <sup>1</sup>Surgery and <sup>2</sup>Medicine, and <sup>3</sup>St. Vincent's Institute of Medical Research, University of Melbourne, Melbourne, Australia;*  
*<sup>4</sup>Department of Biochemistry, Deakin University, Melbourne, Australia; <sup>5</sup>Murdoch Children's Research Institute, Melbourne, Australia*

**P60-23 KINETICS OF THE EARLY STAGES OF BREAST CANCER METASTASIS TO BONE**

P. A. Phadke,<sup>1</sup> R. Mercer,<sup>6</sup> J. F. Harms,<sup>1</sup> J. C. Kappes,<sup>2</sup> Y. Jia,<sup>2</sup> A. R. Frost,<sup>1,3,5</sup> A. M. Mastro,<sup>5,6</sup> D. R. Welch<sup>1,3,4,5,6</sup>

*Departments of <sup>1</sup>Pathology and <sup>2</sup>Medicine-Hematology/Oncology, <sup>3</sup>Comprehensive Cancer Center, <sup>4</sup>Center for Metabolic Bone Disease, <sup>5</sup>NFCR-Center for Metastasis Research, University of Alabama at Birmingham, Birmingham, AL; <sup>6</sup>Department of Biochemistry and Molecular Biology, Penn State University, University Park, PA*

**P60-24 DISSECTING THE MECHANISM OF LOSS OF CLAUDIN-7, A TIGHT JUNCTION PROTEIN IMPORTANT IN EPITHELIAL-MESENCHYMAL TRANSITION, IN BREAST CANCERS**

X. Wu,<sup>1</sup> L. Han,<sup>1</sup> S. Kominsky,<sup>2</sup> S. Sukumar<sup>1</sup>

<sup>1</sup>Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,

<sup>2</sup>Departments of Orthopaedic Surgery and Oncology, Johns Hopkins School of Medicine, Baltimore, MD

Center, New Orleans, LA; Department of Biology, University of Louisville, Louisville KY; Comparative Medicine Clinical Research Center, Wake Forest University School of Medicine, Winston-Salem, NC; University of Toledo, Medical College of Ohio, Toledo, OH

**P61-2 PREVENTION OF MAMMARY TUMOR DEVELOPMENT BY INTERMITTENT CALORIC RESTRICTION. IMPORTANCE OF THE MANNER IN WHICH CALORIES ARE CONSUMED**

M. P. Cleary, J. P. Grande, N. J. Maihle  
Hormel Institute, Austin, MN; Mayo Clinic, Rochester, MN; Yale Medical School, New Haven, CT

**P61-3 ALTERATIONS IN PLATELET ACTIVATING FACTOR SYNTHESIS BY N-3 FATTY ACIDS**

L. W. Daniel, M. Kearns, L. Rogers, R. Wooten, J. Owen, J. T. O'Flaherty, R. L. Wykle  
Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC

**P61-4 EXCESSIVE WEIGHT GAIN DURING MIMICKED PREGNANCY INCREASES MAMMARY TUMORIGENESIS IN ZUCKER RATS**

S. de Assis, M. Wang, L. Hilakivi-Clarke  
Department of Oncology, Georgetown University Medical Center, Washington, DC

**P61-5 DIFFERENTIAL EFFECTS OF OMEGA-3 AND OMEGA-6 FATTY ACIDS ON GLOBAL GENE EXPRESSION IN MDA-MB-231 BREAST CANCER CELL LINE**

R. Hammamieh, N. Chakraborty, M. Barmada, R. Das, M. Jett  
Division of Pathology, Walter Reed Army Institute of Research, Silver Spring, MD

**P61-6 OMEGA 3 FATTY ACIDS TO RETARD BREAST CANCER PROGRESSION**

W. E. Hardman  
Pennington Biomedical Research Center, Baton Rouge, LA

**P61 Nutrition and Neutraceuticals**

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.

**P61-1 GLYCEOLLINS (I-III), NOVEL ANTI-ESTROGENIC PHYTOCHEMICALS ISOLATED FROM SOY**

V. A. Salvo, S. M. Boué, K. Zimmerman, J. P. Fonseca, S. Elliott, C. M. Dugan, Y. Zhu, C. Corbitt, T. J. Curiel, B. Y. Shih, C. Carter-Wientjes, C. Wood, P. Erhardt, J. A. McLachlan, T. E. Cleveland, M. E. Burow  
*Departments of Medicine, Section of Hematology and Medical Oncology, Surgery, Pharmacology, Tulane Cancer Center, Center for Bioenvironmental Research, Tulane University Health Science*

**P61-7 CONSUMPTION OF LONG-CHAIN OMEGA 3 FATTY ACIDS TO PREVENT BREAST CANCER**

W. E. Hardman

*Pennington Biomedical Research Center, Baton Rouge, LA*

**P61-8 DIETARY GENISTEIN NEGATES THE INHIBITORY EFFECT OF LETROZOLE ON THE GROWTH OF AROMATASE-OVEREXPRESSING ESTROGEN-DEPENDENT HUMAN BREAST CANCER (MCF-7CA) CELLS IMPLANTED IN OVARIECTOMIZED ATHYMIC MICE**

W. Helperich, Y. H. Ju

*University of Illinois, Urbana, IL*

**P61-9 CORRELATES OF FULL FIELD DIGITAL MAMMOGRAPHIC DENSITY IN PREMENOPAUSAL WOMEN**

L-J. W. Lu, T. Khamapirad, K. E. Anderson, D. G. Brunder, T. K. Nishino, J. J. Grady, M. Nagamani

*University of Texas Medical Branch, Galveston, TX*

**P61-10 ACRYLAMIDE INTAKE AND BREAST CANCER RISK IN A LARGE, PROSPECTIVE STUDY AMONG SWEDISH WOMEN**

L. A. Mucci,<sup>1,2</sup> S. Sandin,<sup>3</sup> K. Bälter,<sup>3</sup> C. Magnusson,<sup>3</sup> E. Weiderpass,<sup>3,4</sup> H-O. Adami<sup>2,3</sup>

<sup>1</sup>Harvard Medical School, Boston, MA; <sup>2</sup>Harvard School of Public Health, Boston, MA; <sup>3</sup>Karolinska Institutet, Stockholm, Sweden; <sup>4</sup>Finnish Cancer Registry, Helsinki, Finland

**P61-11 EFFECTS OF 1 ALPHA HYDROXYVITAMIN D5 ON METASTATIC 4T1 MURINE MAMMARY CANCER CELLS**

N. Patel, S. Gandhi, G. Murillo, R. G. Mehta

*Department of Surgical Oncology, College of Medicine, University of Illinois at Chicago, Chicago, IL*

**P61-12 EFFECTS OF DIETARY FLAXSEED ON SERUM LEVELS OF ESTROGENS AND ANDROGENS IN POSTMENOPAUSAL WOMEN**

S. R. Sturgeon,<sup>1</sup> J. L. Heersink,<sup>1</sup> E. R. Berone-Johnson,<sup>1</sup>

F. Stanczyck,<sup>2</sup> S. Sabelawski,<sup>1</sup>

M. Kurzer,<sup>3</sup> S. Volpe,<sup>4</sup>

C. Bigelow<sup>1</sup>

<sup>1</sup>University of Massachusetts Amherst, Amherst, MA;

<sup>2</sup>University of Southern California Keck School of Medicine, Los Angeles, CA; <sup>3</sup>University of Pennsylvania, Philadelphia, PA; <sup>4</sup>University of Minnesota, Minneapolis, MN

**P62-4 R-ETODOLAC DECREASES**

**BETA-CATENIN, CYCLIN D1 AND KI-67 EXPRESSION, IN VIVO, IN MAMMARY TUMORS FROM MMTV-WNT1 TRANSGENIC MICE**

D. A. Carson, M. Corr, D. Lu,

R. B. Schwab

*Rebecca and John Moores*

*University of California San Diego Cancer Center, University of California at San Diego, La Jolla, CA*

**P62-5 SERMS AND THEIR EFFECT ON IN VITRO STUDIES OF BREAST CANCER CELLS**

D. M. Czyz, R.G. Mehta,

A. I. Constantinou

*Department of Surgical Oncology, College of Medicine, University of Illinois at Chicago, Chicago, IL*

**P62-6 OVARIAN HORMONES AND PARITY ACCENTUATE AN APOPTOTIC RESPONSE DUE TO IONIZING RADIATION IN THE MAMMARY EPITHELIUM OF BALB/C MICE**

K. A. Dunphy, S. Lawrence, D. J. Jerry

*Departments of Molecular and Cellular Biology and Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA*

**P62-7 Diallyl sulfide inhibits DES-induced DNA adduct formation and modulates both phase I and phase II metabolizing genes in breast of female ACI rats**

M. Green, C. Wilson, O. Newell, A. Aboyade-Cole, R. Thomas

*Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, FL*

**P62-8 EXPLOITING FOR BREAST CANCER CONTROL A PROPOSED UNIFIED MECHANISM FOR REDUCTION OF HUMAN BREAST CANCER RISK BY THE HORMONES OF PREGNANCY**

H. I. Jacobson, T. T. Andersen, J. A. Bennett, N. A. Lemanski

*Albany Medical College, Albany, NY*

**P61-13 SOY FOR THE PREVENTION OF BREAST CANCER – A RANDOMIZED TRIAL**

J. A. Tice, N. Guthrie,

J. Shepherd, K. Kerlikowske,

L. Esserman

*University of California at San Francisco, San Francisco, CA*

**P62 Risk and Prevention**

**7:00–9:00 p.m.**

*Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.*

**P62-1 EMPOWERING FACTORS FOR REGULAR MAMMOGRAPHY SCREENING IN UNDER-SERVED POPULATIONS**

N. U. Ahmed, J. G. Fort,

J. D. Elzey, Y. Belay

*Department of Epidemiology and Biostatistics, Stempel School of Public Health, Florida International University, Miami, FL; Departments of Internal Medicine and Medical Education, Meharry Medical College, Nashville, TN*

**P62-2 A SAFE AND EFFECTIVE NOVEL DRUG FOR THE PREVENTION AND TREATMENT OF BREAST CANCER**

T. T. Anderson, J. A. Bennett, H. I. Jacobson, L. Defreest,

L. Joseph, N. Lemanski,

S. Bacon, N. Gildener-Leapman,

J. Georgekutty

*Albany Medical College, Albany, NY*

**P62-3 BREAST CANCER RESEARCH UNDERGRADUATE SUMMER TRAINING PROGRAM**

T. T. Anderson, J. M. Cornwell

*Albany Medical College, Albany, NY*

**P62-9 FOUR YEAR FOLLOW-UP OF OUTCOMES FOLLOWING RISK-REDUCING SALPINGO-OOPHORECTOMY IN BRCA MUTATION CARRIERS**

N. D. Kauff, Y. Kemerl,  
M. E. Robson, D. J. Goldfrank,  
E. Wadsworth, T. Diiorio,  
J. Boyd, C. A. Hudis,  
R. R. Barakat, K. Offit  
*Memorial Sloan-Kettering Cancer Center, New York, NY*

**P62-10 BREAST CANCER CHEMOPREVENTION BY GRAPE SEED EXTRACT IN RATS AND ITS DEPENDENCE ON DIET COMPOSITION**

H. Kim, P. Hall, M. Smith,  
M. Kirk, J. K. Prasain, S. Barnes,  
C. Grubbs  
*Departments of Pharmacology and Toxicology, and Surgery, University of Alabama at Birmingham, Birmingham, AL*

**P62-11 MODULATION OF BIOMARKERS OF GROWTH AND DIFFERENTIATION IN BREAST CANCER BY SOY ISOFLAVONES**

O. Basturk,<sup>1</sup> V. Adsay,<sup>1</sup>  
M. Banerjee,<sup>2</sup> L. Newman,<sup>2</sup> D. Bouwman,<sup>1</sup> D. Doerge,<sup>3</sup>  
Z. Djuric,<sup>2</sup> R. Parchment,<sup>1</sup>  
A. Majumdar,<sup>1</sup> F. Miller,<sup>1</sup>  
F. Sarkar,<sup>1</sup> O. Kucuk<sup>1</sup>  
<sup>1</sup>Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI; <sup>2</sup>University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; <sup>3</sup>National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR

**P62-12 ASSESSING THE LOCAL ALCOHOL ENVIRONMENT. CONDUCTING A CENSUS OF ADVERTISING SPACES IN CENTRAL HARLEM, NEW YORK CITY**

N. O. A. Kwate  
*Mailman School of Public Health, Columbia University, New York, NY*

**P62-13 GROWTH INHIBITION OF BREAST EPITHELIAL CELLS BY CELECOXIB IS ASSOCIATED WITH UPREGULATION OF IGFBP-3 EXPRESSION**

R. J. Levitt,<sup>1</sup> J. Buckley,<sup>4</sup>  
M. J. Blouin,<sup>2</sup> B. Schaub,<sup>3</sup>  
T. J. Triche,<sup>3</sup> M. Pollak<sup>2</sup>  
<sup>1</sup>Lady Davis Institute for Medical Research, Department of Medicine, Division of Experimental Medicine and <sup>2</sup>Department of Oncology, McGill University, Montreal, QC, Canada; <sup>3</sup>Department of Pathology and Laboratory Medicine, Childrens Hospital Los Angeles, and <sup>4</sup>Department of Preventive Medicine, Norris Cancer Center, University of Southern California, Los Angeles, CA

**P62-14 A HAPLOTYPE BLOCK MAP OF THE HUMAN HOMOLOGOUS REGION TO A RAT QTL**

S. E. Nelson, D. J. Samuelson,  
A. Trentham-Dietz, M. N. Gould  
*University of Wisconsin, Madison, Madison, WI*

**P62-15 MYGENERATIONS. USAGE OF A NEW FAMILY HISTORY AND RISK ASSESSMENT TOOL**

S. M. O'Neill, W. S. Rubinstein  
*Evanston Northwestern Healthcare, Evanston, IL*

**P62-16 USING THE INTERNET TO COLLABORATE WITH CONSUMERS IN REDEFINING A PSYCHOSOCIAL AGENDA FOR FAMILIES WITH HEREDITARY BREAST CANCER**

S. C. Palmer, P. J. Shapiro,  
S. Friedman, J. C. Coyne  
*Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL*

**P62-17 ATM MUTATIONS AND THE DEVELOPMENT OF SEVERE RADIATION-INDUCED MORBIDITY FOLLOWING RADIOTHERAPY FOR BREAST CANCER**

B. S. Rosenstein,<sup>1,2,3,4</sup>  
D. A. Atencio,<sup>1</sup> J. A. Cesaretti,<sup>1</sup>  
S. Green,<sup>1</sup> S. C. Formenti,<sup>4</sup>

J. Bernstein,<sup>2</sup> R. G. Stock,<sup>1</sup>  
B. Haffty<sup>5</sup>

*Departments of <sup>1</sup>Radiation Oncology, <sup>2</sup>Community and Preventive Medicine, and <sup>3</sup>Dermatology, Mount Sinai School of Medicine, New York, NY; <sup>4</sup>Department of Radiation Oncology, NYU School of Medicine, New York, NY; <sup>5</sup>Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT*

**P62-18 SCREENING FOR ATM MUTATIONS IN AN AFRICAN-AMERICAN POPULATION TO IDENTIFY A PREDICTOR OF BREAST CANCER SUSCEPTIBILITY**

B. S. Rosenstein,<sup>1,2,3,5</sup>  
D. A. Atencio,<sup>1</sup> J. A. Cesaretti,<sup>1</sup>  
S. Green, S. C. Formenti,<sup>5</sup>  
J. Bernstein,<sup>2</sup> R. G. Stock,<sup>1</sup>  
B. Haffty,<sup>6</sup> S. Feig,<sup>4</sup> G. Hermann<sup>4</sup>  
*Departments of <sup>1</sup>Radiation Oncology, <sup>2</sup>Community and Preventive Medicine, <sup>3</sup>Dermatology and <sup>4</sup>Radiology, Mount Sinai School of Medicine, New York, NY; <sup>5</sup>Department of Radiation Oncology, NYU School of Medicine, New York, NY; <sup>6</sup>Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT*

**P62-19 THE PENN-FORCE HELPLINE: PROVIDING INDIVIDUALIZED PEER SUPPORT TO WOMEN CONCERNED ABOUT THEIR RISK OF HEREDITARY BREAST AND OVARIAN CANCERS**

P. J. Shapiro, S. Friedman,  
M. Kodranksy, J. C. Coyne  
*Abramson Cancer Center of the University of Pennsylvania, Facing Our Risk of Cancer Empowered, Philadelphia, PA*

**P62-20 EXONIC SPLICING ENHANCER MOTIFS AS PREDICTIVE TOOLS FOR CHARACTERIZING MUTATIONS THAT CAUSE ABERRANT SPLICING IN BREAST CANCER**

P. J. Smith, J. Wang, M. Q. Zhang,  
A. R. Krainer  
*Cold Spring Harbor Laboratory, Cold Spring Harbor, NY*

**P62-21 THE CHEMOPREVENTIVE EFFECTS OF CELECOXIB, TAMOXIFEN AND BEXAROTENE IN THE OVARIAN HORMONE DEPENDENT AND INDEPENDENT NEU-INDUCED RAT BREAST CANCER MODELS**  
 S. Woditschka, Y. Zheng,  
 J. Waller, L. Lubet, M. N. Gould  
*McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI; Chemoprevention Branch, NCI, Bethesda, MD*

**P62-22: EFFECTS OF CALORIC RESTRICTION COMBINED WITH MODERATE AEROBIC EXERCISE ON CIRCULATING ESTROGENS AND IGF-1 IN PREMENOPAUSAL WOMEN**  
 N. Williams, A. Albert, T. Parrott, H. Leidy, B. Frye, M. Snook, K. Duke, E. Richard, J. Gardner  
*Department of Kinesiology and Noll Laboratory, Penn State University, University Park, PA*

### **P63 Magnetic Resonance Imaging**

**7:00–9:00 p.m.**

*Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
 Even-numbered – 8:00–9:00 p.m.*

**P63-1 PROTON MR SPECTROSCOPY USING CHOLINE SIGNAL AS MALIGNANCY MARKER IMPROVES POSITIVE PREDICTIVE VALUE COMPARED TO CONVENTIONAL MRI IN DIAGNOSIS OF BREAST CANCER: A PRELIMINARY STUDY**  
 L. Bartella, E. A. Morris, D. D. Dershaw, L. Liberman, S. Thakkur, W. Huang, H. Hricak  
*Memorial Sloan-Kettering Cancer Center, New York, NY*

**P63-2 ITERATED SENSITIVITY ALGORITHM FOR MAGNETIC RESONANCE ELECTRICAL IMPEDANCE TOMOGRAPHY**  
 O. Birgul, L. T. Muftuler, M. J. Hamamura, O. Nalcioglu  
*Tu and Yuen Center for Functional Onco-Imaging, University of California at Irvine, Irvine, CA*

**P63-3 MOLECULAR AND FUNCTIONAL MRI OF BREAST CANCER**  
 H. Degani, D. Milshtein,<sup>1</sup> E. Furman-Haran, D. Seger, M. Dadiani, Y. Hassid, R. Margalit, E. Eyal, T. Kreizman, R. Hirsch, Y. Ben-David,<sup>1</sup> S. Mukhopadhyay<sup>1</sup>  
*Departments of Biological Regulation and <sup>1</sup>Organic Chemistry, Weizmann Institute of Science, Rehovot, Israel*

**P63-4 USING BOLD AND GD-DTPA CONTRAST ENHANCED MRI FOR EARLY EVALUATION OF BREAST CANCER CHEMOTHERAPY**  
 L. Jian, R. McColl, P. Weatherall, D. Trupathy,<sup>1</sup> R. P. Mason  
*Department of Radiology, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX*

**P63-5 MRI BASED IMPEDANCE IMAGING TO DIAGNOSE BREAST TUMORS**  
 L. T. Muftuler, M. J. Hamamura, O. Birgul, O. Nalcioglu  
*Tu & Yuen Center for Functional Onco-Imaging, University of California at Irvine, Irvine, CA*

**P63-6 APPLICATION OF DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE (MR) IMAGING IN COMBINATION WITH LACTATE-SPECIFIC MR SPECTROSCOPY IN THE ASSESSMENT OF BREAST TUMOR ANGIOGENESIS**  
 M. Muruganandham,<sup>1</sup> M. Lupu,<sup>1</sup> J. P. Dyke,<sup>2</sup> J. A. Koutcher<sup>1</sup>  
*<sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, NY; <sup>2</sup>Weill Cornell Medical College, Cornell University, New York, NY*

**P63-7 CLINICALLY PRACTICAL MAGNETIC RESONANCE IMAGING/SPECTROSCOPY PROTOCOL FOR IMPROVED SPECIFICITY IN BREAST CANCER DIAGNOSIS**  
 L. Tudorica, P. Fisher, K. Dulaimy, W. Huang  
*Department of Radiology, State University of New York, Stony Brook, NY*

**P63-8 LINEAR POLYMERIC CONTRAST AGENTS FOR DISTINGUISHING METASTATIC FROM NON-METASTATIC TUMORS**  
 E. E. Uzgiris, B. Grimmond, L. Schoonmaker  
*GE Global Research Center, Niskayuna, NY*

**P63-9 SIMULTANEOUS MONITORING OF TUMOR OXYGENATION BY NEAR INFRARED SPECTROSCOPY AND 19F MAGNETIC RESONANCE IMAGING**  
 M. Xia,<sup>1</sup> V. Kodibagkar,<sup>2</sup> R. Mason,<sup>1,2</sup> B. Levine,<sup>3</sup> H. Liu<sup>1</sup>  
*<sup>1</sup>Joint Biomedical Engineering Graduate Program, University of Texas at Arlington/University of Texas Southwestern Medical Center, Arlington, TX; <sup>2</sup>Cancer Imaging Program, Department of Radiology, and <sup>3</sup>Institute for Exercise and Environment Medicine, University of Texas Southwestern Medical Center, Dallas, TX*

### **P64 Novel Imaging**

**7:00–9:00 p.m.**

*Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
 Even-numbered – 8:00–9:00 p.m.*

**P64-1 SPECTRAL AND TEMPORAL NEAR-INFRARED IMAGING OF EX VIVO NORMAL AND CANCEROUS HUMAN BREAST TISSUES AND MODEL MEDIA**  
 M. Alrubaiee, S. K. Gayen, R. R. Alfano  
*Institute for Ultrafast Spectroscopy and Lasers, Physics Department, City College of New York, New York, NY*

**P64-2 OPTICAL TOMOGRAPHY USING INDEPENDENT COMPONENT ANALYSIS FOR BREAST CANCER DETECTION**  
 M. Alrubaiee, M. Xu, S. K. Gayen, R. R. Alfano  
*Institute for Ultrafast Spectroscopy and Lasers, Physics Department, City College of New York, New York, NY*

- P64-3 A DUAL MODALITY OPTICAL/SPECT IMAGING SYSTEM FOR MURINE MODELS OF HUMAN BREAST CANCER**  
 P. P. Antich, M. A. Lewis, E. Richer, N. Slavine, T. Soesbe, X. Li, A. Constantinescu, A. Harper, R. P. Mason  
*University of Texas Southwestern Medical Center at Dallas, Dallas, TX*
- P64-4 ACOUSTICALLY MODULATED X-RAY PHASE CONTRAST IMAGING**  
 C. J. Bailart,<sup>1</sup> T. J. Hamilton,<sup>1</sup> S. Gehring,<sup>2</sup> J. R. Wands,<sup>2</sup> C. Rose-Petrucci,<sup>1</sup> G. J. Diebold<sup>1</sup>  
<sup>1</sup>*Department of Chemistry, <sup>2</sup>Bio Med Medicine, Brown University, Providence, RI*
- P64-5 NON-INVASIVE IMAGING OF BREAST CANCER TISSUE UTILIZING METABOLICALLY INCORPORATED UNNATURAL SUGARS**  
 C. R. Bertozzi  
*Departments of Chemistry and Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA*
- P64-6 MOLECULARLY TARGETED AGENTS FOR IMPROVED BREAST CANCER DETECTION**  
 D. J. Bornhop,<sup>1,2</sup> S. K. Wyatt,<sup>3</sup> L. E. Samuelson,<sup>1</sup> H. C. Manning,<sup>1,2</sup> M. Bai,<sup>1</sup> B. M. Anderson,<sup>1</sup> S. M. Smith,<sup>1</sup> R. C. Thompson,<sup>4</sup> N. S. Ningaraj,<sup>4</sup> J. O. McIntyre<sup>5</sup>  
<sup>1</sup>*Departments of Chemistry; <sup>2</sup>Vanderbilt University Institute of Imaging Sciences (VUIIS); <sup>3</sup>Biomedical Engineering, <sup>4</sup>Section of Neurosurgical Oncology, <sup>5</sup>Cancer Biology, Vanderbilt University, Nashville, TN*
- P64-7 A NEW APPROACH TO EARLY DETECTION FOR WOMEN'S MEDICINE**  
 B. Chance, B. Onaral,<sup>1</sup> K. Pour, M. Herr<sup>1</sup>  
*Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA; <sup>1</sup>Drexel University, Philadelphia, PA*
- P64-8 NON-INVASIVE DUAL MODALITY IMAGING FOR THE EARLY DETECTION AND MONITORING OF BREAST CANCER DURING THERAPY**  
 T. R. Chaudhuri, K. R. Zinn  
*University of Alabama at Birmingham, Birmingham, AL*
- P64-9 IMAGING WITH THE ULTRASONIC VIBRATION POTENTIAL**  
 G. J. Diebold,<sup>1</sup> A. Beveridge,<sup>1</sup> S. Wang,<sup>1</sup> V. Gusev<sup>2</sup>  
<sup>1</sup>*Department of Chemistry, Brown University, Providence, RI; <sup>2</sup>Université du Maine, Cedex, France*
- P64-10 OPTICAL MAMMOGRAPHY FOR TUMOR DETECTION AND OXIMETRY**  
 S. Fantini, E. L. Heffer, V. E. Pera, N. Liu, A. Sassaroli  
*Department of Biomedical Engineering, Tufts University, Medford, MA*
- P64-11 BREAST CANCER DETECTION USING OPTICAL VASCULAR FUNCTION**  
 G. W. Faris, K. T. Kotz, K. Amin, J. Orduna  
*Molecular Physics Laboratory, SRI International, Menlo Park, CA*
- P64-12 AUTOMATED STEREO SPOT MAMMOGRAPHY FOR IMPROVED IMAGING OF DENSE BREASTS**  
 M. M. Goodsitt, H.-P. Chan, J. T. Lydick, M. A. Helvie  
*Department of Radiology, University of Michigan, Ann Arbor, MI*
- P64-13 3D BIOLUMINESCENCE TOMOGRAPHY FOR ANIMAL IMAGING**  
 M. B. Unlu, O. Birgul, G. Gulsen  
*Tu & Yuen Center for Functional Onco-Imaging, University of California at Irvine, Irvine, CA*
- P64-14 COMPUTATIONAL AND EXPERIMENTAL FEASIBILITY STUDIES OF ULTRAWIDEBAND MICROWAVE BREAST CANCER DETECTION AND TREATMENT**  
 S. C. Hagness, B. D. van Veen, D. W. van der Weide, F. Kelcz  
*Department of Electrical and Computer Engineering and Department of Radiology, University of Wisconsin-Madison, Madison, WI*
- P64-15 NANOSHELLS FOR INTEGRATED CANCER IMAGING AND THERAPY**  
 C. Loo, A. Lowery, N. J. Halas, J. L. West, R. Drezek  
*Departments of Electrical and Computer Engineering, Chemistry, Bioengineering, and Chemical Engineering, Rice University, Houston, TX*
- P64-16 MONITORING THE RESPONSE OF CHEMOTHERAPY ON BREAST CANCER TUMORS BY PHOTON MIGRATION SPECTROSCOPY**  
 D. Hsiang, A. Cerussi, N. Shah, T. Du, R. Mehta, C. Baick, B. Tromberg, J. Butler  
*University of California Irvine Medical Center, Orange, CA; Beckman Laser Institute, Irvine, CA; Chao Family Comprehensive Cancer Center, Orange, CA*
- P64-17 SIMULTANEOUS RECONSTRUCTION OF ABSORPTION AND SCATTERING MAPS WITH ULTRASOUND LOCALIZATION: REFLECTION GEOMETRY**  
 M. Huang, Q. Zhu  
*University of Connecticut, Storrs, CT*
- P64-18 REFINING FUNCTIONAL OPTICAL IMAGING OF THE BREAST WITH QUANTUM DOTS**  
 J. S. Jaffe  
*Marine Physical Laboratory, Scripps Institution of Oceanography, La Jolla, CA*
- P64-19 OPTICAL BIOPSY FOR REAL-TIME DIAGNOSIS, STAGING AND PROGNOSTICATION IN BREAST CANCER**  
 M. Keshtgar,<sup>1</sup> D. Chicken,<sup>1,2</sup> A. Lee,<sup>1,2</sup> G. Briggs,<sup>1,2</sup> K. Johnson,<sup>2</sup> B. Clark,<sup>2</sup>

D. Pickard,<sup>2</sup> M. Falzon,<sup>3</sup> I. Bigio,<sup>4</sup>  
S. Bown<sup>2</sup>

<sup>1</sup>Department of Surgery, <sup>2</sup>National Medical Laser Centre, and

<sup>3</sup>Department of Histopathology, University College at London, London, United Kingdom;

<sup>4</sup>Department of Biomedical Engineering, Boston University, Boston, MA

### P64-20 APPLICATION OF NEAR INFRARED SPECTROSCOPY TO DETECT EARLY EFFECTS OF CANCER THERAPY

J. G. Kim,<sup>1</sup> D. Zhao,<sup>2</sup>

R. P. Mason,<sup>1,2</sup> H. Liu<sup>1</sup>

<sup>1</sup>Joint Graduate Program of Biomedical Engineering, University of Texas at Arlington and University of Texas Southwestern Medical Center at Dallas, Arlington, TX; <sup>2</sup>Advanced Radiological Science Program, Department of Radiology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX

### P64-21 NOVEL IMAGE ANALYSIS TO LINK SUB-NUCLEAR DISTRIBUTION OF PROTEINS WITH CELL PHENOTYPE IN BREAST NEOPLASIA

D. W. Knowles,<sup>1</sup> F. Long,<sup>1</sup>

D. Sudar,<sup>1</sup> C. Bator-Kelly,<sup>2</sup>

M. J. Bissell,<sup>1</sup> S. A. Lelievre<sup>2</sup>

<sup>1</sup>Biophysics Department, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA; <sup>2</sup>Department of Basic Medical Sciences, Purdue University, West Lafayette, IN

### P64-22 TOWARDS THE EARLY DETECTION OF BREAST CANCER IN YOUNG WOMEN

A. A. Oberai, P. E. Barbone,

N. H. Gokhale, R. Leiderman

Department of Aerospace and Mechanical Engineering, Boston University, Boston, MA

### P64-23 LOIS – NOVEL IMAGING MODALITY FOR EARLY DIAGNOSIS OF BREAST CANCER IN SITU

A. A. Oraevsky,<sup>1</sup> P. M. Henrichs,<sup>1</sup>

K. Mehta,<sup>1</sup> T. Miller,<sup>1</sup> A. Yee,<sup>1</sup>

J. A. Copland,<sup>2</sup> N. Kotov,<sup>3</sup>

V. Popov, M. Eghtedari,<sup>4</sup>  
M. Motamed, <sup>4</sup>T. Khamapirad<sup>4</sup>

<sup>1</sup>Fairway Medical Technologies, Houston, TX; <sup>2</sup>Mayo Clinic, Rochester, MN; <sup>3</sup>University of Michigan, Ann Arbor, MI;

<sup>4</sup>University of Texas Medical Branch, Galveston, TX

### P64-24 MEDICAL HYPERSPECTRAL IMAGING TO FACILITATE RESIDUAL TUMOR IDENTIFICATION DURING RESECTIVE SURGERY

J. E. Freeman,<sup>1</sup> S. Yang,<sup>2</sup>

S. V. Panasyuk,<sup>1</sup> A. E. Rogers<sup>2</sup>

<sup>1</sup>HyperMed, Inc, Weston, MA; <sup>2</sup>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA

### P64-25 APPLICATIONS OF CARBON NANOTUBES FOR BREAST CANCER RESEARCH

B. Panchapakesan, K. Teker  
Department of Electrical and Computer Engineering, University of Delaware, Newark, DE

### P64-26 IN VIVO IMAGING AGENT FOR HISTONE DEACETYLASE

W. P. Tong, S. M. Ronen,

S. Soghomonyan, A. Volgin,

A. Shavrin, J. G. Gelovani

Experimental Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston, TX

### P64-27 HIGH-RESOLUTION BREAST TISSUE MAPPING BY ADAPTIVE PULSE-ECHO ULTRASOUND

R. L. Tutwiler, J. P. Stitt

Applied Research Laboratory, Pennsylvania State University, State College, PA

### P64-28 ADAPTIVE BEAMFORMING IN BREAST ULTRASOUND: INITIAL RESULTS

F. Viola, W. F. Walker

Department of Biomedical Engineering, University of Virginia, Charlottesville, VA

### P64-29 MR ELASTOGRAPHY: BIOLOGICAL MECHANISMS PRODUCING INCREASED STIFFNESS IN BREAST CANCER

J. B. Weaver,<sup>1</sup> P. R. Perrine,<sup>2</sup>

J. A. Bergeron,<sup>1</sup> F. E. Kennedy,<sup>2</sup>

H. Wang,<sup>2</sup> M. M. Doyley,<sup>1</sup>

P. J. Hoopes,<sup>1</sup> K. D. Paulsen<sup>2</sup>

<sup>1</sup>Dartmouth-Hitchcock Medical Center, Lebanon, NH; <sup>2</sup>Thayer School of Engineering, Hanover, NH

### P64-30 IN-VIVO FLUORESCENCE MOLECULAR TOMOGRAPHY OF MAMMARY ADENOCARCINOMAS IN TRANSGENIC MICE BEARING AN ACTIVATED C-NEU ONCOGENE

S. D. Windsor, H. A. Shih,  
V. Ntziachristos

Laboratory for Bio-optics and Molecular Imaging, Center for Molecular Imaging Research, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA

### P64-31 DETECTION OF BREAST CANCER CELLS BY FLUORESCENCE IMAGING OF TUMOR MARKER GENE EXPRESSION USING MOLECULAR BEACONS

X-H. Peng, Z. Cao, G. Carlson,  
M. M. Lewis, W. C. Wood,  
L. Yang

Department of Surgery and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

### P64-32 FLUORESCENT DIFFUSE OPTICAL TOMOGRAPHY WITH REFLECTION BOUNDARY

B. Yuan, Q. Zhu

University of Connecticut, Storrs, CT

### P64-33 OPTICAL SPECTROSCOPIC DIAGNOSIS OF BREAST CANCER: AN EX VIVO STUDY

C. Zhu,<sup>1</sup> G. M. Palmer,<sup>2</sup>

N. Ramanujam<sup>2</sup>

<sup>1</sup>Department of Electrical and Computer Engineering,

<sup>2</sup>Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI

- P64-34 IMAGING TUMOR ANGIOGENESIS USING OPTICAL TOMOGRAPHY WITH ULTRASOUND GUIDANCE**  
Q. Zhu,<sup>1</sup> S. H. Kurtzman,<sup>2</sup>  
E. Cronin,<sup>3</sup> S. Tannenbaum,<sup>2</sup>  
M. Huang,<sup>1</sup> C. Xu,<sup>1</sup> B. Yuan,<sup>1</sup>  
N. Chen,<sup>1</sup> D. Piao,<sup>1</sup> P. Hegde,<sup>2</sup>  
M. Kane,<sup>2</sup> B. Jagjivan,<sup>2</sup>  
K. Zarfos,<sup>2</sup> A. Currier,<sup>3</sup> H. Vinve<sup>3</sup>  
<sup>1</sup>University of Connecticut, Storrs, CT; <sup>2</sup>University of Connecticut Health Center, Farmington, CT; <sup>3</sup>Hartford Hospital, Hartford, CT

**P65 Agent Development**

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.

- P65-1 OPTICAL IMAGING OF MAMMAGLOBIN EXPRESSION**  
T. Fleming, M. Hartman,  
S. Bloch, K. Liang, K. Block,  
X. Sun, M. Welch, C. Anderson,  
S. Achilefu  
*Washington University School of Medicine, St. Louis, MO*

- P65-2 NEW POSITRON-EMITTING PROBE FOR IMAGING CELL PROLIFERATION IN BREAST CANCER**  
J. A. Balatoni, S. Soghomonyan,  
A. Shavrin, J. Gelovani  
*Department of Experimental Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston, TX*

- P65-3 XE-129 MRI BIOSENSORS FOR MULTIPLEXED IMAGING OF BREAST CANCER MARKERS**  
L. Yang, A. Hill, I. Dimitrov,  
L. Spece, O-S. Lee, J. G. Saven,  
I. J. Dmochowski  
*Department of Chemistry, University of Pennsylvania, Philadelphia, PA*

- P65-4 IN VIVO IMAGING OF BREAST CANCER USING RADIOLABELED UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) ANALOGS**  
M. F. Giblin, G. Sieckman,  
L. R. Forte, W. A. Volkert  
*Harry S. Truman Memorial Veteran's Administration Hospital, Columbia, MO;*  
*Department of Radiology, University of Missouri-Columbia, Columbia, MO*

- P65-5 PROTOTYPIC RADIOIMMUNOCONJUGATES OF MOUSE IgG AND HIV-1 TAT PEPTIDES ARE IMPORTED INTO THE NUCLEUS OF CANCER CELLS IN VITRO AND TUMOR XENOGRAFTS IN VIVO**  
M. Hu, P. Chen, J. Wang,  
D. A. Scollard, R. M. Reilly  
*Division of Nuclear Medicine, University Health Network, Departments of Pharmaceutical Sciences and Medical Imaging, University of Toronto, Toronto, ON, Canada*

- P65-6 DEVELOPMENT OF PROTEASE-ACTIVABLE AGENTS FOR IN VIVO OPTOACOUSTIC MOLECULAR TOMOGRAPHY OF BREAST CANCER**  
P. La Riviere, A. Green, J. Souris,  
J. R. Norris  
*University of Chicago, Chicago, IL*

- P65-7 BREAST CANCER GENE THERAPY: DEVELOPMENT OF NOVEL NON-INVASIVE MAGNETIC RESONANCE ASSAY TO OPTIMIZE EFFICACY**  
R. P. Mason, J. Yu, L. Liu,  
V. D. Kodibagkar, W. Cui,  
S. L. Brown  
*University of Texas Southwestern, Dallas, TX; Henry Ford Hospital, Detroit, MI*

- P65-8 QUENCHABLE FLUORESCENT MICROBUBBLES FOR HIGH RESOLUTION OPTICAL-ULTRASOUND IMAGING MODALITY**  
O. L. Padilla De Jesús,  
S. J. Lomnes, D. L. Stutz,  
P. A. Fomitchov, E. J. Olson  
*General Electric Global Research Center, Niskayuna, NY*

- P65-9 NOVEL MOLECULAR IMAGING AGENTS TO DETECT BIOMARKERS OF METASTATIC BREAST CANCER**  
B. Yoo, M. Raam, M. Pagel  
*Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH*

- P65-10 DNA-MIMIC-BASED ANTIBODY PRETARGETING FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING**  
F. A. Syud, N. L. Wood, M. Zhao,  
M. Baillie, D. J. Kramer,  
D. Gonzalez-Trotter  
*General Electric Global Research Center, Niskayuna, NY*

- P65-11 SYNTHESIS AND CHARACTERIZATION OF A NOVEL MACROMOLECULAR MAGNETIC RESONANCE IMAGING CONTRAST AGENT**  
B. Zarabi,<sup>1</sup> J. Zhuo,<sup>2</sup> J. Weaver,<sup>1</sup>  
G. Rosen,<sup>1</sup> R. Gullapalli,<sup>2,3</sup>  
H. Ghandehari<sup>1,3,4</sup>  
<sup>1</sup>Departments of Pharmaceutical Sciences, <sup>2</sup>Radiology, <sup>3</sup>Greenebaum Cancer Center, and <sup>4</sup>Program in Bioengineering, University of Maryland, Baltimore, MD

**P66 Drug Resistance**

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.

- P66-1 A NOVEL siRNA-BASED APPROACH TO STUDY MECHANISMS OF RESISTANCE/ ACTION OF A NEW DRUG IN TREATMENT OF BREAST CANCER**  
D. Banerjee, J. Krouse, Z. Hu,  
J. Bertino  
*Cancer Institute of New Jersey, New Brunswick, NJ*

- P66-2 GENETIC LOCUS-CONTROLLED MDR1A REPORTER GENE EXPRESSION**  
D. A. Brown, S. E. Kane,  
T. W. Synold  
*City of Hope/Beckman Research Institute, Duarte, CA*

- P66-3 BETAIII TUBULIN: A MAJOR CAUSE FOR DRUG-RESISTANCE IN BREAST AND OTHER CANCER CELLS**  
A. R. Chaudhuri  
*University of Texas Health Science Center at San Antonio, San Antonio, TX*

P66-4	<b>X-BOX BINDING PROTEIN-1 IN BREAST CANCER</b> B. Gomez, Y. Zhu, R. Riggins, A. Zwart, R. Clarke <i>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC</i>	P66-10	<b>BCSG1 GENE EXPRESSION CONFERRED THE RESISTANCE OF BREAST CANCER CELLS TO ANTI-MICROTUBULE DRUG TREATMENT</b> J. Liu, Y. Zhou <i>VA Palo Alto Health Care System, Palo Alto, CA</i>	P66-16	<b>ASSOCIATION OF TOPOISOMERASE II-ALPHA (TOP2A) GENE AMPLIFICATION WITH RESPONSIVENESS TO ANTHRACYCLINE-CONTAINING CHEMOTHERAPY AMONG WOMEN WITH METASTATIC BREAST CANCER ENTERED IN THE HERCEPTIN H0648G PIVOTAL CLINICAL TRIAL</b> M. F. Press, R. D. Mass, J-Y. Zhou, J. Sullivan-Halley, I. Villalobos, G. Lieberman, K. Flom, S. Seelig, D. J. Slamon, L. Bernstein <i>Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Genentech Inc., South San Francisco, CA; Abbott-Vysis, Inc., Downers Grove, IL; Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA</i>
P66-5	<b>MECHANISTIC STUDIES OF HUMAN TOPOISOMERASE IIA</b> T. Collins, T-S. Hsieh <i>Department of Biochemistry, Duke University, Durham, NC</i>	P66-11	<b>GLUCOSYL CERAMIDE SYNTHASE IS A NEW THERAPEUTIC TARGET FOR BREAST CANCER</b> Y-Y. Liu, J. Y. Yu, A. E. Giuliano, M. C. Cabot <i>John Wayne Cancer Institute, Santa Monica, CA</i>	P66-12	<b>FATTY ACID SYNTHASE (FAS) MODULATES BREAST CANCER CELL SENSITIVITY TO MICROTUBULE-INTERFERING AGENTS</b> J. A. Menendez, L. Vellon, R. Lupu <i>Evanston Northwestern Healthcare Research Institute, Evanston, IL</i>
P66-6	<b>DETECTION OF PUTATIVE BREAST CANCER TUMOR STEM AND PROGENITOR CELLS IN PRIMARY AND METASTATIC LESIONS</b> V. S. Donnenberg, A. M. Brufsky, A. D. Donnenberg <i>University of Pittsburgh Cancer Institute, Pittsburgh, PA</i>	P66-13	<b>DIETARY ORGANIC ISOTHIOCYANATES INHIBIT BREAST CANCER RESISTANCE PROTEIN (ABCG2)-MEDIATED TRANSPORT</b> M. E. Morris, Y. Ji <i>Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY; State University of New York, Amherst, NY</i>	P66-17	<b>LEARNING HOW TO AWAKEN RARBETA2 TUMOR SUPPRESSOR ACTIVITY IN BREAST CANCER CELLS</b> M. Ren, S. Pozzi, S. Rossetti, G. Bistulfi, G. Somenzi, N. Sacchi <i>Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY</i>
P66-7	<b>DIFFERENTIAL EXPRESSION OF ABCB5 MULTIDRUG RESISTANCE P-GLYCOPROTEIN IN HUMAN BREAST CANCER CELL LINES</b> N. Rigol, N. Y. Frank, A. Margaryan, T. Schatton, M. H. Frank <i>Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA</i>	P66-14	<b>ACTIVATION OF NF-KAPPAB IN BREAST CANCER CELLS</b> R. Nehra, R. B. Riggins, B. Gomez, A. L. Zwart, R. Clarke <i>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC</i>	P66-18	<b>CHARACTERIZATION OF OLIGOMERIC HUMAN HALF-ABC TRANSPORTER ATP-BINDING CASSETTE G2</b> J. Xu, Y. Liu, Y. Yang, S. Bates, J-T. Zhang <i>Indiana University, Indianapolis, IN</i>
P66-8	<b>RELATIONSHIP BETWEEN GLUCOSYL CERAMIDE SYNTHASE AND P-GLYCOPROTEIN IN DRUG RESISTANT HUMAN BREAST CANCER CELLS</b> V. Gouazé, S. Young, J. Y. Yu, Y-Y. Liu, A. E. Giuliano, M. C. Cabot <i>John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA</i>	P66-15	<b>EXPLOITING GENOMIC INSTABILITY TO IDENTIFY GENETIC MEDIATORS OF DRUG RESISTANCE</b> B. Karakas, K. Bachman, B. H. Park <i>Johns Hopkins University School of Medicine, Baltimore, MD</i>	P66-19	<b>TAXOL MEDIATES OVEREXPRESSION AND MODIFICATION OF A MITOTIC CHECKPOINT PROTEIN, CENTROMERE ASSOCIATED PROTEIN-E (CENP-E), IN BREAST CANCER CELLS</b> C-P. H. Yang, A. E. Ikui, S. B. Horwitz <i>Albert Einstein College of Medicine, Bronx, NY</i>
P66-9	<b>THE BREAST CANCER SPECIFIC GENE 1 INTERACTS WITH THE MITOTIC CHECKPOINT KINASE BUBR1</b> J. Liu, A. Gupta <i>VA Palo Alto Health Care System, Palo Alto, CA</i>				

- P66-20 ROLE OF 14-3-3SIGMA IN DRUG RESISTANCE IN BREAST CANCER CELLS AS REVEALED BY PROTEOMIC ANALYSIS**  
 Y. Liu, H. Liu, B. Han, J-T. Zhang  
*Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN*

## P67 Targeted Therapies II

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
 Even-numbered – 8:00–9:00 p.m.

- P67-1 NOVEL COX-2 INHIBITORS WITH ENHANCED ANTI-TUMOR ACTIVITY**  
 R. Boominathan, M. V. R. Reddy, S. C. Cosenza, M. Mallireddigari, S. Sheikh, E. P. Reddy  
*Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA*

- P67-2 ROLE OF URIDINE PHOSPHORYLASE IN TUMOR-SPECIFIC MODULATION OF FLUOROPYRIMIDINE ACTIVITY**  
 D. Cao, J. McCabe, L. Wan, L. Zhao, B. Kim, R. Yan, S. Flynn, G. Pizzorno  
*Cancer Institute, Southern Illinois University School of Medicine, Springfield, IL; Nevada Cancer Institute, Las Vegas, NV*

- P67-3 BIFUNCTIONAL IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER**  
 C. B. Carlson, P. Mowery, R. M. Owen, L. L. Kiessling  
*Departments of Chemistry and Biochemistry, University of Wisconsin at Madison, Madison, WI*

- P67-4 IDENTIFICATION OF BREAST CANCER SPECIFIC PROTEOLYTIC ACTIVITIES FOR TARGETED PRODRUG ACTIVATION**  
 A. Lebeau, S. Janssen, S. R. Denmeade  
*Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD*

- P67-5 MINING THE SURFACE OF CANCER CELLS FOR NEW INTERNALIZED TARGETS**  
 J. Gariepy, L. Revers, X. Wei, R. Kiarash, Q. Zhang  
*Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada; Molecular Templates Inc., Toronto, ON, Canada*

- P67-6 ESTROGENIC REGULATION OF POLYAMINE ANALOGUE CYTOTOXICITY IN HUMAN BREAST CANCER CELLS**  
 Y. Huang, J. C. Keen, A. Pledgie, B. Frydman, A. L. Valasinas, V. K. Reddy, L. J. Marton, R. A. Casero Jr., N. E. Davidson  
*<sup>1</sup>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>2</sup>SLIL Biomedical Corp., Madison, WI; <sup>3</sup>CellGate Inc., Sunnyvale, CA*

- P67-7 THERAPEUTIC POTENTIAL OF CLOSTRIDIUM PERFRINGENS ENTEROTOXIN IN THE TREATMENT OF BREAST CANCER**  
 S. L. Kominsky,<sup>1</sup> P. Argani,<sup>2</sup> J. Sosnowski,<sup>2</sup> T. Gabig,<sup>3</sup> B. McClane,<sup>4</sup> B. Tyler,<sup>5</sup> H. Brem,<sup>5</sup> S. Sukumar<sup>6</sup>  
*Departments of <sup>1</sup>Orthopaedic Surgery, <sup>2</sup>Pathology, <sup>3</sup>Neurosurgery, and <sup>6</sup>Oncology, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Biomedical Research Institute, North Shore-Long Island Jewish Health System, Manhasset, NY; <sup>5</sup>Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA*

- P67-8 A NEW POTENTIAL THERAPEUTIC APPROACH TO SILENCING THYMIDYLATE SYNTHASE**  
 D. K. West, D. C. Porter, R. L. Saxl, F. Maley  
*Wadsworth Center, New York State Department of Health, Albany, NY*

- P67-9 NOTCH SIGNALING IS ALTERED IN BREAST CANCER AND IS A POTENTIAL THERAPEUTIC TARGET**  
 P. Rizzo, H. Miao, K. Siziopikou, L. L. Song, S. Selvaggi, A. Bashir, F. Koerner, V. Chaturvedi, J-Z. Qin, B. J. Nickoloff, L. Miele  
*University of Illinois at Chicago, Chicago, IL; Loyola University, Chicago, IL; Rush University, Chicago, IL; University of Wisconsin at Madison, Madison, WI; Brigham and Women's Hospital, Boston, MA*

- P67-10 ANTIPROTEOLYTIC THERAPY TARGETING UROKINASE-PLASMINOGEN ACTIVATOR FOR THE TREATMENT OF BREAST CANCER – A PHASE I STUDY**  
 O. G. Wilhelm, R. Bartz, R. B. Cohen, R. Swaby, B. Muehlenweg, P. Bevan, L. J. Goldstein  
*Wilex AG, Munich, Germany; Fox Chase Cancer Center, Philadelphia, PA*

- P67-11 PHASE I COMBINED BIOLOGICAL THERAPY OF BREAST CANCER USING TWO HUMANIZED MONOCLONAL ANTIBODIES DIRECTED AGAINST HER2 PROTO-ONCOGENE AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)**  
 M. D. Pegram, L. N. Durna, C. Yeon, N. C. Ku, J. Gaudreault, D. J. Slamon  
*Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA; Genentech, Inc., South San Francisco, CA*

- P67-12 DIFFERENTIAL INDUCTION OF HUMAN SPERMINE OXIDASE SMO(PAOH1) mRNA AND ACTIVITY BY A POLYAMINE ANALOGUE IN HUMAN BREAST CANCER CELL LINES**  
 A. Pledgie, Y. Huang, A. Hacker, Z. Zhang, E. Garrett-Mayer, Y. Wang, P. Wooster, R. Casero, N. Davidson  
*Johns Hopkins University, Baltimore, MD; Wayne State University, Detroit, MI*

- P67-13 PRECLINICAL PHARMACOLOGY AND TOXICOLOGY OF INDIUM-111 LABELED HUMAN EPIDERMAL GROWTH FACTOR**  
R. M. Reilly, J. Wang, P. Chen, K. A. Vallis  
*University Health Network and Departments of Medical Biophysics and Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada*
- P67-14 PRECLINICAL PHARMACOLOGY AND TOXICOLOGY OF INDIUM-111 LABELED FAB FRAGMENTS OF TRASTUZUMAB (HERCEPTIN)**  
R. M. Reilly, J. Wang, P. Chen, R. A. Cameron, C. Holloway  
*University Health Network, Sunnybrook and Women's Health Sciences Centre and Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada*
- P67-15 TARGETING PROTEINS FOR UBIQUITINATION AND DEGRADATION IN CANCER THERAPY**  
A. Rodriguez,<sup>1</sup> Y. Fukuda,<sup>2</sup> M. Jung,<sup>2</sup> K. Kim,<sup>3</sup> C. M. Crews,<sup>4</sup> R. J. Deshaies,<sup>5</sup> K. M. Sakamoto<sup>1,5</sup>  
<sup>1</sup>*Department of Pediatrics,*  
<sup>2</sup>*Department of Chemistry, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA;*  
<sup>3</sup>*Department of Pharmaceutical Sciences, University of Kentucky College of Medicine, Lexington, KY;*  
<sup>4</sup>*Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT;*  
<sup>5</sup>*Division of Biology, California Institute of Technology, Pasadena, CA*
- P67-16 A HIGH THROUGHPUT ASSAY FOR IDENTIFYING INHIBITORS OF RHO GTPASE ACTIVATION BY DBL-FAMILY GUANINE NUCLEOTIDE EXCHANGE FACTORS**  
R. J. Rojas,<sup>1</sup> J. Ni,<sup>2</sup> P. Ho,<sup>2</sup> R. Stein,<sup>2</sup> L-A. Yeh,<sup>3</sup> J. Sondek<sup>1</sup>  
<sup>1</sup>*Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC;*  
<sup>2</sup>*Laboratory for Drug Discovery*
- P67-17 THERAPEUTIC POTENTIAL OF SMAC/DIABLO IN BREAST CANCER**  
S. Shankar, T. Fandy, M. Asim, R. K. Srivastava  
*Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD*
- P67-18 PEPTIDE THERAPY INHIBITS PLGF-MEDIATED BREAST TUMOR AND ENDOTHELIAL CELL MIGRATION, AS WELL AS THE GROWTH OF XENOGRAFT TUMORS**  
A. P. Taylor, D. M. Goldenberg  
*Center for Molecular Medicine and Immunology/Garden State Cancer Center, Belleville, NJ*
- P67-19 THERAPEUTIC POTENTIAL OF BCL-2/BCL-XL SMALL-MOLECULE INHIBITOR IN HUMAN BREAST CANCER IN VITRO AND IN VIVO**  
L. Xu, D. Ynag, S. Wang, W. Tang, M. Liu, J. Chen, J. Rae, M. E. Lippman  
*University of Michigan, Ann Arbor, MI*
- P67-20 NOVEL APPROACH FOR SIMULTANEOUS MR IMAGING AND PROTEIN TRANSDUCTION THERAPY FOR BREAST CANCERS**  
V. C. Yang, Y. M. Kwon, B. Chertok, Y. J. Park  
*College of Pharmacy, University of Michigan, Ann Arbor, MI*
- P67-21 ROSIGLITAZONE THERAPY FOR BREAST CANCER**  
L. Yee, P. Wen, N. Williams, S. Suster, C. Eng  
*Ohio State University, Columbus, OH*
- P67-22 14-3-3 ZETA IS OVEREXPRESSED IN BREAST CANCERS AND PLAYS A CRITICAL ROLE IN CANCER PROGRESSION**  
C. L. Neal, J. Yao, W. Yang, X. Zhou, N. Nguyen, P. Li,
- P67-23 PTEN ACTIVATION CONTRIBUTES TO TUMOR INHIBITION BY TRASTUZUMAB AND LOSS OF PTEN PREDICTS TRASTUZUMAB RESISTANCE IN PATIENTS**  
J. Yang, C. Danes, K-H. Lan, M-C. Hung, R. E. Pollock, D. Yu  
*University of Texas M.D. Anderson Cancer Center, Houston, TX*
- P67-24 IN VIVO MRI MONITORING OF BREAST TUMOR RESPONSE TO THE VASCULAR TARGETING AGENT COMBRETASTATIN A4 PHOSPHATE**  
D. Zhao, L. Jiang, A. Adam, E. W. Hahn, R. P. Mason  
*Department of Radiology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX*
- P67-25 SMALL MOLECULES TARGETING HEC1 AND NEK2 INTERACTION FOR BREAST CANCER TREATMENT**  
L. Zhou, P-L. Chen, W-H. Lee  
*Department of Biological Chemistry, University of California at Irvine, Irvine, CA*

**P68 Health Care Delivery**

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.

- P68-1 QUALITY CARE PROJECT LEAD®: ADVOCATING FOR SYSTEMATIC CHANGE IN ACCESS TO QUALITY BREAST CANCER CARE**  
C. Brunswick  
*National Breast Cancer Coalition Fund, Washington, DC*

- P68-2 INCREASING ADHERENCE TO FOLLOW-UP OF BREAST ABNORMALITIES IN LOW-INCOME KOREAN AMERICAN WOMEN**  
A. E. Maxwell, A. Jo, R. Bastani  
*Division of Cancer Prevention and Control Research, University of California at Los Angeles, School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, CA*

- P68-3 INFLAMMATORY BREAST CANCER BIOBANK AND CLINICAL DATABASE**  
G. Mason, W. Johnson  
*Inflammatory Breast Cancer Research Foundation, Goshen, IN*

- P68-4 ACCESS FOR WOMEN WITH DISABILITIES**  
K. McCarthy-Barnett  
*The Rhode Island Breast Cancer Coalition, Warwick, RI*

- P68-5 CAN MEDICARE CLAIMS BE USED TO ASSESS MAMMOGRAPHY USAGE?**  
R. Smith-Bindman, C. Quale, P. Chu  
*Department of Radiology, University of California at San Francisco, San Francisco, CA*

- P68-6 SCREENING MAMMOGRAPHY IN THE AMERICAN ELDERLY**  
C. Kagay, C. Quale, R. Smith-Bindman  
*Department of Medicine, California Pacific Medical Center, San Francisco, CA; Department of Radiology, University of California at San Francisco, San Francisco, CA*

- P68-7 DELAYS AND REFUSALS IN TREATMENT OF BREAST CANCER AMONG NEW MEXICO WOMEN**  
E. L. Saavedra  
*University of New Mexico, College of Education, Health Education, Albuquerque, NM*

- P68-8 BREAST CANCER PATIENT RACE/ETHNICITY, NEIGHBORHOOD, AND HOSPITAL QUALITY: ARE THEY RELATED?**  
D. Tisnado,<sup>1</sup> J. Malin,<sup>1,2</sup> P. Ganz,<sup>1</sup> M. Tao,<sup>1</sup> A. Hu,<sup>1</sup> J. Adams,<sup>2</sup> K. Kahn<sup>1,2</sup>  
<sup>1</sup>*University of California at Los Angeles, Los Angeles, CA;*  
<sup>2</sup>*RAND, Santa Monica, CA*

**P69 Quality of Life**

7:00–9:00 p.m.

Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.

- P69-1 REDUCING THE BURDEN OF BREAST CANCER AMONG AFRICAN AMERICAN AND LATINA SURVIVORS**  
K. Ashing-Giwa  
*University of California at Los Angeles, Los Angeles, CA*

- P69-2 DEVELOPMENT OF A HAND-HELD COMPUTER APPLICATION TO ASSESS THE BIOPSYCHOSOCIAL CORRELATES OF PAIN IN METASTATIC BREAST CANCER**  
H. Badr, C. Carmack Taylor, K. Basen-Engquist, C. Kalil  
*Department of Behavioral Science, University of Texas M.D. Anderson Cancer Center, Houston, TX*

- P69-3 SPIRITUALITY IN YOUNG BREAST CANCER SURVIVORS ONE TO THREE YEARS POST-DIAGNOSIS**  
D. Farmer, J. Petrek, E. Ip, M. Naughton  
*Wake Forest University School of Medicine, Winston-Salem, NC; Memorial Sloan-Kettering Cancer Center, New York, NY*

- P69-4 PREDICTORS OF SEXUAL AROUSAL AND SATISFACTION AMONG YOUNG BREAST CANCER SURVIVORS ONE YEAR POST-SURGERY**

M. J. Macrae, L. D. Case, J. A. Petrek, M. J. Naughton  
*Wake Forest University School of Medicine, Winston-Salem, NC; Memorial Sloan-Kettering Cancer Center, New York, NY*

- P69-5 HEALTH-RELATED QUALITY OF LIFE OF PREMENOPAUSAL BREAST CANCER SURVIVORS ONE TO THREE YEARS POST-DIAGNOSIS**

M. J. Naughton, J. A. Petrek, E. Ip, E. D. Paskett, E. Naftalis  
*Wake Forest University School of Medicine, Winston-Salem, NC; Memorial Sloan-Kettering Cancer Center, New York, NY; Ohio State University, Columbus, OH; University of Texas-Southwestern, Dallas, TX*

- P69-6 ARM AND HAND SWELLING AMONG YOUNG BREAST CANCER SURVIVORS ONE TO THREE YEARS POST-SURGERY**

E. D. Paskett, J. Abbott, T. McCoy, J. A. Petrek, M. J. Naughton  
*Ohio State University, Columbus, OH; Wake Forest University School of Medicine, Winston-Salem, NC; Memorial Sloan-Kettering Cancer Center, New York, NY*

- P69-7 PREDICTORS OF DEPRESSION IN YOUNGER WOMEN WITH BREAST CANCER DURING THE FIRST TWO YEARS POST-DIAGNOSIS**

S. R. Walsh, E. Ip, J. A. Petrek, M. J. Naughton  
*Wake Forest University School of Medicine, Winston-Salem, NC; Memorial Sloan-Kettering Cancer Center, New York, NY*

**P69-8 CANCER-SPECIFIC DISTRESS IN AFRICAN AMERICAN WOMEN AT INCREASED RISK FOR HEREDITARY BREAST CANCER**  
C. Hughes Halbert, L. Kessler, A. Collier, B. Weathers, K. Brewster

*University of Pennsylvania, Philadelphia, PA*

**P69-9 HOT FLASHES AND QUALITY OF LIFE AMONG BREAST CANCER PATIENTS**

L. A. Jacobs, A. DeMichele, P. J. Shapiro, J. C. Coyne, S. C. Palmer  
*Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA*

**P69-10 THE EFFECTS OF ADJUVANT OR NEO-ADJUVANT CHEMOTHERAPY ON QUALITY OF LIFE AND COGNITION IN PRE-MENOPAUSAL WOMEN WITH BREAST CANCER**

J. R. Klemp, A. Stanton,<sup>1</sup> C. J. Fabian  
*University of Kansas Medical Center, Kansas City, KS;*  
<sup>1</sup>*University of California at Los Angeles, Los Angeles, CA*

**P69-11 INTERDISCIPLINARY RESEARCH TRAINING IN BREAST CANCER**

R. McCorkle, T. Knobf, M. Digiovanna  
*Yale University, School of Nursing and School of Medicine, New Haven, CT*

**P69-12 CHALLENGES OF LIVING WITH BREAST CANCER IN THE FAMILY: SPECIAL ISSUES CONFRONTING ADULT DAUGHTER CAREGIVERS**

V. H. Raveis, S. Pretter  
*Columbia University, Mailman School of Public Health, New York, NY*

**P69-13 LONG TERM OUTCOMES OF BRCA1/BRCA2 MUTATION TESTING**

M. D. Schwartz, B. N. Peshkin, L. Deecheandia, K. L. Taylor, K. Tercyak, T. Demarco, C. Isaacs, S. Feng  
*Department of Oncology, Georgetown University, Lombardi Cancer Center, Washington, DC*

**P69-14 LONGITUDINAL EFFECTS OF INTIMATE PARTNER RELATIONSHIP QUALITY ON SERUM OXYTOCIN LEVELS IN NEWLY DIAGNOSED BREAST CANCER PATIENTS**  
K. Weihs  
*Department of Psychiatry and Arizona Cancer Center, University of Arizona, Tucson, AZ*

**P70-4 MODELLING THE NATURAL HISTORY OF DUCTAL CARCINOMA IN SITU OF THE BREAST USING A COMPUTER BASED SIMULATION**

D. Gertig,<sup>1</sup> J. Dowty,<sup>1</sup> G. Byrnes,<sup>1</sup> B. Erbas,<sup>1</sup> P. Chang,<sup>1</sup> E. Provenzano<sup>1</sup>

<sup>1</sup>*Centre for Genetic Epidemiology, University of Melbourne, VIC, Australia;* <sup>2</sup>*Department of Pathology, Austin Hospital, Melbourne, VIC, Australia*

**P70-5 INCIDENCE OF BILATERAL BREAST CANCER IN RELATION TO AGE OF ONSET AND LATENT PERIOD**

M. Hartman,<sup>1,2</sup> K. Czene,<sup>1</sup> P. Hall<sup>1</sup>

<sup>1</sup>*Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden;* <sup>2</sup>*Department of Surgery, Stockholm Söder Hospital, Stockholm, Sweden*

**P70-6 OUTCOMES BY ETHNICITY. SENTINEL LYMPH NODE STATUS IN WOMEN WITH BREAST CANCER**

M. A. Hassett, K. K. Hunt, K. Keyomarsi  
*University of Texas M.D. Anderson Cancer Center, Houston, TX*

**P70-7 THE IMPACT OF PRIOR MALIGNANCIES ON OUTCOME IN EARLY STAGE BREAST CANCER PATIENTS**

C. Ladva, W-T. Hwang, E. Harris  
*Departments of Radiation, Oncology, and Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA*

**P70-8 RISK FACTORS FOR THE DEVELOPMENT OF AGGRESSIVE INFLAMMATORY AND NON-INFLAMMATORY BREAST CANCER**

P. H. Levine, C. Veneroso, H. Young  
*George Washington University School of Public Health and Health Services, Washington, DC*

- P70-9 THE INFLAMMATORY BREAST CANCER (IBC) REGISTRY: IMPROVING THE CASE DEFINITION FOR IBC**  
P. H. Levine, M. Mondzac, H. Young  
*George Washington University School of Public Health and Health Services, Washington, DC*
- P70-10 USE OF MAMMOGRAPHY BY TEXAS-MEXICO BORDER RESIDENCE AND ETHNICITY**  
G. Peltz, M. Sanderson, A. Perez, J. K. Estrada, M. Johnson  
*University of Texas at Brownsville and University of Texas-Houston School of Public Health at Brownsville, Brownsville, TX*
- P70-11 PERINATAL FACTORS AND MORTALITY FROM BREAST CANCER**  
M. Sanderson, J. R. Daling, K. E. Malone, D. R. Doody, P. L. Porter  
*University of Texas-Houston School of Public Health at Brownsville, Brownsville, TX; Fred Hutchinson Cancer Research Center, Seattle, WA*
- P70-12 ASSOCIATIONS OF RACE AND SMOKING WITH TAMOXIFEN-RELATED SIDE EFFECTS IN WOMEN WITH BREAST CANCER**  
M. Zhan, J. A. Flaws, L. Gallicchio, L. M. Lewis, R. Royak-Schaler  
*Department of Epidemiology and Preventive Medicine, University of Maryland at Baltimore, Baltimore, MD*

---

**P71 Summer Undergraduate Training Programs****7:00–9:00 p.m.**Posters Manned: Odd-numbered – 7:00–8:00 p.m.  
Even-numbered – 8:00–9:00 p.m.

- P71-1 UNDERGRADUATE SUMMER FELLOWSHIPS IN BREAST CANCER RESEARCH**  
S. C. Brooks  
*Karmanos Cancer Institute, Wayne State University, Detroit, MI*

- P71-2 DEFINING THE MOLECULAR DETERMINANTS OF EPIMORPHIN/SYNTAXIN-2-MEDIATED MAMMARY EPITHELIAL MORPHOGENESIS**  
D. Radisky,<sup>1</sup> C. Chen,<sup>1</sup> Y. Hirai,<sup>2</sup> M. J. Bissell<sup>1</sup>  
<sup>1</sup>*Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA;* <sup>2</sup>*Osaka R&D Laboratory (Yokohama-lab), Sumitomo Electric Industries Ltd., Yokohama, Japan*
- P71-3 SUMMER UNDERGRADUATE FELLOWSHIPS IN BREAST CANCER-RELATED RESEARCH IN SAN ANTONIO**  
B. A. Christy  
*University of Texas Health Science Center at San Antonio, San Antonio, TX*
- P71-4 PATHWAYS TO RESEARCH CAREERS: A BREAST CANCER EDUCATION AND RESEARCH PROGRAM FOR UNDERGRADUATES**  
J. K. Griffin, W. L. Anderson  
*Department of Biochemistry and Molecular Biology, University of New Mexico, Albuquerque, NM*
- P71-5 CHARACTER RECOGNITION AND IMAGE MANIPULATION FOR THE CLINICAL TRANSLATION OF CAD FOR BREAST ULTRASOUND**  
N. Grusauskas, K. Drukker, M. L. Giger  
*Department of Radiology, University of Chicago, Chicago, IL*
- P71-6 UNDERGRADUATE SUMMER TRAINING PROGRAM INVESTIGATING THE ROLE OF RADIATION THERAPY IN BREAST CANCER CLINICAL AND TRANSLATIONAL RESEARCH**  
E. E. Harris  
*Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA*
- P71-7 REMOVAL OF THE ER-ALPHA F DOMAIN FACILITATES DETECTION OF DIFFERENCES IN THE ACTIVITY OF MUTATED RECEPTORS**  
C. Knight, J. Goodwin, C. Zhao, D. F. Skafar  
*Department of Physiology and Karmanos Cancer Institute, Wayne State University, School of Medicine, Detroit, MI*
- P71-8 TRAINING PROGRAM IN BREAST CANCER PREVENTION AND THERAPY FOR UNDERGRADUATE STUDENTS**  
R. G. Mehta  
*Department of Surgical Oncology, College of Medicine, University of Illinois, Chicago, IL*
- P71-9 DIFFERENCES IN THE KINETICS AND AMPLITUDE OF ERK AND FLIP(SHORT) ACTIVATION IN HIGHLY HOMOGENEOUS EPITOPE-SPECIFIC HUMAN CD8+ CTL CULTURES**  
D. Craig, R. Vonck, K. Schaubert, M. Bajcz, J. Kan-Mitchell  
*Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI*
- P71-10 NETWORK ARCHITECTURE AND WIRELESS TEST BED DEVELOPMENT FOR TELEDIAGNOSIS AND TELEMMAMMOGRAPHY**  
Y-D. Yao  
*Stevens Institute of Technology, Hoboken, NJ*
- P71-11 OMEGA-3 POLYUNSATURATED FATTY ACIDS INHIBIT GROWTH OF BREAST CANCER CELLS THROUGH A SPHINGOMYELINASE-DEPENDENT PATHWAY**  
G. P. Zaloga, M. Wu, L. Sech, K. Jackson, K. Harvey, Z. Welch, W. Stillwell, R. Siddiqui  
*Methodist Research Institute and Department of Medicine of Indiana University School of Medicine, Indianapolis, IN*

## Poster/Author Index

### A

Aaronson, S. A.....P1-1  
 Aarsvold, J. N.....P15-3  
 Abaan, H. O.....P43-19  
 Abad, P. C.....P32-1  
 Abbas, M.....P13-3  
 Abbott, J.....P69-6  
 Abiri, S. O.....P58-2  
 Aboyade-Cole, A.....P62-7  
 Abraham, J.....P35-11, P35-12  
 Abraham, R. T.....P4-24  
 Abraham, S. A.....P44-9  
 Accili, D.....P9-20  
 Achary, R.....P13-1  
 Achilefu, S.....P15-8, P65-1  
 Ackland, L.....P60-22  
 Ackroyd, N. C.....P15-1  
 Acs, G.....P53-1  
 Acu, I. E.....P29-6  
 Adalberto, C.....P34-5  
 Adam, A.....P67-24  
 Adami, H-O.....P61-10  
 Adamo, C.....P51-10  
 Adams, J.....P68-8  
 Adams, P. D.....P29-1  
 Adams, S. A.....P24-1, P70-1  
 Adams-Campbell, L.....P23-18  
 Adelstein, S. J.....P17-4  
 Adepoju, L.....P48-8  
 Adhami, V. M.....P26-1  
 Adini, A.....P32-2  
 Adsay, V.....P62-11  
 Afrimzon, E.....P38-25  
 Agarwal, A. K.....P43-9  
 Agarwal, M.....P56-19  
 Aggarwal, B. B.....P22-1  
 Ahearn, M. E.....P6-1  
 Ahmed, M.....P46-1  
 Ahmed, N. U.....P62-1  
 Ahn, J.....P17-1  
 Ahsan, H.....P49-1, P49-2, P49-6  
 Aiello, E.....P70-3  
 Aiyar, S. E.....P51-1, P51-14, P51-20  
 Akabani, G.....P15-10  
 Akakura, S.....P52-1  
 Akinsheye, I.....P32-6  
 Akiri, G.....P60-14  
 Akporiaye, E. T.....P45-1, P45-17  
 Akula, N.....P43-19  
 Al Aowad, A. F.....P17-4  
 Al Masri, A. N.....P11-1  
 Alacam, B.....P14-20  
 Alaoui-Jamali, M. A.....P29-23  
 Alarid, E. T.....P7-6  
 Alazraki, N. P.....P15-3  
 Albanell, J.....P13-7  
 Albaraccin, C. T.....P55-18  
 Albert, A.....P62-22  
 Albert, M.....P42-7

Albertson, D. G.....P6-16  
 Aldaz, C. M.....P36-1  
 Al-Dhaheri, M.....P7-19  
 Alexander, A.....P27-16  
 Alexander, C.....P3-4  
 Alexander, H.....P40-18  
 Alexander, S.....P40-18  
 Alfano, R. R.....P14-19, P64-1, P64-2  
 Alfaro, M. P.....P3-6  
 Alivisatos, A. P.....P58-8  
 Al-Katib, W. A.....P10-18  
 Allard, J.....P57-5  
 Allendorf, D. J.....P45-20  
 Alley, J.....P13-3  
 Allinen, M.....P59-15  
 Allred, C. D.....P35-1  
 Allred, D. C.....P6-12  
 Almeida, J. S.....P40-16  
 Almodovar, G. J.....P29-6  
 Aloyz, R.....P25-1  
 Alpaugh, M. L.....P3-2, P3-3  
 Alrubaiee, M.....P14-19, P64-1, P64-2  
 Alsop, K.....P59-8, P59-9  
 Alvey, S.....P52-5  
 Amato, P.....P3-20  
 Ambrosone, C. B.....P17-1, P24-6, P39-3  
 P39-5, P49-9  
 Amend, K.....P39-3  
 Ames, S. J.....P30-27  
 Amin, K.....P64-11  
 Amiri, A.....P1-13  
 Amirika, K. C.....P6-26  
 Amleh, A.....P51-20  
 Amortegui, A.....P3-14, P3-15  
 Anawalt, B.....P36-10  
 Andacht, T.....P6-25  
 Andersen, B.....P28-5  
 Andersen, S. M.....P2-14  
 Andersen, T. T.....P16-7, P62-2, P62-3, P62-8  
 Anderson, A. L.....P9-18  
 Anderson, B. M.....P64-6  
 Anderson, C. J.....P15-8, P65-1  
 Anderson, K. A.....P2-3  
 Anderson, K. E.....P40-8, P61-9  
 Anderson, M.....P70-3  
 Anderson, R.....P10-10, P59-8, P59-9, P60-19  
 Anderson, W. L.....P71-4  
 Andrechek, E.....P52-3, P52-16  
 Andrew, M.....P26-14  
 Andrews, D. W.....P58-1  
 Andrulis, I. L.....P11-19, P25-6, P51-30  
 Angeloni, S.....P7-15  
 Anghel, S.....P7-14  
 Antich, P. P.....P64-3  
 Antonaci, F. C.....P55-1  
 Antufermo, E.....P3-18  
 Anyanwu, S. N. C.....P49-15  
 Aouizerat, B. A.....P23-6  
 Aperavich, B. A.....P6-24  
 Apostolov, E. O.....P58-2

Archer-Evans, S.....P5-4  
 Arciero, C. A.....P51-7  
 Arendell, L.....P13-2  
 Argani, P.....P13-12, P67-7  
 Ariazi, E. A.....P26-11  
 Ariazi, J.....P37-3  
 Armstrong, T. D.....P45-22  
 Arnold, R.....P13-13  
 Arntzen, C. J.....P45-15  
 Arora, T. S.....P5-17  
 Arrues, S.....P38-4  
 Arun, S.....P26-16  
 Arutunov, M.....P3-27  
 Arvanitis, A.....P60-22  
 Asada, S.....P16-4  
 Asaithamby, A.....P30-15  
 Ashayeri, E.....P43-17  
 Ashenafi, M.....P57-1  
 Ashfaq, R.....P38-11  
 Ashing-Giwa, K.....P69-1  
 Asim, M.....P67-17  
 Assad, L.....P48-8  
 Atencio, D. A.....P62-17, P62-18  
 Athwal, R. S.....P30-1  
 Atkinson, C.....P34-1  
 Aud, D.....P57-5  
 Audoly, L. P.....P3-5  
 Auger, A.....P7-14  
 Aupperlee, M. D.....P35-2  
 Autxier, C.....P56-7  
 Auzenne, E.....P16-18  
 Avignan, D.....P45-10  
 Avraham, H.....P2-25, P55-2, P55-3, P55-21  
 Avraham, S.....P2-25, P56-1  
 Ayer, R. E.....P30-27  
 Azhdarinia, A.....P15-4  
 Azizkhan-Clifford, J.....P4-1

### B

Babnigg, G.....P51-8  
 Baccala, R.....P12-1  
 Bacchetti, P.....P42-3  
 Bachelier, R.....P51-11  
 Bachman, K.....P66-15  
 Bacon, S.....P62-2  
 Badr, H.....P69-2  
 Badve, S.....P3-18, P13-13, P59-14  
 Bae, I.....P29-2  
 Baek, S. H.....P5-6  
 Baer, F. W.....P51-17  
 Baer, R.....P36-1, P51-17  
 Baerson, S. R.....P43-9  
 Bafico, A.....P1-1  
 Baggerly, K.....P13-11  
 Baghaei, H.....P15-9  
 Bai, M.....P64-6  
 Bai, R-K.....P56-26, P56-28  
 Bai, W.....P36-2  
 Baick, C.....P64-16  
 Bailat, C. J.....P64-4

## Poster/Author Index

Bailey, C.	P1-20, P3-1	Bass-Gregory, R.	P55-20	Berbaum, M.	P22-4, P22-5
Bailis, A.	P56-17	Bastani, R.	P68-2	Berencsi, K.	P12-9
Baillat, D.	P40-6	Basturk, O.	P62-11	Berg, M. J.	P20-4
Baillie, M.	P65-10	Basu, A.	P7-19	Berg, P. E.	P10-5, P10-6
Bajcz, M.	P71-9	Basu, G. D.	P45-9	Berger, S. H.	P24-1
Bakewell, S.	P11-7	Bataille, A-R.	P6-17	Bergeron, J. A.	P64-29
Bakin, A. V.	P28-1	Bates, S.	P66-18	Bergman, I.	P44-1
Bakitas, M. A.	P20-1	Bathe, O. F.	P45-2	Berki, L.	P54-22
Baksi, K.	P9-1	Batinic-Haberle, I.	P16-1	Berleth, E. S.	P51-3
Balasenthil, S.	P36-16	Batist, G.	P40-10, P40-11, P43-20	Berman, C.	P14-7
Balatoni, J. A.	P65-2	Bator-Kelly, C.	P64-21	Berman, H.	P50-4, P56-11
Baldwin, A. S.	P27-14	Batzell, K. A.	P70-2	Berman, S.	P34-1
Baleja, J. D.	P2-25	Baugher, P. J.	P38-3	Bernardo, G.	P3-25
Ballard, B. R.	P13-8	Baum, D.	P46-14	Bernstein, J.	P62-17, P62-18
Bally, M. B.	P44-9	Baum, J.	P22-4, P22-5	Bernstein, L.	P66-16
Balogh, G. A.	P8-4, P8-5, P13-20	Baumann, H.	P45-4	Berone-Johnson, E. R.	P61-12
Balsara, B. R.	P8-3, P8-4, P8-5	Baumbach, L.	P6-1	Berrino, F.	P34-5
Bälter, K.	P61-10	Baumgartner, B.	P56-2	Berry, J. A.	P60-11
Baltus, R. E.	P35-9	Bautch, V. L.	P9-18	Bertino, J.	P66-1
Band, H.	P52-1	Baydush, A.	P14-8, P14-16	Bertozzi, C. R.	P64-5
Band, V.	P1-2, P11-9, P27-1, P27-8, P52-1	Baylin, S.	P13-4	Berwick, D. C.	P2-6, P2-7
Banerjee, A.	P29-3	Bayliss, J.	P7-5	Bessho, M.	P25-2
Banerjee, D.	P66-1	Beam, C. A.	P6-21, P42-1	Bessho, T.	P25-2
Banerjee, D. K.	P9-1	Bean, G. R.	P5-12	Bevan, A.	P17-10
Banerjee, M.	P62-11	Beaudry-Rodgers, K.	P3-14	Bevan, P.	P67-10
Banerjee, S.	P22-1, P60-21	Beaman, S.	P53-15	Beveridge, A.	P64-9
Banka, C. L.	P60-1	Bechtel, D.	P29-22	Bey, E. A.	P43-1
Banke, A. L.	P11-19	Bechter, O. E.	P4-17	Beyene, D.	P57-1
Bansal, S.	P27-7	Beck Jr., G. R.	P1-26	Beyer, A.	P7-10
Bao, J.	P36-2	Beck, S.	P23-12	Bhat, I.	P27-1
Bao, L. W.	P60-16, P60-17	Beck, W. T.	P4-11, P32-16	Bhati, R.	P9-13
Bao, S.	P32-3	Becker, R.	P52-5	Bhatnagar, R.	P35-11
Barakat, R. R.	P62-9	Bedalov, A.	P16-2	Bhinge, A. A.	P6-13
Barbas, C. F.	P19-8	Bedja, D.	P52-5	Bick, U.	P14-2
Barber, S.	P52-5	Beebe, D. J.	P3-4	Bigelow, C.	P61-12
Barbone, P. E.	P64-22	Beer, D.	P6-3	Bigelow, R.	P60-2
Barcellos-Hoff, M. H.	P28-2, P28-6, P41-2	Beg, A. A.	P39-1	Biggins, S.	P29-15
Barhoumi, R.	P36-6	Bégin, L. R.	P56-15	Bigio, I.	P64-19
Barjhoux, L.	P49-11	Behbod, F.	P3-6	Bilanchone, V.	P3-16
Barker, P.	P54-12	Belay, Y.	P62-1	Billen, L.	P58-1
Barmada, M.	P61-5	Belguise, K.	P1-3	Bills, M. M.	P60-22
Barndollar, A. S.	P3-12	Belka, G. K.	P1-4, P1-20, P3-1, P11-7, P11-15, P57-2	Bilska-Wolak, A.	P14-1
Barnes, C. J.	P35-3	Bello, C. M.	P56-9	Birgul, O.	P63-2, P63-5, P64-13
Barnes, S.	P62-10	Bellovin, D. I.	P11-2	Biroc, S.	P59-19
Barnett, J. B.	P40-1	Bellows, D. S.	P16-3	Birrane, G.	P51-18, P51-19, P52-7
Barnhart, B. C.	P58-13	Ben Lo, S-C.	P17-2	Birrell, S. N.	P35-4
Barnhill, H. N.	P44-19	Benaud, C.	P32-10	Bischof, J.	P21-8
Barrett, J. T.	P26-16	Ben-David, Y.	P63-3	Bisoffi, M.	P56-12
Bar-Sagi, D.	P26-5	Benjamin, L. E.	P32-2	Bissell, M. J.	P3-13, P3-21, P5-15, P5-21, P32-11, P58-6, P59-1, P64-21, P71-2
Barsky, S. H.	P3-2, P3-3	Bennett, B. T.	P4-2	Bistulfi, G.	P66-17
Bartella, L.	P63-1	Bennett, C. B.	P51-2	Bivens, B.	P55-10
Bartholomeusz, G.	P30-2	Bennett, J. A.	P16-7, P62-2, P62-8	Bjorge, J. D.	P2-8
Barton, D. L.	P20-8	Bennett, L. B.	P26-20	Bjornsson, H.	P57-4
Bartsch, L. M.	P30-3	Bennion, B. J.	P7-1	Black, M. B.	P26-18
Bartz, R.	P67-10	Bensen, J. T.	P49-9	Blackburn, A. C.	P57-5
Bascom, J. L.	P59-1	Bentires-Alj, M.	P2-16, P52-2	Blackmore, K.	P40-14
Baselga, J.	P13-7	Bentle, M. S.	P43-1	Blackwell, K.	P26-3
Basen-Engquist, K.	P69-2	Berasi, S. P.	P54-23	Blackwell, T.	P3-27
Bashir, A.	P67-9	Berbaum, K.	P22-4, P22-5	Blair, A.	P51-20

## Poster/Author Index

Blake, C.	P50-7, P50-9, P50-10	Bradley, J.	P45-9	Buist, D.	P70-3
Blakely, C. M.	P1-4	Bradley, L.	P7-18	Bulinski, C.	P10-17
Blanchard, A.	P55-19	Bradley, P.	P40-20	Bull, S.	P11-19
Blaner, W. S.	P34-2	Bradley, S. V.	P53-13	Bunker, C. H.	P49-15
Blend, M.	P15-7	Branam, D. E.	P21-5	Burchard, E.	P49-23
Bleznak, A. D.	P20-9	Brantley-Sieders, D. M.	P9-2, P9-4	Burchard, J.	P5-14
Blick, T.	P58-9, P60-22	Braunstein, S.	P17-11	Burd, R.	P26-7
Bloch, S.	P65-1	Breckman, V.	P60-14	Burgess, S. M.	P27-2
Block, K.	P65-1	Breier, G.	P9-22	Burghardt, R. C.	P36-6
Blommel, E.	P26-14	Brem, H.	P67-7	Burnham, T. R.	P20-6
Blouin, M. J.	P62-13	Bremner, T. A.	P53-2	Burns, K.	P24-3
Blumberg, B.	P35-19	Brennan, K. R.	P53-6	Burow, M. E.	P61-1
Blume, J. E.	P6-2	Brenneman, M. A.	P25-9	Burrows, N. M.	P56-3
Blume, S. W.	P5-1, P5-2	Brewer, G.	P1-18	Burton, F. H.	P11-3
Boackle, R. J.	P45-21	Brewer, G. J.	P60-17	Bussen, W. L.	P4-3
Bockbrader, K. M.	P58-3	Brewster, K.	P69-8	Buster, D. W.	P56-4
Boehmke, M. M.	P20-2	Brickley, D. R.	P2-1	Busy, R.	P29-6
Boernke, W. E.	P51-8	Briggs, G.	P64-19	Butler, J.	P64-16
Bogusz, A. M.	P2-1	Brisken, C.	P3-23	Butler, K. S.	P56-5
Boka, V. L.	P30-4	Britton, J. A.	P49-9, P49-21	Butler, L. M.	P31-12, P35-4
Boland, M. J.	P13-6	Brodsky, A. S.	P6-2	Butt, A. J.	P21-2
Bonner, J. A.	P44-15	Brody, L.	P57-1	Buzaglo, J. S.	P23-10
Bonner, M.	P24-6	Brogi, E.	P11-11	Byrne, B.	P36-3
Booden, M. A.	P38-5	Bronwe, C.	P16-23	Byrnes, G.	P70-4
Bookman, R.	P6-1	Brooks, J.	P29-4	Byrnes, K.	P13-3
Boominathan, R.	P67-1	Brooks, M. N.	P21-1	Byron, S.	P53-4
Boone, B.	P40-13	Brooks, S. C.	P56-25, P71-1	<b>C</b>	
Boothman, D. A.	P43-1, P43-13	Brooksby, B. A.	P14-21	Cabot, M. C.	P66-8, P66-11
Boots, M.	P59-22	Broome, C.	P57-1	Cai, H.	P22-2
Borgeest, C.	P8-1	Brown, A. M. C.	P53-6	Cai, Q.	P21-9, P49-3, P49-17
Borisj, G. G.	P59-10	Brown, D. A.	P66-2	Cai, W.	P14-19
Bornhop, D. J.	P64-6	Brown, J. A.	P56-3	Cai, Y.	P38-23
Boros, M.	P52-19	Brown, J. M.	P56-3	Calabro, J. M.	P59-12, P59-20
Borowicz, S.	P51-8	Brown, K.	P23-22	Caldes, T.	P57-6
Borowiec, J. A.	P54-1	Brown, M.	P5-3, P6-2, P36-5, P50-1		
Bosco, E. E.	P30-5	Brown, P. H.	P7-4	Caldwell, E.	P5-12
Bose, S.	P51-24	Brown, R.	P51-18, P51-19		
Bottazzi, M-E.	P51-16	Brown, S.	P52-3	Callens, S.	P17-3
Boudreau, R. M.	P58-8	Brown, S. L.	P65-7	Cameron, E.	P26-14
Boué, S. M.	P61-1	Bruce, J. E.	P27-6	Cameron, R. A.	P67-14
Bouker, K.	P18-2	Bruck, K.	P54-22	Camp, R. L.	P6-4, P33-7, P40-4
Boutros, P.	P1-16	Brueggemeier, R. W.	P53-12	Campbell, C.	P59-10
Bouwman, D.	P62-11	Bruyé-Sedano, N.	P43-6	Campbell, C. I.	P53-9
Bouyain, S.	P26-8	Brufsky, A. M.	P66-6	Campisi, J.	P59-2, P59-3
Bovbjerg, D. H.	P23-2, P23-22, P29-2, P39-3, P39-4, P39-5	Brugge, J. S.	P38-21, P38-22, P40-21		
Bovik, A.	P14-14	Bruick, R. K.	P43-9	Campo, D. A.	P60-3
Bowden, E. T.	P32-20	Brummer, T.	P2-2	Campoli, M.	P12-2
Bowersox, S. S.	P44-5	Brunder, D. G.	P61-9	Canzian, F.	P49-4, P49-18
Bowie, M. L.	P5-12	Brunswick, C.	P68-1	Cao, C.	P21-9
Bown, S.	P64-19	Brutkiewicz, R. R.	P39-10	Cao, D.	P67-2
Bowser, M. J.	P60-8	Bryant, I.	P26-13	Cao, Q. J.	P57-5
Bowscher, J. E.	P15-10	Brzovic, P. S.	P51-10	Cao, X. (The Burnham	
Bowntell, D. L.	P59-8, P59-9	Brzymialkiewicz, C. N.	P15-2	Institute)	P58-17, P58-18
Boxer, R. B.	P11-6, P11-15	Bucchholz, T. A.	P3-6, P17-9	Cao, X. (Univ. of Alabama)	P30-14
Boyapati, S. M.	P49-17	Buchsbaum, D. J.	P44-15, P45-3, P46-7		
Boyd, J.	P62-9	Buckley, J.	P62-13	Cao, Y.	P11-30
Boyer, T. G.	P51-4, P51-5, P51-26	Buehring, G. C.	P24-2	Cao, Y. A.	P6-2
Brachmann, R. K.	P27-2	Bueso-Ramos, C. E.	P22-1	Cao, Z.	P64-31
Brackett, D. J.	P21-5, P53-12	Buettner, G. R.	P5-18	Cappello, J.	P16-11
		Bugge, T.	P50-21	Caravagliia, G. M.	P15-3
				Carbone, C.	P27-3
				Cardelli, J.	P60-2

## Poster/Author Index

---

Cardiff, R. D.....	P1-3, P9-17, P11-6, P50-11, P50-21	Chambers, S. K.....	P11-4	Chen, N.....	P64-34
Carey, J. L.....	P53-8	Chamness, G. C.....	P1-14, P2-22	Chen, P.....	P65-5, P67-13, P67-14
Carey, L. A.....	P27-4	Champion, S.....	P10-20	Chen, P-L.....	P50-14, P67-25
Carlson, C. B.....	P67-3	Chan, A. M.....	P54-2	Chen, Q.....	P45-4
Carlson, G.....	P64-31	Chan, H-P.....	P14-5, P14-13, P14-18, P41-1, P64-12	Chen, S.....	P26-3
Carmack Taylor, C.....	P69-2	Chan, J.....	P52-17	Chen, S-H.....	P45-13
Carmell, M. A.....	P4-5	Chan, M.....	P53-16	Chen, W. (GMR Epigenetics).....	P44-5
Carmon, K. S.....	P35-9	Chan, R.....	P2-16, P52-2	Chen, W. (Univ. of Chicago).....	P14-2
Carolin-Amrikia, K.....	P31-19	Chance, B.....	P14-20, P64-7	Chen, X. (Fox Chase Cancer Ctr.).....	P40-6, P51-7
Carothers Caraway, C. A.....	P52-16	Chandler, D. S.....	P54-8	Chen, X. (Stanford Univ.).....	P44-2
Carpenter, E.....	P37-7	Chandrasekharan, S.....	P3-5	Chen, X. (Univ. of Alabama).....	P27-10
Carpenter, G.....	P26-20	Chang, C.....	P7-24	Chen, Y. (Boston Univ.).....	P40-5
Carpenter, L. A.....	P20-8	Chang, C-C.....	P37-1	Chen, Y. (Columbia Univ.).....	P49-6
Carpenter, P. B.....	P4-22	Chang, C-W.....	P6-3	Chen, Y. (Univ. of Chicago).....	P51-8
Carraway III, K. L.....	P26-23	Chang, C-Y.....	P35-14	Chen, Z. (Univ. of Arizona).....	P13-2
Carraway, H.....	P13-4, P13-5	Chang, E.....	P30-7, P30-20	Chen, Z. (Univ. of South Florida).....	P14-7
Carraway, K. L.....	P52-16, P53-5	Chang, H.....	P26-14	Cheney, D.....	P38-6
Carroll, J. M.....	P26-17	Chang, H. R.....	P40-2	Cheng, D-S.....	P3-27
Carroll, J. S.....	. P5-3, P6-2	Chang, L. M.....	P60-8	Cheng, H.....	P16-17
Carson, D. A.....	P62-4	Chang, L-Y.....	P35-8	Cheng, H-C.....	P60-7
Carter, S.....	P40-7	Chang, N-S.....	P54-3	Cheng, J. (Henry Ford Hlth.).....	P11-27, P11-28, P11-29
Carter-Wientjes, C.....	P61-1	Chang, P.....	P70-4	Cheng, J. (Univ. of Texas, M.D. Anderson).....	P33-10
Case, D.....	P20-13, P20-14	Chang-Claude, J.....	P17-1	Cheng, K-H.....	P30-22
Case, L. D.....	P69-4	Chao, C.....	P51-6	Cheng, L. (Cornell Univ.).....	P54-13
Casero, R.....	P67-12	Chao, W. R.....	P38-24	Cheng, L. (Indiana Univ.).....	P35-8
Casero Jr., R. A.....	P67-6	Chattfield, E.....	P40-22	Cheng, S-Y.....	P38-1
Casey, P. J.....	P38-5	Chatterjee, G.....	P5-11	Cheng, Z.....	P48-9
Cassidy, P.....	P27-5	Chaturvedi, V.....	P67-9	Chepko, G.....	P3-7
Cassileth, B.....	P22-6	Chaudhuri, A. R.....	P66-3	Chertok, B.....	P67-20
Castaneda, A. J.....	P46-9	Chaudhuri, T. R.....	P45-3, P64-8	Cheung, T. H.....	P28-4
Castelo-Soccio, L. A.....	P53-6	Chaung, K.....	P54-8	Chew, K.....	P56-11
Castono, A.....	P12-3	Chavarria, T.....	P59-11	Chiba, N.....	P51-9
Castro-Rivera, E.....	P30-6	Chavez-Reyes, A.....	P21-7	Chicken, D.....	P64-19
Catarious, D.....	P14-8, P14-16	Chawengsaksophak, K.....	P9-12, P9-20	Chien, Y.....	P31-1
Cavalieri, E. L....	P50-2, P50-3, P50-17, P50-18	Cheatham, R. B.....	P5-5	Childs, J.....	P12-4
Cavalli, I. J.....	P56-6	Chen, B. P-C.....	P30-15	Chin, K.....	P32-24, P54-17
Cavalli, L. R.....	P56-6	Chen, C.....	P71-2	Chin, Y-Y.....	P50-5
Cecchini, G.....	P55-11	Chen, C-C. R.....	P44-3	Chinander, M. A.....	P42-2
Celestino, J.....	P12-15	Chen, D.....	P16-8	Ching, K. H.....	P31-2
Cella, N.....	P54-24	Chen, D. J.....	P4-23, P25-9, P30-15	Chingos, D.....	P50-16
Ceresa, B.....	P26-2	Chen, F.....	P58-4, P58-5	Chirgwin, J. M.....	P38-2
Cerione, R. A.....	P26-19	Chen, H.....	P30-14	Chirstov, K.....	P29-14
Cerone, M. A.....	P56-7	Chen, H-W.....	P19-6	Chisholm, K. M.....	P56-14
Cerussi, A.....	P64-16	Chen, J. (Mayo Clinic, Rochester).....	P4-25, P30-15	Chlebowksi, R. T.....	P24-5
Cervantes, R. B.....	P56-8	Chen, J. (Mount Sinai).....	P49-5, P49-21	Cho, H-M.....	P39-12
Cesaretti, J. A.....	P62-17, P62-18	Chen, J. (Univ. of Michigan).....	P67-19	Cho, H-S.....	P26-8
Chada, K.....	P10-1	Chen, J. (Univ. of Pennsylvania).....	P47-5	Cho, R.....	P3-17, P60-16
Chahal, M. S.....	P27-6	Chen, J. (Vanderbilt Univ.).....	P9-2, P9-4	Chodosh, L. A.....	P1-4, P1-20, P3-1, P11-5, P11-6, P11-7, P11-15, P53-9, P57-2
Chai, K. X.....	P54-4	Chen, K.....	P17-4	Choi, J.....	P58-10
Chai, W.....	P56-22	Chen, K. M.....	P11-28, P11-29	Choi, K. Y.....	P24-2
Chai, X.....	P32-12	Chen, K-Y.....	P2-8	Choi, Y.....	P16-4
Chaiet, S.....	P36-15	Chen, L. (Mayo Clinic, Rochester).....	P45-9	Chong, C. R.....	P16-5
Chair, X.....	P32-13	Chen, L. (Univ. of Central Florida).....	P54-4	Choniedass-Kothari, S.....	P36-8
Chakarova, G.....	P41-4	Chen, L. P.....	P25-1	Chou, Y-C.....	P52-14
Chakraborty, C.....	P10-3	Chen, L-Y. L.....	P32-9	Choudhury, P.....	P2-22
Chakraborty, N.....	P6-7, P61-5	Chen, M.....	P53-1	Chouikha, M. F.....	P14-6, P17-2
Chamaillard, S.....	P53-13	Chen, M. S.....	P3-6		
Chambers, A. F.....	P10-18, P38-8, P60-4	Chen, M. Y.....	P23-23		
Chambers, J. G.....	P13-17				

## Poster/Author Index

Chow, F. A.	P2-3	Collier, A.	P69-8	Cui, X. (Louisiana State Univ.)	P17-3
Chowdhury, I.	P55-20	Collins, C. (UCSF)	P32-24	Cui, Y. (Baylor College of Medicine)	P7-3, P7-7, P7-10
Chrestensen, C. A.	P31-3	Collins, C. (Univ. of Chicago)	P51-23	Cui, Y. (Vanderbilt Univ.)	P22-2
Chretien, M.	P55-19	Collins, M.	P53-15	Cummings, S. S.	P49-8
Christensen, D. E.	P51-10	Collins, P. J.	P28-4	Cunningham, J. E.	P70-1
Christman, J. K.	P13-6	Collins, T.	P66-5	Curiel, T. J.	P61-1
Christy, B. A.	P71-3	Conant, A. R.	P26-7	Curley, M.	P6-15
Chrivia, J. C.	P7-2	Conant, E. F.	P42-1	Curran, E. M.	P39-6
Chu, I.	P26-3	Conklin, D. S.	P4-5, P6-5, P6-15	Currier, A.	P64-34
Chu, L. E.	P29-5	Constantinescu, A.	P64-3	Curtis, L. J.	P13-22
Chu, L-H.	P29-14	Constantinou, A. I.	P62-5	Curtis-Snell, L.	P7-16
Chu, P.	P42-3, P68-5	Contreras, M.	P55-10	Cutler, M. L.	P52-6
Chu, Q.	P13-3	Contreras, M. A.	P9-3	Cutter, G.	P42-3
Chua, H. L.	P59-14	Conway, K.	P49-7	Czene, K.	P70-5
Chubb, L. S.	P43-2	Conzen, S. D.	P2-1	Czyz, D. M.	P62-5
Chuck, T.	P22-6	Cooch, N. S.	P40-6	<b>D</b>	
Chun, N.	P4-8	Cook, R.	P2-22	Dadiani, M.	P63-3
Chung, G. G.	P6-4	Cook, S. L.	P5-10	Dadke, D.	P54-6
Ciarloni, L.	P3-23	Coombes, K. R.	P36-13	Dagar, S.	P15-7
Cinnante, K.	P31-15	Cooper, B.	P23-5, P23-8	Dahiya, S.	P40-22
Cipak, L.	P25-2	Cooper, C. M.	P11-8	Dai, C.	P11-26
Clancy, J. L.	P4-16, P32-18	Cooper, K.	P57-6	Dai, J.	P30-8
Clare, S. E.	P48-1	Copland, J. A.	P64-23	Dai, Q.	P49-3
Clark, B.	P64-19	Coppe, J-P.	P59-3	Dai, X.	P3-16
Clark, D. D.	P33-1	Corbett, H.	P59-8	Daida, Y. G.	P49-12
Clark, D. S.	P43-14	Corbitt, C.	P61-1	Dairkee, S.	P10-20
Clark, G. M.	P6-12	Corio, C.	P4-20	D'alessio, S.	P31-15
Clark, R.	P18-3	Cornejo, J.	P55-10	Daley, D.	P6-6
Clarke, C. A.	P49-10	Cornett, S.	P40-13	Daling, J. R.	P6-23, P70-11
Clarke, C. L.	P8-2	Cornwell, J. M.	P62-3	Dalton, J. T.	P55-17
Clarke, M.	P3-17, P60-16	Corr, M.	P62-4	Daly, M.	P13-20, P23-10
Clarke, R.	P18-1, P18-2, P35-18, P66-4, P66-14	Cortes, M.	P28-5	Daly, R. J.	P2-2
Clearfield, R. J.	P42-4	Cosenza, S. C.	P67-1	D'Andrea, A. D.	P4-18
Cleary, M. A.	P5-14	Cosman, M.	P7-1	Danes, C.	P67-22
Cleary, M. P.	P61-2	Cotarla, I.	P2-4	Dang, T.	P32-3
Cleveland, R. J.	P49-4	Cotroneo, M.	P37-4	Dang, Y.	P12-10
Cleveland, T. E.	P61-1	Cotrutz, C.	P17-6	Daniel, D. B.	P15-10
Clinton, G. M.	P13-7, P26-17	Couch, F. J.	P25-3, P25-4, P40-21, P57-3		
Chattingius, S.	P24-4	Counter, C. M.	P32-4	Daniel, J. M.	P31-4
Coates, C.	P16-8	Coupier, I.	P49-11	Daniel, L. W.	P61-3
Cobb, M. H.	P2-12	Coussens, L.	P50-21	Daniely, Y.	P54-1
Cochrane, B.	P24-5	Couture, M-C.	P35-10	Danishefsky, S. J.	P16-21, P16-25
Cody, J. J.	P46-3	Cowan, J. M.	P45-2	Daoud, S. S.	P27-6
Coffing, S.	P26-14	Cowin, P.	P1-14, P31-8	Darnay, B.	P44-13
Cohen, E. P.	P45-5	Cox, L.	P7-2	Das, G. M.	P27-7
Cohen, I.	P50-16	Coyne, J. C.	P62-16, P62-19, P69-9	Das, R.	P6-7, P61-5
Cohen, R.	P30-29	Craig, D.	P71-9	Das, S.	P19-8
Cohen, R. B.	P67-10	Crawford, Y.	P56-24	Das, S. K.	P13-8
Cohn, B. A.	P8-6	Cregger, M.	P33-7	Dasgupta, R.	P31-5
Colby, S.	P11-19	Creighton, D. J.	P16-6	D'Assoro, A. B.	P29-6
Colditz, G. A.	P24-9	Crews, C. M.	P67-15	Datta, S.	P11-9, P27-8
Cole, B.	P13-17	Cronin, E.	P64-34	Davidson, N. E.	P67-6, P67-12
Cole, C.	P5-13	Crooke, E.	P55-6	Davidson, R.	P45-7
Cole, D. J.	P40-16	Crowe, D. L.	P4-6, P4-7	Davie, J.	P7-16
Cole, G.	P45-10	Cruz, G.	P40-3	Davies, C.	P38-2
Coleman, M. L.	P18-7	Cryns, V. L.	P58-4, P58-5	Davis, M.	P30-18
Colicelli, J.	P54-5	Cui, H.	P37-2	Davis, S. L.	P30-27
Collart, F. R.	P51-8	Cui, H. (Duke Univ.)	P35-14	Davis, T. N.	P56-9
Collie, N.	P59-5	Cui, W.	P65-7	Davo, P. A.	P54-12
		Cui, X. (Baylor College of Medicine)	P30-7		

## Poster/Author Index

Dawlaty, M.....	P13-6	Dewitty, R. L.....	P35-11, P35-12	Donnenberg, V. S.....	P66-6
Dawson, M. I.....	P58-18	Dharmawardhane, S. F.....	P38-3, P38-9	Donover, P. S.....	P45-16
Day, A.....	P6-7	Dheekollu, J.....	P51-21	Dontu, G.....	P3-24
Day, B. W.....	P16-16	Di, X.....	P48-4, P48-5	Doody, D. R.....	P70-11
Dayan, G.....	P7-14	Diamandis, E. P.....	P13-9	Doorenbos, A. Z.....	P23-3
D'Cruz, C. M.....	P1-4	Diaz, N.....	P6-21	Dorgan, J. F.....	P24-13
de Assis, S.....	P61-4	Dick, F.....	P30-26	Dorn, D. C.....	P16-21
de Bruin, A.....	P59-4	Dick, S.....	P40-14	Dorsey, K. C.....	P27-4
de Fail, A.....	P16-9	Dicker, A.....	P30-23	D'orsi, C.....	P41-3
de Haan, J. B.....	P8-2	Dickinson, E. S.....	P57-5	Dotson, P.....	P46-14
de la Cruz, C.....	P51-9	Dickson, R. B.....	P31-23, P32-9, P32-10	Dou, Q. P.....	P16-8
de la Cruz, L.....	P55-8	Diebold, G. J.....	P64-4, P64-9	Douglas, J. T.....	P46-3
de la Fuente, C.....	P51-16	Diefenbach, M.....	P23-10	Douglas, P.....	P4-13
de Lille, A.....	P43-2	Diehl, S.....	P6-27	Dourdin, N.....	P52-12
Dearth, L. R.....	P27-2	Dietze, E. C.....	P5-12	Dovichi, N. J.....	P6-11
Deb, T.....	P31-23	Digiovanna, M.....	P69-11	Dowty, J.....	P70-4
Debies, M. T.....	P1-5	Diiorio, T.....	P62-9	Doxsey, S.....	P32-15
Deblois, G.....	P6-17	Dijkgraaf, G. J. P.....	P53-7	Doley, M. M.....	P64-29
Dedhar, S.....	P58-9	Dilis, R.....	P16-13, P16-14	Draghici, S.....	P6-26
Deecheandia, L.....	P69-13	Dillon, R.....	P52-3	Drescher, J. M.....	P42-4
defazio, A.....	P8-2	Dimitrov, I.....	P65-3	Dressler, L.....	P27-4
Deffenbaugh, A.....	P25-4	Dimitrova, D.....	P54-1	Drezek, R.....	P64-15
DeFreest, L. A.....	P16-7, P62-2	Dimri, G. P.....	P11-9, P27-8	Driskell, R. R.....	P60-18
Degani, H.....	P63-3	Dimri, M.....	P52-1	Drouin, S.....	P27-4
Degnim, A. C.....	P50-4, P50-7, P50-9, P50-10, P50-22	Ding, Q.....	P46-8	Drukker, K.....	P71-5
Degtere, A.....	P2-24	Ding, X.....	P37-2	Dryden, M.....	P48-8
Dehghani, H.....	P14-21	Ding, Y. (Medical College of Georgia) ....	P26-16	Du, J.....	P56-10
Deibler, R. W.....	P56-16	Ding, Y. (New York State Department of Health).....	P7-18	Du, T.....	P64-16
Deisseroth, A. B.....	P45-6	Dingell, J. D.....	P20-7	Du, W.....	P20-7
del Prete, M. J.....	P6-8	Disis, M. L.....	P12-4, P12-10, P12-11, P12-12	Dube, M. G.....	P34-3
dela Rosa, C.....	P12-4	Dissanayake, S. K.....	P12-14	DuBois, G. C.....	P40-18
Delk, J.....	P26-16	Dissmore, T.....	P6-25	Duckett, E.....	P14-6
Delprado, W.....	P37-7	Dixon, J. M.....	P18-1	Duda, D. M.....	P32-19
Demarco, T.....	P69-13	Dixon, R. H.....	P20-9	Dudley, W.....	P23-12
Demayo, F. J.....	P3-20	Djuric, Z.....	P62-11	Duffy, H. X.....	P12-6
Demicco, E. G.....	P3-8, P37-8	Dmochowski, I. J.....	P65-3	Dugan, C. M.....	P61-1
DeMichele, A.....	P45-7, P69-9	Doan, T. B.....	P28-4	Dugan, K. D.....	P1-4
DeNardo, D. G.....	P7-4	Dobhal, M.....	P30-19	DuHadaway, J. B.....	P45-16
Dence, C. S.....	P15-5	Dobrolecki, L. E.....	P13-13	Duke, K.....	P62-22
Deng, C-X.....	P50-13, P51-11, P51-27	Dobrzycka, K. M.....	P30-9, P30-10	Duke, L.....	P30-8
Deng, D.....	P7-9	Dodd, M. J.....	P23-4, P23-5, P23-8	Dulaimy, K.....	P63-7
Deng, Y.....	P54-24	Doerge, D.....	P62-11	Dumont, P.....	P27-15
Deng, Z.....	P51-21	Doering, W. E.....	P41-4	Dumur, C.....	P48-4
Denissova, N. G.....	P29-18	Doerning, R.....	P5-8	Duncan, J.....	P35-18
Denmeade, S. R.....	P67-4	Dolan, B. P.....	P12-5	Duncan, V.....	P59-18
Der, C. J.....	P38-5	Dolan, M. E.....	P51-23	Dunphy, K. A.....	P62-6
Dering, J.....	P3-25, P3-26	Dollof-Filhart, M.....	P40-4	Dunston, G.....	P57-1
Dernell, W. S.....	P43-2	Domann, F.....	P17-5	Dunwoodie, S. L.....	P32-18
Dershaw, D. D.....	P63-1	Domchek, S. M.....	P45-7	Duong, J. K.....	P4-14
Desai, R.....	P2-15	Dominguez, I.....	P2-5	Durna, L. N.....	P67-11
Deshaines, R. J.....	P67-15	Dominiecki, M. E.....	P12-13	Duru, N.....	P39-6
Desilva, D.....	P49-18	Donahoe, P. K.....	P53-8	Duza, T.....	P9-19
Desombre, E. R.....	P16-13	Donahue, H. J.....	P60-5	Dyke, J. P.....	P63-6
Dettenborn, L.....	P23-2	Donaton, M.....	P11-11	<b>E</b>	
Detty, M. R.....	P47-1, P47-2, P47-4	Dong, D.....	P46-2	E.C.U./A.A.M.C. Sentinel Node Study	
Deutsch, M.....	P38-25	Dong, Y.....	P51-7	Group.....	P40-24
Devine, P.....	P23-1	Dong, Z.....	P7-24	E.C.U./A.A.M.C. Sentinel Node Study	
Dewhirst, M. W.....	P11-30, P15-10, P16-1, P38-5, P44-9	Donnelly, D. J.....	P47-1, P47-2	Group.....	P48-9
		Donnenberg, A. D.....	P66-6	Earley, S.....	P33-2

## Poster/Author Index

Early, R.	P55-7	Evans, S.	P45-4	Fisher, P.	P63-7
Ebbinghaus, S.	P52-19	Eyal, E.	P63-3	Fisher, P. B.	P2-21, P46-12
Eddy, S.	P31-6	Eyfjord, J. E.	P49-20	Fitzpatrick, F.	P27-5
Edes, K.	P27-5	Ezeome, E. R.	P49-15	Flanagan, L.	P10-16
Edge, S.	P24-6			Flaws, J. A.	P70-12
Edington, H.	P16-9			Fleisher, L.	P23-10, P23-11
Edmiston, S.	P49-7	F		Fleming, K. G.	P52-4
Edwards, D. C.	P14-3	Fabian, C. J.	P69-10	Fleming, T.	P65-1
Efferson, C.	P12-15	Facciponte, J. G.	P45-8	Flesken-Nikitin, A.	P54-13
Egan, S.	P3-9	Facione, N. C.	P23-5, P23-8	Flom, K.	P66-16
Eghatedari, M.	P64-23	Fackenthal, J.	P51-8	Florence, B.	P30-27
Eidelman, O.	P2-23	Fackler, M. J.	P13-12	Flowers, S.	P29-20
Eiffert, C.	P6-5	Fahkro, A.	P7-15	Floyd, C.	P14-8, P14-16
Ekbom, A.	P24-4	Faintuch, S.	P22-4, P22-5	Floyd Jr., C. E.	P14-1
Eklund, A.	P40-7	Faivre, E. J.	P35-5	Flynn, J. T.	P40-19
Elashoff, D.	P40-2	Falzon, M.	P64-19	Flynn, S.	P67-2
El-Ashry, D.	P7-5	Fan, D.	P35-14	Focht, D.	P3-15
El-Deiry, W. S.	P32-13	Fan, L.	P53-10	Foley, N. A.	P3-5
El-Gharbawy, A.	P7-19	Fan, M.	P7-17	Fomitchov, P. A.	P65-8
Elias, A.	P18-6	Fan, P.	P50-18	Fonnegra, A.	P44-20
Eliceiri, B. P.	P60-1	Fandy, T.	P67-17	Fonseca, D.	P51-17
Eliopoulos, N.	P46-4	Fang, W. B.	P9-2, P9-4	Fonseca, J. P.	P61-1
Elledge, S. J.	P4-22, P29-7, P29-8	Fantini, S.	P64-10	Fonville, N. C.	P56-13
Elliott, B. E.	P53-3, P53-16	Farago, M.	P2-5	Foos, G. E.	P31-7, P33-6
Elliott, J.	P11-12	Farber, M. J.	P40-6	Ford, J. M.	P4-8
Elliott, S.	P61-1	Faris, G. W.	P64-11	Fordyce, C. A.	P56-5, P56-11, P56-12
Elmore, L. W.	P2-20, P48-4	Farley, K.	P6-5	Forman, A.	P23-22
El-Naggar, A.	P54-8	Farlow, S. J.	P46-11	Formenta, S.	P17-11
Elston, R. C.	P6-6	Farmer, D.	P69-3	Formenti, S. C.	P62-17, P62-18
Eltom, S. E.	P29-4	Farrugia, D.	P25-4	Fort, J. G.	P62-1
Elzey, J. D.	P62-1	Farzanfar, R.	P23-12	Forte, L. R.	P65-4
Emberley, E. D.	P7-16, P11-8, P11-25	Fasco, M.	P7-18	Fortier, J.	P39-9
Emerson, J.	P40-4	Fata, J. E.	P58-6, P59-1	Foulkes, W. D.	P25-1, P56-15
Eng, C.	P57-6, P59-4, P67-21	Faull, K.	P40-2	Fowler, A. M.	P7-6
Eng, S. M.	P49-9	Fedarko, N. S.	P9-5, P13-15, P13-16	Fox, K. R.	P45-7
Engel, B. D.	P58-8	Feig, S.	P62-18	Frackelton Jr., A. R.	P54-12
Engelhardt, J. F.	P60-18	Feinberg, A. P.	P57-4	Francisco, E.	P9-12, P9-20
England, E.	P26-16	Feirt, N.	P9-20	Francois, M.	P19-5, P46-4
Erbas, B.	P70-4	Felding-Habermann, B.	P38-4	Frank, M. H.	P66-7
Erdman, A. G.	P48-7	Feldkamp, C. S.	P23-19	Frank, N. Y.	P66-7
Erhardt, P.	P61-1	Feldman, M. D.	P45-7	Franke, T. F.	P2-6, P2-7
Erickson, A. E.	P28-2	Feng, L.	P11-10	Franks, R.	P29-14
Erlander, M. G.	P40-21, P40-22	Feng, S.	P23-23, P69-13	Franzin, C. M.	P58-10
Erlich, H. M.	P49-10	Ferguson, J.	P40-4	Frederick, M.	P12-15
Erramilli, S.	P40-5	Ferguson, S. L.	P14-15	Fredericksen, Z. S.	P57-3
Errington, T. M.	P2-11	Fernandes, G.	P22-3	Freedman, M. T.	P14-6
Eshhar, Z.	P12-7	Fernandez, S. V.	P8-3, P8-4, P8-5, P50-6	Freeman, J. E.	P64-24
Esmay, P.	P57-2	Fernandez-Gonzalez, R.	P41-2	Freese, K. P.	P56-14
Esserman, L.	P23-1, P27-4, P50-5, P61-13	Fernbaugh, R.	P8-4, P8-5	Freudenheim, J. L.	P24-6, P49-8
Essler, M.	P9-23	Ferrari, G.	P31-15	Fridovich, I.	P16-1
Estes, D. M.	P39-6	Ferrell, R. E.	P49-15	Friedman, R.	P23-12
Esteva, F. J.	P13-10, P13-11, P67-23	Ferro, F.	P12-2	Friedman, S.	P62-16, P62-19
Estrada, J. K.	P70-10	Ferrone, S.	P12-2	Friedmann-Morvinski, D.	P12-7
Etchin, J.	P25-8	Fidler, I. J.	P60-20	Frost, A. R.	P59-18, P60-23
Etheridge, K. T.	P32-4	Fields, T. A.	P38-5	Frost, M. H.	P20-8, P50-4, P50-9, P50-10
Ethier, S. P.	P1-23	Fillippo, J. S.	P25-8	Frydman, B.	P67-6
Evan, G. I.	P1-6	Fingleton, B.	P50-21	Frye, B.	P62-22
Evans Jr., Ch. H.	P35-18	Fintak, P.	P12-4	Frye, C.	P48-2
Evans, E. E.	P24-8	Fischer, N. O.	P27-9, P44-14	Fu, D.	P5-8
Evans, J. A. P.	P43-5	Fisher, J. L.	P11-12	Fu, W.	P36-2
		Fisher, L. W.	P9-5, P13-15, P13-16		

## Poster/Author Index

Fu, Y.....	P2-25	Gatenby, R. A.....	P11-26	Giri, D.....	P11-11
Fuchs, E.....	P30-18	Gaudet, M. M.....	P49-9, P49-21	Giuliano, A. E.....	P66-8, P66-11
Fujii, N.....	P16-24	Gaudreault, J.....	P67-11	Given, B.....	P23-3
Fujita, D. J.....	P2-8	Gauger, M. A.....	P29-9	Given, C. W.....	P23-3
Fukino, K.....	P59-4	Gaut, A.....	P17-5	Glaser, S. L.....	P49-10
Fukuda, M.....	P10-2	Gauthier, M.....	P56-24	Glenn, M.....	P20-11
Fukuda, M. N.....	P10-2	Gavini, N.....	P33-8	Glenn, W.....	P37-7
Fukuda, Y.....	P67-15	Gay, C. V.....	P32-5, P38-17, P60-3, P60-13	Gludish, D.....	P1-7
Fulton, A. M.....	P39-7	Gayen, S. K.....	P14-19, P64-1, P64-2	Go, M.....	P29-16
Funahashi, Y.....	P9-12	Gayol, L.....	P6-1	Godbold, J.....	P39-3
Funnell, M.....	P2-8	Ge, W.....	P5-14	Godwin, A. K.....	P23-10, P40-6, P51-7, P54-6
Fuqua, S. A. W.....	P7-3, P7-7, P7-10, P35-12	Geahlen, R. L.....	P33-3	Goetz, M.....	P40-21
Furman-Haran, E.....	P63-3	Gear, R.....	P3-10	Gofinett, D.....	P17-6
Furth, P. A.....	P2-4	Gediya, L.....	P43-11	Gokhale, N. H.....	P64-22
<b>G</b>					
Gabig, T.....	P67-7	Geffel, D. L.....	P32-5	Golan, A.....	P29-24
Gaborieau, V.....	P49-11	Gehan, E.....	P55-16	Goldenberg, D. M.....	P67-18
Gabrielson, K.....	P52-5	Gehring, S.....	P64-4	Goldfrank, D. J.....	P62-9
Gaczynska, M.....	P55-4, P55-5	Gehrs, B.....	P10-12	Goldgar, D.....	P25-4, P49-11
Gaillard, S.....	P7-8	Geiger, T.....	P30-28	Goldin, L.....	P1-1
Galbaugh, T.....	P52-6	Geller, B.....	P42-3	Goldsmith, E. J.....	P2-12
Galipeau, J.....	P19-5, P46-4	Gelovani, J.....	P65-2	Goldstein, L.....	P20-11, P23-10
Galitovskaya, E. N.....	P44-21	Gelovani, J. G.....	P64-26	Goldstein, L. A.....	P2-18
Gallagher, M.....	P20-4	Gendler, S. J.....	P11-1, P45-9, P45-15, P55-9	Goldstein, L. J.....	P67-10
Gallicchio, L.....	P70-12	Gentlemen, R.....	P13-21	Golemis, E. A.....	P54-6
Gallo, R. M.....	P26-13	Georg, G. I.....	P43-21	Gollahon, L.....	P59-5
Gallucci, B.....	P20-6	George, D. L.....	P27-15	Gomez, B.....	P18-2, P18-3, P66-4, P66-14
Galvao, C.....	P5-11	Georgekutty, J.....	P62-2	Gong, H.....	P7-23
Galvez, J.....	P50-11	Geradts, J.....	P38-11	Gong, X.....	P52-15
Gammon, M. D. ....P24-11, P49-5, P49-9, P49-21		Gerald, W. L.....	P11-11, P60-6	Gong, X-M.....	P58-10
Gandhi, S.....	P61-11	Gerson, R.....	P51-15	Gonzalez, D.....	P12-15
Ganott, M. A.....	P42-4	Gertig, D.....	P70-4	Gonzalez-Quintial, R.....	P12-1
Ganschow, P. S.....	P23-16	Gettinger, K. L.....	P26-13	Gonzalez-Trotter, D.....	P65-10
Ganz, P.....	P68-8	Getty, D.....	P41-3	Good, W. F.....	P14-4
Gao, B.....	P11-10	Gewirtz, D. A.....	P48-3, P48-4, P48-5	Goodell, V.....	P12-4
Gao, C.....	P38-4	Ghadehari, H.....	P16-11, P19-4, P65-11	Goodrich, J. S.....	P26-4
Gao, L.....	P6-9	Ghosh, G.....	P31-13	Goodsitt, M. M.....	P41-1, P64-12
Gao, X.....	P35-6	Ghosh, K.....	P50-7, P50-9	Goodwin, J.....	P71-7
Gao, Y.....	P28-4	Ghosh, S. (Mayo Clinic,		Gopal, V.....	P5-17
Gao, Y-T.....	P22-2, P49-3, P49-17	Rochester).....	P51-14, P51-20	Gopalkrishnana, R. V.....	P2-21
Garbe, J.....	P32-24, P54-17	Ghosh, S. (Yale Univ.).....	P6-4	Gorbach, S. L.....	P40-1
Garber, J. (Dana-Farber Cancer Inst.) ....P20-3		Ghosh, S. K.....	P32-6	Gorbsky, G. J.....	P29-26
Garber, J. (Fox Chase Cancer Ctr.) ..P8-4, P8-5		Ghosh-Choudhury, G.....	P22-3	Gordon, F. E. K.....	P36-15
Garcia-Barchino, M-J.....	P13-7	Ghosh-Choudhury, N.....	P22-3	Gorelik, E.....	P13-18
Garcia-Conde, J.....	P13-7	Ghosh-Choudhury, T.....	P22-3	Gornbein, J.....	P40-2
Garcia-Sanz, J. A.....	P6-8	Gibbs Jr., K. D.....	P12-5	Gorospe, M.....	P1-18
Garcia-Sastre, A.....	P12-15	Giblin, M. F.....	P65-4	Gorrin-Rivas, M.....	P19-6
Gardie, B.....	P32-24	Gibson, S. L.....	P47-1, P47-2, P47-4	Gorski, D. H.....	P9-6
Gardiner, J. C.....	P24-13	Gierthy, J. F.....	P7-18	Gouazé, V.....	P66-8
Gardner, J.....	P62-22	Giger, M. L.....	P14-2, P14-3, P71-5	Gould, M. N.....	P6-24, P37-3, P34-7, P62-14, P62-21
Gardner, L. L.....	P6-24	Giguère, V.....	P6-17, P52-12	Goulet, R.....	P35-8
Gariepy, J.....	P44-18, P67-5	Gil, S. G.....	P2-16, P52-2	Grady, J. J.....	P40-8, P61-9
Garini, Y.....	P56-15	Gildener-Leapman, N.....	P62-2	Graham, M. (McMaster Univ.).....	P31-4
Garlatti, M.....	P9-17	Gillanders, W. E.....	P40-16	Graham, M. (Univ. of Iowa Clin. & Hosp.).P17-5	
Garrett, E.....	P13-12	Gillespie, M. T.....	P11-12	Gramatikova, S.....	P16-23
Garrett-Mayer, E.....	P67-12	Gilman, V.....	P60-13	Graña, X.....	P5-9
Garriga, J.....	P5-9	Gilmore, J. L.....	P26-15	Granath, F.....	P24-4, P49-19
Garvik, B.....	P50-19	Gilmore-Hebert, M.....	P11-4	Grande, J. P.....	P61-2
Gatbonton, T.....	P16-2	Gingeras, T.....	P27-17	Grande, S. M.....	P31-11
		Giordano, T.....	P6-9	Grant, S. F.....	P15-3
		Giorgio, T. D.....	P44-3, P44-4		

## Poster/Author Index

Grant, S. G.....	P3-14	Gupta, R.....	P28-2	Han, Y.....	P58-18
Gray, J. W.....	P32-24	Gupta, V.....	P53-8	Hann, S.....	P1-24
Graziano, D.....	P27-16	Gur, D.....	P42-4	Hanna, N.....	P35-10
Green, A.....	P65-6	Gurvich, I.....	P49-6	Hannon, G. J.....	P4-5, P5-14, P6-10, P56-10
Green, B.....	P4-9	Gusev, V.....	P64-9	Hansen, R.....	P45-20
Green, J. E.....	P11-23, P53-8	Gustafson, S.....	P15-6	Hanson, P. R.....	P43-5
Green, M.....	P62-7	Guthrie, N.....	P61-13	Hanson, R. N.....	P16-12, P16-13, P16-14
Green, S.....	P62-17, P62-18	Gutierrez-Hartmann, A.....	P1-17	Harada, N.....	P19-7
Greenberg, C. S.....	P11-13	Guttenplan, J. B.....	P50-8	Hardesty, L.....	P42-4
Greene, C. M.....	P15-3	Guzman, R. C.....	P11-16	Hardman, W. E.....	P61-6, P61-7
Greene, G. L.....	P7-21, P7-22, P50-16	<b>H</b>			
Greene, L. A.....	P2-7	Haag, J. D.....	P6-24, P37-3	Hards, D. K.....	P11-12
Greenwood, T.....	P29-6	Haakenson, C.....	P55-6	Harms, J. F.....	P60-23
Greer, P. A.....	P33-9	Haba, A.....	P19-7	Harms, K. L.....	P27-10
Gregg, J. P.....	P50-21	Haber, D.....	P40-21	Haroon, Z. A.....	P11-13
Gregory, M.....	P1-24	Habibi, B. I.....	P47-3	Harper, A.....	P64-3
Gridley, T.....	P3-9	Hacker, A.....	P67-12	Harper, J. W.....	P29-10
Griffith, J. K.....	P11-14, P56-5, P56-12, P71-4	Hackett, J. (Harvard Med. Sch.).....	P29-7	Harrington, N. N.....	P3-19, P21-3
Griffith, L.....	P11-24	Hackett, J. (Univ. of Oklahoma).....	P53-12	Harris, E. E.....	P70-7, P71-6
Grimmond, B.....	P63-8	Haddad, B. R.....	P38-19, P56-6	Harris, K. W.....	P10-12, P10-13
Grisham, R.....	P16-10	Hadjiski, L. M....	P14-5, P14-13, P14-18, P41-1	Harris, L. N.....	P13-21, P40-7, P40-9
Grizzle, W. E.....	P30-14, P45-3, P5-1	Haeffele, C. L.....	P7-8	Harris, R. S.....	P56-13
Groh, K. E.....	P32-22	Hafer, L.....	P37-8	Harris, V.....	P1-1
Gromeier, M.....	P16-10	Haffty, B.....	P62-17, P62-18	Hartman, M. (Karolinska Institutet).....	P70-5
Gronowicz, G.....	P53-11	Hafsteinsdottir, H.....	P49-20	Hartman, M. (Washington Univ.).....	P65-1
Groom, A. C.....	P38-8	Hagg, J. D.....	P37-4	Hartmann, L. C.....	P49-7, P50-4, P50-7, P50-9, P50-10, P50-22
Gross, R. A.....	P20-4	Hagness, S. C.....	P64-14	Hartney, T.....	P35-14
Grove, D. I.....	P6-23	Hahn, E. W.....	P67-24	Hartwell, K. A.....	P59-7
Grove, J. S.....	P49-12	Hahn, K. T.....	P1-4	Harvell, D.....	P18-6
Grubbs, C.....	P62-10	Haider, M.....	P16-11	Harvey, K.....	P71-11
Gruszauskas, N.....	P71-5	Haiman, C.....	P50-16	Harwood, M. M.....	P6-11
Gruver, A. M.....	P56-20	Haire, T. E.....	P33-4	Haslam, S. Z.....	P35-2, P36-14, P59-23
Grzybowski, B.....	P59-10	Hait, N.....	P2-20	Hassell, J. A.....	P1-7
Gu, H.....	P2-16, P52-2	Hakim, C.....	P42-4	Hassett, M. A.....	P29-13, P70-6
Gu, J.....	P37-2	Hakimi, M-A.....	P40-6, P51-7	Hassid, Y.....	P63-3
Gu, L.....	P52-7	Halas, N. J.....	P64-15	Hastings, P. J.....	P56-16
Gu, W.....	P58-8	Halbert, C. H.....	P69-8	Hasty, P.....	P25-5, P30-4
Guan, A.....	P5-4	Hall, H.....	P50-15	Hathaway, H.....	P55-7, P55-8
Guan, J-L.....	P11-21	Hall, P. (Georgetown Univ.).....	P49-19	Hatsell, S.....	P1-14
Guarcello, V.....	P5-2	Hall, P. (Karolinska Institutet).....	P70-5	Hatsiopoulou, O.....	P22-4, P22-5
Gudas, L. J.....	P32-8, P32-21	Hall, P. (Univ. of Alabama).....	P62-10	Hattrup, C. L.....	P55-9
Guiliano, K.....	P3-15	Hallahan, D. E.....	P44-3	Hatzis, C.....	P36-1
Gullapalli, R.....	P65-11	Hallett, W. H. D.....	P45-14	Hauschka, P.V.....	P38-6, P38-7
Gulsen, G.....	P64-13	Halsey, N.....	P22-4, P22-5	Hauser, C. A.....	P31-7, P33-6
Gumbiner, B.....	P30-18	Hamaguchi, M.....	P30-11	Haviv, I.....	P59-8, P59-9
Gunawardane, R. N.....	P38-21	Hamamura, M. J.....	P63-2, P63-5	Hawke, D.....	P13-10, P13-11
Gunther, E. J. (Penn. State Cancer Inst.)	P53-9	Hamblin, M. R.....	P12-3	Hazen-Martin, D.....	P55-10
Gunther, E. J. (Univ. of Penn., Phila.)	P11-15	Hamedani, M.....	P36-8	Hazlett, T. L.....	P26-12
Günther, W. H. H.....	P43-16	Hamilton, S. P.....	P49-6	He, B.....	P31-24
Guo, F.....	P19-8	Hamilton, T. J.....	P64-4	He, D.....	P29-18
Guo, M.....	P54-20	Hammamieh, R.....	P6-7, P61-5	He, J.....	P40-2
Guo, P. (Purdue Univ.).....	P46-5	Hammer, R.....	P26-14	Heaphy, C.....	P56-12
Guo, P. (Univ. of Pittsburgh).....	P38-1	Han, B. (Indiana Univ.).....	P66-20	Hearnes, J.....	P27-11
Guo, S. (Boston Univ.).....	P1-3, P31-6	Han, B. (Univ. of Minnesota).....	P21-8	Heath, C.....	P5-13
Guo, S. (Fox Chase Cancer Ctr.).....	P40-6	Han, D.....	P24-6	Hebbard, L. W.....	P9-17
Guo, Y.....	P52-11	Han, J.....	P2-18	Hebbing, S.....	P57-3
Gupta, A. (VA Palo Alto Hlth. Care Sys.)	P66-9	Han, L.....	P9-7, P9-8, P60-24	Hebert, J. R.....	P24-1, P70-1
Gupta, A. (Washington Univ.).....	P56-19	Han, S-Y.....	P30-23	Hecht, S. M.....	P2-11
Gupta, G. P.....	P60-6	Han, W.....	P52-15	Hedley, B. D.....	P38-8
Gupta, P. B.....	P59-6, P59-11			Hedlund, L. W.....	P15-10

## Poster/Author Index

Heersink, J. L.	P61-12	Hitchens, M.	P44-12	Huang, J.	P30-24				
Heffelfinger, S. C.	P3-10	Ho, C.	P1-16	Huang, L.	P1-11				
Heffer, E. L.	P64-10	Ho, P.	P67-16	Huang, M.	P64-17, P64-34				
Hegde, P.	P64-34	Ho, S-M.	P16-14	Huang, Q.	P33-10				
Heim, K. C.	P7-9	Ho, W. C.	P27-12, P32-12	Huang, S. (Baylor College of Medicine)	...P1-14				
Heimburg, J.	P12-8	Hoang, T.	P54-2	Huang, S. (Scripps Research Inst.)	.....P46-6				
Helferich, W.	P61-8	Hobbs, S.	P26-14	Huang, T-G.	P45-13				
Helvie, M. A.	P14-5, P14-13, P14-18, P41-1, P64-12	Hochberg, R. B.	P16-12	Huang, W. (Mem. Sloan-Kettering Cancer Ctr.)	.....P63-1				
Henderson, B.	P50-16	Hodges, T. W.	P43-9	Huang, W. (State Univ. of NY, Stony Brook)	.....P63-7				
Henderson, B. S.	P5-5	Hoelz, D. J.	P13-13	Huang, Y. (Johns Hopkins Univ.)	.....P67-6, P67-12				
Henderson, M. J.	P4-16, P32-18	Hoffman, B.	P54-19	Huang, Y. (Univ. of Texas, Galveston)	.....P40-8				
Hendrix, M. J. C.	P5-10, P60-18	Hoffman, R. M.	P3-2	Hudacheck, S. F.	.....P43-2				
Henke, R. T.	P10-19	Hoffmeyer, M.	P38-3, P38-9	Hudis, C. A.	.....P11-11, P62-9				
Henrichs, P. M.	P64-23	Holbert, M.	P51-12	Huebner, K.	.....P30-23				
Herbert, B-S.	P13-13	Holloman, W. K.	P4-10	Huggins, C. J.	.....P25-6				
Herlyn, D.	P12-9	Holloway, C.	P67-14	Hughes, A.	.....P16-13				
Herman, J. (Sidney Kimmel Cancer Ctr.)	P13-4, P13-5	Holloway, J.	P7-5	Hughes, B. D.	.....P40-1				
Herman, J. (Univ. of Texas M.D. Anderson)	P59-13	Holt, D.	P39-7	Hughes, D.	.....P49-11				
Hermann, G.	P62-18	Holt, S. E.	P32-7, P48-4, P56-21	Humphreys, J. C.	.....P23-8				
Herr, M.	P64-7	Hong, M. K.	P40-5	Hung, M-C.	.....P2-13, P30-2, P46-8, P50-11, P67-22, P67-23				
Herrera, A.	P50-5	Hong, R.	P27-9	Hunt, K. K.	.....P29-13, P70-6				
Herrera, R.E.	P35-23	Hoopes, P. J.	P64-29	Huper, G.	.....P51-2				
Hersh, M. N.	P56-13	Hooshmand-Rad, R.	P31-16	Hurley, L.	.....P52-19				
Hertel, N. E.	P15-3	Hopkinson, D. A.	P51-1	Hussain, E. A.	.....P18-4				
Hertzle, P.	P31-22	Horigan, K. C.	P3-12	Hutnick, N. A.	.....P20-9				
Herynk, M. H.	P7-10	Hortobagyi, G. N.	P13-10, P13-11, P30-2, P50-11, P55-18, P67-23	Hyunh, C.	.....P43-11				
Herzog, H.	P29-21	Horwitz, A. A.	P4-18, P51-13	Hwang, C-S.	.....P23-4				
Hess, A. R.	P60-18	Horwitz, K. B.	P18-6	Hwang, H. Y.	.....P45-21				
Hetrick, V.	P50-16	Horwitz, S. B.	P66-19	Hwang, J.	.....P13-21				
Heulings, R.	P8-4, P8-5	Hosokawa, M.	P46-13	Hwang, W-T.	.....P70-7				
Hewitt, S. M.	P54-8	Hossain, C. F.	P43-9	Hylton, N.	.....P23-1, P50-5				
Hickey, R. J.	P13-13	Houser, R. F.	P40-1	Hyun, T. S.	.....P53-13				
Hicks, D.	P9-2	Hovey, R. C.	P3-12	<b>I</b>					
Hickson, I. D.	P4-3	Howard, K.	P12-12	Iacoangeli, A.	.....P13-14				
Hidaka, M.	P9-18	Howe, L. R.	P21-4	Iacopetta, B.	.....P37-7				
Higgins, D.	P12-4	Hricak, H.	P63-1	Iglehart, J. D.	.....P13-21, P40-7				
Higgins, P. J.	P9-9, P9-10	Hryb, D. J.	P36-4	Ikui, A. E.	.....P66-19				
Hilakivi-Clarke, L.	P3-7, P61-4	Hsiang, D.	P64-16	Imamura, T.	.....P59-15				
Hilf, R.	P47-4	Hsieh, T-S.	P66-5	Imanishi, Y.	.....P38-1				
Hilger, A.	P7-5	Hsu, H-T.	P23-4	Immaneni, A.	.....P6-12				
Hilger, J.	P23-13	Hsu, L.	P6-23	Inga, A.	.....P27-13				
Hill, A. (Univ. of Alabama)	P5-1	Hsu, L-J.	P54-3	Ingle, J.	.....P40-21				
Hill, A. (Univ. of Pennsylvania)	P65-3	Hu, A.	P68-8	Ingram, C.	.....P20-5				
Hill, J.	P57-1	Hu, B. (Thomas Jefferson Univ.)	P30-23	Ino, H.	.....P38-6				
Hill, L. Z.	P57-5	Hu, B. (Univ. of Pittsburgh)	P38-1	Ioannides, C. G.	.....P12-15				
Hill, S. R.	P8-8	Hu, G.	P29-7	Ionov, Y.	.....P54-7				
Hilmarsdottir, H.	P49-20	Hu, H.	P54-5	Ip, E.	.....P69-3, P69-5, P69-7				
Hilsenbeck, S. G.	P6-12, P7-10	Hu, J. (GMR Epigenetics)	P44-5	Ip, M. M.	.....P9-11, P35-7				
Himes, R. H.	P43-21	Hu, J. (Univ. of North Carolina)	P32-14	Irani, K.	.....P52-5				
Hinck, L.	P3-11	Hu, M. (Dana-Farber Cancer Inst.)	P59-15	Iruela-Arispe, M. L.	.....P9-15, P19-2				
Hines, W. C.	P11-14, P56-5	Hu, M. (Univ. of California, Irvine)	P3-16	Isaacs, C.	.....P4-20, P69-13				
Hinshaw, J. C.	P43-3, P43-4	Hu, M. (Univ. of Toronto)	P65-5	Isakoff, S.	.....P40-21				
Hinson, S. R.	P25-3, P25-4	Hu, X.	P16-15	Isayeva, T.	.....P46-10				
Hirai, Y.	P71-2	Hu, Y.	P51-14, P51-20	Ishioka, C.	.....P51-9				
Hird, S. L.	P32-18	Hu, Y. C.	P7-24	Ismail, P. M.	.....P3-20				
Hiremath, M. M.	P31-8	Hu, Z. (Cancer Inst. of NJ)	P66-1						
Hirsch, R.	P63-3	Hu, Z. (Univ. of Mich.)	P43-8						

## Poster/Author Index

Itoh, M.....	P31-9	Jin, F.....	P22-2	Kallergi, M.....	P14-7		
Ivanova, M.....	P30-10	Jin, H.....	P44-6	Kalra, S. P.....	P34-3		
Iwamoto, K. S.....	P37-5	Jin, J.....	P29-10	Kamalakaran, S.....	P4-11		
Iwanczyk, J. S.....	P15-3	Jin, T-G.....	P58-7	Kamath, M.....	P40-2		
Iwaniec, U. T.....	P34-3	Jin, Z.....	P53-2	Kamerick, M.....	P50-12		
Iwasio, I.....	P55-19	Jo, A.....	P68-2	Kaminski, R.....	P2-25, P55-21		
Iyer, V. R.....	P6-13	Jobling, M. F.....	P28-6	Kaminsky, M.....	P5-16		
Izen, S.....	P42-8	Joffe, H.....	P20-3	Kampa, D.....	P27-17		
<b>J</b>							
Jaber, B. M.....	P36-15	John, C. M.....	P16-17	Kan, F.....	P37-7		
Jackson, J. G.....	P30-12	John, E. M.....	P24-7, P49-10, P49-23	Kanaan, Y.....	P57-1		
Jackson, K.....	P71-11	Johnson, J. M.....	P3-14, P3-15	Kandere-Grzybowska, K.....	P59-10		
Jackson, N. L.....	P5-2	Johnson, K. (Nat. Medical Laser Ctr.)....	P64-19	Kandouz, M.....	P40-10, P40-11		
Jackson, S. P.....	P4-16	Johnson, K. (Univ. of Pennsylvania).....	P59-21	Kane, C.....	P5-4		
Jacob, J. B.....	P39-8	Johnson, K. (Vanderbilt Univ.).....	P27-11	Kane, M.....	P64-34		
Jacobs, L. A.....	P69-9	Johnson, L.....	P13-3	Kane, S. E.....	P66-2		
Jacobson, H. I.....	P62-2, P62-8	Johnson, M. (Univ. of Illinois, Chicago) ....	P4-11	Kang, D-H.....	P39-11		
Jacques, J.....	P31-10	Johnson, M. (Univ. of Texas) .....	P70-10	Kang, J.....	P40-4		
Jaffe, J. S.....	P64-18	Johnson, M. D.....	P32-9, P38-10	Kang, K.....	P7-12, P30-10, P35-17		
Jaffee, E. M.....	P12-13, P45-22	Johnson, O.....	P68-3	Kang, K. A.....	P44-6		
Jagjivan, B.....	P64-34	Johnson, R. (Univ. of California, San Diego).....	P11-17	Kan-Mitchell, J.....	P71-9		
Jain, A.....	P9-5, P13-15, P13-16	Johnson, R. (Univ. of Pittsburgh) .....	P3-14	Kao, C.....	P35-8		
Jakob, J.....	P54-20	Johnson, S. J.....	P24-1	Kao, Y-H.....	P42-7		
James, G. D.....	P23-2	Johnstone, C. N.....	P60-8	Kappadath, S. C.....	P41-5		
James, S. Y.....	P43-6	Jones, D. K.....	P43-9	Kappes, J. C.....	P60-23		
James, T.....	P24-12	Jones, F. E.....	P26-9, P26-21	Kapranov, P.....	P27-17		
Janda, K. D.....	P38-4	Jones, K. R.....	P48-3	Karakas, B.....	P66-15		
Jang, J. W.....	P11-5, P11-15	Jones, L.....	P55-10	Karellas, A.....	P41-3		
Jania, L.....	..P3-5	Jones, R. A.....	P53-9	Kariagina, A.....	P35-2		
Janic, J. M.....	P16-16	Jones, R. F.....	P39-8	Karlin, N. J.....	P3-2, P3-3		
Janknecht, R.....	P1-8	Jong, R.....	P40-14	Karnaky Jr., K.....	P55-10		
Janssen, S.....	P67-4	Jordan, J. J.....	P27-13	Karnoub, A.....	P59-6		
Jarjanazi, H.....	P6-14	Jordan, V. C.....	P26-11	Karpisheva, K.....	P17-11		
Jarvik, J.....	P27-16	Jorgensen, P.....	P16-3	Kashanchi, F.....	P51-16		
Jarvis, G. A.....	P16-17	Jose, C.....	P52-6	Kashatus, D.....	P27-14		
Jarzynka, M.....	P38-1	Joseph, L.....	P62-2	Kasid, N.....	P35-18		
Jeay, S.....	P52-11	Joshi, S. S.....	P30-19	Kass, D.....	P52-5		
Jeganathan, S.....	P1-13	Joukov, V.....	P51-15	Kassa, A.....	P43-17		
Jendoubi, A.....	P17-2	Ju, B-G.....	P5-6	Kassis, A. I.....	P17-4		
Jeng, M-H.....	P35-8	Ju, Y. H.....	P61-8	Katapodi, M. C. ....P23-5, P23-6, P23-7, P23-8			
Jenkins, C.....	..P5-2	Judy, B. M.....	P39-6	Katz, S.....	P1-16		
Jensen, H. M.....	P24-2	Jun, J. H.....	P43-5	Katz, E.....	P31-11		
Jeon, N. L.....	P10-11, P52-8	Juneja, S.....	P3-9	Katzenellenbogen, J. A.....	P15-1		
Jeong, J-H.....	P18-5	Jung, J.....	P57-5	Kauff, N. D.....	P62-9		
Jepsen, K.....	..P5-6	Jung, M.....	P67-15	Kaufman, S.....	P54-23		
Jerry, D. J.....	P27-9, P44-14, P57-5, P62-6	Jung, S-H.....	P18-5	Kaufmann, Y. J.....	P14-15		
Jerusalmi, A.....	P46-11	Jupe, E. R.....	P21-5	Kaur, G. P.....	P30-1		
Jett, M.....	P6-7, P61-5	Jurukovski, V.....	P12-6	Kaur, M.....	P40-9		
Jewell, J. L.....	P60-13	<b>K</b>					
Ji, Y.....	P66-13	Kaaks, R. J .....P49-4, P49-12, P49-16, P49-18		Kavanagh, K. T.....	P3-8		
Jia, Y.....	P60-23	Kabotyanski, E.....	P5-20	Kawakubo, H.....	P53-8		
Jia, Z.....	P53-16	Kagay, C.....	P68-6	Kawashima, H.....	P10-2		
Jian, H.....	P28-3	Kahn, K.....	P68-8	Kaykas, A.....	P31-5		
Jian, L.....	P63-4	Kahn, S. M.....	P36-4	Kazanietz, M.....	P31-25		
Jiang, C.....	P54-22	Kaiser, C.....	P16-10	Kearns, A. E.....	P20-8		
Jiang, L.....	P67-24	Kaliberov, S. A.....	P46-7	Kearns, M.....	P61-3		
Jiang, S.....	P7-12, P30-7, P30-10	Kaliberova, L. N.....	P46-7	Keaton, M. A.....	P4-12		
Jiang, W.....	P37-6	Kalil, C.....	P69-2	Keck, J.....	P29-12		
Jiang, X.....	P27-11	Kalinowski, A.....	P40-5	Keely, P. J.....	P2-15, P59-16		

## Poster/Author Index

Kehn, K.....	P51-16	Kim, S. (Univ. of Texas Hlth. Sci. Ctr.).....	P51-4	Kolomeichuk, S. N.....	P58-2
Keilhack, H.....	P2-16, P52-2	Kim, S. (Univ. of Texas M.D. Anderson)....	P15-9	Komarova, Y.....	P59-10
Keister, B.....	P1-20	Kim, S. J. ....	P60-20	Kominsky, S. L.....	P60-24, P67-7
Kelcz, F.....	P64-14	Kim, S-W.....	P30-13	Kondraganti, S. R.....	P37-6
Keleti, D.....	P2-9	Kim, T. M. ....	P25-5	Konduri, S. D.....	P27-7
Kelly, C.....	P4-1	Kim, T. S. ....	P45-5	Kong, Y-C. M.....	P39-8
Kelly, C. M. ....	P3-14, P3-15	Kim, W. E.....	P52-9	Konikov-Titievsky, L.....	P24-12
Kelly, J.....	P3-14	Kim, Y-P.....	P43-9	Koo, J.....	P24-7
Kelly, K. F. ....	P31-4	King, E. ....	P70-3	Koo, J-S. ....	P36-13
Kelly, P.....	P38-5	King, L. B. ....	P31-11	Koomen, J.....	P13-11
Kemble, K.....	P20-6	King, M-C.....	P56-14	Koppolu, P.....	P20-7
Kemel, Y.....	P62-9	Kingham, K. ....	P4-8	Korach, K. S.....	P7-21
Kemp, A.....	P7-16	Kinlaw, W. B.....	P13-17	Korah, R.....	P59-22
Kendziorski, C.....	P30-16	Kinnard, L. ....	P14-6	Kornbluth, J.....	P39-9
Kenefick, A. L.....	P48-6	Kip, K. E. ....	P24-5	Kosir, M.....	P20-7
Kennaway, D. J.....	P31-12	Kirk, J. S. ....	P5-18	Kostetskii, I.....	P3-22
Kennedy, C. J.....	P8-2	Kirk, M. ....	P62-10	Kotar, K.....	P56-15
Kennedy, F. E.....	P64-29	Kirsch, K. H. ....	P52-11	Kothari, M. ....	P9-21
Kenyon, G. D.....	P16-8	Kirschmann, D. A. ....	P5-10, P60-18	Koto, K.....	P1-17
Keri, R. A.....	P1-9, P1-10	Kitajewski, J. ....	P9-12, P9-16, P9-20	Kotov, N.....	P64-23
Kerlikowske, K.....	P42-3, P61-13	Kitamura, Y. ....	P9-20	Kotwaliwale, C. ....	P29-15
Kerr, K.....	P2-10	Kiyokawa, H. ....	P29-14	Kotz, K. T. ....	P64-11
Kerver, J.....	P24-13	Kiyomiya, K-I.....	P32-9, P32-10	Kouros-Mehr, H. ....	P53-7
Keshtgar, M.....	P64-19	Klauber-Demore, N. ....	P9-13	Kourtidis, A. ....	P6-15
Kessler, L.....	P69-8	Kleer, C. G. ....	P54-9, P60-17	Koutcher, J. A. ....	P63-6
Ketelson, D.....	P9-13	Kleiman, F. E. ....	P51-17	Kovacs, J. J. ....	P5-7, P26-22
Keyomarsi, K. ....	P29-13, P29-25, P54-8, P70-6	Klein, D. E. ....	P33-5	Kraemer, W. J. ....	P20-9
Khamapirad, T.....	P61-9, P64-23	Klein-Szanto, A. J. P. ....	P40-6	Krager, K.....	P17-5
Khan, S.....	P36-6	Klemp, J. R. ....	P69-10	Krainer, A. R. ....	P62-20
Khanna, K.....	P4-16, P56-19	Klevit, R. E. ....	P51-10	Kramer, D. J. ....	P65-10
Khavar, Y.....	P59-9	Klimberg, S. V. ....	P14-15	Krasieva, T. ....	P4-23
Khazaeli, M. B.....	P44-15	Klinkebiel, D. L. ....	P13-6	Krasnykh, V. ....	P46-7
Kho, J.....	P49-23	Kloos, B. T. ....	P9-14	Kraus, R. R. ....	P26-11
Khodadadian, M.....	P16-18	Klostergaard, J. ....	P16-18	Krause, S. ....	P3-13
Khokha, R.....	P53-9	Klug, T. L. ....	P24-5	Krauss, S. W. ....	P29-16
Khosravi, F.....	P1-16	Kluger, H. M. ....	P11-4	Kreizman, T. ....	P63-3
Khosravi-Far, R.....	P58-7	Klus, G. ....	P38-19	Krejci, L. ....	P4-3, P25-8
Kiarash, R.....	P67-5	Knight, C. ....	P71-7	Kremper, J. M. ....	P31-3
Kibriya, M.....	P49-6	Knobf, T. ....	P69-11	Krendelchtkhikova, V. ....	P46-7
Kido, T.....	P55-11	Knowles, D. W. ....	P40-12, P64-21	Krieg, M. ....	P43-16
Kieber-Emmons, T.....	P18-8	Knowles, L. ....	P16-23	Krishnadas, A. ....	P15-7
Kiessling, L. L.....	P67-3	Knudsen, E. S. ....	P30-5	Krishnamoorthy, A. ....	P31-13
Kilgore, M. W.....	P35-1	Knudsen, K. A. ....	P3-22	Krishnamoorthy, L. ....	P38-3
Killary, A. M.....	P54-8	Knutson, K. L. ....	P12-4, P12-10, P12-11, P12-12	Krogh, V. ....	P34-5
Kim, B.....	P67-2	Kobayashi, N. ....	P30-11	Kron, S. J. ....	P4-21
Kim, E. E.....	P15-4, P44-20	Kobayashi, R. ....	P13-10, P13-11	Krop, I. ....	P53-17
Kim, H. (Baylor College of Medicine)....	P7-4	Koch, C. J. ....	P53-1	Kropp, S. ....	P17-1
Kim, H. (Univ. of Alabama)....	P6-25, P62-10	Kockel, L. ....	P2-10	Krosky, D. J. ....	P43-7
Kim, H. J.....	P26-5	Kodibagkar, V. D. ....	P63-9, P65-7	Krotova, Y. ....	P52-19
Kim, H-S. ....	P53-10	Kodransky, M. ....	P62-19	Krouse, J. ....	P66-1
Kim, J. (Drexel Univ.)....	P4-1	Koeffler, H. P. ....	P51-24	Krtolica, A. ....	P59-3
Kim, J. (Tufts Univ.)....	P54-23	Koehler, K. M. ....	P40-17	Ku, N. C. ....	P67-11
Kim, J. (Univ. of Texas, Austin)....	P6-13	Koerner, F. ....	P67-9	Kuang, S-Q. ....	P30-25, P35-22
Kim, J. G. ....	P64-20	Kohanim, S. ....	P15-4	Kucera, K. ....	P54-15
Kim, J-S. ....	P4-23	Kohle, R. ....	P33-8	Kucuk, O. ....	P62-11
Kim, K. (Texas A&M)....	P36-6	Kojic, M. ....	P4-10	Kuemmel, C. ....	P51-8
Kim, K. (Univ. of Kentucky)....	P67-15	Koland, J. G. ....	P26-6, P26-12	Kuerer, H. ....	P48-8
Kim, M.....	P46-3	Kolanko, P. ....	P48-1	Kufe, D. ....	P1-11, P45-10
Kim, S. (Beth Israel Deaconess Med. Ctr.)....	P2-25	Koller, B. H. ....	P3-5	Kuhn, D. ....	P16-8
		Kolluri, S. K. ....	P43-6, P44-16, P58-18	Kuhn, S. J. ....	P44-3

## Poster/Author Index

Kuller, L.	P24-5	Langenbach, K.	P54-12	Leidy, H.	P62-22
Kuller, L. H.	P49-15	Langton, S.	P32-8	Leizhen, W.	P51-9
Kulp, K. S.	P7-1	Lannigan, D. A.	P2-11	Le-Khac, M.	P2-6
Kumar, A.	P50-5	Lants, G.	P38-26	Lelievre, S. A.	P32-1, P40-12, P64-21
Kumar, R.	P35-3, P36-16	Lanza-Jacoby, S.	P26-7	Lemanski, N. A.	P62-2, P62-8
Kumar Reddy, G. S.	P16-8	Larabell, C. A.	P58-8	Lemmon, M. A.	P2-9, P33-5
Kundel, H. L.	P42-1	Lareef, M. H.	P8-3, P8-4, P8-5, P31-11	Lenertz, L. Y.	P2-12
Kundu, N.	P39-7	Larson, B. T.	P48-7	Lenoir, G. M.	P49-11, P49-18
Kuo, A. H.	P32-20	Lasser, N.	P24-5	Leone, G.	P59-4
Kuo, H-P.	P46-8	Latha, K.	P54-24	Leonis, M.	P53-15
Kuperwasser, C.	P59-6, P59-11	Latimer, J. J.	P3-14, P3-15	Lerner, C.	P5-14
Kurian, A. W.	P4-8	Lau, Y-F. C.	P55-11	Lerner, M. R.	P21-5, P53-12
Kurpios, N. A.	P1-12	Lauderdale, D. S.	P23-16	Lerner, R. A.	P19-8, P38-4
Kurtzman, S. H.	P64-34	Lawrence, J.	P43-15	Letfullin, R. R.	P44-21
Kurumizaka, H.	P4-23	Lawrence, S.	P62-6	Leu, J. I-J.	P27-15
Kurz, E. U.	P4-13	Lawson, J.	P37-7	Leung, J.	P50-5
Kurzer, M. (Univ. of Minnesota)	P24-10	Lawton, T.	P36-10	Leung, J. Y.	P58-9
Kurzer, M. (Univ. of Pennsylvania)	P61-12	Lazard, Z.	P36-7	Lev, D. C.	P60-20
Kurzer, M. S.	P49-16	Lazorik, M.	P10-14	Levcovicci, S.	P11-11
Kwak, H-I.	P54-15	Le, A.	P26-14	Levin, N.	P6-26
Kwan, P.	P28-4	Le Gros, M. A.	P58-8	Levine, B.	P63-9
Kwate, N. O. A.	P62-12	Le Marchand, L.	P49-12, P49-13	Levine, P. H.	P70-8, P70-9
Kwek, S. S.	P6-16	Leader, J. K.	P42-4	Levins, T. A.	P5-5
Kwok, S.	P28-8	Leahy, D. J.	P26-8	Levitt, R. J.	P62-13
Kwon, Y. M.	P67-20	Leal, A. D.	P9-6	Levy, S.	P40-13
Kwong, G.	P43-2	Lebeau, A.	P67-4	Lewis, A.	P7-16
Kwong, K. Y.	P30-2	Leboff, M.	P20-3	Lewis, J.	P54-3
<b>L</b>					
La, P.	P11-11	Lebret, S.	P60-22	Lewis, J. E.	P32-1
La Riviere, P.	P65-6	Leder, P.	P54-10	Lewis, L. M.	P70-12
Labhasetwar, V.	P19-1, P46-15	Lee, A.	P64-19	Lewis, M. A.	P64-3
Lachman, L. B.	P45-11	Lee, A. J.	P8-9	Lewis, M. M.	P64-31
Lacko, A. G.	P44-7	Lee, A. S.	P46-2	Lewis, M. T.	P3-19, P21-3
Lacy, A.	P38-3	Lee, A. V.	P7-4, P30-7, P36-7	Lewis, S.	P6-6
Ladias, J. A. A.	P51-18, P51-19, P52-7	Lee, B-H.	P2-12	Leygue, E.	P7-16, P11-25, P36-8
Ladva, C.	P70-7	Lee, B-S.	P15-7	Li, A.	P50-13, P51-27
Laganière, J.	P6-17	Lee, C.	P16-9	Li, B. (Univ. of California, Irvine)	P3-16
Lahusen, T.	P32-20	Lee, E. Y-H. P.	P50-11, P50-13, P51-27	Li, B. (Univ. of Louisville)	P45-20
Lai, T-S.	P11-13	Lee, H-K.	P43-3	Li, B. D. L.	P13-3
Lakins, J. N.	P59-17, P59-21	Lee, J.	P34-4	Li, C. (Baylor College of Medicine)	P36-9
Lakshmanaswamy, R.	P11-16	Lee, J. M.	P1-13	Li, C. (City of Hope Beckman	
Lala, P. K.	P10-3	Lee, J-D.	P30-13	Research Inst.)	P16-22
Lam, D.	P5-16	Lee, K. A.	P23-4, P23-5, P23-8	Li, C. I.	P6-23
Lam, K. S.	P28-5	Lee, M-S.	P32-9, P32-10	Li, C-M.	P54-20
Lam, W.	P11-19	Lee, N. Y.	P26-12	Li, C-Y.	P11-30
Lamartiniere, C. A.	P6-18	Lee, O-S.	P65-3	Li, D. (State Univ. of NY, Albany)	P42-6
Lambe, M.	P24-4	Lee, P.	P54-22	Li, D. (State Univ. of NY, Stony Brook)	P42-11
Lampe, J. W.	P34-1	Lee, S.	P9-15	Li, H. (Mount Sinai Hospital)	P6-14
Lampson, L. A.	P60-9	Lee, S-H.	P45-18	Li, H. (Univ. of Texas M.D. Anderson)	P15-9
Lan, K-H.	P67-22, P67-23	Lee, S-J.	P4-14	Li, H. (Xavier Univ. of Louisiana	
Lan, L.	P14-2	Lee, T. H.	P7-24	Coll. of Pharm.)	P8-8
Landesman, E.	P2-5	Lee, W-H.	P50-11, P50-14, P67-25	Li, J. (Dana-Farber Cancer Inst.)	P40-9
Landesman-Bollag, E.	P3-8, P31-6	Lee, W. M. F.	P19-9	Li, J. (Photon Imaging, Inc.)	P15-3
Landis, M. D.	P1-9, P1-10	Lees-Miller, S. P.	P4-13	Li, J. (Univ. of California, San Francisco)	P4-9
Landis-Piwowar, K. R.	P16-8	Lefebvre, C.	P6-17	Li, J. J.	P29-5
Lane, T. F.	P28-7	Leffall, L. D.	P35-11	Li, L. (Brigham & Women's Hosp.)	P31-14
Lang, E. V.	P22-4, P22-5	Leflour, M.	P59-9	Li, L. (Indiana Univ.)	P35-8
Lange, C. A.	P35-5	Legembre, P.	P58-13	Li, L. (Univ. of Michigan)	P53-13
Lange, J.	P13-5, P13-12	Lehnes, K.	P35-18	Li, L. (Univ. of South Florida)	P14-7
		Lei, M.	P14-11	Li, L. (Univ. of Utah)	P43-4
		Leiderman, R.	P64-22	Li, L-Y.	P19-3

## Poster/Author Index

Li, M.....	P29-7	Lippman, M. E.....	P67-19	Long, W.....	P26-9
Li, P. (Univ. of Southern Florida).....	P36-2	Lipscomb, E. A.....	P38-22, P58-7	Long, X.....	P35-8
Li, P. (Univ. of Texas M.D. Anderson) .....	P67-22	Lisafeld, B.....	P9-11	Longcope, C.....	P40-1
Li, P-K.....	P53-12	Lisby, M.....	P4-10	Loo, C.....	P64-15
Li, Q. (Baylor College of Medicine) .....	P30-25	List, H-J.....	P55-16	Loo, L. W. M.....	P6-23
Li, Q. (Univ. of Alabama) .....	P30-14	Littles, M.....	P23-21	Lopez, C. R.....	P56-16
Li, R. ....	P51-1, P54-14, P51-20	Liu, A.....	P35-12	Lopez-Berestein, G.....	P21-7
Li, T. (Stanford Univ.).....	P17-6	Liu, D. (Boston Univ.).....	P22-8	Loprinzi, C. L.....	P20-8
Li, T. (Univ. of Kentucky) .....	P16-19	Liu, D. (Roswell Park Cancer Inst.).....	P9-11	Lorenz, U. M.....	P55-13
Li, W. (Mt. Sinai School of Medicine).....	P52-17	Liu, F.....	P29-18	Lorizio, W.....	P49-23
Li, W. (National Institutes of Health).....	P51-11	Liu, G.....	P1-1	Lott, S. T.....	P54-8
Li, W. (Washington Univ.) .....	P15-8	Liu, H. (Indiana Univ.) .....	P66-20	Lou, Z.....	P30-15
Li, X.....	P64-3	Liu, H. (Lawrence Berkeley Nat. Lab.) ...	P32-11	Love, S. M.....	P3-3
Li, Y.....	P1-14	Liu, H. (Univ. of Texas) .....	P63-9, P64-20	Lowe, S. W.....	P30-17
Li, Y.M.....	P46-8	Liu, I.....	P28-3	Lowery, A.....	P64-15
Li, Z. (Baylor College of Medicine).....	P6-12	Liu, J. (Indiana Univ.) .....	P13-13	Lu, B.....	P21-9
Li, Z. (Brigham & Women's Hosp.).....	P2-19, P31-14	Liu, J. (Univ. of New Mexico) .....	P29-11	Lu, C-S.....	P51-22
Li, Z. (Pennsylvania State Univ.) .....	P60-5	Liu, J. (Univ. of North Texas) .....	P19-1	Lu, D.....	P62-4
Liang, G.....	P43-20	Liu, J. (Univ. of Texas M.D. Anderson) .....	P15-9	Lu, H. (Univ. of New Mexico) .....	P25-7
Liang, J.....	P6-19, P6-28	Liu, J. (VA Palo Alto Hlth. Care Sys.).....	P66-9, P66-10	Lu, H. (Univ. of Washington)....	P12-10, P12-12
Liang, K.....	P65-1	Liu, J. O.....	P16-5	Lu, J.....	P54-10
Liang, W.....	P23-23	Liu, K.....	P29-17	Lu, L-J. W.....	P40-8, P61-9
Liao, D.....	P11-17	Liu, L.....	P65-7	Lu, M. (The Burnham Institute).....	P9-22
Liao, J.....	P60-21	Liu, M. (Georgetown Univ.) .....	P18-1	Lu, M. (Henry Ford Health System) .....	P11-29
Liao, L.....	P30-25, P35-22	Liu, M. (Texas A&M).....	P38-23	Lu, S.....	P56-25
Liao, Y.....	P2-13	Liu, M. (Univ. of Michigan).....	P67-19	Lu, W.....	P60-10
Liberman, L.....	P63-1	Liu, M-C.....	P23-4	Lu, X. (Dana-Farber Cancer Inst.) .....	P13-21
Libien, J. M.....	P34-2	Liu, N.....	P64-10	Lu, X. (Univ. of Pittsburgh) .....	P44-12
Libra, M.....	P29-6	Liu, S.....	P3-24	Lu, Y. (M.D. Anderson Cancer Center) ...	P50-15
Lieberman, G.....	P66-16	Liu, W.....	P27-7	Lu, Y. (Univ. of Michigan) .....	P43-8
Lieberman, P. M.....	P51-21	Liu, W. (The Burnham Institute) .	P43-6, P58-18	Lu, Y. (Univ. of Virginia).....	P51-14
Liebermann, D. A.....	P54-19	Liu, W-H.....	P40-9	Lu, Z.....	P28-5
Lieberthal, J.....	P5-16	Liu, X. (Univ. of Colorado-Boulder) .....	P28-4	Lubawy, C.....	P14-9
Lightfoot, S. A.....	P21-5	Liu, X. (Univ. of Texas M.D. Anderson) .....	P41-5	Lubet, L.....	P62-21
Lightstone, F. C.....	P7-1	Liu, X. S.....	P6-2	Lucchesi, J. C.....	P56-19
Lilge, L.....	P40-14	Liu, Y. (Indiana Univ.)...P13-13, P66-18, P66-20	P66-8, P66-11	Lucci, A.....	P60-11
Lillo, A.....	P38-4	Liu, Y. (Univ. of Alabama) .....	P5-1	Lucito, R.....	P52-18
Lim, K-H.....	P1-15	Liu, Y. (Univ. of Pennsylvania).....	P31-25	Luck, L. A.....	P35-9
Lima, R. S.....	P56-6	Liu, Y-Y.....	P30-28	Lucs, A.....	P52-10
Lin, B.....	P58-17, P58-18	Liu, Yan .....	P30-28	Ludwig, T.....	P56-19
Lin, C-Y.....	P32-9, P32-10	Liu, Yang .....	P30-28	Lum, D. H.....	P55-12
Lin, F. (The Burnham Institute)...	P43-6, P58-18	Liu, Z.....	P14-10	Luna, E. J.....	P31-10
Lin, F. (Univ. of California, Irvine) .....	P10-11, P52-8	Livasy, C.....	P27-4	Lundblad, V.....	P56-2, P56-8
Link, F-T.....	P29-17	Livingston, D. M.....	P25-11, P51-15	Luo, M.....	P7-13
Lin, S-C. J.....	P50-13, P51-27	Ljungman, M.....	P6-3	Luo, Y.....	P29-17
Lin, W-C.....	P29-17	Lluch, A.....	P13-7	Luo, Y. P.....	P12-16
Lin, X.....	P50-14	Lo, J.....	P14-8, P14-16	Lupashin, V.....	P13-23
Lin, Y.....	P39-10	Lo, S-C. B.....	P14-6	Lupien, M.....	P7-14
Linden, H.....	P36-10	Lobanenkov, V. V.....	P32-25	Lupu, M.....	P63-6
Lindquist, S. L.....	P11-26	Lobo, N.....	P3-17	Lupu, R.....	P16-20, P66-12
Lindy, M.....	P59-22	LoBuglio, A. F.....	P45-3	Luque, A.....	P19-2
Lingle, W. L.....	P40-21, P50-4, P50-9, P50-10, .....P55-20	Loch, C.....	P7-14	Lurie, G.....	P49-13
Link, J.....	P23-13	Lockley, S. W.....	P24-8	Luster, S.....	P32-16
Linsley, P.....	P5-14	Lokshin, A.....	P13-18	Luster, T.....	P44-13
Lio, Y-C.....	P25-9	Lombardi, D. P.....	P38-11	Lutze-Mann, L.....	P37-7
Liou, J. S.....	P30-27	Lomnnes, S. J.....	P65-8	Luu, T.....	P10-20
Lipkus, I.....	P23-9	Londoño-Vallejo, A. J.....	P56-7	Lv, Y.....	P51-20
		Long, F.....	P40-12, P64-21	Lydick, J. T.....	P64-12
		Long, J.....	P29-18	Lydon, J. P.....	P3-20, P31-8
				Lyle, S.....	P38-22

## Poster/Author Index

Lyles, D. S. .... P46-1  
Lynch, A. .... P43-15  
Lyons, G. R. .... P46-3  
Lyons, P. D. .... P55-13  
Lyons, T. R. .... P2-14

### M

Ma, D. .... P2-24  
Ma, H. .... P54-23  
Ma, J. .... P5-8  
Ma, J-L. .... P4-14  
Ma, L. .... P17-7  
Ma, X. .... P39-7  
Ma, X. J. .... P40-21, P40-22  
MacDonald, C. A. .... P42-5, P42-6  
MacDonald, I. C. .... P38-8  
Macfall, J. R. .... P44-9  
Mach, R. H. .... P15-5  
Machida, K. .... P6-20  
Maciag, P. C. .... P45-12  
MacLachlan, T. K. .... P32-13  
MacLaughlin, D. T. .... P53-8  
Macrae, M. J. .... P69-4  
Mader, S. .... P7-14  
Madsen, M. .... P17-5  
Maffini, M. V. .... P59-12, P59-20  
Magee, J. .... P38-7  
Magliocco, A. M. .... P2-8  
Magnusson, C. .... P61-10  
Mahanivong, C. .... P46-6  
Maheswaran, S. .... P53-8  
Mai, J. .... P44-12  
Mai, S. .... P56-15  
Maidment, A. D. A. .... P42-7  
Maihle, N. J. .... P61-2  
Mail, N. .... P42-6  
Mailo, D. .... P8-4, P8-5  
Maitz, G. S. .... P14-4, P42-4  
Majumdar, A. .... P62-11  
Makariou, E. .... P14-6  
Makary, E. .... P12-11  
Makary, K. .... P12-10  
Makonnen, S. .... P19-9  
Makrigiorgos, G. M. .... P40-9  
Makuch, L. A. .... P32-5  
Malcolm, S. .... P43-18  
Maley, F. .... P67-8  
Malin, J. .... P68-8  
Malkas, L. H. .... P13-13  
Mallireddigari, M. .... P67-1  
Malone, J. L. .... P4-15  
Malone, K. E. .... P20-10, P70-11  
Malone, K. M. .... P6-23  
Maloney, S. D. .... P50-4, P50-9, P50-10, P50-22  
Maltese, W. A. .... P55-14  
Man, Y. .... P10-4, P10-5, P10-6, P10-7,  
P10-8, P10-9, P38-12, P38-13,  
P38-14, P38-15, P60-12  
Manavathi, B. .... P36-16  
Mancini, M. A. .... P51-26

Mancino, A. T. .... P18-8  
Mandal, M. .... P16-21  
Mandavya, C. .... P33-8  
Mandelblatt, J. S. .... P23-23  
Mandell, E. .... P56-2, P56-8  
Mangalik, A. .... P56-12  
Mani, A. .... P36-11, P55-16  
Manjeshwar, S. .... P21-5  
Manka, D. .... P38-16  
Mankoff, D. .... P36-10  
Manley, J. L. .... P51-17  
Manne, S. L. .... P23-10  
Mannie, A. E. .... P40-24  
Manning, H. C. .... P64-6  
Mansukhani, M. .... P2-6, P2-7  
Mantle, I. .... P3-24  
Mao, S. .... P38-4  
Mar, B. G. .... P6-19  
Marassi, F. M. .... P58-10  
Marcom, P. .... P23-9  
Marconi, S. .... P57-5  
Marcouiller, P. .... P25-1  
Margalit, R. .... P63-3  
Margaryan, A. .... P66-7  
Margaryan, N. V. .... P5-10, P60-18  
Margossian, S. .... P4-18  
Markey, M. .... P14-14  
Markowitz, S. D. .... P6-6  
Marks, J. R. .... P51-2  
Marks, L. B. .... P17-8  
Marmorstein, R. .... P32-12, P32-13, P54-11  
Marozkina, N. V. .... P26-10  
Marple, T. .... P25-5  
Marquez, D. C. .... P19-6  
Marra, K. .... P16-9  
Marrangoni, A. .... P13-18  
Marrero, L. .... P26-21  
Marriott, J. J. A. .... P60-4  
Marshall, R. M. .... P5-9  
Marshallack, J. J. .... P35-11, P35-12  
Martin, M. B. .... P7-15, P35-18  
Martin, R. H. .... P40-16  
Martin, T. J. .... P11-12  
Marton, L. J. .... P67-6  
Masckaughan, T. N. H. .... P9-16  
Maskarinec, G. .... P49-13  
Maslen, C. L. .... P11-18  
Masny, A. .... P13-20  
Mason, G. .... P68-3  
Mason, H. S. .... P45-15  
Mason, J. .... P6-7  
Mason, R. P. .... P63-4, P63-9, P64-3,  
P64-20, P65-7, P67-24  
Mass, R. D. .... P66-16  
Massagué, J. .... P60-6  
Masso-Welch, P. A. .... P9-11, P35-7  
Mastracci, T. L. .... P11-19  
Mastro, A. M. .... P20-9, P38-17, P60-13, P60-23  
Mata, J. .... P15-6  
Matallana, H. .... P49-23

Mathews, S. .... P16-9  
Matrisian, L. .... P50-21  
Matsuoka, S. .... P4-22, P29-8  
Matsuura, I. .... P29-18  
Mattison, C. .... P29-19  
Mawson, A. .... P29-22  
Maxwell, A. E. .... P23-13, P68-2  
Mayer, A. .... P30-16  
Mayer, B. J. .... P6-20  
Mayer-Davis, B. .... P70-1  
Mays, D. .... P27-11  
Mazin, A. .... P4-1  
Mazuruk, K. .... P44-8  
McAllister, S. .... P59-6, P59-11  
McCabe, J. .... P67-2  
McCall, C. M. .... P32-14  
McCann, S. E. .... P35-7, P49-8  
McCarthy-Bennett, K. .... P68-4  
McCaskill, E. .... P16-12, P16-13, P16-14  
McClane, B. .... P67-7  
McClay, D. R. .... P31-22  
McColl, R. .... P63-4  
McConathy, W. J. .... P44-7  
McCorkle, R. .... P69-11  
McCoy, T. .... P69-6  
McCubrey, J. .... P29-6  
McDaniel, S. .... P59-19  
McDevitt, M. A. .... P54-23  
McDonald, L. .... P5-8  
McDonnell, D. P. .... P7-8, P7-11, P7-22, P35-14  
McDonnell, K. .... P10-19  
McElroy, N. P. .... P13-21  
McGee, C. .... P55-8  
McGee, S. O. .... P35-7  
McIntyre, J. O. .... P64-6  
McKay, J. .... P49-18  
McKay, J. D. .... P49-4  
McKenzie, W. B. .... P70-1  
McKeon, F. .... P27-17  
McLachlan, J. A. .... P61-1  
McMillen, M. .... P6-6  
McNamara Jr., M. P. .... P42-8  
McPherson, R. .... P43-15  
Means, A. R. .... P2-3  
Mehta, K. (Fairway Medical  
Technologies) .... P64-23  
Mehta, K. (Univ. of Texas  
M.D. Anderson) .... P59-13  
Mehta, R. (Univ. of California, Irvine) .... P64-16  
Mehta, R. (Univ. of Illinois, Chicago) .... P6-28  
Mehta, R. G. .... P18-4, P61-11 P62-5, P71-8  
Meisler, A. .... P2-25  
Meleth, S. .... P5-1  
Melnick, M. .... P2-10  
Melton, L. J. .... P49-7, P50-4, P50-7, P50-9  
Memmott, R. .... P52-19  
Mendez, R. .... P30-8  
Menendez, J. A. .... P16-20, P66-12  
Meng, X. .... P25-7, P25-10, P29-11  
Meng, Z. .... P5-1

## Poster/Author Index

Merajver, S. D.	P54-9, P60-16, P60-17	Minn, A. J.	P60-6	Morton, R.	P32-18
Mercer, R. J.	P60-13, P60-23	Minna, J.	P30-6	Mosbrook-Davis, D.	P27-2
Mercer, R. R.	P38-17	Minter-Dykhouse, K.	P30-15	Moser, A. R.	P30-16, P40-23
Mercurio, A. M.	P11-2, P38-22, P58-7	Mintzer, R. A.	P15-3	Moshin, S. K.	P1-14
Meredith, D. S.	P60-9	Mirabelle, S.	P56-18	Moskaluk, C. A.	P51-1
Merkle, C. J.	P38-18	Miranda-Carboni, G. A.	P28-7	Mosley, J. D.	P1-10
Merrell, M. A.	P10-12, P10-13	Miron, A.	P13-21	Moss, T. J.	P5-10
Mertz, J. E.	P26-11	Missert, J.	P30-19	Motamed, M.	P64-23
Meschonet, C.	P13-3	Mistry, S.	P46-9	Motoyama, A. B.	P31-16
Meseck, M.	P45-13	Mitas, M.	P40-16	Mottram, L.	P2-17
Messick, T.	P54-11	Mitchell, D.	P38-23	Mou, D.	P5-8
Metcalf, J. S.	P40-16	Miyagi, K.	P43-16	Moulder, S. L.	P6-21
Meth, J. L.	P30-11	Miyamoto, C.	P13-1	Mowery, P.	P67-3
Metheny-Barlow, L. J.	P19-3	Mizutani, M.	P12-16	Moy, S.	P51-8
Metz, C. E.	P14-3	Mizutani, N.	P12-16, P45-18	Mroczkowska, J. E.	P32-25
Metz, R.	P54-15, P59-19	Mo, Y-Y.	P32-16	Mrozek, K.	P5-12
Meyer, C. A.	P6-2	Mock, L.	P3-14	Mucci, L. A.	P61-10
Meyer, D.	P56-17	Modugno, F.	P24-5	Muehlenweg, B.	P67-10
Meyer, R.	P7-12	Modzelewska, K.	P2-15	Mueller, B. M.	P1-19, P19-8
Meyn, R. E.	P17-9	Moeller, B. J.	P16-1, P38-5	Mueller, C. R.	P53-3
Meza, J. L.	P36-12	Moffat, F.	P6-1	Mueller, S. C.	P38-19
Mezhevaya, K.	P2-23	Moglia, D.	P23-22	Muesli, C.	P35-18
Mi, Z.	P44-12	Mohamedali, K. A.	P44-13	Muftuler, L. T.	P63-2, P63-5
Mian, I. S.	P32-1	Mohammed, K. A.	P43-9	Muimo, R.	P55-15
Miao, H.	P67-9	Mohammed, S.	P3-18, P38-26	Muir, B.	P40-22
Miao, W-M.	P43-20	Mohan, P.	P13-1	Mukherjee, A.	P3-20
Micheli, A.	P34-5	Mohanty, P.	P40-5	Mukherjee, P.	P45-9, P45-15
Michelich, C. R.	P44-9	Mohapatra, S.	P6-26	Mukherjee, S.	P13-8
Michels, K. B.	P24-9	Mohsin, S. K.	P7-10	Mukhopadhyay, S. (Meharry Medical College)	P13-8
Miele, L.	P67-9	Moin, K.	P50-21	Mukhopadhyay, S. (Weizmann Institute)	P63-3
Miglioretti, D.	P42-3	Mok, M.	P37-7	Mukhtar, H.	P26-1
Mignatti, P.	P31-15	Molina, M. A.	P13-7	Muller, A. J.	P45-16
Mikhitarian, K.	P40-16	Molyneux, S.	P53-16	Muller, W. J.	P52-3, P52-12, P52-16
Mikule, K.	P32-15	Mondzac, M.	P70-9	Munoz, M.	P4-16
Milea, S.	P44-17	Monroe, J. G.	P31-11	Munshi, A.	P17-9
Millender, T.	P10-12	Monroe, S.	P54-9	Muratore, N.	P52-5
Miller, C.	P60-20	Montañez-Wiscovich, M. E.	P1-9	Murillo, G.	P61-11
Miller, D. W.	P32-19	Montgomery, D. W.	P38-18	Murphy, B.	P38-24
Miller, E.	P12-9	Montgomery, G. H.	P23-2	Murphy, D.	P1-6
Miller, F.	P50-21, P62-11	Mooberry, L.	P44-7	Murphy, L. C.	P7-16, P11-25, P55-19
Miller, G. P.	P40-15	Moody, S. E.	P11-5, P11-6, P11-7	Murphy, M. E.	P27-15
Miller, M. A.	P3-18	Moon, R. T.	P31-5	Murphy, P. J. M.	P5-7
Miller, S. M.	P20-11, P23-10, P23-11	Mooney, K.	P23-12	Murphy, W. J.	P45-14
Miller, T.	P64-23	Moore, M. A. S.	P16-21	Murray, S. A.	P37-8
Miller, W. H.	P35-10	Moore, S.	P16-10	Murray, T. J.	P22-8
Miller, W. R.	P18-1	Moorehead, R. A.	P53-9	Murren, J.	P6-4
Millerick, C.	P5-11	Moorthy, B.	P37-6	Murthy, S.	P7-5
Millhorn, D. E.	P38-16	Moos, P.	P27-5	Muruganandham, M.	P63-6
Milliken, E. L.	P1-10	Mora, F. D.	P43-9	Muthiah, K.	P37-6
Mills, G. B.	P50-11, P50-15	Moraes, R. C.	P3-19	Muthuswamy, S. K.	P11-20, P52-10, P52-13, P52-18
Mills, L. H.	P8-9	Morales, J. C.	P4-22	Muti, P.	P24-6, P34-5, P49-8
Mills, M.	P4-8	Moran, E.	P1-26, P29-20, P32-17	Muzikansky, A.	P53-8
Milshtein, D.	P63-3	Moras, D.	P7-14	Myal, Y.	P55-19
Milstein, M.	P54-5	Moreland, M.	P40-24, P48-9	Myatt, E.	P51-8
Milstien, S.	P2-20	Moroni, M.	P38-19		
Min, C.	P52-11	Morris, E. A.	P63-1		
Min, C. J.	P40-24	Morris, G. S.	P53-2		
Min, X.	P2-12	Morris, M. E.	P66-13		
Minami, C.	P17-10	Morrison, C. D.	P57-6		
Minic, V.	P16-8	Morrissey, J. H.	P55-1	Naber, S. P.	P57-5
				Naftalis, E.	P20-13, P69-5

## Poster/Author Index

- Naga, S.....P2-23  
Nagamani, M.....P40-8, P61-9  
Nagata, Y.....P67-23  
Nagl Jr., N. G.....P29-20  
Nagle, D. G.....P43-9  
Nagy, T.....P11-21  
Nair, M.....P44-7  
Nakhla, A.....P36-4  
Nakshatri, H.....P48-1, P59-14  
Nalcioglu, O.....P63-2, P63-5  
Nan, A.....P19-4  
Nanda, R.....P51-23  
Nandi, S.....P11-16  
Nangia-Makker, P.....P11-22  
Napier, K. B.....P16-24  
Nappi, V. M.....P33-5  
Narita, M.....P30-17  
Natarajan, S.....P4-17  
Nathanson, K.....P57-3  
Nathanson, L.....P6-1  
Natoli, A.....P10-10, P60-19  
Naughton, M. J.....P20-13, P20-14, P69-3, P69-4, P69-5, P69-6, P69-7  
Naujoks, R.....P53-11  
Navolanic, P.....P29-6  
Navone, N.....P44-13  
Nawaz, Z.....P35-6  
Nayak, B. K.....P27-7  
Nazarov, V.....P56-27  
Neal, C. L.....P67-22  
Neel, B. G.....P2-16, P52-2  
Neels, C.....P40-1  
Negron, V. C.....P55-20  
Nehra, R.....P18-2, P66-14  
Neighbors, J. D.....P43-10  
Nelson, C. M.....P3-21  
Nelson, L.....P30-7  
Nelson, L. R.....P54-12  
Nelson, S. E.....P62-14  
Neopolitano, M.....P40-4  
Nephew, K. P.....P7-17  
Neslund-Dudas, C.....P23-19  
Neufeld, G.....P60-14  
Neugut, A. I.....P24-11, P49-9, P49-21  
Newell, O.....P62-7  
Newgreen, D. F.....P60-22  
Newman, E. M.....P16-22  
Newman, L. (Univ. of Michigan).....P62-11  
Newman, L. (Univ. of Wisconsin-Madison).....P2-15  
Newman, R. A.....P22-1  
Newstead, G.....P14-2  
Newton, K.....P70-3  
Nguyen, C. M-C.....P52-8  
Nguyen, H. M.....P8-8  
Nguyen, N.....P67-22  
Nguyen, T. X.....P53-12  
Ni, J.....P67-16  
Nichitta, C. V.....P5-7  
Nice, E.....P60-19  
Nickoloff, B. J.....P67-9  
Nicolas, E.....P54-6  
Nie, D.....P60-15  
Nie, J.....P24-6  
Niedre, M.....P47-5  
Nielsen, M.....P40-14  
Nijjar, T.....P32-24  
Nikitin, A. Y.....P54-13  
Nikolcheva, T.....P57-5  
Nikolovska-Coleska, Z.....P43-8  
Ningaraj, N. S.....P64-6  
Nir, U.....P30-29  
Nishikawa, R. M.....P14-3, P42-2  
Nishino, T. K.....P61-9  
Nissen, M. J.....P20-15  
Niu, Q.....P32-2  
Niu, Y.....P7-16  
Njar, V. C. O.....P43-11  
Noeldner, P. K.....P2-3  
Nolan, B.....P13-18  
Nolan, M. E.....P52-13  
Nonet, G.....P32-24  
Noren, N. K.....P33-6  
Norris, J. D.....P7-11, P7-22, P35-14  
Norris, J. R.....P65-6  
Norton, K.....P13-3  
Norwood, L. E.....P5-10  
Notorfrancesco, K. L.....P11-5, P11-6, P11-7  
Novotny, D.....P49-7  
Novotny, R.....P49-12  
Nowell, S.....P49-14  
Noy, N.....P35-20  
Ntziachristos, V.....P64-30  
Nunez, S.....P30-17
- O**
- Oakes, S. R.....P11-23, P29-21  
Oberai, A. A.....P64-22  
Oberley, L. W.....P5-18  
Oberst, M. D.....P32-9  
O'Brien, A.....P47-3  
O'Byrne, S. M.....P34-2  
O'Connell, C.....P54-12  
O'Connell, P.....P6-12  
O'Connor, S.....P20-7  
Odriozola, L.....P54-2  
Oelschlager, D. K.....P30-14  
Oesterreich, S.....P7-12, P30-7, P30-9, P30-10, P35-17, P36-7  
Offit, K.....P62-9  
O'Flaherty, J. T.....P61-3  
Oh, A. S.....P55-16  
Oh, C.....P15-4  
Oh, Y.....P53-10  
Ohashi, A.....P25-4  
Okado-Matsumoto, A.....P16-1  
O'Kelly, J.....P51-24  
Okobia, M. N.....P49-15  
Okunieff, P.....P22-7  
Olafsdottir, E. J.....P49-20
- Oliver, P. G.....P45-3  
Olofsson, B.....P4-1  
Olopade, O. I.....P23-16, P51-8, P51-23  
Olshan, A. F.....P49-9  
Olshen, A.....P11-11  
Olson, E. J.....P65-8  
Olson, J. A.....P51-2  
Olson, J. E.....P57-3  
O'Malley, B. W.....P35-21, P36-9  
O'Malley, F. P.....P11-19  
Onaral, B.....P64-7  
O'Neill, S. M.....P62-15  
Onyuksel, H.....P15-7  
Opanashuk, L.....P20-4  
Oraevsky, A. A.....P64-23  
Oravetz-Wilson, K.....P53-13  
Orduna, J.....P64-11  
Orimo, A.....P59-6  
Ormandy, C. J.....P11-23, P29-21, P32-18  
Ortiz de Solorzano, C.....P41-2  
Osborn, J. C.....P56-20  
Osborne, C. K.....P6-12, P35-13, P35-23  
Osborne, K.....P2-22  
Oshima, R. G.....P1-22, P9-17  
Oshita, S.....P58-4  
Osmulski, P. A.....P55-4, P55-5  
Ostrand-Rosenberg, S.....P12-5, P12-14  
Ostrowski, M. C.....P59-4  
Ostrowski, M. D.....P43-16  
Otchere, A. A.....P31-4  
Otero, J.....P56-8  
Otis, C. N.....P57-5  
Otley, M.....P30-23  
Overmeyer, J. H.....P55-14  
Owen, J.....P61-3  
Owen, R. M.....P67-3  
Ozcelik, H.....P6-14
- P**
- Pabalan, N.....P6-14  
Padilla, G. V.....P23-4  
Padilla De Jesus, O. L.....P65-8  
Page, G.....P59-18  
Pagel, M.....P65-9  
Paisley, T. E.....P53-10  
Palamakumbura, A. H.....P52-11  
Palczewski, K.....P34-2  
Palmer, G. M.....P40-23, P64-33  
Palmer, L.....P70-3  
Palmer, S. C.....P62-16, P69-9  
Palomares, M. R.....P40-17  
Pan, F.....P16-5  
Pan, H.....P30-22  
Pan, Q.....P60-16, P60-17  
Pan, T.....P11-5, P11-6  
Panageas, K.....P11-11  
Panasci, L. C.....P25-1  
Panasyuk, S. V.....P64-24  
Panchapakesan, B.....P64-25  
Pandey, R. K.....P30-19

## Poster/Author Index

Pandita, T. K.	P56-19	Pegram, M. D.	P67-11	Pilch, J.	P9-19
Pandori, M. W.	P46-11	Peiper, S. C.	P16-24	Pin, S.	P52-5
Pang, G.	P42-11	Pellegrino, T.	P58-8	Pinard, G-A.	P7-14
Panigrahi, S.	P56-15	Peltz, G. (Roche Palo Alto)	P57-5	Pink, J. J.	P13-19, P43-13
Pankratz, V. S.	P50-4, P50-7, P50-9, P50-10, P50-22, P57-3	Peltz, G. (Univ. of Texas)	P70-10	Pinkhasov, J.	P45-15
Pantschenko, A. G.	P53-11	Peng, B.	P7-16	Pintucci, G.	P31-15
Papa, M. Z.	P30-29	Peng, X.	P11-21	Pisano, E. D.	P42-9
Pappas, D.	P33-7	Peng, X-H.	P64-31	Pischon, N.	P52-11
Pappin, D.	P4-16	Pennington, D. J.	P26-13	Pitfield, S. E.	P26-13
Parak, W. J.	P58-8	Penn, L. Z.	P1-16	Pittman, D. L.	P56-20
Paramagul, C.	P14-13	Penn, S. G.	P41-4	Pizzorno, G.	P67-2
Paranjape, S.	P44-7	Pennington, J. M.	P56-16	Plachot, C.	P40-12
Parchment, R.	P62-11	Pennington, K. L.	P36-12	Planas-Silva, M. D.	P18-7
Parham, C. A.	P42-9	Pennock, E.	P56-2	Pledgie, A.	P67-6, P67-12
Park, B. H.	P66-15	Pentecost, B. T.	P7-13, P7-18	Plon, S. E.	P51-25
Park, C.	P17-10	Pento, J. T.	P53-12	Plopper, G. E.	P33-2
Park, J-E.	P45-8	Peppler, W. W.	P42-5, P42-6	Poblenz, A. T.	P44-13
Park, N-J.	P39-11	Pera, V. E.	P64-10	Podgrabska, S.	P9-12, P9-20
Park, W-H.	P4-18	Perczak, R.	P20-7	Podsypanina, K.	P1-14
Park, Y.J.	P67-20	Pereira-Smith, O.	P30-12	Pokhriyal, N.	P1-2
Parker, B. (Peter MacCallum Cancer Ctr.)	P10-10, P60-19	Perez, A.	P70-10	Pollak, M.	P62-13
Parker, B.	P50-16	Perez, C. A.	P54-14	Pollock, R. E.	P67-22
Parkhurst, C.	P5-16	Perez, D.	P11-5, P11-6, P11-7	Polyak, K.	P53-17, P59-15
Parra, I.	P7-10	Perez-Moreno, M.	P30-18	Pommier, Y.	P27-6
Parrinello, S.	P59-3	Perissi, V.	P5-6	Ponce, A. M.	P44-9
Parrish, E.	P49-7	Perkins, A. S.	P5-11	Ponnazhagan, S.	P46-10
Parrish, J.	P58-16	Perotti, J.	P23-15	Ponte, J. F.	P30-22
Parrott, T.	P62-22	Perou, C. M.	P9-13, P27-4	Ponzielli, R.	P1-16
Parsons, M.	P58-11	Perri, S. R.	P19-5	Poola, I.	P35-11, P35-12
Parsons, R.	P54-20	Perrimon, N.	P2-10, P31-5, P54-10	Popanda, O.	P17-1
Parsons, S. J.	P26-10	Perrinez, P. R.	P64-29	Popko, B.	P27-4
Partridge, N. C.	P28-8	Perron, S.	P1-7	Popov, V.	P64-23
Parvin, J. D.	P4-18, P51-9, P51-13, P51-28	Peshkin, B. N.	P69-13	Poque, B. W.	P14-21
Paskett, E. D.	P20-13, P69-5, P69-6	Petan, T.	P54-18	Porter, D.	P53-17
Pasquale, E. B.	P9-22, P33-6	Peter, M. E.	P58-13	Porter, D. C.	P67-8
Passanese, J.	P45-4	Peters, E.	P23-9	Porter, P. L.	P6-23, P70-11
Patel, B.	P51-23	Petersen, A. S.	P46-7	Porter, W.	P54-15, P59-19
Patel, J. B.	P43-11	Peterson, B. R.	P2-17, P33-1	Portocarrero, C. P.	P11-5, P11-6, P57-2
Patel, N.	P61-11	Peterson, D. R.	P6-22	Posner, G. H.	P30-29
Patel, P.	P48-2	Peterson, L. K.	P50-11	Possakony, J.	P16-2
Patel, S.	P9-6	Peterson, N.	P52-5	Post, S.	P56-8
Paterson, Y.	P12-13, P45-12	Pettersson, G.	P24-4	Postenka, C. O.	P10-18, P38-8, P60-4
Pathaney, L. B.	P45-9	Petkovska, A.	P13-21	Post-White, J.	P20-15
Patil, C. K.	P59-3	Petra, P.	P36-10	Poteet-Smith, C. E.	P2-11
Patrick Jr, C. W.	P48-2	Petrek, J. A.	P20-13, P20-14, P69-3, P69-4, P69-5, P69-6, P69-7	Potoczek, M. B.	P30-23
Patsialou, A.	P29-20, P32-17	Petrra, H. M.	P49-16	Pouliot, N.	P10-10, P60-19
Patt, B. E.	P15-3	Pettersson, F.	P35-10	Pour, K.	P64-7
Pattabiraman, N.	P43-19	Petti, L. M.	P58-12	Povirk, L.	P48-3
Patterson, C.	P9-13, P9-18	Phadke, P. A.	P60-13, P60-23	Powell, J. D.	P45-22
Paul, S. M.	P23-4	Phelps, M. A.	P55-17	Poynter, K. R.	P56-21
Pauli, B. U.	P60-7	Phipps, A. I.	P24-7	Pozner-Moulis, S.	P33-7
Paulsen, K. D.	P14-21, P64-29	Pi, J.	P30-19	Pozzi, S.	P66-17
Paulsen, M. T.	P6-3	Piao, D.	P64-34	Prasain, J. K.	P62-10
Paulson, K. E.	P54-23	Pickard, D.	P64-19	Pratt, W. B.	P5-7
Pawlowski, D.	P20-7	Pickering, C.	P56-24	Prendergast, G. C.	P45-16
Payne, S. L.	P60-18	Pickett, R.	P41-3	Prendes, M.	P39-1
Peace, B. E.	P53-15	Pierce, P. F.	P23-14	Prescott, J.	P1-17
Pecha, J.	P54-22	Pietenpol, J. A.	P27-11, P54-14	Press, M. F.	P50-16, P66-16
		Pietras, R. J.	P19-6	Pretter, S.	P69-12
				Price, J. E.	P22-1, P38-3, P60-20

## Poster/Author Index

Price, J. T.	P60-22	Rangarajan, A.	P31-17	Riquelme, C.	P28-4
Price, R. E.	P16-18	Rani, P.	P12-9	Rittenhouse-Olson, K.	P12-8
Price-Schiavi, S. A.	P52-16	Ranscht, B.	P9-17	Rivera, B.	P16-18
Primorac, S.	.P58-1	Rao, D. S.	P53-13	Rizzo, P.	P67-9
Prokhorova, T.	.P51-15	Rao, M.	P49-21	Rizzo, S. A.	P43-2
Prossnitz, E. R.	P31-21, P55-7	Rassa, J. C.	P31-11	Robbie, M. J.	P59-8, P59-9
Proteau, R.	.P15-6	Rausch, M.	P45-1	Robbins, P. D.	P44-12
Provenzano, E.	.P70-4	Raveis, V. H.	P69-12	Robert, F.	P6-17
Provenzano, P. P.	P59-16	Ray, D.	P29-14	Roberts, A. L.	P57-5
Puckett, C. L.	P40-20	Ray, S. A.	P56-16	Roberts Jr., C. T.	P26-17
Pulakat, L.	.P33-8	Ray, T.	P13-1	Roberts, D.	P56-5
Pumfery, A.	.P51-16	Raz, A.	P11-22	Roberts, D. M.	P9-18
Pukkes, J.	.P20-15	Rebbeck, T.	P57-3	Robertson, F. G.	P11-23
Purohit, A.	.P32-15	Recio, A.	P45-7	Robinson-Benion, C.	P3-27
Pusztai, L.	P48-8, P55-18	Redd, W. H.	P39-4	Robson, M. E.	P62-9
<b>Q</b>					
Qi, C.	P54-16	Reddy, E. P.	P27-3, P67-1	Rodoletz, M.	P20-11
Qi, H.	P14-10	Reddy, M. V. R.	P67-1	Rodriguez, A.	P67-15
Qi, Y.	.P1-24	Reddy, V. K.	P67-6	Rodriguez, M.	P54-8
Qian, W.	P14-11, P14-12, P14-17	Redmon, B.	P24-10	Rodriguez, R.	P52-5
Qiao, W-H.	.P51-11	Reed, J. C.	P58-10, P58-18	Roe, T.	P9-20
Qin, J-Z.	.P67-9	Reed, S. (The Scripps Research Inst.)	P29-12	Rogan, E. G.	P50-2, P50-3, P50-17, P50-18
Qin, L.	P35-13, P35-23	Reed, S. (Univ. of Washington)	P70-3	Rogers, A. E.	P37-8, P64-24
Qin, W.	P40-19, P40-20	Reed, S. M.	P47-3	Rogers, L.	P61-3
Qin, X.	.P55-5	Reeves, G. T.	P33-5	Rohan, T. E.	P24-5
Quale, C.	P42-3, P68-5, P68-6	Rehman, A.	P27-6	Rojas, M. B.	P38-16
Quenneville, L.	.P25-1	Reibarkh, M.	P2-24	Rojas, R. J.	P67-16
Quinn, R. H.	.P53-11	Reilly, R. M.	P44-18, P65-5, P67-13, P67-14	Rojo, F.	P13-7
Qureshi, H.	.P11-29	Reinicke, K. E.	P43-13	Romesberg, F.	P4-19
<b>R</b>		Reisfeld, R. A.	P12-16, P45-18	Romieu-Mourez, R.	P3-8
Raab, M.	P65-9	Reiss, M.	P29-18	Romilly, P. A.	P14-11, P42-1
Raatz, S.	P24-10	Reiter, R.	P36-11, P55-16	Ronen, S. M.	P64-26
Rabinowich, H.	.P2-18	Ren, C.	P46-10	Rong, H. M.	P3-25
Rachlin, K.	P10-20	Ren, M.	P66-17	Rong, M.	P52-16
Rader, C.	.P19-8	Ren, S.	P7-23	Rorie, C. J.	P54-1
Radice, G. L.	.P3-22	Ren, Z. (Renz Research, Inc.)	P7-22	Roscoe, J.	P20-4
Radisky, D. C.	P32-11, P71-2	Ren, Z. (Vanderbilt Univ.)	P21-9	Rosen, C. J.	P24-13
Radivoyevitch, T.	P13-19	Repasky, E.	P45-4	Rosen, G.	P65-11
Radunsky, G.	P32-22	Resnick, M. A.	P27-4, P27-13	Rosen, J. M.	P3-6, P5-20, P32-23
Rae, J.	P67-19	Restall, C.	P59-8, P59-9	Rosenberg, A.	P11-20
Rahim-Bata, R.	P43-12	Retzinger, G. S.	P44-11	Rosenberg, C. L.	P40-5
Rahman, K.M. W.	P60-21	Revankar, C.	P55-7	Rosenberg, R.	P42-3
Railey, E.	P23-15	Revers, L.	P67-5	Rosenberg, S. M.	P56-13, P56-16
Raisch, K. P.	P44-10, P44-15	Reynolds, A.	P30-18	Rosenblatt, J.	P45-10
Rajan, R.	.P48-8	Rezonzew, G.	P38-20	Rosenblatt, J. D.	P39-12
Rajaram, R. D.	.P3-23	Riboli, E.	P49-4, P49-18	Rosenblum, M. G.	P44-13
Rajasekaran, A. K.	.P27-7	Richard, E.	P62-22	Rosenfeld, M. G.	P5-6
Rajasekaran, S. A.	.P27-7	Richards-Kortum, R.	P38-3	Rosenquist, T. A.	P4-5
Raju, U.	P11-27, P11-28, P11-29	Richardson, A.	P40-7, P59-15	Rosenstein, B. S.	P62-17, P62-18
Rakoff, M.	P23-13, P23-20	Richardson, R.	P16-23	Rosenthal, E.	P10-12
Ramachandra, M.	P46-13	Richer, E.	P64-3	Rose-Petruck, C.	P64-4
Ramachandran, N.	.P44-8	Richer, J. K.	P18-6	Rosner, B.	P40-1
Ramanathapuram, L.	.P45-17	Rickert, E.	P16-26	Rosner, W.	P36-4
Ramanujam, N.	P14-9, P40-23, P64-33	Ricketts, R. St. J.	P57-5	Ross, E.	P23-10
Ramaprasad, S.	.P30-19	Riegel, A. T.	P10-19, P36-11, P55-16	Ross, G.	P45-20
Ramirez, R.	.P15-9	Rieger-Christ, K.	P54-23	Ross, S. R.	P31-11
Ramsey, E. E.	.P13-7	Riese II, D. J.	P26-13, P26-14, P26-15	Ross, T. S.	P53-13
Ran, S.	P30-6	Riggins, R. B.	P18-2, P18-3, P66-4, P66-14	Rossant, J.	P9-12, P-20
		Rigol, N.	P66-7	Rossetti, S.	P66-17
		Rimm, D. L.	P6-4, P33-7, P40-4	Rossing, M. A.	P20-10
		Rinaldi, S.	P49-4, P49-16	Rotello, V. M.	P27-9, P44-14

## Poster/Author Index

Rouibidoux, M. A.	P14-5, P14-13, P14-18	Salisbury, J. L.	P25-3, P29-6	Schmidt, M.	P10-19
Rouzier, R.	P55-18	Salvo, V. A.	P61-1	Schmitt, E.	P35-13, P35-23
Rovai, L.	P40-2	Samei, E.	P42-10	Schnaper, L.	P13-13
Rowan, B. G.	P7-19	Sampat, M.	P14-14	Schneider, J.	P3-10
Rowell, C.	P6-18	Sampson, R. W.	P43-16	Schneider, R. J.	P17-11
Rowlands, J. A.	P42-11	Samuelson, D. J.	P6-24, P62-14	Schnitt, S.	P59-15
Rowley, M.	P25-3	Samuelson, L. E.	P64-6	Schnoll, R. A.	P23-10, P23-11
Roy, M.	P2-19	Sancar, A.	P29-9	Schoenlein, P.	P26-16
Royak-Schaler, R.	P70-12	Sanchez, A.	P9-1	Scholler, N.	P50-19
Rozenberg, G. I.	P59-17	Sanders, M.	P53-11	Schoonmaker, L.	P63-8
Ruan, Z. X.	P22-2, P49-17	Sanderson, M.	P70-10, P70-11	Schramek, D.	P2-2
Rubinstein, I.	P15-7	Sandin, S.	P61-10	Schroeder, J.	P49-9
Rubinstein, W. S.	P62-15	Sang, Q-X. A.	P10-5, P59-24	Schroeder, T.	P15-10
Ruf, W.	P1-19	Sankala, H.	P2-20	Schroit, A. J.	P60-10
Ruh, M. F.	P7-2	Sankaran, S.	P51-28	Schubert, E.	P36-10
Ruhf, L.	P54-10	Sankarasharma, D.	P10-1	Schuchter, L. M.	P45-7
Rui, H.	P30-21	Sano, T.	P46-11	Schulman, B. A.	P32-19
Ruidiaz, E. M.	P1-18	Santella, R. M.	P24-11, P49-5, P49-6, P49-9, P49-21	Schultz, L.	P54-3
Rumer, K.	P59-19	Santen, R. J.	P26-18, P43-15, P50-18	Schupbach, T.	P26-4
Ruosahti, E.	P9-19, P9-23	Santi-Ruiz, L.	P4-20	Schupf, N.	P54-20
Russell, A. J.	P4-16	Santos, S. L.	P56-6	Schuster, G.	P40-17
Russell, R.	P35-18	Sap, J.	P30-7	Schwab, R. B.	P62-4
Russo, I. H.	P8-3, P8-4, P8-5, P8-7, P8-8, P13-20, P50-6	Sarcevic, B.	P29-21, P29-22	Schwartz, D.	P50-21
Russo, J.	P8-3, P8-4, P8-5, P8-7, P13-20, P31-11, P50-6	Sarkar, D.	P46-12	Schwartz, G. K.	P22-6
Russo, P. A.	P8-4, P8-5, P8-7	Sarkar, F. H.	P60-21, P62-11	Schwartz, G. N.	P13-17
Rustgi, A. K.	P60-8	Sarkisian, C. J.	P11-6	Schwartz, M. D.	P69-13
Ryan, J. D.	P43-14	Sarna, M.	P45-2	Schweitzer, A.	P6-2
Ryan, P.	P20-3, P40-21	Sassaroli, A.	P64-10	Scallard, D. A.	P44-18, P65-5
Rymal, C.	P20-7	Satterthwait, A. C.	P44-16	Scrivens, P. J.	P29-23
<b>S</b>					
Saadi, W.	P10-11, P52-8	Sauane, M.	P2-21	Scudder, J. M.	P3-12
Saavedra, E. L.	P68-7	Sauer, C. L.	P3-22	Scurr, L. L.	P8-2
Sabath, D. E.	P40-17	Saunders, D. N.	P4-16, P32-18	Seachrist, D. D.	P1-9
Sabatini, D. M.	P31-18	Saunders, R. S.	P42-10	Seagroves, T.	P11-17
Sabelawski, S.	P61-12	Sauter, E. R.	P40-18, P40-19, P40-20	Sech, L.	P71-11
Sacchi, N.	P66-17	Saven, A.	P38-4	Secreto, G.	P34-5
Saceda, M.	P7-15	Saven, J. G.	P65-3	See, B. K.	P16-6
Sacks, D. B.	P2-19, P31-14	Sawyer, K.	P48-9	Seelig, S.	P66-16
Sadekova, S.	P52-3	Sawyer, S.	P48-5	Seewaldt, V. L.	P5-12
Sadlonova, A.	P59-18	Saxena, A.	P54-1	Seftor, E. A.	P60-18
Sadowski, M.	P29-22	Saxena, D.	P38-7	Segar, D. (Group Health Cooperative)	P70-3
Saeed, M.	P50-2	Saxena, N. K.	P7-20	Seger, D. (Weizmann Inst. of Science)	P63-3
Sáez, R.	P13-7	Saxl, R. L.	P67-8	Sehon, K.	P13-3
Safavy, A.	P44-10, P44-15	Schaeberly, C.	P59-12	Seidah, N.	P55-19
Safavy, K.	P44-15	Schaffer, B. S.	P36-12	Sekhar, K. R.	P21-9
Safe, S.	P36-6	Schatton, T.	P66-7	Sekosan, M.	P15-7
Safina, A.	P28-1	Schatz, D. G.	P48-3	Selander, K. S.	P10-12, P10-13
Saha, S.	P9-1	Schaub, B.	P62-13	Seldin, D. C.	P1-3, P2-5, 3-8, P31-6
Sahin, A.	P29-13, P30-8, P36-16, P50-11, P67-23	Schaubert, K.	P71-9	Selim, A. L.	P51-2
Sahiner, B.	P14-5, P14-13, P14-18, P41-1	Schavolt, K.	P27-11	Seller, T. A. P49-7, P50-7P50-9, P50-10, P57-3	
Saini, S. S. P.	P7-23	Schedin, P.	P59-19	Selvaggi, S.	P67-9
Saito, W. Y.	P51-2	Schell, M.	P27-4	Selvakumar, B.	P16-1
Sakamoto, K. M.	P67-15	Schernhammer, E. S.	P24-8	Selvamurugan, N.	P28-8
Salant, T.	P23-16	Schickel, R.	P58-13	Sempere, L.	P5-13
Salazar, L.	P12-4, P12-12	Schiff, R.	P1-14, P2-22, P35-13, P35-23	Sen, S.	P54-8
Salem, A.	P14-7	Schiffer, M.	P51-8	Senaratne, S.	P6-27
		Schlabauch, M.	P29-7	Senie, R. T.	P49-6
		Schlatter, L.	P40-19	Seo, H-S.	P36-13
		Schmandt, R.	P12-15	Seon, B. K.	P19-7
		Schmezer, P.	P17-1	Serrero, G.	P52-9
				Servinsky, M.	P52-5

## Poster/Author Index

Seth, P.....	P46-13	Shi, W.....	P52-5	Singh, S. (Univ. of Nebraska Medical Ctr.) .....	P30-19
Sethi, S.....	P11-29	Shi, Y.....	P58-16	Singletary, E.....	P20-13
Sexton, G.....	P13-7	Shi, Y. E.....	P35-15, P35-16	Sinha, J.....	P46-14
Seyed, M. A.....	P30-2	Shiekhattar, R.....	P40-6, P51-7	Sinha, M. S.....	P38-11
Sfeir, A. J.....	P56-22	Shields, P. G.....	P4-20, P24-6, P49-8, P49-19	Sinha, S. C.....	P19-8
Sgroi, D. C.....	P40-7, P40-21, P40-22	Shih, B. Y.....	P61-1	Sinilnikova, O. M.....	P49-11, P49-18, P57-3
Sha, J.....	P43-3	Shih, H. A.....	P64-30	Sinkevicius, K. W.....	P7-21
Sha, Z.....	P30-20	Shim, J-Y.....	P16-8	Sintasath, L.....	P1-4
Shaaf, S.....	P18-8	Shim, K. D.....	P39-8	Siolas, D.....	P5-14
Shadeo, A.....	P11-19	Shimogawa, H.....	P16-4	Siponen, M. I.....	P4-13
Shafirstein, G.....	P14-15	Shimogawa, M.....	P56-9	Siripurapu, V.....	P30-11
Shah, D.....	P24-12	Shin, G.....	P3-11	Sison, J.....	P38-7
Shah, N.....	P64-16	Shin, S. (Mayo Clinic, Rochester) .....	P1-8	Siu, S.....	P15-9
Shah, S. V.....	P58-2	Shin, S. (New York University).....	P30-7	Siziopikou, K.....	P67-9
Shah, V.....	P11-28	Shin, S. R.....	P3-8	Skafar, D. F.....	P71-7
Shah, Y.....	P7-19	Shin, S-U.....	P39-12	Skala, M. C.....	P40-23
Shameih, L. S.....	P26-17	Shinozawa, E. T.....	P21-9	Skliris, G.....	P7-16
Shankar, S.....	P67-17	Shioda, T.....	P59-12	Skobe, M.....	P9-12, P9-20
Shapiro, P. J.....	P62-16, P62-19, P69-9	Shiozaki, K.....	P19-7	Slamon, D. J.....	P66-16, P67-11
Sharifpoor, S.....	P53-3	Shiraishi, K.....	P9-12, P9-20	Slauson, M.....	P15-6
Sharma, A.....	P14-12	Shishodia, S.....	P22-1	Slavin, J.....	P11-12
Sharma, D.....	P7-20	Shiu, R.....	P7-16, P55-19	Slavin, S. A.....	P9-3
Sharma, G. G.....	P56-19	Shoher, A.....	P60-11	Slavine, N.....	P64-3
Sharma, M.....	P10-14	Shostak, G. A.....	P2-6, P2-7	Sledge, G.....	P35-8
Sharma, P.....	P38-6	Shou, J.....	P2-22	Slingerland, J.....	P26-3
Sharma, V. B.....	P4-8	Shrama, M.....	P10-14	Sloan, E.....	P60-19
Sharp, D. J.....	P56-4	Shrestha, K.....	P5-2	Sloan, J. A.....	P20-8
Sharp, Z. D.....	P51-26	Shrikhande, U.....	P33-3	Sloane, B. F.....	P50-21
Shavrin, A.....	P64-26, P65-2	Shu, X. O.....	P22-2, P49-3, P49-17	Smiraldo, P. G.....	P56-20
Shaw, C. C.....	P41-5	Shull, J. D.....	P30-3, P36-12	Smith, B.....	P40-21
Shaw, D. R.....	P5-2	Shvartsman, S. Y.....	P33-5	Smith, C. L. (Baylor College of Medicine).....	P36-15
Shaw, H.....	P40-2	Shyamala, G.....	P52-14	Smith, C. L. (Boston Univ.) .....	P44-17
Shawber, C. J.....	P9-12, P9-20	Shyr, Y.....	P9-4	Smith, C. R.....	P50-13, P51-27
Shay, J. W.....	P4-17, P56-22	Sickles, E. A.....	P42-1, P42-3	Smith, D.....	P20-7
Shaye, A.....	P54-20	Siddiqui, K.....	P56-23	Smith, D. R.....	P20-8
She, X.....	P19-7	Siddiqui, R.....	P71-11	Smith, E. R.....	P56-19
Sheen, J-H.....	P31-18	Sieber, F.....	P43-16	Smith, J. A.....	P2-11
Sheffer, R.....	P11-27	Sieckman, G.....	P65-4	Smith, J. R.....	P49-3, P49-17
Sheikh, S.....	P67-1	Siegel, G. P.....	P38-20	Smith, J. W.....	P16-23
Sheilds, P.G.....	P50-20	Siegel, C. S.....	P38-6, P38-7	Smith, K. T.....	P35-2, P36-14
Shekhar, M. P.V.....	P11-22, P31-19	Siegel, R.....	P40-1	Smith, M.....	P62-10
Shen, H-M.....	P24-2	Siiteri, P. K.....	P8-6	Smith, M. L.....	P23-15
Shen, K. C.....	P56-25	Sikes, C.....	P44-13	Smith, P. J.....	P62-20
Shen, L. (Boston Univ.).....	P30-27	Silha, J.....	P55-19	Smith, S. M.....	P64-6
Shen, L. (Ohio State Univ.) .....	P57-6	Silver, E. S.....	P24-8	Smith-Bindman, R.....	P42-3, P68-5, P68-6
Shen, T-L.....	P11-21	Silver, P. A.....	P6-2	Snijders, A. M.....	P6-16
Shen, X.....	P28-3	Silverman, W.....	P54-20	Snook, M.....	P62-22
Shen, Z.....	P25-7, P25-10, P29-11	Simon, S. R.....	P9-21	Snyder, C. L.....	P23-17
Sheng, X.....	P11-27	Simoneaux, M.....	P35-18	Snyder, P.....	P3-18
Shenolikar, S.....	P5-19	Simons, A. M.....	P4-18	Soesbe, T.....	P64-3
Shepherd, J.....	P61-13	Simpson, K. J.....	P38-22	Soghomonyan, S. ....	P64-26, P65-2
Shepherd, T.....	P1-7	Sims, N. A.....	P11-12	Sohail, H.....	P9-6
Sheriff, F.....	P8-4, P8-5, P13-20	Singh, A. B.....	P58-2	Soler, A. P.....	P3-22
Sherk, A. B.....	P35-14	Singh, B.....	P60-11	Solheim, J. C.....	P45-19
Sherman, A.....	P40-19	Singh, M.....	P18-6	Somenzi, G.....	P66-17
Sherman, K.....	P20-11	Singh, R. (Univ. of Pennsylvania) .....	P12-13	Sommer, P.....	P52-11
Sherr, D. H.....	P22-8, P37-8	Singh, R. (Univ. of Texas M.D. Anderson).P35-3		Sondek, J.....	P67-16
Sherrill, T.....	P3-27	Singh, R. K.....	P45-19	Sonenshein, G. E.....	P1-3, P3-8, P31-6, P37-8, P52-11
Shi, C.....	P27-16	Singh, S. (Duke Univ. Medical Ctr.) .....	P14-8, P14-16		
Shi, Q.....	P13-21				

## Poster/Author Index

Song, D.	P14-11, P14-12, P14-17	Stivers, J. T.	P43-7	Sweet, K.	P57-6
Song, L. L.	P67-9	Stock, R. G.	P62-17, P62-18	Swenson, K.	P20-15
Song, R. X-D.	P26-18	Stockard, C. R.	P5-1, P30-14	Swetenburg, R. L.	P9-18
Sonnenschein, C.	P3-13, P59-12, P59-20	Stoica, A.	P35-18	Swift, M. R.	P53-14
Sosnoski, D. M.	P32-5	Stoica, G. E.	P32-20, P35-18	Swift-Scanlan, T.	P13-12
Sosnowski, J.	P67-7	Stoltz, D. B.	P3-15, P11-24	Swigart, L. B.	P1-6
Soto, A. M.	P3-13, P59-12, P59-20	Stone, M. C.	P18-7	Symmans, W. F.	P48-8
Soucek, L.	P1-6	Stoppa-Lyonnet, D.	P49-11	Synold, T. W.	P66-2
Souris, J.	P65-6	Storchan, G.	P7-15	Sythowski, A. J.	P54-18
Spanjaard, R. A.	P30-27	Storre, J.	P3-23	Syud, F. A.	P65-10
Spasojevic, I.	P16-1	Strat, A.	P6-9	Szabo, C.	P57-3
Spece, L.	P65-3	Stricker, C. T.	P20-12	Szallasi, Z.	P40-7
Spence, J. R.	P29-16	Strickland, P.	P3-11	Sze, C-I.	P54-3
Spencer, D. M.	P5-5	Strobl, J. S.	P43-12		
Spencer, V. A.	P5-15	Strohecker, A.	P58-5		
Spensor, V.	P5-21	Strome, E.	P51-25		
Spicer, Z.	P38-16	Struhl, K.	P27-17		
Spiegel, S.	P2-20	Sturgeon, S. R.	P61-12		
Spinella, M. J.	P7-9	Sturgill, T. W.	P31-3		
Spitz, D.	P43-13	Stutz, D. L.	P65-8		
Spoelstra, N.	P18-6	Stybilo, T. M.	P15-3		
Sprague, B. J.	P40-23	Su, B.	P33-10		
Sprague, J. E.	P15-8	Su, D.	P32-21		
Spruck, C.	P10-15	Su, M.	P54-3		
Sridhar, J.	P43-19	Su, Y.	P22-7		
Sridhar, R.	P43-17	Su, Z.	P46-12		
Srivastava, M.	P2-23	Subjeck, J. R.	P45-8		
Srivastava, P.	P27-7	Sudar, D.	P64-21		
Srivastava, R. K.	P67-17	Suen, T-C.	P51-29		
Stafford, L. J.	P38-23	Sugg, S. L.	P7-21		
Stallcup, M.	P50-16	Sugiro, F. R.	P42-6		
Stampfer, M. R.	P32-24, P32-25, P54-17	Sukumar, S.	P9-7, P9-8, P13-12, P60-24, P67-7		
Stanczyck, F.	P61-12	Sukumvanich, P.	P20-14		
Stanford, W. L.	P9-18	Sullivan-Halley, J.	P66-16		
Stanley, A. M.	P52-4	Sultan, A. S.	P30-21		
Stanton, A.	P69-10	Suman, V.	P40-21		
Starita, L. M.	P51-13, P51-28	Sumkin, J. H.	P42-4		
Stearns, T.	P43-18	Summe, H.	P35-18		
Steele, S. L.	P23-18	Summerhayes, I.	P54-23		
Stefanick, M. L.	P24-5	Summerton, J.	P15-6		
Stefansdottir, S.	P49-20	Sun, J.	P51-20		
Stefflova, K.	P47-5	Sun, W.	P2-24		
Stegner, A. L.	P40-18	Sun, X. (Univ. of South Florida)	P14-11, P14-12, P14-17		
Stein, R.	P67-16	Sun, X. (Washington Univ.)	P65-1		
Steingrinsson, E.	P57-4	Sun, Y.	P58-3		
Steiniger, S.	P9-19	Sundaram, S.	P21-6		
Stephens, T.	P48-8	Sung, P.	P4-3, P25-8		
Stern, D. F.	P4-14	Suo, J.	P30-7		
Stern, F.	P29-24	Surdi, G.	P44-17		
Sternier, C. J.	P11-6, P57-2	Susser, E.	P24-12		
Sterns, C. J.	P26-19	Sussman, L.	P32-2		
Stevens, F. J.	P51-8	Suster, S.	P67-21		
Stevens, R. G.	P24-8	Sutanto-Ward, E.	P45-16		
Stiles, J. K.	P55-20	Sutherland, R. L.	P21-2, P32-18		
Stillman, B.	P56-23	Swaan, P.W.	P55-17		
Stillwell, W.	P71-11	Swaby, R.	P67-10		
Stitsiel, N. O.	P6-19	Swansonlund, D.	P21-8		
Stitt, J. P.	P64-27	Sweeney, C. A.	P26-23		
Stitzel, N. O.	P6-28				
Stivala, F.	P29-6				

## Poster/Author Index

Teker, K.....	P64-25	Ton, C.....	P6-23	Tyers, M.....	P16-3
Telmer, C.....	P27-16	Toney, K.....	P53-15	Tyler, B.....	P67-7
Temple, K. A.....	.P7-21	Tong, C.....	P54-21	Tynan, J. A.....	P1-22
Tennis, M.....	P49-19	Tong, W. P.....	P64-26		
Tenniswood, M.....	P10-16	Tongcharoensirikul, P.....	P16-12, P16-13	<b>U</b>	
Terao, Y.....	P29-14	Toole, B. P.....	P3-13	Uche, E. E. O.....	P49-15
Tercyak, K.....	P69-13	Torabi, B.....	P4-1	Uesugi, M.....	P16-4
Terry, K. L.....	.P24-9	Torchinsky, C.....	P30-27	Ullrich, R. L.....	P4-15
Terry, M. B.....	P24-12, P49-9, P49-21	Tornai, M. P.....	P15-2	Ulukus, E. C.....	P11-4
Testa, S. M.....	P46-14	Torosian, M.....	P13-20	Umbrecht, C. B.....	P6-27
Thakkur, S.....	.P63-1	Torrång, A.....	P24-4	Uneda, S.....	P19-7
Theodore, G.....	P52-16	Torto, R.....	P34-3	Ung, K.....	P7-16
Theofilopoulos, A. N.....	P12-1	Town, J.....	P43-6	Unlu, M. B.....	P64-13
Thiagalingam, S.....	P30-22	Townson, S. M.....	P35-17	Urban, C. A.....	P56-6
Thibodeau, S. N.....	P57-3	Trackman, P.C.....	P52-11	Urban, N.....	P50-19
Thiel, K. W.....	P26-20	Tran, A.....	P10-17	Uren, A.....	P43-19
Thimio, J. P.....	P30-26	Trask, D.....	P17-5	Uribe, J.....	P15-9
Thomas, A. K.....	P40-17	Träuernicht, A. M.....	P51-5	Utley, K.....	P57-1
Thomas, L. R.....	P58-14	Trebley, J.....	P16-26	Uzgiris, E. E.....	P63-8
Thomas, R.....	P62-7	Tremblay, E. A.....	P53-3		
Thomas, R. J.....	P11-12	Trent, J. O.....	P16-24	<b>V</b>	
Thomas, W. K.....	.P34-1	Trentham-Dietz, A.....	P62-14	Vadas, Z.....	P60-14
Thompson, B.....	P20-4	Trevisan, M.....	P24-6, P49-8	Vadlamudi, R. K.....	P36-16
Thompson, C.....	P6-20	Triche, T. J.....	P62-13	Valasinas, A. L.....	P67-6
Thompson, C. B.....	.P43-1	Trimboli, A. J.....	P59-4	Valdimarsdottir, H. B.....	P23-2, P23-22,
Thompson, E. W.....	P58-9, P59-9, P60-22	Tripathy, D.....	P38-11	P39-2, P39-5	
Thompson, H. S.....	P23-21	Tripp, C. A.....	P60-9	Valencia, F.....	P9-22
Thompson, R. C.....	P64-6	Trivedi, A.....	P16-17	Valerie, K.....	P48-3
Thompson, W. E.....	P55-20	Tromberg, B.....	P64-16		
Thompsonston, J. A.....	P12-14	Tront, J. S.....	P54-19	Vallis, K. A.....	P67-13
Thorburn, A.....	P58-14, P58-15	Trott, J. F.....	P3-12	Valrance, M.....	P36-17
Thorburn, J. S.....	P58-15	Truesdell, P.....	P33-9	van der Hel, O.....	P49-16
Thorne, C.....	.P36-7	Trupathy, D.....	P63-4	van der Weide, D. W.....	P64-14
Thorpe, P.....	P44-13	Tryggvadottir, L.....	P49-20	van Deursen, J.....	P54-21
Tian, C.....	P17-1	Tsai, H.....	P19-7	van Dyke, M. W.....	P5-17, P5-22
Tian, K.....	P12-6	Tsai, J. H.....	P19-9	van Golen, K. L.....	P32-22, P60-17
Tice, J. A.....	P61-13	Tsai, M. Y.....	P7-24	van Rooijen, N.....	P11-10
Tiedge, H.....	P13-14	Tsai, M-J.....	P35-21	van Veen, B. D.....	P64-14
Tighe, A.....	P32-8	Tsai, S. Y.....	P35-21	Vanegas, J.....	P8-7
Tilley, W. D.....	P31-12, P35-4	Tsan, M-F.....	P11-10	Vantyghem, S. A.....	P10-18, P60-4
Tillitz, E.....	P5-8	Tsan, Y-C.....	P6-3	Vanzee, K.....	P11-11
Timoshenko, A. V.....	P10-3	Tsimelzon, A.....	P6-12	Varela, J. C.....	P40-16
Tinder, T. L.....	P45-9	Tsuda, N.....	P12-15	Vargis, E.....	P52-14
Ting, C.....	P7-15	Tsujie, M.....	P19-7	Vargo-Gogola, T.....	P32-23
Tisnado, D.....	P68-8	Tsvekova, R.....	P29-24	Varma, A.....	P51-18, P51-19
Tius, M. A.....	P43-14	Tsvetkov, L.....	P29-24	Varnes, M.....	P43-13
Tiwari, N.....	P11-28, P11-29	Tu, A. W.....	P28-9	Vasic, J.....	P19-1
Tjan, S.....	P11-19	Tu, Z.....	P15-5	Vasir, B.....	P45-10
Tlsty, T.....	P50-4, P50-7, P50-9, P50-10, P54-17, P56-11, P56-24	Tuck, A. B.....	P10-18	Vasir, J. K.....	P46-15
Toal, K. T.....	P38-11	Tuck, D.....	P40-4	Vaz, D.....	P1-7
Tochacek, M.....	P36-12	Tudorica, L.....	P63-7	Velie, E. M.....	P24-13
Tockman, M. S.....	P14-12	Tuna, M.....	P21-7	Velikokhatnaya, L.....	P13-18
Tod, T.....	P50-13, P51-27	Tung, N.....	P20-3	Vellon, L.....	P66-12
Toft, D. O.....	P5-7	Turner, R. T.....	P34-3	Venditti, M.....	P55-19
Tolba, K.....	P39-12	Turnquist, H. R.....	P45-19	Veneroso, C.....	P70-8
Tolbert, D.....	P49-7	Turos, E.....	P16-8	Venkataramani, R. N.....	P32-13
Toma, D.....	.P7-23	Tuszynski, G. P.....	P10-14	Verbanac, K. M.....	P40-24, P48-9
Tomes, L.....	P13-22	Tutwiler, R. L.....	P64-27	Verma, S.....	P35-19
Tomita, Y.....	P43-8, P43-19	Twait, E. C.....	P26-6	Vermolen, B.....	P56-15
		Tycko, B.....	P54-20	Versteeg, H. H.....	P1-19
				Vertino, P.....	P58-11

## Poster/Author Index

Vervoort, V. S.	P9-22	Waltz, S. E.	P53-15	Wang, X-Y.	P45-8
Vickers, A.	P22-6	Wan, L.	P67-2	Wang, Y.	P16-8
Vidal, G.	P26-21	Wan, M.	P30-14	Wang, Y. (Georgetown Univ.)	P31-23
Vidya, R.	P43-21	Wan, Q.	P12-9	Wang, Y. (Johns Hopkins Univ.)	P67-12
Vielhauer, G.	P12-11	Wands, J. R.	P64-4	Wang, Y. (Ohio State Univ.)	P30-28
Vierkant, R. A.	P50-4, P50-9, P50-10, P50-22, P57-3	Wang, B. (Brigham & Women's Hosp.)	P4-22, P29-8	Wang, Y. (Thomas Jefferson Univ.)	P30-23
Viglianti, B. L.	P44-9	Wang, B. (Univ. of Texas M.D. Anderson)	P55-18	Wang, Y. Alan (Wayne State Univ.)	P56-25
Villacorte, D.	P16-22	Wang, C. (Biocyte, Inc.)	P14-10	Wang, Yaolin (Wayne State Univ.)	P56-25
Villalobos, I.	P66-16	Wang, C. (New York Univ.)	P30-7	Wang, Yu (Univ. of Texas M.D. Anderson)	P15-9
Vinve, H.	P64-34	Wang, F.	P32-11	Wang, Yuetang (Univ. of Texas M.D. Anderson)	P44-20
Viola, F.	P64-28	Wang, G. (Dana-Farber Cancer Inst.)	P40-9	Wang, Z.	P40-21, P40-22
Visaria, R.	P21-8	Wang, G. (State Univ. of NJ)	P29-18	Wang, Z. (Medical College of Georgia)	P16-24
Vishwanatha, J.	P19-1	Wang, H. (Thayer School of Engineering)	P64-29	Wang, Z-G.	P46-13
Visscher, D. W.	P50-4, P50-7, P50-9, P50-10	Wang, H. (Univ. of Wisconsin-Madison)	P30-16	Warren, J. D.	P16-25
Vito, D.	P24-6, P49-8	Wang, J.	P18-1	Watering, R.	P53-3
Viyajadeva, V.	P49-12	Wang, J. (Cold Spring Harbor)	P62-20	Watson, P. H.	P7-16, P11-8, P11-25, P13-22, P55-19
Vogel, V. G.	P3-14, P3-15	Wang, J. (Roche Palo Alto)	P57-5	Watts, C. K. W.	P4-16, P21-2, P32-18
Volgin, A.	P64-26	Wang, J. (Univ. of Toronto)	P65-5, P67-13, P67-14	Wazer, D.	P54-23
Volkert, W. A.	P65-4	Wang, J. H.	P23-23	Weatherall, P.	P63-4
Volpe, S.	P61-12	Wang, J-P.	P50-18	Weatherman, R. V.	P16-26
Voltz, J. W.	P31-20	Wang, K.	P17-4	Weathers, B.	P69-8
Vonck, R.	P71-9	Wang, L. (Baylor College of Medicine)	P37-6	Weaver, J.	P65-11
Vonderheide, R. H.	P45-7	Wang, L. (Dana-Farber Cancer Inst.)	P40-9	Weaver, J. B.	P64-29
Voronchikhina, M.	P9-12	Wang, L. (Mayo Clinic, Rochester)	P57-3	Weaver, V. M.	P59-17, P59-21
Voultsios, A.	P31-12	Wang, L. (Univ. of Texas M.D. Anderson)	P30-8	Weber, B.	P57-3
Vujaskovic, Z.	P16-1	Wang, L-H.	P52-17	Weber, F.	P57-6
Vuori, K.	P31-16	Wang, M.	P18-1	Weber, G. F.	P31-24
<b>W</b>					
Wachtman, L.	P52-5	Wang, M. (Georgetown Univ.)	P61-4	Weber, J. D.	P1-25
Waddell, B.	P32-19	Wang, M. (Univ. of Iowa)	P5-18	Weber, M. R.	P38-4
Wadsworth, E.	P62-9	Wang, M. (Univ. of Pennsylvania)	P1-20, P3-1	Webster, D.	P12-4
Wafai, R.	P60-22	Wang, N. (Case Western Reserve Univ.)	P13-19	Wei, J.	P14-18
Wagener, B. M.	P31-21	Wang, N. (Univ. of Alabama)	P30-14	Wei, W-Z.	P39-8
Wagner, G.	P2-24	Wang, P.	P17-2	Wei, X.	P67-5
Wagner, W.	P12-11	Wang, P. H.	P7-24	Wei, Z.	P1-11
Wagner-Mann, C.	P40-18	Wang, Q. (Columbia Univ.)	P49-6	Weichselbaum, R. R.	P4-21
Wahl, E.	P23-22	Wang, Q. (Univ. of South Carolina)	P44-19	Weiderpass, E.	P61-10
Wakchoure, S.	P10-13	Wang, R.	P13-20	Weihls, K.	P69-14
Wakefield, L.	P46-13	Wang, R. S.	P7-24	Weinberg, R. A.	P31-17, P59-6, P59-7
Waks, T.	P12-7	Wang, R-H.	P51-11	Weiner, A. A.	P44-4
Waldman, F.	P50-21	Wang, S. (Brown Univ.)	P64-9	Weiser, D. C.	P5-19
Waleh, N.	P38-24	Wang, S. (Univ. of Michigan)	P43-8, P67-19	Weitzel, J.	P57-3
Walker, E. C.	P60-22	Wang, S-J.	P10-11, P52-8	Welch, D. R.	P38-8, P38-17, P60-13, P60-23
Walker, T. D.	P48-5	Wang, W. (Cincinnati Children's Hosp. Res. Found.)	P5-8	Welch, M. J.	P15-5, P65-1
Walker, W. F.	P64-28	Wang, W. (Uniformed Services Univ. of Hlth. Sci.)	P52-6	Welch, Z.	P71-11
Wall, K.	P38-9	Wang, W-C.	P45-4	Wells, A.	P11-24
Wallace, L.	P42-4	Wang, X. (Columbia Univ.)	P39-1	Wells, W. A.	P13-17
Wallace, P.	P9-11	Wang, X. (Roswell Park Cancer Inst.)	P12-2	Wellstein, A.	P10-19, P32-20, P53-14, P55-16
Waller, J.	P62-21	Wang, X. (Temple Univ.)	P29-20	Welm, B.	P1-21, P55-12
Wallrath, L. L.	P5-10	Wang, X. (Thomas Jefferson Univ.)	P30-23	Welsch, P. L.	P51-10, P56-14
Walls, E. W.	P38-26	Wang, X. (Univ. of Colorado-Boulder)	P58-16	Welsh, J.	P36-3, P36-17
Walmsley, A. M.	P45-15	Wang, X. (Univ. of Texas M.D. Anderson)	P45-11	Wen, F.	P1-22
Walser, T.	P39-7	Wang, X. H.	P14-4	Wen, P.	P67-21
Walsh, S.	P23-20	Wang, X-F.	P28-3, P32-3	Wen, W.	P49-3, P49-17
Walsh, S. R.	P69-7			Wen, Y. (Cincinnati Children's Hosp. Res. Found.)	P5-8
Walter, J. C.	P51-15			Wen, Y. (Univ. of Texas M.D. Anderson)	P46-8
Waltham, M.	P58-9, P60-22			Wen, Y-J.	P18-8

## Poster/Author Index

- Werb, Z. .... P1-21, P53-7, P55-12, P58-6  
Weremowicz, J. .... P59-11  
Wessel, A. .... P40-20  
Wessner, L. W. .... P38-2  
West, D. K. .... P67-8  
West, J. L. .... P64-15  
Westbrook, C. A. .... P6-19, P6-28  
Westbrook, T. .... P29-7  
Westmoreland, T. J. .... P51-2  
Wetmur, J. G. .... P49-5, P49-21  
Wheeler, C. T. .... P15-10  
Wheeler, K. T. .... P15-5  
Whitaker, N. .... P37-7  
Whitaker-Dowling, P. .... P44-1  
White, E. .... P51-15  
White, K. A. .... P7-9  
White, M. A. .... P31-1  
Whitelegge, J. P. .... P40-2  
Whitesell, L. .... P11-26  
Whitington, A. .... P40-13  
Whitman, G. J. .... P41-5, P48-8  
Whittaker, J. L. .... P11-3  
Whittemore, A. S. .... P49-6  
Whittington, P. J. .... P39-8  
Whyte, L. .... P10-16  
Wicha, M. S. .... P3-24  
Wieder, R. .... P59-22  
Wieloch, C. .... P59-20  
Wiemer, D. F. .... P43-10  
Wiese, T. E. .... P8-8  
Wiesner, G. L. .... P6-6  
Wilhelm, O. G. .... P67-10  
Willett, W. C. .... P24-9  
Williams, B. .... P4-16  
Williams, C. A. .... P32-9  
Williams, E. .... P26-14  
Williams, N. (Ohio State Univ.) .... P67-21  
Williams, N. I. (Penn. State Univ.) .... P20-9, P62-22  
Williamson, E. A. .... P51-24  
Willmert, L. .... P35-20  
Wilsker, D. .... P29-20, P32-17  
Wilson, A. .... P29-21, P29-22  
Wilson, B. .... P47-5  
Wilson, C. .... P62-7  
Wilson, C. A. .... P3-25, P3-26  
Wilson, K. .... P26-14  
Wilson, S. M. .... P10-18, P38-8, P60-4  
Wilson, T. M. .... P7-22  
Wilton, R. .... P51-8  
Winans, M. .... P13-18  
Winder, A. .... P35-18  
Windsor, S. D. .... P64-30  
Winey, M. .... P29-19  
Wingate, H. .... P29-25  
Winkelman, J. .... P22-6  
Winter, S. L. .... P51-30  
Wipf, P. .... P16-16  
Wissmann, K. .... P50-16  
Withington, S. L. .... P32-18  
Woditschka, S. .... P62-21  
Wojciechowski, J. .... P6-26  
Wojcik, E. J. .... P53-3  
Wold, L. .... P49-7  
Wolf, I. .... P51-24  
Wolff, M. S. .... P24-11  
Wondimu, A. .... P12-9  
Wondisford, F. E. .... P7-21  
Wong, F. C. .... P44-20  
Wong, J. (Baylor College of Medicine) .... P7-12, P35-21  
Wong, J. (Children's Hospital Boston) .... P38-6  
Wong, L-J. C. .... P56-26, P56-27, P56-28  
Wong, W-H. .... P15-9  
Woo, S. L. C. .... P45-13  
Wood, C. .... P61-1  
Wood, J. .... P13-5  
Wood, N. L. .... P65-10  
Wood, W. C. .... P64-31  
Woods, M. N. .... P40-1  
Woodward, W. A. .... P3-6  
Woon Kim, K. .... P21-9  
Wooten, R. .... P61-3  
Worsham, M. J. .... P11-27, P11-28, P11-29  
Woster, P. .... P67-12  
Wright, L. .... P5-10  
Wright, T. G. .... P53-3, P53-16  
Wright, W. E. .... P4-17, P56-22  
Wronski, T. J. .... P34-3  
Wu, C. .... P30-28  
Wu, H. (Fox Chase Cancer Center) .... P54-6  
Wu, H. (Southern Illinois Univ.) .... P32-16  
Wu, J. (GMR Epigenetics) .... P44-5  
Wu, J. (Mayo Clinic, Rochester) .... P25-3  
Wu, J-H. .... P43-20  
Wu, J-T. .... P5-7  
Wu, K. (Baylor College of Medicine) .... P7-4  
Wu, K. (Mayo Clinic, Rochester) .... P25-4  
Wu, M. (Indiana Univ.) .... P71-11  
Wu, M. (Univ. of Texas M.D. Anderson) .... P36-1  
Wu, T. D. .... P1-13  
Wu, T-Y. .... P23-24  
Wu, X. (Johns Hopkins Univ.) .... P60-24  
Wu, X. (Univ. of California, Davis) .... P26-23  
Wu, Y. .... P30-2  
Wu, Y-L. .... P7-22  
Wu, Z. (Dana-Farber Cancer Inst.) .... P45-10  
Wu, Z. (Univ. of South Florida) .... P14-7  
Wurtz, J-M. .... P7-14  
Wy, L. .... P30-14  
Wyatt, S. K. .... P64-6  
Wykle, R. L. .... P61-3
- X**
- Xia, B. .... P25-11  
Xia, M. .... P63-9  
Xia, W. .... P30-2  
Xian, W. .... P5-20  
Xiang, B. .... P11-20, P52-18  
Xiang, R. .... P12-16
- Xiao, A. .... P59-24  
Xiao, H. .... P54-22  
Xiao, S. .... P30-24  
Xiao, Z. (Univ. of Oklahoma) .... P53-12  
Xiao, Z. (Univ. of Rochester) .... P22-7  
Xiao, Z. X. .... P37-8  
Xie, C. .... P7-24  
Xie, H. .... P54-8  
Xie, J-W. .... P59-23  
Xie, S. .... P15-9  
Xie, W. (Rutgers, State Univ. of NJ) .... P29-18  
Xie, W. (Univ. of Pittsburgh) .... P7-23  
Xing, L. .... P17-6  
Xiong, Y. .... P32-14  
Xu, B. (Louisiana State Univ.) .... P17-3  
Xu, B. (Univ. of Texas Southwestern Med. Ctr.) .... P2-12  
Xu, C. .... P64-34  
Xu, D. .... P49-22  
Xu, J. (Baylor College of Medicine) .... P30-25, p35-22  
Xu, J. (Indiana Univ.) .... P66-18  
Xu, J. (Univ. of Chicago) .... P51-23  
Xu, J. (Washington Univ.) .... P15-5  
Xu, K. .... P3-9  
Xu, L. .... P43-8, P67-19  
Xu, M. .... P14-19, P64-2  
Xu, Q. .... P7-24  
Xu, R. .... P5-15, P5-21  
Xu, X. (Boston Univ.) .... P2-5  
Xu, X. (Dana-Farber Cancer Inst.) .... P13-21  
Xu, X. (Mount Sinai School of Medicine) .... P49-21  
Xu, X. (National Inst. of Health) .... P51-11  
Xu, X. (Univ. of Pennsylvania) .... P53-1  
Xu, Y. (Univ. of California, San Diego) .... P51-6  
Xu, Y. (Univ. of Virginia) .... P2-11  
Xu, Z. .... P2-7  
Xuan, J. .... P18-1  
Xue, D. .... P58-16  
Xue, F. .... P24-9
- Y**
- Yadav, A. .... P27-8  
Yager, J. D. .... P8-1  
Yamada, H. Y. .... P29-26  
Yan, J. (National Inst. of Health) .... P27-2  
Yan, J. (Univ. of Louisville) .... P45-20  
Yan, M. .... P3-10  
Yan, R. .... P67-2  
Yang, A. .... P27-17  
Yang, C. (Univ. of Colorado-Boulder) .... P58-16  
Yang, C. (Univ. of Pennsylvania) .... P31-25  
Yang, C-P. H. .... P66-19  
Yang, D. .... P43-8  
Yang, D. J. .... P15-4  
Yang, J. (Shanghai Int'l Joint Inst.) .... P13-6  
Yang, J. (Univ. of Texas M.D. Anderson) .... P67-22  
Yang, J. J. .... P11-27, P11-28, P11-29

## Poster/Author Index

- Yang, K.....P43-21  
Yang, L. (Emory Univ.).....P64-31  
Yang, L. (Univ. of Pennsylvania).....P65-3  
Yang, N.....P58-16  
Yang, Q-L.....P38-7  
Yang, S. (Boston Univ.).....P37-8, P64-24  
Yang, S. (Univ. of Rochester).....P22-7  
Yang, S. (Univ. of Toronto).....P44-18  
Yang, V. C.....P67-20  
Yang, W.....P67-22  
Yang, X. (Boston Univ.).....P22-8  
Yang, X. (Renz Research, Inc.).....P7-22  
Yang, X. (Univ. of South Carolina).....P45-21  
Yang, Y. (Indiana Univ.).....P66-18  
Yang, Y. (Univ. of Kentucky).....P16-19  
Yang, Z.....P36-16  
Yang, Z-Q.....P1-23  
Yannone, S. M.....P48-3  
Yano, K.....P25-9  
Yao, J. (Dana-Farber Cancer Inst.).....P53-17  
Yao, J. (Univ. of Texas M.D. Anderson) ...P67-22  
Yao, T-P.....P4-12, P5-7, P26-22  
Yao, Y-D.....P71-10  
Yarden, R. I.....P30-29  
Yarmill, A.....P55-19  
Yarmolenko, P. S.....P44-9  
Yaswen, P.....P32-24, P32-25, P54-17  
Yater, C.....P11-24  
Yazici, B.....P14-20  
Yazici, S.....P60-20  
Ye, Y.....P3-2, P3-3  
Yeatman, T.....P6-21  
Yee, A.....P64-23  
Yee, A. S.....P54-23  
Yee, D.....P53-4  
Yee, L.....P67-21  
Yeh, L-A.....P67-16  
Yeh, S.....P7-24  
Yennu Nanda, V. G.....P5-22  
Yeon, C.....P67-11  
Yew, P. R.....P29-27, P51-22  
Yi, B.....P23-23  
Yi, P.....P35-21  
Yi, T.....P24-13  
Yin, X.....P58-2  
Ying, H.....P37-8  
Ylstra, B.....P6-16  
Ynag, D.....P67-19  
Yokomori, K.....P4-23  
Yoo, B.....P65-9  
Yore, M. M.....P7-9  
Yoshida, M.....P5-7  
You, F.....P40-7  
You, Y.....P47-4  
Young, C. S. H.....P56-19  
Young, H.....P70-8, P70-9  
Young, L. J. T.....P9-17  
Young, S.....P66-8  
Younger, J.....P40-21  
Yount, G.....P10-20  
Yu, D.....P67-22, P67-23  
Yu, D-F.....P15-4  
Yu, F.....P26-16  
Yu, H. (Georgetown Univ.) .....P52-15  
Yu, H. (Louisiana State Univ.  
Health Sciences Ctr.).....P13-3  
Yu, H. (Univ. of Wisconsin-Madison) .....P3-4  
Yu, J. (Columbia Univ.).....P54-20  
Yu, J. (Univ. of Texas Southwestern) .....P65-7  
Yu, J.Y.....P66-8, P66-11  
Yu, L.....P33-10  
Yu, Q.....P50-15  
Yu, S.....P50-15  
Yu, X.....P4-25  
Yu, Y.....P1-25  
Yuan, B.....P64-32, P64-34  
Yuan, E.....P54-20  
Yuan, H.....P15-10  
Yuan, J.....P2-24  
Yuan, K.....P38-20  
Yuan, Y. (Univ. of New Mexico) .....P25-10  
Yuan, Y. (Univ. of Texas M.D. Anderson) ...P30-8  
Yue, W.....P43-15, P50-18, P51-14  
Yue, X.....P51-31  
Yuen, C.....P45-2  
Yull, F.....P3-27
- Z**
- Zackenhaus, E.....P30-26  
Zagozdzon, R.....P2-25  
Zahasky, K. M.....P20-8  
Zahedi, R.....P3-13  
Zaidi, M.....P10-1  
Zaloga, G. P.....P71-11  
Zamurs, L.....P60-19  
Zang, X-P.....P53-12  
Zapata-Benavides, P.....P21-7  
Zarabi, B.....P65-11  
Zarek, P. E.....P45-22  
Zarfos, K.....P64-34  
Zaveri, N.....P38-24  
Zechiedrich, E. L.....P56-16  
Zeiger, M. A.....P6-27  
Zeng, J.....P17-2  
Zeng, J. (Univ. of California, Irvine).....P27-2  
Zeng, X.....P55-14  
Zerkowski, M. P.....P6-4  
Zhai, D.....P58-10  
Zhan, M.....P70-12  
Zhang, B.....P13-10, P13-11  
Zhang, D.....P29-8  
Zhang, G.....P31-24  
Zhang, H.....P30-25, P35-22  
Zhang, J.....P18-1  
Zhang, J. (Indiana Univ.).....P35-8  
Zhang, J. (Univ. of California,  
San Francisco).....P56-24  
Zhang, J-T.....P66-18, P66-20  
Zhang, K.....P16-21  
Zhang, L.....P43-9  
Zhang, L. (The Burnham Inst.) .... P9-19, P9-23  
Zhang, L. (State Univ. of New York,  
Albany) .....P37-2  
Zhang, L. (State Univ. of New York,  
Stony Brook).....P4-5  
Zhang, L. (Univ. of Rochester Med. Ctr.)..P22-7  
Zhang, M.....P54-24  
Zhang, M. Q.....P62-20  
Zhang, N.....P29-25  
Zhang, P.....P36-7  
Zhang, Q.....P67-5  
Zhang, Q-Y.....P37-2  
Zhang, X. (Baylor College of Medicine) ...P1-14  
Zhang, X. (The Burnham  
Inst.).....P43-6, P44-16, P58-18  
Zhang, X. (Purdue Univ.) .....P33-3  
Zhang, X. (Tufts Univ.) .....P54-23  
Zhang, X. (Univ. of Southern Florida) .....P36-2  
Zhang, X-K.....P58-17  
Zhang, Y. (Georgetown Univ.) .....P55-16  
Zhang, Y. (Univ. of Michigan).....P54-9  
Zhang, Y. (Univ. of Texas M.D. Anderson). P15-9  
Zhang, Y-J.....P49-5  
Zhang, Y-W.....P4-24  
Zhang, Z. (Johns Hopkins Univ.).....P67-12  
Zhang, Z. (Univ. of Virginia).....P26-18  
Zhao, C.....P71-7  
Zhao, D.....P64-20, P67-24  
Zhao, H. (Temple Univ.) .....P13-1  
Zhao, H. (Univ. of Rochester).....P48-10  
Zhao, H. (Univ. of Texas  
M.D. Anderson).....P13-11  
Zhao, K.....P32-12  
Zhao, L.....P67-2  
Zhao, M.....P65-10  
Zhao, W. (Hokkaido Univ.).....P46-13  
Zhao, W. (State Univ. of New York,  
Stony Brook).....P42-11  
Zhao, X. (Boston Univ.).....P30-27  
Zhao, X. (Duke Univ.).....P5-7  
Zhao, X. (Northwestern Univ.) .....P1-2  
Zhao, Y. (Duke Univ.).....P16-1  
Zhao, Y. (Florida State Univ.).....P59-24  
Zhao, Y. (Northwestern Univ.) .....P27-1  
Zharov, V. P.....P44-21  
Zhe, J.....P30-26  
Zheng, G.....P47-5  
Zheng, P.....P30-28  
Zheng, Q.....P28-1  
Zheng, W. (Univ. of Arizona).....P11-4  
Zheng, W. (Vanderbilt Univ.).....P21-9, P22-2,  
P49-3, P49-17  
Zheng, X.....P30-28  
Zheng, Y.....P62-21  
Zheng, Z.....P30-28  
Zhou, B. P.....P46-8  
Zhou, C.....P14-5  
Zhou, H.....P12-16  
Zhou, J. (Univ. of South Florida) .....P14-12  
Zhou, J. (The Wistar Institute).....P51-21

---

## *Poster/Author Index*

---

Zhou, J-Y.....	P66-16	Zhu, C.....	P64-33	Zigman, W.....	P54-20
Zhou, L.....	P50-14, P67-25	Zhu, J.....	P50-14	Zimmerman, K.....	P61-1
Zhou, P.....	P52-1	Zhu, P.....	P40-9	Zinn, K. R.....	P45-3, P64-8
Zhou, Q. (Cornell Univ.) .....	P4-10	Zhu, Q.....	P64-17, P64-32, P64-34	Ziv, E.....	P49-23
Zhou, Q. (Purdue Univ.).....	P33-3	Zhu, W.....	P40-20	Zolov, S.....	P13-23
Zhou, S.....	P35-22	Zhu, X. (The Burnham Institute) .....	P44-16	Zong, W-X.....	P43-1
Zhou, T.....	P45-3	Zhu, X. (Univ. of Texas M.D. Anderson)..	P29-27	Zou, X.....	P29-14
Zhou, W.....	P42-5	Zhu, Y. (Georgetown Univ.) .....	P18-1, P18-2, P18-3, P66-4	Zou, Y.....	P16-18
Zhou, X.....	P67-22, P67-23	Zhu, Y. (Northwestern Univ.) .....	P54-16	Zurgil, N.....	P38-25
Zhou, Y. (Univ. of Arizona) .....	P11-4	Zhu, Y.....	P61-1	Zwart, A.....	P18-1, P18-2, P18-3, P66-4, P66-14
Zhou, Y. (VA Palo Alto) .....	P66-10	Zhu, Z.....	P27-17	Zweitzig, D. R.....	P1-26, P29-20
Zhou, Y-D.....	P43-9	Zhuang, S.....	P38-4		
Zhou, Z. (Cornell Univ.).....	P54-13	Zhuo, J.....	P65-11		
Zhou, Z. (Pennsylvania State Univ.).....	P60-5	Ziemba, A.....	P52-19		
Zhu, B. T.....	P8-9, P34-4				

## ***Faculty Disclosure Statement***

The Era of Hope meeting speakers have provided the following disclosure of interest information.

<b>Speaker Last Name</b>	<b>Speaker First Name</b>	<b>Source of Funding for Clinical Grants*</b>	<b>Consulting Agreements</b>	<b>Financial Interests or Stock Ownership</b>	<b>Unlabeled Use**</b>	<b>Investigational Products***</b>
Aggarwal	Bharat	None	None	None	None	None
Akporiaye	Emmanuel	None	None	None	None	None
Allred	Clinton	None	None	None	None	None
Ambrosone	Christine B.	None	None	None	None	None
Andrews	David	None	None	None	None	None
Baccala	Roberto	None	None	None	None	None
Barnett	Junaideah	NIH	None	None	None	None
Barsky	Sanford	None	None	None	None	None
Bartella	Lia	None	None	None	None	None
Bascom	Jamie	None	None	None	None	None
Basilion	James	None	None	None	None	None
Beam	Craig	None	None	None	None	None
Bellows	David	None	None	None	None	None
Bennett	Craig	None	None	None	None	None
Bentires-Alj	Mohamed	None	None	None	None	None
Bernstein	Leslie	None	None	None	None	None
Berry	Donald	None	None	None	None	None
Bissell	Mina J.	None	None	None	None	None
Blakely	Collin	None	None	None	None	None
Bockbrader	Katrina	None	None	None	None	Smac mimic compound 3 for anticancer therapy
Bornhop	Darryl	None	None	None	None	Multi-modal imaging agents targeted to the peripheral benzodiazepine receptor
Bovbjerg	Dana	None	None	None	None	None
Boyer	Thomas	None	None	None	None	None
Brugge	Joan S.	Sanofi-Aventis	Millenium Pharmaceuticals	None	None	None
Buchsbaum	Donald	None	None	None	None	None
Bundred	Nigel	Breast Cancer Campaign, Pfizer, AstraZeneca, Novartis	AstraZeneca, Novartis, Pfizer, Organon	None	None	Iressa (gefitinib), exemestane, celecoxib, RAD001
Byrne	Belinda	None	None	None	None	None
Cardiff	Robert D.	None	None	None	None	None
Carmell	Michelle	None	None	None	None	None
Cavalieri	Ercole	None	None	None	None	None
Chambers	Ann	None	None	None	None	None
Chan	Heang-Ping	None	None	None	None	None
Chance	Britton	NIH	None	None	None	None
Chang	Chia-Cheng	None	None	None	None	None
Chang	Helena	None	None	None	None	None
Chang	Jenny	Genentech, Aventis	None	None	None	None
Chen	Jin	None	None	None	None	None
Chen	Mercy	None	None	None	None	None
Chen	Yu	None	None	None	None	None
Chirgwin	John	None	None	None	None	None

## Faculty Disclosure Statement

Speaker Last Name	Speaker First Name	Source of Funding for Clinical Grants*	Consulting Agreements	Financial Interests or Stock Ownership	Unlabeled Use**	Investigational Products***
Chu	Philip	None	None	None	None	None
Clarke	Robert	None	None	None	None	None
Cleary	Margot	None	None	None	None	None
Cnatttingius	Sven	None	None	None	None	None
Cohen	Edward	NIDCR	None	Immune Cell Therapy	None	None
Couch	Fergus	None	None	None	None	None
Daoud	Sayed	None	None	None	None	None
Dasgupta	Ramanuj	None	None	None	None	None
de Assis	Sonia	None	None	None	None	None
de Bruin	Alain	None	None	None	None	None
deFazio	Anna	None	None	None	None	None
Degani	Hadassa	None	None	YEDA Ltd., the commercial arm of Weizmann Institute of Science	None	Estrogen receptor ligands affecting the MRI signal and/or fluorescent used for <i>in vivo</i> imaging of estrogen receptor
Degnim	Amy	None	None	None	None	None
Deisseroth	Albert	Breast Cancer Research Foundation, NIH	None	None	None	None
Demark-Wahnefried	Wendy	None	None	None	None	None
Demicco	Elizabeth	None	None	None	None	None
Deng	Chu-Xia	None	None	None	None	None
Dickersin	Kay	NIH, AHRQ, Cochrane Collaboration	None	None	None	None
Diebold	Gerald	None	None	Owns stock in a company that owns the patent on vibration potential imaging	None	None
Dillon	Rachelle	None	None	None	None	None
Domchek	Susan	Avon/NCI Progress for Patients, Beckman Foundation	None	The sponsor of this study, Dr. Vonderheide, is one of the inventors on a pending patent application submitted and owned by the Dana-Farber Cancer Institute and the Whitehead Institute, which relates to aspects of the hypothesis being tested in these clinical trials. Dr. Vonderheide and Dr. Domchek (the PI) are married. It is theoretically possible that the investigators could benefit financially from the results of this study.	None	hTERT vaccine used in metastatic breast cancer patients
Donnenberg	Albert	None	Beckman-Coulter Cytomics	None	None	None
Du	Jian	None	None	None	None	None
Elledge	Stephen	None	None	None	None	None

## ***Faculty Disclosure Statement***

<b>Speaker Last Name</b>	<b>Speaker First Name</b>	<b>Source of Funding for Clinical Grants*</b>	<b>Consulting Agreements</b>	<b>Financial Interests or Stock Ownership</b>	<b>Unlabeled Use**</b>	<b>Investigational Products***</b>
Eshhar	Zelig	Prostate Cancer Foundation, Israel Cancer Fund, Israel Science Foundation	None	None	None	None
Esteva	Francisco	None	None	None	None	None
Felding-Habermann	Brunhilde	None	None	None	None	Assay for early detection of breast cancer
Fernandez	Sandra	None	None	None	None	None
Fleisher	Linda	None	None	None	None	None
Folkman	M. Judah	None	None	None	None	None
Fowler	Amy	None	None	None	None	None
Fukuda	Michiko	None	None	None	None	None
Gaillard	Stephanie	None	None	None	None	None
Gelovani	Juri G.	None	None	None	None	None
Gendler	Sandra	None	None	None	None	None
Ghosh	Karthik	None	None	None	None	None
Gillespie	Matthew	None	None	None	None	None
Giorgio	Todd	None	None	None	None	None
Glaser	Sally	None	None	None	None	None
Godwin	Andrew	NIH, Eileen Stein Jacoby Fund	None	None	None	None
Gollahon	Lauren	None	None	None	None	None
Gray	Joe W.	Genentech, Celera	Keryx	Affymetrix	None	None
Gunawardane	Ruwanthi	None	None	None	None	None
Gupta	Gaorav	None	None	None	None	None
Gupta	Piyush	None	None	None	None	None
Guttenplan	Joseph	None	None	None	None	None
Hadjiski	Lubomir	None	None	None	None	None
Han	Daikwon	None	None	None	None	None
Han	Liangfeng	None	None	None	None	None
Hannon	Gregory	None	None	None	None	None
Harris	Lyndsay N.	None	None	None	None	None
Hartmann	Lynn	None	None	None	None	None
Hartwell	Kimberly	None	None	None	None	None
Hauschka	Peter	None	None	None	None	None
Haviv	Izhak	None	None	None	None	None
Heim	Kelly	None	None	None	None	None
Helperich	William	None	None	None	None	None
Hill	P. Aru	None	None	None	None	None
Hinck	Lindsay	None	None	None	None	None
Hines	William	None	None	None	None	None
Hinestrosa	M. Carolina	None	None	None	None	None
Hoelz	Derek	None	None	None	None	None
Hu	Yanfen	None	None	None	None	None
Hughes Halbert	Chanita	None	None	None	None	None
Ip	Margot	None	None	None	None	None
Iwaniec	Urszula	None	None	None	None	rAAV-leptin used in gene therapy for weight loss

## Faculty Disclosure Statement

Speaker Last Name	Speaker First Name	Source of Funding for Clinical Grants*	Consulting Agreements	Financial Interests or Stock Ownership	Unlabeled Use**	Investigational Products***
Jain	Alka	None	None	None	None	None
Jerry	Joseph D.	None	None	None	None	None
Jiang	Lan	None	None	None	None	None
Jiang	Shiming	None	None	None	None	None
John	Esther	None	None	None	None	None
Kauff	Noah	None	None	None	None	None
Kemble	Katherine	None	None	None	None	None
Keshtgar	Mohammed	None	None	None	None	None
Kim	Helen	None	Grapeseed extract provided by Kikkoman Corporation, Chiba, Japan	None	None	Grapeseed extract used for breast cancer prevention in animal studies
Kim	Jae	None	None	None	None	None
Kim	Wes	None	None	None	None	None
Klein	Pamela M.	None	None	Genentech	Herceptin, Avastin	None
Knowles	David	None	None	None	None	None
Knutson	Keith	None	None	None	None	None
Kucuk	Omer	NIH, Lycored	None	None	Soy used for cancer prevention	Soy used for cancer prevention
Kufe	Donald	None	None	None	None	Fusions of breast cancer cells and dendritic cells used for anticancer vaccine
LaBaer	Joshua	None	None	None	None	None
Lampson	Lois	None	None	None	None	None
Lang	Elvira	None	None	None	None	None
Lanza-Jacoby	Susan	None	None	None	Iressa for breast cancer	None
Latimer	Jean	None	None	None	None	None
Le Marchand	Loic	None	None	None	None	None
Leygue	Etienne	None	None	None	None	None
Li	Benjamin	None	None	None	None	None
Lobo	Neethan	None	None	None	None	None
Love	Susan M.	Cytyc Corporation	Cytyc Corporation, PepsiCo, PacifiCare, Dover Medical Ventures	Sanarus Medical, Inc., Windy Hill Medical	None	None
Lu	Jianrong	None	None	None	None	None
Lubawy	Carmalyn	NIH	None	None	None	Photon migration spectroscopy instrument to enable photon migration measurements
Lucci	Anthony	None	None	None	None	None
Luck	Linda	None	None	None	None	None
Lyerly	Herbert Kim	None	None	None	None	None
MacRae	Marla	None	None	None	None	None
Makrigiorgos	G. Mike	None	None	None	None	None
Marple	Teresa	None	None	None	None	None
Mason	Ralph	None	None	None	None	None
Mastracci	Theresa	None	None	None	None	None
Mastro	Andrea	None	None	None	None	None
Matrisian	Lynn M.	NIH	None	None	None	None

## ***Faculty Disclosure Statement***

<b>Speaker Last Name</b>	<b>Speaker First Name</b>	<b>Source of Funding for Clinical Grants*</b>	<b>Consulting Agreements</b>	<b>Financial Interests or Stock Ownership</b>	<b>Unlabeled Use**</b>	<b>Investigational Products***</b>
Medina	Daniel	None	None	None	None	None
Meltzer	Paul S.	None	None	None	None	None
Mercer	Robyn	None	None	None	None	None
Mertz	Janet	None	None	None	None	Trastuzumab, fentinib, faslodex, U0126, LY294002, used in cell culture studies to examine effects on ERR-alpha activities
Miller	Suzanne M.	None	None	None	N/A	N/A
Mitas	Michael	None	None	None	None	None
Moorehead	Roger	None	None	None	None	None
Mucci	Lorelei	None	None	None	None	None
Murphy	Leigh	None	None	None	None	None
Murphy	William	None	None	None	Velcade (bortezomib) for breast cancer	None
Muruganandham	Manickam	None	None	None	None	None
Muti	Paola	NIH	None	None	None	None
Nagle	Dale	None	None	None	None	None
Nelson	Celeste	None	None	None	None	None
Noss	Karin	None	None	None	None	None
Oh	Youngman	None	None	None	None	None
Okobia	Michael	None	None	None	None	None
Olopade	Olufunmilayo Falusi	None	None	None	None	None
Onyuksel	Hayat	None	None	None	None	Targeted imaging agent for enhanced breast cancer imaging
Oraevsky	Alexander	NCI	None	Laser Sonix Technologies	None	LOIS (laser optioacoustic imaging system) for clinical studies to detect and diagnose breast cancer
Oshima	Robert G.	None	None	None	None	None
Padilla De Jesús	Omayra	None	General Electric	General Electric	Optison used for investigation of OFMBs	Sonazoid and OFMBs (fluorescently labeled human serum albumin microbubbles and surfactant-based microbubbles) used for ultrasound imaging
Paik	Soonmyung	NCI, Pennsylvania State Department of Health	None	None	None	Oncotype diagnostic assay (Genomic Health, Inc.), GeneChip (Affymetrix) used to predict response to therapy
Pankrantz	Shane V.	None	None	None	None	None
Parker	Belinda	None	None	None	None	None
Paskett	Electra	NIA, NCI, NHLBI, Breast Cancer Research Foundation	None	None	None	None
Pazdur	Rick	None	None	None	None	None
Pegram	Mark D.	None	Genentech, Inc.	None	Herceptin, Avastin used in combination in breast cancer	Avastin for breast cancer

## Faculty Disclosure Statement

Speaker Last Name	Speaker First Name	Source of Funding for Clinical Grants*	Consulting Agreements	Financial Interests or Stock Ownership	Unlabeled Use**	Investigational Products***
Perez	Denise	None	None	None	None	None
Pink	John	None	None	None	None	None
Pinkhasov	Julia	None	None	None	None	None
Planas-Silva	Maricarmen	None	None	None	None	None
Polyak	Kornelia	None	None	None	None	None
Poola	Indira	None	None	None	None	None
Porter	Weston	None	None	None	None	None
Press	Michael	None	None	None	None	None
Price	Janet	None	None	None	ST1571/Gleevec used to target PDGF receptors in breast cancer	None
Prosnitz	Robert	None	None	None	None	None
Quale	Christopher	None	None	None	None	None
Qin	Lanofang	None	None	None	None	None
Ranscht	Barbara	None	None	None	None	None
Ransohoff	David	NIH	None	None	None	None
Raveis	Victoria	None	None	None	None	None
Rebbeck	Timothy R.	NIH	None	None	None	None
Reilly	Raymond	None	MDS-Nordion, Inc.	None	None	Indium-III labeled trastuzumab FAB for imaging and radioguided surgery of breast cancer
Rosenstein	Barry	None	None	None	None	None
Rossing	Mary Anne	None	None	None	None	None
Ruoslahti	Erkki	None	None	None	None	None
Russo	Jose	None	None	None	None	None
Saavedra	Elba	None	None	None	None	None
Sadlonova	Andrea	None	None	None	None	None
Sanderson	Maureen	None	None	None	None	None
Santen	Richard	None	None	None	None	None
Sauter	Edward	Pfizer	None	None	Celecoxib used for breast cancer prevention	None
Schaffer	Beverly	None	None	None	None	None
Schneider	Robert	None	None	None	None	None
Scholler	Nathalie	None	None	None	None	None
Selander	Katri	None	None	None	None	None
Sellers	William R.	None	Novartis Pharmaceuticals	None	None	None
Seon	Ben	None	None	None	None	None
Sgroi	Dennis	None	None	None	None	None
Shak	Steven	None	None	Genomic Health, Inc.	None	None
Sharma	Dipali	None	None	None	None	None
Sharma	Girdhar	None	None	None	None	None
Shi	Qian	None	None	None	None	None
Shin	Seung-Uon	None	None	None	None	None
Shiu	Robert	None	None	None	None	None
Simha	Joy	None	None	None	None	None

## ***Faculty Disclosure Statement***

<b>Speaker Last Name</b>	<b>Speaker First Name</b>	<b>Source of Funding for Clinical Grants*</b>	<b>Consulting Agreements</b>	<b>Financial Interests or Stock Ownership</b>	<b>Unlabeled Use**</b>	<b>Investigational Products***</b>
Singh	Reshma	None	None	None	None	None
Slamon	Dennis J.	None	Aventis Pharmaceuticals, Genetech BioOncology, NewBiotics, Roche Pharmaceuticals	Amgen, Schering Plough/Canji	None	None
Sledge Jr.	George	None	Genentech, Pfizer, Novartis	None	Genentech, Avastin	None
Smith	Christopher	None	None	None	None	None
Sporn	Michael B.	None	None	None	None	None
Stampfer	Martha	None	None	None	None	GRN163L from Geron Corporation used for inhibitor of telomerase activity
Starita	Lea	None	None	None	None	None
Steeg	Patricia	None	None	None	None	None
Sukumar	Saraswati	NIH, Susan B. Komen Breast Cancer Foundation	Oncomethylome Sciences	None	None	None
Symmans	W. Fraser	Susan B. Komen Foundation	None	None	None	None
Tabb	Michelle	None	None	None	None	None
Teicher	Beverly	None	None	Genzyme Corporation	None	None
Terry	Mary Beth	None	None	None	None	None
Thompson	James	None	None	None	None	None
Tisty	Thea	None	None	None	None	None
Townson	Steven	None	None	None	None	None
Tryggvadottir	Laufey	None	None	None	None	None
Tudorica	Luminita	None	None	None	None	None
Uzgiris	Egidijus	None	None	None	None	None
Valrance	Meggan	None	None	None	None	None
Velie	Ellen	None	None	None	None	None
Verbanac	Kathryn	Ortho Clinical Diagnostics	Ortho Clinical Diagnostics	None	None	None
Vervoort	Virginie	None	None	None	None	None
Walsh	Stephanie	None	None	None	None	None
Wang	Judy	None	None	None	None	None
Wang	Lu-Hai	None	None	None	None	None
Wang	Y. Alan	None	None	None	None	None
Wang	Ya	None	None	None	None	None
Weaver	Valerie M.	None	None	None	None	None
Weber	Frank	None	None	None	None	None
Welcsh	Piri	None	None	None	None	None
Wellstein	Anton	None	None	None	None	None
Welm	Bryan	None	None	None	None	None
Wicha	Max S.	None	OncoMed	OncoMed	None	None
Wigler	Michael H.	None	None	None	None	None
Wilhelm	Olaf	None	None	Wilex AG	Xeloda combined with WX-UK1	WX-UK1 for prevention of solid tumor metastasis
Willmert	Leslie	None	None	None	None	None
Wilson	Cindy	None	None	None	None	None

## ***Faculty Disclosure Statement***

Speaker Last Name	Speaker First Name	Source of Funding for Clinical Grants*	Consulting Agreements	Financial Interests or Stock Ownership	Unlabeled Use**	Investigational Products***
Windsor	Stephen	None	None	None	Optison	None
Woditschka	Stephan	None	None	None	None	None
Worsham	Maria	None	None	None	None	None
Xiang	Rong	None	None	None	None	None
Xu	Min	None	None	None	None	None
Yang	Lily	None	None	None	None	None
Yang	Xiaofeng	None	None	None	None	Bi-specific antibody used for tumor cells
Yaswen	Paul	None	None	None	None	None
Yokomori	Kyoko	None	None	None	None	None
Yu	Dihua	None	None	None	None	None
Yuan	Junying	None	None	None	None	None
Zhang	Lianglin	None	None	None	None	None
Zhu	Quing	None	None	None	None	None

\* Other than DOD

\*\* Unlabeled use – A commercial product approved by the FDA for use in the United States for purposes OTHER than those being discussed (NOT approved for purpose being discussed)

\*\*\* Investigational products – Products being investigated for a specific purpose NOT yet approved by the FDA for use in the United States

---

## *Notes*

---

---

## *Notes*

---